<SEC-DOCUMENT>0001558370-20-004500.txt : 20200428
<SEC-HEADER>0001558370-20-004500.hdr.sgml : 20200428
<ACCEPTANCE-DATETIME>20200428170238
ACCESSION NUMBER:		0001558370-20-004500
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		107
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200428
DATE AS OF CHANGE:		20200428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Affimed N.V.
		CENTRAL INDEX KEY:			0001608390
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			2M
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36619
		FILM NUMBER:		20825962

	BUSINESS ADDRESS:	
		STREET 1:		IM NEUENHEIMER FELD 582, 69120
		CITY:			HEIDELBERG
		STATE:			2M
		ZIP:			000000
		BUSINESS PHONE:		49-6221-65307

	MAIL ADDRESS:	
		STREET 1:		IM NEUENHEIMER FELD 582, 69120
		CITY:			HEIDELBERG
		STATE:			2M
		ZIP:			000000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Affimed Therapeutics B.V.
		DATE OF NAME CHANGE:	20140516
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>afmd-20191231x20f.htm
<DESCRIPTION>20-F
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:56:26 PM-->
<html>
	<head>
		<title>
			afmd_Current_Folio_20F
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 15pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:15pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 15pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:15pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:12pt;">Washington, D.C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 15pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:15pt;">FORM&nbsp;20-F</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">(Mark One)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 4pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:4pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;">
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">REGISTRATION STATEMENT PURSUANT TO SECTION&nbsp;12(b)&nbsp;OR (g)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">OR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&#x2612;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">ANNUAL REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">For the fiscal&nbsp;year ended December&nbsp;31, 2019.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">OR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">TRANSITION REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">For the transition period from </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">&nbsp;&nbsp; to </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">OR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">SHELL COMPANY REPORT PURSUANT TO SECTION&nbsp;13 OR 15(d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:06.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:93.50%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Date of event requiring this shell company report ______________.</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Commission file number: 001&#8209;36619</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 15pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:15pt;">AFFIMED N.V.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Exact name of Registrant as specified in its charter</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">The Netherlands</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Jurisdiction of incorporation or organization</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Technologiepark, Im Neuenheimer Feld 582</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">69120 Heidelberg, Germany,</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">(+49) 6221&#8209;6743&#8209;60</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Address of principal executive offices</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Adi Hoess, Chief Executive Officer</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Tel: (+49) 6221&#8209;6743&#8209;60</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Technologiepark, Im Neuenheimer Feld 582</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">69120 Heidelberg, Germany</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">(</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 6pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:6pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">Copy to</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Sophia Hudson </font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Kirkland &amp; Ellis LLP</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">601 Lexington Avenue</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">New York, NY 10022</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Phone: 212 446 4750</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Fax: 212 446 4900</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Securities registered or to be registered pursuant to Section&nbsp;12(b)&nbsp;of the Act:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:34.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:01.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:14.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:47.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Title of each class</font></p>
				</td>
				<td valign="top" style="width:01.86%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:14.72%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Trading Symbol</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:47.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Name of each exchange on which registered</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:34.28%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Common shares, nominal value &#x20AC;0.01 per share</font></p>
				</td>
				<td valign="top" style="width:01.86%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:14.72%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">AFMD</font></p>
				</td>
				<td valign="top" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:47.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">The NASDAQ Stock Market LLC</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Securities registered or to be registered pursuant to Section&nbsp;12(g)&nbsp;of the Act:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">None</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">(Title of Class)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9pt;">Securities for which there is a reporting obligation pursuant to Section&nbsp;15(d)&nbsp;of the Act:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">None</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:9pt;">(Title of Class)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate the number of outstanding shares of each of the issuer&#x2019;s classes of capital stock or common stock as of the close of the period covered by the annual report.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Common shares: 76,249,901</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;No</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;No</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934 during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90&nbsp;days.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> No</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit such files).</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;No (not required)</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#x201C;large accelerated filer," "accelerated filer," and "emerging growth company&#x201D; in Rule&nbsp;12b&#8209;2 of the Exchange Act.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;font-family:Calibri;">
			<tr>
				<td valign="top" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:33.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:33.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.34%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Large Accelerated Filer&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.32%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Accelerated Filer&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:33.34%;padding:0pt;">
					<p style="margin:0pt 18pt 0pt 0pt;line-height:100%;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Non-accelerated Filer&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.34%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.32%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.34%;padding:0pt;">
					<p style="margin:0pt 18pt 0pt 0pt;line-height:100%;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Emerging growth company&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards&#x2020; provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. &nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&#x2020;&nbsp;&nbsp;The term &#x201C;new or revised financial accounting standard&#x201D; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April&nbsp;5, 2012.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.08%;">
			<tr>
				<td valign="top" style="width:24.34%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">U.S. GAAP </font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
				<td valign="top" style="width:51.00%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">International Financial Reporting&nbsp;<br>Standards as issued by the International&nbsp;<br>Accounting Standards Board </font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font></p>
				</td>
				<td valign="top" style="width:24.66%;border-top:1pt solid #000000 ;border-left:1pt solid #000000 ;border-bottom:1pt solid #000000 ;border-right:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Other </font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">If &#x201C;Other&#x201D; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Item&nbsp;17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Item&nbsp;18</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule&nbsp;12b&#8209;2 of the Exchange Act).</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
			<font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:MS Gothic;font-size:9pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;"> No</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 5pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">TABLE OF CONTENTS<a name="TOC"></a></font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #auto;">
			<tr>
				<td valign="top" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">PAGE</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FORWARDLOOKINGSTATEMENTS_409206"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">FORWARD-LOOKING STATEMENTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:right;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">iii</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#PARTI_999488"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">PART&nbsp;I</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM1IDENTITYOFDIRECTORSSENIORMANAGEMENT"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADirectorsandseniormanagement_586269"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADirectorsandseniormanagement_586269"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Directors and senior management</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BAdvisers_615943"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BAdvisers_615943"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Advisers</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CAuditors_379140"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CAuditors_379140"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Auditors</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM2OFFERSTATISTICSANDEXPECTEDTIMETABLE"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;2. OFFER STATISTICS AND EXPECTED TIMETABLE</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOfferstatistics_226025"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOfferstatistics_226025"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Offer statistics</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BMethodandexpectedtimetable_217810"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BMethodandexpectedtimetable_217810"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Method and expected timetable</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM3KEYINFORMATION_193122"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;3. KEY INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ASelectedFinancialData_875003"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ASelectedFinancialData_875003"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Selected Financial Data</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BCapitalizationandindebtedness_313019"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BCapitalizationandindebtedness_313019"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Capitalization and indebtedness</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CReasonsfortheofferanduseofproceeds_9300"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CReasonsfortheofferanduseofproceeds_9300"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Reasons for the offer and use of proceeds</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DRiskfactors_83889"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D</font><font style="display:inline;">.</font></a>&nbsp;</p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DRiskfactors_83889"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Risk factors</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM4INFORMATIONONTHECOMPANY_954084"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;4. INFORMATION ON THE COMPANY</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AHistoryanddevelopmentofthecompany_71562"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AHistoryanddevelopmentofthecompany_71562"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">History and development of the company</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>50
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BBusinessoverview_423562"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BBusinessoverview_423562"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Business overview</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>51
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#COrganizationalstructure_547242"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#COrganizationalstructure_547242"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Organizational structure</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DPropertyplantandequipment_216484"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DPropertyplantandequipment_216484"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Property, plant and equipment</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM4AUNRESOLVEDSTAFFCOMMENTS_165300"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;4A. UNRESOLVED STAFF COMMENTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOperatingresults_63656"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOperatingresults_63656"><font style="display:inline;">Operating Results Overview</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BLiquidityandCapitalResources_983984"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BLiquidityandCapitalResources_983984"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Liquidity and Capital Resources</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>96
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CResearchanddevelopmentpatentsandlicense"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CResearchanddevelopmentpatentsandlicense"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development, patents and licenses, etc. </font></a>&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>98
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DTrendinformation_783559"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DTrendinformation_783559"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trend information</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>98
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EOffbalancesheetarrangements_755138"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">E.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EOffbalancesheetarrangements_755138"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Off-balance sheet arrangements</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FTabulardisclosureofcontractualobligatio"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">F.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FTabulardisclosureofcontractualobligatio"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Tabular disclosure of contractual obligations</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#GSafeharbor_499863"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">G.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#GSafeharbor_499863"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Safe harbor</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADirectorsandseniormanagement_808607"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADirectorsandseniormanagement_808607"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Directors and senior management</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BCompensation_794417"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BCompensation_794417"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compensation</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CBoardpractices_426435"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CBoardpractices_426435"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Board practices</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DEmployees_175966"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DEmployees_175966"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Employees</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>108
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EShareownership_483404"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">E.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EShareownership_483404"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share ownership</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM7MAJORSHAREHOLDERSANDRELATEDPARTYTRA"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AMajorshareholders_620742"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AMajorshareholders_620742"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Major shareholders</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>109
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BRelatedpartytransactions9_456724"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BRelatedpartytransactions9_456724"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Related party transactions</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>111
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CInterestsofExpertsandCounsel_818925"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CInterestsofExpertsandCounsel_818925"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Interests of Experts and Counsel</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM8FINANCIALINFORMATION_64979"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;8. FINANCIAL INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AConsolidatedstatementsandotherfinancial"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AConsolidatedstatementsandotherfinancial"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements and other financial information</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>112
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BSignificantchanges_185362"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BSignificantchanges_185362"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Significant changes</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM9THEOFFERANDLISTING_267929"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;9. THE OFFER AND LISTING</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOfferingandlistingdetails_190546"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AOfferingandlistingdetails_190546"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Offering and listing details</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BPlanofdistribution_97425"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BPlanofdistribution_97425"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Plan of distribution</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CMarkets_438402"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CMarkets_438402"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Markets</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DSellingshareholders_783512"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DSellingshareholders_783512"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Selling shareholders</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EDilution_544617"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">E.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#EDilution_544617"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dilution</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FExpensesoftheissue_66157"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">F.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FExpensesoftheissue_66157"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Expenses of the issue</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>113
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">i</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #auto;">
			<tr>
				<td valign="top" style="width:09.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM10ADDITIONALINFORMATION_596766"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;10. ADDITIONAL INFORMATION</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ASharecapital_719569"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ASharecapital_719569"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share capital</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BMemorandumandarticlesofassociation_9543"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BMemorandumandarticlesofassociation_9543"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Memorandum and articles of association</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CMaterialcontracts_131115"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CMaterialcontracts_131115"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Material contracts</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DExchangecontrols_281790"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DExchangecontrols_281790"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Exchange controls</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ETaxation_990591"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">E.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ETaxation_990591"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Taxation</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>114
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FDividendsandpayingagents_639992"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">F.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#FDividendsandpayingagents_639992"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dividends and paying agents</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#GStatementbyexperts_865754"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">G.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#GStatementbyexperts_865754"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Statement by experts</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#HDocumentsondisplay_350959"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">H.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#HDocumentsondisplay_350959"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Documents on display</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ISubsidiaryinformation_389287"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">I.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ISubsidiaryinformation_389287"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Subsidiary information</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT RISK</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADebtsecurities_74825"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADebtsecurities_74825"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Debt securities</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BWarrantsandrights_600411"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BWarrantsandrights_600411"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Warrants and rights</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#COthersecurities_767426"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#COthersecurities_767426"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other securities</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DAmericanDepositaryShares_935554"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DAmericanDepositaryShares_935554"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">American Depositary Shares</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>132
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#PARTII_649967"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">PART&nbsp;II</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM13DEFAULTSDIVIDENDARREARAGESANDDELIN"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADefaults_106395"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADefaults_106395"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Defaults</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BArrearsanddelinquencies_781930"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BArrearsanddelinquencies_781930"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Arrears and delinquencies</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AUseofProceeds_969111"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AUseofProceeds_969111"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Use of Proceeds</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM15CONTROLSANDPROCEDURES_67132"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;15. CONTROLS AND PROCEDURES</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADisclosureControlsandProcedures_332106"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ADisclosureControlsandProcedures_332106"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Disclosure Controls and Procedures</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>133
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BManagementsAnnualReportonInternalContro"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">B.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#BManagementsAnnualReportonInternalContro"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CAttestationReportoftheRegisteredPublicA"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">C.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#CAttestationReportoftheRegisteredPublicA"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Attestation Report of the Registered Public Accounting Firm</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:09.28%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DChangesinInternalControloverFinancialRe"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">D.</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:82.52%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#DChangesinInternalControloverFinancialRe"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Changes in Internal Control over Financial Reporting</font></a></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16RESERVED_65925"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16. [RESERVED]</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16AAuditcommitteefinancialexpert_894"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16A. Audit committee financial expert</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16BCodeofethics_579954"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16B. Code of ethics</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16CPrincipalAccountantFeesandService"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16C. Principal Accountant Fees and Services</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>134
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16DExemptionsfromthelistingstandards"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16D. Exemptions from the listing standards for audit committees</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16EPurchasesofequitysecuritiesbythei"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16E. Purchases of equity securities by the issuer and affiliated purchasers</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16FChangeinregistrantscertifyingacco"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16F. Change in registrant&#x2019;s certifying accountant</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16GCorporategovernance_414333"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16G. Corporate governance</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM16HMinesafetydisclosure_355779"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;16H. Mine safety disclosure</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#PARTIII_169335"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">PART&nbsp;III</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM17Financialstatements_88089"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;17. Financial statements</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM18Financialstatements_944544"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;18. Financial statements</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>136
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="width:91.80%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ITEM19Exhibits_808635"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ITEM&nbsp;19. Exhibits</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>137
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Unless otherwise indicated or the context otherwise requires, all references in this Annual Report on Form&nbsp;20&#8209;F (the &#x201C;Annual Report&#x201D;) to &#x201C;Affimed N.V.&#x201D; or &#x201C;Affimed,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; &#x201C;ours,&#x201D; &#x201C;us&#x201D; or similar terms refer to Affimed N.V., together with its subsidiaries.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">TRADEMARKS</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9pt;font-size:5pt;top:-4pt;position:relative;line-height:106.67%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">is our registered trademark. The trademarks, trade names and service marks appearing in this Annual Report are property of their respective </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">owners.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ii</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">FORWARD-LOOKING STATEMENTS<a name="FORWARDLOOKINGSTATEMENTS_409206"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This Annual Report contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this Annual Report can be identified by the use of forward-looking words such as &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;could,&#x201D; &#x201C;expect,&#x201D; &#x201C;should,&#x201D; &#x201C;plan,&#x201D; &#x201C;intend,&#x201D; &#x201C;will,&#x201D; &#x201C;estimate&#x201D; and &#x201C;potential,&#x201D; among others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Forward-looking statements appear in a number of places in this Annual Report and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#x2019;s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified under the section &#x201C;Item&nbsp;3. Key Information&#x2014;D. Risk factors&#x201D; in this Annual Report. These risks and uncertainties include factors relating to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our operation as a development stage company with a history of operating losses; as of December&nbsp;31, 2019, our accumulated deficit was &#x20AC;234.5 million;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the chance our clinical trials may be delayed or put on clinical hold, for example, due to slower than expected enrollment or regulatory actions, or not be successful and clinical results may not reflect results seen in previously conducted preclinical studies and clinical trials, or expectations based on these preclinical studies and clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our reliance on contract manufacturers and contract research organizations over which we have limited control;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our lack of adequate funding to complete development of our product candidates and the risk we may be unable to access additional capital on reasonable terms or at all to complete development and begin commercialization of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our dependence on the success of AFM24 and AFM13 (which are still in clinical development)&nbsp;and certain of our other product candidates, &nbsp;each of which may eventually prove to be unsuccessful or commercially not exploitable;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">uncertainty surrounding whether any of our product candidates will gain regulatory approval, which is necessary before they can be commercialized;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the outcome of any, or any discussions we may enter regarding, acquisitions, dispositions, partnerships, license transactions or changes to our capital structure, including our receipt of any milestone payments or royalties or any future securities offerings;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the chance that we may become exposed to costly and damaging liability claims resulting from the testing of our product candidates in the clinic or in the commercial stage;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">if our product candidates obtain regulatory approval, our being subject to expensive ongoing obligations and continued regulatory overview;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval and commercialization;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">future legislation may materially impact our ability to realize revenue from any approved and commercialized products;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">iii</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the chance that our products may not gain market acceptance, in which case we may not be able to generate product revenues;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our reliance on our current strategic relationships with LLS, Merck, The MD Anderson Cancer Center, Genentech, Amphivena and the potential failure to enter into new strategic relationships;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our reliance on third parties to conduct our nonclinical and clinical trials and on third-party single-source suppliers to supply or produce our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our ability to scale-up manufacturing processes of our product candidates and reduce the cost of manufacturing our product candidates in advance of any commercialization;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our future growth and ability to compete, which depends on retaining our key personnel and recruiting additional qualified personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the length and severity of the COVID-19 outbreak and its impact on our business, including our supply chain, clinical trials and operations; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">other risk factors discussed under &#x201C;Item&nbsp;3. Key Information&#x2014;D. Risk Factors.&#x201D;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our actual results or performance could differ materially from those expressed in, or implied by, any forward-looking statements relating to those matters. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations, cash flows or financial condition. Additionally, some of the risks and uncertainties identified above may be amplified by the recent COVID-19 outbreak. It is not possible to predict or identify all such risks. There may be additional risks that we consider immaterial or which are unknown. Except as required by law, we are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">iv</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">PART&nbsp;I<a name="PARTI_999488"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS<a name="ITEM1IDENTITYOFDIRECTORSSENIORMANAGEMENT"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Directors and senior management<a name="ADirectorsandseniormanagement_586269"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Advisers<a name="BAdvisers_615943"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Auditors<a name="CAuditors_379140"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;2. OFFER STATISTICS AND EXPECTED TIMETABLE<a name="ITEM2OFFERSTATISTICSANDEXPECTEDTIMETABLE"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Offer statistics<a name="AOfferstatistics_226025"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Method and expected timetable<a name="BMethodandexpectedtimetable_217810"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;3. KEY INFORMATION<a name="ITEM3KEYINFORMATION_193122"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Selected Financial Data<a name="ASelectedFinancialData_875003"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The comprehensive loss and financial position data as of and for the&nbsp;years ended December&nbsp;31, 2015, 2016, 2017,&nbsp;2018 and 2019 of Affimed N.V. are derived from our consolidated financial statements. We maintain our books and records in euros, and we prepare our financial statements under International Financial Reporting Standards as issued by the International Accounting Standards Board (&#x201C;IFRS&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial information presented in the consolidated financial statements of Affimed N.V. for periods prior to the corporate reorganization on September&nbsp;17, 2014 is that of Affimed Therapeutics AG, Heidelberg, Germany, and its subsidiary.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This financial information should be read in conjunction with &#x201C;Item&nbsp;5&#x2014;Operating and Financial Review and Prospects&#x201D; and our consolidated audited financial statements, including the notes thereto, included in this Annual Report.</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:61.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated Statements of Comprehensive Loss Data For </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:61.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">the years ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in thousands of &#x20AC; except for per share data)</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 7,562</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 6,314</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,010</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 21,391</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other income/(expenses)&#x2014;net</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">651&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">145&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">205&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1,515&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">290&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (22,008)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,180)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (21,489)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (35,148)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (43,791)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">General and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (7,548)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (8,323)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (7,986)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,638)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (10,266)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating loss</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (21,343)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,044)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (27,260)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,536)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,376)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Finance income/(costs)&#x2014;net</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1,104&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (230)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,983)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">60&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">15&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss before tax</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (20,239)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,274)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,243)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,361)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">58&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">20&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (20,239)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,216)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (30,223)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (19,477)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,365)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (4,731)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (632)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (20,239)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,216)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (30,223)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (24,208)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Calibri;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,997)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Loss per share in &#x20AC; per share</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (0.71)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (0.97)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (0.69)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (0.32)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:2pt double #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (0.50)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="14" valign="bottom" style="width:61.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">As of December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2015</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2016</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2017</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:10.46%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">76,740&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">35,407&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">39,837&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">94,829&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">95,234&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Financial assets</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">9,487&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">13,974&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">8,902&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Total assets</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">79,322&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">48,739&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">43,158&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">116,174&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">112,359&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Total liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">12,048&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">9,988&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">11,579&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">76,045&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">73,692&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (120,228)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (152,444)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (182,667)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (202,144)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (234,508)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:36.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:left;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Total equity</font></p>
				</td>
				<td valign="bottom" style="width:02.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">67,274&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">38,751&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">31,579&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">40,129&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">38,667&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Capitalization and indebtedness<a name="BCapitalizationandindebtedness_313019"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Reasons for the offer and use of proceeds<a name="CReasonsfortheofferanduseofproceeds_9300"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Risk factors<a name="DRiskfactors_83889"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">You should carefully consider the risks and uncertainties described below and the other information in this Annual Report before making an investment in our common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common shares could decline and you could lose all or part of your investment. This Annual Report also contains forward-looking statements that involve risks and uncertainties. See &#x201C;Forward-Looking Statements.&#x201D; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">2</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">All of our product candidates are in preclinical or clinical development. Drug development is expensive, time consuming and uncertain, and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, the European Medicines Agency, or EMA, national competent authorities in Europe, including the Paul-Ehrlich-Institute or PEI, and other non-U.S. regulatory authorities, which establish regulations that differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical studies necessary to obtain regulatory approvals, including approval by the FDA or the European Commission. Obtaining approval of a BLA or a marketing authorization application can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA, EMA and other non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">restrictions on our ability to conduct clinical studies, including full or partial clinical holds, or other regulatory objections to ongoing or planned trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">restrictions on the products, manufacturers, or manufacturing process;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">warning letters;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">civil and criminal penalties;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">injunctions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">suspension or withdrawal of regulatory approvals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">product seizures, detentions or import bans;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">voluntary or mandatory product recalls and publicity requirements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">total or partial suspension of production;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">imposition of restrictions on operations, including costly new manufacturing requirements; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">refusal to approve pending BLAs or supplements to approved BLAs in the United States and refusal to approve marketing&nbsp;authorization applications in other jurisdictions.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The FDA, the EMA and other non-U.S. regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical studies that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a product candidate may not be deemed safe or effective;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">3</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the results may not confirm the positive results from earlier preclinical studies or clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory agencies may not find the data from preclinical studies and clinical studies sufficient or well-controlled;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;font-size:10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory agencies may change their approval policies or adopt new regulations.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For example, during the fourth quarter of 2018, the FDA concurred with our decision to place AFM11, a T cell-engaging bispecific antibody, on clinical hold after the occurrence of serious adverse events, or SAEs, in three patients, which included a death in the ALL study and two life-threatening events in the NHL study, and formally placed the AFM11 IND application on full clinical hold</font><font style="display:inline;">.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> We subsequently discontinued the development of AFM11.&nbsp;Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our share price.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, even if regulatory approval is granted, pricing and reimbursement may not be achieved due to a multitude of factors, including formulary restrictions, health service providers not considering the benefit to patients of a new medicine to be sufficient to support reimbursement, as well as others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier trials may not be predictive of future trial results. If clinical studies of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have no history of conducting large-scale or pivotal clinical studies or commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our operations to date have been limited to financing and staffing our company, developing our technology and developing AFM13, AFM24, AFM11 (prior to the termination of such program) and our other product candidates. We have not yet successfully demonstrated an ability to complete a large-scale or pivotal clinical study, obtain</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">marketing approval, manufacture a commercial scale product or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing pharmaceutical products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If clinical studies for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay or restrict our receipt of any product revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">There have been significant developments in the highly dynamic field of immuno-oncology such as the earlier availability of product candidates or earlier approval of drugs for the same indications as our product candidates, which led us to adapt our clinical programs accordingly.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For example, in the past, the marketing authorization of Blincyto&#xAE; (blinatumomab) in acute lymphocytic leukemia, or ALL, and of anti-PD-1 antibodies in Hodgkin Lymphoma, or HL, resulted in delays in clinical study initiation and/or patient recruitment for our phase 1 trials of AFM11 in ALL and NHL, and the phase 2a investigator-sponsored trial (IST) of AFM13 in HL.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Certain clinical studies of our product candidates are sponsored by academic sites, which are known as ISTs. By definition, the financing, design, and conduct of such studies are under the responsibility of the academic site sponsor.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Therefore, we have limited control over these studies and we do not have control over the timing and reporting </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">4</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of the data from these trials. In addition, we may have limited information about ISTs while they are being conducted, including the timing of planned trial initiation, the status of patient recruitment, changes to trial design, and clinical study results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A phase 2a IST of AFM13 in patients with relapsed/refractory HL started recruitment in the second quarter of 2015. Due to delays in opening trial sites and the availability of anti-PD1 antibodies for the treatment of relapsed/refractory HL patients, the study underwent slower than anticipated recruitment during its initial stages.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consequently, the overall study design was revised in order to adapt to the changing treatment landscape, namely the availability of anti-PD1 antibodies.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The study subsequently included HL patients relapsed or refractory to treatment with both Adcetris&#xAE; (brentuximab vedotin) and anti-PD1 antibodies. The study has now completed recruitment under the new study design. In addition, we conducted a phase 1b clinical study of AFM13 in combination with Merck&#x2019;s anti-PD1 antibody Keytruda&#xAE; (pembrolizumab) in patients with relapsed/refractory HL.</font><font style="display:inline;">&nbsp;In this study, we completed recruitment of a total of 30 patients, comprising a dose escalation cohort of 12 patients as well as an expansion cohort of an additional 18 patients. In addition, there is an ongoing IST of AFM13 in patients with CD30+ lymphoma led by Columbia University. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This translational phase 1b/2a study of AFM13 in patients with relapsed or refractory CD30+ lymphoma with cutaneous manifestations is designed to allow for serial biopsies, thereby enabling assessment of innate cell biology and tumor cell killing within the tumor microenvironment.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In March 2020, enrollment of all 15 patients was completed in this study.&nbsp;&nbsp;During the fourth quarter of 2018, we announced our registrational pathway and updated clinical development plans for AFM13</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">following discussions with the FDA. Following a lengthy review and approval process of a phase 2 clinical study protocol by the FDA in the first half of 2019, we initiated a phase 2 study in the fourth quarter of 2019 that will evaluate the efficacy and safety of AFM13 as monotherapy in patients with relapsed or refractory CD30 positive</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">peripheral T cell lymphoma, or PTCL, or transformed mycosis fungoides (TMF), a subset of cutaneous T cell lymphoma (CTCL). Based on the unmet medical need for safe and effective new treatments in these hard-to-treat populations and preliminary feedback from the FDA during an end of phase 1 meeting held in the fourth quarter of 2018, we believe that results from an open-label,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">single-arm phase 2 study could form the basis for a BLA submission and support a potential&nbsp;accelerated approval for patients with relapsed or refractory CD30 positive PTCL or TMF.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In October 2019, we announced the submission of an investigational new drug, or IND, application to the FDA to initiate a first-in-human phase 1/2a study of AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR) and CD16A-binding innate cell engager. The initial goal of the study is to determine the maximum tolerated dose and recommended phase 2 dose of AFM24, as well as to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced cancers known to express EGFR. The second part of the study will evaluate the preliminary efficacy of AFM24 in patients with select solid tumor subtypes. On November 7, 2019, our IND application for AFM24 cleared the required 30-day review period by the FDA and is in effect for a phase 1/2a clinical trial of AFM24 in patients with advanced cancers known to express EGFR. In April 2020, the first patient was successfully dosed in a first-in-human Phase 1/2a clinical trial of AFM24. At this stage, we cannot assure you of its safety or tolerability, or of its ability to demonstrate efficacy in humans.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The commencement of planned clinical studies could be substantially delayed or prevented by several factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">further discussions with the FDA, the EMA, the PEI (the national competent authority in Germany regulating, among others, antibody products) or other regulatory agencies regarding the scope or design of our clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the limited number of, and competition for, suitable sites to conduct our clinical studies, many of which may already be engaged in other clinical study programs, including some that may be for the same indication as our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">approval of drugs for the same indications as our product candidates;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">5</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">any delay or failure to obtain regulatory approval or agreement to commence a clinical study in any of the countries where enrollment is planned;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">inability to obtain sufficient funds required for a clinical study;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">clinical holds on, or other regulatory objections to, a new or ongoing clinical study;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">delay or failure in the testing, validation, manufacture and delivery of sufficient supplies of product candidate for our clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">delay or failure to reach agreement on acceptable clinical study agreement terms with prospective sites or clinical research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">delay or failure to obtain institutional review board, or IRB, or ethics committee approval to conduct a clinical study at a prospective site.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The completion of our clinical studies has been and could in the future be substantially delayed or prevented by several factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">slower than expected rates of patient recruitment and enrollment, due to factors including, but not limited to, the availability of other drugs to treat potential patients, the unwillingness of patients to participate in low-dose groups of dose-ranging studies and lack of recruitment by clinical study sites;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">delays relating to adding new clinical study sites;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure of patients to complete the clinical study or return for post-treatment follow-up;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure of our collaborators to provide us with products necessary for us to conduct our combination studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the FDA or other regulatory authorities requiring us to suspend or terminate a clinical study, or requiring us to submit additional data or imposing other requirements before permitting us to continue a clinical study;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">lack of efficacy during clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">errors in trial design or conduct;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">termination of our clinical studies by one or more clinical study sites;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">inability or unwillingness of patients or clinical investigators to follow our clinical study protocols, including clinical investigators&#x2019; failure to comply with our clinical study protocols without our notice;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">inability to monitor patients adequately during or after treatment by us and/or our CROs; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the need to repeat or terminate clinical studies as a result of inconclusive or negative results or unforeseen complications in testing.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical study protocols or submit new clinical study protocols to reflect these changes with appropriate </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">6</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory authorities. In addition, changes in the competitive environment have occurred and may continue to occur.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Amendments may require us to renegotiate terms with CROs or resubmit clinical study protocols to IRBs or ethics committees for re-examination, which may impact the costs, timing or successful completion of a clinical study.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our clinical studies may be suspended or terminated at any time by the FDA, the PEI, other regulatory authorities, the IRBs or ethics committees overseeing the clinical study at issue, any of our clinical study sites, or us, due to a number of factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure to conduct the clinical study in accordance with regulatory requirements or our clinical protocols;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">safety issues or any determination that a clinical study presents unacceptable health risks;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">lack of adequate funding to continue the clinical study due to unforeseen costs or other business decisions; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For example, during the fourth quarter of 2018, we placed AFM11, a T cell-engaging bispecific antibody, on clinical hold after the occurrence of SAEs in three patients, which included a death in the ALL study and two life-threatening events in the NHL study.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The SAEs occurred in patients enrolled in the highest dose cohorts of each study. Subsequently, we received a formal notification from the FDA that the regulatory agency has concurred with our decision to stop recruitment and formally placed the AFM11 IND application on full clinical hold.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In May 2019, we received notification from the FDA that additional data would be needed to determine whether the AFM11 clinical hold could be lifted. In line with the strategic focus on our innate immunity portfolio, we made the decision to terminate the phase 1 clinical programs of AFM11.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company took into consideration the competitive landscape of B-cell directed therapies currently in development and associated resources needed for further development of AFM11. We informed the FDA of our intention to terminate the AFM11 clinical program in its entirety.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our product development costs will increase if we experience delays in clinical studies or marketing approvals or if we are required to conduct additional clinical studies or other testing of our product candidates. We may be required to obtain additional funding to conduct and complete such clinical studies. We cannot assure you that our clinical studies will begin as planned or be completed on schedule, if at all, or that we will not need to restructure our trials after they have begun. Significant clinical study delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which may harm our business and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any failure or significant delay in completing clinical studies for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">The results of previous clinical studies may not be predictive of future results, our progress in trials for one product candidate may not be indicative of progress in trials for other product candidates and the results of our current and planned clinical studies may not satisfy the requirements of the FDA, the EMA or other non-U.S. regulatory authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical studies may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. We will be required to demonstrate with </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">7</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">substantial evidence through well-controlled clinical studies that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future larger registration clinical studies will be successful, because product candidates in later-stage clinical studies may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical studies. Product candidates that have shown promising results in early clinical studies may still suffer significant setbacks in subsequent registration clinical studies. Similarly, the outcome of preclinical testing and early clinical studies may not be predictive of the success of later clinical studies, and interim results of a clinical study do not necessarily predict final results. Progress in trials of one product candidate does not indicate that we will make similar progress in additional trials for that product candidate or in trials for our other product candidates. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical studies, even after obtaining promising results in earlier clinical studies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, the design of a clinical study can determine whether its results will support approval of a product and flaws in the design of a clinical study may not become apparent until the clinical study is well advanced. We may be unable to design and execute a clinical study to support regulatory approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical study participants. We do not know whether any phase 2, phase 3 or other clinical studies we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Further, our product candidates may not be approved even if they achieve their primary endpoints in phase 3 clinical studies or registration trials. The FDA, the EMA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from preclinical and clinical studies. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a clinical study. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical studies. The FDA, the EMA or other non-U.S. regulatory authorities may not accept the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We depend on enrollment of patients in our clinical studies for our product candidates. </font><font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">We compete with other sponsors who have ongoing clinical studies of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">investigational therapies for patients for our clinical studies. If we are unable to enroll patients in our clinical studies, our research and development efforts could be materially adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Successful and timely completion of clinical studies will require that we enroll a sufficient number of patients. Trials may be subject to delays as a result of patient enrollment taking longer than anticipated. Patient enrollment depends on many factors, including the size and nature of the patient population, eligibility criteria for the trial, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical studies, the availability of new drugs approved for the indication the clinical study is investigating, and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. In addition, we compete with approved immunotherapies and investigational immunotherapies for patients for our clinical studies. Our product candidate AFM13 has orphan drug designation for the treatment of HL, which means that the potential patient population is limited. Under the current, revised protocol of the German Hodgkin Study Group, or GHSG, phase 2a clinical study of AFM13, we have enrolled patients with relapsed/refractory HL who have been treated with Adcetris&#xAE; (brentuximab vedotin) and anti-PD1 antibodies, which is an even more limited population of patients. As we are developing AFM13 and certain of our other product candidates for patients for whom previous therapies have failed and who may not have long to live, patients may elect not to participate in our, or any, clinical study. The FDA has granted </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">8</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">orphan drug designation to AFM13 for the treatment of HL and T-cell lymphoma. The FDA&#x2019;s Orphan Drug Designation program grants orphan status to support development of medicines for underserved patient populations, or rare disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The approval of new immuno-oncology drugs such as checkpoint inhibitors (CPIs) has changed the landscape for conducting clinical studies of other oncology drugs, including ours, both for indications for which such drugs are approved as well as for indications in which additional trials are being conducted. In addition, there are several other types of drugs in development for the indications for which we are developing AFM13 and certain of our other product candidates. We compete for patients with the sponsors of trials for all of these drugs. These factors may make it difficult for us to enroll enough patients to complete our clinical studies in a timely and cost-effective manner.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For example, although the GHSG, phase 2a clinical study of AFM13 in patients with HL started recruitment in the second quarter of 2015, the study experienced slower recruitment than anticipated due to the availability of anti-PD-1 antibodies for the treatment of relapsed/refractory HL patients.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the current revised protocol of the GHSG phase 2a clinical study of AFM13, we have enrolled patients with relapsed/refractory HL who have been treated with Adcetris&#xAE; (brentuximab vedotin) and anti-PD1 antibodies, which is an even more limited population of patients.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Further delays in the completion of any clinical study of our product candidates will increase our costs, prolong our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">COVID-19 could adversely impact our business, including our supply chain, clinical trials and operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The recent outbreak of COVID-19 has evolved from a regional epidemic to a global pandemic, impacting almost every corner of the globe. The continued spread of COVID-19 is adversely impacting clinical and preclinical trials globally and in different therapeutic areas. As a result, our clinical trials or preclinical studies, including our ability to recruit and retain patients, principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be significantly impacted. In response to the COVID-19 pandemic, we are implementing mitigation procedures designed to enable us to address the various issues that may arise from the COVID-19 pandemic, although there can be no assurance that these procedures will be successful or that we can avoid a material and adverse disruption to our business. As the pandemic continues, we may experience the prioritization of hospital resources toward the outbreak and further restrictions on travel. Furthermore, some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines or travel restrictions impede patient movement or interrupt healthcare services. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">COVID-19 may also negatively affect the operations of third-party contract research organizations that we rely upon to carry out our clinical trials or the operations of our third-party manufacturers, each of which could result in delays or disruptions in the supply of our product candidates. While we do not currently believe our supply chain has been affected, there can be no assurances that we will not experience supply disruptions in the future. The negative impact COVID-19 has had and may continue to have on patient enrollment and treatment, and the timing and execution of our clinical trials could cause costly delays to our clinical trial activities, which could adversely affect our ability to obtain regulatory approval for and to advance towards commercialization, increase operating expenses and have a material adverse effect on our business and financial results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, COVID-19 has resulted in significant governmental measures being implemented to control the spread of the virus. Public health officials have recommended and mandated precautions to mitigate the spread of COVID-19, including prohibitions on congregating, traveling across borders, shelter-in-place orders and other similar measures. We have taken precautionary measures intended to help minimize the risk of the virus to our employees, including temporarily requiring some or all of our employees to work remotely, suspending all non-</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">9</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">essential travel and discouraging employee attendance at industry events and in-person work-related meetings. Such measures could negatively affect our business. For instance, temporarily requiring employees to work remotely may disrupt our operations or create unforeseen issues related to the use of technology designed to allow for remote communication and collaboration. The COVID-19 pandemic has also caused volatility in the global financial markets and has threatened a slowdown in the global economy, which may negatively affect our ability to raise additional capital on attractive terms or at all. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The full extent to which the COVID-19 pandemic may impact our business will depend on future developments, which are highly uncertain and cannot be predicted at this time. As such, we cannot presently predict the scope and severity of any potential business shutdowns or disruptions, the impacts on our business, financing or clinical trial activities or on the healthcare system and the global economy as a whole. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our innate cell engager product candidates in development are based on our fit-for-purpose ROCK&#xAE; (&#x201C;Redirected Optimized Cell Killing&#x201D;) platform and are capable of recruiting NK cells and / or macrophages. Regulatory approval of our product candidates is less certain than the approval of drugs that do not employ such novel technologies or methods of action. We intend to work closely with the FDA, the EMA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. For example, final assays and specifications of our product candidates, have yet to be developed, and the FDA, EMA or other regulatory authorities may require additional analyses to evaluate different aspects of our product quality. It is possible that the validation process may take time and resources, may require independent third-party analyses, or may not be accepted by the FDA, the EMA or other regulatory authorities. Delays or failure to obtain regulatory approval of any of the product candidates that we are developing would adversely affect our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Even if our product candidates obtain regulatory approval, they will be subject to continuous regulatory review.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If marketing authorization is obtained for any of our product candidates, the product will remain subject to continuous review and therefore authorization could be subsequently withdrawn or restricted. We will be subject to ongoing obligations and oversight by regulatory authorities, including adverse event reporting requirements, marketing restrictions and, potentially, other post-marketing obligations, all of which may result in significant expense and limit our ability to commercialize such products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a product or our manufacture of a product, or if we or one of our distributors, licensees or co-marketers fails to comply with regulatory requirements, the regulators could take various actions. These include imposing fines on us, imposing restrictions on the product or its manufacture and requiring us to recall or remove the product from the market. The regulators could also suspend or withdraw our marketing authorizations, requiring us to conduct additional clinical studies, change our product labeling or submit additional applications for marketing authorization. If any of these events occurs, our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at various cancers, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">10</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our share price.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Even if we obtain marketing approval of any of our product candidates in a major pharmaceutical market such as the United States or Europe, we may never obtain approval or commercialize our products in other major markets, which would limit our ability to realize their full market potential.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In order to market any products in a country or territory, we must establish and comply with numerous and varying regulatory requirements of such countries or territories regarding safety and efficacy. Clinical studies conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in all major markets could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical studies which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 2.2pt;line-height:100%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-style:italic;color:#000000;">In the United States, we may seek fast track designation of AFM13 and certain of our other product candidates, with the intent to pursue an accelerated approval pathway and potentially, breakthrough designation of AFM13 and/or certain of our other product candidates. There is no assurance that the FDA will grant such designations; and, even if it does grant such designations to AFM13 and/or certain of our other product candidates, such designation may not actually lead to a faster development or regulatory review or approval process and does not increase the likelihood that our product candidates will receive marketing approval in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on clinical data, either from ongoing or new clinical studies, we plan to seek fast track designation of AFM13 as a monotherapy and/or as a combination in relevant indications. In addition, we may seek fast track designation of certain of our other product candidates.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fast track program, a provision of the FDA Modernization Act of 1997, is designed to facilitate interactions between a sponsoring company and the FDA before and during submission of a BLA for an investigational agent that, alone or in combination with one or more other drugs, is intended to treat a serious or life-threatening disease or condition, and which demonstrates the potential to address an unmet medical</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">need for that disease or condition. Under the fast track program, the FDA may consider reviewing portions of a marketing application before the sponsor submits the complete application if the FDA determines, after a preliminary evaluation of the clinical data, that a product that has been granted fast track designation may be effective. A fast track</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">designation provides the opportunity for more frequent interactions with the FDA, and a product that has been granted fast track designation could be eligible for priority review if supported by clinical data at the time of submission of the BLA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The FDA is authorized to designate a product candidate as a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">11</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA are also eligible for accelerated approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The FDA has broad discretion whether or not to grant fast track or breakthrough designation. Accordingly, even if we believe one of our product candidates meets the criteria for fast track or breakthrough designation, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of fast-track or breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as fast track or breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may be unable to obtain orphan product designation or exclusivity for some of our product candidates. If our competitors are able to obtain orphan product exclusivity for their products in the same indications for which we are developing our product candidates, we may not be able to have our products approved by the applicable regulatory authority for a significant period of time. Conversely, if we obtain orphan drug exclusivity for some of our product candidates, we may not be able to benefit from the associated marketing exclusivity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. In the European Union, or the EU, the European Commission may designate a product candidate as an orphan medicinal product if it is a medicine for the diagnosis, prevention or treatment of life-threatening or very serious conditions that affect not more than five in 10,000 persons in the European Union, or it is unlikely that marketing of the medicine would generate sufficient returns to justify the investment needed for its development. We have received orphan drug designation for AFM13 for the treatment of HL in the United States and Europe, and for T-cell lymphoma in the US; but orphan drug status may not ensure that we have market exclusivity in a particular market and there is no assurance we will be able to receive orphan drug designation for certain of our other product candidates or any additional product candidates. Further, the granting of a request for orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which, subject to certain exceptions, precludes the FDA from approving the marketing application of another drug for the same indication for that time period or precludes the EMA, and other national drug regulators in the EU, from accepting the marketing application for another medicinal product for the same indication. The applicable period is seven&nbsp;years in the United States and ten&nbsp;years in the European Union. The EU period can be reduced to six&nbsp;years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. In the EU, orphan exclusivity may also be extended for an additional two&nbsp;years (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">i.e.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, a maximum of 12&nbsp;years&#x2019; orphan exclusivity) if the product is approved on the basis of a dossier that includes pediatric clinical study data generated in accordance with an approved pediatric investigation plan. Orphan drug exclusivity may be lost in the United States if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Even if we obtain orphan drug exclusivity for one or more of our products that exclusivity may not effectively protect the product from competition because exclusivity can be suspended under certain circumstances. In the United States, even after an orphan drug is approved, the FDA can subsequently approve another drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, orphan exclusivity will not </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">12</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">prevent a marketing authorization being granted for a similar medicinal product in the same indication if the new product is safer, more effective or otherwise clinically superior to the first product or if the marketing authorization holder of the first product is unable to supply sufficient quantities of the product.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our product candidates may result in serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our product candidates or following approval, if any, we may need to abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Although all of our product candidates have undergone or will undergo safety testing to the extent possible and agreed with health authorities, not all adverse effects of drugs can be predicted or anticipated. Immunotherapy and its method of action of harnessing the body&#x2019;s immune system, especially with respect to immune cell engagers, is powerful and could lead to serious side effects that we only discover in clinical studies. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if such side effects are rarer, after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. All of our product candidates are still in clinical or preclinical development. While our phase 1 clinical studies for AFM13 demonstrated a favorable safety profile, the results from ongoing and future trials of AFM13 or other NK cell-engaging bispecific antibodies may not confirm these results. During the fourth quarter of 2018, we placed AFM11, a T cell-engaging bispecific antibody, on clinical hold after the occurrence of SAEs in three patients, which included a death in the ALL study and two life-threatening events in the NHL study. The SAEs occurred in patients enrolled in the highest dose cohorts of each study. Subsequently, we received a formal notification from the FDA that the regulatory agency has concurred with our decision to stop recruitment and formally placed the AFM11 IND application on full clinical hold.&nbsp;In early March 2019, we submitted a complete response document to the FDA that summarizes the clinical data from the two AFM11 phase 1 studies to request that the clinical hold be lifted so that clinical development of AFM11 may proceed in ALL patients.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In May 2019, we received notification from the FDA that additional data would be needed to determine whether the AFM11 clinical hold could be lifted. In line with the strategic focus on our innate immunity portfolio, we made the decision to terminate the phase 1 clinical programs of AFM11.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company took into consideration the competitive landscape of B-cell directed therapies currently in development and associated resources needed for further development of AFM11. We informed the FDA of our intention to terminate the AFM11 clinical program in its entirety.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are developing our AFM13 and AFM24 product candidate for patients with relapsed or refractory HL, CD30+ lymphoma and EGFR+ solid tumor indications, respectively, for which other therapies have limited benefit and survival times may be short.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Therefore, we expect that certain patients may die during the clinical studies of our product candidates, and it may be difficult to ascertain whether such deaths are attributable to the underlying disease, complications from the disease, our product candidate, or a combination thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The results of&nbsp;ongoing and future clinical studies may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical studies, and result in the delay of, or failure to obtain, marketing approval from the FDA, the European Commission and other regulatory authorities, or result in marketing approval from the FDA, the European Commission and other regulatory authorities with restrictive label warnings or potential product liability claims. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the study, or make the product candidate less attractive for partnering. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, particularly outside of our existing or future collaborators as toxicities resulting from cancer immunotherapies are not normally encountered in the general patient population and by medical personnel. The inability to recognize and manage the potential side effects of our product candidates could result in patient deaths. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">13</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Additionally, if any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory authorities may require us to take our approved product off the market;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we may be required to change the way the product is administered, conduct additional clinical studies or change the labeling of the product;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we may be subject to limitations on how we may promote the product;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">sales of the product may decrease significantly;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we may be subject to litigation or product liability claims; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our reputation may suffer.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Adverse events in the field of immuno-oncology could damage public perception of our product candidates and negatively affect our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The commercial success of our products will depend in part on public acceptance of the use of cancer immunotherapies. SAEs and other adverse events in clinical studies of our product candidates or in clinical studies of others developing similar products and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for any products that we may develop. Although the mode of action of our innate cell engagers&nbsp;differs from that of other immuno-oncology approaches in development, the public may not always differentiate between our therapies and others in the field. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, our products may not be accepted by the general public or the medical community.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products. Any increased scrutiny could delay or increase the costs of obtaining regulatory approval for our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community and third-party payors, our revenue generated from their sales will be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">limitations or warnings contained in the approved labeling for a product candidate;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in the standard of care for the targeted indications for any of our product candidates;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">14</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">limitations in the approved clinical indications for our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">demonstrated clinical safety and efficacy compared to other products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">lack of significant adverse side effects;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">sales, marketing and distribution support;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">availability and extent of reimbursement from managed care plans and other third-party payors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">timing of market introduction and perceived effectiveness of competitive products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the degree of cost-effectiveness of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">whether the product is designated</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">under physician treatment guidelines as a first-line, second-line, third-line, or subsequent line of therapy for particular diseases;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">adverse publicity about our product candidates or favorable publicity about competitive products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">convenience and ease of administration of our products; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">potential product liability claims.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We are subject to manufacturing risks that could substantially increase our costs and limit supply of our product or prevent us from achieving a commercially viable production process.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The process of manufacturing our products is complex, highly regulated and subject to several risks, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We do not have experience in manufacturing our product candidates at commercial scale. We contract with external manufacturers to develop a larger scale manufacturing process for AFM13 in order to have material supply available for the registration directed phase 2b trial. We may not succeed in the scaling up the process to commercial scale. We may need a larger scale manufacturing process for certain of our product candidates than what we have planned, depending on the dose and regimen. Any changes in our manufacturing processes as a result of scaling up may result in the need to obtain additional regulatory approvals. Difficulties in achieving commercial-scale production or the need for additional regulatory approvals as a result of scaling up could delay the development and regulatory approval of our product candidates and ultimately affect our success.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We may not achieve the manufacturing productivity, or yield, required to achieve a commercially viable cost of goods. Our molecules are novel antibody structures and there is very limited knowledge as to which productivities can be achieved at commercial scale. Low productivities may result in a cost of goods which </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">15</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">are too high to allow profitable commercialization, or give rise to the need for additional manufacturing process optimization which would require additional funding and time.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The process</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of manufacturing biologics, such as AFM13 and certain of our other product candidates, is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, and difficulties in scaling up the production process. Even minor</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, health epidemics, power failures and numerous other factors.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We must comply with applicable current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, leading to significant delays in the availability of drug product for our clinical studies or the termination or hold on a clinical study, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our product candidates that have been produced and are stored for later use may degrade, become contaminated or suffer other quality defects, which may cause the affected product candidates to no longer be suitable for their intended use in clinical studies or other development activities. If the defective product candidates cannot be replaced in a timely fashion, we may incur significant delays in our development programs that could adversely affect the value of such product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, or if we fail to achieve adequate pricing and/or reimbursement we will not be successful in commercializing our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We currently have no marketing, sales and distribution capabilities because our lead product candidates are still in clinical development. If any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">16</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">addition, we may not be able to hire a sales force that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To the extent that we enter into collaboration agreements with respect to marketing, sales or distribution, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third-party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We may not be able to achieve the prices for our products that we may need for sustained profitability. In particular, there are different and changing reimbursement regulations in major market countries and other countries, and we might not be able to show the specific benefit or other requirements required for reimbursement or reimbursement at a specified pricing level in one or more jurisdictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, if we successfully develop combinations of our product candidates with other potentially expensive agents, the market may not allow for premium pricing of our products and hence may impair our ability to achieve profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals,&nbsp;recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or marketing approval or discovering, developing and commercializing products in our field before we do.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">There are many companies developing or marketing treatments for cancer disorders, including many major pharmaceutical and biotechnology companies. These treatments consist of small molecule drug products, biologic therapeutics that work, among others, either by using next-generation antibody technology platforms or new immunological approaches to address specific cancer targets, as well as genetically engineered cellular therapeutics. These treatments are often combined with one another in an attempt to maximize the response rate. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule, as we are.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Clinical phase 2 data with the anti-PD-1 CPIs nivolumab and pembrolizumab in HL have been published. These data indicate that treatment with anti-PD-1 antibodies results in high response rates in the salvage setting of HL. In 2016, the FDA granted accelerated approval, and the European Commission granted approval for nivolumab in classical HL patients who have relapsed or progressed after autologous hematopoietic stem cell </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">17</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;color:#000000;">transplantation and brentuximab vedotin (Adcetris&#xAE;). In 2017, the FDA granted accelerated approval, and the European Commission granted approval for pembrolizumab in adult and pediatric patients with refractory cHL who have relapsed after 3 or more prior lines of therapy, and the European Commission granted approval for pembrolizumab in adult patients with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin. Phase 2 and phase 3 studies of brentuximab vedotin in combination with nivolumab are ongoing. If AFM13 were to be approved for HL, we could be in competition with these therapies, as well as any other therapies or combination regimens that comprise the standard of care that AFM13 could potentially displace. Several other agents have reached proof of concept clinical studies in HL, including Afinitor (Novartis AG), and lenalidomide (Celgene).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">Bretuximab vedotin, or Adcetris&#xAE;, an antibody-drug conjugate targeting CD30, was approved by the FDA in relapsed/refractory HL in 2011. In addition, Adcetris&#xAE; was approved by the FDA in 2018 for the treatment of previously untreated Stage 3/4 cHL in combination with chemotherapy. In the European Union, Adcetris&#xAE; is approved for similar indications. Adcetris&#xAE; is also indicated for previously treated systemic anaplastic large cell lymphoma (ALCL), primary cutaneous ALCL, and CD30 positive mycosis fungoides, as well as for previously untreated systemic ALCL or other CD30 positive peripheral T-cell lymphomas in combination with chemotherapy in the US and for previously untreated systemic ALCL in Europe. Adcetris&#xAE; is currently being investigated in various combinations in HL, including checkpoint inhibitors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;color:#000000;">We expect that our ROCK&#xAE; platform as well as our novel antibody formats derived from this platform will serve as the basis for future product candidates and collaborations with pharmaceutical companies. Other companies also have developed platform technologies that compete with our platforms. For example, Dragonfly Therapeutics is developing TriNKET, which specifically activates cells of the innate and adaptive immune system and has recently started clinical development of one of these TriNKET assets. GT Biopharma is developing its TriKEs and TetraKEs platform designed to target natural killer cells and tumor cells forming an immune synapse between the NK cell and the tumor cell thereby inducing NK cell activation at that site, and recently started its clinical development.&nbsp;&nbsp;Compass Therapeutics is also developing bispecific antibodies that engage the innate immune system, but these have not yet reached the clinic.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain FDA, European Commission or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, our ability to compete in the future may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. In March&nbsp;2010, former President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Health Care Reform Law, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Health Care Reform Law also created a new regulatory scheme authorizing the FDA to approve biosimilars. Under the Health Care Reform Law, a manufacturer may submit an application for licensure of a biologic product that is &#x201C;biosimilar to&#x201D; or &#x201C;interchangeable with&#x201D; a previously approved biological product or &#x201C;reference product,&#x201D; without the need to submit a full package of preclinical and clinical data. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four&nbsp;years following approval of the reference product. The FDA may not approve a biosimilar product until 12&nbsp;years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical studies to demonstrate </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">18</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the safety, purity and potency of their product. Furthermore, recent legislation has proposed that the 12&#8209;year exclusivity period for each a reference product may be reduced to seven&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. The successful commercialization of our product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the United States, the European Union, its member states and some other foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system. These changes could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to sell profitably any products for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sale prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any therapeutic class. Cost-reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. If we successfully develop combinations of our product candidates with other potentially expensive agents, we may not achieve premium pricing for our products, which may impair our ability to achieve profitability. While the Medicare Modernization Act applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar reduction in payments from private payors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, the Health Care Reform Law, among other things, increased rebates a manufacturer must pay to the Medicaid program, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, established a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must provide 50% point-of-sale discounts on products covered under Part&nbsp;D and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Further, the new law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were enacted, which may affect our business practices with health care practitioners. The goal of the Health Care Reform Law is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the Health Care Reform Law may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. Subsequent to the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">19</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">2016 presidential election, some members of the U.S. Congress have been working to repeal the Health Care Reform Law. For example, since January&nbsp;2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Health Care Reform Law. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Health Care Reform Law. In addition, the Tax Cuts and the Jobs Act includes a provision that repeals, effective January&nbsp;1, 2019, the&nbsp;tax-based&nbsp;shared responsibility payment imposed by the Health Care Reform Law on certain individuals who fail to maintain qualifying health coverage for all or part of a&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Further, on June&nbsp;14, 2018 the United States Court of Appeals for the Federal Circuit ruled that the federal government was not required to pay more than $12.0 billion in Health Care Reform Law risk corridor payments to third-party payors. The effects of this gap in reimbursement on third-party payors, the viability of the Health Care Reform Law marketplace, providers, and our business, are not yet known. In addition, the Centers for Medicare and Medicaid Services, or CMS, have recently proposed regulations that would give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Health Care Reform Law for plans sold through such marketplaces. The Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Health Care Reform Law, effective January&nbsp;1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201C;donut hole.&#x201D; In July&nbsp;2018, the CMS published a final rule&nbsp;permitting further collections and payments to and from certain Health Care Reform Law qualified health plans and health insurance issuers under the Health Care Reform Law risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. Moreover, CMS issued a final rule&nbsp;in 2018 that will give states greater flexibility, starting in 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Health Care Reform Law for plans sold through such marketplaces. On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Health Care Reform Law, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the Health Care Reform Law are invalid as well. The Texas District Court Judge subsequently issued an order staying the judgment pending appeal, and both the Trump Administration and CMS have stated the ruling will have no immediate impact.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Because of the continued uncertainty about the implementation of the Health Care Reform Law, including the potential for further legal challenges or repeal of that legislation, we cannot quantify or predict with any certainty the likely impact of the Health Care Reform Law or its repeal on our business model, prospects, financial condition or results of operations, in particular on the pricing, coverage or reimbursement of any of our product candidates that may receive marketing approval. We also anticipate that Congress, state legislatures, and third-party payors may continue to review and assess alternative healthcare delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations effecting additional fundamental changes in the healthcare delivery system. We cannot assure you as to the ultimate content, timing, or effect of changes, nor is it possible at this time to estimate the impact of any such potential legislation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Moreover, other legislative changes have also been proposed and adopted in the United States since the Health Care Reform Law was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the&nbsp;years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of 2% per fiscal&nbsp;year, which went into effect on April&nbsp;1, 2013. On January&nbsp;2, 2013, former President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&nbsp;years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">20</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize any products for which we obtain marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Despite mandatory product liability insurances in the countries in which we are conducting our clinical studies, we cannot exclude that any claims will be brought against us or our collaborators although product liability claims by participants enrolled in our clinical studies will be usually covered by our insurances. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">decreased demand for our future approved products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">injury to our reputation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">withdrawal of clinical study participants;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">termination of clinical study sites or entire trial programs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">increased regulatory scrutiny;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">significant litigation costs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">substantial monetary awards to or costly settlement with patients or other claimants;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">product recalls or a change in the indications for which they may be used;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">loss of revenue;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">diversion of management and scientific resources from our business operations; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the inability to commercialize our product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#x2019; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have insurance, but our current insurance coverage and any additional coverage for further clinical studies may not be adequate to cover all liabilities that we may incur. We may need to increase and expand our </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">21</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our business may become subject to economic, political, regulatory and other risks associated with international operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our business is subject to risks associated with conducting business internationally. A number of our suppliers and collaborative and clinical study relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">differing regulatory requirements for drug approvals in non-U.S. countries;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">potentially reduced protection for intellectual property rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">difficulties in compliance with non-U.S. laws and regulations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in non-U.S. regulations and customs, tariffs and trade barriers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in non-U.S. currency exchange rates and currency controls;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in a specific country&#x2019;s or region&#x2019;s political or economic environment;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">negative consequences from changes in tax laws;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">workforce uncertainty in countries where labor unrest is more common than in the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">difficulties associated with staffing and managing international operations, including differing labor relations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">business interruptions resulting from geo-political actions, including war and terrorism, health epidemics (See &#x201C;&#x2014; COVID-19 could adversely impact our business, including our supply chain, clinical trials and operations.&#x201D;) or natural disasters including earthquakes, typhoons, floods and fires.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company&#x2019;s sole tax residency in Germany for purposes of the convention between Germany and the Netherlands for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on income (the &#x201C;German-Dutch tax treaty&#x201D;) is subject to the application of the provisions on tax residency as stipulated in the German-Dutch tax treaty as effective as of the date of this annual report. However, among others, Germany and the Netherlands</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">entered into a Multilateral Convention to Implement Tax Treaty Related Measures to Prevent Base Erosion and Profit Shifting (&#x201C;MLI&#x201D;). The MLI operates to amend bilateral tax treaties between participating states, provided there is a match between certain options made by the relevant states. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">22</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The MLI provides, amongst others, for an amendment of relevant rules regarding tax residency. According to provisional elections, the Netherlands applies such deviating rules</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">on tax residency, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">i.e.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, did not opt out. With regard to Germany, provisional statements made at the time of signing the MLI indicate that it is intended to opt-out of the application of such provisions. However, given that the MLI has to date not been ratified in Germany and the options provided for in the MLI remain subject to discussion, it cannot be ruled out that Germany ultimately opts to amend the current rules regarding tax residency in line with the option</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">exercised by the Netherlands. If Germany changed its provisional view on the election, the MLI rules on tax residency would become applicable to the German-Dutch tax treaty. In this case, the competent authorities of the Netherlands and Germany shall endeavour to determine by mutual agreement the sole tax residency of the Company. During the period in which a mutual agreement between both states is absent, the Company may not be entitled to any relief or</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">exemption from tax provided by the German - Dutch tax treaty. During such period, there would be a risk that both Germany and the Netherlands would levy dividend withholding tax, in addition to the risk of double taxation on the profits of the Company itself. If the sole tax residency is found to be in the Netherlands based on the mutual agreement, Dutch dividend withholding tax would apply exclusively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Exchange rate fluctuations or abandonment of the euro currency may materially affect our results of operations and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Potential future revenue may be derived from abroad, particularly from the United States. As a result, our business and share price may be affected by fluctuations in foreign exchange rates between the euro and these other currencies, which may also have a significant impact on our reported results of operations and cash flows from period to period, such as the US$. We have converted into euros only the portion of the proceeds from our financings and our research</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaboration and license agreement with Genentech that will be spent in euros according to our budget. If the projected payments in either euro or US$ change, we may be subject to foreign exchange-rate risk. Currently, we do not have any other exchange rate hedging measures in place.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Despite measures taken by the European Union to provide funding to certain EU member states in financial difficulties and by a number of European countries to stabilize their economies and reduce their debt burdens, it is possible that the euro could be abandoned in the future as a currency by countries that have adopted its use. This could lead to the re-introduction of individual currencies in one or more EU member states, or in more extreme circumstances, the dissolution of the European Union. The effects on our business of a potential dissolution of the European Union, the exit of one or more EU member states from the European Union or the abandonment of the euro as a currency, are impossible to predict with certainty, and any such events could have a material adverse effect on our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Future acquisitions, strategic investments, partnerships or alliances could be difficult to integrate and/or identify, divert the attention of key management personnel, disrupt our business, dilute shareholder value and/or adversely affect our financial results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We may consider entering into partnerships or into acquisitions of other companies, businesses, assets or technologies that are complementary to our business and operations as part of our growth strategy. Acquisitions, partnerships, alliances and subsequent integrations thereof would require significant managerial, operational and financial resources and could result in a diversion of resources from our existing business, which in turn could have an adverse effect on</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our growth and business operations. We must necessarily base any assessment of potential acquisitions, partnerships or alliances on assumptions with respect to operations, profitability and other matters that may subsequently prove to be incorrect. Future acquisitions and alliances, as well as other investments, may not produce anticipated synergies or perform in accordance with our expectations. The cost and duration of integrating newly acquired businesses could</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">also materially exceed our expectations. It is also possible that we may not identify suitable acquisition targets, strategic investments or partnership candidates. Our inability to identify such opportunities, or our inability to complete such transactions, may negatively affect our competitiveness and growth prospects. Any of these developments could have a material adverse effect on our business, financial condition and results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">23</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a clinical-stage immuno-oncology company. We have incurred significant losses since our inception. As of December 31, 2019, our accumulated deficit was &#x20AC;234.5&nbsp;million. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from general and administrative expenses that we have incurred while building our business infrastructure. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our shareholders&#x2019; equity and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA or the EMA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical studies or in the development of any of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">completing research and clinical development of our product candidates, including successfully completing registration clinical studies of AFM13 or certain of our other product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">obtaining marketing approvals for our product candidates, including AFM13 or AFM24, for which we complete clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">developing a sustainable and scalable manufacturing process for any approved product candidates and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate (in amount and quality) products to support clinical development and the market demand for our product candidates, if approved;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">launching and commercializing product candidates for which we obtain marketing approval, either directly or with a collaborator or distributor;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">establishing sales, marketing, and distribution capabilities in the United States, and potentially other major markets;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">obtaining market acceptance of our product candidates as viable treatment options;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">addressing any competing technological and market developments;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">24</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">identifying, assessing, acquiring and/or developing new product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">attracting, hiring and retaining qualified personnel.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Because of the numerous risks and uncertainties with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical studies, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical studies for each indication for each of our product candidates. We will require additional funding to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we anticipate that our existing liquidity will enable us to fund our operating expenses and capital expenditure requirements at least into the first half of 2022, assuming all of our programs advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our future funding requirements will depend on many factors, including but not limited to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the number and characteristics of other product candidates that we pursue;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the scope, progress, timing, cost and results of research, preclinical development, and clinical studies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the extent to which we acquire or in-license other products or technologies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our need and ability to hire additional management, scientific, and medical personnel;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">25</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the effect of competing products that may limit market penetration of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the amount and timing of revenues, if any, we receive from commercial sales of any product candidates for which we receive marketing approval in the future;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of achievement of milestones and receipt of any milestone or royalty payments under these agreements.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations or even go bankrupt.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue streams.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings, grants and licenses and development agreements in connection with any collaborations. We do not have any committed external source of funds. In the event we need to seek additional funds, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, our shareholders&#x2019; ownership interests will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect our shareholders&#x2019; rights as holders of our common shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November&nbsp;30, 2016, our subsidiary Affimed GmbH entered into a loan agreement with Silicon Valley Bank, a California corporation,&nbsp;or SVB, as lender, which we fully guarantee. The loan agreement provides us with a senior secured term loan facility for originally up to &#x20AC;10.0&nbsp;million, which agreement was amended in May&nbsp;2017 to provide that such amount would be available in three tranches. On December&nbsp;8, 2016, we fully drew down the initial tranche of &#x20AC;5.0&nbsp;million, and on May&nbsp;31, 2017 we drew down the second tranche of &#x20AC;2.5 million; the availability of the third tranche expired in September&nbsp;2017 with such amount remaining undrawn. In connection with such drawdowns, we issued SVB warrants to purchase 219,692 of our common shares, at a weighted-average exercise price of $2.07 per common share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, intellectual property or future revenue streams. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We have broad discretion in the use of our cash on hand and may not use it effectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019, we had &#x20AC;104.1&nbsp;million in cash and cash equivalents and current financial assets. Our management will have broad discretion in the use of such funds and could spend them in ways that do not improve our results of operations or enhance the value of our common shares. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">26</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">business, cause the price of our common shares to decline and delay the development of our product candidates. Pending their use, we may invest our cash and cash equivalents in a manner that does not produce income or that loses value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our ability to use our net operating loss carry forwards and other tax attributes may be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our ability to utilize our net operating losses, or NOLs, is currently limited, and may be limited further, under Section&nbsp;8c of the</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> &nbsp;K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (the German Corporation Income Tax Act) and Section&nbsp;10a of the</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> Gewerbesteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (the German Trade Tax Act). These limitations apply if a qualified ownership change, as defined by Section&nbsp;8c of the</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, occurs and no exemption is applicable. Generally, a qualified ownership change occurs if more than 50% of the share capital or the voting rights are directly or indirectly transferred to a shareholder or a group of shareholders within a period of five&nbsp;years. A qualified ownership change may also occur in case of an increase in capital leading to a respective change in the shareholding. In the case of such qualified ownership change all tax losses and tax loss carry forwards available as of the time of the ownership change, cannot be utilized in the future. However, to the extent that the tax losses and tax loss carry forwards do not exceed hidden reserves taxable in Germany or the qualified ownership change is made for purposes of the Company&#x2019;s restructuring (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">zum Zwecke der Sanierung</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), they may be further utilized despite a qualified ownership change. Furthermore, Section&nbsp;8c of the</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> is&#x2014;under strict requirements&#x2014;not applicable to a company provided that such company continues only those operations which are causing the loss (Section&nbsp;8d</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">). In addition, the question whether the aforementioned described provisions of Section&nbsp;8c of the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> do comply with the German constitution is currently pending with the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Bundesverfassungsgericht</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (German Supreme Court). On March&nbsp;29, 2017, the German Supreme Court ruled that Section&nbsp;8c of the&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">K&#xF6;rperschaftsteuergesetz </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">has not complied with the German constitution to the extent it formerly stated that a harmful ownership change should occur partially if more than 25% but less than 50% of the share capital or the voting rights are directly or indirectly transferred to a shareholder or a group of shareholders within a period of five&nbsp;years. As a consequence of this decision, the German legislator abolished such part of the provision.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019, we had estimated NOL carry forwards for German tax purposes of &#x20AC;199.2&nbsp;million. Future changes in share ownership may also trigger an ownership change and, consequently, a Section&nbsp;8c </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">K&#xF6;rperschaftsteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> or a Section&nbsp;10a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Gewerbesteuergesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> limitation. Any limitation may result in the expiration of a portion or the complete tax loss carry forwards before they can be utilized. As a result, if we earn net taxable income, our ability to use our pre-change NOL carry forwards to reduce German income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Our Dependence on Third Parties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our existing collaborations on research and development candidates are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, if these collaborations are not successful or if we fail to enter into new strategic relationships, our business could be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into collaborations with other companies that we believe have provided us with valuable funding or other resources such as access to technologies, including our collaborations with The Leukemia &amp; Lymphoma Society, Genentech, Merck, The MD Anderson Cancer Center, and our former collaboration and Amphivena. In the future, we may enter into additional collaborations to leverage our technology platforms, fund our research and development programs or to gain access to sales, marketing or distribution capabilities. Our existing collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may not perform their obligations as expected;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">27</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical study results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study or abandon a product candidate, repeat or conduct new clinical studies or require a new formulation of a product candidate for clinical testing;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If our collaborations on research and development candidates do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report also apply to the activities of our program collaborators. For example, Amphivena had entered into a warrant agreement with Janssen Biotech&nbsp;Inc. that gave Janssen the option to acquire Amphivena following IND acceptance by the FDA, upon predetermined terms, in exchange for payments under the warrant. Upon effectiveness of such IND application in July&nbsp;2016, Janssen decided to not exercise its option to purchase Amphivena, which could potentially be viewed as having negative implications for our business and prospects. We have been supporting the clinical development of Amphivena&#x2019;s product candidate. Additionally, subject to </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">28</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. These factors may include the design or results of clinical studies, the likelihood of approval by the FDA, the EMA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Collaborations are complex and time-consuming to negotiate and document.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Negotiation and diligence of potential partnerships, collaborations and alliances could require diversion of significant business resources, which could adversely impact our business operations. Furthermore, these negotiations and diligences may not eventually result in a signed agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Subject to certain specified exceptions, our former collaboration with Amphivena contains restrictions on our engaging in activities that were the subject of the collaboration with third parties for specified periods of time. These restrictions survived the expiration of the agreement in July&nbsp;2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">CROs and independent clinical investigators that we engage to conduct our clinical studies may not devote sufficient time or attention to our clinical studies or be able to repeat their past success.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical studies. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical studies. In addition, certain clinical studies in which we are involved and </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">29</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">which are testing our product candidates are sponsored by academic sites, known as</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">investigator-sponsored study, or ISTs. By definition, the financing, design, and conduct of the clinical study are under the sole responsibility of the respective sponsor. Therefore, we have limited control over these clinical studies and we do not have control over the timing and reporting of the data from these trials. In addition, we may have limited information about ISTs while they are being conducted, including the status of trial initiation and patient recruitment, changes to trial design and clinical study results.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The AFM13 phase 2a study in HL and the phase 1b/2a study in CD30+ lymphoma with cutaneous manifestations are ISTs. An AFM13 phase 1 IST is planned to be initiated by The MD Anderson Cancer Center with CD30+ lymphoma patients. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the completion of trials of our product candidates as well as</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA and other regulatory authorities require that we comply with standards, commonly referred to as current Good Clinical Practice, or cGCP, and other local legal</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">requirements, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">e.g</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">., data privacy, for conducting, recording and reporting clinical studies to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with cGCP procedures or other applicable legal requirements could adversely affect the clinical development of our product candidates and harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We contract with third parties for the manufacture of our product candidates for clinical testing in mono- and combination therapy settings and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products, or compounds of such third parties, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We anticipate continuing our engagement of contract manufacturing organizations to provide our clinical supply and internal capacity as we advance our product candidates into and through clinical development. We expect to use third parties for the manufacture of our product candidates for clinical testing, as well as for commercial manufacture. We plan to eventually enter into long-term supply agreements with several manufacturers for commercial supplies. We may be unable to reach agreement on satisfactory terms with contract manufacturers to manufacture our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Additionally, the facilities to manufacture our product candidates must be the subject of a satisfactory inspection before the FDA, the EMA or other regulatory authorities approve a BLA or grant a marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#x2019;s and the EMA&#x2019;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA, European Commission and other regulatory authorities&#x2019; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">30</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet supply demand for our products and could lose potential revenue. It may take several&nbsp;years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA, the EMA or any other relevant regulatory authorities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For our clinical development of AFM13 in combination with the anti-PD&#8209;1 Keytruda&#xAE; (pembrolizumab), we entered into an agreement with Merck pursuant to which Merck provided us with pembrolizumab to conduct a phase 1b clinical combination trial in relapsed/refractory HL. We were dependent on Merck for this supply of pembrolizumab. In addition, if we wish to pursue further development of AFM13 in combination with pembrolizumab or any other CPI, we will need to reach an agreement with Merck or another partner for such supply of pembrolizumab or another CPI, respectively. If we do not have an adequate supply and/or cannot reach an agreement with the applicable partner, we may not be able to develop AFM13 in such a combination. Any future supply agreement with a partner for combination trials with AFM13 could influence our clinical development strategy or our intellectual property or our economic rights, and therefore might impact the content we can derive from such clinical development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Our Intellectual Property</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of non-U.S. countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States and Europe. Because patent applications in the United States, Europe and many other non-U.S. jurisdictions are typically not published until 18&nbsp;months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States, Europe and in other non-U.S. countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We own and/or control our AFM13 patent portfolio, which includes two patent families. The first patent family on AFM13 consists of European patents relating to the use of the specific target combination for the treatment of cancer using a bispecific molecule and will expire in 2020. Our second patent family relates to the mode of action of AFM13, the recruitment of immune effector cells via a specific receptor, i.e., an antibody or antigen-binding fragment thereof having the complimentary determining regions of AFM13. These patents will expire in 2026 in Europe and in 2029 in the US. The latest patent application on AFM13 relates to its combination with anti-PD1 antibodies, and was filed in 2016. Moreover, we own and/or control our AFM24 patent portfolio, which includes one patent family directed to the compound of AFM24. The latest non-provisional patent application in such patent family was filed in 2019. Further, we own and/or control our AFM26 patent portfolio, which includes one patent family directed to the compound of AFM26. The latest non-provisional patent application in such patent family was filed in 2019.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">31</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous, or we may financially not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations for which legal principles remain unsolved. The standards which the United States Patent and Trademark Office, or USPTO, and its non-U.S. counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some non-U.S. countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these non-U.S. countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in non-U.S. jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Even after they have issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">32</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the U.S. Patent and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#x2019;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we might not have been the first to make the inventions covered by patents or pending patent applications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we might not have been the first to file patent applications for these inventions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we may not develop additional proprietary technologies that are patentable.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">33</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties&#x2019; patents;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#x2019;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management&#x2019;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">34</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">The patent protection and patent prosecution for some of our product candidates is dependent on third parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents relating to our product candidates are controlled by our licensors. Although we monitor&nbsp;&nbsp;the ongoing prosecution and maintenance of the licensed patents, if any of our future licensing partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering AFM13, AFM24, or any of our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">from making, using, and selling competing products</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our business may be adversely affected if we are unable to gain access to relevant intellectual property rights of third parties, or if our licensing partners terminate our rights in certain technologies that are licensed or sublicensed to us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We currently rely, and may in the future rely, on certain intellectual property rights licensed from third parties in order to be able to use various proprietary technologies that are material to our business. For example, the immune cell engager technology was developed under certain patents licensed exclusively to us by the German Cancer Research Center (known as the Deutsches Krebsforschungszentrum, or DKFZ, in German) under a 2001 license agreement,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">which was subsequently amended in 2006 and terminated in 2018 due to expiry of the last patent under this license agreement. Additionally, an antibody generated in the development of our immune cell engager candidates was developed using antibody phage display technologies licensed to us by Xoma Corporation. In March 2018, the last of the licensed Xoma patent rights expired. In each</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of these cases, the licensor retained their full ownership interest with respect to the licensed patent rights, and our rights to use the technologies associated with those patents and to employ the inventions claimed in the licensed patent rights were subject to the continuation of and our compliance with the terms of those licenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In some cases, we do not control the prosecution, maintenance or filing of the patents to which we hold licenses, and the enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents is subject to the control or cooperation of our licensors. We cannot be certain that our licensors will prosecute, maintain, enforce and defend the licensed patent rights in a manner consistent with the best interests of our business. We also cannot be certain that drafting or prosecution of the licensed patents by our licensors have been conducted in compliance with applicable laws and regulations and will result in valid and enforceable patents and other intellectual property rights.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">35</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a party to a number of agreements, including license agreements, through which we have gained rights to certain intellectual property that relate to our business and we expect to enter into additional such agreements in the future. We expect that future agreements will impose, various diligence, commercialization, milestone payment, royalty, and other obligations on us. Certain of our licenses contain provisions that allow the licensor to terminate the license upon the occurrence of specific events or conditions. For example, our rights under each of the licenses described above are subject to our continued compliance with the terms of the licenses, certain diligence and development obligations, the payment of royalties, milestone payments and other fees, and certain disclosure and confidentiality obligations. If we are found to be in breach of any of our license agreements, in certain circumstances our licensors may take action against us, including by terminating the applicable license. Because of the complexity of our product candidates and the patents we have licensed, determining the scope of the licenses and related obligations may be difficult and could lead to disputes between us and the licensor. An unfavorable resolution of such a dispute could lead to an increase in the royalties payable pursuant to the license or a termination of the license. If any of our licensors were to terminate our license agreement with them, we may be prevented from the continued use of certain technologies, in clinical studies or, if our products are approved for marketing, from using such technologies in the manufacturing of products that could be sold commercially. This could delay or prevent us from offering our product candidates. We might not have the necessary rights or the financial resources to develop, manufacture or market our current or future product candidates without the rights granted under these licenses, and the loss of sales or potential sales in such product candidates could have a material adverse effect on our business, financial condition, results of operations and prospects.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under certain of our agreements, our licensors have the right to convert an exclusive license to a non-exclusive license upon the expiration of the initial exclusivity period or upon the occurrence of certain events. Such a conversion would potentially allow third parties to practice the technologies licensed under the agreement, and could materially adversely affect the value of the product candidate we are developing under the agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition to the above risks, certain of our intellectual property rights are sublicenses under intellectual property owned by third parties. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For example, we sometimes collaborate with U.S. and non-U.S. academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our applicable product candidate or program.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">36</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, to the extent a confidentiality obligation is not covered by their employment agreements, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#x2019;s relationship with us be kept confidential and not disclosed to third parties and the public domain, so that it cannot be used for patent protection anymore, either by local law or if not applicable pursuant to specific agreements with employees and our personnel policies it is intended that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements or may not comply with their terms or with local law. Thus, despite such legal provisions or agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these legal provisions or agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not an employee of us and thus not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#x2019;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">37</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various non-U.S. patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various non-U.S. patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules&nbsp;applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States and Europe. In addition, the laws of some countries outside the United States and Europe, such as China, do not protect intellectual property rights to the same extent as federal and state laws in the United States and laws in Europe. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States and Europe, or from selling or importing products made using our inventions in and into the United States, Europe or other jurisdictions. As part of ordinary course prosecution and maintenance activities, we determine whether and in which countries to seek patent protection outside the United States and Europe. This also applies to patents we have acquired or in-licensed from third parties. In some cases this means that we, or our predecessors in interest or licensors of patents within our portfolio, have sought patent protection in a limited number of countries for patents covering our product candidates. Competitors may use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States and Europe. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Many companies have encountered significant problems in protecting and defending intellectual property rights in jurisdictions outside the United States and Europe. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, the reproduction of our manufacturing or other know-how or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in jurisdictions outside the United States and Europe, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">38</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Certain of our employees and patents are subject to German law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Approximately 90 of our personnel, including our managing directors and most of our employees working in research and development, work in Germany and are subject to German employment law. Ideas, developments, discoveries and inventions made by such employees are subject to the provisions of the German Act on Employees&#x2019; Inventions (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Arbeitnehmererfindungsgesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), which regulates the ownership of, and compensation for, inventions made by employees. We face the risk that disputes may occur between us and our employees or ex-employees pertaining to the sufficiency of compensation paid by us, allocation of rights to inventions under this act or alleged non-adherence to the provisions of this act, any of which may be costly to resolve and take up our management&#x2019;s time and efforts whether we prevail or fail in such dispute.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If we do not obtain protection under the Hatch-Waxman Amendments and similar non-U.S. legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&nbsp;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our information technology systems could face serious disruptions that could adversely affect our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations with our partners and delays in our research and development work.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Legal Compliance Matters</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Because we and our suppliers are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities which may adversely affect our business and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our operations, including our research, development, testing and manufacturing activities, are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of, and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. If we fail to comply with such laws and regulations, we could be subject to fines or other sanctions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">39</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, our production and development efforts may be interrupted or delayed and our financial condition and results of operations may be materially adversely affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The third parties with whom we contract to manufacture our product candidates are also subject to these and other environmental, health and safety laws and regulations. Liabilities they incur pursuant to these laws and regulations could result in significant costs or in certain circumstances, an interruption in operations, any of which could adversely impact our business and financial condition if we are unable to find an alternate supplier in a timely manner.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA or EMA regulations, to provide accurate information to the FDA or the EMA or intentional failures to report financial information or data accurately or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Compliance Management System (comprising the code of conduct and the compliance policy) which is based on three pillars: prevent, detect and respond to misconduct and an insider trading policy, each of which is communicated on a regular basis. However, it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We are subject to governmental regulation and other legal obligations in the EU and European Economic Area, or EEA, related to privacy, data protection and data security. Our actual or perceived failure to comply with such obligations could harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are subject to diverse laws and regulations relating to data privacy and security in the EU and eventually in the EEA, including Regulation 2016/679, known as the GDPR. The GDPR applies extraterritorially and implements stringent operational requirements for controllers and processors of personal data. New global privacy rules are being enacted and existing ones are being updated and strengthened. We are likely to be required to expend capital and other resources to ensure ongoing compliance with these laws and regulations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Complying with these numerous, complex and often changing regulations is expensive and difficult. Failure by us, any partners, our service providers, or our employees or contractors to comply with the GDPR could result in regulatory investigations, enforcement notices and/or fines of up to the higher of &#x20AC;20 million or up to 4% of our total worldwide annual revenue. In addition to the foregoing, a breach of privacy laws or data security laws, particularly those resulting in a significant security incident or breach involving the misappropriation, loss or other unauthorized use or disclosure of sensitive or confidential patient or consumer information, could have a material adverse effect on our business, reputation and financial condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a data controller, we are accountable for any third-party service providers we engage to process personal data on our behalf, including our clinical research organizations, or CROs. We attempt to mitigate the associated risks by performing security assessments and due diligence of our vendors and requiring all such third-party providers with data access to sign agreements and obligating them to only process data according to our instructions and to take sufficient security measures to protect such data. There is no assurance that these contractual measures and our own privacy and security-related safeguards will protect us from the risks associated with the third-party processing, storage and transmission of such information. Any violation of data or security laws by our third-party processors could have a material adverse effect on our business and result in the fines and penalties outlined above.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">40</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Where we transfer personal data out of the EU and EEA, we do so in compliance with the relevant data export requirements from time to time. There is currently ongoing litigation challenging the commonly used transfer mechanism, the EU Commission approved model clauses. In addition, the U.S. Privacy Shield (a mechanism for complying with data protection requirements when transferring personal data from the EU to the U.S.) is currently under review by the European Commission. As such, it is uncertain whether the Privacy Shield framework and/or model clauses will be invalidated in the near future. These changes may require us to find alternative bases for the compliant transfer of personal data outside the EEA and we are monitoring developments in this area.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are also subject to evolving European privacy laws on cookies and on e-marketing. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation, which will be directly implemented in the laws of each European member state. The draft e-Privacy Regulation imposes strict opt-in marketing rules with limited exceptions for business-to-business communications, alters rules on third-party cookies, web beacons and similar technology and significantly increases fining powers to the greater of &#x20AC;20 million or 4% of total worldwide annual revenue. While the e-Privacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process and commentators now expect it to be adopted during the second half of 2020 or during 2021 following a transition period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We process personal data in relation to participants in our clinical trials in the EEA, including the health and medical information of these participants. The GDPR is directly applicable in each EU Member State, however, it provides that EU Member States may introduce further conditions, including limitations which could limit our ability to collect, use and share personal data (including health and medical information), or could cause our compliance costs to increase, ultimately having an adverse impact on our business. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and implement policies as part of its mandated privacy governance framework. It also requires data controllers to be transparent and disclose to data subjects (in a concise, intelligible and easily accessible form) how their personal information is to be used, imposes limitations on retention of personal data; defines for the first time pseudonymized (i.e., key-coded) data; introduces mandatory data breach notification requirements; and sets higher standards for data controllers to demonstrate that they have obtained valid consent for certain data processing activities. In addition to the foregoing, a breach of the GDPR could result in regulatory investigations, reputational damage, orders to cease/change our use of data, enforcement notices, as well potential civil claims including class action type litigation where individuals suffer harm.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Relating to Employee Matters and Managing Growth</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are highly dependent on the research and development, clinical and business development expertise of our managing directors and other key employees. We have entered into multi-year executive agreements with our managing directors. If any of our managing directors or other key employees becomes unavailable to perform services for us, we may not be able to find a qualified replacement in a timely fashion, which could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. The contracts with our current managing directors, Dr. Adi Hoess, and Dr. Wolfgang Fischer, run until the end of the general meeting in 2020. We do not maintain any key man insurance for our managing directors at this time. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We recently made two key appointments with Dr. Andreas Harstrick joining us as our Chief Medical Officer in March 2020 and Dr. Arndt Schottelius joining us as our Chief Scientific Officer in April 2020. Our Supervisory Board has nominated Dr. Harstrick and Dr. Schottelius for appointment to our Management Board during our annual general meeting in 2020. Denise Mueller, our Chief Business Officer, has also been nominated by our Supervisory Board for appointment to our Management Board. Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will continue to be critical to our success.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">41</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing managing directors and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We will need to grow our organization, specifically to expand our development, and regulatory capabilities, and we may experience difficulties in managing this growth, which could disrupt our operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have 137 employees (128 full time equivalents), including those of our subsidiaries. As our development and commercialization plans and strategies develop, we expect to expand our employee base on an as-needed basis. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Risks Related to Our Common Shares</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our share price has been and may in the future be volatile, which could cause holders of our common shares to incur substantial losses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">You should consider an investment in our common shares as risky and invest only if you can withstand a significant loss and wide fluctuations in the market value of your investment. Our share price has been and in the future may be subject to substantial price volatility. In addition, the stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of pharmaceutical, biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the market price of our common shares to fluctuate include:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">results and timing of our clinical studies and clinical studies of our competitors&#x2019; products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure or discontinuation of any of our development programs;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">issues in manufacturing our product candidates or future approved products;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">42</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">regulatory developments or enforcement in the United States and non-U.S. countries with respect to our product candidates or our competitors&#x2019; products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure to achieve pricing and/or reimbursement;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">competition from existing products or new products that may emerge;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">developments or disputes concerning patents or other proprietary rights;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">introduction of technological innovations or new commercial products by us or our competitors;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in estimates or recommendations by securities analysts, if any cover our common shares;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">public concern over our product candidates or any future approved products;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">litigation;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">future sales of our common shares;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">additions or departures of key personnel;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changes in the structure of health care payment systems in the United States or overseas;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure of any of our product candidates, if approved, to achieve commercial success;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">economic and other external factors or other disasters or crises, including health epidemics;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">general market conditions and market conditions for biopharmaceutical stocks; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">overall fluctuations in U.S. equity markets.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our shareholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely affect the price of the shares and dilute shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Future sales of a substantial number of our common shares, or the perception that such sales will occur, could cause a decline in the market price of our common shares. We had 76,249,901 common shares outstanding as of April 28, 2020. If our existing shareholders sell substantial amounts of common shares in the public </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">43</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">market, or the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital through an issue of equity securities in the future could be adversely affected. In addition, we have registered on a Form S-8 registration statement all common shares that we may issue under our equity compensation plans. As a result, these shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also entered into a registration rights agreement upon consummation of our initial public offering pursuant to which we have agreed under certain circumstances to file a registration statement to register the resale of the common shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On October&nbsp;22, 2018, we filed a shelf registration statement on Form&nbsp;F&#8209;3 for the potential offer and sale by us of up to $150&nbsp;million of our common shares, senior debt securities, subordinated debt securities, warrants, purchase contracts or units. The registration statement was declared effective by the SEC on November&nbsp;7, 2018. Because the price per share of each share sold under the registration statement will depend on the market price of our shares at the time of the sale and other market conditions, it is not possible at this stage to predict the number of shares that ultimately may be offered and sold under the registration statement. If we sell common shares, convertible securities or other equity securities, existing shareholders may be diluted by such sales, and in certain cases new investors could gain rights superior to our existing shareholders. Any sales of our common shares, or the perception that such sales could occur, could have a negative impact on the trading price of our shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules&nbsp;and are subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we are subject to Dutch laws and regulations with regard to such matters and intend to furnish quarterly financial information to the U.S. Securities and Exchange Commission, or SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act, (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time and (iii)&nbsp;the rules&nbsp;under the Exchange Act requiring the filing with the SEC of quarterly reports on Form&nbsp;10&#8209;Q containing unaudited financial and other specified information, or current reports on Form&nbsp;8&#8209;K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form&nbsp;20&#8209;F until four&nbsp;months after the end of each fiscal&nbsp;year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form&nbsp;10&#8209;K within 75&nbsp;days after the end of each fiscal&nbsp;year. Foreign private issuers are also exempt from Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">As a foreign private issuer and as permitted by the listing requirements of Nasdaq, we follow certain home country governance practices rather than the corporate governance requirements of Nasdaq.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a foreign private issuer. As a result, in accordance with the listing requirements of The Nasdaq Global Market, or Nasdaq, we follow home country governance requirements and certain exemptions thereunder rather than comply with the corporate governance requirements of Nasdaq. In accordance with Dutch law and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule&nbsp;5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">44</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">stock. Although we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice will vary from the requirement of Nasdaq Listing Rule&nbsp;5620(b). As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule&nbsp;5605(d), which requires, inter alia, an issuer to have a compensation committee that consists entirely of independent directors, and Nasdaq Listing Rule&nbsp;5605(e), which requires independent director oversight of director nominations. Also, Dutch law does not require that we disclose information regarding third party compensation of our directors or director nominees. As a result, our practice varies from the third-party compensation disclosure requirements of Nasdaq Listing Rule&nbsp;5250(b)(3). In addition, we have opted out of shareholder approval requirements, as included in the Nasdaq Listing Rules, for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Rule&nbsp;5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. Accordingly, you may not have the same protections afforded to shareholders of companies that are subject to these Nasdaq requirements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#x2019;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. If in the future we are not a foreign private issuer as of the end of the second fiscal quarter in any fiscal&nbsp;year, we would be required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers in the subsequent fiscal&nbsp;year. In order to maintain our current status as a foreign private issuer, either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i)&nbsp;a majority of our managing directors or supervisory directors may not be United States citizens or residents, (ii)&nbsp;more than 50&nbsp;percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United States. If we were to lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules&nbsp;and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules&nbsp;and regulations could also make it more difficult for us to attract and retain qualified supervisory directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Failure to comply with Nasdaq continued listing requirements may result in our common shares being delisted from Nasdaq.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If our stock price falls below $1.00 per common share, we may not continue to qualify for continued listing on Nasdaq. To maintain listing, we are required, among other things, to maintain a minimum closing bid price of $1.00 per common share. If the closing bid price of our common shares is below $1.00 per share for 30 consecutive business&nbsp;days, we will receive a deficiency notice from Nasdaq advising us that we have a certain period of time, typically 180&nbsp;days, to regain compliance by maintaining a minimum closing bid price of at least $1.00 for at least ten consecutive business&nbsp;days, although Nasdaq could require a longer period.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">45</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The delisting of our common shares would significantly affect the ability of investors to trade our common shares and negatively impact the liquidity and price of our common shares. In addition, the delisting of our common shares could materially adversely impact our ability to raise capital on acceptable terms or at all. Delisting from Nasdaq could also have other negative results, including the potential loss of confidence by our current or prospective collaboration partners and third-party service providers, the loss of institutional investor interest, and fewer licensing and partnering opportunities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We do not anticipate paying cash dividends, and accordingly, shareholders must rely on stock appreciation for any return on their investment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We currently intend to retain our future earnings, if any, to fund the development and growth of our businesses. As a result, capital appreciation, if any, of our common shares will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The trading market for our common shares depends on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our shares or change their opinion of our shares, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We are a Dutch public company with limited liability. The rights of our shareholders may be different from the rights of shareholders in companies governed by the laws of U.S. jurisdictions and may not protect investors in a similar fashion afforded by incorporation in a U.S. jurisdiction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a Dutch public company with limited liability (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">naamloze vennootschap</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) organized under the laws of the Netherlands. Our corporate affairs are governed by our Articles of Association and by the laws governing companies incorporated in the Netherlands. However, there can be no assurance that Dutch law will not change in the future or that it will serve to protect investors in a similar fashion afforded under corporate law principles in the United States, which could adversely affect the rights of investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The rights of shareholders and the responsibilities of managing directors and supervisory directors may be different from the rights and obligations of shareholders and board members in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our management board and supervisory board are required by Dutch law to consider the interests of our company, its shareholders, its employees and other stakeholders, in all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our authorized share capital increased as of June&nbsp;19, 2018, following an amendment of our Articles of Association approved by a resolution of the general meeting of shareholders. Our authorized share capital currently amounts to &#x20AC;3,119,500, divided into 155,975,000 common shares, each with a nominal value of &#x20AC;0.01 and 155,975,000 cumulative preferred shares, each with a nominal value of &#x20AC;0.01.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Provisions of our Articles of Association or Dutch corporate law might deter acquisition bids for us that might be considered favorable and prevent or frustrate any attempt to replace or remove the then management board and supervisory board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Certain provisions of our Articles of Association may make it more difficult for a third party to acquire control of us or effect a change in our management board or supervisory board. These provisions include: staggered </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">46</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">maximum four-year terms of our supervisory directors; a provision that our managing directors and supervisory directors may only be removed by the general meeting of shareholders by a two-thirds majority of votes cast representing more than 50% of our outstanding share capital (unless the removal was proposed by the supervisory board); and a requirement that certain matters, including an amendment of our Articles of Association, may only be brought to our shareholders for a vote upon a proposal by our management board that has been approved by our supervisory board.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, our articles of association include, in addition to the common shares, a class of cumulative preferred shares. Currently, our management board has not been authorized by the general meeting of shareholders to issue (or grant the right to acquire) cumulative preferred shares. If the general meeting of shareholders would grant such authorization to the</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">management board, then the management board, subject to approval of the supervisory board, could decide to use such cumulative preferred shares as an anti-takeover measure. If implemented following a shareholder authorization to the management board, this anti-takeover measure would have the effect of making a takeover of us more difficult or less attractive and as a result, our shareholders could be unable to benefit from a change of control and realize any</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">potential change of control premium. This could materially and adversely affect the market price of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">We are not obligated to and do not comply with all the best practice provisions of the Dutch Corporate Governance Code. This may affect your rights as a shareholder</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a Dutch company we are subject to the Dutch Corporate Governance Code, or DCGC. The DCGC contains both principles and best practice provisions that regulate relations between the management board, the supervisory board and the shareholders (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">i.e.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, the general meeting of shareholders). The DCGC is based on a &#x201C;comply or explain&#x201D; principle. Accordingly, companies are required to disclose in their annual reports, filed in the Netherlands, whether they comply with the provisions of the DCGC. If they do not comply with those provisions (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">e.g.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, because of a conflicting Nasdaq requirement), the company is required to give the reasons for such non-compliance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including Nasdaq. We do not comply with all the best practice provisions of the DCGC. The DCGC was revised as per January 1, 2017, and in our annual report for the fiscal year ended December 31, 2019, we will report on our compliance with this revised Code. This may affect your rights as a shareholder and you may not have the same level of protection as a shareholder in a Dutch company that fully complies with the DCGC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Claims of U.S. civil liabilities may not be enforceable against us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are incorporated under the laws of the Netherlands, and our headquarters are located in Germany. Substantially all of our assets are located outside the United States. The majority of our managing directors and supervisory directors reside outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon such persons or to enforce against them or us in U.S. courts, including judgments predicated upon the civil liability provisions of the federal securities laws of the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may submit to the Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the jurisdiction of the U.S. court has been based on grounds which are internationally acceptable, that the proceedings before the U.S. court complied with principles of proper procedures, that recognition and/or enforcement of such judgment would not contravene the public policy of the Netherlands, and that recognition and/or enforcement of the judgment is not irreconcilable with a decision </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">47</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of a Dutch court rendered between the same parties or with an earlier decision of a foreign court rendered between the same parties in a dispute that is about the same subject matter and that is based on the same cause, provided that earlier judgment can be recognized in the Netherlands, the court of the Netherlands will, in principle, give binding effect to the judgment of the U.S. court. Dutch courts may deny the recognition and enforcement of punitive damages or other awards on the basis that recognition and enforcement would contravene public policy of the Netherlands. Moreover, a Dutch court may reduce the amount of damages granted by a U.S. court and recognize damages only to the extent that they are necessary to compensate actual losses or damages. In addition, there is doubt as to whether a Dutch court would impose civil liability on us, our managing directors or supervisory directors or certain experts named herein in an original action predicated solely upon the U.S. federal securities laws brought in a court of competent jurisdiction in the Netherlands against us or such directors or experts, respectively. Enforcement and recognition of judgments of U.S. courts in the Netherlands are solely governed by the provisions of the Dutch Civil Procedure Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The United States and Germany currently do not have a treaty providing for the reciprocal recognition and enforcement of judgments, other than arbitration awards, in civil and commercial matters. Consequently, a final judgment for payment given by a court in the United States, whether or not predicated solely upon U.S. securities laws, would not automatically be recognized or enforceable in Germany. German courts may deny the recognition and enforcement of a judgment rendered by a U.S. court if they consider the U.S. court not to be competent or the decision not in line with German public policy principles. For example, recognition of court decisions based on class actions brought in the United States typically raises public policy concerns and judgments awarding punitive damages are generally not enforceable in Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, actions brought in a German court against us, our managing directors or supervisory directors, our senior management and the experts named herein to enforce liabilities based on U.S. federal securities laws may be subject to certain restrictions. In particular, German courts generally do not award punitive damages. Litigation in Germany is also subject to rules&nbsp;of procedure that differ from the U.S. rules, including with respect to the taking and admissibility of evidence, the conduct of the proceedings and the allocation of costs. Proceedings in Germany would have to be conducted in the German language and all documents submitted to the court would, in principle, have to be translated into German. For these reasons, it may be difficult for a U.S. investor to bring an original action in a German court predicated upon the civil liability provisions of the U.S. federal securities laws against us, our managing directors or supervisory directors, our senior management and the experts named in this Annual Report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on the lack of a treaty as described above, U.S. investors may not be able to enforce against us or managing directors or supervisory directors, officers or certain experts named herein who are residents of the Netherlands, Germany, or other countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also impair our ability to raise revenue, result in the loss of investor confidence in the reliability of our financial statements and subject us to regulatory scrutiny and sanctions, which in turn could harm the market value of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">48</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are required to disclose changes made in our internal controls and procedures and our management is required to assess the effectiveness of these controls annually. As September 17, 2019 represented the fifth anniversary of the date of the first sale of our common shares pursuant to an effective registration statement under the Securities Act, we no longer qualify as an &#x201C;emerging growth company&#x201D; as defined in the JOBS Act, commencing December 31, 2019.</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a result, our independent registered public accounting firm is required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#x2019;s assessment might not. Undetected material weaknesses</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Changes in accounting standards could impact our results.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The IASB, or other regulatory bodies, periodically introduce modifications to financial accounting and reporting standards or issue new financial accounting and reporting standards under which we prepare our consolidated financial statements. These changes can materially impact the means by which we report financial information, affecting our results of operations. Also, we could be required to apply new or revised standards retroactively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">More specifically, several new or amended standards and interpretations to IFRS are expected over the coming&nbsp;years. In particular, both IFRS 9 &#x201C;Financial Instruments&#x201D; and IFRS 15 &#x201C;Revenues from Contracts with Customers&#x201D; went into effect on January&nbsp;1, 2018 and IFRS 16 &#x201C;Leases&#x201D; went into effect on January&nbsp;1, 2019. With respect to the first time adoption of IFRS 9 and IFRS 15, any transition effects are described in note 3 to the consolidated financial statements as of December&nbsp;31, 2018. With respect to IFRS 16, during 2018, we </font><font style="display:inline;">completed the assessment of the impact of IFRS 16 on our consolidated financial statements and have identified our leases including contractual payments, renewal options and other terms. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any transition effects are described in note 4 to our consolidated financial statements as of December 31, 2019. The first time adoption of IFRS 16 has not substantially affected our results of operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Although we do not believe we were a &#x201C;passive foreign investment company&#x201D; (a &#x201C;PFIC&#x201D;) in 2019, we may be a PFIC in <a name="_cp_text_1_7"></a>2020 or one or more&nbsp;future taxable&nbsp;years. A U.S. investor may suffer adverse U.S. federal income tax consequences if we are a PFIC for any taxable&nbsp;year during which the U.S. investor holds common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year in which, after the application of certain &#x201C;look-through&#x201D; rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#x201C;passive income,&#x201D; or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of, &#x201C;passive income.&#x201D; Passive income generally includes interest,&nbsp;dividends, rents, certain non-active royalties and capital gains. Although we have not performed a definitive PFIC analysis using U.S. federal income tax principles, based on certain estimates as to composition of our income and assets, including the implied value, based on our market capitalization, of our assets that produce non-passive income, during 2019, we do not believe that we were a PFIC for our 2019 taxable year. However, there can be no assurance&nbsp;that the Internal Revenue Service, or the IRS, will agree with our conclusion. In addition, whether we will be a PFIC in 2020 or any future taxable year is uncertain because, among other things, we currently own a substantial amount of passive assets, including cash, and because the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time and the composition of&nbsp;our income may vary substantially over time. The average quarterly value of our assets for purposes of determining our PFIC status for any taxable year will generally be determined in part by reference to our market capitalization, which has fluctuated and may continue to fluctuate significantly over time. Accordingly, there can be no assurance that we will not be a PFIC for any future taxable year. In addition, we may, directly or indirectly, hold equity interests&nbsp;in other entities, including certain of our subsidiaries that are PFICs, or &#x201C;Lower-tier PFICs.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">If we are a PFIC for any taxable year during which a U.S. investor holds common shares, we generally will continue to be treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds common shares, even if we cease to meet the threshold requirements for PFIC status. Such </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">49</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">a U.S. investor may be subject to adverse tax consequences, including (i) the treatment of all or a portion of any gain on disposition as ordinary&nbsp;income, (ii) the application of a deferred interest charge on such gain and the receipt of certain dividends and (iii) compliance with certain reporting requirements. To avoid the application of the foregoing rules, a U.S. investor can make an election to treat us and each Lower-tier PFIC as a qualified electing fund (a &#x201C;QEF Election&#x201D;) in the first taxable year that we and each Lower-tier PFIC are treated as PFICs with respect to the U.S. investor. We currently&nbsp;intend to provide the information necessary for a U.S. investor to make a QEF Election with respect to us and each Lower-tier PFIC that we control for 2020 and for any future years with respect to which we determine that we or any Lower-tier PFIC that we control are or are likely to be a PFIC. A U.S. investor can also avoid certain of the adverse U.S. federal income tax consequences described above by making a mark-to-market election with respect to its&nbsp;common shares, provided that the common shares are &#x201C;marketable.&#x201D; U.S. investors should consult their tax advisers regarding the availability and advisability of making a QEF Election or a mark-to-market election in their particular circumstances. See &#x201C;Material U.S. Federal Income Tax Considerations&#x201D; for further information regarding the consequences to a U.S. investor if we are a PFIC for any taxable year during which the U.S. investor holds common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;4. INFORMATION ON THE COMPANY<a name="ITEM4INFORMATIONONTHECOMPANY_954084"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;History and development of the company<a name="AHistoryanddevelopmentofthecompany_71562"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a clinical-stage immuno-oncology&nbsp;company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates represent an innovative approach to cancer treatment that seeks to harness the body&#x2019;s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (Natural Killer cells, or NK cells, and macrophages) and T cells. Leveraging our fit-for-purpose ROCK&#xAE; platform, we develop proprietary, next-generation bispecific antibodies, so-called innate cell engagers, which are designed to direct innate immune cells and establish a bridge to cancer cells. Our innate cell engagers have the ability to bring innate immune cells into the proximity of tumor cells and trigger an activation cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture with four binding domains, our innate cell engagers bind to their targets with high affinity. Different dosing schemes are being explored to allow for improved exposure in heavily pretreated patient populations. Based on their mechanism of action as well as the preclinical and clinical data we have generated to date, we believe that our product candidates as monotherapy and / or in combination, may ultimately improve response rates, clinical outcomes and survival in cancer patients, and could eventually become a cornerstone of modern targeted oncology care. Building on our leadership in the innate cell engager space, we are also developing novel antibody formats with the potential to tailor innate cell-engaging therapy to different indications and settings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed was founded in 2000 based on technology developed by the group led by Professor Melvyn Little at Deutsches Krebsforschungszentrum (DKFZ), the German Cancer Research Center, in Heidelberg, Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Focusing our efforts on antibodies that specifically bind to innate cells through CD16A, a key activating receptor, we have built a clinical and preclinical pipeline of innate cell-engaging bispecific antibodies designed to activate both innate and adaptive immunity. Compared to a variety of T cell-engaging technologies, our innate cell engagers appear</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">to have a better safety profile and have the potential to achieve more potent and deeper immune responses potentially through enhancing crosstalk of innate to adaptive immunity. The safety profiles of our molecules make them suitable for development as combination therapies (e.g. with checkpoint inhibitors, or CPIs, adoptive NK cells or cytokines).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are focusing our research and development efforts on two programs, for which we retain full global commercial rights, AFM13 and AFM24. Because our tetravalent bispecific antibodies can be engineered to bind to different antigens that are known to be present on various cancer cells, our product candidates could be developed for the treatment of different cancer indications. We intend to clinically develop our two product candidates to treat high-</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">medical need indications, including as a salvage therapy for patients who have relapsed after treatment with standard therapies, or patients who are refractory to these therapies, meaning they do not respond to treatment with standard therapies, whom we collectively refer to as relapsed/refractory </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">50</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">patients. These patients have a limited life expectancy and few therapeutic options. We believe this strategy will allow for a faster path to approval and will likely require</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">smaller clinical studies compared to indications with more therapeutic options and larger patient populations. We believe such specialized market segments in oncology can be effectively targeted with a small and dedicated marketing and sales team. We currently intend to establish a commercial sales force in the United States and/or Europe to commercialize our product candidates when and if they are approved.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also see an opportunity in the clinical development of our innate cell engagers in combination with other agents that harness the immune system to fight cancer cells, such as CPIs, adoptive NK cell transfer and cytokines. Such combinations of cancer immunotherapies may ultimately prove beneficial for larger patient populations in earlier stages of diseases, beyond the relapsed/refractory disease setting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our main offices and laboratories are located at the Technology Park adjacent to the German Cancer Research Center (DKFZ) in Heidelberg, where we employ 90 people, approximately 62% of whom have an advanced academic degree. Including AbCheck (see description below) and Affimed Inc. personnel, our total headcount is 137 (128 full time equivalents). We are led by experienced executives with a track record of successful product development, approvals and launches, specifically in the area of biologics and biopharmaceuticals. Our supervisory board is made up of highly experienced experts from the pharmaceutical and biotech industries, including individuals with a background and expertise in hematological malignancies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2009, we formed AbCheck s.r.o., our 100% owned, independently run antibody screening platform company, located in the Czech Republic. AbCheck is devoted to the generation and optimization of fully human antibodies. Its technologies include a na&#xEF;ve human antibody library combined with phage and yeast display antibody library, a proprietary algorithm to optimize affinity, stability and manufacturing efficiency and a mass humanization technology</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">to discover and optimize high-quality human antibodies. In addition to providing candidates for Affimed projects, AbCheck is recognized for its expertise in antibody discovery throughout the United States and Europe and has been working with globally active pharmaceutical and biotechnology companies such as Tusk Therapeutics, bluebird bio, Eli Lilly, Daiichi Sankyo, Pierre Fabre, Icosagen and others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Business overview<a name="BBusinessoverview_423562"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our Strategy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our goal is to develop new treatment options for patients in need by activating innate immunity (e.g. NK cells and macrophages), the body&#x2019;s first line of defense, to fight cancer. We are developing single and combination therapies to treat a variety of cancers. Our novel proprietary antibody platform, ROCK&#xAE;, delivers several unique types of next-generation tetravalent antibody formats, including bispecific and trispecific innate cell engagers. Based on the</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">distinctive properties and mechanism of action of these products, which have demonstrated preclinical and / or clinical activity, we believe that our product candidates, alone or in combination, could eventually become a key element of improving clinical outcomes in cancer patients. Key elements of our strategy to achieve this goal are to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Rapidly advance the development of our clinical stage product candidates, including combinations with other agents and immunotherapies;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Establish R&amp;D and commercialization capabilities in Europe and in the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Use our technology platforms and intellectual property portfolio to continue to build our cancer immunotherapy pipeline;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Maximize the value of our collaboration arrangements with Genentech, LLS, Merck and MD Anderson;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">51</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intensify our collaboration with academia; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Utilize AbCheck to generate and optimize antibodies.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 10.8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our Strengths</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We believe we are a leader in developing cancer immunotherapies due to several factors:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our lead product candidate, AFM13, is a first-in-class innate cell engager;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our development candidate, AFM24, is a first-in-class innate cell engager for solid tumor indications;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our modular and versatile ROCK&#xAE; (Redirected Optimized Cell Killing) platform;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We retain global commercial rights for AFM13 and AFM24;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our experienced management team has a strong track record in the development and commercialization of new medicines; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have a strong technology base and solid patent portfolio in the field of targeted immuno-oncology.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Our Research and Development Pipeline</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are developing a pipeline of innate cell engagers for the treatment of cancer as shown below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f001.jpg" style="width: 6.499187in; height: 2.855198in" alt="Picture 1"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">14</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our lead candidate, AFM13, is a first-in-class innate cell engager designed for the treatment of certain CD30-positive (CD30+) malignancies including T cell lymphomas. AFM13 selectively binds to CD30, a clinically validated target, and CD16A, an integral membrane glycoprotein receptor expressed on the surface of NK cells and macrophages, triggering a signal cascade that leads to the destruction of CD30-positive tumor cells. In contrast to</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">conventional full-length antibodies, AFM13 does not bind to CD16B, which prevents binding to other cell types, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">e.g</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">., neutrophils, and binds with equal affinity to CD16A polymorphisms at position 158. Furthermore, AFM13 binds CD16A with an approximately 1000-fold higher affinity than monoclonal antibodies thereby significantly increasing potency and efficacy as preclinically demonstrated.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">52</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are currently investigating AFM13 as monotherapy and as combination therapy in relapsed/refractory CD30&#8209;positive lymphoma patients and relapsed/refractory HL patients.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the completed first-in-human phase 1 dose-escalation clinical study, AFM13 was well-tolerated and demonstrated tumor shrinkage or slowing of tumor growth, with disease control shown in 16 of 26 patients eligible for efficacy evaluation. AFM13 also demonstrated tumor shrinkage in patients who had relapsed after, or were refractory to Adcetris&#xAE; (brentuximab vedotin), a CD30-targeted chemotherapy approved by the FDA in August 2011 as a salvage</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">therapy for HL. Approximately half of the patients treated with Adcetris&#xAE; experienced disease progression in less than half a year after initiation of therapy. Six out of seven patients who became refractory to Adcetris&#xAE; as the immediate prior therapy experienced stabilization of disease under AFM13 treatment according to Cheson&#x2019;s criteria, standard criteria for assessing treatment response in lymphoma. We believe that based on its novel mode of action,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM13 may be beneficial to patients who have relapsed or are refractory to treatment with Adcetris&#xAE; and may provide more durable clinical benefit.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed also supports an IST led by GHSG. This phase 2a clinical study of AFM13 in patients with relapsed/refractory HL started recruitment in the second quarter of 2015. Due to delays in opening trial sites and the availability of anti-PD1 antibodies for the treatment of relapsed/refractory HL patients, the study underwent slower than anticipated recruitment during its initial stages. Consequently, the study design was revised to adapt to the</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">changing treatment landscape, namely the availability of anti-PD1 antibodies. The study subsequently included HL patients relapsed or refractory to treatment with both Adcetris&#xAE; (brentuximab vedotin) and anti-PD1 antibodies. The study has now completed recruitment under the new study design.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Furthermore, we have completed a phase 1b clinical study of AFM13 with Merck&#x2019;s anti-PD-1 antibody Keytruda&#xAE; (pembrolizumab) in HL. In this study, the combination was well-tolerated with most of the observed adverse events mild to moderate in nature and manageable with standard of care. Best response assessment data from 24 patients</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">treated at the highest AFM13 dose level (7 mg/kg) as reported by central read, showed an ORR of 88% (21 of 24 patients), including complete metabolic responses (CmR) of 46% (11 of 24 patients) and partial metabolic responses (PmRs) of 42% (10 of 24 patients). One patient experienced stable disease (SD).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are also supporting a phase 1b/2a IST of AFM13 in patients with relapsed or refractory CD30+ lymphoma led by investigators at Columbia University in New York. In addition to determining clinical efficacy, this translational study in patients with cutaneous manifestations is also designed to allow for serial biopsies, thereby enabling assessment of immunobiology and tumor cell killing within the tumor microenvironment. Enrollment for the study is completed. An</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">interim analysis of this study was recently presented. In 10 patients (dosed at 1.5-7.0 mg/kg) AFM13 was well-tolerated and showed therapeutic activity as a single agent, with an ORR of 50% (5 of 10 patients). In detail, one complete response (CR), four partial responses (PRs) and two stable diseases (SDs) were observed. An analysis of biomarker correlatives showed a decrease in circulating NK cells (CD56+ CD3- , CD56+ CD16+, NKp46+) during</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">therapy, with post-therapy recovery. In addition, increased CD69 expression on circulating NK cells from responders vs. non-responders was demonstrated. Tumor biopsies showed increased infiltration of CD56+ NK cells pre-therapy in responders compared to nonresponders, while circulating CD4+ CD25+ T cells (Tregs) decreased in responders compared to nonresponders. In order to prepare for further clinical development, we performed preclinical studies</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">investigating the combination of AFM13 with check-point modulators (CPMs) with collaboration partners. We believe that AFM13 and CPMs administered together could lead to greater tumor cell killing because these molecules may have a synergistic anti-tumor effect, involving both innate and adaptive immune cells. Based on preclinical data, we entered into a collaboration with Merck and initiated the clinical phase 1b study investigating the combination of</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM13 with Merck&#x2019;s anti-PD-1 antibody Keytruda&#xAE; (pembrolizumab) in patients with relapsed/refractory HL. In addition, the LLS committed to co-fund the development of AFM13 including its development as part of a combination therapy in June 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In December 2016, we entered into a clinical development and commercialization collaboration with MD Anderson to evaluate AFM13 in combination with MD Anderson&#x2019;s NK cell product. MD Anderson is responsible for conducting preclinical research activities, investigating cord blood-derived NK cells in combination with </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">53</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM13, followed by a phase 1 clinical study of the combination. In December 2018, preclinical data was presented at the American Society</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of Hematology Annual Meeting, outlining the successful approach of a novel premixed product, comprised of expanded cord-blood derived NK cells loaded with AFM13 to redirect their specificity against CD30+ tumor cells. The data showed that AFM13 can enhance efficacy on cord blood-derived NK cells both in vitro and in vivo. We fund</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">research and development expenses for this collaboration and hold an option for exclusive worldwide rights to develop and commercialize any product developed under the collaboration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In August 2018, we entered into a research collaboration and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of certain product candidates that contain novel NK cell engager-based immunotherapeutics to treat multiple cancers. We believe that our collaborations help to validate and more rapidly advance our discovery efforts, technology platforms and product candidates, and will enable us to</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">leverage our platforms through additional high-value partnerships. As part of our business development strategy, we aim to enter into additional research collaborations in order to derive further value from our platform and more fully realize its&nbsp;potential.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Together with the German Cancer Research Center (DKFZ), we published data presenting evidence of AFM13&nbsp;&nbsp;modulating NK cells by sensitizing them to IL-2 and/or IL-15 stimulation. In this study, after exposure to AFM13, NK cells showed improved IL-2- and IL-15-mediated proliferation and cytotoxicity. These data support the strategy of combining our innate cell engagers with IL-2- or IL-15 to potentially achieve stronger clinical responses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our second candidate, AFM24, is a tetravalent, bispecific epidermal growth factor receptor (EGFR)- and CD16A-binding innate cell engager. AFM24 is designed to address limitations, such as toxicities or treatment resistance, associated with current therapeutic anti-EGFR monoclonal antibodies, while also offering the potential for better efficacy and safety by using activation of innate immunity to target EGFR-expressing solid tumors rather than</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">inhibition of EGFR-mediated signal transduction. We have successfully completed a toxicology study of AFM24 in cynomolgus monkeys at a range of dose levels up to 75mg/kg over 4 weeks with no observed toxicities even at high dose levels, demonstrating AFM24&#x2019;s potential to have lower toxicities in humans compared to other EGFR-targeted therapeutics. In contrast, Cetuximab, an approved anti-EGFR antibody, revealed significant toxicity in the same dose-</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">range as that tested in the AFM24 toxicology study. On October 15, 2019, we announced the submission of an IND application to the FDA to initiate a first-in-human phase 1/2a study of AFM24 in patients with advanced cancers known to express EGFR. The initial goal of the study is to determine the maximum tolerated dose and recommended phase 2 dose of AFM24, as well as to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">efficacy. The second part of the study is designed to evaluate the preliminary efficacy of AFM24 in patients with select solid tumor subtypes. On November 7, 2019, the IND application for AFM24 cleared the required 30-day review by the FDA and is in effect. AFM24 has also received regulatory approval to commence a trial in the UK and in Spain. On April 16, 2020, we announced the successful dosing of the first patient in the phase 1/2a study of AFM24.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have also developed AFM26, a tetravalent, bispecific B cell maturation antigen (BCMA)- and CD16A-binding innate cell engager from our fit-for-purpose ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, as a novel approach to treat multiple myeloma. AFM26 employs a unique mechanism of action through high affinity engagement of NK cells that has demonstrated in vitro efficacy against cells with very low levels of BCMA expression. NK cell binding of AFM26 is largely unaffected by</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">IgG competition. In addition, AFM26 offers the opportunity for a combination with adoptive NK cell transfer, as it appears to have a favorable safety profile with lower cytokine release as compared to BiTE. In the third quarter of 2018, we successfully partnered AFM26 with an undisclosed partner, and no longer control its development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM11 is a T cell engager that we designed for the treatment of certain CD19+ B cell malignancies, including non-Hodgkin Lymphoma, or NHL and Acute Lymphocytic Leukemia, or ALL. We conducted two phase 1 clinical studies of AFM11, one in patients with relapsed/refractory NHL and one in patients with relapsed/refractory ALL. However, on October 8, 2018, we suspended enrollment in studies ofAFM11 after the occurrence of life-threatening or fatal</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">SAEs in three patients, which included two life threatening events in the NHL study and one </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">54</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">death in the ALL study. Subsequently, we received notification from the FDA that the regulatory agency formally placed the AFM11 IND application on full clinical hold. In line with the strategic focus on our innate immunity portfolio, we made the decision to terminate the phase 1 clinical programs of AFM11. The Company took into consideration the competitive landscape</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of B-cell directed therapies currently in development and associated resources needed for further development of AFM11. In 2019, we informed the FDA of our intention to terminate the AFM11 clinical program in its entirety.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Amphivena&#x2019;s product candidate, AMV564, is a CD33/CD3-specific T cell engager derived from our ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform. Amphivena is clinically developing AMV564 for the treatment of acute myeloid leukemia (AML), for which Amphivena has obtained Orphan Drug Designation, and other hematologic malignancies. In preclinical studies, AMV564 has demonstrated potent and selective cytotoxic activity in AML patient samples, as well as robust tumor</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">growth inhibition and a complete elimination of leukemic blasts in xenograft models. In July 2016, the IND application for AMV564 was accepted.&nbsp;&nbsp;Amphivena is conducting a phase 1 clinical study of AMV564 in relapsed or refractory AML. In June 2018, Amphivena reported initial data from this study. The data showed that AMV564 engages and activates T cells resulting in leukemic cytoreduction. Amphivena has also initiated a Phase 1 dose escalation study of</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AMV564 in myelodysplastic syndrome (MDS).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, we have selected two early stage innate cell engager candidates, AFM28 and AFM32, from our ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform for various undisclosed targets. The selection of the new development candidates followed our evaluation of oncology indications with a high level of innate immune cell activity, and where there was past clinical experience with therapeutic antibodies and antibody drug conjugates. We plan to advance one of these early stage candidates</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">into preclinical studies in 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">COVID-19</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In response to the recent COVID-19 pandemic, we have implemented mitigation procedures to ensure the safety of trial participants and healthcare professionals and that drug supply and other trial-related materials are ready and available for the patients enrolled in our clinical trials. We are closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of our global workforce and help</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">limit the spread of COVID-19, while maintaining business continuity. We mandated a work-from-home policy for all employees not involved in preclinical research, and adjusted operations for laboratory personnel at Affimed&#x2019;s headquarters in Heidelberg, Germany. In addition, we eliminated nonessential travel to minimize exposure to COVID-19. We will continue to work closely with clinical sites as well as</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">respective competent authorities to ensure the safety of trial participants and healthcare professionals, as well as the appropriate use of healthcare resources during the COVID-19 pandemic, while preserving the conduct and data integrity of our clinical studies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">At this time, our contract manufacturers are operating without interruption, and there is sufficient material for the AFM13 Phase 2 registration-directed study in pTCL, the investigator sponsored trial of cord blood-derived allogeneic natural killer (NK) cells in combination with AFM13, and the AFM24 Phase 1/2a clinical study. Additionally, we currently do not foresee any interruption in our ability to continue to</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">manufacture additional products to be used beyond the current ongoing clinical studies. Our assessment of the potential impact of the COVID-19 pandemic on patient enrollment and site activation in our clinical studies is ongoing and we will update trial timelines once we have more visibility on the length and extent of the COVID-19 crisis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Immune System and Cancer Background</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Immune System</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The human immune system is characterized by an early, nonspecific initial response called innate immunity, and a highly specific response adapted to pathogenic or tumorigenic antigenes called adaptive immunity. Although the human immune system is normally capable of recognizing foreign or aberrant cells, cancer cells have developed highly effective ways to escape the surveillance and defense mechanisms of the immune system. As a result, immune cells such as NK cells and macrophages (parts of the innate immune system) and </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">55</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T cells (a part of the adaptive immune system) cannot recognize tumor cells as foreign or aberrant and therefore cannot fight them.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">NK cells: NK cells are important mediators of the innate immune system and can display cytotoxic, or cell-killing, activity against &#x201C;altered self&#x201D; (virus-infected and cancerous) cells. They were named &#x201C;natural killers&#x201D; because they recognize altered structures without the need for antigen processing and presentation. NK cells possess a large number of receptors that activate NK cells to destroy deviant cells.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Macrophages: Macrophages are mature monocytes that are present in all tissues and patrol the body in order to engulf and digest microorganisms, dead cells or cellular debris in a process called phagocytosis. In this role they are an important first line of defense of innate immunity and very important for inducing inflammation, secreting signaling molecules and presenting antigens to adaptive immune cells, all being important for the induction of immune responses.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T cells: T cells are part of the adaptive immune system and only target cells that present an antigen on their surface which has been presented before to the T cells by so-called antigen-presenting cells, such as dendritic cells and macrophages. The antigen presentation triggers a biological cascade, resulting in the clonal expansion of antigen-specific T cells.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Increased understanding of the fundamentals of cellular and molecular tumor immunology has identified many ways by which the immune system can be augmented to treat cancer, including priming/boosting of the immune system, T cell modulation, reducing immunosuppression in the tumor microenvironment and enhancing adaptive immunity. This new area of medicine, termed cancer immunotherapy, has the potential to offer adaptable and durable cancer control across a variety of tumor types. Our ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform-based immune cell engagers enable a direct interaction of NK cells, macrophages or T cells with cancer cells on the level of single cells, leading to the destruction of the tumor cells.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Cancer</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of gene mutations, causing unregulated cell growth that leads to tumor formation. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">According to the American Cancer Society, cancer is the second most common cause of death in the United States. In the United States, more than 1.8 million new cases of cancer are expected to be diagnosed in 2020, and more than 606,000 deaths from cancer are expected to occur. The 5-year relative survival rate for all cancers diagnosed during 2009-2015 was 69%. According to a United States National Institute of Health National Cancer Institute estimate, national expenditures for cancer care in the United States in 2017 were approximately $147 billion.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. For patients with localized disease, surgery and radiation therapy are particularly effective. Drug therapies are generally used by physicians in patients who have cancer that has spread beyond the primary site or cannot otherwise be treated through surgery, such as most hematological malignancies. The goal of drug therapies is to damage and kill cancer cells or to interfere with the molecular and cellular processes that control the proliferation, growth and survival of cancer cells. In many cases, drug therapy entails the administration of several different drugs in combination. Over the past several decades, drug therapy has evolved from non-specific drugs that kill both healthy and cancerous cells, to drugs that target specific molecular pathways involved in cancer.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">56</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">An early approach to pharmacological cancer treatment was to develop drugs, referred to as chemotherapies or cytotoxic drugs, which kill rapidly proliferating cancer cells through mechanisms, such as stopping cell division, disrupting cell metabolism or causing damage to cellular components required for tumor survival and rapid growth. While these drugs have been effective in the treatment of some cancers, cytotoxic drug therapies act in an indiscriminate manner, killing healthy cells along with cancerous cells. Due to their mechanism of action, many cytotoxic drugs have a narrow therapeutic window, i.e., dose range above which the toxicity causes unacceptable or even fatal levels of damage and below which the drugs are not effective in eradicating cancer cells.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The next approach to pharmacological cancer treatment was to develop drugs, referred to as targeted therapeutics, including monoclonal antibodies, which are antibodies that derive from a single parent cell, that target specific biological molecules in the human body that play a role in cell growth and the spread of cancer. Included in this category are small molecule drugs as well as large molecule drugs, also known as biologics. With heightened vigilance and new diagnostic tests, targeted therapies (including monoclonal antibodies such as Herceptin&#xAE;, Rituxan&#xAE;, Erbitux&#xAE; and Avastin&#xAE; as well as small molecules such as Nexavar&#xAE; and Tarceva&#xAE;), have resulted in improvements in overall survival for many cancer patients. More recently, antibodies have been developed that are optimized regarding their effector function, also known as Fc optimized antibody drugs, for example obinutuzumab. These molecules are designed to engage NK cells and macrophages more effectively in the elimination of cancer cells.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cancer immunotherapy plays an increasing role among emerging cancer drug therapies. The intention is to harness the body&#x2019;s own immune system to fight tumor cells. There are different approaches: vaccinations, checkpoint modulators, T cell and innate cell engagers, for example, bispecific antibodies, or cellular therapies involving transforming patient&#x2019;s own T cells to express a specific chimeric antigen receptors (CARs). Ipilimumab (Yervoy&#xAE;), sipuleucel-T (Provenge&#xAE;), and more recently nivolumab (Opdivo&#xAE;), pembrolizumab (Keytruda&#xAE;), and blinatumomab (Blincyto&#xAE;) were amongst the first cancer immunotherapies to enter the market. Our platforms of bi- and trispecific antibodies add further promise to the field of immuno-oncology.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Our Technologies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have developed our proprietary fit-for-purpose ROCK&#xAE; antibody platform to enable the generation of first-in-class multivalent, multi-specific immune cell engagers. Our antibodies have been shown to retarget innate and adaptive immune cells. ROCK&#xAE; enables us to tailor tetravalent, bispecific immune cell engagers with high affinity and avidity, as well as variable pharmacokinetic (PK) profiles for different indications and settings. Leveraging this</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">platform, we are able to generate molecules against validated oncology targets to address the limitations of existing standard treatments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Schematic Representation of our Fit-For-Purpose ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">&nbsp;Platform</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f002.jpg" style="width: 5.582635in; height: 2.114319in" alt="Picture 2"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">57</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our ROCK&#xAE; platform offers modularity and versatility for customizable antibody generation and is differentiated from other technologies and is designed to deliver immune cell engagers that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">target different tumor-associated antigens</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">enable tumor cell killing even with low target expression</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">demonstrate high affinity binding and avidity based on bivalency</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">recruit innate immune cells through anti-CD16A-specific epitopes </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">offer different PK profiles</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">possess long cell retention time</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">show evidence of specific innate immune cell activation and their tumor infiltration (CD16A engagers)</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Leveraging our fit-for-purpose ROCK&#xAE; platform, we develop proprietary, next-generation bispecific antibodies, so-called innate cell engagers, which are designed to direct and establish a bridge between innate immune cells and cancer cells. Our innate cell engagers have the ability to create an immunological synapse between innate immune cells and cancer cells and trigger an activation cascade that leads to the destruction of cancer cells. Due to their novel tetravalent</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">architecture (which provides for four binding domains), our innate cell engagers bind to their targets with high affinity and have half-lives that support intravenous administration and dosing schedules similar to monoclonal antibodies (mAbs) to achieve potent antitumor efficacy. We are developing a variety of tetravalent, bispecific antibody formats with the potential to tailor immune-engaging therapies to different indications and settings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Innate Cell Engagers</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our fit-for-purpose ROCK&#xAE; platform enables the design and development of various antibody formats. Our lead product candidate, AFM13, is an innate cell engager binding to CD16A on NK cells and macrophages and CD30, a receptor found on the tumor cells of patients with HL and other CD30+ malignancies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Specifically, our innate cell engagers are designed to have the following properties:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">bispecific or trispecific targeting;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">binding with high specificity, or selectivity;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">binding with high affinity/avidity, or strength;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">molecular weight allowing for intravenous bolus administration; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">stable structure conducive to efficient and cost-effective manufacturing.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Innate cell engagers bind to innate immune cells and enable both the recognition of tumor cells and their redirection to these tumor cells by forming an immunological synapse. These cells then release perforins, creating pores in the tumor cell membrane through which granzymes enter the cell, triggering apoptosis and resulting in tumor cell death.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">58</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Schematic representation of the mode of action of a tetravalent bispecific innate cell engager</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f003.jpg" style="width: 5.936758in; height: 2.353873in" alt="Picture 6"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Innate immune cells, such as NK cells and macrophages, distinguish between healthy cells and foreign or aberrant cells through a process that is governed by a complex interaction of activating and inhibitory receptors that regulate their activity. While innate immune cells can bind to the Fc regions of native full-length antibodies through Fc&#x3B3; receptors to induce a cytotoxic effect, our Innate Cell Engagers are designed to enhance the activity of innate immune</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">cells in killing targeted tumor cells because they bind the Fc&#x3B3;RIIIA (CD16A) receptor on innate immune cells with high specificity and approximately 1,000-fold higher affinity than IgG-based antibodies, and greater than 25-fold higher affinity than typical Fc-optimized IgG antibodies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">CD16A is an integral membrane glycoprotein found on the surface of innate immune cells,</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">namely NK cells and marcophages, but not neutrophils. Classical mAbs bind not only to CD16A, but, to our knowledge, also to the highly homologous CD16B, an isoform differing from CD16A by only a few amino acids. CD16B is expressed on neutrophils, which are the most numerous white blood cells (leukocytes), and blood plasma contains high levels of soluble CD16B cleaved from the daily turnover of apoptotic neutrophils. Thus CD16B, being readily available to bind to any Fc-based antibody formats, facilitates target-mediated drug disposition for such antibodies. To engage and activate innate immune cells, we have generated a highly effective and specific human antibody that specifically targets the CD16A receptor and does not cross-react with CD16B. This antibody also binds to both CD16A allotypes (amino acid 158 with either valine or phenyalanine) with equal affinity, a polymorphism that has been shown to reduce efficacy of marketed classical antibodies such as trastuzumab or elotuzumab (see figure below).</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">59</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Binding of Innate Cell Engager to CD16A (high-and low affinity genetic variants (allotypes) 158V and 158F, respectively) and to CD16B (SH, NA1 and NA2 allotypes), the latter showing no response</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">(i.e. no binding)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f004.jpg" style="width: 5.374329in; height: 3.989085in" alt="Picture 7"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our lead innate cell engager AFM13, binds to CD16A on innate immune cells and to CD30, a receptor found on malignant cells that have been implicated in lymphoma, including HL and T cell lymphoma.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">HL and CD30-positive Malignancies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">HL is a type of lymphoma, which is a cancer originating from white blood cells called lymphocytes.&nbsp;CD30 is a cell membrane protein and tumor marker of different hematological malignancies, including PTCL, CTCL, HL and DLBCL. There are approximately 9,000 new cases of HL in the United States every year and about 23,000 new cases in North America, the European Union and Japan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Patients with newly diagnosed HL, depending on disease stage, are treated primarily with chemotherapy, sometimes in combination with radiotherapy. The current initial standard regimens are highly effective, but associated with acute and chronic toxicity. A number of patients are either refractory to or relapsing from standard therapy that included chemotherapy followed by Adcetris&#xAE;, and we believe these represent a total of approximately 4,000&#8209;5,000 patients every&nbsp;year in North America, the European Union and Japan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Adcetris&#xAE; is the first approved targeted therapy for HL patients that are relapsed/refractory to second line treatments. Adcetris&#xAE; targets CD30, the same target as AFM13, but has a different mode of action, acting as a targeted chemotherapy, rather than as a targeted immunotherapy. As an antibody-drug conjugate, Adcetris&#xAE; delivers a toxin (monomethyl auristatin E) to the cells that carry the CD30 antigen. The drug conjugate is internalized by the tumor cell, which is then destroyed. In a phase 2 clinical study, Adcetris&#xAE; treatment in relapsed/ refractory HL patients resulted in an overall response rate of 75% and a complete response rate of 34%. However, the median progression free survival after Adcetris&#xAE; is only 9.3&nbsp;months. In addition, the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">60</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">treatment is associated with considerable adverse events like neutropenia (low neutrophils) and neuropathy (damage to the peripheral nervous system).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">FDA and EMA have approved nivolumab in classical HL that has relapsed or progressed after autologous hematopoietic stem cell transplantation and Acetris&#xAE; in 2016. Recently, the FDA has approved pembrolizumab for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy. Overall response rates for the anti-PD&#8209;1 antibodies (nivolumab and pembrolizumab) in relapsed/refractory classical HL patients post brentuximab vedotin are 64 to 74%, with complete remission rates of 12&#8209;25%. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Beyond HL, other CD30+ hematological malignancies include T cell lymphoma, or TCL, and diffuse large B cell lymphoma, or DLBCL .</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">4% of all new cancer cases in the US are NHL (SEER Database). In 2016, approximately 72, 000 new cases of NHL were diagnosed in the US (SEER estimate). 5-10% of all Non-Hodgkin Lymphomas (NHL) are peripheral T-Cell Lymphomas (pTCL) and the majority are B-Cell Lymphomas, with approximately a third of NHL being DLBCL.&nbsp;&nbsp;There are between 4000-8000 newly diagnosed cases of pTCL in the US every year, of which 50-60% are positive for</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">CD30.&nbsp;&nbsp;There are approximately 26,000 newly diagnosed DLBCL patients in the US every year, of which approximately a third are CD30+.&nbsp;&nbsp;&nbsp;&nbsp;Together, TCL and DLBCL which together contribute approximately 6,000-8,000 relapsed/refractory CD30+ cancer cases per year in North America, the European Union and Japan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">EGFR-positive Malignancies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Current treatment options for solid tumors consist of a mix of surgery, chemotherapy, radiotherapy and targeted therapies. While chemotherapy or radiotherapy were historically standard treatment strategies, specific tumor characteristics currently guide decision-making for an optimal treatment regimen for individual patients. This has led</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">to the implementation of innovative treatments as standard of care, in particular, monoclonal antibodies and tyrosine kinase inhibitors, in many solid tumors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Epidermal growth factor receptor (EGFR), an important target that is exploited by these targeted therapies, is expressed in a wide range of solid tumors and is considered a validated target for their treatment. Erbitux&#xAE; and Vectibix&#xAE; are anti-EGFR monoclonal antibodies that are approved for the treatment of RAS-wild type metastatic colorectal cancer (CRC), which represents a subset of ~45-50% of all CRC patients. However, Erbitux&#xAE; and</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Vectibix&#xAE; are not effective in KRAS mutated CRC. The activating KRAS mutations put RAS in a constitutively activated status that bypasses the signal transduction inhibition produced by EGFR targeting antibodies. In addition, Erbitux&#xAE; is also approved for the treatment of locally advanced and recurrent/metastatic head and neck cancer (HNSCC). The anti-EGFR mAb Necitumumab is approved for squamous cell carcinoma of the lung.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Beyond these approved indications, there are signals of clinical activity of anti-EGFR mAbs from early clinical studies in a wide range of different indications.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Immunotherapies play an increasing role in solid tumors. PD-1 checkpoint inhibitors have been approved for the treatment of many different types of cancer, including melanoma, lung cancer, renal cancer, bladder cancer and head and neck cancer. Many studies with cancer immunotherapies are ongoing. It is expected that immunotherapies will</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">play an increasing role in the standard treatment of solid tumors. However, even with these advances, cure is still the exception for the majority of late stage tumors, in particular metastatic tumors, and the medical need for new and safe treatment approaches remains generally high for solid tumors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">There is a broad spectrum of development opportunities for our tetravalent bispecifc EGFR-targeting antibody.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">RAS</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">-mutant colorectal cancer: The main mode-of-action of monoclonal antibodies (mAbs) Erbitux&#xAE; and Vectibix&#xAE; is the inhibition of the downstream signaling cascade of EGFR. However, certain mutations within </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">61</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the RAS-oncogene result in a lack of activity of both mAbs In contrast, AFM24 introduces a novel MoA inducing direct innate immune cell mediated killing of EGFR-positive cells. It might therefore be able to overcome these limitations and be clinically active regardless of RAS mutation status.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Combination therapy: It has been demonstrated that the PD1/PDL1 checkpoint pathway plays an important role in different solid tumor types. This supports the rationale for investigating the combination of AFM24 with a checkpoint inhibitor in several EGFR-positive tumors in which the checkpoint inhibitors are approved, e.g., NSCLC and HNSCC.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Improved benefit/risk profile versus the established EGFR-targeting mAbs: By its mode-of-action our antibody might be more efficacious than the available EGFR-targeting mAbs in their approved indications (mCRC RAS WT, HNSCC, squamous NSCLC) and might exhibit an improved safety profile, especially</font><font style="display:inline;color:#000000;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">with respect to skin toxicity, which is the most common side effect of Vectibix&#xAE; and Erbitux&#xAE;. Eventually an improved benefit/risk profile could result in a replacement of the existing therapies.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Development on EGFR-positive solid tumors in which no other EGFR mAbs are approved: Clinical signals of anti-tumor activity have been observed in a broad range of indications aside from the approved ones, including triple negative breast cancer and esophageal cancer. These indications might be further pursued with AFM24.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Our Product Candidates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our development pipeline currently comprises three distinct product candidates for which we retain full commercial rights. Initially, we will pursue indications in which the medical need is high and for which there is a significant population of patients needing treatment in the salvage setting, expecting to expedite the time to market. If and when we obtain approval for our product candidates as salvage therapies, we plan to explore whether they could also be</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">used as first- or second-line treatments, most likely in combination with one or more treatments that comprise the existing standard of care. All of our product candidates have the potential to target several indications, which could represent significant additional commercial opportunities in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM13</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM13 is a first-in-class innate cell engager that is engineered to bind with high affinity to both CD30-expressing tumor cells and to CD16A surface proteins to activate NK cells and macrophages. AFM13 is intravenously administered and has several advantageous characteristics:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">By targeting CD16A, AFM13 binds to NK cells and macrophages but not to neutrophils and is therefore more selective than full-length antibodies that bind to both CD16A and CD16B.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Preclinical experiments have demonstrated that the cytotoxic potency of AFM13 is consistently higher than native and Fc-enhanced anti-CD30 full-length antibodies.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFM13 has the potential to be effective for all known and relevant genetic variants of CD16A.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The clinical and preclinical data that we have generated to date suggest that AFM13 appears to be well-differentiated from Adcetris&#xAE;, an approved targeted therapy for HL and TCL patients. Although AFM13 employs the same disease target as Adcetris&#xAE;, namely CD30, the two compounds are fundamentally different in their mechanism of action. Adcetris&#xAE; is a targeted chemotherapy, while AFM13 is a targeted immunotherapy. Adcetris&#xAE; delivers a toxin (monomethyl auristatin E) to the cells that carry the CD30 receptor, and the cell is killed by the action of the toxin after its internalization and release from the antibody. In contrast, AFM13 does </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">62</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">not need to enter the cell, but serves as a connector on the cell surface between the CD30 receptor and a CD16A-positive immune cell. Once the cells are in contact, the killing activity of the immune cell is triggered.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Tumor cells have the ability to activate a multi-drug resistance system, or MDR, which we believe may contribute to the development of resistance to Adcetris&#xAE;. The MDR, however, does not affect the efficacy of an immunotherapy like AFM13. We believe that this difference may not only translate into efficacy of AFM13 in patients relapsing from Adcetris&#xAE; therapy, but ultimately into a longer clinical benefit. In addition, the off-target toxicity of Adcetris&#xAE;&#x2019; toxin monomethyl auristatin E causes severe neutropenia (low neutrophils) and neuropathy (damage to the peripheral nervous system). We believe AFM13 may avoid these side effects because it does not introduce a toxin such as monomethyl auristatin E into the cells. Hence, AFM13 may address Adcetris&#xAE;&#x2019; safety limitation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Clinical development of AFM13</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A phase 2a clinical study of AFM13 in patients with HL started recruitment in the second quarter of 2015. After slower-than-expected patient recruitment due to delays in opening trial sites and the availability of anti-PD-1 antibodies for the treatment of relapsed/refractory HL patients, the overall study design was revised in order to enhance patient recruitment. The study now includes HL patients relapsed or refractory to treatment with both brentuximab vedotin (Adcetris&#xAE;) and anti-PD-1 antibodies. Different dosing protocols of AFM13 are being explored to allow for improved exposure in more heavily pretreated patient populations. The study has completed recruitment under the new study design. AFM13 has been granted orphan drug status for the treatment of HL in the United States and the European Union, and for T-cell lymphoma in the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, we completed a phase 1b clinical study investigating the combination of AFM13 with Merck&#x2019;s anti-PD-1 antibody Keytruda&#xAE; (pembrolizumab) in HL patients that have relapsed after or are refractory to chemotherapy and Adcetris&#xAE;. The study is designed to establish a dosing regimen for the combination therapy and to assess its safety and efficacy. In this study, the combination was well-tolerated with most of the adverse events observed mild to moderate in nature and manageable with standard of care. Best response assessment data from 24 patients treated at the highest AFM13 dose level (7 mg/kg) as reported by central read, showed an objective response rate (ORR) of 88% (21 of 24 patients), including complete metabolic responses (CmR) in 46% (11 of 24 patients) and partial metabolic responses (PmRs) in 42% (10 of 24 patients). One patient experienced stable disease (SD).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are also supporting a phase 1b/2a IST of AFM13 in patients with relapsed or refractory CD30-positive lymphoma led by investigators at Columbia University in New York. In addition to determining clinical efficacy, this is also a translational study in patients with cutaneous manifestations and is designed to allow for serial biopsies, thereby enabling assessment of NK cell biology and tumor cell killing within the tumor microenvironment. Enrollment for the study is completed. An interim analysis of this study was recently presented. In 10 patients (dosed at 1.5-7.0 mg/kg) AFM13 was well-tolerated and showed therapeutic activity as a single agent, with an ORR of 50% (5 of 10 patients). In detail, one complete response (CR), four partial responses (PRs) and two stable diseases (SDs) were observed. An analysis of biomarker correlatives showed a decrease in circulating NK cells (CD56+ CD3- , CD56+ CD16+, NKp46+) during therapy, with post-therapy recovery. In addition, increased CD69 expression on circulating NK cells from responders vs. non-responders was demonstrated. Tumor biopsies showed increased infiltration of CD56+ NK cells pre-therapy in responders compared to nonresponders, while circulating CD4+ CD25+ T cells (Tregs) decreased in responders compared to nonresponders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In December 2016, we entered into a clinical development and commercialization collaboration with MD Anderson to evaluate AFM13 in combination with MD Anderson&#x2019;s cord-blood derived NK cell product. In December, 2018, we presented data at the American Society of Hematology Annual Meeting, outlining the successful approach of a novel premixed product comprising expanded cord-blood derived NK cells loaded with AFM13 to redirect their specificity against CD30-positive malignancies. MD Anderson is responsible for conducting preclinical research activities aimed at investigating its NK cells derived from umbilical cord blood in combination with AFM13, which are intended to be followed by a clinical phase 1 study. The FDA has cleared </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">63</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an investigational new drug application (IND) for the phase 1 study, in which MD Anderson plans to investigate the combination of AFM13 with allogeneic NK cells. MDACC intends to administer a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells in different doses (numbers of pre-loaded NK cells) to patients with relapsed/refractory CD30-positive lymphoid malignancies. We fund research and development expenses for this collaboration and hold an option to exclusive worldwide rights to further develop and commercialize any product developed under the collaboration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Together with the German Cancer Research Center (DKFZ), we published data presenting evidence of AFM13 modulating NK cells by sensitizing them to IL-2 and/or IL-15 stimulation. In this study, after exposure to AFM13, the NK cells showed improved IL-2- and IL-15-mediated proliferation and cytotoxicity. These data support the rationale for further investigation of combining our NK cell engagers with IL-2- or IL-15 to potentially achieve deeper clinical responses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM13&#8209;101 phase 1 dose escalation clinical study</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have conducted a phase 1 clinical study of AFM13, AFM13&#8209;101, in patients with HL. All patients in this study suffered from heavily pretreated relapsed/refractory disease and had documented progression of disease at study entry. The objectives of the study were: to determine the safety and tolerability of increasing doses of single cycles of AFM13 as a monotherapy; to determine the maximum tolerated dose and optimal biological dose of AFM13; to determine the pharmacokinetic (PK) profile of AFM13; to analyze immunological markers, NK cell activity, NK cell markers, serum outcome markers and cytokine release; to assess the immunogenicity, or ability to provoke an immune response, of AFM13; and to assess the activity of AFM13. The phase 1 study was conducted in Germany and the United States. We submitted a CTA for the phase 1 study to the PEI in May&nbsp;2010 and an IND application to the FDA in June&nbsp;2010.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The study enrolled 28 patients (16 males, 12 females) in eight dose cohorts. In the dose escalation part, 24 patients received increasing doses of AFM13 ranging from 0.01 mg/kg to 7.0 mg/kg on a weekly dosing schedule for four weeks. In addition, four patients were treated with 4.5 mg/kg twice weekly for four weeks. Of the 28 patients, 14 had refractory disease and the remainder had relapsed disease. The patients had received a median of six (range three to 11) previous lines of therapy for HL. Nine patients had previously received Adcetris&#xAE;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The clinical results were first presented to the medical community by Professor Andreas Engert, University Hospital of Cologne, the lead investigator for the study, at the Lugano International Meeting on Malignant Lymphoma in 2013. AFM13 showed an acceptable safety profile. An independent data monitoring committee, or IDMC, was responsible for the review of safety data on an ongoing basis. It was concluded that the maximum feasible single dose of 7 mg/kg was reached without any toxicity concerns, and consequently the maximum tolerated dose was not reached. The four patients who were treated with 4.5 mg/kg twice weekly completed treatment without raising any toxicity concerns for the IDMC. The most common adverse events were fever and chills, and in general, they were of mild to moderate severity. Overall, less than 30% of all adverse events were severe.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Twenty-six of 28 patients were eligible for efficacy evaluation. For the remaining two patients, efficacy assessments have not been performed. Of the 26 patients, three had a partial remission, 13 had stable disease and 10 had disease progression as best overall response. With the exception of the 0.04 mg/kg dose cohort, anti-tumor activity was observed at all dose levels tested but was more pronounced at or above 1.5 mg/kg. In this subgroup (n=13), 3 partial responses (=50% tumor shrinkage) and 7 cases with stable disease were observed, with an overall response rate of 23% (3/13) and a disease control rate of 77%. The chart below shows for these 13 individual patients the best overall response measured as a&nbsp;percentage change in tumor volume from baseline (baseline = 0 at the y-axis). The volume is calculated as sum of perpendicular diameters (SPD) for selected lesions of the tumors based on CT-scans.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">64</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM13&#8209;101 Best Overall Response in % Change in Tumor Volume from Baseline in 13 Patients who Received 1.5 mg/kg</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f005.jpg" style="width: 5.426405in; height: 3.634962in" alt="Picture 8"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Six of seven patients refractory to Adcetris&#xAE; as their most recent treatment experienced stabilization of disease, or SD, following AFM13 treatment. One experienced progressive disease, or PD.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM13&#8209;101 Data for Patients Refractory to Adcetris&#xAE; as Immediate Prior Therapy</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">AFM13 DOSE </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"># PRIOR </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">MOST RECENT </font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">TIME LAST ADCETRIS&#xAE;-</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">AFM BEST </font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">PATIENT</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(mg/kg)</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">TREATMENTS</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">TREATMENT</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">FIRST AFM13</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">RESPONSE</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-01</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.01 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">6&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 5 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1 month</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-02</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.01 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">7&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 8 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1 month</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-07</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.15 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">11&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 7 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">3 months</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-11</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.5 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">7&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 5 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">3 months</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-12</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.5 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">7&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 9 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1 month</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">003-01</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">0.5 weekly</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">9&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 4 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1.5 months</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SD</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">001-21</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">4.5 twice</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">8&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adcetris&#xAE;, 8 cycles</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2.5 months</font></p>
				</td>
				<td valign="bottom" style="width:02.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">PD</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Certain biomarkers indicated dose-dependent effects suggesting most active doses at or above 1.5 mg/kg. PK data were assessed in patients of all dosing cohorts. A dose proportional increase of systemic exposure (AUC0- (or Area Under the Curve from zero to infinity in a plot of the concentration of the drug in blood plasma against time, which represents the total drug exposure over time) and Cmax (or the maximum (or peak) concentration of the drug measured in plasma after the drug has been administered)) was observed. AFM13 was detectable in peripheral blood up to 168 hours post infusion in the highest dosing cohort. The mean half-life (t1/2) for dose cohorts 1.5 mg/kg and above was 9-19 hours. AFM13 treatment resulted in an increase of activated NK cells, which are characterized by CD69 expression at their surface. There was a trend showing that higher doses result in a more pronounced increase of CD69+ NK cells. Moreover, CD69 levels rose after AFM13 administration and fell to about baseline prior to the next dose (see figure below), indicating a pattern that reflected the PK of AFM13. All 28 patients in the study had measurable levels of soluble CD30 (sCD30), at the start of AFM13 treatment. sCD30 is shed by the tumor and measurable in peripheral blood. In 24 patients the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">65</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">level was decreased at the end of treatment. Patients treated in dosing cohorts 1.5 mg/kg and higher all had a marked decrease of sCD30.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM13&#8209;101: Relative number of activated (CD69+) NK cells in patients receiving 7 mg/kg AFM13 (mean,&nbsp;n=3)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"><img src="afmd20191231x20f006.jpg" style="width: 5.41599in; height: 3.676624in" alt="Picture 10"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on the phase 1 data we concluded, together with experts and authorities, that AFM13 has a favorable safety profile. In addition, AFM13 showed activity in terms of tumor response and pharmacodynamics (PD), even in Adcetris&#xAE; refractory patients. However, PK and PD indicate that the dose regimen has to be optimized and that the measured clinical effect is likely to underestimate the potency of AFM13 in HL. Consequently, in the phase 2a proof of concept study, the dose has to be 1.5 mg/kg; AFM13 has to be administered more frequently, at least for a certain time; the treatment duration has to be longer than four weeks; and a second cycle has to be mandatory in patients that showed benefit from AFM13 treatment in the first cycle, i.e., complete response, partial response or SD.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Relapsed/refractory Hodgkin Lymphoma after failure of standard treatments and subsequent clinical development for AFM13</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The proof of concept was demonstrated in the phase 2a study of AFM13 as a monotherapy in relapsed/refractory HL or relapsed/refractory CD30-positive lymphoma, and we are in the process of initiating a phase 2b study. The nature and design of this study, which will be submitted to the authorities, has been determined based on end-of-phase-2 meetings with the FDA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We believe that the phase 2b study could support an application for registration in relapsed/refractory HL or CD30-positive lymphoma. This belief is based on the fact that AFM13 is being developed in salvage settings with high medical need and currently very limited treatment options.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In November 2019, the first patient was dosed in a Phase 2 registration-directed study of AFM13 as monotherapy in relapsed or refractory patients with CD30-positive peripheral T cell lymphoma (pTCL). The results of the study, if positive, could form the basis for a Biologics License Application submission and support </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">66</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an accelerated approval given the unmet medical need for safe and effective new treatments in this hard-to-treat patient population. The study will also enroll a cohort of patients with transformed mycosis fungoides, an aggressive subtype of cutaneous T cell lymphoma.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM24</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are developing AFM24, a tetravalent, bispecific epidermal growth factor receptor (EGFR) and CD16A-binding innate cell engager, in patients with advanced cancers known to express epidermal growth factor receptor. AFM24 is engineered to broadly treat EGFR-expressing solid tumors through innate immune cell activation, potentially avoiding safety and mutational status limitations, as well as resistance mechanisms associated with other therapies. AFM24 is unique because it activates innate immunity to kill solid tumors, inducing both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as compared to other therapies that rely heavily on signal or checkpoint inhibition. We have successfully completed a toxicology study in cynomolgus monkeys at a range of dose levels up to 75mg/kg over 4 weeks with no observed toxicities even at high dose levels. In contrast, Cetuximab an approved anti-EGFR antibody revealed significant toxicity in the same dose-range. In November 2019, our IND application for AFM24 cleared the required 30-day review by the FDA and is in effect for a phase 1/2a clinical trial of AFM24 in patients with advanced cancers known to express&nbsp;&nbsp;EGFR. We also received regulatory approval to commence a clinical trial of AFM24 from the UK and Spain. The initial goal of the study is to determine the maximum tolerated dose and recommended phase 2 dose of AFM24, as well as to evaluate the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy in patients with advanced cancers known to express EGFR. The dose expansion phase of the study is intended to collect preliminary evidence of efficacy and to further confirm the safety of AFM24 as a monotherapy in patients with select solid tumor subtypes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">AFM26</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have also developed AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) to address the medical need for a novel approach to treat multiple myeloma. AFM26 employs a unique mechanism of action through high affinity engagement of NK cells which demonstrates in vitro efficacy against cells expressing even very low levels of BCMA. NK cell binding of AFM26 is largely unaffected by IgG competition. In addition, AFM26 offers the opportunity for a combination with adoptive NK cell transfer, as it appears to have a favorable safety profile with lower cytokine release as compared to BiTE. In the third quarter of 2018, we successfully partnered AFM26 and no longer control its development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Antibody generation at AbCheck</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AbCheck is our wholly owned, independently operated proprietary antibody screening platform company. AbCheck combines four different technologies to supply high-quality antibodies to us as well as others on a fee-for-service basis. AbCheck offers phage display antibody libraries, yeast display, affinity maturation algorithm technologies and Rabbit Mass Humanization. AbCheck is recognized for its expertise in antibody discovery throughout the United States and Europe and has been working with globally active pharmaceutical and biotechnology companies such as Tusk Therapeutics, bluebird bio, Eli Lilly, Daiichi Sankyo, Pierre Fabre and others.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">The Na&#xEF;ve Human Antibody Library</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Na&#xEF;ve Human Antibody Library leverages the power of the human immune system by using antibody sequences generated </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">in vivo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. Sequences of variable heavy chains are taken from the IgM pool of healthy human donors, where the highest diversity of antibody sequences can be found. The heavy chains are recombined with variable light chains in the phage display vector to maximize diversity. This library ensures the fast and reliable discovery of highly specific and highly affine human antibodies for virtually every possible target protein. AbCheck has conducted more than 30 successful antibody discovery projects, including antibodies against complex cell surface receptors.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">67</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Yeast display</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AbCheck uses yeast display to screen for enhanced expression levels and stability of antibodies and thereby select candidates that can be manufactured with high yield and are stable. The yeast system guarantees expression of the product candidate in customary cell culture systems. Furthermore, yeast display in combination with fluorescence activated cell sorting allows real-time monitoring and full control over the selection process. Screening in the final drug format, including full-length IgGs and novel antibody formats, ensures a fast and efficient lead discovery process.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Affinity maturation algorithm</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AbCheck has a proprietary algorithm, AbAccel, for incorporating the results of high-throughput antibody sequencing, structural analysis and therapeutic biochemistry to optimize antibodies with regard to affinity, immunogenicity, stability and expression levels.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Mass Humanization</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AbCheck has developed the mass humanization technology in partnership with Distributed Bio. It is an entirely new approach for multi-parameter engineering and optimization of monoclonal therapeutics. By analyzing the matured repertoire of rabbits and humans, AbCheck was able to pre-compute and pre-encode the complete humanization landscape in a &#x201C;mass humanization&#x201D; technology, in which they humanize the </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">in vivo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> immune response of a rabbit in a single experiment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Collaborations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into strategic collaborations for some of our development programs. As part of our business development strategy, we aim to increase the number of our research collaborations in order to derive further value from our platforms and additionally exploit their potential. Key terms of our current material collaborations are summarized below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Genentech</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On August 24, 2018 we entered into a research collaboration and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of certain product candidates that contain novel NK cell engager-based immunotherapeutics to treat multiple cancers. Under the terms of the agreement, in the fourth quarter of 2018, we received $96 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Research collaboration and license agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the terms of the research collaboration and license agreement (for purposes of this subsection, the &#x201C;Agreement&#x201D;), we granted Genentech an exclusive, royalty-bearing, sublicensable worldwide license during the term of the Agreement and thereafter under patent rights and know-how to commercialize the licensed portfolio and any additional product candidates developed pursuant to the Agreement against the exclusive targets designated by Genentech. Genentech has granted us a non-exclusive, royalty-free, non-sublicensable, worldwide license under certain of its intellectual property solely to fulfill our research obligations under the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition to the $96 million in payments received in 2018, we are eligible to receive up to approximately $5.0 billion in total milestone payments upon successful development and commercialization of all product candidates developed pursuant to the Agreement. Of the $5.0 billion in milestone payments, approximately $250 million relate to development activities, $1.1 billion relate to receipt of regulatory approvals, and $3.6 billion relate to achievement of specified thresholds of worldwide net sales. In addition, we are eligible to receive </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">68</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">tiered royalties from Genentech on net sales of licensed product candidates on a product-by-product and country-by-country basis until the later of the date when there are no valid patent claims under our licensed patents covering such licensed product in the applicable country and the tenth anniversary of the date of first commercial sale of such licensed product in such country. In March 2019, we were informed that an initial pre-clinical milestone was approved by Genentech. In November 7, 2019, we also announced that Genentech exercised its final option for an exclusive target under the companies&#x2019; collaboration agreement to develop and commercialize novel NK cell engager-based immunotherapeutics generated by our ROCK&#xAE; platform to treat multiple cancers. The target selection triggered a milestone payment, in an undisclosed amount, to us from Genentech.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the terms of the Agreement, Genentech will be responsible for a majority of the research, development and commercialization costs incurred in respect of each product candidate. The development of each product candidate will be overseen by a joint project team, which will in turn be overseen by a joint research committee, or JRC, consisting of an equal number of representatives of Genentech and us. If the JRC is unable to reach agreement, Genentech generally has final decision-making authority, provided that the JRC may not increase or decrease costs dedicated to our research activities under any research plan without our consent.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are subject to certain efforts requirements in connection with our research activities under the Agreement, provision of technical assistance to Genentech and agreement with Genentech upon designation of the exclusive targets. Genentech must use commercially reasonable efforts to develop and commercialize in one of the United States, European Union or Japan at least one licensed product that binds to each exclusive target.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We will own intellectual property that we solely develop under the Agreement or that predominantly relates to its antibody engineering platform or molecule fragments that bind to the NK cell. Genentech will own intellectual property that it solely develops under the Agreement or that predominantly relates to an antibody designed to solely bind to an exclusive target. Other newly developed intellectual property will be jointly owned by us and Genentech. The parties will jointly prosecute related patents, provided that Genentech will make final decisions regarding prosecution of patents that claim exclusive targets or relate to developed intellectual property that it solely owns under the Agreement and we will make final decisions regarding prosecution of patents that relate to developed intellectual property that we solely own under the Agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Agreement will expire on a country-by-country basis and licensed product-by-licensed product basis until there is no remaining royalty payment or other payment obligation in such country with respect to a licensed product. Either party may terminate the Agreement in its entirety, or with respect to a particular target, for any uncured material breach of the Agreement by the other party. Either party may also terminate the Agreement upon the other party&#x2019;s insolvency. Genentech also has the right to unilaterally terminate the Agreement in its entirety or with respect to a particular target, in its sole discretion, upon certain advance written notice. If the Agreement is terminated in its entirety or with respect to a particular exclusive target, either by Genentech for convenience or by us for material breach, we have a right to negotiate commercially reasonable terms under which Genentech grants to us (i)&nbsp;the right to transfer licensed products under any terminated exclusive target to us and (ii)&nbsp;a license for Genentech&#x2019;s intellectually property to such licensed products for further commercialization of such licensed products. If we do not agree with Genentech on such terms, the dispute will be finally settled by arbitration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Amphivena</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2013, we entered into a license and development agreement, which amended and restated a 2012 license agreement, with Amphivena Therapeutics,&nbsp;Inc., or Amphivena, based in South San Francisco, CA, to develop a CD33xCD3 immune cell engager antibody to be used in patients suffering from AML in exchange for an interest in Amphivena and certain milestone payments. Amphivena received funding from MPM Capital, Calibrium (formerly Aeris Capital) and us. Amphivena had entered into an agreement with Janssen that gave Janssen the option to acquire Amphivena upon predetermined terms following acceptance by the FDA of an </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">69</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">IND filing for the product candidate, but Janssen declined to exercise this option in July&nbsp;2016 and Amphivena retains full rights to the product candidate. We successfully reached our first three milestones, up to the generation and acceptance of a CD33xCD3 development candidate immune cell engager meeting certain target features. The third milestone was reached in the first quarter of 2015. Following the achievement of the third milestone of the Amphivena collaboration we were eligible to receive a milestone payment of &#x20AC;7.5 million payable in three installments. The first installment of &#x20AC;1.3 million was paid in the first quarter of 2015, and the second installment of &#x20AC;4.2 million was paid in October&nbsp;2015. An additional amount of &#x20AC;0.5 million was received in October&nbsp;2016, which comprised &#x20AC;1.5 million as partial payment for the third installment, net of &#x20AC;1.0 million of additional financing we provided to Amphivena to support the future clinical development of its product candidate, AMV564. Following the expiration of the license and development agreement with Amphivena when the IND became effective, we continued to provide services on a smaller scale to complete the deliverables required under the agreement, and have been financially supporting the future clinical development of AMV564.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In exchange for the technology license to Amphivena, we received shares of stock of Amphivena, and, in connection with an equity financing involving us and other third-party investors, we made cash investments in Amphivena in exchange for additional shares of stock and entered into certain related agreements governing our rights as a shareholder of Amphivena. As of December 31, 2019, those cash investments totaled $4.0 million (&#x20AC;3.5 million), and we owned approximately 4% of the outstanding equity of Amphivena on a fully diluted basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Amphivena has separately entered into a warrant agreement with Janssen Biotech Inc. that gave Janssen the option to acquire Amphivena following IND acceptance by the FDA of such product candidate, upon predetermined terms, in exchange for payments under the warrant. Upon effectiveness of such IND application in July 2016, Janssen decided to not exercise its option. We have received payments for research and development services provided by us under the license and development agreement entered into with Amphivena prior to its expiration. Through December 31, 2019, &#x20AC;14.5 million (net of our share in funding Amphivena) was paid to us under the license and development agreement. We do not expect to provide any additional significant services or generate significant additional revenues under the license and development agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">License and development agreement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Pursuant to the July&nbsp;2013 license and development agreement with Amphivena, we historically performed certain services for Amphivena related to the development of a product candidate for hematological malignancies. The license and development agreement with Amphivena expired when the IND became effective.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Licenses</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. Pursuant to the license and development agreement, we have granted Amphivena certain product and technology licenses, each of which includes the right to grant sublicenses to its affiliates or third parties through multiple tiers, subject to certain notice requirements, including the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an exclusive, worldwide, royalty-free license under the technology of certain immune cell engagers to research, develop, make, have made, use and commercialize any immune cell engagers developed under the agreement;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a non-exclusive, worldwide, royalty-free license under other antibody-specific intellectual property we control to research, develop, make, have made, use and commercialize any immune cell engagers developed under the agreement; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an exclusive, worldwide, royalty-free license under certain antibody-specific intellectual property we control to research, develop, make, have made, use and import certain antibodies and portions thereof or products derived therefrom developed under the agreement.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">70</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, we have assigned our right and interest to certain intellectual property specifically related to certain antibodies covered under the agreement to Amphivena, and Amphivena solely owns all right, title and interest in certain intellectual property that specifically relates to such antibodies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We and Amphivena have granted exclusive, worldwide, royalty-free cross-licenses to each other&#x2019;s know-how that is disclosed while the Janssen warrant agreement is in effect and otherwise not covered by patent rights, for use in connection with the development plan and on certain occasions in which the development plan continues to be carried out surviving termination of the license and development agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Exclusivity</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. We and our affiliates, including AbCheck, are subject to restrictions on researching, developing, manufacturing, using or commercializing antibodies developed under the agreement for specified periods of time. These restrictions survived the expiration of the agreement in July&nbsp;2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Term and termination. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The license and development agreement terminated upon the completion of all services to be performed by us under the license and development agreement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">The Leukemia&nbsp;&amp; Lymphoma Society</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Overview</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. In 2013, we entered into a research funding agreement with The Leukemia&nbsp;&amp; Lymphoma Society, or LLS, for the clinical development of AFM13. Pursuant to the research funding agreement, LLS agreed to co-fund the clinical phase 2a development of AFM13 and to contribute up to approximately $4.4 million over two&nbsp;years to support the project. We have agreed to match LLS&#x2019;s contributions toward the project budget. Our receipt of the $4.4 million total that LLS has agreed to contribute is conditioned on the achievement of certain milestones in connection with the development of AFM13. The majority of the milestones have been met and we have already received $4.2 million in funds from LLS. We must use the funding provided by LLS exclusively with the development program, and return any excess funding to LLS. We are solely responsible for and have control over all development work and are obligated to use commercially reasonable efforts, as defined in the research funding agreement, in our conduct of the development program to achieve the specified milestones. We also have retained exclusive commercialization and distribution rights to AFM13. The research funding agreement was amended in April&nbsp;2014 to amend the projected milestone event dates and modify certain aspects of the agreement regarding the phase 2a study design. The research funding agreement was further amended in June&nbsp;2016 to reflect a shift in development focus of AFM13. Recent changes within the rapidly evolving cancer immunotherapy treatment landscape have resulted in a shift to development of combination therapeutic approaches. Having successfully established a collaboration with Merck in January&nbsp;2016 to test AFM13 in combination with Keytruda&#xAE; in relapsed/refractory Hodgkin lymphoma patients, we have prioritized the development of AFM13 as a combination therapy. Consequently, we have agreed with LLS to amend the research funding agreement so that the milestones now relate primarily to the development of AFM13 as a combination therapy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Intellectual property and licenses.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Each party owns inventions made and data and know-how generated exclusively by such party or its affiliates prior to and during the term of the research funding agreement relating to the AFM13 development program. If any of such data, inventions and know-how is jointly made, it is jointly owned. LLS grants us an exclusive, worldwide, fully paid-up license to its rights in any such joint inventions and any invention made by any LLS employee resulting from the AFM13 development program for purposes specified in the research funding agreement. We have granted LLS an exclusive license to AFM13 that is only effective if we have ceased, or ceased commercially reasonable efforts with respect to, research, development and commercialization of all AFM13 products for a specified period, which period may be extended. As an alternative to this license, we may elect to pay LLS a payment equal to the amount that LLS actually funded to us plus interest. LLS has agreed to make reasonable adjustments and accommodations to this license in the event it impedes our ability to seek a partner to commercialize AFM13.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Royalties</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. In consideration of LLS&#x2019;s payments to us, we have agreed to pay LLS a mid-single digit royalty on net sales of products containing AFM13 until we have paid LLS a low single digit multiple of the funding they provided to us. After we have reached this initial royalty cap, we will pay LLS a sub-single digit royalty on net </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">71</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">sales until the earlier of (i)&nbsp;the expiration of the last to expire patent covering the AFM13 products and (ii)&nbsp;ten&nbsp;years after the initial royalty cap is satisfied. These royalty payments are calculated on a country-by-country and product-by-product basis. We have also agreed to make certain low-to-mid-single digit royalty payments to LLS in the event of certain transfers of rights to any product containing AFM13 or in the event we undergo certain change of control transactions, in each case up to the royalty cap described above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Term and termination.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Unless earlier terminated pursuant to the terms of the agreement, the research funding agreement terminates when there are no longer any payment obligations owing from one party to another. The research funding agreement may be terminated by either party for the other party&#x2019;s material breach, material violation of applicable law, or if a representation or warranty made by the other party in the research funding agreement is not true in any material respect, subject to a specified cure period. If LLS terminates for our default, our royalty obligations and the interruption license will survive such termination. Either party may terminate if the other party undergoes specified bankruptcy or insolvency-related events.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Intellectual Property</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our technology platforms and ongoing development of our product candidates. Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and processes for manufacturing these molecules and the use of these molecules in a variety of therapies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions. To date, we have not identified any potential infringement of our patents by third parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Our Platforms and Programs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The patent portfolios for our most advanced programs are summarized below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM13</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We own and/or control our AFM13 (CD30 NK cell TandAb) patent portfolio, which includes three patent families. Our first patent family is issued and relates to the engineered antibody format, which is called TandAb, and the methods of making or using such bispecific, tetravalent domain antibodies. This patent family expired in 2019. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">72</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The patents were granted in several major markets, including Australia, Canada, Europe (Austria, Belgium, Denmark, France, Germany, Great Britain, Italy, the Netherlands, Spain, Sweden and Switzerland/Liechtenstein), Japan and the United States. The second patent family on AFM13 is granted for the use of the specific target combination for the treatment of cancer using a bispecific molecule. This patent family is granted in Europe (Austria, Belgium, France, Germany, Great Britain, Ireland, Italy, the Netherlands, Spain and Switzerland/Liechtenstein) and will expire in 2020. Our third patent family relates to the mode of action of AFM13, the recruitment of immune effector cells via a specific receptor. We filed a related PCT application and respective national phases are pending in Brazil, Canada and the United States. Any patents resulting from these patent applications, if issued, also will expire in 2026. Patents have been granted in Australia, China, India, Japan, Russia, Europe (France, Great Britain, Germany, Switzerland and Liechtenstein, Belgium, the Netherlands, Italy, Spain, Austria, Denmark and Sweden) and certain claims have been allowed in the United States (expiry of the US patent in 2029). The latest patent application on AFM13 relates to its combination with PD-1 antibodies, and was filed in 2016. We filed a related PCT application which entered the national phases in Australia, Brazil, Canada, China, Europe, India, Japan, Russia and the United States. Patents have been granted in Europe (Austria, Belgium, Switzerland/Lichtenstein, Czech Republic, Germany, Denmark, Spain, Finland, France, Great Britain, Greece, Hungarya, Ireland, Italy, Luxembourg, Monaco, Malta, Netherlands, Norway, Poland, Portugal, Sweden, San Marino und Turkey) and Japan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM11</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We own and/or control our AFM11 patent portfolio. This portfolio includes one patent family granted in Australia, Canada, Europe, Japan and the United States and one patent family pending in Australia, Brazil, Canada, China, Europe, Japan, Mexico, Russia and the United States. As in the case of AFM13, our issued patents relate to the engineered antibody format, which is called TandAb, and on which the AFM11 compound is based upon. These patents expired in 2019. The patent application family in our AFM11 patent portfolio claims a new TandAb structure which was specifically used in AFM11 to increase its potency. This patent family was granted in Australia, China, Japan, Mexico, Russia and certain countries in Europe, and is pending in other countries. The issued patents in this family will expire either in 2030 or 2031.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM24</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We own and/or control the patents which cover our EGFR/CD16A compound. These include one granted patent family which is, comparable to AFM11 and AFM13, the patents on the TandAb format issued in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Great Britain, Italy, Japan, the Netherlands, Spain, Sweden, Switzerland/Liechtenstein and the United States. As for AFM13, another patent family relates to the recruiting of immune effector cells via a specific receptor, and will expire in 2026/United states in 2029. Patents have been granted in Australia, China, India, Russia, Europe (France, Great Britain, Germany, Switzerland and Liechtenstein, Belgium, the Netherlands, Italy, Spain, Austria, Denmark and Sweden) and certain claims have been allowed in the United States. In 2019 a patent application was filed which relates to the specific AFM24 compound. The application is presently in the PCT phase. Any patents resulting from these patent applications, if issued, will expire in 2039.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM26</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have out-licensed the patents which cover our BCMA/CD16A compound.&nbsp;&nbsp;These include a patent family directed to BCMA/CD16A TandAb constructs pending in Australia, Canada, China, Europe, Japan and the United States. In 2019 a patent application was filed which relates to specific multivalent antibody constructs and the specific AFM26 compound. The application is presently in the PCT phase. Any patents resulting from these patent applications, if issued, will expire in 2039.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ROCK</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:5pt;top:-4pt;position:relative;line-height:100%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">platform</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We own and/or control our immune cell engager platform patent portfolio. This includes a patent family that covers multivalent antibody constructs comprised of four variable domains which are fused by linkers in different </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">73</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">length. The claims with regard to use of such immune cell engager antibodies cover general diagnostic and therapeutic use, in particular for viral, bacterial or tumoral diseases. These patents expired in 2019 and were granted in Australia, Canada, certain countries in Europe, Japan and the United States. Another pending patent application covers immune cell engagers that have a different immune cell engager structure which shows increased potency. The application is currently pending in Australia, Brazil, Canada, China, Europe, Japan, Mexico, Russia and the United States and if issued the patent will expire in 2030. Closely related to the immune cell engager platform is the Flexibody format, which is covered by a patent family fully owned by us, granted in Europe and Japan. A U.S. application in this family is still pending. These patents and applications (if issued) will expire in 2021. The latest patent application relating to specific Fc-comprising ROCK&#xAE; antibody constructs, which also claims the specific AFM26 compound was filed in 2019. The application is presently in the PCT phase. Any patents resulting from these patent applications, if issued, will expire in 2039.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Trispecific Antibodies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Another platform development effort resulted in the successful generation of a trispecific antibody format, for which we submitted patent applications in Australia, Brazil, Canada, China, Europe, India, Japan, Mexico, Russia, South Africa, South Korea and the U.S. in 2015. Patents based on this application have been granted in Europe, Japan and South Africa. Another International PCT-application was filed in 2016 for further trispecific antibody formats. These patent applications were submitted to cover several, dimeric and trispecific antibody formats which are based on variable domains characterized by a common specific dimerization pattern. The application is currently pending in Australia, Brazil, Canada, China, Europe, Hong Kong, India, Israel, Japan, Mexico, Russia, Singapore, South Africa, South Korea and the United States and if issued the patent will expire in 2026.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Novel Tetravalent Bispecific Antibody Formats</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are exploring various tetravalent, bispecific immune cell engagement formats designed to prolong both serum PK and pharmacodynamics.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">In-Licensed Intellectual Property</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into exclusive as well as non-exclusive patent and know-how license agreements which grant us the right to develop, use and commercialize our immune cell engager antibody platform and product candidates derived thereof. The licenses include obligations to pay development milestones and sales royalties on products we develop and commercialize that were generated using the patented technologies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">FDA Regulatory Review Process</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs of up to five&nbsp;years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14&nbsp;years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in other jurisdictions to extend the term of a patent that covers an approved drug, or to offer similar protection for an extended period, as is the case in the European Union. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">74</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Trade Secrets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also rely on trade secret protection for our confidential and proprietary information. Included in our trade secrets are various aspects of our manufacturing process that we conduct in cooperation with contract manufacturers.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees, contractors and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, contractors, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#x2019;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. German law provides that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Manufacturing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We express our tetravalent bispecific Innate Cell Engager product candidates in mammalian cells and develop our production processes on a laboratory scale. The research grade material made in our laboratories is suitable for conducting compound profiling activities. In the course of preclinical development, we transfer the process to external manufacturers (Contract Manufacturing Organizations, or CMOs) which we select according to a standardized operating procedure. Before and during the cooperation with a CMO we conduct audits to assess quality and compliance with the mutually agreed process descriptions and current Good Manufacturing Practice (GMP) regulations. The CMOs themselves are controlled by their in-house quality assurance functions and inspected by regulatory by agencies, including EMEA and the FDA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The technology transfer generally includes several different aspects: the development of a production cell line, the development of a research a master and working cell banks, the development and qualification of upstream and downstream processes, the development of the drug product process and the development of suitable validated analytical methods for test and release, as well as stability testing. During the development of our drug candidates, our CMOs scale the manufacturing process to suitable size. Such upscaling typically takes several steps and may involve modification of the process, in which case comparability of the resulting material to earlier preclinical and clinical material must be demonstrated to the relevant authorities before proceeding with further clinical studies. From our CMOs we receive process development-derived material for preclinical testing and material meeting GMP standards for clinical supplies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We rely on and will continue to rely on CMOs for both, drug substance and drug product. We seek to establish a good relationship in order to expeditiously solve problems should they arise. Our contract manufacturers have extensive capacities and a certain flexibility to adjust to demand. Likewise, our manufacturers purchase and stock materials required for production usually from multiple sources and should therefore be less vulnerable to potential shortages. Generally, we need to commit to certain manufacturing slots and capacities in advance, which typically involves the payment of reservation fees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have successfully scaled up the AFM13 process and manufacturing material to meet the clinical drug supply demands for our clinical studies. We are currently working with several external companies to establish a manufacturing process with a productivity adequate for the commercial phase.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">75</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Commercialization</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have not yet established a sales, marketing or product distribution infrastructure because our lead product candidate is still at an early stage in clinical development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Prior to receiving marketing approvals, we plan to build a focused sales and marketing organization to sell our products if and when marketing approval is granted. We believe that such an organization will be able to address the community of oncologists who are the key specialists in treating the patient populations for which our product candidates are being developed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also plan to build a marketing and sales management organization to create and implement marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to approved products and establishing relationships with thought leaders in relevant fields of medicine.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Competition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">There are many companies developing or marketing treatments for cancer disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work, among others, either by using next-generation antibody technology platforms or by new immunological approaches to address specific cancer targets. These treatments are often combined with one another in an attempt to maximize the response rate. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule, as we are.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Clinical phase 2 data with the anti-PD-1 CPIs nivolumab and pembrolizumab in HL have been published. These data indicate that treatment with anti-PD-1 antibodies results in high response rates in the salvage setting of HL. In 2016, the FDA granted accelerated approval, and the European Commission granted approval for nivolumab in classical HL patients who have relapsed or progressed after autologous hematopoietic stem cell transplantation and brentuximab vedotin (Adcetris&#xAE;). In 2017, the FDA granted accelerated approval, and the European Commission granted approval for pembrolizumab in adult and pediatric patients with refractory cHL who have relapsed after 3 or more prior lines of therapy, and the European Commission granted approval for pembrolizumab in adult patients with relapsed or refractory cHL who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin. Phase 2 and phase 3 studies of brentuximab vedotin in combination with nivolumab are ongoing. If AFM13 were to be approved for HL, we could be in competition with these therapies, as well as any other therapies or combination regimens that comprise the standard of care that AFM13 could potentially displace. Several other agents have reached proof of concept clinical studies in HL, including Afinitor (Novartis AG), and lenalidomide (Celgene).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Bretuximab vedotin, or Adcetris&#xAE;, an antibody-drug conjugate targeting CD30, was approved by the FDA in relapsed/refractory HL in 2011. In addition, Adcetris&#xAE; was approved by the FDA in 2018 for the treatment of previously untreated Stage 3/4 cHL in combination with chemotherapy. In the European Union, Adcetris&#xAE; is approved for similar indications. Adcetris&#xAE; is also indicated for previously treated systemic anaplastic large cell lymphoma (ALCL), primary cutaneous ALCL, and CD30 positive mycosis fungoides, as well as for previously untreated systemic ALCL or other CD30 positive peripheral T-cell lymphomas in combination with </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">76</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">chemotherapy in the US and for previously untreated systemic ALCL in Europe. Adcetris&#xAE; is currently being investigated in various combinations in HL, including checkpoint inhibitors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We expect that our ROCK&#xAE; platform as well as our novel antibody formats derived from this platform will serve as the basis for future product candidates and collaborations with pharmaceutical companies. Other companies also have developed platform technologies that compete with our platforms. For example, Dragonfly Therapeutics is developing TriNKET, which specifically activates cells of the innate and adaptive immune system and has recently started clinical development of one of these TriNKET assets. GT Biopharma is developing its TriKEs and TetraKEs platform designed to target natural killer cells and tumor cells forming an immune synapse between the NK cell and the tumor cell thereby inducing NK cell activation at that site, and recently started its clinical development.&nbsp;&nbsp;Compass Therapeutics is also developing bispecific antibodies that engage the innate immune system, but these have not yet reached the clinic.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies complementary to, or necessary for, our programs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, our marketing capabilities, the level of generic competition and the availability of reimbursement from government and other third-party payors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our competitors also may obtain FDA, European Commission or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. The regulatory framework to approve biosimilar products has already been created in Europe and the United States.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with them as such. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition to currently marketed therapies, there are also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety, dosing </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">77</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">convenience and other benefits that are not provided by currently marketed therapies or our drugs. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If our lead product candidates are approved for the indications for which we are currently undertaking clinical studies, they will compete with the therapies and currently marketed drugs discussed elsewhere in this document.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Government Regulation and Product Approval</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government authorities in all major pharmaceutical markets extensively regulate, among other things, the research, non-clinical and clinical development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing and import and export of pharmaceutical products such as those we are developing. Although our initial focus will be on the United States and Europe, we will develop and seek marketing approval for our products also in other countries and territories, such as Canada or Japan, and for markets that follow the leading authorities, such as Brazil or South Korea. The processes for obtaining regulatory approvals in the United States, Europe and in other countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">International Conference on Harmonization (ICH)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, or the ICH, is a project that brings together the regulatory authorities of Europe, Japan and the United States and experts from the pharmaceutical industry in the three regions to discuss scientific and technical aspects of pharmaceutical product registration. The purpose of ICH is to reduce or obviate the need to duplicate the testing carried out during the research and development of new medicines by recommending ways to achieve greater harmonization in the interpretation and application of technical guidelines and requirements for product registration. Harmonization would lead to a more economical use of human, animal and material resources, the elimination of unnecessary delay in the global development and availability of new medicines while maintaining safeguards on quality, safety, and efficacy, and regulatory obligations to protect public health.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ICH guidelines have been adopted as law in several countries. In many areas of drug development ICH has resulted in comparable requirements, for instance with respect to the Common Technical Document, or the CTD, which has become the standard dossier format&nbsp;&nbsp;for filings for market authorization in several jurisdictions. Thus, ICH has facilitated a more efficient path to markets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">FDA Approval Process</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act (PHSA), the Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations govern, among other things, the research, non-clinical and clinical development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines or civil or criminal penalties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The PHSA emphasizes the importance of manufacturing control for biological products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases in the United States and between states.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">78</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The process required by the FDA before a new biologic may be marketed in the United States is long and expensive and due to the nature of biological products inherently uncertain. Biologics development in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND application which must become effective before clinical testing may commence. Furthermore, adequate and well-controlled clinical studies are required in order to establish the safety and effectiveness of the biologic for each indication for which FDA approval is sought. Developing the data to satisfy FDA marketing authorization pre requirements typically takes many&nbsp;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory (GLP) principles. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical study protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">An IND must become effective before United States clinical studies may begin. A 30&#8209;day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30&#8209;day period, the clinical study proposed in the IND may begin.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Clinical studies involve the administration of the IND or biologic to healthy volunteers or patients with the condition under investigation, all under the supervision of a qualified investigator. Clinical studies must be conducted: (i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical study sponsors, investigators, and monitors; as well as (iii)&nbsp;under protocols detailing the objectives of the study, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The FDA may order the temporary, or permanent, discontinuation of a clinical study at any time, or impose other sanctions, if it believes that the clinical study either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical study participants. The study protocol and informed consent information for participants in clinical studies must also be submitted to an institutional review board (IRB) for approval. An IRB may also require the clinical study at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#x2019;s requirements, or may impose other conditions. The study sponsor may also suspend a clinical study at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable health risk.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Clinical studies to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap or be combined. In phase 1, the biologic is initially introduced into healthy human subjects or patients and is tested to assess PK, pharmacological actions, side effects associated with increasing doses, and, if possible, early evidence on effectiveness. In the case of some products for more severe or life-threatening diseases, such as cancer treatments, initial human testing may be conducted in the intended patient population. Phase 2 usually involves studies in a limited patient population to determine the effectiveness of the biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in phase 2 studies, phase 3 studies are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical study sites. These phase 3 clinical studies are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit the FDA to evaluate the overall benefit-risk relationship of the biologic and to provide adequate information for the labeling of the biologic. Studies conducted outside of the US under similar, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">79</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">GCP-compliant conditions in accordance with local applicable laws may also be acceptable to the FDA in support of product licensing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Sponsors of clinical studies for investigational drugs must publicly disclose certain clinical study information, including detailed study design and study results in NIH public ClinicalTrials.gov databases. These requirements are subject to specific timelines and apply to most controlled clinical studies of FDA-regulated products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">After completion of the required clinical testing, a Biologics License Application (BLA) is prepared and submitted to the FDA. FDA review and approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#x2019;s pharmacology, chemistry, manufacture and controls and must demonstrate the safety and efficacy of the product based on these results. The BLA must also contain extensive manufacturing information. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, as well as annual product and establishment user fees, which may total several million dollars and are typically increased annually.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The FDA has 60&nbsp;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the agency&#x2019;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of BLAs. Most such applications for standard review biologics are reviewed within ten&nbsp;months from the date the application is accepted for filing. Although the FDA often meets its user fee performance goals, it can extend these timelines if necessary, and its review may not occur on a timely basis at all. The FDA usually refers applications for novel biologics many times to an advisory committee&#x2014;typically a panel that includes clinicians and other experts&#x2014;for review and evaluation of data concerning the safety and efficacy of marketed investigational drug products for use in the treatment of patients and makes appropriate recommendations to the FDA Commissioner.&nbsp;The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic is manufactured. The FDA will not approve the product unless it verifies that compliance with cGMP standards is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe and effective in the indication studied.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">After the FDA evaluates the BLA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission which requires substantial additional testing and / or information, in order for the FDA to reconsider the application. Once those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&nbsp;months depending on the type of information included. The FDA approval is never guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, effective, pure and potent and the facility where the product will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. The extension of an approval for a biologic may be significantly more limited than initially requested in the application, which might restrict the commercial value of the product. The FDA may also require that certain contraindications, warnings, or precautions are included in the prescription leaflet. In addition, as a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (REMS) in order to track and thereby ensure that the benefits of the biologic outweigh the potential risks for patients. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS might materially affect the potential market and profitability of the biologic. Moreover, product approval may require, as a condition of approval, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">80</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">substantial post-approval commitments, including, e.g., the testing and surveillance of the biologic&#x2019;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or safety concerns are identified following initial marketing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As part of the manufacturing process, the marketing authorization holder is required to perform specific tests for each drug substance and drug product batch before it is released for distribution. If the product is subject to official lot release by the FDA, marketing authorization holder has to submit specific release data of each product batch to the FDA together with a release protocol, showing a summary of previous release specification data from all the batches produced so far as well as the data from the current batch. The FDA may also perform certain confirmatory tests on batches of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. After approval of biologics, marketing authorization holder must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Expedited Program</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Speeding the availability of drugs that treat serious diseases are in everyone&#x2019;s interest, in particular when the drugs are the first available treatment or if the drug has advantages over existing treatments. The FDA has developed four distinct approaches to making such drugs available as rapidly as possible: a) Priority Review, b) Breakthrough Therapy, c) Accelerated Approval and d) Fast Track. In short:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Priority Review</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">: A Priority Review designation means that FDA&#x2019;s goal is to take action on the application within 6&nbsp;months.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Breakthrough Therapy:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> A process designed to expedite the development and review of drugs which may demonstrate substantial improvement over available therapy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Accelerated Approval:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> These regulations allow drugs for serious conditions that fill an unmet medical need to be approved based on a surrogate endpoint.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Fast Track:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> This is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Biosimilars</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Patient Protection and Affordable Care Act, which we refer to as the Affordable Care Act, signed into law on March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009. That Act created an approval pathway authorizing the FDA to approve biosimilars. Biosimilars are biological products which are &#x201C;highly similar&#x201D; to a previously approved biologic product or &#x201C;reference product&#x201D; and for which there are no meaningful differences between the biosimilar product and the reference product in terms of analytics, safety, purity, potency and clinical efficacy. To date, several biosimilars have been approved under the BPCIA framework.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Advertising and promotion</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Once a BLA is approved, a product will be subject to continuing post-approval regulatory requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these regulations can result in significant penalties, including the issuance of warning letters directing a company to correct deviations from FDA standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA, and federal and state civil and criminal investigations and prosecutions.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">81</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Adverse event reporting and cGMP compliance</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Adverse event reporting and submission of periodic safety reports are required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, manufacturing, packaging, labeling, storage and distribution procedures must continue to conform to cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Orphan drug</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics intended to treat a rare disease or condition&#x2014;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a particular product to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different biologic for the same disease or condition, or the same biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have received orphan drug designation for AFM13 for the treatment of HL in the United States and Europe and for and T-cell lymphoma in the United States</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Other healthcare laws and compliance requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (for example, the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">EU Approval Process</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The EMA is a decentralized scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally-authorized medicinal products. It is responsible for the scientific evaluation of </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">82</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">applications for EU marketing authorizations, as well as the development of technical guidance and the provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts throughout the European Union, nominated by the member states. The EMA draws on resources of over 40 National Competent Authorities (the NCAs) of EU member states. The Paul Ehrlich Institute, or PEI, is one of the NCAs for Germany, and regulates, among others, antibody products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The process regarding approval of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU Good Laboratory Practice regulations;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">submission to the relevant national authorities of a clinical study application or CTA for each study in humans, which must be approved before the study may begin;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">performance of adequate and well-controlled clinical studies to establish the safety and efficacy of the product for each proposed indication;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">submission to the relevant competent authorities of a Marketing Authorization Application or MAA, which includes the data supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced current Good Manufacturing Practices;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">potential audits of the non-clinical and clinical study sites that generated the data in support of the MAA; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the product.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Preclinical studies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds for testing must comply with the relevant EU regulations and requirements. The results of the preclinical tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Clinical study approval</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Pursuant to the Clinical Trials Directive 2001/20/EC, as amended, a system for the approval of clinical studies in the European Union has been implemented through national legislation of the member states. Under this system, approval must be obtained from the competent national authority of each EU member state in which a study is planned to be conducted. To this end, a CTA is submitted, which must be supported by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents. Furthermore, a clinical study may only be started after a competent ethics committee has issued a favorable opinion on the clinical study application in that country.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">83</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Manufacturing and import into the EU of investigational medicinal products is subject to the holding of appropriate authorizations and must be carried out in accordance with current Good Manufacturing Practices.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Health authority interactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the development of a medicinal product, frequent interactions with the health authorities are important to ensure all relevant input and guidelines/regulations are taken into account in the overall program. We have established an ongoing dialogue with the PEI, the national competent authority in Germany regulating, among others, antibody products.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Informal interactions:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> We have had several informal discussions by phone with the PEI.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Formal CHMP scientific advice:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> We had a formal scientific advice meeting with the Committee for Medicinal Products for Human Use or CHMP at the EMA in October&nbsp;2018 to discuss the further clinical development of AFM13.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Formal feedback:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;We have had several scientific advice meetings with the PEI on AFM13 and AFM11. We also received written scientific advice from the PEI on special questions of the non-clinical development of AFM13 and AFM11. In the most recent scientific advice meeting with the FDA (October 2018) the planned phase 2 study for AFM13 was reviewed and guidance was received which has been incorporated in our clinical development plan. Following discussions with the FDA, we announced our registrational pathway and updated clinical development plans for AFM13. We are in the process of initiating a phase 2 study evaluating the efficacy and safety of AFM13 as monotherapy in patients with relapsed or refractory CD30 positive peripheral T cell lymphoma (PTCL) or transformed mycosis fungoides (TMF), a subset of cutaneous T cell lymphoma (CTCL), in the first half of 2019.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Business pipeline meetings:</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> We have not yet sought business pipeline meetings.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Paediatric studies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regulation (EC) 1901/2006, which came into force on January&nbsp;26, 2007, aims to facilitate the development and accessibility of medical products for use in children without subjecting children to unnecessary studies, or delaying the authorization of medicinal products for use in adults. The regulation established the Paediatric Committee, or PDCO, which is responsible for coordinating the EMA&#x2019;s activities regarding medicines for children. The PDCO&#x2019;s main role is to determine all the studies that marketing authorization applicants need to do in the pediatric population as part of the so-called Paediatric Investigation Plans, or PIPs. All applications for marketing authorization for new medicines that were not authorized in the European Union before January&nbsp;26, 2007 have to include either the results of studies carried out in children of different ages (as agreed with the PDCO), or proof that a waiver or a deferral of these studies has been obtained from the PDCO. As indicated, the PDCO determines what pediatric studies are necessary and describes them in a PIP. This requirement for pediatric studies also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The PDCO can grant deferrals for some medicines, allowing a company to delay development of the medicine in children until there is enough information to demonstrate its effectiveness and safety in adults and can also grant waivers when development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Before a MAA can be filed, or an existing marketing authorization can be varied, the EMA checks that companies are in compliance with the agreed studies and measures listed in each relevant PIP.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">84</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regulation (EC) 1901/2006 also introduced several incentives for the development of medicines for children in the EU:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">medicines that have been authorized across the European Union in compliance with an agreed PIP are eligible for an extension of their patent protection by six&nbsp;months. This is the case even when the pediatric studies&#x2019; results are negative;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">for orphan medicines, the incentive is an additional two&nbsp;years of market exclusivity, extending the typical 10&#8209;year period to 12&nbsp;years;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">scientific advice and protocol assistance at the EMA are free of charge for questions relating to the development of medicines for children; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">medicines developed specifically for children that are already authorized but are not protected by a patent or supplementary protection certificate may be eligible for a paediatric use marketing authorization, or PUMA. If a PUMA is granted, the product will benefit from 10&nbsp;years of market protection as an incentive for the development of the product for use in children.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The indications we pursue, especially those in certain hematologic malignancies, involve pediatric patients and we shall prepare PIPs at the appropriate time.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Marketing authorization application</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Authorization to market a product in the EU member states proceeds under one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the mandatory scope of the centralized procedure, only this procedure will be described here.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Centralized authorization procedure</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Certain drugs, including medicinal products developed by means of biotechnological processes, must be approved via the centralized authorization procedure for marketing authorization. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid in all EU member states. The other European Economic Area member states (namely Norway, Iceland and Liechtenstein) are also obligated to recognize the Commission decision. The EMA and the European Commission administer the centralized authorization procedure.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the centralized authorization procedure, the CHMP serves as the scientific committee that renders opinions about the safety, efficacy and quality of human products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#x2019;s national drug authority, with one of them appointed to act as Rapporteur for the co-ordination of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s)&nbsp;continue to monitor the product throughout its life cycle. The CHMP is required to issue an opinion on an initial MAA within 210&nbsp;days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of experts. If the CHMP concludes that the quality, safety and efficacy of the medicinal product are sufficiently proven, it adopts a positive opinion. The CHMP&#x2019;s opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. Once the procedure is completed, a European Public Assessment Report, or EPAR, is produced.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">After a drug has been authorized and launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">85</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Accelerated assessment procedure</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">When an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article&nbsp;14(9)&nbsp;of Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to issue an opinion within 150&nbsp;days of receipt of a valid application, subject to clock stops. We believe that many of our product candidates may qualify for this provision and we will take advantage of this provision as appropriate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Conditional approval</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As per Article&nbsp;14(7)&nbsp;of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data than are normally required, subject to specific obligations being imposed on the authorization holder. These specific obligations are to be reviewed annually by the EMA. The list of these obligations shall be made publicly accessible. Such an authorization shall be valid for one&nbsp;year, on a renewable basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Period of authorization and renewals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A marketing authorization is initially valid for five&nbsp;years and may then be renewed on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder shall provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variants introduced since the marketing authorization was granted, at least six&nbsp;months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three&nbsp;years after authorization shall cease to be valid (the so-called sunset clause).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Orphan drug designation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regulation (EC) 141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(a)(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union when the application is made, or;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(a)(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment; and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regulation (EC) 847/2000 sets out criteria for the designation of orphan drugs.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">86</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. This period may, however, be reduced to six&nbsp;years if, at the end of the fifth&nbsp;year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#x201C;clinically relevant superiority&#x201D; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth&nbsp;year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 shall be eligible for incentives made available by the European Union and by the member states to support research into, and the development and availability of, orphan drugs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have applied for and been granted orphan status in the European Union for AFM13 for the treatment of HL.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Regulatory data protection</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for new medicinal products benefit from an 8+2+1&nbsp;year period of regulatory protection.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This regime consists of a regulatory data protection period of eight&nbsp;years plus a concurrent market exclusivity of ten&nbsp;years plus an additional market exclusivity of one further&nbsp;year if, during the first eight&nbsp;years of those ten&nbsp;years, the marketing approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party may reference the preclinical and clinical data of the reference product beginning eight&nbsp;years after first approval, but the third party may market a generic version only after ten (or eleven)&nbsp;years have lapsed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As indicated, an additional period of exclusivity&nbsp;can be applied for when an applicant has complied with all requirements as set forth in an approved PIP.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">International Regulation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical studies, commercial sales, and distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Pharmaceutical Coverage, Pricing, and Reimbursement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the United States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The division of competences within the European Union leaves to Member States the power to organize their own social security systems, including health care policies to promote the financial stability of their health care insurance systems. According to Article&nbsp;168 of the Treaty on the Functioning of the European Union or TFEU, &#x201C;Union action shall respect the responsibilities of the Member States for the definition of their health policy and for the organization and delivery of health services and medical care.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">87</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In this context, the national authorities are free to set the prices of medicinal products and to designate the treatments that they wish to reimburse under their social security system. However, the European Union has defined a common procedural framework through the adoption of Council Directive 89/105/EEC, which is generally known as the &#x201C;Transparency Directive.&#x201D; This instrument aims to ensure that national pricing and reimbursement decisions are made in a transparent manner and do not disrupt the operation of the internal market.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Pharmaceutical Pricing and Reimbursement systems established by Member States are usually quite complex. Each country uses different schemes and policies, adapted to its own economic and health needs. We would have to develop or access special expertise in this field to prepare health economic dossiers on our medicinal products if we would market our products, if and when approved, in the EU.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Organizational structure<a name="COrganizationalstructure_547242"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The registrant corporation Affimed N.V. has three direct or indirect wholly owned subsidiaries &#x2013; Affimed GmbH, AbCheck s.r.o.&nbsp;and Affimed, Inc. that are each listed in Exhibit 8.1 filed hereto. We primarily operate our business out of our operating subsidiary, Affimed GmbH. AbCheck s.r.o.,&nbsp;&nbsp;and Affimed, Inc. are direct subsidiaries of the operating subsidiary Affimed GmbH.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Property, plant and equipment<a name="DPropertyplantandequipment_216484"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our headquarters are in Heidelberg, Germany, where we occupy office and laboratory space at the Technologiepark (Technology Park). Approximately 75% of this space is under a revolving 24-month lease period, with a 12-month termination period. The lease could expire in 2021 if notice to terminate is provided by either party by February 2020. No such notice has been received to date. The remaining 25% of this facility is under a fixed term lease period until February 2021. This facility serves as the corporate headquarters and central laboratory facility. We also lease office and laboratory space in the Czech Republic that is contracted until 2020 with a period of notice of three months. We believe that our existing facilities are adequate to meet current needs and that suitable additional alternative spaces will be available in the future on commercially reasonable terms.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;4A. UNRESOLVED STAFF COMMENTS<a name="ITEM4AUNRESOLVEDSTAFFCOMMENTS_165300"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS<a name="ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">You should read the following discussion and analysis of our financial condition and results of operations together with the information under &#x201C;Selected Financial Data&#x201D; and our consolidated audited financial statements, including the notes thereto, included in this Annual Report. The following discussion is based on our financial information prepared in accordance with IFRS as issued by the IASB, which might differ in material respects from generally accepted accounting principles in other jurisdictions. The following discussion includes forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including, but not limited to, those described under &#x201C;Risk Factors&#x201D; and elsewhere in this Annual Report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Operating Results<a name="AOperatingresults_63656"></a>&nbsp;Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are a clinical-stage immuno-oncology company focused on discovering and developing highly targeted cancer immunotherapies. Our product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body&#x2019;s own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called innate immune cells (Natural Killer cells, or NK cells and macrophages) and T cells. Leveraging our fit-for-purpose ROCK&#xAE; platform, we develop proprietary, next-generation bispecific antibodies, so-called innate cell </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">88</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">engagers, which are designed to direct and establish a bridge between innate immune cells and cancer cells. Our innate cell engagers have the ability to bring innate immune cells into proximity and trigger a signal cascade that leads to the destruction of cancer cells. Due to their novel tetravalent architecture (which provides for four binding domains), our innate cell engagers bind to their targets with high affinity and have half-lives that allow regular intravenous administration, with different dosing schemes being explored to allow for improved exposure in heavily pretreated patient populations. Antibodies developed from our ROCK&#xAE; platform include molecules which we refer to as innate cell engagers. We believe, based on their mechanism of action and the preclinical and clinical data we have generated to date, that our product candidates, alone or in combination, may ultimately improve response rates, clinical outcomes and survival in cancer patients and could eventually become a cornerstone of modern targeted oncology care. Building on our leadership in the innate immune cell space, we are also developing novel tetravalent, bispecific antibody formats with the potential to tailor immune-engaging therapy to different indications and settings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To date, we have financed our operations primarily through our public offerings of our common shares, private placements of equity securities, the incurrence of loans including convertible loans and through government grants and payments for collaborative research and development services. Through December 31, 2019, we have raised an aggregate of &#x20AC;258.4 million through the issuance of equity and incurrence of loans. To date, we have not generated any revenues from product sales or royalties. Based on our current plans, we do not expect to generate product or royalty revenues unless and until we or any collaboration partner obtain marketing approval for, and commercialize, any of our product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have generated losses since we began our drug development operations in 2000. For the year ended December 31, 2019, we incurred a net loss of &#x20AC;32.4 million. As of December 31, 2019, we had an accumulated deficit of &#x20AC;234.5 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We expect to continue incurring losses as we continue our preclinical and clinical development programs, apply for marketing approval for our product candidates and, subject to obtaining regulatory approval for our product candidates, build a marketing and sales team to commercialize our product candidates. Our profitability is dependent upon the successful development, approval, and commercialization of our product candidates and achieving a level of revenues adequate to support our cost structure. We may never achieve profitability, and unless and until we do, we will continue to need to raise additional cash. We intend to fund future operations through additional equity and debt financings, and we may seek additional capital through arrangements with strategic partners or from other sources.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Collaboration Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into strategic collaborations for some of our therapeutic programs. As part of our business development strategy, we aim to increase the number of our research collaborations in order to derive further value from our platforms and more fully exploit their potential. Key terms of our current material collaborations are summarized below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Genentech</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On August 24, 2018 we entered into a research collaboration and license agreement with Genentech, a member of the Roche Group, for the development and commercialization of certain product candidates that contain novel NK cell engager-based immunotherapeutics to treat multiple cancers. Under the terms of the agreement, in the fourth quarter of 2018 we received $96 million in initial upfront payments and other funding and additional payments in 2019 for development milestones and a final target nomination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We recognized revenues of &#x20AC;19.7 million in 2019.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">89</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Financial Operations Overview</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Revenue</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To date, our revenues have consisted principally of collaboration and service revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Collaboration revenue.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;Collaboration revenue of &#x20AC;0.4 million for the year ended December 31, 2017 was from research and development services under the license and development agreement with Amphivena (&#x20AC;0.2 million) and from the LLS collaboration (&#x20AC;0.2 million). Collaboration revenue of &#x20AC;22.0 million for the year ended December 31, 2018 was from the Genentech collaboration (&#x20AC;21.8 million) and from the LLS collaboration (&#x20AC;0.2 million). Collaboration revenue of &#x20AC;19.7 million for the year ended December 31, 2019 was from the Genentech collaboration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Service revenue.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;Service revenue is primarily revenue from service contracts entered into by AbCheck, our wholly owned, independently operated antibody screening platform. We recognized &#x20AC;1.6 million, &#x20AC;1.7 million and &#x20AC;1.7 million of service revenue in 2017, 2018 and 2019, respectively. Service revenue of AbCheck is dependent from third party contracts as well as from the utilization of the Unit by Affimed. The increase or decrease of the use of AbCheck&#x2019;s service capabilities by Affimed has an impact on AbCheck&#x2019;s ability to generate third party revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the future, the timing of our revenue may vary significantly from the receipt of the related cash flows, as the revenue from some upfront or initiation payments is deferred and recognized as revenue over the estimated service period, while other revenue is earned when received, such as milestone payments or service fees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our revenue has varied substantially, especially due to the impact of collaboration revenue received from Genentech. The amount of future revenue is dependent on the services performed and milestones reached for our existing collaborations and on our ability to conclude new collaboration arrangements and the terms we are able to negotiate with our partners.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Other Income</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other Income in 2017 primarily relates to earned income through several grants and/or contracts with the German government, the European Union and other educational institutions on behalf of the German government, primarily with respect to research and development activities related to the use of the immune cell engager technology in various indication areas. In 2018 and 2019, other Income primarily relates to foreign exchange gains.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Research and Development Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development expenses consist principally of:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">salaries for research and development staff and related expenses, including management benefits;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">costs for production of preclinical compounds and drug substances by contract manufacturers;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">fees and other costs paid to contract research organizations in connection with additional preclinical testing and the performance of clinical trials;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">costs of related facilities, materials and equipment;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">costs associated with obtaining and maintaining patents and other intellectual property;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">90</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">amortization and depreciation of tangible and intangible fixed assets used to develop our product candidates; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">expenses for share-based payments.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on our current budget we expect that our total research and development expenses in 2020 will be in the range of &#x20AC;40 to &#x20AC;50 million. Our research and development expenses primarily relate to the following key programs:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM13. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In November 2019, we initiated a registration directed phase 2 study of AFM13 as monotherapy in relapsed or refractory patients suffering from peripheral T cell lymphoma (pTCL). The study protocol has been agreed upon with the U.S. Food and Drug Administration (FDA). In addition, this study will, as a separate cohort, investigate the initial efficacy of AFM13 as monotherapy in patients suffering from transformed mycosis fungoides (T-MF). In September 2019, the FDA cleared an investigational new drug application (IND) for an investigator-sponsored Phase 1 study, in which the University of Texas MD Anderson Cancer Center (MDACC) plans to investigate the combination of AFM13 with allogeneic NK cells. MDACC intends to administer a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells in different doses (numbers of pre-loaded NK cells) into patients with relapsed/refractory CD30-positive lymphoid malignancies. In 2017, an investigator-sponsored Phase 1b/2a study was initiated by Columbia University to investigate AFM13 as monotherapy in patients with relapsed or refractory CD30-positive lymphoma with cutaneous manifestation. In 2016, we initiated a phase 1b study investigating the combination of AFM13 with Merck&#x2019;s anti-PD1 antibody Keytruda&#xAE; (pembrolizumab) in patients with relapsed/refractory HL. In this study, enrollment is complete and final data were recently presented. Different dosing protocols are being explored in the investigator-initiated monotherapeutic phase 2a clinical trial of AFM13 in relapsed/refractory Hodgkin Lymphoma, or relapsed/refractory HL, to allow for improved exposure in more heavily pretreated patient populations. The study has now completed recruitment under the new study design. We anticipate that our research and development expenses in 2020 for AFM13 will increase compared to those for 2019 due to the initiation of new clinical studies, pre-clinical studies with collaboration partners and the preparation of the production of AFM13 for commercial purposes.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM11</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. &nbsp;The phase 1 clinical trials of AFM11 were placed on clinical hold and recruitment stopped in October 2018. In May 2019, we received notification from the FDA that additional data would be needed to determine whether the AFM11 clinical hold may be lifted. In line with the strategic focus on our innate immunity portfolio, we have made the decision to terminate the Phase 1 clinical program of AFM11. This decision took into consideration the competitive landscape of B-cell directed therapies currently in development and associated resources needed for further development of AFM11. We subsequently informed the FDA of our intention to terminate the clinical program.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM24. AFM24,&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, is in effect for a phase 1/2a clinical trial in patients with advanced cancers known to express EGFR. We anticipate that our research and development expenses in 2020 for AFM24 will increase compared to those for 2019 due to the beginning of the clinical trial of AFM24 in patients.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Other projects and infrastructure costs.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;Our other research and development expenses relate to our multiple myeloma program AFM26 (through the third quarter of 2018) and our Genentech collaboration and early stage development/discovery activities. We have allocated a material amount of our resources to such discovery activities. The expenses mainly consist of salaries, manufacturing costs for pre-clinical study material and pre-clinical studies. In addition, we incur a significant amount of costs associated with our research and development that are non-project specific, including intellectual property-related expenses, depreciation expenses and facility costs. Because these are less dependent on individual ongoing programs, they are not allocated to specific projects. We assume that other projects and infrastructure costs will increase in 2020 due to increased early stage development/discovery activities.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">91</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Since January 1, 2012, we have cumulatively spent &#x20AC;185.3 million on research and development. In the years ended December 31, 2017, 2018, and 2019, we spent &#x20AC;21.5 million, &#x20AC;35.1 million and &#x20AC;43.8 million, respectively, on research and development; &#x20AC;5.6 million, &#x20AC;8.7 million, and &#x20AC;19.5 million thereof on AFM13; &#x20AC;2.8 million, &#x20AC;5.8 million, and &#x20AC;2.4 million thereof on AFM11 and &#x20AC;2.5 million, &#x20AC;5.8 million, and &#x20AC;4.3 million thereof on AFM24. Our research and development expenses may vary substantially from period to period based on the timing of our research and development activities, including due to timing of initiation of clinical trials and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance and broaden the clinical development of AFM13, AFM24 and certain of our other product candidates and further advance the research and development of our preclinical product candidates. The successful development of our product candidates is highly uncertain. At this time we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any products that we may develop;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the number and characteristics of product candidates that we pursue;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost, timing, and outcomes of regulatory approvals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost and timing of establishing sales, marketing, and distribution capabilities; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the terms and timing of any collaborative, licensing, and other arrangements that we may establish, including any milestone and royalty payments thereunder.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A change in the outcome of any of these variables with respect to the development of AFM13 or any other product candidate that we may develop could mean a significant change in the costs and timing associated with the development of such product candidate. For example, if the FDA or other regulatory authority were to require us to conduct preclinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development, if we experience significant delays in enrollment in any clinical trials or if we encounter difficulties in manufacturing our clinical supplies, we could be required to expend significant additional financial resources and time on the completion of the clinical development.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">General and Administrative Expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our general and administrative expenses consist principally of:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">salaries for employees other than research and development staff, including benefits;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">business development expenses, including travel expenses;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">professional fees for auditors and other consulting expenses not related to research and development activities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">professional fees for lawyers not related to the protection and maintenance of our intellectual property;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">cost of facilities, communication and office expenses;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">IT expenses;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">92</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">amortization and depreciation of tangible and intangible fixed assets not related to research and development activities; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">expenses for share-based payments.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We expect that our general and administrative expenses in 2020 will be higher compared to the expenses in 2019, and will further increase in the future as our business expands. These increases will likely include costs of additional personnel, additional legal fees, accounting and audit fees, managing directors&#x2019; and supervisory directors&#x2019; liability insurance premiums and costs related to investor relations. In addition, we may grant share-based compensation awards to key management personnel and other employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Results of Operations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The numbers below have been derived from our audited consolidated financial statements for the years ended December 31, 2017, 2018 and 2019. The discussion below should be read along with these financial statements, and it is qualified in its entirety by reference to them.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Comparison of the years ended December 31, 2018 and 2019</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in &#x20AC; thousand)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">23,735&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">21,391&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other income/(expenses)&#x2014;net</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1,515&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">290&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (35,148)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(43,791)
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">General and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,638)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (10,266)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating income/(loss)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,536)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,376)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Finance income/(costs)&#x2014;net</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">60&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">15&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income/(Loss) before tax</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,361)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Income/(loss) for the period</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (19,477)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,365)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total comprehensive income/(loss)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (24,208)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,997)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Earnings/(loss) per common share in &#x20AC; per share</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (0.32)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (0.50)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Revenue</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue decreased from &#x20AC;23.7 million for the year ended December 31, 2018 to &#x20AC;21.4 million for the year ended December 31, 2019. Revenue for the year ended December 31, 2019 mainly consisted of revenue from the Genentech collaboration.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Research and development expenses</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">R&amp;D Expenses by Project</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Change %</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:18.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in &#x20AC; thousand)</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Project</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">AFM13</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,711</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,471</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">124&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">AFM11</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,776</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,418</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58)
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">AFM24</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,788</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,327</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(25)
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other projects and infrastructure costs</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 14,021</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16,671</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">19&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share-based payment expense</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 852</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 904</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">6&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 35,148</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 43,791</font></p>
				</td>
				<td valign="bottom" style="width:02.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">25&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">93</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development expenses increased 25% from &#x20AC;35.1 million in the year ended December 31, 2018 to &#x20AC;43.8 million in the year ended December 31, 2019, due to higher expenses for AFM13 and for other projects and infrastructure. The variances in project related expenses between the year ended December 31, 2018 and the corresponding period in 2019 are mainly due to the following projects:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM13. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the year ended December 31, 2019, we incurred higher expenses than in the year ended December 31, 2018 primarily due to higher expenses for the preparation of new clinical trials and manufacturing activities for the clinical trial material.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM11. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the year ended December 31, 2019, clinical expenses were lower than in the year ended December 31, 2018. The majority of the expenses in the year ended December 31, 2019 are related to costs for the termination of the phase 1 dose-finding study in NHL and the phase 1 dose-finding study in ALL.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">AFM24.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;In the year ended December 31, 2019, we incurred lower expenses than in the year ended December 31, 2018. Expenses in the year ended December 31, 2019 primarily relate to the preparation of the phase 1/2a clinical trial and manufacturing activities for the clinical trial material.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Other projects and infrastructure costs. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the year ended December 31, 2019, expenses increased compared to the year ended December 31, 2018, primarily due to&nbsp;&nbsp;higher expenses incurred in relation to our earlier stage programs and discovery/early stage development activities and infrastructure costs.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">General and administrative expenses</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">General and administrative expenses increased 7% from &#x20AC;9.6 million in the year ended December 31, 2018 to &#x20AC;10.3 million in the year ended December 31, 2019. In 2019, general and administrative expenses were largely affected by personnel expenses (&#x20AC;5.4 million) and legal, consulting and audit costs (&#x20AC;3.1 million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Finance income / (costs)-net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We recognized finance net income for the year ended December 31, 2019 of &#x20AC;15,000 compared &#x20AC;60,000 for the year ended December 31, 2018. The year ended December 31, 2019 was primarily affected by interest income of &#x20AC;0.6 million and interest expenses of &#x20AC;0.5 million. The year ended December 31, 2018 was primarily affected by foreign exchange gains of &#x20AC;0.7 million and interest expenses of &#x20AC;0.8 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Income tax expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the year ended December 31, 2019, we recorded income tax expense of &#x20AC;4,000 due to changes in deferred taxes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Comparison of the years ended December 31, 2017 and 2018</font>
		</p>
		<p style="margin:0pt 0pt 12pt 10.8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Refer to our Annual Report on Form 20-F for fiscal year ended December 31, 2018</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Critical Judgments and Accounting Estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">94</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial&nbsp;year are included in note 4 to our consolidated financial statements included elsewhere in this Annual Report and below:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Share-Based Payments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We issue share-based payment awards under the terms of our Equity Incentive Plan 2014. We determine the compensation expense by estimating the fair value of a stock option as of the date of grant.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, we allocate the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, we have continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We estimate that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Financial instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">We recognize our preferred shares in Amphivena at fair value (level 2). As Amphivena is not a public company, substantial judgment was required in order to estimate the fair value as at December 31, 2019 (see note 13 to our consolidated financial statements). We based our judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Recent Accounting Pronouncements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We refer to note 4 to our consolidated financial statements as of and for the year ended December 31, 2019 with regards to new standards and interpretations not yet adopted by us.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">95</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">JOBS Act Exemptions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As September 17, 2019 represented the fifth anniversary of the date of the first sale of our common shares pursuant to an effective registration statement under the Securities Act, we no longer qualify as an &#x201C;emerging growth company&#x201D; as defined in the JOBS Act, commencing December 31, 2019. As a result, our independent registered public accounting firm is required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#x2019;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Liquidity and Capital Resources<a name="BLiquidityandCapitalResources_983984"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Since inception, we have incurred significant operating losses. To date, we have not generated any product sale revenue. We have financed our operations primarily through our public offerings of our common shares, private placements of equity securities and loans, and grants and payments from collaboration partners.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For the years ended December 31, 2017, 2018, and 2019 we incurred net losses of &#x20AC;30.2 million, &#x20AC;19.5 million, and &#x20AC;32.4 million, respectively. To date, we have financed our operations primarily through public offerings of our common shares, private placements of equity securities and loans, grants and revenues from collaboration partners. As of December 31, 2019, we had cash and cash equivalents and current financial assets, which we refer to as liquidity, of &#x20AC;104.1 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our cash and cash equivalents and current financial assets as of December 31, 2019 consist primarily of deposits in savings and deposit accounts with original maturities of three months or less and certificates of deposit with original maturities of more than three months which generate interest income. We expect to continue this investment philosophy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Cash Flows</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Comparison of the years ended December 31, 2018 and 2019</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The table below summarizes our consolidated statement of cash flows for the years ended December 31, 2018 and 2019:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Year ended December 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:21.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in &#x20AC; thousand)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Net cash from/(used) in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">49,438&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (29,056)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Net cash from/(used) for investing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (15,610)</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">4,340&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Net cash generated from financing activities</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">20,495&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">26,038&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Net changes to cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">54,323&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">1,322&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents at the beginning of the year</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">39,837&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 94,829</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exchange-rate related changes of cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">669&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Cash and cash equivalents at the end of the year</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">94,829&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 95,234</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Net cash from operating activities amounted to &#x20AC;49.4 million in the year ended December 31, 2018 whereas net cash used in operating activities amounted to &#x20AC;29.1 million in the year ended December 31, 2019. The amount received in 2018 includes an initial upfront payment and committed funding of &#x20AC;83.2 million from the Genentech collaboration.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">96</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We used cash for investing activities of &#x20AC;15.6 million in the year ended December 31, 2018, where net cash from investing activities amounted to &#x20AC;4.3 million in the year ended December 31, 2019. The investing activities primarily relate to investments in and proceeds from the sale or maturity of financial assets.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Net cash generated from financing activities in the year ended December 31, 2019 amounted to &#x20AC;26.0 million and relate primarily to the proceeds from the public offering in November 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Comparison of the years ended December 31, 2017 and 2018</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Refer to our Annual Report on Form 20-F for fiscal year ended December 31, 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Cash and Funding Sources</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our liquidity (cash and cash equivalents and current financial assets) as of December 31, 2019 was &#x20AC;104.1 million. Funding sources generally comprise proceeds from the issuance of equity instruments, loans, payments from collaboration agreements and government grants.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November&nbsp;30, 2016, our subsidiary Affimed GmbH entered into a loan agreement with Silicon Valley Bank, a California corporation (&#x201C;SVB&#x201D;), as lender, which we fully guarantee. The loan agreement provides us with a senior secured term loan facility (the &#x201C;SVB Credit Facility&#x201D;) for originally up to &#x20AC;10.0 million, which agreement was amended in May&nbsp;2017 to provide that such amount would be available in three tranches.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On December&nbsp;8, 2016, we drew down the initial tranche of &#x20AC;5.0 million, and on May&nbsp;31, 2017 we drew down the second tranche of &#x20AC;2.5 million; the availability of the third tranche expired in September&nbsp;2017 with such amount remaining undrawn. In connection with such drawdowns, we issued SVB warrants to purchase 219,692 of our common shares, at a weighted-average exercise price of $2.07 per common share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The interest rate on amounts borrowed under the SVB Credit Facility is calculated as the sum of (i)&nbsp;one-month EURIBOR plus (ii)&nbsp;an applicable margin of 5.5%, with EURIBOR deemed to equal zero&nbsp;percent if EURIBOR is less than zero&nbsp;percent. The SVB Credit Facility has a maturity date of May&nbsp;31, 2020 with an interest-only period through December&nbsp;1, 2017 with amortized payments of principal and interest thereafter in equal&nbsp;monthly installments. Borrowings under the SVB Credit Facility are secured by a pledge of 100% of our shares in Affimed GmbH, all intercompany accounts receivables owed by our subsidiaries to us and a security assignment of essentially all our bank accounts, inventory, trade receivables and payment claims as specified in the loan agreement governing the facility.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On January&nbsp;25, 2017, we sold 10,000,000 of our common shares at a price of $1.80 per share in an underwritten public offering and received $16.6 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses. The underwriters partially executed an option to purchase additional shares and on February&nbsp;9, 2017 we sold an additional 646,762 shares at a price of $1.80 per share and received $1.1 million, after deducting underwriting discounts and commissions and other offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On February&nbsp;15, 2018, we sold an additional 13,225,000 of our common shares at a price of $2.00 per share in an underwritten public offering and received $24.5 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November 13, 2019, we sold an additional 13,800,000 of our common shares at a price of $2.50 per share in an underwritten public offering and received $32.0 million in net proceeds, after deducting underwriting discounts and commissions and other offering expenses.&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Funding Requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We expect that we will require additional funding to complete the development of our product candidates and to continue to advance the development of our other product candidates. In addition, we expect that we will </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">97</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">require additional capital to commercialize our product candidates AFM13 and AFM24.If we receive regulatory approval for AFM13, AFM24 or other earlier programs, and if we choose not to grant any licenses to partners, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We also continue to incur substantial costs associated with operating as a public company. Additional funds may not be available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on our current operating and budget assumptions, we believe that our existing liquidity, will enable us to fund our operating expenses and capital expenditure requirements at least into the first half of 2022. We have based this estimate on assumptions that may prove to be incorrect, and we could use our capital resources sooner than we currently expect. Our future funding requirements will depend on many factors, including but not limited to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the scope, rate of progress, results and cost of our clinical trials, nonclinical testing, and other related activities;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidates and any products that we may develop;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the number and characteristics of product candidates that we pursue;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost, timing, and outcomes of regulatory approvals;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the cost and timing of establishing sales, marketing, and distribution capabilities; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the terms and timing of any collaboration, licensing, and other arrangements that we may establish, including any required milestone and royalty payments thereunder.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To address our financing needs, we may raise additional capital through the sale of equity or convertible debt securities. In such an event, the ownership interest of our shareholders will be diluted, and the terms of any such securities may include liquidation or other preferences that adversely affect the rights of holders of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">For more information as to the risks associated with our future funding needs, see &#x201C;Item&nbsp;3. Key Information&#x2014;D. Risk Factors&#x2014;Risks Related to Our Financial Position and Need for Additional Capital&#x2014;We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Research and development, patents and licenses, etc.<a name="CResearchanddevelopmentpatentsandlicense"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Item&nbsp;4. Information on the Company&#x2014;A. History and Development of the Company&#x201D; and &#x201C;Item&nbsp;4. Information on the Company&#x2014;B. Business Overview.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Trend information<a name="DTrendinformation_783559"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Item&nbsp;5. Operating and Financial Review and Prospects.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">98</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">E.&nbsp;&nbsp;&nbsp;Off-balance sheet arrangements<a name="EOffbalancesheetarrangements_755138"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of the date of this Annual Report, we do not have any off-balance sheet arrangements other than operating leases as described under &#x201C;Item&nbsp;5. Operating and Financial Review and Prospects&#x2014;F. Tabular disclosure of contractual obligations&#x201D; below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">F.&nbsp;&nbsp;&nbsp;Tabular disclosure of contractual obligations<a name="FTabulardisclosureofcontractualobligatio"></a></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The table below sets forth our contractual obligations and commercial commitments as of December&nbsp;31, 2019 that are expected to have an impact on liquidity and cash flow in future periods. In addition to license agreements with fixed payment obligations, we have entered into various collaboration and license agreements that may trigger milestone payments and royalty payments upon the achievement of certain milestones and net sales in the future. Because the achievement and timing of these milestones and net sales is not fixed or determinable, our commitments under these agreements have not been included in the table below.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="9" valign="bottom" style="width:42.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Payments Due by Period</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Less than</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Between</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Between</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">More than</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">1 year</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">1 and 3 years</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">3 and 5 years</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">5 years</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="9" valign="bottom" style="width:42.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in &#x20AC; thousand)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating lease obligations</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,526
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>649
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>827
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 50</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fixed license payments</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">SVB Credit Facility</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,017
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,017
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:56.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,568
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2,691
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>827
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">50</font></p>
				</td>
				<td valign="bottom" style="width:01.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Operating lease obligations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Operating lease obligations consist of payments pursuant to non-cancellable operating lease agreements relating to our lease of office space. The lease term of our premises in the Czech Republic is contracted until the&nbsp;year end 2020 with a period of notice of three&nbsp;months. Approximately 75% of the premises in Germany is under a revolving 24&#8209;month lease period, with a 12&#8209;month termination period. The lease could expire in 2021 if notice to terminate is provided by either party by February&nbsp;2020. No such notice has been received to date. The remaining 25% of the German facility is under a fixed term lease period until February 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into various license agreements that contingently trigger on-off payments upon achievement of certain milestones and royalty payments in the future. Because the achievement and timing of these milestones and net sales is not fixed and determinable, our commitments under these agreements have not been included in the Contractual Obligations table above.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">G.&nbsp;&nbsp;&nbsp;Safe harbor<a name="GSafeharbor_499863"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Forward-Looking Statements.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES<a name="ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Directors and senior management<a name="ADirectorsandseniormanagement_808607"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have a two-tier board structure consisting of our supervisory board (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">raad van commissarissen</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) and a separate management board (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">raad van bestuur</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our supervisory board supervises the policies of the management board and the general course of the affairs of our business. The supervisory board gives advice to the management board and is guided by the interests of the business when performing its duties. The management board is in charge of managing the Company&nbsp;</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">99</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">under the supervision of the supervisory board. The management board provides the supervisory board with such necessary information as the supervisory board requires to perform its duties.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table presents our supervisory directors. Bernhard R.M. Ehmer was re-appointed by the general meeting of shareholders on June 25, 2019. Ulrich M. Grau was appointed by the general meeting of shareholders on June&nbsp;9, 2015, and his term was effective as of July&nbsp;1, 2015. Mathieu Simon was appointed by the general meeting of shareholders on June&nbsp;19, 2018. Our other supervisory directors were appointed by the general meeting of shareholders on September&nbsp;12, 2014, with effect from September&nbsp;17, 2014; Thomas Hecht, Berndt Modig and Ferdinand Verdonck were reappointed by the general meeting of shareholders on June&nbsp;20, 2017 and Ulrich M. Grau was reappointed by the general meeting of shareholders on June&nbsp;19, 2018. Thomas Hecht is the chairman of our supervisory board. The term of each of our supervisory directors will terminate on the date of the annual general meeting of shareholders in the&nbsp;year indicated below.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Name</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Age</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Term</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">69</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2020&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard R.M. Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">65&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2022&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich M. Grau</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">71&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2021&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">61&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2020&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">63&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2021&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:76.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">77&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2020&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following is a brief summary of the business experience of our supervisory directors. Each director&#x2019;s tenure reflects their tenure on the board of our predecessor Affimed Therapeutics AG. Unless otherwise indicated, the current business address for each of our supervisory directors is Affimed N.V., c/o Affimed GmbH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Thomas Hecht, Chairman.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;Dr. Hecht has been the chairman of our supervisory board since 2014, and previously had been the chairman of the supervisory board of our German operating subsidiary since 2007. He is head of Hecht Healthcare Consulting in K&#xFC;ssnacht, Switzerland, a biopharmaceutical consulting company founded in 2002. Dr. Hecht also serves as member of the board of directors of Kuur Therapeutics and as chairman of the board of directors of Vaximm AG and Aelix Therapeutics S.L. Until the beginning of March 2015, he served as chairman of the supervisory council of SuppreMol GmbH and until June 2016, of Delenex AG. Dr. Hecht was previously Vice President Marketing at Amgen Europe. A seasoned manager and industry professional, he held various positions of increasing responsibility in clinical development, medical affairs and marketing at Amgen between 1989 and 2002. Prior to joining the biopharmaceutical industry, he was certified in internal medicine and served as Co-Head of the Program for Bone Marrow Transplantation at the University of Freiburg, Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Bernhard R.M. Ehmer, Director</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dr.&nbsp;Ehmer has been a member of our supervisory board since 2016. Since September&nbsp;1, 2018 he serves as chairman of the board of directors at Symphogen A/S, Denmark. He has been chairman of the board of management of Biotest AG since January&nbsp;2015. Prior to this, he worked for the Imclone Group, a wholly owned subsidiary of Eli Lilly, as president of Imclone Systems Corporation in the United States and as managing director in Germany. In 2007/2008 he was CEO of Fresenius Biotech, Germany and before this, Dr.&nbsp;Ehmer headed the Business Area Oncology of Merck KGaA, Darmstadt and served as head of Global Clinical Operations at Merck. Between 1986 and 1998 he held various functions at Boehringer Mannheim in Germany, Italy and Singapore. Dr.&nbsp;Ehmer holds a degree in medicine and worked in the Department of Internal Medicine at the Academic Teaching Hospital of the University of Heidelberg.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Ulrich M. Grau, Director</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">. &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dr.&nbsp;Grau has been a member of our supervisory board since July&nbsp;2015. Prior to that, he served as an advisor to the management board of our German operating subsidiary beginning in May&nbsp;2013. He has over 30&nbsp;years of experience in the biotechnology and pharmaceutical industries including in general management, business development, corporate strategy and the development of new products and technologies. Dr.&nbsp;Grau was Chief Operating Officer at Micromet from 2011 to 2012. Between 2006 and 2010, Dr.&nbsp;Grau was a founder, President and CEO of Lux Biosciences,&nbsp;Inc., a clinical stage ophthalmic company. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">100</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Previously, Dr.&nbsp;Grau served as President of Research and Development at BASF Pharma/ Knoll where he directed a global R&amp;D organization with a development pipeline which included Humira. The majority of his career was at Aventis Pharma (now Sanofi), where he last held the position of Senior Vice President of global late stage development. Sanofi&#x2019;s product Lantus for the treatment of type 2 and type 1 diabetes is based on his inventions made during his early&nbsp;years as a scientist with Hoechst AG. Dr.&nbsp;Grau received his Ph.D. in chemistry and biochemistry from the University of Stuttgart and spent three&nbsp;years as a post-doctoral fellow at Purdue University in the field of protein crystallography.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Berndt Modig, Director.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Mr.&nbsp;Modig has been a member of our supervisory board since 2014. He has been CEO of Pharvaris B.V. since April&nbsp;2016. Prior to this, he has served as Chief Financial Officer of Prosensa Holding N.V. from March&nbsp;2010 through January&nbsp;2015 when Prosensa was acquired by BioMarin Pharmaceutical&nbsp;Inc. Mr.&nbsp;Modig also serves as member of the board of directors and as member of the audit committee of Axovant Sciences Ltd and as vice chairman of the supervisory board and chairman of the audit committee of Kiadis Pharma N.V.&nbsp;He is member of the supervisory board and audit committee chairman of Centogene N.V. Mr.&nbsp;Modig has more than 25&nbsp;years of international experience in finance and operations, private equity and mergers and acquisitions. Before joining Prosensa, Mr.&nbsp;Modig was Chief Financial Officer at Jerini AG from October&nbsp;2003 to November&nbsp;2008, where he directed private financing rounds, its initial public offering in 2005 and its acquisition by Shire plc in 2008. Prior to Jerini, Mr.&nbsp;Modig served as Chief Financial Officer at Surplex AG from 2001 to 2003 and as Finance Director Europe of U.S.-based Hayward Industrial Products&nbsp;Inc. from 1999 to 2001. In previous positions, Mr.&nbsp;Modig was a partner in the Brussels-based private equity firm Agra Industria from 1994 to 1999 and a Senior Manager in the Financial Services Industry Group of Price Waterhouse LLP in New York from 1991 to 1994. Mr.&nbsp;Modig served as a director of Mobile Loyalty plc from 2012 to 2013. Mr.&nbsp;Modig has a bachelor&#x2019;s degree in business administration, economics and German from the University of Lund, Sweden and an M.B.A. degree from INSEAD, Fontainebleau, France and is a Certified Public Accountant.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Mathieu Simon, Director.&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dr. Simon has been a member of our supervisory board since 2018. He also serves as Senior Strategic Advisor at Messier Maris, an M&amp;A advisory firm in the healthcare sector, located in New York, London and Paris. He is an independent director on the Board of Vaximm, headquartered in Basel, Switzerland as well as an independent director at Idorsia Pharmaceuticals (Switzerland), Lysogene (France) and Asarina (Sweden). Dr. Simon has served as Cellectis&#x2019; Executive Vice-President since 2012 and as Chief Operating Officer since 2013. Dr. Simon also served as Chief Executive Officer of a former subsidiary of Cellectis. He has been instrumental to the development of Cellectis and its CAR Allogenic T-Cell platform. He also served as Chief Executive Officer of Ectycell in 2012. He served as Chairman of the Board of Celleartis AB until 2014 before its acquisition by Takara Bio. Prior to joining Cellectis, Dr. Simon was Managing Director, Head of Global Pharma at Pierre Fabre SA, the third largest French Pharma Company. Beginning in 1994, he served at Wyeth Pharmaceuticals in both general management roles (President Managing Director of Wyeth SMA) and senior corporate role in Philadelphia, United States (SVP / Head of International Marketing and Medical Affairs).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Ferdinand Verdonck, Director.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Mr.&nbsp;Verdonck has been a member of our supervisory board since July&nbsp;2014. He is a director of Laco Information Services. In recent&nbsp;years he was director and member of the audit committee of Virtus Funds and J.P. Morgan European Investment Trust, director of Groupe SNEF, and director and chairman of the audit committee of biotechnology companies: uniQure N.V. in the Netherlands, of which he was also the chairman, and Movetis and Galapagos in Belgium. He has previously served as chairman of Banco Urquijo and of Nasdaq Europe and as a director of Dictaphone Corporation. From 1992 to 2003, he was the managing director of Almanij NV, a financial services company which has since merged with KBC, and his responsibilities included strategy, financial control, supervision of executive management and corporate governance, including board participation in publicly-traded and privately-held affiliated companies in many countries. Mr.&nbsp;Verdonck holds a law degree from KU Leuven and degrees in economics from KU Leuven and the University of Chicago.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">101</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table lists the members of our current management board:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:48.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:39.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;">Name</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;">Age</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:39.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:8pt;">Position</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.04%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:100%;text-indent: -7.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Adi Hoess</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">58</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:39.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:48.04%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;line-height:100%;text-indent: -7.2pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">56</font></p>
				</td>
				<td valign="bottom" style="width:02.00%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:39.96%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Chief Operating Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following is a brief summary of the business experience of the members of our management board. Unless otherwise indicated, the current business addresses for the members of our management board is Affimed N.V., c/o Affimed GmbH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Adi Hoess, Chief Executive Officer.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Dr.&nbsp;Hoess joined us in October&nbsp;2010 as Chief Commercial Officer and since September&nbsp;2011 has served as our Chief Executive Officer. He has more than 20&nbsp;years of professional experience with an extensive background in general management, business development, product commercialization, fund raising and M&amp;A. Prior to joining us, Dr.&nbsp;Hoess was Chief Commercial Officer at Jerini AG and Chief Executive Officer of Jenowis AG. At Jerini AG he was responsible for business development, marketing and sales and the market introduction of Firazyr. He also played a major role in the sale of Jerini to Shire&nbsp;plc. Dr.&nbsp;Hoess began his professional career in 1993 at MorphoSys. Dr.&nbsp;Hoess received his Ph.D. in chemistry and biochemistry from the University of Munich in 1991 and an M.D. from the Technical University of Munich in 1997.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Wolfgang Fischer, Chief Operating Officer. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dr.&nbsp;Fischer joined us in 2017 from Sandoz Biopharmaceuticals (Novartis Group). He has 20&nbsp;years of experience in research and drug development with a focus on oncology, immunology and pharmacology. At Sandoz he managed the development and registration of Sandoz&#x2019; biosimilar pipeline assets since 2012 and served as Global Head of Program and Project Management since 2014. Prior to joining Sandoz, he held various positions of increasing responsibility within the Novartis Group since 2003, including Medical Director Oncology for Novartis Pharma Switzerland AG as well as Regional Medical Director Hematology (Emerging Growth Markets), where he was responsible for the Hematology Medical Affairs program and supported the launch of several products in various countries. Dr.&nbsp;Fischer holds a Ph.D. in Cancer Research from the Swiss Federal Institute of Technology (ETH), Zurich, Switzerland. Thereafter, he completed postdoctoral fellowships at the Swiss Institute of Experimental Cancer Research, Lausanne, Switzerland and at the Scripps Research Institute, Department of Immunology, La Jolla, CA, USA, followed by a state doctorate (Habilitation) in Pharmacology and Toxicology at the Medical School of the University of W&#xFC;rzburg in Germany in 2003.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following is a brief summary of the business experience of certain other key employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Andreas Harstrick, M.D., Chief Medical Officer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. Dr. Harstrick agreed to serve as our Chief Medical Officer, starting in March 2020. He brings 30 years of extensive experience in cancer drug development, including the successful designing of clinical trials leading to approval of antibody drugs (Erbitux&#xAE;; Cyramza&#xAE;) and in-depth experience in setting-up and managing clinical oncology teams. Dr. Harstrick was Chief Medical Officer at Molecular Partners AG from 2015 to 2019, where he oversaw clinical activities, including expansion of the clinical team, and was a member of the Management Board. Between 2012 and 2014, Dr. Harstrick was Senior Vice President Medical Sciences at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, where he was also a member of the Lilly Oncology Program Review Board and the Lilly Oncology Business Unit Development Committee. Prior to joining ImClone in 2008, Dr. Harstrick was Senior Vice President Global Clinical Development Unit Oncology at Merck Serono until 2008. Dr. Harstrick is an oncologist by training. He spent his medical career at the University Hospital and Cancer Center Hannover, Germany; the Roswell Park Cancer Institute, Buffalo NY; as well as the West German Cancer Center, Essen, Germany. He earned his MD at Medical School Hannover, Germany, and in 1999 he became Associate Professor for Internal Medicine, University of Essen, Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Arndt Schottelius, M.D. Ph.D., Chief Scientific Officer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. Dr. Schottelius joined Affimed as Chief Scientific Officer in April 2020. He brings over 20 years of deep drug discovery and development experience in cancer and immunology with a strong track record in building therapeutic antibody pipelines and advancing drugs through development. Most recently, Dr. Schottelius was Executive Vice President and Head of Research &amp; </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">102</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Development at Kymab Group Limited, where he was responsible for expanding the therapeutic antibody portfolio. Dr. Schottelius previously served as Chief Development Officer at MorphoSys AG, developing the portfolio of proprietary therapeutic antibody programs in cancer and immunology. He was instrumental in in-licensing tafasitamab (MOR208) and drove strategic direction and development of the MOR208 program into multiple Phase 2 trials, which were the basis for a fast-to-market registration path. Prior to his role at MorphoSys, Dr. Schottelius was a Director and Medical Director, Immunology Development at Genentech Inc., where he directed early and late-stage development programs of therapeutic antibodies. Before joining Genentech, Dr. Schottelius held science and management positions in immunology research at Schering AG and Berlex Biosciences. Dr. Schottelius holds a PhD and MD degree from the Albert Ludwigs University of Freiburg and is a lecturer at Ludwig Maximilian University of Munich with a habilitation in Experimental Internal Medicine. He practiced medicine as a resident physician in gastroenterology at the Charit&#xE9;-Universit&#xE4;tsmedizin in Berlin, Germany, and completed a postdoctoral fellowship at the Lineberger Cancer Center, University of North Carolina at Chapel Hill.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Denise Mueller, Chief Business Officer and President Affimed&nbsp;Inc. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Ms.&nbsp;Mueller joined us in 2016 following a 17&nbsp;year career at Wyeth and Pfizer&nbsp;Inc. She has held leadership roles in U.S. and global marketing including launch of new products and line extensions in-line and globally. Ms.&nbsp;Mueller has also held the position of Disease Area Lead for multiple therapeutic areas where she was responsible for disease area strategy, indication strategy for multiple assets, early commercial development and market shaping. In addition to broad and extensive commercial experience, Ms.&nbsp;Mueller led and managed two of Pfizer&#x2019;s largest alliances and was the business development lead for Pfizer&#x2019;s rare disease business unit. Prior to joining pharmaceuticals, Ms.&nbsp;Mueller worked in hospital management running Emergency Medicine, Critical Care, in-house Pediatrics and hospitalist programs. Ms.&nbsp;Mueller holds a B.A. in Mathematics from Virginia Polytechnic and State University.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Compensation<a name="BCompensation_794417"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Management services agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our managing directors have entered into management services agreements with us. The management services agreements of Adi Hoess&nbsp;&nbsp;became effective upon the consummation of our initial public offering. The management services agreement of Wolfgang Fischer became effective upon his appointment by the general meeting of shareholders on June 20, 2017. These agreements comprise the following elements: fixed salary, bonus payments, earmarked pension and social security payments and share based compensation components. In addition, these agreements provide for benefits upon a termination of service. Adi Hoess was reappointed as managing director by the general meeting of shareholders on June 20, 2017, which prolonged his management services agreements until 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Long-term incentive plans</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Equity Incentive Plan 2014</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In conjunction with the closing of our initial public offering, we established the Affimed N.V. Equity Incentive Plan 2014 (&#x201C;the 2014 Plan&#x201D;) with the purpose of advancing the interests of our shareholders by enhancing our ability to attract, retain and motivate individuals who are expected to make important contributions to us. The maximum number of shares available for issuance under the 2014 Plan equals 7% of the total outstanding common shares on September 17, 2014, or approximately 1.7 million common shares. On January 1 of any calendar year thereafter (including January 1, 2020), an additional 5% of the total outstanding common shares on that date becomes available for issuance under the 2014 Plan. As of January 1, 2020, we had approximately 9.8 million common shares available for issuance, and approximately 8.3 million common shares subject to issuance under outstanding awards. The absolute number of shares available for issuance under the 2014 Plan will increase automatically upon the issuance of additional shares by the Company. The option exercise price for options under the 2014 Plan is the fair market value of a share as defined in the 2014 Plan on the relevant grant date. We are following home country rules relating to the re-pricing of stock options. Under applicable </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">103</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dutch law, re-pricing is permissible, provided this falls within the framework set by the remuneration policy for the Management Board and the 2014 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Plan administration.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> The 2014 Plan is administered by our compensation committee. Approval of the compensation committee is required for all grants of awards under the 2014 Plan. The compensation committee may delegate to the managing directors the authority to grant equity awards under the 2014 Plan to our employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Eligibility.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Supervisory directors, managing directors and other employees and consultants of the Company are eligible for awards under the 2014 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Awards.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Awards include options and restricted stock units.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Vesting period.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Subject to any additional vesting conditions that may be specified in an individual grant agreement, and the accelerated vesting conditions below, the plan provides for three&nbsp;year vesting of stock options. One-third of the stock options granted to participants in connection with the start of their employment vest on the first anniversary of the grant date, with the remainder vesting in equal tranches at the end of each 3&#8209;month period thereafter. Stock options granted to other participants vest in equal tranches at the end of each 3&#8209;month period after the grant date over the course of the vesting period. The compensation committee will establish a vesting schedule for awards granted to supervisory directors as well as for any awards in the form of restricted stock units.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Accelerated vesting.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Unless otherwise specified in an individual grant agreement, the 2014 Plan provides that upon a change of control of the Company (as defined in the 2014 Plan) all then outstanding equity awards will vest and become immediately exercisable. It also provides that upon a participant&#x2019;s termination of service due to (i)&nbsp;retirement (or after reaching the statutory retirement age), (ii)&nbsp;permanent disability rendering the relevant participant incapable of continuing employment or (iii)&nbsp;death, all outstanding equity awards that would have vested during a 12&nbsp;month period following such termination of service will vest and become immediately exercisable. Otherwise at termination all unvested awards will be forfeited. If a participant experiences a termination of service without &#x201C;cause&#x201D; or for &#x201C;good reason&#x201D; (in each case, as defined in the 2014 Plan) within six&nbsp;months prior to a change of control, the Company will make a cash payment equivalent to the economic value that the participant would have realized in connection with the change of control upon the exercise and sale of the equity awards that such participant forfeited upon his or her termination of service. In connection with a change of control and subject to the approval of the supervisory board, the management board may amend the exercise provisions of the 2014 Plan.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Stock Option Equity Incentive Plan 2007</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the Stock Option Equity Incentive Plan 2007 (the &#x201C;2007 SOP&#x201D;), we granted options that were exercisable for preferred shares. In conjunction with the corporate reorganization in connection with our initial public offering, all outstanding awards granted under the 2007 SOP were converted into awards exercisable for common shares of Affimed N.V. and no additional grants were be made under the 2007 SOP. On December 31, 2019, the 2007 SOP terminated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Compensation of Managing Directors and Supervisory Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The compensation, including benefits in kind, accrued or paid to our managing directors and supervisory directors with respect to the year ended December 31, 2019, for services in all capacities is shown below on an individual basis. Further details for the compensation for our managing directors and supervisory directors are given in notes 17 and 23 to our consolidated financial statements as of and for the year ending December 31, 2019. As of December 31, 2019, we have no amounts set aside or accrued to provide pension, retirement or similar benefits to our managing directors and supervisory directors.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">104</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Directors compensation 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Managing directors</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:61.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">(in &#x20AC; thousand)</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">A.&nbsp;Hoess</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">W.&nbsp;Fischer</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Periodically paid compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>474
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:12.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>402
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>876
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Bonuses</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>156
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>103
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>259
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Total cash compensation</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>630
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:12.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>505
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,135
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.16%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.72%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.96%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">2014 Plan share-based payment expense</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>686
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:12.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>367
				</td>
				<td valign="bottom" style="width:02.74%;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,053
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:61.94%;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;">Total share-based payment expense</font></p>
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:10.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>686
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:12.72%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>367
				</td>
				<td valign="bottom" style="width:02.74%;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,053
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Supervisory directors</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">(in &#x20AC; thousand)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Periodically paid compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>382
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total cash compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>56
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>46
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>48
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>58
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>382
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2014 Plan share-based payment expense</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:45.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total share-based payment expense</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>61
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:05.96%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>42
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:07.52%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:03.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>243
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Stock options granted under the Equity Incentive Plan 2014</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Managing directors</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Strike price</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Beneficiary</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Grant date</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">USD</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Expiration date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adi Hoess</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>360,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>160,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>520,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Supervisory directors</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Number of</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Strike price</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Beneficiary</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Grant date</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">options</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">USD</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Expiration date</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>35,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich M. Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>20,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:08.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.91
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:11.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-align:right;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">June 25, 2029</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:48.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.06%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.94%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>135,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.98%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.92%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dutch law provides that we must establish a policy in respect of the remuneration of our managing directors and supervisory directors. With respect to remuneration in the form of plans for shares or rights to shares (such as the Equity Incentive Plan 2014 mentioned above) the policy for managing directors must set out the maximum number of shares or rights to shares to be granted as well as the criteria for grants and for amending existing grants. The remuneration policies for the supervisory board and for the managing directors were adopted and approved by the general meeting of shareholders prior to the consummation of our initial public offering. The remuneration policy for the supervisory board established the compensation for our supervisory directors. The remuneration policy for the managing directors provides the supervisory board with a framework within which the supervisory board determines the remuneration of the managing directors.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">105</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our remuneration policy for our managing directors provides the supervisory board with the authority to enter into management services agreements with managing directors that provide for compensation consisting of base compensation, performance-related variable compensation, long-term equity incentive compensation (as detailed in the terms of the Equity Incentive Plan 2014 described above), pension and other benefits and severance pay and benefits. The remuneration policy for the managing directors provides that the annual cash bonus payable to managing directors may not exceed 100% of the annual base gross salary and will be based upon the achievement of set financial and operating goals for the period. The bonus payments may be increased in any given&nbsp;year by the supervisory board upon a proposal of the compensation committee based on any exceptional achievements of that managing director. In addition, the remuneration policy for managing directors allows for cash termination payments, which may not exceed 100% of the managing director&#x2019;s base salary. This policy also allows for additional compensation and benefits to our managing directors following a change of control.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our remuneration policy for the supervisory directors provides for payments and initial and annual equity awards. This is permissible under Dutch law, but constitutes a deviation from the DCGC. The remuneration policy for our supervisory directors establishes that each supervisory director will be entitled to an annual retainer of &#x20AC;20,000, provided that the chairman of the supervisory board will be entitled to an annual retainer of &#x20AC;75,000. In addition, the chairman of the audit committee is entitled to an additional annual retainer of &#x20AC;15,000 and the chairmen of the compensation and nomination and corporate governance committees are each entitled to annual retainers of &#x20AC;7,500. Supervisory directors will also be paid &#x20AC;3,000 for each supervisory board meeting attended in person and &#x20AC;1,500 for each supervisory board meeting attended by telephone, provided the meeting attended by telephone exceeds 30 minutes. For other, including non-formal Board meetings attended either in person or by phone the Company will pay each member of the Supervisory Board &#x20AC;500 per meeting, provided that the duration of such meeting exceeds 30 minutes. The members of each committee will be paid &#x20AC;1,500 for each committee meeting attended in person and &#x20AC;750 for each committee meeting attended by telephone, provided the meeting attended by telephone exceeds 30 minutes. In addition, we will grant any future chairman of the supervisory board an initial award of stock options to purchase 45,000 common shares on the date of election as the chairman. Further, under the remuneration policy we will grant any future supervisory director an initial award of stock options to purchase 20,000 common shares on the date of election as a supervisory director. These initial stock options will vest over a three-year period in three equal installments on the anniversaries of the grant date. In addition, the remuneration policy provides that each supervisory director is entitled to a total annual grant of 20,000 stock options, with the chairman of the supervisory board entitled to an annual grant of 35,000 stock options. These annual awards will vest in four quarterly installments and will be fully vested on the first anniversary of the grant date. Initial awards and annual awards will be granted automatically on the respective dates of issuance based on the approval by the shareholders of the remuneration policy and will not require any further approval by the supervisory board or the company. Supervisory directors are also entitled to be reimbursed for their reasonable expenses incurred in attending meetings of the supervisory board and its committees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Insurance and Indemnification</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our managing directors and supervisory directors have the benefit of indemnification provisions in our Articles of Association. These provisions give managing directors and supervisory directors the right, to the fullest extent permitted by law, to recover from us amounts, including but not limited to litigation expenses, and any damages they are ordered to pay, in relation to acts or omissions in the performance of their duties. However, there is generally no entitlement to indemnification for acts or omissions that amount to willful (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">opzettelijk</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), intentionally reckless (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">bewust roekeloos</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) or seriously culpable (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">ernstig verwijtbaar</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) conduct. In addition, upon consummation of our initial public offering, we entered into agreements with our managing directors and supervisory directors to indemnify them against expenses and liabilities to the fullest extent permitted by law. These agreements also provide, subject to certain exceptions, for indemnification for related expenses including, among others, attorneys&#x2019; fees, judgments, penalties, fines and settlement amounts incurred by any of these individuals in any action or proceeding. In addition to such indemnification, we provide our managing directors and supervisory directors with directors&#x2019; and officers&#x2019; liability insurance.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">106</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Insofar as indemnification of liabilities arising under the Securities Act may be permitted to supervisory directors, managing directors or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Board practices<a name="CBoardpractices_426435"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Supervisory board</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our supervisory board supervises the policies of the management board and the general course of the affairs of our business. The supervisory board gives advice to the management board and is guided by our interests and our business when performing its duties. The management board provides the supervisory board with such necessary information as is required to perform its duties. Supervisory directors are appointed by the general meeting of shareholders upon a binding nomination of the supervisory board for a term of up to four&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our Articles of Association provide for a term of appointment of supervisory directors of up to four&nbsp;years. Furthermore, our Articles of Association state that a supervisory director may be reappointed, but that any supervisory director may be a supervisory director for no longer than twelve (12)&nbsp;years. Our supervisory directors are appointed for different terms as a result of which only approximately one third of our supervisory directors will be subject to election in any one&nbsp;year. Such an appointment has the effect of creating a staggered board and may deter a takeover attempt.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The supervisory board meets as often as a supervisory board member deems necessary. In a meeting of the supervisory board, each supervisory director has a right to cast one vote. All resolutions by the supervisory board are adopted by an absolute majority of the votes cast. In the event the votes are equally divided, the chairman has the decisive vote. A supervisory director may grant another supervisory director a written proxy to represent him at the meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our supervisory board can pass resolutions outside of meetings, provided that the resolution is adopted in writing and all supervisory directors have consented to adopting the resolution outside of a meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our supervisory directors do not have a retirement age requirement under our Articles of Association.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Management board</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The management board is in charge of managing us under the supervision of the supervisory board. The number of managing directors is determined by our supervisory board. Managing directors are appointed by the general meeting of shareholders upon a binding nomination of the supervisory board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">At least once per&nbsp;year the management board informs the supervisory board in writing of the main lines of our strategic policy, the general and financial risks and the management and control system.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have a strong centralized management board led by Adi Hoess, our Chief Executive Officer, who has a strong track record in the development and commercialization of new medicines. Our management team has extensive experience in the biopharmaceutical industry, and key members of our team have played an important role in the development and commercialization of approved drugs.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Supervisory Board Committees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Audit committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The audit committee, which consists of Ferdinand Verdonck (Chairman), Berndt Modig and Bernhard Ehmer, assists the board in overseeing our accounting and financial reporting processes and the audits of our financial statements. In addition, the audit committee is directly responsible for the appointment, compensation, retention </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">107</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">and oversight of the work of our independent registered public accounting firm. Our supervisory board has determined that Ferdinand Verdonck, Berndt Modig and Bernhard Ehmer satisfy the &#x201C;independence&#x201D; requirements set forth in Rule 10A-3 under the Exchange Act. The supervisory board has determined that both, Ferdinand Verdonck and Berndt Modig, qualify as an &#x201C;audit committee financial expert,&#x201D; as such term is defined in the rules of the SEC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The audit committee is responsible for recommending the appointment of the independent auditor to the general meeting of shareholders; the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services; pre-approving the audit services and non-audit services to be provided by our independent auditor before the auditor is engaged to render such services; evaluating the independent auditor&#x2019;s qualifications, performance and independence, and presenting its conclusions to the full supervisory board on at least an annual basis and reviewing and discussing with the management board and the independent auditor our annual audited financial statements and quarterly financial statements prior to the filing of the respective annual and quarterly reports, among other things.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The audit committee meets as often as one or more members of the audit committee deem necessary, but in any event at least four times per&nbsp;year. The audit committee meets at least once per&nbsp;year with our independent accountant, without our management board being present.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Compensation committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The compensation committee, which consists of Thomas Hecht (Chairman), Ulrich Grau and Berndt Modig, assists the supervisory board in determining management board compensation. The committee recommends to the supervisory board for determination the compensation of each of our managing directors. Under SEC and Nasdaq rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard supervisory director fees. As permitted by the listing requirements of Nasdaq, we have opted out of Nasdaq Listing Rule&nbsp;5605(d)&nbsp;which requires that a compensation committee consist entirely of independent directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The compensation committee is responsible for identifying, reviewing and approving corporate goals and objectives relevant to management board compensation; analyzing the possible outcomes of the variable remuneration components and how they may affect the remuneration of the managing directors; evaluating each managing director&#x2019;s performance in light of such goals and objectives and determining each managing director&#x2019;s compensation based on such evaluation and determining any long-term incentive component of each managing director&#x2019;s compensation in line with the remuneration policy and reviewing our management board compensation and benefits policies generally, among other things.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Nomination and corporate governance committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The nomination and corporate governance committee, which consists of Ulrich Grau (Chairman), Thomas Hecht, Bernhard Ehmer and Mathieu Simon, assists our supervisory board in identifying individuals qualified to become members of our supervisory board consistent with criteria established by our supervisory board and in developing our corporate governance principles. As permitted by the listing requirements of Nasdaq, we have opted out of Nasdaq Listing Rule&nbsp;5605(e)&nbsp;which requires independent director oversight of director nominations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Employees<a name="DEmployees_175966"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of April 15, 2020, our total headcount is 137 (128 full time equivalents), approximately 65% of whom have an advanced academic degree (Diploma/ Master, PhD, MD).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be good.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">108</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">E.&nbsp;&nbsp;&nbsp;Share ownership<a name="EShareownership_483404"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Item&nbsp;7. Major Shareholders and Related Party Transactions&#x2014;A. Major shareholders.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS<a name="ITEM7MAJORSHAREHOLDERSANDRELATEDPARTYTRA"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Major shareholders<a name="AMajorshareholders_620742"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table presents information relating to the beneficial ownership of our common shares as of March&nbsp;15, 2020, by:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares (as of the date of such stockholder&#x2019;s Schedule 13D or Schedule 13G filing for Affimed N.V. with the SEC);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">each of our managing directors and supervisory directors; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">all managing directors and supervisory directors as a group.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The number of common shares beneficially owned by each entity, person, managing director or supervisory director is determined in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days of March&nbsp;15, 2020 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The percentage of shares beneficially owned is computed on the basis of 76,249,901 of our common shares outstanding as of March&nbsp;15, 2020. Common shares that a person has the right to acquire within 60 days of March 15, 2020 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all managing directors and supervisory directors as a group. Each common share confers the right on the holder to cast one vote at the general meeting of shareholders and no shareholder has different voting rights. Unless otherwise indicated below, the address </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">109</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">for each beneficial owner listed is c/o Affimed N.V., c/o Affimed GmbH, Technologiepark, Im Neuenheimer Feld 582, 69120 Heidelberg, Germany.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Shares beneficially owned</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Name and address of beneficial owner</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Percent (%)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Entities affiliated with New Enterprise Associates, Inc. (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6,126,488
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8.0
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Wellington Management Group LLP (2)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5,801,222
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7.6
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">Entities affiliates with Blackrock, Inc. (3) &nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,505,449
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.9
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Entities affiliated with Stonepine Capital Management LLC (4)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,010,155
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.3
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Managing Directors and Supervisory Directors</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:left;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adi Hoess (5)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1,804,621
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2.3
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>399,983
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.5
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>206,618
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.3
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard R.M. Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>90,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich M. Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>85,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,667
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.0
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>95,000
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;border-bottom:1pt solid #000000 ;text-align:right;" nowrap="nowrap"><div style="float:left"></div>0.1
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:74.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">All managing directors and supervisory directors as a group (8 persons)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:13.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,552,850
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;font-weight:bold;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4.5
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (1)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">New Enterprise Associates 15,&nbsp;L.P. (&#x201C;NEA 15&#x201D;) is the sole member of Growth Equity Opportunities Fund IV, LLC (&#x201C;GEO&#x201D;). NEA Partners 15,&nbsp;L.P. (&#x201C;NEA Partners 15&#x201D;) is the sole general partner of NEA 15. NEA 15 GP, LLC (&#x201C;NEA 15 LLC&#x201D;) is the sole general partner of NEA Partners 15. Peter J. Barris, Forest Baskett, Anthony A Florence,&nbsp;Jr., Krishna S. Joshua Makower, David M. Mott, Jon M. Sakoda, Scott D. Sandell, Peter W. Sonsini and Ravi Viswanathan are the managers of NEA 15&nbsp;LLC. The address for GEO, NEA Partners 15 and NEA 15 LLC is New Enterprise Associates, 1954 Greenspring Drive, Suite&nbsp;600, Timonium, MD 21093. This information is based on a statement filed on Schedule 13D with the SEC on November 18, 2019.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (2)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Represents shares beneficially owned by clients of Wellington Management Company LLP, Wellington Management Canada LLC, Wellington Management Singapore Pte Ltd, Wellington Management Hong Kong Ltd, Wellington Management International Ltd, Wellington Management Japan Pte Ltd and Wellington Management Australia Pty Ltd (collectively, the &#x201C;Wellington Investment Advisors&#x201D;). Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisors. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP. The address for Wellington Management Group LLP, Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP and Wellington Management Company LLP is c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA 02210. This information is based on a statement filed on Schedule&nbsp;13G with the SEC on January 8, 2020.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:106.67%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:106.67%;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (3)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:106.67%;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Represents shares beneficially owned by BlackRock, Inc and that were purchased by BlackRock Advisors, LLC, BlackRock Fund Advisors, BlackRock Asset Management Ireland Limited, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., BlackRock Investment Management, LLC, all of which are subdiaries of BlackRock, Inc. The address for BlackRock, Inc. is BlackRock, Inc., 55 East 52nd Street New York, NY 10055. This information is based on a statement filed on Schedule&nbsp;13G with the SEC on February 7, 2020.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (4)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Stonepine Capital Management, LLC, a California limited liability company, is the general partner of Stonepine Capital, L.P., a Delaware limited partnership. Stonepine Capital Management, LLC&#x2019;s control persons are Mr. Plexico and Mr. Lynch. The address for Stonepine Capital Management, LLC, Stonepine Capital, L.P., Mr. Plexico and Mr. Lynchon is 919 NW Bond Street, Suite 204, Bend, OR 97703-2767. Each of Stonepine Capital Management, LLC, Stonepine Capital, L.P., Mr. Plexico and Mr. Lynchon disclaims </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">110</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 18pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">membership in a group and disclaims beneficial ownership of the Stock except to the extent of each person&#x2019;s pecuniary interest therein. This information is based on a statement filed on Schedule&nbsp;13G with the SEC on February 13, 2020.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (5)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">Indicates that the director is entitled to receive common shares in connection with the carve-out plan described in Note 2 to our consolidated financial statements for the year ended December 31, 2016 pursuant to which 7.78% of the common shares of the Company outstanding immediately prior to the initial public offering owned by pre-IPO existing shareholders will be transferred to the beneficiaries upon the conditions set forth therein.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Significant Changes in Ownership by Major Shareholders</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have experienced significant changes in the&nbsp;percentage ownership held by major shareholders as a result of our initial public offering and subsequent offerings. Immediately prior to our initial public offering in September&nbsp;2014, our principal shareholders were entities affiliated with Calibrium AG (formerly Aeris Capital AG, 32.2% ownership), entities affiliated with OrbiMed Advisors LLC (30.7% ownership), Novo Nordisk A/S (14.3% ownership), BioMedInvestI&nbsp;Ltd. (9.2% ownership) and entities affiliated with Life Sciences Partners (9.2% ownership).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On September&nbsp;17, 2014, we completed our initial public offering and listed our common shares on the Nasdaq Global Market. In the initial public offering, we sold 8,000,000 common shares. Certain of our pre-IPO investors purchased approximately $23.7 million of our common shares in the initial public offering.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On May&nbsp;12, 2015 we completed a public offering and sold 5,750,000 common shares to new investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On October&nbsp;14, 2015 we sold 3.3 million shares to SGR Sagittarius Holding AG, an existing shareholder affiliated with Calibrium AG (formerly Aeris Capital AG).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In January&nbsp;and February&nbsp;2017, we completed a public offering and sold 10,646,762 common shares primarily to new investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On February&nbsp;15, 2018, we completed a public offering and sold 13,225,000 common shares primarily to new investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November 7, 2019, we completed a public offering and issued 13,800,000 common shares primarily to new investors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Holders</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of April 28, 2020, we had approximately six shareholders of record of our common shares; two of those shareholders of record are in the United States and hold a total of approximately 75.2&nbsp;million common shares in the aggregate, or approximately 99% of our common shares. One of the U.S. shareholders of record is Cede and Company, a specialist United States financial institution that processes transfers of stock certificates on behalf of the Depository Trust Company, or DTC. Cede and Company therefore is the technical shareholder of record for nearly all of our issued shares held by DTC participants, as our shareholders do not themselves hold direct property rights in our common shares, but rather have contractual rights in such shares that are part of a chain of contractual rights involving Cede and Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Related party transactions<a name="BRelatedpartytransactions9_456724"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following is a description of related party transactions we have entered into since January&nbsp;1, 2019 with any of our members of our supervisory board or management board and the holders of more than 5% of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">111</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Agreements with Supervisory Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">According to a services agreement with i-novion Inc., of which Dr. Ulrich Grau serves as Chairman of the Board of Directors, i-novion Inc. conducted certain preclinical services for us. In 2019, i-novion Inc. did not receive any related payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Agreements with former Managing Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2017, we entered into a consulting agreement with our former Managing Director J&#xF6;rg Windisch consisting of high level consultancy and strategic guidance in the field of clinical manufacturing. The consulting agreement was terminated in July 2019, Dr. Windisch provided no services and received no payments in 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Agreements with Amphivena</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2013, we entered into a license and development agreement, which amended and restated a 2012 license agreement, with Amphivena Therapeutics, Inc., or Amphivena, based in South San Francisco, to develop an undisclosed product candidate for hematologic malignancies in exchange for an interest in Amphivena and certain milestone payments. We also assigned and licensed certain technology to Amphivena and provided it with funding. The license and development agreement with Amphivena expired when the product candidate&#x2019;s IND became effective in July 2016. Following the expiration, we continued to provide services on a smaller scale to complete the deliverables required under the agreement, and have been financially supporting the future clinical development of AMV564 with &#x20AC;2.8 million in financing, &#x20AC;1.0 million of which was invested in Amphivena in October 2016, &#x20AC;0.6 million of which was invested in March 2017, &#x20AC;0.3 million of which was invested in December 2017, &#x20AC;0.9 million of which was invested in June 2018. See &#x201C;Item 4. Information on the Company&#x2014; B. Business overview&#x2014;Amphivena&#x201D; for more information.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Indemnification Agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have entered into indemnification agreements with our managing directors and supervisory directors. The indemnification agreements and our Articles of Association require us to indemnify our managing directors and supervisory directors to the fullest extent permitted by law. See &#x201C;Item&nbsp;6B. Compensation&#x2014;Insurance and Indemnification&#x201D; for a description of these indemnification agreements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Other Agreements with Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Item&nbsp;6. Directors, Senior Management and Employees&#x2014;B. Compensation&#x201D; for a description of other agreements with our managing directors and supervisory directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Interests of Experts and Counsel<a name="CInterestsofExpertsandCounsel_818925"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;8. FINANCIAL INFORMATION<a name="ITEM8FINANCIALINFORMATION_64979"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Consolidated statements and other financial information<a name="AConsolidatedstatementsandotherfinancial"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Financial statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See &#x201C;Item&nbsp;18. Financial Statements,&#x201D; which contains our financial statements prepared in accordance with IFRS.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">112</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Legal Proceedings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">From time to time we are involved in legal proceedings that arise in the ordinary course of business. We believe that the outcome of these proceedings, if determined adversely, will not have a material adverse effect on our financial position. During the period covered by the audited and approved financial statements contained herein, we have not been a party to or paid any damages in connection with litigation that has had a material adverse effect on our financial position. Any future litigation may result in substantial costs and be a distraction to management and employer. No assurance can be given that future litigation will not have a material adverse effect on our financial position. See &#x201C;Item&nbsp;3. Key Information&#x2014;D. Risk factors.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Dividends and Dividend Policy</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have not declared cash dividends on our common shares in the years 2017, 2018 or 2019. We currently expect to retain future earnings, if any, to finance the operation and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our supervisory board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Significant changes<a name="BSignificantchanges_185362"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A discussion of the significant changes in our business can be found under &#x201C;Item&nbsp;4. Information on the Company&#x2014;A. History and development of the company.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;9. THE OFFER AND LISTING<a name="ITEM9THEOFFERANDLISTING_267929"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Offering and listing details<a name="AOfferingandlistingdetails_190546"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Plan of distribution<a name="BPlanofdistribution_97425"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Markets<a name="CMarkets_438402"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our common shares began trading on the Nasdaq Global Market on September&nbsp;12, 2014 under the symbol AFMD.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Selling shareholders<a name="DSellingshareholders_783512"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">E.&nbsp;&nbsp;&nbsp;Dilution<a name="EDilution_544617"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">F.&nbsp;&nbsp;&nbsp;Expenses of the issue<a name="FExpensesoftheissue_66157"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">113</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;10. ADDITIONAL INFORMATION<a name="ITEM10ADDITIONALINFORMATION_596766"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Share capital<a name="ASharecapital_719569"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Memorandum and articles of association<a name="BMemorandumandarticlesofassociation_9543"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our shareholders adopted the Articles of Association filed as Exhibit&nbsp;3.1 to our registration statement on Form&nbsp;F&#8209;1 (file no. 333&#8209;197097) with the SEC on September&nbsp;17, 2014, and have subsequently adopted amendments to the Articles of Association, most recently on June&nbsp;19, 2018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We incorporate by reference into this Annual Report on Form&nbsp;20&#8209;F the description of our Articles of Association effective upon the closing of our IPO contained in our F&#8209;1 registration statement (File No.&nbsp;333&#8209;197097) originally filed with the SEC on June&nbsp;27, 2014, as amended. Such description sets forth a summary of certain provisions of our articles of association as currently in effect, other than certain updates (including to our authorized share capital) reflected in our amended Articles of Association filed as Exhibit&nbsp;3.1 to our report on Form&nbsp;6&#8209;K (file no. 333&#8209;197097) with the SEC on June&nbsp;20, 2018, incorporated by reference herein.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Material contracts<a name="CMaterialcontracts_131115"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Except as otherwise disclosed in this Annual Report on Form&nbsp;20&#8209;F (including the Exhibits), we are not currently, and have not been in the last two&nbsp;years, party to any material contract, other than contracts entered into in the ordinary course of business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Exchange controls<a name="DExchangecontrols_281790"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cash dividends payable on our common shares and cash interest payments to holders of our debt securities may be remitted from the Netherlands to non-residents without legal restrictions imposed by the laws of the Netherlands, except that (i)&nbsp;such payments must be reported, if requested, to the Dutch Central Bank for statistical purposes only and (ii)&nbsp;the transfer of funds to jurisdictions subject to general economic sanctions adopted in connection with policies of the United Nations, European Commission or similar measures imposed directly by the Government of the Netherlands may be restricted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">E.&nbsp;&nbsp;&nbsp;Taxation<a name="ETaxation_990591"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following summary contains a description of material German, Dutch and U.S. federal income tax consequences of the acquisition, ownership and disposition of common shares, but it does not purport to be a comprehensive description of all the tax considerations that may be relevant to a decision to purchase common shares. The summary is based upon the tax laws of Germany, the Netherlands and the United States and regulations thereunder as of the date hereof, which are subject to change.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">German Tax Considerations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following discussion is a summary of the material German tax considerations which&#x2014;as the Company has its place of management in Germany and is therefore tax resident in Germany&#x2014;relate to the purchase, ownership and disposition of our common shares both by a shareholder (an individual, a partnership or corporation) that has a tax domicile in Germany (that is, whose place of residence, habitual abode, registered office or place of management is in Germany) and by a shareholder without a tax domicile in Germany. This discussion does not cover the treatment of certain special companies such as those engaged in the financial and insurance sectors and pension funds. The information is not exhaustive and does not constitute a definitive explanation of all possible aspects of taxation that could be relevant for shareholders. The information is based on the tax law in force in Germany as of the date hereof (and its interpretation by administrative directives and courts) as well as typical provisions of double taxation treaties that Germany has concluded with other countries. </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">114</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Tax law can change&#x2014;sometimes retrospectively. Moreover, it cannot be ruled out that the German tax authorities or courts may consider an alternative assessment to be correct that differs from the one described in this section.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This section cannot replace tailored tax advice to individual shareholders. They are therefore advised to consult their tax advisors regarding the tax implications of the acquisition, holding or transfer of shares and regarding the procedures to be followed to achieve a possible reimbursement of German withholding tax. Only such advisors are in a position to take the specific tax-relevant circumstances of individual shareholders into due account.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Income Tax Implications of the Purchase, Holding and Disposal of Shares</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In terms of the taxation of shareholders of the Company, a distinction must be made between taxation in connection with the holding of shares (&#x201C;Taxation of Dividends&#x201D;), taxation in connection with the sale of shares (&#x201C;Taxation of Capital Gains&#x201D;) and taxation in connection with the mortis causa or inter vivos (munificent) transfer of shares (&#x201C;Inheritance and Gift Tax&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Taxation of Dividends</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Withholding tax</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a general rule, the dividends distributed to the shareholder are subject to a withholding tax (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Kapitalertragsteuer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) of 25% and a solidarity surcharge of 5.5% thereon (i.e., 26.375% in total plus church tax, if applicable). The withholding tax is withheld and discharged for the account of the shareholders by the Company. Dividend payments that are funded from the Company&#x2019;s contribution account for tax purposes (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">steuerliches Einlagekonto</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">; &#xA7; 27 K&#xF6;rperschaftsteuergesetz, German Corporation Income Tax Act) are generally not taxable in Germany and are not subject to withholding tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In general, the withholding tax must be withheld regardless of whether and to which extent the dividend is exempt from tax at the level of the shareholder and whether the shareholder is domiciled in Germany or abroad.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">However, withholding tax on dividends distributed to a company domiciled in another EU Member State within the meaning of &#xA7; 43b Einkommensteuergesetz, German Income Tax Act, in connection with Article 2 of Council Directive 2011/96/EU of November 30, 2011 on the common system of taxation applicable in the case of parent companies and subsidiaries of different member states, as amended (the &#x201C;Parent-Subsidiary Directive&#x201D;) may be refunded or exempted upon application and subject to further conditions. This also applies to dividends distributed to a permanent establishment of such a parent company resident in another Member State of the European Union or to a parent company that is subject to unlimited tax liability in Germany, provided that the participation in the Company actually forms part of such permanent establishment&#x2019;s business assets. As further requirements for the refund or exemption of withholding tax under the Parent-Subsidiary Directive, the shareholder needs to hold &#x2013; for corporate income tax purposes - at least a 10% direct stake in the company&#x2019;s registered capital since the beginning of the relevant tax assessment period and to file a respective application with the German Federal Central Tax Office (Bundeszentralamt f&#xFC;r Steuern, Hauptdienstsitz Bonn-Beuel, An der K&#xFC;ppe 1, 53225 Bonn) using an official form. With the annual tax bill in 2019 the German legislature raised the threshold for the aforementioned exemption from trade tax for dividends for corporations within the meaning of Article 2 of the Parent-Subsidiary Directive to 15% for assessment periods beginning January 1, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">With respect to distributions made to other shareholders without a tax domicile in Germany, the withholding tax rate can be reduced in accordance with a double taxation treaty if Germany has entered into a double taxation treaty with the shareholder&#x2019;s state of residence and if the shares neither form part of the assets of a permanent establishment or a fixed place of business in Germany, nor form part of business assets for which a permanent representative in Germany has been appointed. Pursuant to most German tax treaties, including the income tax treaty between Germany and the United States, the German withholding tax rate is reduced to 15% (or, in certain cases, depending on the size of the shareholding, to a lower rate) with respect to distributions received </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">115</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">by shareholders eligible for treaty benefits. The withholding tax reduction is generally granted by the German Federal Central Tax Office (Bundeszentralamt f&#xFC;r Steuern) upon application in such a manner that the difference between the total amount withheld, including the solidarity surcharge, and the reduced withholding tax actually owed under the relevant double taxation treaty is refunded by the German Federal Central Tax Office.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Forms for the reimbursement and exemption from the withholding at source procedure are available at the German Federal Central Tax Office (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">http://www.bzst.bund.de</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) as well as at German embassies and consulates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If dividends are distributed to corporations subject to limited tax liability, i.e., corporations with no registered office or place of management in Germany and if the shares neither belong to the assets of a permanent establishment or fixed place of business in Germany nor form part of business assets for which a permanent representative in Germany has been appointed, two-fifths of the tax withheld at the source can generally be refunded even if the prerequisites for a refund under the Parent-Subsidiary Directive or the relevant double taxation treaty are not fulfilled. The relevant application forms are available at the German Federal Central Tax Office (at the address specified above).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The exemption from withholding tax under the Parent-Subsidiary Directive as well as the aforementioned possibilities for a refund of withholding tax depend on certain other conditions being met (particularly the fulfillment of so-called substance requirements&#x2014;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Substanzerfordernisse</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For shareholders resident in Germany (i.e., shareholders whose place of residence or usual place of abode or, in case of corporations, its statutory seat or place of management, is situated in Germany) holding their shares as business assets as well as for shareholders residing outside Germany (foreign shareholders) holding their shares in a permanent establishment or a fixed base in Germany, or as assets for which a permanent representative has been appointed in Germany, the tax withheld is credited against the shareholders&#x2019; personal income tax or corporate income tax. Such crediting of withholding tax requires a certificate within the meaning of Section&nbsp;45a (2)&nbsp;sentence 3 Income Tax Act.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any tax withheld in excess of the shareholders&#x2019; personal tax is refunded. The same principles apply to the solidarity surcharge.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For taxpayers who are subject to church tax, an automatic procedure for deducting church tax applies unless the shareholder has filed a blocking notice (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sperrvermerk</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) with the German Federal Central Tax Office. The church tax payable will be withheld together with the withholding tax. The taxpayer may refuse (block) the automatic query to the Federal Central Tax Office, which will then force an assessment by the taxpayer and the shareholder will be obliged to declare the dividends in his income tax return. The respective forms may be obtained from the German Federal Central Tax Office (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Bundeszentralamt f&#xFC;r Steuern</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), An der Kuppe 1, 53225 Bonn, Germany (www.bzst.bund.de). If the church tax is withheld together with the withholding tax, the withholding tax will be reduced by 25% of the church tax levied on the withholding tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In case the shares are entrusted to a central securities depository (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Wertpapiersammelbank</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) outside of Germany for custody as it is the case with the shares in the Company, the aforementioned withholding tax relief in accordance with applicable double taxation treaties as well as the credit of withholding tax described for shares held as private and as business assets is, pursuant to a special rule&nbsp;on the restriction of withholding tax credit, subject to the following three cumulative prerequisites: (i)&nbsp;the relevant shareholder must qualify as beneficial owner of the shares in the Company for a minimum holding period of 45 consecutive&nbsp;days occurring within a period of 45&nbsp;days prior and 45&nbsp;days after the due date of the dividends, (ii)&nbsp;the shareholder has to bear at least 70% of the risk in value change related to the shares in the Company during the minimum holding period without being directly or indirectly hedged and (iii)&nbsp;the shareholder is not required to fully or largely, directly or indirectly, transfer the dividends to third parties.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">116</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of dividends of shareholders with a tax domicile in Germany</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shares held as non-business assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dividends distributed to shareholders with a tax domicile in Germany whose shares are held as non-business assets form part of their taxable capital investment income, which is subject to a flat tax at a rate of 25% plus solidarity surcharge of 5.5% thereon (i.e., 26.375% in total plus church tax, if applicable). The income tax owed for this dividend income is in general discharged by the withholding tax levied by the Company (flat tax&#x2014;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Abgeltungsteuer</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">). Income-related expenses cannot be deducted from the capital investment income, except for an annual lump-sum deduction (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sparer-Pauschbetrag</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) of &#x20AC;801 (&#x20AC;1,602 for married couples filing jointly). However, the shareholder may request that his capital investment income (including dividends) along with his other taxable income is taxed at his individual progressive income tax rate (instead of the flat tax on capital investment income) if this results in a lower tax burden. In this case the withholding tax will be credited against the individual progressive income tax and any excess amount will be refunded. In this case as well income-related expenses cannot be deducted from the capital investment income, except for the aforementioned annual lump-sum deduction.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Exceptions from the flat tax apply upon application for shareholders who have a shareholding of at least 25% in the Company and for shareholders who have a shareholding of at least 1% in the Company and can take significant entrepreneurial influence on the Company&#x2019;s economic activity by a professional activity for the Company. In this case 60 % of the dividend income is taxed at the individual progressive income tax rate and 60% of the expenses in relation to the shareholding are deductible.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shares held as business assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dividends from shares held as business assets by a shareholder with a tax domicile in Germany are not subject to the flat tax. The taxation depends on whether the shareholder is a corporation, a sole proprietor or a partnership (co-entrepreneurship). The withholding tax (including the solidarity surcharge thereon and church tax, if applicable) withheld and paid by the Company will be credited against the shareholder&#x2019;s income tax or corporate income tax liability (including the solidarity surcharge thereon and church tax, if applicable) or refunded in the amount of any excess.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Corporations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shareholder is a corporation with a tax domicile in Germany, the dividends are in general effectively 95% exempt from corporate income tax and the solidarity surcharge. Five&nbsp;percent of the dividends are treated as non-deductible business expenses and are therefore subject to corporate income tax (plus the solidarity surcharge thereon) at a total tax rate of 15.825%. In other respects, business expenses actually incurred in direct relation to the dividends may be deducted. However dividends are not exempt from corporate income tax (including solidarity surcharge thereon), if the shareholder only held (or holds) a direct participation of less than 10% in the share capital of the distributing corporation at the beginning of the calendar&nbsp;year (hereinafter in all cases, a &#x201C;Portfolio Participation&#x201D; (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Streubesitzbeteiligung</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">)). Participations of at least 10% acquired during a calendar&nbsp;year are deemed to have been acquired at the beginning of the calendar&nbsp;year. Participations which a corporate shareholder holds through a partnership (including those that are co-entrepreneurships (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Mitunternehmerschaften</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">)) are attributable to the shareholder only on a </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">pro rata</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> basis at the ratio of the interest share of the shareholder in the assets of the relevant partnership. Shareholders affected by the rules&nbsp;for the taxation of dividends from Portfolio Participations are recommended to discuss the potential consequences with their tax advisors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dividends (after deducting business expenses economically related to the dividends) are subject to trade tax in the full amount, unless the participation amounts to at least 15% at the beginning of the relevant assessment period (trade tax participation exemption privilege). In this latter case, the dividends are not subject to trade tax; however, trade tax is levied on amounts considered to be non-deductible business expenses (amounting to 5% </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">117</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">of the dividend). Trade tax ranges from 7% to approximately 18% depending on the municipal trade tax multiplier applied by the relevant municipal authority.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sole proprietors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shares are held as business assets by a sole proprietor with a tax domicile in Germany, only 60% of the dividends are subject to progressive income tax (plus the solidarity surcharge thereon) at a total tax rate of up to approximately 47.5% (plus church tax, if applicable), under the so-called partial income method (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Teileink&#xFC;nfteverfahren</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">). Only 60% of the business expenses economically related to the dividends are tax-deductible. If the shares belong to a domestic permanent establishment in Germany of a business operation of the shareholder, the dividend income (after deducting business expenses economically related thereto) is fully subject to trade tax, unless the shareholder holds at least 15% of the share capital of the Company at the beginning of the relevant assessment period (trade tax participation exemption privilege). In this latter case the net amount of dividends, i.e., after deducting directly related expenses, is exempt from trade tax. As a rule, trade tax can be credited against the shareholder&#x2019;s personal income tax, either in full or in part, by means of a lump-sum tax credit method&#x2014;depending on the level of the municipal trade tax multiplier and certain individual tax-relevant circumstances of the taxpayer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Partnerships</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shareholder is a genuine business partnership or a deemed business partnership (co-entrepreneurship) with a permanent establishment in Germany, the income tax or corporate income tax is not levied at the level of the partnership but at the level of the respective partner. The taxation of every partner depends on whether the partner is a corporation or an individual. If the partner is a corporation, the dividends contained in the profit share of the partner will be taxed in accordance with the rules&nbsp;applicable for corporations (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Corporations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D; above). If the partner is an individual, the taxation follows the rules&nbsp;described for sole proprietors, (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sole proprietors</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D; above). Upon application and subject to further conditions, an individual as a partner can have his personal income tax rate reduced for earnings retained at the level of the partnership.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, the dividends are generally subject to trade tax in the full amount at the partnership level if the shares are attributed to a German permanent establishment of the partnership. If a partner of the partnership is an individual, the portion of the trade tax paid by the partnership pertaining to his profit share will generally be credited, either in full or in part, against his personal income tax by means of a lump-sum method&#x2014;depending on the level of the municipal trade tax multiplier and certain individual tax-relevant circumstances of the taxpayer. Due to a lack of case law and administrative guidance, it is currently unclear how the rules&nbsp;for the taxation of dividends from Portfolio Participations (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Corporations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D; above) might impact the trade tax treatment at the level of the partnership. Shareholders are strongly recommended to consult their tax advisors. Under a literal reading of the law, if the partnership qualifies for the trade tax exemption privilege at the beginning of the relevant assessment period, the dividends should generally not be subject to trade tax. However, in this case, trade tax should be levied on 5% of the dividends to the extent they are attributable to the profit share of such corporate partners to whom at least 10% of the shares in the Company are attributable on a look-through basis, since such portion of the dividends should be deemed to be non-deductible business expenses. The remaining portion of the dividend income attributable to other than such specific corporate partners (which includes individual partners and should, under a literal reading of the law, also include corporate partners to whom, on a look-through basis, only Portfolio Participations are attributable) should (after the deduction of business expenses economically related thereto) not be subject to trade tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of dividends of shareholders without a tax domicile in Germany</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shareholders without a tax domicile in Germany whose shares are attributable to a German permanent establishment or fixed place of business or are part of business assets for which a permanent representative in Germany has been appointed, are also subject to tax in Germany on their dividend income. In this respect the provisions outlined above for shareholders with a tax domicile in Germany whose shares are held as business assets apply accordingly (&#x201C;&#x2014;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of dividends of shareholders with a tax domicile in Germany&#x2014;</font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">118</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shares held as business assets</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;). The withholding tax (including the solidarity surcharge thereon) withheld and passed on will be credited against the income or corporate income tax liability or refunded in the amount of any excess.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In all other cases, any German limited tax liability on dividends is discharged by withholding tax imposed by the Company. Withholding tax is only reimbursed in the cases and to the extent described above under &#x201C;&#x2014;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Withholding tax</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Taxation of Capital Gains</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of capital gains of shareholders with a tax domicile in Germany</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shares held as non-business assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Gains from the disposal of shares acquired after December&nbsp;31, 2008 by a shareholder with a tax domicile in Germany and held as non-business assets are generally&#x2014;regardless of the holding period&#x2014;subject to a flat tax on capital investment income at a rate of 25% (plus the solidarity surcharge of 5.5% thereon, i.e., 26.375% in total plus church tax, if applicable).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The taxable capital gain is computed as the difference between (a)&nbsp;the sale proceeds and (b)&nbsp;the acquisition costs of the shares and the expenses related directly and economically to the disposal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Only an annual lump-sum deduction of &#x20AC;801 (&#x20AC;1,602 for married couples filing jointly) may be deducted from the entire capital investments income. It is not possible to deduct income-related expenses in connection with capital gains, except for the expenses directly related in substance to the disposal which can be deducted when calculating the capital gains. Losses from disposals of shares may only be offset against capital gains from the disposal of shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the disposal of the shares is executed by a domestic credit institution, or domestic financial services institution (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">inl&#xE4;ndisches Kredit-oder Finanzdienstleistungsinstitut</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) (including domestic branches of foreign credit and financial services institutions), domestic securities trading company (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">inl&#xE4;ndisches Wertpapierhandelsunternehmen</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) or a domestic securities trading bank (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">inl&#xE4;ndische Wertpapierhandelsbank</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), and such office pays out or credits the capital gains (a &#x201C;Domestic Paying Agent&#x201D;), the tax on the capital gains will in general be discharged for the account of the seller by the Domestic Paying Agent imposing the withholding tax on investment income at the rate of 26.375% (including the solidarity surcharge thereon plus church tax, if applicable) on the capital gain.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">However, the shareholder can apply for his total capital investment income together with his other taxable income to be subject to his progressive income tax rate, as opposed to the flat tax on investment income, if this results in a lower tax liability. In this case the withholding tax is credited against the individual progressive income tax and any resulting excess amount will be refunded. In this case as well income-related expenses cannot be deducted from the capital investment income, except for the aforementioned annual lump-sum deduction. Further, the limitations on offsetting losses are also applicable under the income tax assessment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the withholding tax or, if applicable, the church tax on capital gains, is not withheld by a Domestic Paying Agent, the shareholder is required to declare the capital gains in his income tax return. The income tax and any applicable church tax on the capital gains will then be collected by way of assessment.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Regardless of the holding period and the time of acquisition, gains from the disposal of shares are not subject to the flat tax but to individual progressive income tax if a shareholder domiciled in Germany, or, in the event of a munificent transfer, their legal predecessor, or, if the shares have been munificently transferred several times in succession, one of his legal predecessors at any point during the five&nbsp;years preceding the disposal directly or indirectly held at least 1% of the share capital of the Company (a &#x201C;Qualified Holding&#x201D;). In this case the partial income method applies to gains from the disposal of shares, which means that only 60% of the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">119</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">capital gains are subject to tax and only 60% of the losses on the disposal and expenses economically related thereto are tax deductible. Even though withholding tax has to be withheld by a Domestic Paying Agent in the case of a Qualified Holding, this does not discharge the tax liability of the shareholder. Consequently, a shareholder must declare his capital gains in his income tax return. The withholding tax (including the solidarity surcharge thereon and church tax, if applicable) levied and paid will be credited against the shareholder&#x2019;s income tax liability as assessed (including the solidarity surcharge thereon and any church tax, if applicable) or refunded in the amount of any excess.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shares held as business assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Gains from the sale of shares held as business assets of a shareholder with a tax domicile in Germany are not subject to the flat tax. The taxation of the capital gains depends on whether the shareholder is a corporation, a sole proprietor or a partnership (co-entrepreneurship).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Corporations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shareholder is a corporation with a tax domicile in Germany, the gains from the disposal of shares are in general effectively 95% exempt from corporate income tax (including the solidarity surcharge thereon) and trade tax, regardless of the size of the participation and the holding period, and 5% of the gains are treated as non-deductible business expenses and are therefore subject to corporate income tax (plus the solidarity surcharge thereon) at a rate of 15.825% and trade tax (at a rate depending on the municipal trade tax multiplier applied by the municipal authority, generally between 7% and approximately 18%). As a rule, capital losses and other profit reductions in connection with shares (e.g., from a write-down) cannot be deducted for tax purposes. Currently, there are no specific rules&nbsp;for the taxation of gains arising from the disposal of Portfolio Participations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sole proprietors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shares are held as business assets by a sole proprietor with a tax domicile in Germany, only 60% of the gains from the disposal of the shares are subject to progressive income tax (plus the solidarity surcharge thereon) at a total tax rate of up to approximately 47.5%, and, if applicable, church tax (partial-income method). Only 60% of the losses on the disposal and expenses economically related thereto are tax deductible. If the shares belong to a German permanent establishment of a business operation of the sole proprietor, 60% of the gains of the disposal of the shares are, in addition, subject to trade tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade tax can be credited against the shareholder&#x2019;s personal income tax liability, either in full or in part, by means of a lump-sum tax credit method&#x2014;depending on the level of the municipal trade tax multiplier and certain individual tax-relevant circumstances of the taxpayer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Partnerships</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the shareholder is a genuine business partnership or a deemed business partnership (co-entrepreneurship) with a permanent establishment in Germany, the income or corporate income tax is not levied at the level of the partnership but at the level of the respective partner. The taxation depends on whether the partner is a corporation or an individual. If the partner is a corporation, the capital gains from the shares as contained in the profit share of the partner will be taxed in accordance with the rules&nbsp;applicable to corporations (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Corporations</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D; above). For capital gains in the profit share of a partner that is an individual, the principles outlined above for sole proprietors apply accordingly (partial-income method, see above under &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Sole proprietors</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;). Upon application and subject to further conditions, a partner that is an individual can obtain a reduction of his personal income tax rate for earnings retained at the level of the partnership.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, capital gains from the shares are subject to trade tax at the level of the partnership if the shares are attributed to a domestic permanent establishment of a business operation of the partnership generally, (i)&nbsp;at 60% as far as they are attributable to the profit share of an individual partner, and (ii)&nbsp;currently, at 5% as far as </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">120</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">they are attributable to the profit share of a corporate partner. Capital losses and other profit reductions in connection with the shares are currently not deductible for trade tax purposes if they are attributable to the profit share of a corporation; however, 60% of the capital losses are deductible, subject to general limitations, to the extent such losses are attributable to the profit share of an individual.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If the partner is an individual, the portion of the trade tax paid by the partnership attributable to his profit share will generally be credited, either in full or in part, against his personal income tax by means of a lump-sum method&#x2014;depending on the level of the municipal trade tax multiplier and certain individual tax-relevant circumstances of the taxpayer.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Withholding tax</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In case of a Domestic Paying Agent, the capital gains from shares held as business assets are in general subject to withholding tax in the same way as shares held as non-business assets by a shareholder (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">&#x2014;Taxation of capital gains of shareholders with a tax domicile in Germany&#x2014;Shares held as non-business assets</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;). However, the Domestic Paying Agent will not levy the withholding tax, provided that (i)&nbsp;the shareholder is a corporation, association of persons or estate with a tax domicile in Germany, or (ii)&nbsp;the shares belong to the domestic business assets of a shareholder, and the shareholder declares so to the Domestic Paying Agent using the designated official form and certain other requirements are met. If withholding tax is imposed by a Domestic Paying Agent, the withholding tax (including the solidarity surcharge thereon and church tax, if applicable) imposed and discharged will be credited against the income tax or corporate income tax liability (including the solidarity surcharge thereon and church tax, if applicable) or will be refunded in the amount of any excess.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of capital gains of shareholders without a tax domicile in Germany</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Capital gains derived by shareholders not tax resident in Germany are only subject to German tax if the shareholder has a Qualified Holding in the Company or the shares belong to a domestic permanent establishment or fixed place of business or are part of business assets for which a permanent representative in Germany has been appointed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In case of a Qualified Holding (as defined in &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">&#x2014;Taxation of capital gains of shareholders with a tax domicile in Germany&#x2014;Shares held as non-business assets</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;), only 60% of the gains from the disposal of the shares are subject to progressive income tax plus the solidarity surcharge thereon (partial-income method), if the shareholder is a private individual. If the shareholder is a corporation and the shares do not belong to a domestic permanent establishment or fixed place of business and are not part of business assets for which a permanent representative in Germany has been appointed, the gains from the disposal of the shares should, according to a judgement of the German Federal Fiscal Court of 31 May&nbsp;2017, I R 37/15, not be subject to corporate income tax; the legal fiction according to which 5% of the gains are treated as non-deductible business expenses shall not apply. The judgment seems to be accepted by tax authorities. Furthermore, most double taxation treaties provide for exemption from German taxation and attribute the right of taxation to the shareholder&#x2019;s state of residence. According to the tax authorities there is no obligation to levy withholding tax at source in the case of a Qualified Holding if the shareholder submits to the Domestic Paying Agent a certificate of residence issued by a competent foreign tax authority.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">With regard to capital gains or losses from shares attributable to a domestic permanent establishment or fixed place of business or which form part of business assets for which a permanent representative in Germany has been appointed, the above-mentioned provisions pertaining to shareholders with a tax domicile in Germany whose shares are business assets apply mutatis mutandis (see &#x201C;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Taxation of capital gains of shareholders with a tax domicile in Germany&#x2014;Shares held as business assets</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201D;). The Domestic Paying Agent can refrain from deducting the withholding tax if the shareholder declares to the Domestic Paying Agent on an official form that the shares form part of domestic business assets and certain other requirements are met.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Abolishment of Solidarity Surcharge&#xB6;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">121</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">According to a bill enacted in December 2019, the solidarity surcharge will be partially abolished as of the assessment period 2021 for certain individual shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Inheritance and Gift Tax</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The transfer of shares to another person </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">mortis causa</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> or by way of munificent donation is generally subject to German inheritance or gift tax if:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the place of residence, habitual abode, place of management or registered office of the decedent, the donor, the heir, the donee or another acquirer is, at the time of the asset transfer, in Germany, or such person, as a German national, has not spent more than five continuous&nbsp;years outside of Germany without maintaining a place of residence in Germany, or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the decedent&#x2019;s or donor&#x2019;s shares belonged to business assets for which there had been a permanent establishment in Germany or a permanent representative had been appointed, or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the decedent or the donor, at the time of the succession or gift, held a direct or indirect interest of at least 10% of the Company&#x2019;s share capital either alone or jointly with other related parties.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The small number of double taxation treaties in respect of inheritance and gift tax which Germany has concluded to date usually provide for German inheritance or gift tax only to be levied in the cases under (i)&nbsp;and, subject to certain restrictions, in the cases under (ii). Special provisions apply to certain German nationals living outside of Germany and to former German nationals.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Other Taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No German financial transfer taxes, VAT, stamp duties or similar taxes are currently levied on the purchase or disposal or other forms of transfer of the shares. However, for VAT purposes, an entrepreneur may opt for taxation in relation to disposals of shares, which are in principle exempt from value-added-tax, if the sale is made to another entrepreneur for the entrepreneur&#x2019;s business. Wealth tax is currently not levied in Germany.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">However, on February&nbsp;14, 2013, the European Commission published a proposal for a Directive for a common financial transaction tax in Belgium, Germany, Estonia, Greece, Spain, France, Italy, Austria, Portugal, Slovenia and Slovakia. The Commission&#x2019;s proposal is currently under review and it is unclear if and to what extent it will be implemented, if ever. The implementation of a financial transaction tax is now included in the coalition agreement as of February&nbsp;2, 2018. Prospective holders are advised to seek their own professional advice in relation to the Commission&#x2019;s proposal to introduce a financial transaction tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Dutch Tax Considerations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This &#x201C;Dutch Tax Considerations&#x201D; section outlines the principal Dutch tax consequences of the acquisition, holding, settlement, redemption and disposal of common shares in the capital of the Company, or the Shares. It does not present a comprehensive or complete description of all aspects of Dutch tax law which could be relevant to a holder of Shares (a &#x201C;Shareholder&#x201D;). For Dutch tax purposes, a Shareholder may include an individual or entity not holding the legal title to the Shares, but to whom, or to which, the Shares are, or the income from the Shares is, nevertheless attributed based either on this individual or entity owning a beneficial interest in the Shares or on specific statutory provisions. These include statutory provisions attributing Shares to an individual who is, or who has directly or indirectly inherited from a person who was, the settlor, grantor or similar originator of a trust, foundation or similar entity that holds the Shares. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This &#x201C;Dutch Tax Considerations&#x201D; section is intended as general information only. A prospective Shareholder should consult his own tax adviser regarding the tax consequences of any acquisition, holding or disposal of Shares. </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">122</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This &#x201C;Dutch Tax Considerations&#x201D; section is based on Dutch tax law as applied and interpreted by Dutch tax courts and as published and in effect on the date of this Annual Report, including the tax rates applicable on that date, without prejudice to any amendments introduced at a later date and implemented with or without retroactive effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any reference in This &#x201C;Dutch Tax Considerations&#x201D; section made to Dutch taxes, Dutch tax or Dutch tax law should be construed as a reference to any taxes of any nature levied by or on behalf of the Netherlands or any of its subdivisions or taxing authorities or to the law governing such taxes, respectively. The Netherlands means the part of the Kingdom of the Netherlands located in Europe.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Any reference made to a treaty for the avoidance of double taxation concluded by the Netherlands includes the Tax Regulation for the Kingdom of the Netherlands (Belastingregeling voor het Koninkrijk), the Tax Regulation for the State of the Netherlands (Belastingregeling voor het land Nederland), the Tax Regulations for the Netherlands and Curacao (Belastingregeling Nederland Curacao), the Tax Regulations for the Netherlands and St. Maarten (Belastingregeling Nederland Sint Maarten) and the Agreement between the Taipei Representative Office in the Netherlands and the Netherlands Trade and Investment Office in Taipei for the avoidance of double taxation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This &#x201C;Dutch Tax Considerations" section does not describe any Dutch tax considerations or consequences that may be relevant where a Shareholder:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;is an individual and the Shareholder's income or capital gains derived from the Shares are attributable to&nbsp;employment activities, the income from which is taxable in the Netherlands;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;has a substantial interest (aanmerkelijk belang) or a fictitious substantial interest (fictief aanmerkelijk belang)&nbsp;in the Company within the meaning of chapter 4 of the Dutch Income Tax Act 2001 (Wet inkomstenbelasting&nbsp;2001). Generally, a Shareholder has a substantial interest in the Company if the Shareholder, alone or-in&nbsp;case of an individual-together with a partner for Dutch tax purposes, or any relative by blood or by marriage&nbsp;in the ascending or descending line (including foster children) or either of them, owns or holds, or is deemed&nbsp;to own or hold, certain rights to shares, including rights to directly or indirectly acquire shares, directly or&nbsp;indirectly representing 5% or more of the Company's issued capital as a whole or of any class of Shares or&nbsp;profit participating certificates (winstbewijzen) relating to 5%;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;is an entity which under the Dutch Corporate Income Tax Act 1969 (Wet op de vennootschapsbelasting 1969)&nbsp;("CITA"), is not subject to Dutch corporate income tax or is fully or partly exempt from Dutch corporate&nbsp;income tax (such as a qualifying pension fund);</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(iv)&nbsp;&nbsp;&nbsp;is an investment institution (beleggingsinstelling) as described in Section 6a or 28 CITA;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;is required to apply the participation exemption (deelnemingsvrijstelling) with respect to the Shares (as&nbsp;defined in Section 13 CITA). Generally, a Shareholder is required to apply the participation exemption if it&nbsp;is subject to Dutch corporate income tax and it, alone or together with a related entity, holds an interest of&nbsp;5% or more of the nominal paid-up share capital in the Company; or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(vi)&nbsp;&nbsp;&nbsp;holds the Shares through an entity which is treated as transparent for Dutch tax purposes, while being treated&nbsp;as a resident under the laws of another state.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Withholding Tax </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A Shareholder is generally subject to Dutch dividend withholding tax at a rate of 15% on dividends distributed by the Company. Generally, the Company is responsible for the withholding of such dividend withholding tax at source.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">123</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">However, a Shareholder will not be subject to Dutch dividend withholding tax on dividends distributed by the Company if, and for as long as, the Company is resident solely in Germany for purposes of the convention between Germany and the Netherlands for the avoidance of double taxation and the prevention of fiscal evasion with respect to taxes on income (the &#x201C;German - Dutch tax treaty&#x201D;), unless:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Shareholder is a Dutch Individual (as defined below) or a Dutch Corporate Entity (as defined below); or</font>
		</p>
		<p style="margin:0pt 0pt 12pt 21.6pt;line-height:100%;text-indent: -21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;the Shareholder is a Non-Dutch Individual (as defined below) or a Non-Dutch Corporate Entity (as defined below) and derives profits from an enterprise, which enterprise is, in whole or in part, carried on through a permanent establishment (vaste inrichting) or a permanent representative (vaste vertegenwoordiger) in the Netherlands, to which the Shares are attributable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dividends distributed by the Company include, but are not limited to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">distributions of profits in cash or in kind, whatever they be named or in whatever form;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">proceeds from the liquidation of the Company or proceeds from the repurchase of Shares by the Company, other than as a temporary portfolio investment (tijdelijke belegging), in excess of the average paid-in capital recognized for Dutch dividend withholding tax purposes;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the par value of the Shares issued to a Shareholder or an increase in the par value of the Shares, to the extent that no related contribution, recognized for Dutch dividend withholding tax purposes, has been made or will be made; and </font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">partial repayment of paid-in capital, that is</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (a)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">not recognized for Dutch dividend withholding tax purposes, or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (b)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">recognized for Dutch dividend withholding tax purposes, to the extent that the Company has &#x201C;net profits&#x201D; (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">zuivere winst</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">), unless</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the general meeting of shareholders has resolved in advance to make this repayment, and</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;line-height:100%;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the par value of the Shares concerned has been reduced by an equal amount by way of an amendment to the articles of association of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The term &#x201C;net profits&#x201D; includes anticipated profits that have yet to be realized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If a Shareholder is resident or deemed to be resident in the Netherlands, such Shareholder is generally entitled to an exemption or a credit for any Dutch dividend withholding tax against his Dutch tax liability and to a refund of any residual Dutch dividend withholding tax.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Depending on specific circumstances, a Shareholder resident in a country other than the Netherlands may be entitled to exemptions from, reduction of, or full or partial refund of, Dutch dividend withholding tax under Dutch law, European Union, or the EU, law or treaties for the avoidance of double taxation. According to Dutch domestic anti-dividend stripping rules, no credit against Dutch tax, exemption from, reduction, or refund of Dutch dividend withholding tax will be granted if the recipient of the dividends paid by the Company is not considered to be the beneficial owner (uiteindelijk gerechtigde) of those dividends.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Dutch Dividend Withholding Tax Act 1965 (Wet op de dividendbelasting 1965) (&#x201C;DWTA&#x201D;), provides for a non-exhaustive negative description of a beneficial owner. According to the DWTA, a Shareholder will not be </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">124</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">considered the beneficial owner of the dividends for this purpose if as a consequence of a combination of transactions:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a person other than the Shareholder wholly or partly, directly or indirectly, benefits from the dividends;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">whereby this other person retains or acquires, directly or indirectly, an interest similar to that in the Shares&nbsp;on which the dividends were paid; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">that other person is entitled to a credit, reduction or refund of Dutch dividend withholding tax that is less than&nbsp;that of the Shareholder.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Please refer to the paragraph &#x201C;Risk Factors&#x201D; for a risk regarding the Company&#x2019;s tax residency and the consequences thereof.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Taxes on Income and Capital Gains</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;text-decoration:underline;">Residents of the Netherlands</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The description of certain Dutch tax consequences in this subsection is only intended for the following Shareholders:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (a)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">individuals who are resident or deemed to be resident in the Netherlands (&#x201C;Dutch Individuals&#x201D;); and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (b)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">entities or enterprises that are subject to the CITA and are resident or deemed to be resident in the Netherlands (&#x201C;Dutch Corporate Entities&#x201D;).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Dutch Individuals engaged or deemed to be engaged in an enterprise or in miscellaneous activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dutch Individuals engaged or deemed to be engaged in an enterprise or in miscellaneous activities (resultaat uit overige werkzaamheden) are generally subject to income tax at statutory progressive rates with a maximum of 49.50% (2020) on any benefits derived or deemed to be derived from the Shares, including any capital gains realized on any disposal of the Shares, where those benefits are attributable to:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an enterprise from which a Dutch Individual derives profits, whether as an entrepreneur (ondernemer) or by being co-entitled (medegerechtigde) to the net worth of this enterprise other than as an entrepreneur or shareholder; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">miscellaneous activities, including activities which are beyond the scope of active portfolio investment activities (meer dan normaal vermogensbeheer).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Dutch Individuals not engaged or deemed to be engaged in an enterprise or in miscellaneous activities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Generally, the Shares held by a Dutch Individual who is not engaged or deemed to be engaged in an enterprise or in miscellaneous activities, will be subject to annual income tax imposed on a fictitious yield on the Shares. The Shares held by this Dutch Individual will be taxed under the regime for savings and investments (inkomen uit sparen en beleggen). Irrespective of the actual income or capital gains realized, the annual taxable benefit from a Dutch Individual&#x2019;s assets and liabilities taxed under this regime, including the Shares, is set at a percentage of the positive balance of the fair market value of these assets, including the Shares, and the fair market value of these liabilities. The percentage (2020), which is subject to an annual indexation, increases:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">from 1.799% over the first EUR 72,797;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">to 4,223% over EUR 72,798 up to and including EUR 1,005,572; and</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">125</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">to a maximum of 5.33% over EUR 1,005,573 or higher</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No taxation occurs if this positive balance does not exceed a certain threshold (heffingvrij vermogen), which is EUR 30,846 in 2020. The fair market value of assets, including the Shares, and liabilities that are taxed under this regime is measured exclusively on 1 January of every calendar year. The tax rate under the regime for savings and investments is a flat rate of 30%.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Dutch Corporate Entities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Dutch Corporate Entities are generally subject to corporate income tax at statutory rates up to 25% (2020) on any benefits derived or deemed to be derived from the Shares, including any capital gains realized on their disposal.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;text-decoration:underline;">Non-residents of the Netherlands</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The description of certain Dutch tax consequences in this subsection is only intended for the following Shareholders:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (a)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">individuals who are not resident and not deemed to be resident in the Netherlands (&#x201C;Non-Dutch Individuals&#x201D;); and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (b)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">entities that are not resident and not deemed to be resident in the Netherlands (&#x201C;Non-Dutch Corporate Entities&#x201D;).</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Non-Dutch Individuals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A Non-Dutch Individual will not be subject to any Dutch taxes on income or capital gains derived from the purchase, ownership and disposal or transfer of the Shares, other than withholding tax as described above, unless:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Non-Dutch Individual derives profits from an enterprise, whether as entrepreneur or by being co-entitled to the net worth of this enterprise other than as an entrepreneur or shareholder and this enterprise is carried on through a permanent establishment (vaste inrichting) or a permanent representative (vaste vertegenwoordiger) in the Netherlands, to which the Shares are attributable;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Non-Dutch Individual derives benefits from miscellaneous activities carried on in the Netherlands in respect of the Shares, including activities which are beyond the scope of active portfolio investment activities; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Non-Dutch Individual is entitled to a share&#x2014;other than by way of securities&#x2014;in the profits of an enterprise which is effectively managed in the Netherlands and to which enterprise the Shares are attributable.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Non-Dutch Corporate Entities</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A Non-Dutch Corporate Entity will not be subject to any Dutch taxes on income or capital gains in respect of the purchase, ownership and disposal or transfer of the Shares, other than withholding tax as described above, unless:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Non-Dutch Corporate Entity derives profits from an enterprise, which enterprise is, in whole or in part, carried on through a permanent establishment or a permanent representative in the Netherlands, to which the Shares are attributable; or</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">126</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Non-Dutch Corporate Entity is entitled to a share in the profits of an enterprise or a co-entitlement to the net worth of an enterprise, other than by way of securities, which enterprise is effectively managed in the Netherlands and to which enterprise the Shares are attributable.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under certain specific circumstances, Dutch taxation rights may be restricted for Non-Dutch Individuals and Non-Dutch Corporate Entities pursuant to treaties for the avoidance of double taxation concluded by the Netherlands.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Dutch Gift Tax or Inheritance Tax</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No Dutch gift tax or inheritance tax is due in respect of any gift of the Shares by, or inheritance of the Shares on the death of, a Shareholder, unless:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Shareholder is resident, or is deemed to be resident, in the Netherlands at the time of the gift or death of the Shareholder;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Shareholder dies within 180 days after the date of the gift of the Shares and was or was deemed to be, resident in the Netherlands at the time of his death but not at the time of the gift; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the gift of the Shares is made under a condition precedent and the Shareholder is resident, or is deemed to be resident, in the Netherlands at the time the condition is fulfilled.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Other Taxes and Duties</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No other Dutch taxes, including turnover or value added taxes and taxes of a documentary nature, such as capital tax, stamp or registration tax or duty, are payable by, or on behalf of, the Shareholder by reason only of the purchase, ownership and disposal of the Shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Residency</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A Shareholder will not become a resident or deemed resident of the Netherlands by reason only of holding the Shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Material U.S. Federal Income Tax Considerations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following is a description of the material U.S. federal income tax consequences to the U.S. Holders described below of owning and disposing of common shares. It does not describe all tax considerations that may be relevant to a particular person&#x2019;s decision to acquire, own or dispose of the common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This section applies only to a U.S. Holder that holds common shares as capital assets within the meaning of Section 1221 of the Code (generally, property held for investment) for U.S. federal income tax purposes. In addition, it does not set forth all of the U.S. federal income tax consequences that may be relevant in light of the U.S. Holder&#x2019;s particular circumstances, including alternative minimum tax consequences, the potential application of the provisions of the Code known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">certain financial institutions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">dealers or traders in securities who use a mark-to-market method of tax accounting;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">127</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">entities&nbsp; or arrangements classified as partnerships for U.S. federal income tax purposes;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">tax-exempt entities, including an &#x201C;individual retirement account&#x201D; or &#x201C;Roth IRA&#x201D;;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">persons that own or are deemed to own ten&nbsp;percent or more of our shares (by vote or value);</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">persons who are subject to Section 451(b) of the Code; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">persons holding common shares in connection with a trade or business conducted outside of the United States.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If an entity that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax treatment of a partner will depend on the status of the partner and the activities of the partner and the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal income tax consequences of owning and disposing of the common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">This section is based on the Code, administrative pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Germany and the United States and the income tax treaty between the Netherlands and the United States (as applicable and as the context requires the &#x201C;Treaty&#x201D;) all as of the date hereof, any of which is subject to change or differing interpretations, possibly with retroactive effect. No assurance can be given that the IRS will agree with the views expressed in this discussion, or that a court will not sustain any challenge by the IRS in the event of litigation. We have not obtained, nor do we intend to obtain, a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A &#x201C;U.S. Holder&#x201D; is a holder who, for U.S. federal income tax purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty and who is:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a citizen or individual resident of the United States;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:1pt;"><p style="width:1pt;width:1pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing of common shares in their particular circumstances. In particular, because our group includes an U.S. subsidiary, (Affimed Inc., a Delaware corporation) and therefore under current law our non-U.S. subsidiaries (Affimed GmbH and AbCheck s.r.o.) are treated as controlled foreign corporations (regardless of whether we are or are not treated as a controlled foreign corporation), any U.S. Holder that owns or is deemed to own ten percent or more of our shares (by vote or value) is urged to consult </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">128</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">its tax advisor regarding the potential application of the &#x201C;Subpart F income&#x201D; and &#x201C;global intangible low-taxed income&#x201D; rules to an investment in our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 10.8pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Taxation of Distributions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We do not currently expect to make distributions on our common shares. In the event that we do make distributions of cash or other property, subject to the passive foreign investment company rules described below, distributions paid on common shares, other than certain pro rata distributions of common shares, will be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). If we are not treated as a PFIC with respect to a U.S. Holder and were not treated as a PFIC with the respect to the U.S. Holder in the preceding taxable year, for so long as our common shares are listed on NASDAQ or another established securities market in the United States or we are eligible for benefits under the Treaty, dividends paid to such a U.S. Holder that is not a corporation would generally be eligible for taxation as &#x201C;qualified dividend income&#x201D; if certain other requirements are met, which is taxable at rates not in excess of the long-term capital gain rate applicable to such U.S. Holders. The amount of a dividend will include any amounts withheld by us in respect of German or Dutch income taxes. Subject to the passive foreign investment company rules described below, the amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction available to U.S. corporations under the Code. Subject to the passive foreign investment company rules described below, dividends will be included in a U.S. Holder&#x2019;s income on the date of the U.S. Holder&#x2019;s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Subject to applicable limitations, German or Dutch income taxes withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be eligible for credit against the U.S. Holder&#x2019;s U.S. federal income tax liability. German or Dutch taxes withheld in excess of the rate applicable with respect to such U.S. Holder under the Treaty will not be eligible for credit against a U.S. Holder&#x2019;s federal income tax liability. The rules governing foreign tax credits are complex and U.S. Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may deduct foreign taxes, including any German or Dutch withholding tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Sale or Other Disposition of Common Shares</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Subject to the passive foreign investment company rules described below, gain or loss realized on the sale or other disposition of common shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#x2019;s tax basis in the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Passive Foreign Investment Company Rules</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the Code, we may be a PFIC for any taxable year in which, after the application of certain look-through rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of &#x201C;passive income&#x201D; or (ii) 50% or more of the average quarterly value of our assets consists of assets that produce, or are held for the production of, &#x201C;passive income.&#x201D; Passive income generally includes, among other things, dividends, interest, certain non-active rents and royalties, and capital gains. Although we have not performed a definitive PFIC analysis using U.S. federal income tax principles, based on certain estimates as to composition of our income and assets, including the implied value, based on our market capitalization, of our assets that produce non-passive income, during 2019, we do not believe that we were a PFIC for our 2019 taxable year. However, there </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">129</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">can be no assurance that the IRS will agree with our conclusion. In addition, whether we will be a PFIC in 2020 or any future taxable year is uncertain because, among other things, we currently own a substantial amount of passive assets, including cash, and because the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time and the composition of our income may vary substantially over time. The average quarterly value of our assets for purposes of determining our PFIC status for any taxable year will generally be determined in part by reference to our market capitalization, which has fluctuated and may continue to fluctuate significantly over time. Accordingly, there can be no assurance that we will not be a PFIC for any taxable year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The IRS recently released proposed Treasury Regulations that address various issues related to determining whether a foreign corporation is a PFIC and whether a U.S. shareholder holds PFIC stock. If finalized, these proposed Treasury Regulations may affect whether we are a PFIC in any future year. You should consult your own tax adviser regarding the effect, if any, these proposed Treasury Regulations would have on the determination of our PFIC status.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, we may, directly or indirectly, hold equity interests in Lower-tier PFICs. Under attribution rules, if we are a PFIC, U.S. Holders will be deemed to own their proportionate shares of Lower-tier PFICs and will be subject to U.S. federal income tax according to the rules described in the following paragraphs on (i) certain distributions by a Lower-tier PFIC and (ii) a disposition of shares of a Lower-tier PFIC, in each case as if the U.S. Holders held such shares directly, even though the U.S. Holders have not received the proceeds of those distributions or dispositions directly.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">For so long as we are treated as a PFIC with respect to a U.S. Holder (or were treated as a PFIC with respect to the U.S. Holder in the preceding taxable year), dividends paid to certain non-corporate U.S. Holders will not be eligible for taxation as &#x201C;qualified dividend income.&#x201D; In addition, if we were a PFIC for any taxable year during which a U.S. Holder held common shares (assuming such U.S. Holder has not made a timely mark-to-market election, as described below), gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of the common shares, or an indirect disposition of shares of a Lower-tier PFIC, would be allocated ratably over the U.S. Holder&#x2019;s holding period for the common shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any distribution received by a U.S. Holder on its common shares (or a distribution by a Lower-tier PFIC to its shareholder that is deemed to be received by a U.S. Holder) exceeds 125% of the average of the annual distributions on the common shares received during the preceding three years or the U.S. Holder&#x2019;s holding period, whichever is shorter, that distribution would be subject to taxation in the same manner as gain, described immediately above.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">If we are a PFIC for any year during which a U.S. Holder holds common shares, we would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which the U.S. Holder holds common shares, even if we ceased to meet the threshold requirements for PFIC status.</font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A U.S. Holder can avoid certain of the adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are &#x201C;marketable.&#x201D; Common shares will be marketable if they are &#x201C;regularly traded&#x201D; on a &#x201C;qualified exchange&#x201D; or other market within the meaning of applicable Treasury regulations. Our common shares will be treated as &#x201C;regularly traded&#x201D; in any calendar year in which more than a de minimis quantity of the common shares is traded on a qualified exchange on at least 15 days during each calendar quarter. Nasdaq, on which the common shares are currently listed, is a qualified exchange for this purpose. If a U.S. Holder makes the mark-to-market election, it will recognize as ordinary income any excess of the fair market value of the common shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#x2019;s tax basis in the common shares will be adjusted to reflect the income or loss amounts </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">130</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 10pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">recognized. Any gain recognized on the sale or other disposition of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). U.S. Holders should consult their tax advisers regarding the availability and advisability of making a mark-to-market election with respect to their common shares because we may have Lower-tier PFICs for which a mark-to-market election may not be available.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, in order to avoid the application of the foregoing rules, a U.S Holder can make qualified electing fund elections (any such election, a &#x201C;QEF Election&#x201D;) with respect to us and each Lower-tier PFIC in the first taxable year that we and each Lower-tier PFIC are treated as PFICs with respect to the U.S. Holder. A U.S. Holder must make the QEF Election for each PFIC by attaching a separate properly completed IRS Form 8621 for each PFIC to the U.S. Holder&#x2019;s timely filed U.S. federal income tax return generally for the first taxable year that the entity is treated as a PFIC with respect to the U.S. Holder. A U.S. Holder generally may make a separate election to defer payment of taxes on the undistributed income inclusion under the QEF rules, but if deferred, any such taxes are subject to an interest charge. We currently intend to provide the information necessary for a U.S. investor to make a QEF Election with respect to us and each Lower-tier PFIC that we control for 2019 and for any future years with respect to which we determine that we or any Lower-tier PFIC that we control are or are likely to be a PFIC. If a U.S. Holder makes a QEF Election with respect to us or a Lower-tier PFIC that we control, the U.S. Holder will be currently taxable on its pro rata share of the PFIC&#x2019;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is classified as a PFIC and will not be required to include such amounts in income when actually distributed by the PFIC. If a U.S. Holder makes a QEF Election with respect to us, any distributions paid by us out of our earnings and profits that were previously included in the U.S. Holder&#x2019;s income under the QEF Election will not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its common shares by an amount equal to any income included under the QEF Election and will decrease its tax basis by any amount distributed, if any, on the common shares that is not included in its income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of common shares in an amount equal to the difference between the amount realized and its adjusted tax basis in the common shares. U.S. Holders should note that if they make QEF Elections with respect to us and Lower-tier PFICs, if any, they may be required to pay U.S. federal income tax with respect to their common shares for any taxable year significantly in excess of any cash distributions, if any, received on the shares for such taxable year. U.S. Holders should consult their tax advisers regarding making QEF Elections in their particular circumstances.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">In addition, if we were a PFIC or, with respect to a particular U.S. Holder, were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential dividend rates with respect to dividends paid to certain non-corporate U.S. Holders would not apply. If a U.S. Holder owns common shares during any year in which we are a PFIC, the U.S. Holder must file annual reports containing such information as the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us (regardless of whether a mark-to-market election or QEF Election is made), generally with the U.S. Holder&#x2019;s federal income tax return for that year, unless otherwise specified in the instructions with respect to such form. U.S. Holders should consult their tax advisers regarding whether we are or were a PFIC and the potential application of the PFIC rules. Information Reporting with Respect to Foreign Financial Assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Certain U.S. Holders who are individuals and certain entities may be required to report information relating to an interest in our common shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding whether or not they are obligated to report information relating to their ownership and disposition of the common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Information Reporting and Backup Withholding</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">131</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit against the holder&#x2019;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">F.&nbsp;&nbsp;&nbsp;Dividends and paying agents<a name="FDividendsandpayingagents_639992"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">G.&nbsp;&nbsp;&nbsp;Statement by experts<a name="GStatementbyexperts_865754"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">H.&nbsp;&nbsp;&nbsp;Documents on display<a name="HDocumentsondisplay_350959"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including Annual Reports on Form&nbsp;20&#8209;F and reports on Form&nbsp;6&#8209;K. The SEC maintains an Internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">www.sec.gov</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">I.&nbsp;&nbsp;&nbsp;Subsidiary information<a name="ISubsidiaryinformation_389287"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT RISK<a name="ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">See note 21 to the consolidated financial statements as of December 31, 2019 for more information about our exposure to market risks.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES<a name="ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Debt securities<a name="ADebtsecurities_74825"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Warrants and rights<a name="BWarrantsandrights_600411"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Other securities<a name="COthersecurities_767426"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;American Depositary Shares<a name="DAmericanDepositaryShares_935554"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">132</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">PART&nbsp;II<a name="PARTII_649967"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES<a name="ITEM13DEFAULTSDIVIDENDARREARAGESANDDELIN"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Defaults<a name="ADefaults_106395"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No matters to report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Arrears and delinquencies<a name="BArrearsanddelinquencies_781930"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No matters to report.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF<a name="ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"></a> PROCEEDS</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Use of Proceeds<a name="AUseofProceeds_969111"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On September&nbsp;17, 2014, we completed our initial public offering of our common shares pursuant to a Registration Statement on Form&nbsp;F&#8209;1, as amended (File No.&nbsp;333&#8209;197097) that was declared effective on September&nbsp;12, 2014. Under the registration statement, we sold an aggregate of 8,000,000 common shares. All of these common shares were sold at a price to the public of US$7.00 per share, yielding gross proceeds of $56.0 million or net proceeds of $52.1 million after underwriting discounts and commissions. Jefferies LLC, Leerink Partners LLC and BMO Capital Markets Corp. were joint book-running managers for the initial public offering. We paid the offering expenses in connection with the initial public offering, which were approximately $3.0 million, and which included SEC registration fees, FINRA filing fees, NASDAQ listing fees and expenses, legal fees and expenses, printing and engraving expenses, accounting fees and expenses as well as other miscellaneous fees and expenses, but excluded the underwriting discounts and commissions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Between the effective date of the Registration Statement and December&nbsp;31, 2019, we used all of the net proceeds to fund research and development expenses for AFM13, AFM11 and AFM21/22/24/26. None of the net proceeds (other than compensation to our management board and supervisory board as disclosed in this Annual Report) were used to make payments, directly or indirectly, to (i)&nbsp;any of our directors, officers or their associates, (ii)&nbsp;any persons owning 10% or more of our common shares or (iii)&nbsp;any of our affiliates. The use of these proceeds did not change from the information mentioned in the prospectus relating to the Registration Statement.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;15. CONTROLS AND PROCEDURES<a name="ITEM15CONTROLSANDPROCEDURES_67132"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">A.&nbsp;&nbsp;&nbsp;Disclosure Controls and Procedures<a name="ADisclosureControlsandProcedures_332106"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of the end of the period covered by this Annual Report, an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule&nbsp;13a&#8209;15(e)&nbsp;under the Exchange Act) was performed under the supervision and with the participation of our managing board, including our Chief Executive Officer and Chief Financial Officer, our principal executive officer and principal financial officer, respectively. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective, as of the end of the period covered by this Annual Report, in providing a reasonable level of assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods in SEC rules&nbsp;and forms, including providing a reasonable level of assurance that information required to be disclosed </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">133</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">by us in such reports is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">B.&nbsp;&nbsp;&nbsp;Management&#x2019;s Annual Report on Internal Control over Financial Reporting<a name="BManagementsAnnualReportonInternalContro"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&nbsp;13a&#8209;15(f)&nbsp;of the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based upon criteria established in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Internal Control&nbsp;&#x2013; Integrated Framework</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (2013) by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">C.&nbsp;&nbsp;&nbsp;Attestation Report of the Registered Public Accounting Firm<a name="CAttestationReportoftheRegisteredPublicA"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our independent registered public accounting firm, KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft, has audited the consolidated financial statements included in this Annual Report, and as part of its audit, has issued its report on the effectiveness of our internal control over financial reporting. This report is included on page 142 of this Form 20-F and is incorporated herein by reference.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">D.&nbsp;&nbsp;&nbsp;Changes in Internal Control over Financial Reporting<a name="DChangesinInternalControloverFinancialRe"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">No change in our internal control over financial reporting (as defined in Rules&nbsp;13a&#8209;15(f)&nbsp;and 15d&#8209;15(f)&nbsp;under the Exchange Act) occurred during the financial&nbsp;year ended December&nbsp;31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16. [RESERVED]<a name="ITEM16RESERVED_65925"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16A. Audit committee financial expert<a name="ITEM16AAuditcommitteefinancialexpert_894"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our supervisory board has determined that each of Ferdinand Verdonck and Berndt Modig is an audit committee financial expert, as that term is defined by the SEC, and is independent for the purposes of SEC and Nasdaq rules.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16B. Code of ethics<a name="ITEM16BCodeofethics_579954"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Code of Conduct</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have adopted a Code of Conduct which covers a broad range of matters including the handling of conflicts of interest, compliance issues and other corporate policies such as insider trading and equal opportunity and non-discrimination standards. Our Code of Conduct applies to all of our supervisory directors, managing directors and employees. We have published our Code of Conduct on our website, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">www.affimed.com</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16C. Principal Accountant Fees and Services<a name="ITEM16CPrincipalAccountantFeesandService"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">a)&nbsp;&nbsp;&nbsp;Audit Fees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Audit fees in 2019 and 2018 amounted to &#x20AC;355,000 and &#x20AC;194,000, respectively, and relate to audit services provided by our principal accountants, KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft and other KPMG International member firms, in connection with the audit of the consolidated financial statements and statutory audits and, quarterly reviews. The aggregate audit fees include fees and expenses billed or accrued for professional services rendered by the principal accountant for the audit of our annual financial statements and review of the interim condensed consolidated financial statements and additional services that are normally </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">134</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">provided by the accountant in connection with statutory and regulatory filings or engagements, except for those not required by statute or regulation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">b)&nbsp;&nbsp;&nbsp;Audit-Related Fees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Audit-Related fees in 2019 and 2018 amounted to &#x20AC;75,000 and &#x20AC;138,000, respectively, and relate to services provided by our principal accountants, KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft for the review of registration statements and comfort letters for the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">c)&nbsp;&nbsp;&nbsp;Tax Fees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">None.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">d)&nbsp;&nbsp;&nbsp;All Other Fees</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other fees in 2019 and 2018 amounted to &#x20AC;0 and &#x20AC;6,000, respectively, and relate to other services provided by our principal accountants, KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">e)&nbsp;&nbsp;&nbsp;Audit Committee&#x2019;s Pre-Approval Policies and Procedures</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Audit Committee is responsible for the appointment, replacement, compensation, evaluation and oversight of the work of the independent auditors. As part of this responsibility, the Audit Committee pre-approves all audit and non-audit services performed by the independent auditors in order to assure that they do not impair the auditor&#x2019;s independence from the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">f)&nbsp;&nbsp;&nbsp;Audit Work Performed by Other Than Principal Accountant if Greater Than 50%</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16D. Exemptions from the listing standards for audit committees<a name="ITEM16DExemptionsfromthelistingstandards"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16E. Purchases of equity securities by the issuer and affiliated purchasers<a name="ITEM16EPurchasesofequitysecuritiesbythei"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, no purchases of our equity securities were made by or on behalf of Affimed or any affiliated purchaser.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16F. Change in registrant&#x2019;s certifying accountant<a name="ITEM16FChangeinregistrantscertifyingacco"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16G. Corporate governance<a name="ITEM16GCorporategovernance_414333"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-style:italic;">Summary of Significant Corporate Governance Differences from Nasdaq Listing Standards</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Our common shares are listed on the Nasdaq Global Select Market, or Nasdaq. We are therefore required to comply with certain of the Nasdaq&#x2019;s corporate governance listing standards, or the Nasdaq Standards. As a foreign private issuer, we may follow our home country&#x2019;s corporate governance practices in lieu of certain of the Nasdaq Standards. Our corporate governance practices differ in certain respects from those that U.S. companies must adopt in order to maintain a Nasdaq listing. A brief, general summary of those differences is provided as follows.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">135</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Quorum requirements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In accordance with Dutch law and generally accepted business practices, our Articles of Association do not provide quorum requirements generally applicable to general meetings of shareholders in the United States. To this extent, our practice varies from the requirement of Nasdaq Listing Rule&nbsp;5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Solicitation of proxies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Although we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders, Dutch law does not have a regulatory regime for the solicitation of proxies and the solicitation of proxies is not a generally accepted business practice in the Netherlands, thus our practice will vary from the requirement of Nasdaq Listing Rule&nbsp;5620(b).</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Compensation Committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule&nbsp;5605(d), which requires an issuer to have a compensation committee that, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">inter alia</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">, consists entirely of independent directors.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Nominating and Corporate Governance Committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule&nbsp;5605(e), which requires an issuer to have independent director oversight of director nominations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Director Compensation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As permitted by the listing requirements of Nasdaq, we have also opted out of the requirements of Nasdaq Listing Rule&nbsp;5250(b)(3), which requires an issuer to disclose information regarding third party compensation of its directors or director nominees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Shareholder approval</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company, the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of Nasdaq Rule&nbsp;5635, which generally requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;16H. Mine safety disclosure<a name="ITEM16HMinesafetydisclosure_355779"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">PART&nbsp;III<a name="PARTIII_169335"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;17. Financial statements<a name="ITEM17Financialstatements_88089"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have responded to Item&nbsp;18 in lieu of this item.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;18. Financial statements<a name="ITEM18Financialstatements_944544"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial Statements are filed as part of this Annual Report, see page&nbsp;F&#8209;3.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">136</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 6pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">ITEM&nbsp;19. Exhibits<a name="ITEM19Exhibits_808635"></a></font>
		</p>
		<p style="margin:0pt 0pt 6pt 36pt;line-height:100%;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(a)&nbsp;&nbsp;The following documents are filed as part of this registration statement:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">Exhibit&nbsp;No.</font></p>
				</td>
				<td valign="bottom" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:87.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">Exhibit</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">1.1</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010318007610/dp92447_ex0301.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Articles of Association of Affimed N.V. (incorporated by reference to exhibit 3.1 of the Affimed&nbsp;N.V. report on Form&nbsp;6&#8209;K (Registration no. 001&#8209;36619) filed with the Commission on June&nbsp;20, 2018).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">2*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231xex2.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Description of rights of each applicable class of securities registered under Section 12 of the Securities Exchange Act of 1934.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.1&#x2020;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex106.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Research Funding Agreement dated August&nbsp;15, 2013 between Affimed Therapeutics AG and The Leukemia and Lymphoma Society (incorporated by reference to exhibit 10.6 of the Affimed N.V. registration statement on Form&nbsp;F&#8209;1 (Registration no. 333&#8209;197097) filed with the Commission on June&nbsp;27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.2&#x2020;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex107.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Amendment No.&nbsp;1 to the Research Funding Agreement, dated April&nbsp;29, 2014 between Affimed Therapeutics AG and The Leukemia and Lymphoma Society (incorporated by reference to exhibit&nbsp;10.7 of the Affimed N.V. registration statement on Form&nbsp;F&#8209;1 (Registration no. 333&#8209;197097) filed with the Commission on June&nbsp;27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.2</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex108.htm"><font style="display:inline;">English language summary of Lease Agreement, dated September 19, 2000 and amendments thereto between Affimed Therapeutics AG and Technologiepark Heidelberg II GmbH &amp; Co. KG (incorporated by reference to exhibit 10.8 of the Affimed N.V. registration statement on Form F-1 (Registration no. 333-197097) filed with the Commission on June 27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.3</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex109.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Lease Contract dated October 1, 2009, between Abcheck s.r.o. and V&#xE8;deckotechnick&#x2019; park Plze&#xF1; a.s. (incorporated by reference to exhibit 10.9 of the Affimed N.V. registration statement on Form F-1 (Registration no. 333-197097) filed with the Commission on June 27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.4</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex1010.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Amendment No. 4 to Lease Contract dated October 1, 2009, between Abcheck s.r.o. and V&#xE8;deckotechnick&#x2019; park Plze&#xF1; a.s., dated June 30, 2011 (incorporated by reference to exhibit 10.10 of the Affimed N.V. registration statement on Form F-1 (Registration no. 333-197097) filed with the Commission on June 27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.5</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514253523/d720174dex1011.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Amendment No. 5 to Lease Contract dated October 1, 2009, between Abcheck s.r.o. and V&#xE8;deckotechnick&#x2019; park Plze&#xF1; a.s., dated November 14, 2012 (incorporated by reference to exhibit 10.11 of the Affimed N.V. registration statement on Form F-1 (Registration no. 333-197097) filed with the Commission on June 27, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.6</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000119312514314314/d720174dex1016.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Form&nbsp;of Supervisory Director and Managing Director Indemnification Agreement (incorporated by reference to exhibit 10.16 of the Affimed N.V. registration statement on Form&nbsp;F&#8209;1 (Registration no. 333&#8209;197097) filed with the Commission on August&nbsp;19, 2014).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.7</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1001.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Loan Agreement, dated November&nbsp;30, 2016 between Affimed GmbH and Silicon Valley Bank (incorporated by reference to exhibit 10.1 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no.&nbsp;001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.8</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1002.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Deed of Guaranty and Indemnity, dated November&nbsp;30, 2016 between Affimed N.V. and Silicon Valley Bank (incorporated by reference to exhibit 10.2 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no. 001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.9</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1003.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Omnibus Deed of Pledge, dated November&nbsp;30, 2016 between Affimed N.V. and Silicon Valley Bank (incorporated by reference to exhibit 10.3 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no.&nbsp;001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.10</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1004.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Share Pledge Agreement, dated November&nbsp;30, 2016 between Affimed N.V. and Silicon Valley Bank (incorporated by reference to exhibit 10.4 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no.&nbsp;001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">137</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

  <tr>

    <td valign="bottom" style="width:10.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">Exhibit&nbsp;No.</font>

      </p>

    </td>

    <td valign="bottom" style="width:02.40%;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font>

      </p>

    </td>

    <td valign="bottom" style="width:87.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:9.5pt;">Exhibit</font>

      </p>

    </td>

  </tr>

  <tr>

    <td valign="top" style="width:10.44%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>

      </p>

    </td>

    <td valign="top" style="width:02.40%;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>

      </p>

    </td>

    <td valign="top" style="width:87.16%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">

      <p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

        <font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>

      </p>

    </td>

  </tr>


			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.11</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1005.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Account Pledge Agreement, dated November&nbsp;30, 2016 between Affimed N.V. and Silicon Valley Bank (incorporated by reference to exhibit 10.5 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no.&nbsp;001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.12</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1006.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Account Pledge Agreement, dated November&nbsp;30, 2016 between Affimed GmbH and Silicon Valley Bank (incorporated by reference to exhibit 10.6 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no. 001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.13</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1007.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Security Assignment Agreement, dated November&nbsp;30, 2016 between Affimed GmbH and Silicon Valley Bank (incorporated by reference to exhibit 10.7 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no. 001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.14</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010316018537/dp70740_ex1008.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Security Transfer Agreement, dated November&nbsp;30, 2016 between Affimed GmbH and Silicon Valley Bank (incorporated by reference to exhibit 10.8 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no. 001&#8209;36619) filed with the Commission on December&nbsp;6, 2016).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.15</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010317007425/dp78863_ex1001.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Loan Modification Agreement, dated May&nbsp;31, 2017, between Affimed GmbH and Silicon Valley Bank (incorporated by reference to exhibit 10.1 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no.&nbsp;001&#8209;36619) filed with the Commission on August&nbsp;1, 2017).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">4.16&#x2020;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="http://www.sec.gov/Archives/edgar/data/1608390/000095010318009978/dp94808_ex1001.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Research Collaboration and License Agreement, dated as of August&nbsp;24, 2018 by and between Affimed GmbH and Genentech,&nbsp;Inc. (incorporated by reference to exhibit 10.1 of the Affimed N.V. report on Form&nbsp;6&#8209;K (File no. 001&#8209;36619) filed with the Commission on August&nbsp;27, 2018).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">8.1*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex81e6860d1.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">List of subsidiaries</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">12.1*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex1218376bb.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Certification of Principal Executive Officer pursuant to 17 CFR 240.13a&#8209;14(a).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">12.2*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex122365eaa.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Certification of Principal Financial and Accounting Officer pursuant to 17 CFR 240.13a&#8209;14(a).</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">13.1*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex131834e0f.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Certification of Principal Executive Officer pursuant to 17 CFR 240.13a&#8209;14(b)&nbsp;and 18 U.S.C. 1350.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">13.2*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex132b927c5.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Certification of Principal Financial and Accounting Officer pursuant to 17 CFR 240.13a&#8209;14(b)&nbsp;and 18 U.S.C. 1350.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">15.1*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<a href="afmd-20191231ex15114476d.htm"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">Consent of KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft.</font></a></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.INS*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Instance Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.SCH*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Taxonomy Extension Schema Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.CAL*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Taxonomy Extension Calculation Linkbase Document </font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.DEF*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.LAB*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Taxonomy Extension Label Linkbase Document</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.44%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">101.PRE*</font></p>
				</td>
				<td valign="top" style="width:02.40%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:87.16%;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 9pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:9.5pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></div>
		<p style="margin:0pt 0pt 6pt 18pt;line-height:100%;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filed herewith</font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;line-height:100%;text-indent: -18pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x2020;&nbsp;&nbsp;&nbsp;&nbsp;Confidential treatment requested as to portions of the exhibit. Confidential materials omitted and filed separately with the Securities and Exchange Commission.</font>
		</p>
		<p style="margin:0pt 0pt 6pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(b)&nbsp;&nbsp;Financial Statement Schedules</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">None.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">138</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Signatures</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;font-family:Arial,Helvetica,sans-serif;">
			<tr>
				<td valign="top" style="width:242.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:27.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:215.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">April&nbsp;28, 2020</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">AFFIMED N.V.</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ Adi Hoess</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Name:</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Adi Hoess</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Title:</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Chief Executive Officer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ Wolfgang Fischer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:215.30pt;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Name:</font><font style="display:inline;">&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Wolfgang Fischer</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:242.65pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:27.35pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:215.30pt;padding:0pt;">
					<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Title:</font><font style="display:inline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Chief Operating Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">139</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Index to consolidated financial statements</font>
		</p>
		<p style="margin:0pt 0pt 8pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;background-color: #auto;">
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#ReportofIndependentRegisteredPublicAcc"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Report of independent registered public accounting firm</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>141
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#AttestationReportRegisteredPublicAccount"><font style="display:inline;">Attestation report of the registered public accounting firm</font></a>&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>142
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#Consolidatedstatementsofcomprehensivelos"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of comprehensive loss</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>144
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#Consolidatedstatementsoffinancialpositio"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of financial position</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>145
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#Consolidatedstatementsofcashflows_98271"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of cash flows</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>146
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#Consolidatedstatementsofchangesinequity_"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of changes in equity</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>147
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:89.26%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 5pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<a href="#a1Reportingentity_514365"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Notes to the consolidated financial statements</font></a><font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.74%;background-color: #auto;;font-family:Arial,Helvetica,sans-serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>148
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">140</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Report of Independent Registered Public Accounting Firm<a name="ReportofIndependentRegisteredPublicAcc"></a></font>
		</p>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;line-height:106.67%;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">To the Shareholders and Supervisory Board of Affimed N.V.:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Opinion on the Consolidated Financial Statements</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have audited the accompanying consolidated statements of financial position of Affimed N.V. and&nbsp;subsidiaries (the Company) as of December&nbsp;31, 2019 and 2018, the related consolidated statements of comprehensive loss, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2019, in conformity with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December&nbsp;31, 2019, based on criteria established in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Internal Control &#x2013; Integrated Framework (2013)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated April 28, 2020 expressed an unqualified opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Change in Accounting Principle</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As discussed in Note 4 to the consolidated financial statements, the Company has changed its method of accounting for leases as of January 1, 2019 due to the adoption of IFRS 16, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Leases</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-style:italic;">Basis for Opinion</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">/s/ KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft</font>
		</p>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">We have served as the Company&#x2019;s auditor since 2014.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Mannheim, Germany</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">April 28, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">141</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Report of Independent Registered Public Accounting Firm<a name="AttestationReportRegisteredPublicAccount"></a></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">To the Shareholders and Supervisory Board of Affimed N.V.:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Opinion on Internal Control Over Financial Reporting</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We have audited Affimed N.V.&#x2019;s and subsidiaries&#x2019; (the Company) internal control over financial reporting as of December&nbsp;31, 2019, based on criteria established in</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"> Internal Control &#x2013; Integrated Framework (2013)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&nbsp;31, 2019, based on criteria established in </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Internal Control &#x2013; Integrated Framework (2013)</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">statements of financial position</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> of the Company as of December&nbsp;31, 2019 and 2018, the related consolidated statements of comprehensive loss, changes in equity, and cash flows for each of the years in the three-year period ended December 31, 2019, and the related notes (collectively, the consolidated financial statements), and our report dated April 28, 2020 expressed an unqualified opinion on those consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Basis for Opinion</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Management&#x2019;s Annual Report on Internal Control over Financial Reporting</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Definition and Limitations of Internal Control Over Financial Reporting</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">142</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Mannheim, Germany</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">April 28, 2020</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:left;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">143</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V.</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of comprehensive loss<a name="Consolidatedstatementsofcomprehensivelos"></a></font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(in &#x20AC; thousand)</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.30%;">
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Note</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;6</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other income - net</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;7</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 290</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,515</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 205</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Research and development expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;8</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (43,791)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (35,148)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (21,489)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">General and administrative expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (10,266)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,638)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (7,986)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Operating loss</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,376)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (19,536)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (27,260)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Finance income / (costs) - net</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 15</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 60</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (2,983)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Loss before tax</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,361)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (30,243)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 12</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,365)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (19,477)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (30,223)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other comprehensive income / (loss) Items that will not be reclassified to profit or loss</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Equity investments at fair value OCI - net change in fair value</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (632)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4,731)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other comprehensive income / (loss)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (632)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (4,731)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total comprehensive loss</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (32,997)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (24,208)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (30,223)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Loss per share in &#x20AC; per share</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (0.50)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (0.32)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (0.69)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">(undiluted = diluted)</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:54.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Weighted number of common shares outstanding</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:04.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 64,242,396</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 60,514,407</font></p>
				</td>
				<td valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 43,746,073</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Notes are an integral part of these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">144</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V.</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of financial position<a name="Consolidatedstatementsoffinancialpositio"></a></font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(in &#x20AC; thousand)</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.14%;">
			<tr>
				<td valign="bottom" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Note</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">ASSETS</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Non-current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Intangible assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 137</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 56</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,291</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,414</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Long term financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,193</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,825</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 824</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 6,445</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,295</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Current assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 95,234</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 94,829</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 14</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Trade and other receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,482</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,429</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 296</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 260</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 387</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 105,914</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 110,879</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">TOTAL ASSETS</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 112,359</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 116,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">EQUITY AND LIABILITIES</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Equity</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Issued capital</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 762</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 624</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Capital reserves</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 270,451</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 239,055</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value reserves</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,962</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,594</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Accumulated deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (234,508)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (202,144)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total equity</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 38,667</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 40,129</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Non-current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Borrowings</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 278</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,690</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;6</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 37,961</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 37,512</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 272</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total non-current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 38,511</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 39,202</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Trade and other payables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,674</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,425</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Provisions</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 18</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 517</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Borrowings</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,105</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,083</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 532</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;6</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,353</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 24,335</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Total current liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 35,181</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 36,843</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:57.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">TOTAL EQUITY AND LIABILITIES</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:06.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 112,359</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 116,174</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Notes are an integral part of these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">145</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V.</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of cash flows<a name="Consolidatedstatementsofcashflows_98271"></a></font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(in &#x20AC; thousand)</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Note</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash flow from operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (32,365)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (19,477)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (30,223)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Adjustments for the period:</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">- Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;4</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (20)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">- Depreciation and amortisation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 906</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 403</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 351</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">- Net gain from disposal of leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (5)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 25</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (19)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">- Share based payments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 17</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 2,469</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 2,035</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 1,943</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">- Finance income / costs - net</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 11</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (15)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (60)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 2,983</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (29,006)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (17,073)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (24,985)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Change in trade and other receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 33</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (322)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 1,140</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Change in inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (36)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (19)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (44)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Change in other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 340</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 121</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (399)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Change in trade, other payables, provisions and contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (791)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 66,856</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (1,018)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (29,460)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 49,563</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (25,306)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Interest received</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 628</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 218</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 106</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Paid interest</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (224)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (342)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (349)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Paid income tax</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Net cash used in operating activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> (29,056)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 49,438</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> (25,549)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash flow from investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Purchase of intangible assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (150)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (30)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (43)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Purchase of leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (1,324)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (691)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (625)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash received from the sale of leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 35</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash paid for investments in convertible note and warrants</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (296)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash paid for investments in financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 14</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (45,131)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (14,029)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (13,084)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash received from maturity of financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 50,945</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 22,063</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Cash paid for investments in long term financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (861)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Net cash used for investing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 4,340</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> (15,610)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 8,050</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash flow from financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Proceeds from issue of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 16</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 31,373</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 25,113</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 23,123</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Transaction costs related to issue of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 16</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (2,215)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (1,701)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (1,648)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Proceeds from borrowings</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 19</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 562</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 2,500</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Transaction costs related to borrowings</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 19</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (11)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (405)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">Repayment of borrowings</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> 19</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (3,277)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (2,917)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"> (167)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash flow from financing activities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 26,038</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 20,495</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 23,797</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Exchange-rate related changes of cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> (917)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 669</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> (1,867)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Net changes to cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 1,322</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 54,323</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 6,297</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash and cash equivalents at the beginning of the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 94,829</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 39,837</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 35,407</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:58.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cash and cash equivalents at the end of the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 95,234</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 94,829</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"> 39,837</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 5pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Notes are an integral part of these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">146</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 30pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:left;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V.</font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidated statements of changes in equity<a name="Consolidatedstatementsofchangesinequity_"></a></font>
		</p>
		<p style="margin:0pt;text-align:left;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(in &#x20AC; thousand)</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Issued</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Capital</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Fair&nbsp;value</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Accumulated</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Note</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">capital</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">reserves</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">reserves</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">deficit</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">equity</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of January&nbsp;1, 2017</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 333</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 190,862</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (152,444)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 38,751</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Issue of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 135</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20,922</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,057</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Equity-settled share based payment awards</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,943</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,943</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Issue of warrant note (loan Silicon Valley Bank)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 51</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 51</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,223)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,223)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of December&nbsp;31,&nbsp;2017</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 468</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 213,778</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (182,667)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 31,579</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Revaluation shares Amphivena (first time adoption IFRS 9)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,325</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,325</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of January&nbsp;1, 2018</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 468</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 213,778</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 7,325</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (182,667)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 38,904</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Issue of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 156</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,171</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,327</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exercise of share based payment awards</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 71</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 71</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Equity-settled share based payment awards</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,035</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,035</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,477)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,477)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4,731)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4,731)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of December&nbsp;31,&nbsp;2018</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 624</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 239,055</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,594</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (202,144)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 40,129</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of January&nbsp;1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 624</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 239,055</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 2,594</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (202,144)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 40,129</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Issue of common shares</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 138</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 28,901</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 29,039</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exercise of share based payment awards</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 17</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 26</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 26</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Equity-settled share based payment awards</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 17</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,469</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,469</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss for the period</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,365)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,365)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other comprehensive income</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (632)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (632)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:37.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Balance as of December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 762</font></p>
				</td>
				<td valign="bottom" style="width:01.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 270,451</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 1,962</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.98%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (234,508)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 38,667</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Notes are an integral part of these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">147</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting entity<a name="a1Reportingentity_514365"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V. is a Dutch company with limited liability (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">naamloze vennootschap</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) and has its corporate seat in Amsterdam, the Netherlands.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed&nbsp;Inc., Delaware, USA and AbCheck&nbsp;Inc., Delaware, USA (together &#x201C;Affimed&#x201D; or the &#x201C;Group&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The Group&#x2019;s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body&#x2019;s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, where the Group is performing research services for third parties.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Local exemption rules applied by subsidiaries of the Group</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed GmbH, Heidelberg, Germany, makes use of the exemption clause, available under &#xA7; 264 (3) HGB in 2019. The consolidated financial statements of Affimed N.V. as of and for the year ended 31 December 2019 will be filed in Germany as a supplement to the financial statements of Affimed&nbsp;&nbsp;GmbH, in order to meet the requirements of the exemption clause available under &#xA7; 264 (3) HGB in 2019.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of preparation &#x2013; consolidated financial statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Statement of compliance</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements were authorized for issuance by the management board on April&nbsp;28, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Basis of measurement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements have been prepared on the historical cost basis except for financial instruments measured at fair value (see note 13) and monetary assets and liabilities denominated in foreign currencies which are translated at period-end exchange rates. The Group did not opt for a valuation of liabilities at fair value through profit or loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group controls an entity when it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control is obtained by the Group. It is de-consolidated from the date control ceases.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">148</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Functional and presentation currency</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements are presented in euro, which is also the functional currency. All financial information presented in euro unless otherwise noted has been rounded to the nearest thousand (abbreviated &#x20AC;) or million (abbreviated &#x20AC; million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Presentation of consolidated statements of comprehensive loss</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a clinical-stage biopharmaceutical company with a primary focus on research and development activities, cost of sales and gross profit are not considered meaningful measures for Affimed and therefore are not presented. </font><font style="display:inline;">See note 4 for the Group&#x2019;s accounting policies related to revenue recognition and research and development expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Transactions denominated in currencies other than the euro are translated at exchange rates at the date of the transaction. Monetary assets and liabilities denominated in currencies other than the euro are translated at the exchange rate at the date of the consolidated statement of financial position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency gains or losses that relate to borrowings, cash and cash equivalents and financial assets, except for financial instruments at fair value through other comprehensive income are presented in the statement of comprehensive loss within &#x2018;Finance income / (costs)&nbsp;- net&#x2019;. All other foreign exchange gains and losses are presented in the statement of comprehensive loss within &#x2018;Other income&nbsp;&#x2013; net&#x2019;.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant accounting policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a &#x201C;best efforts&#x201D; basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provide the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Such agreements may comprise more than one research program, platform licenses or intellectual property </font><font style="display:inline;">licenses </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">originally generated by the Group. Usually each of those promises is considered to meet the </font><font style="display:inline;">definition</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> of a separate performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">149</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses, a residual approach is used. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight-line basis until the use of the license by the customer ends. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group&#x2019;s view, uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group&#x2019;s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">150</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Employee benefits</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefits</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a)&nbsp;the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b)&nbsp;the obligation can be estimated reliably.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payment transactions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s share-based payment awards outstanding as of December&nbsp;31, 2018 and 2019, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(iii)<font style="display:inline;font-family:Arial,Helvetica,sans-serif;;font-size: 10pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Termination benefits</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Termination benefits are expensed when the Group can no longer withdraw the offer of those benefits. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group receives certain government grants that support its research effort in specific projects. </font><font style="display:inline;">These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group recognizes income from government grants under &#x2018;Other income&nbsp;- net&#x2019; in the consolidated statement of comprehensive loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Policy applicable from 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred. Subsequently, the right-of-use asset is&nbsp;&nbsp;depreciated using the straight-line method from the commencement date to the end of the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">151</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;">lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Affimed&#x2019;s incremental borrowing rate. Generally, Affimed uses its incremental borrowing rate as the discount rate. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group determines the incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and the type of the asset leased.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is subsequently&nbsp;&nbsp;measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has elected not to recognize right-of-use assets and lease liabilities for some short-term leases (leases with less than 12 months of lease term) and right-of-use assets and liabilities for leases of low value assets. Lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Policy applicable before 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">For impact on transition please refer to &#x201C;New standards and interpretations applied for the first time&#x201D; below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income and finance costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance costs comprise primarily interest expense on borrowings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial assets</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group&#x2019;s non-derivative financial assets include preferred shares in Amphivena, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three&nbsp;months.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">152</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cash and cash equivalents comprise cash balances and call deposits with original maturities of three&nbsp;months or less.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group holds </font><font style="display:inline;">preferred shares in Amphivena </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">designated at fair value through other comprehensive income (see note 13).</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial liabilities</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compound financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 19). The number of shares to be issued does not vary with changes in their fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Impairment</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group&#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed determines the counterparties&#x2019; lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2017, 2018 or 2019.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">153</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intangible assets and leasehold improvements and equipment</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the&nbsp;year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Fair Value Measurement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All assets and liabilities for which fair value is recognized in the consolidated financial statements are </font><font style="display:inline;">classified </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 1&nbsp;&#x2013; Prices for identical assets or liabilities quoted in active markets (non-adjusted)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 2&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;border-top:1pt none #D9D9D9;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 3&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 19).</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">154</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group has granted warrants under certain loan agreements (see note 19) and options under share-based payment programs (see note 17) which potentially have a dilutive effect; no instruments actually had a dilutive effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Critical judgments and accounting estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In preparing these financial statements, the critical judgments made by management in applying the Group&#x2019;s accounting policies resulted in the following accounting estimates</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On April&nbsp;20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in note&nbsp;17. Incorporating the market condition in the fair value estimate requires the use of a simulation technique&nbsp;(Monte Carlo simulation), which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be &#x20AC;133.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">The Group&#x2019;s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;border-top:1pt none #D9D9D9 ;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">155</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Accrued expenses</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group holds preferred shares in Amphivena classified as equity instruments at fair value through other comprehensive income (level 2) and&nbsp;&nbsp;recognized as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2019 (see note 13). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (v)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Lease payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether Affimed is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognized. As at December 31, 2019, no renewal options were incorporated into the determining the lease term.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vi)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Provisions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In the second quarter of 2019, Affimed decided to terminate the Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager as a part of its strategic plans (see note 18).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">New standards and interpretations applied for the first time</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&nbsp;1, 2019, and have been applied in preparing these financial statements:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRS 16 Leases</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9: Prepayment Features with Negative Compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Annual Improvements to IFRS Standards 2015</font><font style="display:inline;font-family:MS Gothic;color:#000000;">&#x2011;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2017 Cycle</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRIC 23 Uncertainty over Income Tax Treatments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">156</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &#xB4;Determining Whether an Arrangement contains a Lease&#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Transition </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, Affimed elected to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not reassessed. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a lessee, Affimed previously classified leases as operating or finance leases based on its assessment of whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Affimed recognizes right-of-use assets and lease liabilities for most leases &#x2013; i.e. these leases are on-balance sheet.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">At transition, for leases classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Company&#x2019;s incremental borrowing rates for similar assets as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, the Company recognized additional right-of-use assets, including property, plant and equipment and additional lease liabilities. The impact on transition is summarized below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Right-of-use assets </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group discounted lease payments using a weighted average discount rate of 4.05% as of January 1, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In relation to those leases under IFRS 16, Affimed has recognized depreciation and interest costs, instead of operating lease expense. In 2019, the Group recognized depreciation expense for right-of-use assets of &#x20AC;385 and interest cost related to the lease liability of &#x20AC;24 instead of operating lease expense of &#x20AC;406.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The transition between operating lease commitments disclosed applying IAS 17 as of December 31, 2018 and the lease liabilities recognized in the statement of financial position at the date of initial application, January 1, 2019, is shown below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">157</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating lease commitment as of December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,154</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Recognition exemption for short-term leases</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (98)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments for incidental rental costs and other rental payments (Not part of the lease)</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (312)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Discounting using the incremental borrowing rate as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (27)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">New standards and interpretations not yet adopted</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2019, and have not been applied in preparing these consolidated financial statements.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to References to the Conceptional Framework</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 1 and IAS 8: Definition of Material</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 3 Business Combination</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1 Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment reporting</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Information about reportable segment</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project development or for third party companies. Management of resources and reporting to the chief operating decision maker is based on the Group as a whole.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Geographic information</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The geographic information below analyses the Group&#x2019;s revenue and non-current assets by country. In presenting the following information, segment revenue has been based on the geographic location of the customers and segment assets were based on the geographic location of the assets.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Discovery activities and research services are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from Heidelberg.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 31</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Europe</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,646</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,175</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,236</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,745</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,529</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 694</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Non-current assets as of December, 31:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,017</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,224</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 957</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Czech Republic</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 870</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 246</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 221</font></p>
				</td>
			</tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">158</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;"></font></p>
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,558</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,825</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 6,445</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,295</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,178</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Major Customers</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2018 and 2019, the Group&#x2019;s revenue with Genentech&nbsp;Inc. exceeded 10% of total revenues. For the year ended December 31, 2017, the Group&#x2019;s revenue with four customers exceeded 10% of total revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Collaboration agreement with Amphivena</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Until July 2016, Affimed was party to a collaboration with Amphivena. The purpose of the collaboration was the development of a product candidate for hematological malignancies. The collaboration included a License and Development Agreement between Amphivena and Affimed, which expired when Amphivena obtained the approval of an investigational new drug application (IND) from the FDA in July 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the license and development agreement between Affimed and Amphivena, Affimed granted a license to intellectual property and agreed to perform certain services for Amphivena related to the development of a product candidate for hematological malignancies. In </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">consideration</font><font style="display:inline;"> for the research and development work that was performed, Amphivena was required to pay to Affimed service fees totaling approximately &#x20AC;16 million payable according to the achievement of milestones and phase progressions as described under the license and development agreement. Since the expiration of the agreement, the parties have been closing out the collaboration by exchanging documentation and transferring materials and third-party contracts. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the year ended December 31, 2017, the Company recognized revenue upon achievement of milestones and for the performance of research and development services totaling &#x20AC;0.2 million. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Collaboration agreement The Leukemia&nbsp;&amp; Lymphoma Society (LLS)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed is party to a collaboration with LLS to fund the development of a specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group&#x2019;s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In June&nbsp;2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the&nbsp;years ended December&nbsp;31, 2017 and 2018, the Group achieved several milestones and recognized revenue totaling &#x20AC;0.2 million and &#x20AC;0.2 million, respectively. Open milestones as at December 31, 2019 are expected to have no significant impact on future revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Collaboration with Genentech&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed is providing services related to the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">159</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">development of novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October&nbsp;2018. Under the terms of the agreement, Affimed received $96.0 million (&#x20AC;83.2 million) in an initial upfront payment and committed funding on October&nbsp;31, 2018. The Group recognized &#x20AC;19.7 million as revenue in 2019 (2018: &#x20AC;21.8 million) and &#x20AC;59.3 million (December 31, 2018: &#x20AC;61.4 million) under contract liabilities, which will be recognized as revenue in subsequent periods as services are provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research service agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group, through its subsidiary AbCheck has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Group recognized revenue of &#x20AC;1.7 million, &#x20AC;1.7 million and &#x20AC;1.6 million during the&nbsp;years ended December&nbsp;31, 2019, 2018 and 2017 respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Contract balances</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table provides information about receivables and contract liabilities from contracts with customers.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 204</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 210</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 59,314</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 61,847</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">An amount of &#x20AC;14,795&nbsp;that was recognized in contract liabilities at the beginning of the period was recognized as revenue during the period ended December 31,&nbsp;2019 (2018: &#x20AC;230).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The remaining performance obligations at December&nbsp;31, 2019 are approximately &#x20AC;59.3 million and are expected to be recognized as revenue to a large extent over the next two&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Disaggregation of revenue</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Major service lines:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Collaboration revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,685</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 390</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Service revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,706</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,717</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Point in time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,783</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,863</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Over time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15,608</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,872</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,777</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income and expenses&nbsp;- net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other income and expenses, net mainly comprises foreign exchange gains of &#x20AC;251 (2018: &#x20AC;1,523, 2017: losses of &#x20AC;7). Income from government grants for research and development projects amounted to&nbsp;&#x20AC;19 in 2019,&nbsp;&#x20AC;10 in 2018 and &#x20AC;195 in 2017.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">160</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the different types of expenses allocated to research and development costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Third-party services</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 27,338</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,127</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 12,299</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,154</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,639</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,983</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,672</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 890</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cost of Materials</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,547</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,140</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 994</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amortisation and depreciation</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 725</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 351</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 309</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,044</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,804</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,358</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 43,791</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 35,148</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,489</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the different types of expenses allocated to general and administrative costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,357</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,929</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,521</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and audit expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,881</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,945</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,853</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,828</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,520</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,266</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,638</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,986</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee benefits</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the items of employee benefits for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wages and salaries</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,587</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,027</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,475</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Social security costs</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,092</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 931</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,207</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,119</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,406</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The employer&#x2019;s contributions to pension insurance plans of &#x20AC;696 (2018: &#x20AC;502, 2017: &#x20AC;438) are classified as payments under a defined contribution plan, and are recognized as an expense.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance income and finance costs</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the items of finance income and costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest SVB Loan Agreement (see note 19)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (483)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (847)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (690)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Foreign exchange differences</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (175)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 651</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,378)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on certificates of deposit with maturities of more than three months</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 602</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 77</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other finance income/finance costs - net</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 71</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 251</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 60</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,983)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">161</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group did not incur any material income tax in the periods presented. As of December 31, 2019, deferred tax assets from differences resulting from intangible assets (&#x20AC;283; 2018: &#x20AC;415), trade and other receivables (&#x20AC;243; 2018: &#x20AC;334), borrowings (&#x20AC;70; 2018: &#x20AC;0), lease liabilities (&#x20AC;121; 2018: &#x20AC;0) and trade and other payables (&#x20AC;23; 2018: &#x20AC;27) have not been recognized as deferred tax assets as no sufficient future taxable profits or offsetting deferred tax liabilities are available. As of December 31, 2019 deferred tax liabilities from temporary differences result mainly leasehold improvements and equipment and right-of-use assets (&#x20AC;226; 2018: &#x20AC;0), long term financial assets (&#x20AC;1,218; 2018: &#x20AC;774) and contract liabilities (&#x20AC;308; 2018: &#x20AC;0). Deferred tax liabilities are not recognized as there is an excess of deferred tax assets over deferred tax liabilities.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&#x2019;s applicable tax rate is presented below for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss before tax</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,361)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,243)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income tax benefit at tax rate of 29.825 %</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,652</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,809</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments of deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,822)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (5,318)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,036)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (29)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (462)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (93)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments for local tax rates</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (34)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Non deductible expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (43)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (53)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 57</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (82)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In Germany, Affimed has tax losses carried forward of &#x20AC;199.2 million (2018: &#x20AC;166.2 million) for corporate income tax purposes and of &#x20AC;198.4 million (2018: &#x20AC;165.4 million) for trade tax purposes that are available indefinitely for offsetting against future taxable profits of that entity. Restrictions on the utilization of tax losses in case of a change of control of ownership in Affimed were mitigated by the enactment of the Economic Growth Acceleration Act (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Wachstumsbeschleunigungsgesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">2009</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">). According to the provisions of this act unused tax losses of a corporation as at the date of a qualified change in ownership are preserved to the extent they are compensated by an excess of the fair value of equity for tax purposes above its carrying amount of the Group. The maximum amount of tax losses at risk of being lost due to ownership changes is approximately &#x20AC;59 million. Deferred tax assets have not been recognized in respect of any losses carried forward as no sufficient taxable profits of Affimed are expected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Tax losses of Abcheck s.r.o. amount to &#x20AC;296 as at December&nbsp;31, 2019 (2018: &#x20AC;423).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long term financial assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company holds preferred shares in Amphivena recognized at their fair value of &#x20AC;3.2 million (2018: &#x20AC;3.8 million). The Company recognized losses from the change in fair value of &#x20AC;0.6 million in other comprehensive income in 2019 (2018: &#x20AC;4.7 million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial assets contain of U.S. Dollar denominated certificates of deposit with original maturities of more than three&nbsp;months. As of December 31, 2019, the fair value (level 1) of the financial assets did not differ significantly from its carrying amount.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">162</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other receivables</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The trade receivables as of December&nbsp;31, 2019 and 2018, of &#x20AC;204 and &#x20AC;210, respectively, are all due in the short-term, do not bear interest and are not impaired. Other receivables are all due short-term and mainly comprise value-added tax receivables of &#x20AC;453 (2018: &#x20AC;839).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December 31, 2019, the share capital of &#x20AC;762 (2018: &#x20AC;624) is composed of 76,249,901 (2018: 62,430,106) common shares with a par value of &#x20AC;0.01.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November 13, 2019,&nbsp;&nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &#x20AC;29.5 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As at 31, December 2019 and 2018, the authorized share capital amounted to &#x20AC;3,200 consisting of 155,975,000 common shares and 155,975,000 cumulative preference shares, each with a par value of &#x20AC;0.01 per share.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share based payments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under this program, the Group granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payments with service condition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The majority of the awards vest in installments over three&nbsp;years and can be exercised up to 10&nbsp;years after the grant date. In 2019 and 2018, the Group granted 1,736,803 awards and 2,332,296 awards to employees, the Management Board and Supervisory Board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, 357,879</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ESOP 2014 awards were cancelled or forfeited due to termination of employment or termination of consulting agreements with non-employees (2018: 424,688), and 19,795 options were exercised at an average exercise price of $1.54 (2018: 40,038 ESOP 2014 awards </font><font style="display:inline;">at an average exercise price of $1.98).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019, 7,307,567 ESOP 2014 awards were outstanding (December&nbsp;31, 2018: 5,948,438), 4,773,840 awards (December&nbsp;31, 2018: &nbsp;2,814,547) were vested. The options outstanding at December&nbsp;31, 2019 had an exercise price in the range of $1.30 to $13.47 (2018: $1.30 to $13.47) and weighted average remaining contractual life of 8.9&nbsp;years (2018: 9.3&nbsp;years). In 2019 and 2018, the Group estimated an annual forfeiture rate of 4.0% for unvested options.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payments with market condition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On April&nbsp;20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading&nbsp;days) reaches a certain hurdle ($6.15, &nbsp;$8.20 and $10.25). Fair value of the awards at grant date amounts to &#x20AC;133 &nbsp;($164 thousand) and the contractual life time of the options is two&nbsp;years. As at December&nbsp;31, 2019 no options were exercisable. Fair value was determined using the Monte Carlo Simulation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payment expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, an expense of &#x20AC;2,469 was recognized affecting research and development expenses (&#x20AC;904) and general and administrative expenses (&#x20AC;1,565). In 2018, an expense of &#x20AC;2,035 was recognized affecting </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">163</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">research and development expenses (&#x20AC;852) and general and administrative expenses (&#x20AC;1,183). In 2017, an expense of &#x20AC;1,943 was recognized affecting research and development expenses (&#x20AC;522) and general and administrative expenses (&#x20AC;1,421). </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Fair value measurement</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value at grant date </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.10</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.20</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share price at grant date</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.91</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exercise price </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.92</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 82</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 72</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected life</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.09</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.34</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to &#x20AC;1.4 million, whereof &#x20AC;0.9 million were already incurred in 2019 and estimated costs of &#x20AC;0.5 million expected to incur in 2020 were recognized in provisions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Silicon Valley Bank</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November&nbsp;30, 2016, Affimed entered into a loan agreement with Silicon Valley Bank (the &#x201C;SVB loan&#x201D;) which provides the Group with a senior secured term loan facility originally for up to &#x20AC;10.0 million, which agreement was amended in May&nbsp;2017 to provide that such amount would be available in three tranches. In December&nbsp;2016, the Group drew an initial tranche of &#x20AC;5.0 million and in May&nbsp;2017, a second tranche of &#x20AC;2.5 million; the availability of a third tranche of &#x20AC;2.5 million expired in September&nbsp;2017 with such amount remaining undrawn.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of &#x20AC;236 and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement, the Group also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten&nbsp;years from the grant date. The fair value of the warrants of &#x20AC;192 less deferred taxes and transaction costs of &#x20AC;81 and &#x20AC;8, respectively, was recorded as an addition to capital reserves in equity. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75&#8209;80% and an expected exercise period of five&nbsp;years to exercise of the warrant. The contractual maturity of the warrants is ten&nbsp;years.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The loan is secured by a pledge of 100% of Group&#x2019;s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">164</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements with the following book values:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.80%;">
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof&nbsp;assets</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,291</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,503</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,414</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 296</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 247</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 260</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 235</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Trade and other receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,482</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 864</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,429</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,007</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 387</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 95,234</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 93,606</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 94,829</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 92,933</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 108,205</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 105,122</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 112,293</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 109,323</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019 and 2018, the fair value of the liability did not differ significantly from its carrying amount (&#x20AC;2,013 and &#x20AC;4,773). The loan has a maturity date of May&nbsp;31, 2020, repayment started in December&nbsp;2017 with amortized payments of principal and interest in equal&nbsp;monthly installments. As of December&nbsp;31, 2019, &#x20AC;2,013 (2018: &#x20AC;3,083) were classified as current liabilities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">UniCredit Leasing CZ</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for &#x20AC;562. After an initial instalment of &#x20AC;127 in the second quarter of 2019, repayment is effected in monthly instalments of &#x20AC;8 until November 2023. As at December 31, 2019, an amount of &#x20AC;368 was outstanding, of which &#x20AC;91 was classified as current liabilities. As of December 31, 2019, the fair value of the liability did not differ significantly from its carrying amount.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Reconciliation to cash flows from financing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Movements of liabilities reconcile to cash flows arising from financing activities as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,169</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Proceeds from borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 562</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (3,277)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,715)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Capitalized borrowing costs</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 489</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 847</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest paid</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (164)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (326)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 325</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 531</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,383</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other payables</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other payables comprise trade payables of &#x20AC;10,249 (2018: &#x20AC;8,482). Other payables mainly comprise payroll and employee related liabilities for withholding taxes and social security contributions of &#x20AC;801 (2018: &#x20AC;885) and payables due to employees for unused holidays and other accruals. Other payables are normally settled within 30&nbsp;days.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">165</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">Affimed presents right-of-use assets for offices, laboratories and vehicles leased in a separate line item from the line item &#x201C;Leasehold improvements and equipment&#x201D; that presents other assets of the same nature that Affimed owns. The agreements have an average non-cancellable term of between one and four&nbsp;years with renewal options included in some contracts. For equipment leased with contract terms that are short&nbsp;term and/or leases of low-value items the Group has elected not to recognize right-of-use assets and lease liabilities for these leases.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of right-of-use assets reconcile as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying&nbsp;amount</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Buildings</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cars</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1, 2019 </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 695</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Depreciation charge for the year</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (371)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (13)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (384)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Additions to right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 816</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 824</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">Cash outflow related to leases are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 405</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 24</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Cash outflow from leasing</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 495</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In 2018 and 2017, lease expenses of &#x20AC;562 and &#x20AC;472 have been recognized in the consolidated statement of comprehensive income.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Future contractually agreed undiscounted lease payments are as follows:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019: Leases<br>under IFRS<br>16</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018:<br>Operating<br>Leases under<br>IAS 17</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments within one year</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 553</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 675</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments between one and five years</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 276</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 541</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 829</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,216</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Movements of lease liabilities reconcile to cash flows arising from financing activities as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">New lease contracts</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 804</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">166</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other commitments and contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Commitments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">The Group has entered into agreements for the use of licenses. In 2019, license fees of &#x20AC;92 have been recognized in consolidated statement of comprehensive income (2018: &#x20AC;124, 2017: &#x20AC;174), related future payment obligations under non-cancellable fees amount to &#x20AC;25.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has entered into various license agreements that contingently trigger payments upon achievement of certain milestones and royalty payments upon commercialization of a product in the future.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related parties</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shareholders</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019 and 2018, no shareholder holds more than 20% of the voting rights.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Transactions with key management personnel</font></p></td></tr></table></div>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The compensation of managing directors and other key management personnel comprised of the following:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,598</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,683</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,538</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Termination benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 264</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share-based payments</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,738</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,229</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,379</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,600</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,912</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,917</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Remuneration of Affimed&#x2019;s managing directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive a severance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compensation for other key management personnel comprises fixed and variable components and share-based payment awards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of &#x20AC;382 (2018: &#x20AC;382; 2017: &#x20AC;375). In 2019, the Group recognized expenses for share-based payments for supervisory board members of &#x20AC;243 (2018: &#x20AC;117, 2017: &#x20AC;144).</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">167</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table provides the total amounts of outstanding balances for supervisory board compensation and expense reimbursement related to key management personnel:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding&nbsp;balances</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adi Hoess</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Martin Treder</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leila Alland</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 40</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 26</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 17</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial risk management</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial risk management objectives and policies</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s principal financial instruments comprise cash and cash equivalents, certificates of deposit at commercial banks, a convertible loan, warrants and investor loans presented in borrowings. The main purpose of these financial instruments is to raise funds for the Group&#x2019;s operations. The Group has various other financial assets and liabilities such as trade and other receivables and trade and other payables, which arise directly from its operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The main risks arising from the Group&#x2019;s financial instruments are credit risk and liquidity risk. The measures taken by management to manage each of these risks are summarized below.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Credit risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s financial assets comprise to a large extent cash and cash equivalents. In addition, financial assets include shares, certificates of deposit, trade and other receivables. The total carrying amount of shares (&#x20AC;3.2 million, 2018: &#x20AC;3.8 million) cash and cash equivalents&nbsp;&nbsp;(&#x20AC;95.2 million, 2018: &#x20AC;94.8 million), trade and other receivables (&#x20AC;1.5 million, 2018: &#x20AC;1.4 million), and certificates of deposit (&#x20AC;8.9 million, 2018: &#x20AC;14.0 million), represents the maximum credit exposure of &#x20AC;108.8 million (2018: &#x20AC;114.1 million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The cash and cash equivalents and certificates of deposit are held with banks, which are rated BBB+ to AA- based on Standard&nbsp;&amp; Poor&#x2019;s and Moody&#x2019;s.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Interest rate risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s interest rate risk arises from cash accounts and long-term borrowings at variable rates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed entered into the SVB loan pursuant to which the Group borrowed &#x20AC;7.5 million with an outstanding balance of &#x20AC;2.0 million as at December&nbsp;31, 2019, with a variable interest rate of an annual rate of 5.5% plus one-month EURIBOR, with EURIBOR deemed to equal zero&nbsp;percent if EURIBOR is less than zero&nbsp;percent. The Group does not expect the EURIBOR to exceed the floor of 0% within the foreseeable future, and considers the interest risk to be low.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">168</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Market interest</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> rates on cash and cash equivalents as well as on term deposits </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">were</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> low</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> in 2019,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> resulting in interest income of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x20AC;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">715 in 2019. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A shift in interest rates (increase or decrease) would not have a material impact on the loss of the Group.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other price risks</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of the shares in Amphivena depends on the share price. The total exposure of the Group amounts to &#x20AC;3.2 million.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (v)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign exchange risk arises when future commercial transactions or recognized assets or liabilities are denominated in a currency that is not the entity&#x2019;s functional currency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s entities are exposed to Czech Koruna (CZK) and US Dollars (USD) and British Pound (GBP). The net exposure as of December&nbsp;31, 2019 was &#x20AC;56,531 (2018: &#x20AC;47,524) and mainly relates to US Dollars.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, if the Euro had weakened/strengthened by 10% against the US dollar with all other variables held constant, the loss would have been &#x20AC;5,677 (2018: &#x20AC;4,787) higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated financial assets. The Group considers a shift in the exchange rates of 10% as a realistic scenario.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss is more sensitive to movement in exchange rates shifts in 2019 than in 2018 because of the increased volume of US dollar-denominated transactions.</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following significant exchange rates have been applied during the&nbsp;year:</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">or GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03896</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03899</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03799</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03936</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03887</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03916</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89326</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.84674</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.88519</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.87336</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.83382</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1393</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.13031</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1754</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.11791</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vi)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Liquidity risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities which are normally settled by delivering cash. The Group&#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group continually monitors its risk of a shortage of funds using short and mid-term liquidity planning. This takes account of the expected cash flows from all activities. The supervisory board undertakes regular reviews of the budget.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">169</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%">

		<p style="margin:0pt 0pt 12pt;text-align:left;color:#0563C1;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<a href="#TOC"><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#0563C1;">Table of Contents</font></a>

		</p>

		<p style="margin:3pt 0pt 0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Affimed N.V.</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-weight:bold;">Notes to the consolidated financial statements</font>

		</p>

		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2017 and 2018 and 2019, Affimed raised significant funding that it estimates will enable the Group to fund operating expenses and capital expenditure requirements at least into the fourth quarter of 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2017, the Group issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of &#x20AC;16.4 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2018, the Group issued 13,225,000 common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately &#x20AC;19.7 million and 2,373,716 common shares in connection with its at-the-market sales agreement for net proceeds of &#x20AC;3.8 million.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019,&nbsp;&nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &#x20AC;29.5 million (see note 16).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group expects to require additional funding to complete the development of the existing product candidates. In addition, the Group expects to require additional capital to commercialize the products if regulatory approval is received.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Capital management</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The primary objective of the Group&#x2019;s capital management is to ensure that it maintains its liquidity in order to finance its operating activities and meet its liabilities when due.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group manages its capital structure primarily through equity.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent events</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company announced early February 2020 that Dr. Florian Fischer, Chief Financial Officer (CFO) of Affimed, passed away. Affimed has commenced a process for a new permanent CFO. As part of the transition, Harry Welten will assume the operating responsibilities as CFO advisor to Affimed during the search and will continue to operate in that capacity until a permanent successor has been appointed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, the Company announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020 and the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As circumstances around the COVID-19 pandemic continue to rapidly evolve, the Group is continuously assessing possible effects on its clinical trials and adapting the risk mitigation measures implemented. Affimed is closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of its global workforce and help limit the spread of COVID-19, while maintaining business continuity. The Group has taken mitigation steps to ensure that drug supply and other trial-related materials are ready and available for the patients enrolled in its clinical trials. Due to the ongoing assessment of the potential impact of the COVID-19 pandemic on patient enrollment and site activation in its clinical studies, Affimed will update trial timelines after it has more visibility on the length and extent of the COVID-19 crisis.&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;line-height:100%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">170</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2
<SEQUENCE>2
<FILENAME>afmd-20191231xex2.htm
<DESCRIPTION>EX-2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:58:49 PM-->
<html>
	<head>
		<title>
			afmd_Ex 2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt 36pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Exhibit&nbsp;2</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">Description of rights of each applicable class of securities registered under Section&nbsp;12 of the Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">As of December&nbsp;31, 2019, Affimed N.V.&#x2019;s (&#x201C;Affimed,&#x201D; &#x201C;we,&#x201D; &#x201C;our&#x201D; or &#x201C;us&#x201D;) common shares were registered under Section&nbsp;12 of the Securities Exchange Act of 1934, as amended. Our common shares are listed on The Nasdaq Global Market (&#x201C;Nasdaq&#x201D;) under the trading symbol &#x201C;AFMD.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The following summary of the general terms and provisions of our common shares does not purport to be complete and is subject to and qualified in its entirety by reference to our articles of association (the &#x201C;Articles&#x201D;), which are incorporated herein by reference to&nbsp;Exhibit&nbsp;3.1 to our Report on Form&nbsp;6</font><font style="display:inline;font-family:MS Mincho;">&#x2011;</font><font style="display:inline;">K (Registration no. 001</font><font style="display:inline;font-family:MS Mincho;">&#x2011;</font><font style="display:inline;">36619) filed with the U.S. Securities and Exchange Commission on June&nbsp;20, 2</font><font style="display:inline;font-style:italic;">018.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Type and &nbsp;Class&nbsp;of Securities &nbsp;(Item&nbsp;9.A.5)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Our common shares are issued in registered form and our Articles do not provide for the issuance of share certificates. </font><font style="display:inline;color:#000000;">As of April&nbsp;28, 2020, we had 76,249,901 common shares issued and outstanding.</font><font style="display:inline;"> All of the issued and outstanding common shares are duly authorized, validly issued and fully paid. &nbsp;Our authorized share capital currently amounts to &#x20AC;3,119,500, divided into 155,975,000 common shares, each with a par value of &#x20AC;0.01 and 155,975,000 cumulative preference shares, each with a par value of &#x20AC;0.01.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, there are no arrangements for the transfer or restrictions on the transferability of our common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Almost all of &nbsp;our common shares are held through the Depository Trust Company (&#x201C;DTC&#x201D;). Cede and Company, a specialist United States financial institution that processes transfers of stock certificates on behalf of DTC, is the technical shareholder of record for our issued common shares held by DTC participants. Our shareholders owning common shares through DTC do not themselves hold direct property rights in our common shares, but rather have contractual rights in such shares that are part of a chain of contractual rights involving Cede and Company. Each person owning common shares held through DTC must rely on the procedures of DTC and on institutions that have accounts with DTC to exercise any rights of a holder of the common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre-emptive Rights &nbsp;(Item&nbsp;9.A.3)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Upon the issue of common shares, each holder of common shares shall have a pre-emptive right to acquire such newly issued shares in proportion to the aggregate amount of his common shares, it being understood that this pre-emptive right shall not apply to (i)&nbsp;the issuance of shares to employees of Affimed or employees of a group company&#x37E; and (ii)&nbsp;the issuance of shares against payment in kind. No pre-emptive right shall exist with respect to the issue of cumulative preference shares.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, if and insofar as the management board is not authorized to limit or exclude pre-emptive rights, &nbsp;the pre-emptive rights in respect of newly issued common shares may be restricted or excluded by a resolution of the general meeting of shareholders upon proposal of the management board, which proposal has been approved by the supervisory board. The management board, subject to approval of the supervisory board, may also resolve to restrict or exclude the pre-emptive rights in respect of newly issued common shares if the management board has been authorized by the general meeting of shareholders. Such authorization can be granted for a specific period not exceeding five&nbsp;years. &nbsp;A resolution of the general meeting of shareholders to restrict or exclude the pre-emptive rights or to authorize the management board for that purpose requires a majority of not less than two-thirds of the votes cast if less than one-half of our issued share capital is represented at the meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">At a general meeting held on June&nbsp;25, 2019, the general meeting of shareholders authorized our management board, subject to the approval of our supervisory board, for a period of five&nbsp;years from the date of the meeting &nbsp;(up to and including June&nbsp;25, &nbsp;2024) to restrict or exclude pre-emptive rights accruing to shareholders in connection with the issue of common shares and/or rights to subscribe for common shares in relation to any issuance or granting of rights to subscribe for common shares in the share capital of Affimed, up to the maximum number of common shares that can be issued under the size of the authorized share capital of Affimed as per the date of adoption of such resolution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations or Qualifications &nbsp;(Item&nbsp;9.A.6)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Rights (Item&nbsp;9.A.7)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights, Preferences and Restrictions &nbsp;(Item&nbsp;10.B.3)</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Dividend Rights and Rights to Share in Profits</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under Dutch law, we may only pay dividends if and to the extent that our shareholders&#x2019; equity (</font><font style="display:inline;font-style:italic;">eigen vermogen</font><font style="display:inline;">) exceeds the sum of the paid-up and called-up share capital plus the reserves required to be maintained by Dutch law or by our Articles. &nbsp;Subject to such restrictions, any future determination to pay dividends will be at the discretion of our management board, &nbsp;requires approval of our supervisory board and will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions imposed by applicable law and other factors our management board and supervisory board deem relevant.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, first, a dividend is paid out of the profit, if available for distribution, on the cumulative preference shares. Any amount remaining out of the profit is carried to reserve as the management board determines, subject to the approval of the supervisory board. After reservation by the management board of any profit, the remaining profit will be at the disposal of the general meeting of shareholders. We only make a distribution of dividends to our shareholders after the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">2</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;">adoption of our annual accounts demonstrating that such distribution is legally permitted. The management board may resolve with the approval of the supervisory board, to make interim distribution to the shareholders or to holders of shares of a particular class if an interim statement of assets and liabilities shows that Affimed&#x2019;s shareholders&#x2019; equity exceeds the sum of the paid-up and called-up part of the capital and the reserves which must be maintained by Dutch law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Dividends and other distributions shall be made payable no later than thirty&nbsp;days after the date when they were declared, unless the corporate body authorised to declare the dividend determines a different date. Claims to dividends and other distributions not made within five&nbsp;years and one day after the date that such dividends or distributions became payable, shall be forfeited to us (</font><font style="display:inline;font-style:italic;">verjaring</font><font style="display:inline;">) and shall be carried to the reserves.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Cash dividends payable to our common shares and cash interest payments to holders of our debt securities may be remitted from the Netherlands to non-residents without legal restrictions imposed by Dutch laws, except that (i)&nbsp;such payments must be reported, if requested, to the Dutch Central Bank for statistical purposes only and (ii)&nbsp;the transfer of funds to jurisdictions subject to general economic sanctions adopted in connection with policies of the United Nations, European Commission or similar measures imposed directly by the Government of the Netherlands may be restricted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Liquidation Preference</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Upon liquidation, the surplus assets of Affimed remaining after satisfaction of all its debts will be divided, in accordance with the provisions of section 2:23b of the Dutch Civil Code (the &#x201C;DCC&#x201D;) as follows:</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;firstly, the holders of the cumulative preference shares will be paid, if possible, the nominal value amount of their shares or, if those shares are not fully paid-up, the amount paid thereon, that payment to be increased by an amount equal to the average of the EURIBOR interest charged for cash loans with a term of twelve&nbsp;months as set by the European Central Bank&nbsp;- weighted by the number of&nbsp;days to which this interest was applicable&nbsp;- during the financial&nbsp;year for which this distribution is made, increased by a maximum margin of five hundred basis points to be fixed upon issue by the management board, of the amount called up and paid-up on the cumulative preference shares, calculated over each&nbsp;year or part of a&nbsp;year in the period beginning on the day following the period over which the last dividend on the cumulative preference shares was paid and ending on the day of the distribution, as referred to in this paragraph, made on cumulative preference shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">If our surplus assets are not sufficient to make the distributions as referred to in the above paragraph, these distributions will be made to the holders of the cumulative preference shares pro rata to the amounts that would be paid if the surplus assets were sufficient for distribution in full.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">3</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;secondly, the balance, if any, remaining after the payments referred to under paragraph (i)&nbsp;above will be for the benefit of the holders of common shares in proportion to the nominal value amount of common shares held by each of them.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">In accordance with Dutch law and our Articles, each issued common share and each issued cumulative preference share confers the right to cast one vote at the general meeting of shareholders. Each holder of shares may cast as many votes as it holds shares. Shares that are held by us or our direct or indirect subsidiaries do not confer the right to vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">In accordance with our Articles, for each general meeting of shareholders, the management board may determine that a record date will be applied in order to establish which shareholders are entitled to attend and vote at the general meeting of shareholders. Such record date shall be the 28</font><font style="display:inline;font-size:6pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;"> day prior to the day of the general meeting. The record date and the manner in which shareholders can register and exercise their rights will be set out in the notice of the general meeting of shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Redemption Provisions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under Dutch law, when issuing shares, a public company with limited liability (</font><font style="display:inline;font-style:italic;">naamloze vennootschap</font><font style="display:inline;">) &nbsp;such as ours may not subscribe for newly issued shares in its own capital. &nbsp;Such company may, however, subject to certain restrictions of Dutch law and its articles of association, acquire shares in its own capital. A listed public company with limited liability may acquire fully paid shares in its own capital at any time for no consideration. Furthermore, subject to certain provisions of Dutch law and its articles of association, such company may repurchase fully paid shares in its own capital if (i)&nbsp;the company&#x2019;s shareholders&#x2019; equity less the payment required to make the acquisition does not fall below the sum of paid-up and called-up capital and any reserves required by Dutch law or its articles of association and (ii)&nbsp;the company and its subsidiaries would not thereafter hold shares or hold a pledge over shares with an aggregate par value exceeding fifty&nbsp;percent&nbsp;of its then current issued share capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;color:#000000;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">An acquisition of common shares by Affimed for consideration may only take place if its general meeting of shareholders has granted the management board the authority to effect such acquisitions. Such authorization may be granted for a maximum period of 18&nbsp;months and must specify the number of common shares that may be acquired, the manner in which common shares may be acquired and the price limits within which common shares may be acquired. The actual acquisition may only be effected by a resolution of our management board. At the general meeting held on June&nbsp;25, 2019, the general meeting of shareholders authorized our management board, subject to the approval of our supervisory board, for a period of 18&nbsp;months (until December&nbsp;25, 2020) to cause the repurchase of common shares by Affimed of up to 10% of our issued share capital, for a price per share not exceeding 110% </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">of the market price of the common shares on Nasdaq; the market price being the average of the closing prices on the five trading&nbsp;days prior to the date of the acquisition. </font><font style="display:inline;">No authorization of the general meeting of shareholders is required </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">if Affimed acquires fully paid-up shares for the purpose of transferring such shares, by virtue of an </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">4</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">applicable employee stock purchase plan, to persons employed by Affimed or a group company, provided such shares are quoted on the official list of any stock exchange.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Requirements for Amendments (Item&nbsp;10.B.4)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">A resolution to amend our Articles, which may include a modification of the rights of holders of our common shares, &nbsp;may only be adopted by the general meeting at the proposal of the management board with the prior approval of the supervisory board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations on the Rights to Own Shares (Item&nbsp;10.B.6)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under out Articles, there is no restriction on the ownership of our shares. Most of our common shares are held through DTC and therefore the shareholders owning their shares through DTC do not themselves hold direct property rights in our common shares, but rather have contractual rights in such shares that are part of a chain of contractual rights involving Cede and Company, a specialist United States financial institution that processes transfers of stock certificates on behalf of DTC. Each person owning common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the common shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions Affecting Any Change of Control (Item&nbsp;10.B.7)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. We have adopted several provisions that may have the effect of making a takeover of Affimed more difficult or less attractive, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the authorization given by the general meeting of shareholders to our management board to issue a class of preference shares to a friendly party, subject to the approval of our supervisory board, in such a manner as to dilute the interest of any potential acquirer. &nbsp;To date, our management board has not been authorized by the general meeting of shareholders to issue (or grant the right to acquire) cumulative preference shares. If the general meeting of shareholders would grant such authorization to the management board, then the management board, subject to the approval of the supervisory board, could decide to use such cumulative preference shares as an anti-takeover measure;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the staggered four-year terms of our supervisory directors, as a result of which only approximately one-fourth of our supervisory directors will be subject to election in any one&nbsp;year;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a provision that our managing directors and supervisory directors may only be removed by the general meeting of shareholders by a two-thirds majority of votes cast representing at least 50% of our outstanding share capital if such removal is not proposed by our supervisory board; and</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">5</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">requirements that certain matters, including an amendment of our Articles, may only be brought to our shareholders for a vote upon a proposal by our management board that has been approved by our supervisory board.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership Threshold (Item&nbsp;10.B.8)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Differences Between the Laws of Different Jurisdictions (Item&nbsp;10.B.9)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Set forth below is a summary of certain significant differences between the law applicable to us and the laws applicable to companies incorporated in the United States and their shareholders. Although we believe this summary is materially accurate, the summary is subject to Dutch law, including Book 2 of the DCC and the Dutch Corporate Governance Code (the &#x201C;DCGC&#x201D;) and Delaware corporation law, including the Delaware General Corporation Law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">a)&nbsp;&nbsp;&nbsp;Corporate Governance</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Duties of Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. We have a&nbsp;two-tier&nbsp;board structure consisting of our supervisory board (</font><font style="display:inline;font-style:italic;">raad van commissarissen</font><font style="display:inline;">) and a separate management board (</font><font style="display:inline;font-style:italic;">raad van bestuur</font><font style="display:inline;">).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under Dutch law, the management board is collectively responsible for the management and the strategy, policy and operations of the company. The supervisory board is responsible for supervising the conduct of and providing advice to the management board and for supervising the business generally. Furthermore, each member of the management board and the supervisory board has a duty to act in the corporate interest of the company and the business connected with it. Under Dutch law, the corporate interest extends to the interests of all corporate stakeholders, such as shareholders, creditors, employees, customers and suppliers. The duty to act in the corporate interest of the company also applies in the event of a proposed sale or&nbsp;break-up&nbsp;of the company, whereby the circumstances are taken into account when determining how such duty is applied.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. The board of directors bears the ultimate responsibility for managing the business and affairs of a corporation. In discharging this function, directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its stockholders. Delaware courts have decided that the directors of a Delaware corporation are required to exercise informed business judgment in the performance of their duties. Informed business judgment means that the directors have informed themselves of all material information reasonably available to them. Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation. In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or&nbsp;break-up&nbsp;of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the stockholders.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">6</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Director Terms</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;">The Netherlands</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">. &nbsp;</font><font style="display:inline;">Managing directors and supervisory directors of a Dutch listed company are generally appointed for an individual term of a maximum of four&nbsp;years. There is no limit to the number of consecutive terms managing directors may serve. &nbsp;Following the DCGC, &nbsp;supervisory directors of a Dutch listed company are appointed for a period of four&nbsp;years and may then be reappointed once for another four-year period. The supervisory board member may then subsequently be reappointed again for a period of two&nbsp;years, which appointment may be extended by at most two&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Our managing directors are appointed by the general meeting of shareholders. As a condition to such appointment, the supervisory board must make a binding nomination. &nbsp;However, the general meeting may at all times overrule&nbsp;the binding nomination by a resolution adopted by at least a two thirds majority of the votes cast, representing more than one half of the issued share capital. If the general meeting overrules&nbsp;the binding nomination, the supervisory board shall make a new nomination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Our supervisory directors are also appointed by the general meeting of shareholders upon a binding nomination by the supervisory board. &nbsp;The general meeting may at all times overrule&nbsp;the binding nomination by a two thirds majority of the votes cast, representing more than one half of the issued share capital. If the general meeting overrules&nbsp;the binding nomination, the supervisory board shall make a new nomination.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">There are no restrictions on the number of reelections of a management director. Pursuant to the Articles, a supervisory director shall be appointed for a maximum term of four&nbsp;years, and may be reappointed for a term of not more than four&nbsp;years at a time. A supervisory director may be a supervisory director for a period not longer than twelve&nbsp;years, which period may not be interrupted, unless the general meeting of shareholders resolves otherwise. Under the DCGC, in the event of a re-appointment of a supervisory director after he or she has served as supervisory director for eight&nbsp;years, the supervisory board report should include the reasons for such re-appointment. As a result of our supervisory directors&#x2019; staggered four-year term, only approximately one-fourth of our supervisory directors will be subject to election in any one&nbsp;year.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The general meeting of shareholders shall at all times be entitled to suspend or dismiss a member of the management board or supervisory board. The general meeting of shareholders may only adopt a resolution to suspend or dismiss such a member by at least a two-thirds majority of the votes cast, if such majority represents more than one half of the issued share capital, unless the proposal was made by the supervisory board in which case a simple majority is sufficient.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. The Delaware General Corporation Law generally provides for a&nbsp;one-year&nbsp;term for directors, but permits directorships to be divided into up to three classes with up to three-year terms, with the&nbsp;years for each class expiring in different&nbsp;years, if permitted by the certificate of incorporation, an initial bylaw or a bylaw adopted by the stockholders. A director elected to serve a term on a &#x201C;classified&#x201D; board may not be removed by stockholders without cause. There is no limit in the number of terms a director may serve.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">7</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Director Vacancies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under Dutch law, new managing directors and supervisory directors are generally appointed by the general meeting of shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, in the case of a vacancy or vacancies of one or more managing directors, the remaining managing directors shall temporarily be in charge of the management, without prejudice to the right of the supervisory board to replace the managing director with a temporary managing director. In the case of a vacancy or vacancies of one or more supervisory directors, the remaining supervisory directors shall temporarily be in charge of the supervision, without prejudice to the right of the general meeting to appoint a temporary member of the supervisory board to replace the member of the supervisory board concerned.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. The Delaware General Corporation Law provides that vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) unless (i)&nbsp;otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii)&nbsp;the certificate of incorporation directs that a particular class of stock is to elect such director, in which case any other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Conflict-of-Interest&nbsp;Transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. &nbsp;Pursuant to Dutch law and our Articles, a managing director or a supervisory director shall not take part in the deliberations and the decision-making process of the management board or the supervisory board, as applicable, if he or she has a direct or indirect personal conflict of interest with the company or the business connected with it. Our Articles provide that if as a result of the conflict of interest of managing directors no resolution of the management board can be adopted, the resolution is adopted by the supervisory board. If as a result of the conflict of interest of supervisory directors no resolution of the supervisory board can be adopted, the resolution can nonetheless be adopted by the supervisory board. In that case, each supervisory board member is entitled to participate in the deliberation and the decision-making process of the supervisory board and to cast a vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. The Delaware General Corporation Law generally permits transactions involving a Delaware corporation and an interested director of that corporation if:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the material facts as to the director&#x2019;s relationship or interest are disclosed and a majority of disinterested directors consent;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the material facts are disclosed as to the director&#x2019;s relationship or interest and a majority of shares entitle</font><font style="display:inline;color:#000000;">d to vote thereon consent; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the transaction </font><font style="display:inline;">is fair to the corporation at the time it is authorized by the board of directors, a committee of the board of directors or the stockholders.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">8</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Proxy Voting by Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;">The Netherlands</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">. &nbsp;Under our Articles, </font><font style="display:inline;">at a meeting of the management board, a managing director may only be represented by another managing director holding a written proxy. At a meeting of the supervisory board, a supervisory director may only be represented by another supervisory director holding a written proxy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. A director of a Delaware corporation may not issue a proxy representing the director&#x2019;s voting rights as a director.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">b)&nbsp;&nbsp;&nbsp;Dutch Corporate Governance Code</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The DCGC contains both principles and best practice provisions for management boards, supervisory boards, shareholders and general meetings of shareholders. A copy of the DCGC can be found on</font><font style="display:inline;font-style:italic;">&nbsp;www.mccg.nl</font><font style="display:inline;">. As a Dutch company, we are subject to the DCGC and are required to disclose in our annual report, filed in the Netherlands, whether we comply with the provisions of the DCGC. The DCGC applies to all Dutch companies listed on a government-recognized stock exchange, whether in the Netherlands or elsewhere, including Nasdaq. If we do not comply with the provisions of the DCGC (for example, because of a conflicting Nasdaq requirement or otherwise), we must list the reasons for any deviation from the DCGC in our annual report. Our deviations from the DCGC are summarized below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Profile of the Supervisory Board</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The Supervisory Board is currently working on an update of its profile and we have therefore not yet published such profile on our website, which qualifies as a deviation from best practice provision 2.1.1 of the DCGC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Remuneration</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">We have granted and intend to grant options and restricted stock units in the future to members of our management board. These options provide for vesting conditions which allow exercise of one third of the options after the first anniversary of the grant date, which qualifies as a deviation from best practice provision 3.1.2 of the DCGC. Such vesting conditions are market practice among companies listed on Nasdaq. We are in competition with other companies in this field and intend to maintain an attractive compensation package for current and future management board members.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">We have granted and intend to grant options and restricted stock units in the future to members of our supervisory board, which qualifies as a deviation from best practice provision 3.3.2 of the DCGC. Such remuneration is in accordance with Nasdaq corporate governance requirements and market practice among companies listed on Nasdaq. We are in competition with other companies in this field and intend to maintain an attractive compensation package for current and future supervisory board members. The number of option rights granted to each supervisory board member is determined by the general meeting of shareholders.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">9</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The compensation committee of the Supervisory Board has not prepared a remuneration report, which qualifies as a deviation from best practice provision 3.4.1 of the DCGC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Board nominations and Shareholder Voting</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Pursuant to our Articles, the supervisory board will nominate one or more candidates for each vacant seat on the management board or the supervisory board. A resolution of our general meeting of shareholders to appoint a member of the management board or the supervisory board other than pursuant to a nomination by our supervisory board requires at least two-thirds of the votes cast representing more than half of our issued share capital, which qualifies as a deviation from best practice provision 4.3.3 of the DCGC. Although a deviation from the provision 4.3.3 of the DCGC, the supervisory board and the management board hold the view that these provisions will enhance the continuity of our management and policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Chairman of the Compensation Committee</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Thomas Hecht, chairman of our supervisory board, chairs the compensation committee, which qualifies as a deviation from best practice provision 2.3.4 of the DCGC.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">c)&nbsp;&nbsp;&nbsp;Shareholder Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Voting Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. &nbsp;In accordance with Dutch law and our Articles, each issued common share and each issued cumulative preference share confers the right to cast one vote at the general meeting of shareholders. Each holder of shares may cast as many votes as it holds shares. Shares that are held by us or our direct or indirect subsidiaries do not confer the right to vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">In accordance with our Articles, for each general meeting of shareholders, the management board may determine that a record date will be applied in order to establish which shareholders are entitled to attend and vote at the general meeting of shareholders. Such record date shall be the 28th day prior to the day of the general meeting. The record date and the manner in which shareholders can register and exercise their rights will be set out in the notice of the meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, each stockholder is entitled to one vote per share of stock, unless the certificate of incorporation provides otherwise. In addition, the certificate of incorporation may provide for cumulative voting at all elections of directors of the corporation, or at elections held under specified circumstances. Either the certificate of incorporation or the bylaws may specify the number of shares and/or the amount of other securities that must be represented at a meeting in order to constitute a quorum, but in no event will a quorum consist of less than one third of the shares entitled to vote at a meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Stockholders as of the record date for the meeting are entitled to vote at the meeting, and the board of directors may fix a record date that is no more than 60 nor less than 10&nbsp;days before the date of the meeting, and if no record date is set then the record date is the close of business on the day next preceding the day on which notice is given, or if notice is waived then the record date is the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">10</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;">close of business on the day next preceding the day on which the meeting is held. The determination of the stockholders of record entitled to notice or to vote at a meeting of stockholders shall apply to any adjournment of the meeting, but the board of directors may fix a new record date for the adjourned meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Shareholder Proposals</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. &nbsp;Pursuant to Dutch law, the management board and the supervisory board are authorized to convene general meetings. Pursuant to Dutch law, one or more shareholders representing at least&nbsp;ten&nbsp;percent&nbsp;of the issued capital may, on their application, be authorized by a Dutch district court to convene a general meeting of shareholders. The district court shall disallow the application if it does not appear that the applicants have previously requested the management board and the supervisory board to convene a general meeting of shareholders, with a precise description of the matters to be discussed at such meeting, and neither the management nor the supervisory board has taken the necessary steps so that the general meeting of shareholders could be held within six weeks after the request.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Also, the agenda for a general meeting of shareholders shall include such items requested by one or more shareholders representing at least 3% of the issued share capital, except where the articles of association state a lower&nbsp;percentage. Our Articles do not state such lower&nbsp;percentage. Requests must be made in writing and received by the management board at least 60&nbsp;days before the day of the convocation of the meeting. In accordance with the DCGC, a shareholder shall exercise the right of putting an item on the agenda only after consulting the management board in that respect. If one or more shareholders intend to request that an item be put on the agenda that may result in a change in the company&#x2019;s strategy, the management board may invoke a response time of a maximum of 180&nbsp;days&nbsp;from the moment the management board is informed by one of more shareholders of their intention to put an item on the agenda to the day of the general meeting of shareholders at which the item is to be dealt with.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Delaware law does not specifically grant stockholders the right to bring business before an annual or special meeting. However, if a Delaware corporation is subject to the SEC&#x2019;s proxy rules, a stockholder who owns at least $2,000 in market value, or 1% of the corporation&#x2019;s securities entitled to vote, and has owned such securities for at least one&nbsp;year, may propose a matter for a vote at an annual or special meeting in accordance with those rules. Affimed is not subject to such proxy rules&nbsp;because it is a &#x201C;foreign private issuer.&#x201D;</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Action by Written Consent</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under Dutch law, resolutions of the general meeting of shareholders of a Dutch public limited liability company (</font><font style="display:inline;font-style:italic;">naamloze vennootschap</font><font style="display:inline;">) &nbsp;may be adopted in writing without holding a meeting of shareholders, provided that (i)&nbsp;the articles of association allow such action by written consent and (ii)&nbsp;the resolution is adopted unanimously by all shareholders that are entitled to vote.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Although permitted by Delaware law, many publicly listed companies do not permit stockholders of a corporation to take action by written consent.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">11</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Appraisal Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. The concept of appraisal rights is not known as such under Dutch law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">However, in accordance with the directive 2005/56/EC of the European Parliament and the Council of 26&nbsp;October&nbsp;2005 on cross-border mergers of limited liability companies, Dutch law provides that, to the extent that the acquiring company in a cross-border merger is organized under the laws of another EU member state, a shareholder of a Dutch disappearing company who has voted against the cross-border merger may file a claim with the Dutch company for compensation. Such compensation is to be determined by one or more independent experts. &nbsp;The independent experts will take into account any provisions in the articles of association or agreements between the company and shareholders concerning the determination of the fair value of shares and the compensation to be paid to shareholders demanding their shares to be acquired at fair value. &nbsp;If the articles of association or an agreement between the company and the shareholders contains &nbsp;criteria for the unequivocal determination of the fair value of shares and the compensation to be paid to shareholders demanding their shares to be acquired at fair value, no independent experts are required to be appointed. The shares of shareholders that are subject to such appraisal claims will cease to exist as of the moment of effectiveness of the cross-border merger. If the acquiring company is a company incorporated under the laws of another member state of the European Union or the European Economic Area, the Dutch notary may only issue a &nbsp;declaration according to which the pre-merger formalities have been complied with if no appraisal claim has been filed, &nbsp;the compensation shareholders have been demanding has been paid or the other merging companies have decided that the acquiring company must pay the compensation due to shareholders.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. The Delaware General Corporation Law provides for stockholder appraisal rights, or the right to demand payment in cash of the judicially determined fair value of the stockholder&#x2019;s shares, in connection with certain mergers and consolidations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Shareholder Suits</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. In the event a third party is liable to a Dutch company, only the company itself can bring a civil action against that party. The individual shareholders do not have the right to bring an action on behalf of the company. Only in the event that the cause for the liability of a third party to the company also constitutes a tortious act directly against a shareholder does that shareholder have an individual right of action against such third party in its own name. The DCC provides for the possibility to initiate such actions collectively. A foundation or an association whose objective is to protect the rights of a group of persons having similar interests can institute a collective action if such representative organisation meets certain statutory criteria. Until recently a collective action could only result in a declaratory judgment (</font><font style="display:inline;font-style:italic;">verklaring voor recht</font><font style="display:inline;">). In order to obtain compensation for damages, the foundation or association and the defendant may reach&#x2014; for instance, on the basis of such declaratory judgment&#x2014;a settlement. Pursuant to the Dutch Act on the Collective Settlement of Mass Claims (the &#x201C;WCAM&#x201D;), a Dutch court may declare the settlement agreement binding upon all the injured parties with an&nbsp;opt-out&nbsp;choice for an individual injured party. However, as of January&nbsp;1, 2020 new legislation allows Dutch courts to award monetary damages in class action cases. The new legislation encourages parties to explore the options of a collective settlement pending the class action. The new legislation also introduces higher thresholds for class </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">12</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;">actions and statutory criteria on the basis of which representative organisations can only bring a collective claim before the Dutch courts if they, inter alia, have sufficient expertise on the matter brought before the court, their governance meets certain threshold criteria and are sufficiently funded and transparent concerning their funding. The new legislation also contains stricter rules&nbsp;with regard to the jurisdiction of the Dutch courts. A class action will only be admissible if it has a sufficiently substantive connection with the Netherlands. This will be the case if the majority of the claimants are based in the Netherlands, the defendant is domiciled in the Netherlands or where the unlawful event took place in the Netherlands. Finally, class actions under the new legislation will, as a rule, only apply to injured Dutch parties that have not chosen to opt-out of the class action. Foreign plaintiffs will, in principle, only be bound by the outcome of the class action proceedings if they explicitly opt-in.&nbsp;If a settlement is reached during the proceedings, there is an additional possibility for an injured party to opt-out.&nbsp;This is different than under the WCAM (see above), which does not feature an opt-in for foreign injured parties. If a settlement is declared binding by the Dutch courts pursuant to the WCAM, all intended beneficiaries are bound by the settlement unless they opt-out. An individual injured party may also itself&#x2014;outside the collective action&#x2014;institute a civil claim for damages.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, a stockholder may bring a derivative action on behalf of the corporation to enforce the rights of the corporation. An individual also may commence a class action suit on behalf of himself and other similarly situated stockholders where the requirements for maintaining a class action under Delaware law have been met. A person may institute and maintain such a suit only if that person was a stockholder at the time of the transaction which is the subject of the suit. In addition, under Delaware case law, the plaintiff normally must be a stockholder at the time of the transaction that is the subject of the suit and throughout the duration of the derivative suit. Delaware law also requires that the derivative plaintiff make a demand on the directors of the corporation to assert the corporate claim before the suit may be prosecuted by the derivative plaintiff in court, unless such a demand would be futile.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 48.25pt;text-decoration:underline;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Repurchase of Shares</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands. &nbsp;</font><font style="display:inline;">Under Dutch law, a public company with limited liability (</font><font style="display:inline;font-style:italic;">naamloze vennootschap</font><font style="display:inline;">) &nbsp;may, subject to certain restrictions of Dutch law and its articles of association, acquire shares in its own capital. A listed public company with limited liability may acquire fully paid shares in its own capital at any time for no consideration. Furthermore, subject to certain provisions of Dutch law and its articles of association, such company may repurchase fully paid shares in its own capital if (i)&nbsp;the company&#x2019;s shareholders&#x2019; equity less the payment required to make the acquisition does not fall below the sum of&nbsp;paid-up&nbsp;and&nbsp;called-up&nbsp;capital and any reserves required by Dutch law or its articles of association and (ii)&nbsp;the company and its subsidiaries would not thereafter hold shares or hold a pledge over shares with an aggregate par value exceeding fifty&nbsp;percent of its then current issued share capital.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">An acquisition of common shares by the company for a consideration </font><font style="display:inline;">may only take place if its general meeting of shareholders has granted the management board the authority to effect such acquisitions. </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Such authorization may be granted for a maximum period of 18&nbsp;months and must specify the number of common shares that may be acquired, the manner in which common shares </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">13</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">may be acquired and the price limits within which common shares may be acquired. Authorization is not required for the acquisition of common shares in order to transfer them to our employees. The actual acquisition may only be effected by a of our management board. </font><font style="display:inline;">At the general meeting held on June&nbsp;25, 2019, the general meeting of shareholders authorized our management board, subject to the approval of our supervisory board, for a period of 18&nbsp;months (until December&nbsp;25, 2020) to cause the repurchase of common shares by Affimed of up to 10% of our issued share capital, for a price per share not exceeding 110% </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">of the market price of the common shares on Nasdaq; the market price being the average of the closing prices on the five trading&nbsp;days prior to the date of the acquisition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">No authorization of the general meeting of shareholders is required if Affimed acquires fully paid-up shares for the purpose of transferring such shares, by virtue of an applicable employee stock purchase plan, to persons employed by Affimed or a group company, provided such shares are quoted on the official list of any stock exchange.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">If we would decide to repurchase any of our shares, no votes could be cast at a general meeting of shareholders on the shares held by us or our subsidiaries or on shares for which we or our subsidiaries hold depositary receipts. Nonetheless, the holders of a right of use and enjoyment (</font><font style="display:inline;font-style:italic;">vruchtgebruik</font><font style="display:inline;">) and the holders of a right of pledge in respect of shares held by us or our subsidiaries in our share capital are not excluded from the right to vote on such shares, if the right of use and enjoyment (</font><font style="display:inline;font-style:italic;">vruchtgebruik</font><font style="display:inline;">) or the right of pledge was granted prior to the time such shares were acquired by us or any of our subsidiaries. Neither we nor any of our subsidiaries may cast votes in respect of a share on which we or such subsidiary holds a right of use and enjoyment (</font><font style="display:inline;font-style:italic;">vruchtgebruik</font><font style="display:inline;">) or a right of pledge.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, a corporation may purchase or redeem its own shares unless the capital of the corporation is impaired or the purchase or redemption would cause an impairment of the capital of the corporation. A Delaware corporation may, however, purchase or redeem out of capital any of its preferred shares or, if no preferred shares are outstanding, any of its own shares if such shares will be retired upon acquisition and the capital of the corporation will be reduced in accordance with specified limitations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">d)&nbsp;&nbsp;&nbsp;Anti-Takeover Provisions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under Dutch law, various protective measures are possible and permissible within the boundaries set by Dutch law and Dutch case law. We have adopted several provisions that may have the effect of making a takeover of our company more difficult or less attractive, including:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;color:#000000;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the authorization given by the general meeting of shareholders to our management board to issue a class of </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">preference </font><font style="display:inline;">shares to a friendly party, subject to the approval of our supervisory board, in such a manner as to dilute the interest of any potential acquirer. To date, our management board has not been authorized by the general meeting of shareholders to issue (or grant the right to acquire) cumulative preference shares. </font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">If the general meeting of shareholders would grant such authorization to the management board, then the management board, subject to the approval of the supervisory board, could decide to use such cumulative preference shares as an anti-takeover measure;</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">14</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;color:#000000;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">the staggered four-year terms of our supervisory directors, as a result of which only approximately one-fourth of our supervisory directors will be subject to election in any one&nbsp;year;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;color:#000000;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">a provision that our managing directors and supervisory directors may only be removed byd &nbsp;the general meeting of shareholders by a two-thirds majority of votes cast representing at least 50% of our outstanding share capital if such removal is not proposed by our supervisory board; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;color:#000000;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;color:#000000;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">requirements that certain matters, including an amendment of our Articles, may only be brought to our shareholders for a vote upon a proposal by our management board that has been approved by our supervisory board.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. In addition to other aspects of Delaware law governing fiduciary duties of directors during a potential takeover, the Delaware General Corporation Law also contains a business combination statute that protects Delaware companies from hostile takeovers and from actions following the takeover by prohibiting some transactions once an acquirer has gained a significant holding in the corporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Section&nbsp;203 of the Delaware General Corporation Law prohibits &#x201C;business combinations,&#x201D; including mergers, sales and leases of assets, issuances of securities and similar transactions by a corporation or a subsidiary with an interested stockholder that beneficially owns 15% or more of a corporation&#x2019;s voting stock, within three&nbsp;years after the person becomes an interested stockholder, unless:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">the transaction that will cause the person to become an interested stockholder is approved by the board of directors of the target prior to the transactions;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">after the completion of the transaction in which the person becomes an interested stockholder, the interested stockholder holds at least 85% of the voting stock of the corporation not including shares owned by persons who are directors and officers of interested stockholders and shares owned by specified employee benefit plans; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;">after the person becomes an interested stockholder, the business combination is approved by the board of directors of the corporation and holders of at least 66.67% of the outstanding voting stock, excluding shares held by the interested stockholder.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">A Delaware corporation may elect not to be governed by Section&nbsp;203 by a provision contained in the original certificate of incorporation of the corporation or an amendment to the original certificate of incorporation or to the bylaws of the company, which amendment must be approved by a majority of the shares entitled to vote and may not be further amended by the board of directors of the corporation. In most cases, such an amendment is not effective until twelve&nbsp;months following its adoption.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">15</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">e)&nbsp;&nbsp;&nbsp;Inspection of Books and Records</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. The management board and the supervisory board provide the general meeting of shareholders with all information that the shareholders require for the exercise of their powers, unless this would be contrary to an overriding interest of us.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, any stockholder may inspect for any proper purpose certain of the corporation&#x2019;s books and records during the corporation&#x2019;s usual hours of business.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">f)&nbsp;&nbsp;&nbsp;&nbsp;Removal of Directors</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under our Articles, the general meeting of shareholders shall at all times be entitled to suspend or dismiss a member of the management board or supervisory board. The general meeting of shareholders may only adopt a resolution to suspend or dismiss such a member by at least a&nbsp;two-thirds&nbsp;majority of the votes cast, if such majority represents more than half of the issued share capital, unless the proposal was made by the supervisory board in which case a simple majority is sufficient.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i)&nbsp;unless the certificate of incorporation provides otherwise, in the case of a corporation whose board is classified, stockholders may effect such removal only for cause, or (ii)&nbsp;in the case of a corporation having cumulative voting, if less than the entire board is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">g)&nbsp;&nbsp;&nbsp;Pre-emptive Rights</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;font-style:italic;color:#000000;">The Netherlands</font><font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">. &nbsp;</font><font style="display:inline;">Upon the issue of common shares, each holder of common shares shall have a pre-emptive right to acquire such newly issued shares in proportion to the aggregate amount of his common shares, it being understood that this pre-emptive right shall not apply to (i)&nbsp;the issuance of shares to employees of the company or employees of a group company&#x37E; and (ii)&nbsp;the issuance of shares against payment in kind. No pre-emptive right shall exist with respect to the issue of cumulative preference shares.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, if and insofar as the management board is not authorized to limit or exclude pre-emptive rights, the pre-emptive rights in respect of newly issued common shares may be restricted or excluded by a resolution of the general meeting of shareholders upon proposal of the management board, which proposal has been approved by the supervisory board. The management board, subject to approval of the supervisory board, may also resolve to restrict or exclude the pre-emptive rights in respect of newly issued common shares if management board has been authorized by the general meeting of shareholders. Such authorization can be granted for a specific period not exceeding five&nbsp;years. A resolution of the general meeting of shareholders to restrict or exclude the </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">16</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;">pre-emptive rights or to authorize the management board for that purpose requires a majority of two-thirds of the votes cast, if less than one-half of our issued share capital is represented at the meeting.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">At a general meeting held on June&nbsp;25, 2019, the general meeting of shareholders authorized our management board, subject to the approval of our supervisory board, for a period of five&nbsp;years from the date of the meeting (up to and including June&nbsp;25, 2024) to restrict or exclude pre-emptive rights accruing to shareholders in connection with the issue of common shares and/or rights to subscribe for common shares in relation to any issuance or granting of rights to subscribe for common shares in the share capital of Affimed, up to the maximum number of common shares that can be issued under the size of the authorized share capital of Affimed as per the date of adoption of such resolution.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, stockholders have no preemptive rights to subscribe for additional issues of stock or to any security convertible into such stock unless, and to the extent that, such rights are expressly provided for in the certificate of incorporation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">h)&nbsp;&nbsp;&nbsp;Dividends</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Dutch law provides that dividends may be distributed after adoption of the annual accounts by the general meeting of shareholders from which it appears that such dividend distribution is allowed. Moreover, dividends may be distributed only to the extent the shareholders&#x2019; equity exceeds the amount of the&nbsp;paid-up&nbsp;and&nbsp;called-up&nbsp;part of the issued share capital and the reserves that must be maintained under the law or the articles of association. Interim dividends may be declared as provided in the articles of association and may be distributed to the extent that the shareholders&#x2019; equity exceeds the amount of the issued and&nbsp;paid-up&nbsp;and&nbsp;called-up&nbsp;part of the issued share capital and the required legal reserves as described above as apparent from our financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under our Articles, first, a dividend is paid out of the profit, if available for distribution, on the cumulative preference shares. Any amount remaining out of the profit is carried to reserve as the management board determines, subject to the approval of the supervisory board. After reservation by the management board of any profit, the remaining profit will be at the disposal of the general meeting of shareholders. We only make a distribution of dividends to our shareholders after the adoption of our annual accounts demonstrating that such distribution is legally permitted. The management board may resolve with the approval of the supervisory board, to make interim distribution to the shareholders or to holders of shares of a particular class if an interim statement of assets and liabilities shows that Affimed&#x2019;s shareholders&#x2019; equity exceeds the sum of the paid-up and called-up part of the capital and the reserves which must be maintained by Dutch law.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Dividends and other distributions shall be made payable no later than thirty&nbsp;days after the date when they were declared, unless the corporate body authorised to declare the dividend determines a different date. Claims to dividends and other distributions not made within five&nbsp;years and one day after the date that such dividends or distributions became payable, shall be forfeited to us (</font><font style="display:inline;font-style:italic;">verjaring</font><font style="display:inline;">) and shall be carried to the reserves.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">17</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, a Delaware corporation may pay dividends out of its surplus (the excess of net assets over capital), or in case there is no surplus, out of its net profits for the fiscal&nbsp;year in which the dividend is declared and/or the preceding fiscal&nbsp;year (provided that the amount of the capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). In determining the amount of surplus of a Delaware corporation, the assets of the corporation, including stock of subsidiaries owned by the corporation, must be valued at their fair market value as determined by the board of directors, without regard to their historical book value. Dividends may be paid in the form of common stock, property or cash.</font>
		</p>
		<p style="margin:0pt 0pt 12pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">i)&nbsp;&nbsp;&nbsp;&nbsp;Shareholder Vote on Certain Reorganizations</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under Dutch law, the general meeting of shareholders must approve resolutions of the management board relating to a significant change in the identity or the character of the company or the business of the company, which includes:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">a transfer of the business or virtually the entire business to a third party;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the entry into or termination of a long-term cooperation of the company or a subsidiary with another legal entity or company or as a fully liable partner in a limited partnership or general partnership, if such cooperation or termination is of a far-reaching significance for the company; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Wingdings;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">the acquisition or divestment by the company or a subsidiary of a participating interest in the capital of a company having a value of at least one third of the amount of its assets according to its balance sheet and explanatory notes or, if the company prepares a consolidated balance sheet, according to its consolidated balance sheet and explanatory notes in the last adopted annual accounts of the company.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, the vote of a majority of the outstanding shares of capital stock entitled to vote thereon generally is necessary to approve a merger or consolidation or the sale of all or substantially all of the assets of a corporation. The Delaware General Corporation Law permits a corporation to include in its certificate of incorporation a provision requiring for any corporate action the vote of a larger portion of the stock or of any class or series of stock than would otherwise be required.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Under the Delaware General Corporation Law, no vote of the stockholders of a surviving corporation to a merger is needed, however, unless required by the certificate of incorporation, if (i)&nbsp;the agreement of merger does not amend in any respect the certificate of incorporation of the surviving corporation, (ii)&nbsp;the shares of stock of the surviving corporation are not changed in the merger and (iii)&nbsp;the number of shares of common stock of the surviving corporation into which any other shares, securities or obligations to be issued in the merger may be converted does not exceed 20% of the surviving corporation&#x2019;s common stock outstanding immediately prior to the effective date of the merger. In addition, stockholders may not be entitled to vote in certain mergers with other corporations that own 90% or more of the outstanding shares of each class of stock of such corporation, but the stockholders will be entitled to appraisal rights.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">18</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">j)&nbsp;&nbsp;&nbsp;&nbsp;Remuneration of Directors</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">The Netherlands</font><font style="display:inline;">. Under Dutch law and our Articles, we must adopt a remuneration policy for our managing directors. Such remuneration policy shall be adopted by the general meeting of shareholders upon the proposal of the supervisory board. The supervisory board determines the remuneration of the management board in accordance with the remuneration policy. A proposal with respect to remuneration schemes in the form of shares or rights to shares must be submitted to the general meeting of shareholders for its approval.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The general meeting may determine the remuneration of supervisory directors. The supervisory directors shall be reimbursed for their expenses.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-style:italic;">Delaware</font><font style="display:inline;">. Under the Delaware General Corporation Law, the stockholders do not generally have the right to approve the compensation policy for directors or the senior management of the corporation, although certain aspects of executive compensation may be subject to stockholder vote due to the provisions of U.S. federal securities and tax law, as well as exchange requirements.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in Capital (Item&nbsp;10.B.10)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Pursuant to Dutch law, the general meeting of shareholders is authorized to resolve to reduce the issued share capital. Pursuant to our Articles, the general meeting of shareholders, upon proposal of the management board, which proposal must be approved by the supervisory board, may resolve to reduce the issued share capital by (i)&nbsp;reducing the nominal value of shares, or (ii)&nbsp;canceling:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 10.5pt;">
				<font style="margin:0pt 0pt 10.5pt;font-family:Wingdings;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 10.5pt;">
			<font style="display:inline;color:#000000;">shares which Affimed holds in its own share capital; or</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 10.5pt;">
				<font style="margin:0pt 0pt 10.5pt;font-family:Wingdings;border-top:1pt none #D9D9D9;font-size:12pt;;"> &#xA7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 10.5pt;">
			<font style="display:inline;color:#000000;">all issued shares of a specific class against repayment of the amount paid-up on those shares and, to the extent applicable, repayment of the share premium reserve attached to the relevant class of shares; and against a simultaneous release from the obligation to pay any further calls on the shares to the extent that the shares had not been fully paid-up.</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 10.5pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Partial repayment on shares pursuant to a resolution to reduce their nominal value may also be made exclusively on the shares of a specific class.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt Securities (Item&nbsp;12.A)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 18pt;text-indent:18pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Warrants and Rights (Item&nbsp;12.B)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 18pt;text-indent:18pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Securities (Item&nbsp;12.C)</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt 18pt;text-indent:18pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p>
		<p style="margin:0pt 0pt 10.5pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-style:italic;font-size: 12pt;">
			<font style="display:inline;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;American Depositary Shares (Items 12.D.1 and 12.D.2)</font>
		</p>
		<p style="margin:0pt 0pt 0pt 18pt;text-indent:18pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Not applicable.</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			<font style="display:inline;">19</font>

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>afmd-20191231ex81e6860d1.htm
<DESCRIPTION>EX-8.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:58:55 PM-->
<html>
	<head>
		<title>
			afmd_Ex 8_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT&nbsp;8.1</font>
		</p>
		<p style="margin:0pt 0pt 24pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">SUBSIDIARIES OF THE REGISTRANT</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;font-family:Times New Roman,Times,serif;">
			<tr>
				<td valign="bottom" style="width:239.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:239.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:239.40pt;padding:0pt 6.5pt">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;">Name of Subsidiary</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:239.40pt;padding:0pt 6.5pt">
					<p style="margin:0pt;border-bottom:1pt solid #000000 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;">Jurisdiction of incorporation or<br>organization</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">AbCheck s.r.o.</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">Czech Republic</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">Affimed GmbH</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">Germany</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">Affimed, Inc.</font></p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:239.40pt;height:24.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
						<font style="display:inline;font-weight:normal;">Delaware</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>afmd-20191231ex1218376bb.htm
<DESCRIPTION>EX-12.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:59:01 PM-->
<html>
	<head>
		<title>
			afmd_Ex 12_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT&nbsp;12.1</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">I, Adi Hoess, certify that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">I have reviewed this annual report on Form&nbsp;20&#8209;F of Affimed N.V.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 3.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 4.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">The company&#x2019;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a&#8209;15(e)&nbsp;and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a&#8209;15(f)&nbsp;and 15d&#8209;15(f)) for the company and have:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> c.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> d.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Disclosed in this report any change in the company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#x2019;s internal control over financial reporting; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 5.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">The company&#x2019;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#x2019;s auditors </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;;"><font style="display:inline;font-size:12pt;">and the audit committee of the company&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:12pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:24pt 0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Date: April&nbsp;28, 2020</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 99.96%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:&nbsp;</font><font style="display:inline;font-size:12pt;"> Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:&nbsp;</font><font style="display:inline;font-size:12pt;"> Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">(</font><font style="display:inline;font-style:italic;font-size:12pt;">Principal Executive Officer</font><font style="display:inline;font-size:12pt;">)</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>afmd-20191231ex122365eaa.htm
<DESCRIPTION>EX-12.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:59:07 PM-->
<html>
	<head>
		<title>
			afmd_Ex 12_2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT&nbsp;12.2</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt 72pt;text-indent: -36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">I, Adi Hoess, certify that:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">I have reviewed this annual report on Form&nbsp;20&#8209;F of Affimed N.V.;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 3.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 4.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">The company&#x2019;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a&#8209;15(e)&nbsp;and 15d&#8209;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a&#8209;15(f)&nbsp;and 15d&#8209;15(f)) for the company and have:</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> c.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Evaluated the effectiveness of the company&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> d.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Disclosed in this report any change in the company&#x2019;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#x2019;s internal control over financial reporting; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;"><p style="width:36pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 5.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">The company&#x2019;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#x2019;s auditors </font></p></td></tr></table></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td align="left" valign="top"><p style="margin:0pt 0pt 12pt 72pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;;"><font style="display:inline;font-size:12pt;">and the audit committee of the company&#x2019;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> a.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#x2019;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;"><p style="width:72pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:12pt;;"> b.</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#x2019;s internal control over financial reporting.</font></p></td></tr></table></div>
		<p style="margin:24pt 0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Date: April&nbsp;28, 2020</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 99.96%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:&nbsp;</font><font style="display:inline;font-size:12pt;"> Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:&nbsp;</font><font style="display:inline;font-size:12pt;"> Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">(</font><font style="display:inline;font-style:italic;">Principal Financial and Accounting Officer</font><font style="display:inline;">)</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>afmd-20191231ex131834e0f.htm
<DESCRIPTION>EX-13.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:59:14 PM-->
<html>
	<head>
		<title>
			afmd_Ex 13_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT&nbsp;13.1</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The certification set forth below is being submitted in connection with Affimed N.V.&#x2019;s Annual Report on Form&nbsp;20&#8209;F for the fiscal&nbsp;year ended December&nbsp;31, 2019 (the &#x201C;</font><font style="display:inline;font-weight:bold;">Report</font><font style="display:inline;">&#x201D;) for the purpose of complying with Rule&nbsp;13a&#8209;14(b)&nbsp;or Rule&nbsp;15d&#8209;14(b)&nbsp;of the Securities Exchange Act of 1934 (the &#x201C;</font><font style="display:inline;font-weight:bold;">Exchange Act</font><font style="display:inline;">&#x201D;) and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Adi Hoess, the principal executive officer of Affimed N.V., certifies that, to the best of his knowledge:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">the Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Affimed N.V.</font></p></td></tr></table></div>
		<p style="margin:24pt 0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-size:12pt;">Date:&nbsp;&nbsp;April 28, 2020</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 99.96%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:&nbsp;</font><font style="display:inline;font-size:12pt;"> Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:&nbsp;</font><font style="display:inline;font-size:12pt;"> Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">(</font><font style="display:inline;font-style:italic;font-size:12pt;">Principal Executive Officer</font><font style="display:inline;font-size:12pt;">)</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>afmd-20191231ex132b927c5.htm
<DESCRIPTION>EX-13.2
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:59:20 PM-->
<html>
	<head>
		<title>
			afmd_Ex 13_2
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">EXHIBIT&nbsp;13.2</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">CERTIFICATION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-bottom:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">The certification set forth below is being submitted in connection with Affimed N.V.&#x2019;s Annual Report on Form&nbsp;20&#8209;F for the fiscal&nbsp;year ended December&nbsp;31, 2019 (the &#x201C;</font><font style="display:inline;font-weight:bold;">Report</font><font style="display:inline;">&#x201D;) for the purpose of complying with Rule&nbsp;13a&#8209;14(b)&nbsp;or Rule&nbsp;15d&#8209;14(b)&nbsp;of the Securities Exchange Act of 1934 (the &#x201C;</font><font style="display:inline;font-weight:bold;">Exchange Act</font><font style="display:inline;">&#x201D;) and Section&nbsp;1350 of Chapter&nbsp;63 of Title 18 of the United States Code.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;border-top:1pt none #D9D9D9 ;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Adi Hoess, the principal financial and accounting officer of Affimed N.V., certifies that, to the best of his knowledge:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:12pt;;"> 1.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">the Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Exchange Act; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 22.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:12pt;;"> 2.</font>
			</p>
		</td><td style="width:14pt;"><p style="width:14pt;width:14pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 12pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-size:12pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Affimed N.V.</font></p></td></tr></table></div>
		<p style="margin:24pt 0pt;text-indent:0pt;text-align:left;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">Date:&nbsp;April&nbsp;28,&nbsp;2020</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 99.96%;">
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:50.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-bottom:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">/s/ Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;border-top:1pt solid #000000 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Name:&nbsp;</font><font style="display:inline;font-size:12pt;"> Adi Hoess</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">Title:&nbsp;</font><font style="display:inline;font-size:12pt;"> Chief Executive Officer</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:50.00%;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;text-indent:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;">(</font><font style="display:inline;font-style:italic;">Principal Financial and Accounting Officer</font><font style="display:inline;">)</font></p>
				</td>
				<td valign="top" style="width:50.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
						<font style="display:inline;font-size:12pt;">&nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>afmd-20191231ex15114476d.htm
<DESCRIPTION>EX-15.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.6.0.116-->
<!--Created on: 4/28/2020 3:59:26 PM-->
<html>
	<head>
		<title>
			afmd_Ex15_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Exhibit 15.1</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font>
		</p>
		<p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Supervisory Board of Affimed N.V.:</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333-198812)&nbsp;and on Form F-3 (No. 333-227933) of Affimed N.V. of our reports dated April 28, 2020, with respect to the consolidated statements of financial position of Affimed N.V. as of December&nbsp;31, 2019 and 2018, and the related consolidated statements of comprehensive loss, cash flows and changes in equity for each of the years in the three-year period ended December&nbsp;31, 2019, and the related notes, and the effectiveness of internal control over financial reporting as of December 31, 2019, which reports appear in the December&nbsp;31, 2019 annual report on Form 20-F of Affimed N.V.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/&nbsp;&nbsp; KPMG AG Wirtschaftspr&#xFC;fungsgesellschaft</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 10pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Mannheim, Germany<br></font><font style="display:inline;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">April 28, 2020</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>afmd20191231x20f001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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MM>+9+'P?Y:^-1X,TRUM],N[FXS]K$9NFB6??<,(R5%M"H=F!<.!\E'U'"_\
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MW'[E_D2\PQ2_Y>2_\"?^9S/_  I;P;_T*7AG_P %<'_Q-'_"EO!O_0I>&?\
MP5P?_$UTU%'U#"_\^X_<O\@_M#%?\_)?^!/_ #.9_P"%+>#?^A2\,_\ @K@_
M^)H_X4MX-_Z%+PS_ ."N#_XFNFHH^H87_GW'[E_D']H8K_GY+_P)_P"9S/\
MPI;P;_T*7AG_ ,%<'_Q-'_"EO!O_ $*7AG_P5P?_ !-=-11]0PO_ #[C]R_R
M#^T,5_S\E_X$_P#,YG_A2W@W_H4O#/\ X*X/_B:/^%+>#?\ H4O#/_@K@_\
MB:Z:BCZAA?\ GW'[E_D']H8K_GY+_P "?^9S/_"EO!O_ $*7AG_P5P?_ !-'
M_"EO!O\ T*7AG_P5P?\ Q-=-11]0PO\ S[C]R_R#^T,5_P _)?\ @3_S.9_X
M4MX-_P"A2\,_^"N#_P")H_X4MX-_Z%+PS_X*X/\ XFNFHH^H87_GW'[E_D']
MH8K_ )^2_P# G_F<S_PI;P;_ -"EX9_\%<'_ ,31_P *6\&_]"EX9_\ !7!_
M\37344?4,+_S[C]R_P @_M#%?\_)?^!/_,YG_A2W@W_H4O#/_@K@_P#B:/\
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M ."N#_XFC_A2W@W_ *%+PS_X*X/_ (FNFHH^H87_ )]Q^Y?Y!_:&*_Y^2_\
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MAG_P5P?_ !-=-11]0PO_ #[C]R_R#^T,5_S\E_X$_P#,YG_A2W@W_H4O#/\
MX*X/_B:/^%+>#?\ H4O#/_@K@_\ B:Z:BCZAA?\ GW'[E_D']H8K_GY+_P "
M?^9S/_"EO!O_ $*7AG_P5P?_ !-'_"EO!O\ T*7AG_P5P?\ Q-=-11]0PO\
MS[C]R_R#^T,5_P _)?\ @3_S.9_X4MX-_P"A2\,_^"N#_P")H_X4MX-_Z%+P
MS_X*X/\ XFNFHH^H87_GW'[E_D']H8K_ )^2_P# G_F<S_PI;P;_ -"EX9_\
M%<'_ ,31_P *6\&_]"EX9_\ !7!_\37344?4,+_S[C]R_P @_M#%?\_)?^!/
M_,YG_A2W@W_H4O#/_@K@_P#B:/\ A2W@W_H4O#/_ (*X/_B:Z:BCZAA?^?<?
MN7^0?VABO^?DO_ G_F<S_P *6\&_]"EX9_\ !7!_\31_PI;P;_T*7AG_ ,%<
M'_Q-=-11]0PO_/N/W+_(/[0Q7_/R7_@3_P SF?\ A2W@W_H4O#/_ (*X/_B:
M/^%+>#?^A2\,_P#@K@_^)KS']M+XJ^(?AS?>!+/0_%%OX1A\0:JUG?:C/:P3
MQV\6%^=A,-H"Y)/*_6O%?&/[3/C/5O@'XI:;Q0U^_AGQ39V5KXBTE39?VG"W
MF%Q^ZP"/E4X7@AQU&"?C\TXDRK XBKA:E"\J:;O:%G:'/9:\WP]7&U]+W/LL
MIX9S;'X>EBJ>(M&HTK7G=7GR7>G+\712O;6UCZX_X4MX-_Z%+PS_ ."N#_XF
MC_A2W@W_ *%+PS_X*X/_ (FN/\$?M?\ ASQO;^)-NE>*M-O/"]E_:-S8WVF&
M.ZG@*[E>*,%B0PP1G;PP/3)#?!?[8GAWQ7?:U:WFD>*_#-UH>DR:Y-#K6F_9
M9)K./[TL:AF+ ?AGMG!QZ\<RR27+:4/>O;1=+I]--GOV/'EEF>QY^:-3W;7U
M?6S7771K:^YV7_"EO!O_ $*7AG_P5P?_ !-'_"EO!O\ T*7AG_P5P?\ Q-<3
MX9_;0\*^(? .N>)+BQ\2:+INAQ6\['4;#R7O8YRRPM  S"0.5(!!';H.:VO@
M[^TEH_QEUR_TF#2_$>@ZOI\"73V.M6'V2=X7.%E4;F!4G'.>XJJ&/R6M.%.D
MX-SUBK+7==N\7;O9VV)Q&7YW1A4J5542INTG=Z;/OVDK]KJ^YN?\*6\&_P#0
MI>&?_!7!_P#$T?\ "EO!O_0I>&?_  5P?_$UY;^U]\2O'OPNUKPG>:+J>EZ;
MX>U'7+/2I46W$UY=-+YC/N,BE$0+'@;?F)8G(P!7O%;86>"KXFMA8T4I4[7O
M&-GS7::ZVTZI>1CBZ>.P^&HXJ59N-7FM:4KKE:33Z7U6S?G9G,_\*6\&_P#0
MI>&?_!7!_P#$T?\ "EO!O_0I>&?_  5P?_$UTU%>C]0PO_/N/W+_ "/-_M#%
M?\_)?^!/_,YG_A2W@W_H4O#/_@K@_P#B:/\ A2W@W_H4O#/_ (*X/_B:Z:BC
MZAA?^?<?N7^0?VABO^?DO_ G_F<S_P *6\&_]"EX9_\ !7!_\31_PI;P;_T*
M7AG_ ,%<'_Q-=-11]0PO_/N/W+_(/[0Q7_/R7_@3_P SF?\ A2W@W_H4O#/_
M (*X/_B:/^%+>#?^A2\,_P#@K@_^)KIJ*/J&%_Y]Q^Y?Y!_:&*_Y^2_\"?\
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M  5P?_$UTU%'U#"_\^X_<O\ (/[0Q7_/R7_@3_S.9_X4MX-_Z%+PS_X*X/\
MXFC_ (4MX-_Z%+PS_P""N#_XFNFHH^H87_GW'[E_D']H8K_GY+_P)_YG,_\
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M'EPESK[6>MWUFVI,D;1!7,4RD1E'93&N$;/S*<"NY_X2:Q_Y[_\ CC?X4?\
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M6[%I^KL?F.<GJ ,56_X>\_L[_P#10O\ RA:G_P#(]'_#WG]G?_HH7_E"U/\
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M%_Y0M3_^1Z/]7<V_Z!:G_@$O\@_UIR7_ *"Z7_@R'^9])T5\V?\ #WG]G?\
MZ*%_Y0M3_P#D>C_A[S^SO_T4+_RA:G_\CT?ZNYM_T"U/_ )?Y!_K3DO_ $%T
MO_!D/\SZ3HKYL_X>\_L[_P#10O\ RA:G_P#(]'_#WG]G?_HH7_E"U/\ ^1Z/
M]7<V_P"@6I_X!+_(/]:<E_Z"Z7_@R'^9])T5\V?\/>?V=_\ HH7_ )0M3_\
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MFS_A[S^SO_T4+_RA:G_\CT?\/>?V=_\ HH7_ )0M3_\ D>C_ %=S;_H%J?\
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M$EU+) \<<\BSAD9BSY95")A>%.34G_#X#P%_T)'Q8_\ !#%_\?H_X? > O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'ZX?\$$_^3/_ !)_V.-U_P"D5C7R?\#O^29:?_UTN/\ THDKZP_X()_\F?\
MB3_L<;K_ -(K&OD_X'?\DRT__KI<?^E$E?Q'](+_ '+%?]A5+_TU7/[X^CG_
M +[@_P#L$K?^G<.=91117\CG]D!1110 5WGCCX :AX'T[5)FU;0]0GT,6[:C
M:VCS>=:).!Y;GS(D5ERR [&8@N,C&2.#KWSQU\?O#_BC6?$D/G6[62R:9?Z?
M-#9FW.J&W$0EM+@J@>0'YRAE!"M&,, 17MY7A\'5HU/K,E&6BC=_W9N^_=16
MSWMHVFO#S7$8RE6I+#1<HZN5E?[4%;;LY/=;7U2:?C>J?#WQ!H:V)O=#UBS&
MJ$+9F>RDC^UDXP(\@;\[E^[GJ/6M*7X,>)-.BNI-4T?5M%6VM);Q3?:;=()E
MCV[@I6,X^\/F;:@SRPR,^X>&?B?9>)OC9I_]BS>';ZSU?Q$-7EBMUU$:@NR*
M<B24W+&!-J,P?R23P-H8*HK#U+Q!I?@[P1&([RS_ .$<O?"^JZ/HTL<T]U-<
M7+7,<LB2,]M 1S)P?+"@ _,3FO7_ +!P,82JJKS15U>ZMIR]5NGS+JK.RUO<
M\?\ U@QTIPI.ERR=G:SOKS='LUROH^97EI:QYKX,_9\\7>-M<LK&'0]3L_[0
MMY+J"XN[*:."2-$WE@P0Y!RB@C(+2(/XA6/<_##Q-9V-Q=3>'=<BM;1MD\SV
M$JQPMO*89BN%.\%<'N,=:]<TKXE>%;7XA^']?U;6-+NM?=[N#5-1TNVO1;20
MM9>1'+*DT:MYQD))\E NW)QG%8*^-_#]OI'PST:XUZYEL?#FI74NI3:<)X_*
M5KE626,LJ-DJ"00-ZCL#Q7/4RO+U3=JBNF[/GCK?V:C=6TMS2;M>W*U=VN=%
M/-<Q=17I.S2NN26EO:.5G?6_+%*]F^9.RO8YCPM^S_XM\4>-8= _L74M-U":
MVDNPM]9S0[8D!)<C86VE@$!Q@NRC/-9U_P#"W6K'^S(?[/OI-0U22:&.P6QN
M%N4>)MK+AHP&;/:,L5QAMIXKU^S^*_@_0M:^'T4%]I-M:Z+_ &PEZ=-@OWM;
M074(2)@;A3,_)); X(.!C&<KP_\ $CPWHW@72/#TFM6[31Z1K6E27T5M.8+5
M[B56BD.8Q(8W52IVH6 <Y7M6LLIRY1</:J_?G3W]D[+;^::YGI[KNE;3..<9
MDY*?L7;MR26WM5=[_P L'RK7WDDW?7R]?AEXD?6YM,'A[7#J5NJO+:"PE\^)
M6("EDV[@"64 D<EAZU#9^"-2G\:6OA^XMI=.U2ZNH[3RKR-H6A>1@%WJ1N4?
M,#TSCM7J,OQ8T71?A]J&@0:PU]>6WA<Z1%J,44R+?O)>K.8$W*'$4<3.F9 @
M/S@#!&<#7?B#I>I?%WP3K'VQI;?2[32$U"=HWW)) D8FSD;F*[3R,YQQFN&O
ME^"IJ#C5NVXW5UHFVFKKK&V^SW6C1W8?,<=4<E.E9)2L[/5I)IV?25]$]5L]
M4RGK/P OM.COFM-8T/6!H]ZEAJ2V1N#)I[M((E9D>%'=2YVYB#\\=QG"OOAA
MKUJ=2DBTG5+RRTF::&XO(;&<0(8CAR2R*4QD$APK+D;@#Q7I=GXY\,^!/&WB
MC6[;Q%;ZM<>*+\1PI:6MPJ6=JU['<2R3>;$AW[8U55CW<EO;,?C?XTZ+/<6$
MEK=RWUO:^.K_ %Z:U6-U$]NTD31/A@%)91( #R,G.,UUU\NR[D<N=1:Z*2?V
MFE9W?2TFM7OJKV7'A\RS+G4?9N2?5Q<?LINZLNMXIZ+;1VN_,=7^'GB#P_<6
M,-_H>L6,NIMMLTN+*2-KL\#$88#>?F7[N?O#UKH--_9P\::CH.L7Q\/ZM;?V
M*L32VT]C.EQ.';'[M=GS;1\S9(PO->F'XZ:'HWC^&XAU#PZNB7FNW&I32Z;!
MJ;:A#)-!/"MQ*+G,>5\T,RQ$DLHP" *XW0-7T71_ GB;PQ-XNL[QM4TVU^RW
M9M[O[%;O%>-*UNN8O-Y5BX/EJN]G!_O,O[+RZ$VG44E[^TXJS4;QUZ\TG:]D
ME:SON5_:V8S@FJ3B_<WA)W3G:6G3EBKV;;=[JVQP.H>"=:TG0+?5KK2-4M=+
MO&"P7DMJZ6\Y() 60C:Q(4G@] ?2MJ^^#6L:%X U'7-6L=2T?['<VL$$%W8O
M#]K6=9B75FQPOE#H#G?U&.?2O&_QTT74)[K4M/\ ^$9:TU0:8+VQ>/43J;QV
M[P.8L/FS&UHR 5(RF>[$4W5)M'^)#Z_H.G>+FU:X\:^*[?488EL[A5L+?_2#
M+,_F!5WJKKO .-L2X<\[7_8V"4Y0I554=FE[T5>34N7JF[M1T6S=G=:N?[:Q
MSA&=6DZ:NF_=D[13CS=&E9.6KW2NK/1>4?#SX?7'Q&U6[M8+RQT];&RFU">>
M[,GEQQ1+N<_NT=B<=@IS3U^&6I:OJCVWAY9/%JQA=\VD65U*B,P8A2'B1PV$
M8_=P0#@G!QTGP.\3Z3X"\?:_YVK6<5I<:5?:?97MW8O-;RNZ[8FDA"2':W!*
MLC#&00>E6+WQG8Z9\._'6FOKFCWU_P"('TQXAI-A)9VLRPO+O79Y$2KM_=L?
ME 8G().<<6'P>$>&BZDES>_?WE?W8MQ2][[35D^5[Z/H^[$8S&+$RC2BW'W+
M>Z[>])*3?N_93NUS*UM5U7%V'PW\1:HMXUKH.M7"Z>[QW1BL97^S,GWU?"_*
M5[@XQWJUI/PKUNZO-#-[I>J:;INO74-M;W\]E(L$GFD;61B K_+E@ >0*]&^
M.?QDT7Q9X6\16NEZD]U)JGB6WU#RO+FC6Y@6R5&9L@?\M1T)SD9QWJ]<_%CP
MW9>+O$FMKXB:^A\7:GIUS'9?99EETR.*ZCG;SLH$_=(AB41-)D-V%=?]DY?&
MJX>V34>O-%)_%MK_ '4M'?WK[+7D_M;,94E/V+3ETY9-KX-].G-)ZJWN6W>G
M%^)/V?I=%GM88=46XDNM1U:Q -E,<"PVY?$0D<[PQ.-N$VY+8R1R=Q\//$%I
MX>;5IM#UB+25",;U[*1;<!]I0^9C;\VY<<\[ACJ*]C?XT^&3XNTNZ_M+]Q;Z
MGXHN)&^SR_+'>0[;8XVY^=N,#E?XL5G2_%W1[N:.%=2EDC_X5X- 2/RI2/MF
MT?N0-O\ > ^;[N1G-:XG+<LDY.G44=;)*2?V(.[NWIS.7S35]-,L+F>:1454
MIN6EVW%K[<U962UY5'?I9VUU\OO?AMXBTWPZNL7&@:U;Z3(B2+>R6,JV[*^-
MC"0KMPV1@YYR*Q:^AOVHT_M?0_%*Z7]CD73]:M;G7(VO99;BUE$+V\0"-"D2
MC[P98Y9CN*X.U<U\\UY&=9?3P6(]C3;DK;][-IVT7:S71IJ[L>QD>8U,;AO;
MU4HN^W:Z35]7WNGU33LKA1117CGL!1110!Z1^P)\:/\ A07[3K>'KR7R_"_Q
M1=8DR?DM-71<1GV\]!LXZNJ5^C%?E/\ #/X33_M*?M!>%? =J9H[6.=-=UNZ
MA8I)8V5NX8;7'*222;8U8<@DGI7ZL5_6G"N)Q.)X?P=?&JU3E<5WE3B^6G)]
MFTG'SC",OM'\@\48;#8;B+'8? N])24GVC4FN:I!=TFU*_24Y0^R%%%%>P>2
M9/C+_D%Q_P#74?R-<S7>45QUL)[27-<[*.+]G'EL<'17>45C_9_][\/^";?V
MA_=_'_@'!USOPK^&MC\(O!-OH.FS7<]G;37$ZO<LK2%IIY)WR551@-(P''0#
MJ>3Z]11_9_3F_#_@A_:']W\?^ <'17>44?V?_>_#_@A_:']W\?\ @'!T5WE%
M']G_ -[\/^"']H?W?Q_X!P=%=Y11_9_][\/^"']H?W?Q_P" <'17>44?V?\
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M^)7_ (4U[_\ ':/^&S/C!_T5;XE?^%->_P#QVCV?$/\ /1_\ G_\F'M.&?\
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M!Z3_ ,.AOVB/^B>_^5W3/_DBC_AT-^T1_P!$]_\ *[IG_P D5YM_PV9\8/\
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M_P .AOVB/^B>_P#E=TS_ .2*\V_X;,^,'_15OB5_X4U[_P#':/\ ALSXP?\
M15OB5_X4U[_\=H]GQ#_/1_\  )__ "8>TX9_Y]U__ Z?_P @>D_\.AOVB/\
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MSXP?]%6^)7_A37O_ ,=H_P"&S/C!_P!%6^)7_A37O_QVCV?$/\]'_P  G_\
M)A[3AG_GW7_\#I__ "!Z3_PZ&_:(_P"B>_\ E=TS_P"2*/\ AT-^T1_T3W_R
MNZ9_\D5YM_PV9\8/^BK?$K_PIKW_ ..T?\-F?&#_ **M\2O_  IKW_X[1[/B
M'^>C_P" 3_\ DP]IPS_S[K_^!T__ ) ])_X=#?M$?]$]_P#*[IG_ ,D4?\.A
MOVB/^B>_^5W3/_DBO-O^&S/C!_T5;XE?^%->_P#QVC_ALSXP?]%6^)7_ (4U
M[_\ ':/9\0_ST?\ P"?_ ,F'M.&?^?=?_P #I_\ R!Z3_P .AOVB/^B>_P#E
M=TS_ .2*/^'0W[1'_1/?_*[IG_R17FW_  V9\8/^BK?$K_PIKW_X[1_PV9\8
M/^BK?$K_ ,*:]_\ CM'L^(?YZ/\ X!/_ .3#VG#/_/NO_P"!T_\ Y ])_P"'
M0W[1'_1/?_*[IG_R11_PZ&_:(_Z)[_Y7=,_^2*\V_P"&S/C!_P!%6^)7_A37
MO_QVC_ALSXP?]%6^)7_A37O_ ,=H]GQ#_/1_\ G_ /)A[3AG_GW7_P# Z?\
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M/Q]_Z)3#_P"%38?_ !5?G/14?\2Y\,?\^8?^7'_S2:?\3.<4_P#/ZI]^'_\
MF4_1C_ADGX^_]$IA_P#"IL/_ (JC_ADGX^_]$IA_\*FP_P#BJ_.>BC_B7/AC
M_GS#_P N/_FD/^)G.*?^?U3[\/\ _,I^C'_#)/Q]_P"B4P_^%38?_%4?\,D_
M'W_HE,/_ (5-A_\ %5^<]%'_ !+GPQ_SYA_Y<?\ S2'_ !,YQ3_S^J??A_\
MYE/T8_X9)^/O_1*8?_"IL/\ XJC_ (9)^/O_ $2F'_PJ;#_XJOSGHH_XESX8
M_P"?,/\ RX_^:0_XF<XI_P"?U3[\/_\ ,I^C'_#)/Q]_Z)3#_P"%38?_ !5'
M_#)/Q]_Z)3#_ .%38?\ Q5?G/11_Q+GPQ_SYA_Y<?_-(?\3.<4_\_JGWX?\
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M#_X5-A_\51_PR3\??^B4P_\ A4V'_P 57YST4?\ $N?#'_/F'_EQ_P#-(?\
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MOPO4^)/VF?B)H'BF'P6%\%S>*%\:67AR75/L%RNGR6EWIMQ>I.MMYY=9D\H
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M ()M_#OQ!H-MIMWJT/A[PQ:017^_[._VEK&V;<4(8869B",X(!PP&T^E:_\
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MHH **** /-?VS/\ DS_XK?\ 8G:O_P"D4U?S^U_0%^V9_P F?_%;_L3M7_\
M2*:OY_:_</"C_=*_^)?D?SWXS_[[AO\ "_S"BBBOU@_%PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOVY_X*\_\H[_ (A?]PW_ -.=I7XC5^W/_!7G_E'?\0O^X;_Z<[2OS3CC_D;9
M7_U\_P#;J9^L>'O_ ")<X_Z]?^V53\1J***_2S\G"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _7#_@@G_R9_XD_P"QQNO_ $BL:_(^OUP_X()_\F?^)/\ L<;K
M_P!(K&OR/KX'A;_D=9G_ (H?E,_2N,?^1!E'^"I^< HHHK[X_-0HHHH ****
M "BBB@ HHHH *_2+XW_$#POK?[4NL?#WQUXMA\96WB+Q]X?CTO0I8[J6+PI#
M'(OVC=)<1+%&LR.(BENSJ5<EBN*_-VKWB3Q-J7C+7+C5-8U"^U74KQM\]W>3
MM//.V ,L[$LQP ,D]J\7-,G6-J0G*3CRJ25K7NW%IWZ6Y=;6;VO:Y[V3YX\!
M2G",%+F<6[WM9*:::OK?FTNFEO:]CZL\&_$GQ=\6-1^.6A_%B\U"X\)^'-(O
M99;&[)DL/"VJ17 ALTM PVVL@=I(42(+O0NNU@"!B?ME>-OB79_'GX@?#K1X
M]87P38 6UAX;LK9KG2[;2E>(VMS';[2D;.#"_GHH??*?GRYSX5XV^.WCCXEZ
M#;Z7XD\9>*O$&EV<BRP6>I:M<7=O ZJ55E21RJD*S $#(!(Z&M/PI^TUXV\,
MQ:'93>(M:UKP[X?NK>ZM_#^I:E<S:0Q@D$D:-;B0+L#*#@8KCIY+4IU5748:
M?9^RG:/O+3XO=[+=:Z._H5<^IU:3P\IS5WK._O-7E>+U^'WN[U3]W5*/H'_!
M/:QO/!G[:VFVVH?VIH6H:38:]%<@0M'>Z?+'I%\'^1BA65&!^4E2&7!*]1O^
M&-3\,?$GPA\5O''BBZ\5?&2;P5HVF#29_%]S=6,\<D][Y)1U@O)6:%3*6VB8
M$_-C826KP2#XL^)[+XD7/C"UU_5K'Q5=W4][)JMG<O;79FFW>:XDC*E2^]P<
M8R&(Z'%6?%OQS\;>/S>?V]XP\5:U_:%O%:77V_5I[G[3#%(98XGWN=R)(2ZJ
M<A6)8 'FNC$Y76K8CV_,E>,$[-IKEFY22:5[23:TDO-,Y<)G%"AA?J_*Y6E4
MDKI-/F@HQ;3?+>+2EK%^31]%_%+X3_#GX5^!?B5XDM_ =EJ;6EYX8&C65]JM
M]]GTI=3TDWLZ$Q31R3*K$A=S[AM0DD!E:I\7?@%X+T&X^*_A&U\+PZ4_PT\/
MV&KV7BPWEVT^HSO]C!BN4>4VQ6Z^TN8A%'&R[4Y<!\_-VJ?$7Q!KFGW%G?:]
MK-Y:WAMVGAGO9)(YS;Q>3 64L0WE1?(F?N+\HP.*LZ[\7O%GBGP98^&]3\4>
M(M2\.Z6R/9:7=:E--96A5653'"S%$*JS*-H& Q'0FLJ64XN#BW6;M:_O2Z*&
MMKV?PRT>CY[N[5GM6SK!34DJ"5[V]V/5U-+VNOBC9K5<B2LG=?HYX@T&'Q/\
M?KRQN)M0@AG^,NO;GLKZ:QG7'AV-AMFA=)%Y'.UAD9!R"0?G63X/_#E/!7AO
M0?\ A!X/[:USX37_ (SFU[^UKS[1%?007<L>R'S/)V'[(0ZLC9\P;=FWYOG7
M_A>?C;^T_MO_  F'BK[8;V34C/\ VM/YINI(_*DGW;\^:T8"%_O%?E)QQ6<?
MB-XA,EN_]O:SNM=.?2(&^VR9ALG5U>U7YOEA99) 8Q\I$C CDYXL'PYB:"25
M:UDEHY+5<VKLU=:K1]M3OQO%.%Q$G*5"]Y-ZJ+T?)HKIV=HO5:J^A]+_ +0?
MPD^&WP5^"6N6<GA_PFOB;^S= &@W1\07%QKEQ/<VPGU![JRCNBEN8R0$\R!$
MP5 \PMD?)]?17Q8_;W;XE?"36_#4.A:W8C7M.T_3VLYO$/VGP_HZVOD$MIVG
M?9U%JSF #)ED*K(X!);=7SK7JY%1Q5.C)8R_,WUES?9BM-797OI?>[5DTCQN
M(J^#JXB+P-N1+I'E^U)V>BN[-:VVLG=IME%%%>V?/A1110 4444 %%%% !11
M10!Z)^R3XB\5>%?VF/!%[X*B:X\3IJ\$=E!DJMP7;8T;D XC=&97/92Q[5_0
M-&6,:[U56Q\P!R ?8\?RK\SO^"%G[)W]HZMJGQ<UBVS%8E]+T .O64C%Q<#_
M '5/E ]#OE'5:_3.OY]\3,SHXG,E0I)7I*S?=O6WI'\VS^F?";*:^$RJ6)K-
MVK/FC'HDM+^LOR2"BBBOSD_4S.\37TNGV"O"VQC(%)P#Q@^M8?\ PDU]_P ]
M_P#QQ?\ "M?QE_R"X_\ KJ/Y&N9KR<94G&I9-GK8.G"5.[2+_P#PDU]_SW_\
M<7_"C_A)K[_GO_XXO^%>1:]\0?%WC/XIZ_X9\&R^'=*7PI:6\E]>ZS8S7HN[
MFX5GBACCBFAV(J+N:0LQS(H"<$GF[_XO_$B_\8?$"/2X_!:6_@ 64DFE3VUS
M)+J/F6<5S/$EZ)46,_,ZH[6Q'W2R]16*G5?VG]YO[.G_ "K[CZ!_X2:^_P">
M_P#XXO\ A1_PDU]_SW_\<7_"OG/Q)^U%KAO/!NH:-?>"YK?QDFD7.G^%I1+)
MX@OK6\VF6<,)56)8E+MDQ.F(')=2=HGL_P!I#Q/=76D^)!#X?;P3K?C%O"EK
M:+;3#4/+$\MFMX9S)L^:YB)\DP B-OOY')S5?YG][%RTOY5]Q]"_\)-??\]_
M_'%_PH_X2:^_Y[_^.+_A7G7Q4^-UK\+?$'A_2/[%U_7M5\3O.EA:Z7%"S.T*
MJS[FEDC1 %;.YF"X4Y(. <*V_:OTK6M*T>31?#OBKQ!J6K6MS>-I-E!;K>6$
M=M,8)_.\V9(U99@8]JNQ9E.T, 34^TJO6[^\KV=+:R^X]B_X2:^_Y[_^.+_A
M1_PDU]_SW_\ '%_PKRGPI^TSI/Q!\1Z5I_AW2=<UI=2TVVU:6YB6WMXK"VN)
M)(T>59YHY&PT,@81)(5*X(R0#PWP\_:VU[QE\3?!.CP^'[C5-*\36&HW-Q?Q
M6D%FRM;WBVX=8WO7*QQ@GS =[OE2BGYD6N:KW?WB]G2[+[CZ/_X2:^_Y[_\
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M^(Z*/]4<K_DE_P"#*G_R8?Z[YO\ SQ_\%4O_ ) ^W/\ AZ3\'_\ HTOX:_\
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M^(Z*/]4<K_DE_P"#*G_R8?Z[YO\ SQ_\%4O_ ) ^W/\ AZ3\'_\ HTOX:_\
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M^(Z*/]4<K_DE_P"#*G_R8?Z[YO\ SQ_\%4O_ ) ^W/\ AZ3\'_\ HTOX:_\
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M^(Z*/]4<K_DE_P"#*G_R8?Z[YO\ SQ_\%4O_ ) ^W/\ AZ3\'_\ HTOX:_\
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M&E_#7_ONR_\ E?7Q'11_JCE?\DO_  94_P#DP_UWS?\ GC_X*I?_ "!]N?\
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MZM2+MWLYIV\[&LN(.);M1BI6=KQHTI*_:\8-7U6ESZ*_X>D_!_\ Z-+^&O\
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M[DY.<<HX?:3;:;=K.K4O=NRTY[HTEG?$R<DDFHJ[:HTK62N]>2S_ . >Z?\
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MO^>EO_WT?\*/^$-NO^>EO_WT?\*/9U^PO;4>YYY\6/A=_P +0_X1G_3OL/\
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M4?ZW97_/+_P74_\ D _U(S?^2/\ X-I?_)GQ'7[<_P#!7G_E'?\ $+_N&_\
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M)") ZQDD9 'S$?,>Z_X=O_\ 5>OV;/\ PMO_ +31_P .W_\ JO7[-G_A;?\
MVFMH8_+8)P59\EFN6SMKVTOIK;U[)&%3+LUFU4="/.G%\UXWT[^];72^VW=L
MOZW^V#X=N?C?J?BZZ\9?%+QE:W^G:]8VFGZWI\2+HJW]K-%$D#&_F&Q6D0,
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M0HB)#-)@JL*@Y8[CEOE!"+V/_#M__JO7[-G_ (6W_P!IH_X=O_\ 5>OV;/\
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M?%#Q'X2AAO%U+PQ:6-Y=2.BB"1+OS_+"$,6)'V=]V5 &5P3SCF?@[^U-X?\
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MU_[95/Q&HHHK]+/R<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ=S%>ZC#;O;VAD\H7#AV!6(R?)O.%W<9SQ4^E_$;P]KGB,Z/9:]HUYJXLTU
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MQX?L/$*6ZZA8V=\MG<)=P"XA640S(<I(NX':ZGD,.0>E7*** "BBB@ HHHH
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M^?$?O8?\08P7_03/[D?S^_\ #&?Q@_Z)3\2O_"8O?_C5'_#&?Q@_Z)3\2O\
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M_$&,%_T$S^Y'\_O_  QG\8/^B4_$K_PF+W_XU1_PQG\8/^B4_$K_ ,)B]_\
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M?]!,_N1_/[_PQG\8/^B4_$K_ ,)B]_\ C5'_  QG\8/^B4_$K_PF+W_XU7]
M5%'_ !%?%_\ /B/WL/\ B#&"_P"@F?W(_G]_X8S^,'_1*?B5_P"$Q>__ !JC
M_AC/XP?]$I^)7_A,7O\ \:K^@*BC_B*^+_Y\1^]A_P 08P7_ $$S^Y'\_O\
MPQG\8/\ HE/Q*_\ "8O?_C5'_#&?Q@_Z)3\2O_"8O?\ XU7] 5%'_$5\7_SX
MC][#_B#&"_Z"9_<CX^_X(H?#/Q)\*OV5_$&G^*/#^N>&]0F\5W%Q';:K8RV<
MTD1L[-1($D525+*PR!C*D=C7XZ5_2917DY/Q]+!8S$XN=#F=9Q=E*UK7_NN]
M[^1[.>>&\<?@<)@88CD6'4E=QYG+FY?[T;6MY[G\V=%?TF45]%_Q%K_J%_\
M*G_VA\O_ ,04_P"HS_RG_P#=#^;.BOZ3**/^(M?]0O\ Y4_^T#_B"G_49_Y3
M_P#NA_-G17])E%'_ !%K_J%_\J?_ &@?\04_ZC/_ "G_ /=#^;.BOZ3**/\
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M "9_\5O^Q.U?_P!(IJ_G]K]<\.,CP&.PU:>+I*;4DE?IH?B?BIQ!F.78JA#
MUG!2BV[=7<^W/^']GQ@_Z%OX:_\ @OO?_DNC_A_9\8/^A;^&O_@OO?\ Y+KX
MCHK]&_U-R7_H&C^/^9^5_P"O6?\ _05/\/\ (^W/^']GQ@_Z%OX:_P#@OO?_
M )+H_P"']GQ@_P"A;^&O_@OO?_DNOB.BC_4W)?\ H&C^/^8?Z]9__P!!4_P_
MR/MS_A_9\8/^A;^&O_@OO?\ Y+H_X?V?&#_H6_AK_P""^]_^2Z^(Z*/]3<E_
MZ!H_C_F'^O6?_P#05/\ #_(^W/\ A_9\8/\ H6_AK_X+[W_Y+H_X?V?&#_H6
M_AK_ ."^]_\ DNOB.BC_ %-R7_H&C^/^8?Z]9_\ ]!4_P_R/MS_A_9\8/^A;
M^&O_ (+[W_Y+H_X?V?&#_H6_AK_X+[W_ .2Z^(Z*/]3<E_Z!H_C_ )A_KUG_
M /T%3_#_ "/MS_A_9\8/^A;^&O\ X+[W_P"2Z/\ A_9\8/\ H6_AK_X+[W_Y
M+KXCHH_U-R7_ *!H_C_F'^O6?_\ 05/\/\C[<_X?V?&#_H6_AK_X+[W_ .2Z
M/^']GQ@_Z%OX:_\ @OO?_DNOB.BC_4W)?^@:/X_YA_KUG_\ T%3_  _R/MS_
M (?V?&#_ *%OX:_^"^]_^2Z/^']GQ@_Z%OX:_P#@OO?_ )+KXCHH_P!3<E_Z
M!H_C_F'^O6?_ /05/\/\C[<_X?V?&#_H6_AK_P""^]_^2Z/^']GQ@_Z%OX:_
M^"^]_P#DNOB.BC_4W)?^@:/X_P"8?Z]9_P#]!4_P_P C[<_X?V?&#_H6_AK_
M ."^]_\ DNC_ (?V?&#_ *%OX:_^"^]_^2Z^(Z*/]3<E_P"@:/X_YA_KUG__
M $%3_#_(^W/^']GQ@_Z%OX:_^"^]_P#DNC_A_9\8/^A;^&O_ (+[W_Y+KXCH
MH_U-R7_H&C^/^8?Z]9__ -!4_P /\C[<_P"']GQ@_P"A;^&O_@OO?_DNC_A_
M9\8/^A;^&O\ X+[W_P"2Z^(Z*/\ 4W)?^@:/X_YA_KUG_P#T%3_#_(^W/^']
MGQ@_Z%OX:_\ @OO?_DNC_A_9\8/^A;^&O_@OO?\ Y+KXCHH_U-R7_H&C^/\
MF'^O6?\ _05/\/\ (^W/^']GQ@_Z%OX:_P#@OO?_ )+H_P"']GQ@_P"A;^&O
M_@OO?_DNOB.BC_4W)?\ H&C^/^8?Z]9__P!!4_P_R/MS_A_9\8/^A;^&O_@O
MO?\ Y+H_X?V?&#_H6_AK_P""^]_^2Z^(Z*/]3<E_Z!H_C_F'^O6?_P#05/\
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MU_\ !?>__)=?$=.A02S*K.L:L0"[9VK[G )X]@31_J=DO_0-'\?\P_UZS_\
MZ"I?>O\ (^VO^']GQ@_Z%OX:_P#@OO?_ )+H_P"']GQ@_P"A;^&O_@OO?_DN
MO)/VD?V6_#OPZ\=Z/X?T$>(-)MM2N66S\4^(;^V?P[XBL?)CE-_;7$4:!%4.
M"84-PY$BKD2CRWW?@/\ L;:+IWC;4+SQ=X@\&Z[H,/@>\\7:/)OU9=-U55,L
M >4PP1W2QP2QL9$'ERDA-H<%A7CRRKAM8=8CZNK-722;;]-;7?:_>]K.WNQS
MCBIXEX7ZT[IV;;22];J]EWM9W5KW5^^_X?V?&#_H6_AK_P""^]_^2Z/^']GQ
M@_Z%OX:_^"^]_P#DNO#K_P#8XU;4["?5$U[P3IL\VDCQ6=#BFOWFL=&DF"K=
MY,+CREC=9?+,KW/E8)C+9%;/[4_[$MG\(?$/CB;PGXITO7-'\#PZ9-J%G,]Q
M_:EJEXD05VW6T4+IYLB\QL2JRQ _-N TCD_#3J1I*A&[\G;>*WVU<DET?1F4
ML\XLC2E6>(E:/FK[2EMOHHMM;KJCUC_A_9\8/^A;^&O_ (+[W_Y+H_X?V?&#
M_H6_AK_X+[W_ .2Z\.^%_P"S3!H?[<.@_#+QDC:U#'K$%CJL6AO+-N)0.\6Y
M4W@(3ME*KE DA!^4-5O]L_X-Z9\,-2TNPT_PW;Z)XDT.U6'QE!HKWMUH>G74
M\DDEG&DUT\C^;); ,V)&C.!L.5D K^P^'GB(8>.&BW.*DFEI9WL][[JVV[BN
MJ%_K!Q.L-/%2Q4DH2<6F]>96NMK7LV]]HR>R9[-_P_L^,'_0M_#7_P %][_\
MET?\/[/C!_T+?PU_\%][_P#)=><_ G]E+P3\1O!7PMAU0>,6\0_%;4=6TVWO
M=/O(/L>B-:^4L<TELT#//&#+ODQ/%A$8@USVI_!SX<?!2R\$6?CY_%FK:IXP
ML8M:NKS0=2M[>ST2PGE*0E4DMY7NY=B/*RAH1AD0$G+UG_8_#SJ.E'"IR3>B
M6KLY)M:[)QDM;/31:J^CSSB>--5IXQJ+2=V]%=1:3TW:G%Z76KN]';V?_A_9
M\8/^A;^&O_@OO?\ Y+H_X?V?&#_H6_AK_P""^]_^2Z\K^*?[*WA?]DZSD;XB
M_P#"2^([K4/$.HZ1IEMH-_;Z:!:6,BQR7DLDL-Q\TK2)LA"C 5RT@.%KP'7D
ML8M<O%TN6ZGTU9W%I)=1+%/)#N.QI$5F57*X)4,P!R 3UKJP?#F08J//1PT7
M'I*VCMH[:WT>FJ7E<X\=Q3Q)A)>SKXJ2GUC=75]5?2VJUT;\['VE_P /[/C!
M_P!"W\-?_!?>_P#R71_P_L^,'_0M_#7_ ,%][_\ )=<_!_P3R\,^(?$/Q8T'
M2]9UN+6_#%OH">%H[F>#R]2OK_3Y+QK:8[%&9&B,,1#)M:1-V_H>;L/V3_!7
MAWPI/KFN+XMOH;#X;V7C"XLK348+*5[R;4OL;1"1[:4)&JD-@HS9!^;T\^.
MX9EI'#IOW=+:^^DX[NVM_ON>G+,N+8ZSQ+2][6ZM[DG&6ROHXWVU5K;GHG_#
M^SXP?]"W\-?_  7WO_R71_P_L^,'_0M_#7_P7WO_ ,EU\X_'OX/Z+X0\&^"O
M&7A6XU0^&?'5K<-!9:HZ27VF75K((KF%Y(U1)DW,KI*$0LKX**5)/5?%[]DW
M2_ ?[,^A>*=.U._O/%=E'97'BW3G*-%ID.I1R3:>R@ /'^ZC4/O+9:>/&T?>
M[/[!X=M!O#Q]]N*T>C3LT^UI>[?:[2ZG#_K%Q1>HEB9>Y%2>JU32::TUO'WK
M;\J;:T9[)_P_L^,'_0M_#7_P7WO_ ,ET?\/[/C!_T+?PU_\ !?>__)=>.>*_
M^"?/BCPSXFU#1(O$O@K5M9T35]/TC5[.QN;IFTEKZ016TTC/;HCQ%FC#>2TC
MH9%#(IW (_\ P3\\37/C+3]#TSQ1X&UN]NO$8\)WAL;RY:/2-1:-Y%BG+P+D
M,L4H#P^8N8G&01BLUE/"[7-[.%K7V>UD[^C337>ZM>Z-'G7%Z?+[6=[VW6]V
MK>;33371IWM9GLG_  _L^,'_ $+?PU_\%][_ /)='_#^SXP?]"W\-?\ P7WO
M_P EUX+9_L@M<0W%[)\1OAQ:Z##JD>AIK<MQ?G3[B_969K='6T+$1H S3%1
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M&W$Y;!7(Q0\(?LHZ/X,\;:+K%OKGB6:W\-W6H7>E:7-+;FSLFO3(;@ K")I
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M_P#Z&3XE?^#"R_\ D2C_ (<)_!__ *&3XE?^#"R_^1*/^(E9+_-+_P !8?\
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MZ3?\0]7_ %5[_P M7_[LH_XAZO\ JKW_ ):O_P!V4?\ $0,@_P"?_P#Y)/\
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M%KHL6GR^(M2:]N9HIQ(?M3;P;B+CI++("0,KP"(_$7[+GQ(T/XI_&F[\(P^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!7U/4X]*@621796;;\H^O\ A5'_ (3*U_YYW'_?
M(_QH\9?\@N/_ *ZC^1KF:\[$XJ<)\L3T<+AH3AS2.F_X3*U_YYW'_?(_QH_X
M3*U_YYW'_?(_QK@],\<Z7K'C#5=!M[KS-6T2&WN+V#RW7R8Y_,\H[B-K;O*D
MX4DC;SC(R>!?'.E_$OP?IVO:)=?;=)U:$7%K/Y;Q^;&>AVN P^A -8?7*O\
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MKL// 81<V]W )H)D5OG"D;E(=58/&X*\ E;;XR:--<^,/,:XM['P.0NIW\B
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M-?>NYWR\3N)HMJ6%A=*[_=U-%KJ_?VT?W/LS];_^'O/[._\ T4+_ ,H6I_\
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M^X76\6N(*23JT*<4]KPFK^EYZ[H_;G_A[S^SO_T4+_RA:G_\CT?\/>?V=_\
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M_P#T4+_RA:G_ /(]'_#WG]G?_HH7_E"U/_Y'K\1J*/\ B%>4_P#/RI]\?_D
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M^%.MWGP_\:6?C+PEXB\7>-;OP7I-IH%[:Z9+J317,5HXO!'<Q@K _P!H\QY
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M,YQC:PY1BW>Y\L:5^S[_ ,(AK\^J:3X/NK.^TOXKVL>ER06$B_8-&8PF;[.
M,16A,UP7\L",DMNSMXYOX!^$[77-'\(W'AOPGK5OXMM_$&MS:OK[:7*+:XT[
M_3HS%]J(*2*S-#&D*DE9$+;5P6/W%_95U_S[7'_?LUD>!_AC:?#?PU#H^BZ9
M<6>G022RI#F23:TLKRR'<Y+<N['KQG P,"G[2=M4R?9POHT?)'@+X!^(O _P
MQ\!2>#] U'P_XOU;X=ZO9:G=""2WF-_Y%L;1+F1L;)%D+B,R$% N!\J;17^(
M'PQ76_ GB0?#SP-XF\/Z1-X-@L]2L3HMSI\U_J/VVW>+]TT:/<3Q1+<[YT#9
M\P?.:^UO[*NO^?:X_P"_9H_LJZ_Y]KC_ +]FCVL[WL/V<+6N?'/Q/_9KA\-W
M7Q8F\-^#;N)M%71;[PFMG92LMO>9C-Q/9A1CSSY$/F21_O#L&YCDYN:EI&N:
MI^UYH^J6O@^ZTNXM?&$R7=]%X<OGN9M.%I)$)9M6>0PR6\K%"MLB8B 494H=
MWUU_95U_S[7'_?LT?V5=?\^UQ_W[-'M)]5_6@^2'1GSK\? 8_C-XX\S[LWPH
MO?L_']R>7S<?]]P_I7DOAOP!?:W\,!<_#OPCXDT61_ *6_B.3[%+8RZ_=/<V
ML@6*5ROVF8PI?$3H\@VSHNX%EK[$\:?!C2_B%=V]QK&D7%U-:VMU91,'EB*P
MW,8CG3Y",AU"]<X*@C! -:GA_P &_P#"+Z#8Z98V-Q!8Z=;QVMO'M=O+C10J
MKELDX  R231&<DM$Q.,6]6CY7U[X7:+KK>,&\/Z'KG@WX?WL6E*+./P7>O!J
M&J6\[S,YTE8EE>V,/DQRDHB2<#<3'D2?"7X>VO\ PNKX=^*=>^&-AH/VSPW=
M642Z?X6=8-/U"._B^SRM&L;-9EX-TBF8KY89T+Y!S]8?V5=?\^UQ_P!^S1_9
M5U_S[7'_ '[-+VD[6L_Z0^6%[W1\H_M:>$=0UGXU>+/WOQ L=/UGX?PZ9"WA
M[0)=0AU2<7-\QM9I$MI?+!#ID*\1VR<N <B;XM?#[QE+K>GV-OH,UI'\7/#^
MGZ%XH&E0F2WT*X@EC%Q(S+D)&;.>ZB4[L$PQC/(-?5']E77_ #[7'_?LT?V5
M=?\ /M<?]^S0IS5M <8N^IY!X=LTA_;)UJ.QCBCLM.\$Z=:SQQ* D+&\O#"F
M!PN$$A"^C#M7EVI:;X@\5?#KQGX2T'2CJE_XE^)E[::GO>2WMX+$,ES)YTZH
M_E*]ND<08JQ/G#:K'BOIO1OAM:^'_$.L:K9Z;/%J&OR12W\Q\QC.T<2Q)P20
MH5% VJ ,DG&6))H_PUMM!\2:QJUGIMQ#J&O-$]_(/,(N&BC$:-M)V@A %RH!
M(49S@8GWM[=BM.Y\J:IX!\>%KCPI?:/J&CK%\1=.\1:==Z&KZA:Z?:W4LDLY
MBFFMQ'^YG$CL'B 7S1E2I!._\;O@?XDU;XL0W-K=:[X@U3P_X/N-0TK6;VTA
M&[4H-2MKFW@9H(HH=SB,IM"9*,V0W.?J'^RKK_GVN/\ OV:/[*NO^?:X_P"_
M9I\T[WL%H6M<^6_AYX5UV\^./@OXC:UH.N6=UXBCU[4M2A>QE>71K?R;2*RM
M) JDB3R8<[,!FD:0 $YSJ_!SQVVD:7\5I&TOXB::VK>*)M3M)[?PG>)="UF2
MSMQ<0I<6Y21D8.YCVO)MC8B-N ?H_P#LJZ_Y]KC_ +]FC^RKK_GVN/\ OV:5
MY/= N5;,^>_@'X=\:>7XPDT.\BTVUOM=-W%K?BOPQ<?VEKP:! [RVXFM3'Y;
M 1(1'&I2,8C!R[6O%'B/[7^V7I\D>G>+([6/PM?: VHQ^'-0:UAO)[RS>,>>
M(?+V[8W;S WEKMY<5[U_95U_S[7'_?LT?V5=?\^UQ_W[-+WKWL.\;6N?)?PR
ML-:TK0OA'ITGA?Q=%J7PGL=3EUT)I,B!WCL9K54M99%6&Z>:1P\?E,X(&6Q1
MK"7$'ACXW:M=?\))K&AZAX+DBDU[Q-HSZ3J$TZP3HME'$T5NK0J&W I I,DQ
M!>0X"_6G]E77_/M<?]^S65XS^&UM\0?#\FE:QIL]YI\TD4LD)\Q [12K*F2I
M!(WHI*YPP!!!!(-<TK[?U>XO=MN5?A_:W5CX#T2&^W?;8;"!+C(P?,$:AOUS
M6O5C^RKK_GVN/^_9H_LJZ_Y]KC_OV:QY9=C3GCW*]%6/[*NO^?:X_P"_9H_L
MJZ_Y]KC_ +]FCDEV#GCW*]%6/[*NO^?:X_[]FC^RKK_GVN/^_9HY)=@YX]SM
M****^B/G3S7]LS_DS_XK?]B=J_\ Z135_/[7]"O[3/A#4?B#^S?\0= T>W^V
M:MKGAK4=/LH/,6/SIY;62.--S$*N68#+$ 9Y(%?C[_PZ&_:(_P"B>_\ E=TS
M_P"2*_8O#/-,'A<+6CB:L8-R5N:25]/-H_"_%K*,=C,7AY82C.HE%W<8RE;7
MK9,^;**^D_\ AT-^T1_T3W_RNZ9_\D4?\.AOVB/^B>_^5W3/_DBOTW_6/*?^
M@JG_ .!Q_P S\E_U6SK_ * ZO_@N?^1\V45])_\ #H;]HC_HGO\ Y7=,_P#D
MBC_AT-^T1_T3W_RNZ9_\D4?ZQY3_ -!5/_P./^8?ZK9U_P! =7_P7/\ R/FR
MBOI/_AT-^T1_T3W_ ,KNF?\ R11_PZ&_:(_Z)[_Y7=,_^2*/]8\I_P"@JG_X
M''_,/]5LZ_Z ZO\ X+G_ )'S917TG_PZ&_:(_P"B>_\ E=TS_P"2*/\ AT-^
MT1_T3W_RNZ9_\D4?ZQY3_P!!5/\ \#C_ )A_JMG7_0'5_P#!<_\ (^;**^D_
M^'0W[1'_ $3W_P KNF?_ "11_P .AOVB/^B>_P#E=TS_ .2*/]8\I_Z"J?\
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MY'S917TG_P .AOVB/^B>_P#E=TS_ .2*/^'0W[1'_1/?_*[IG_R11_K'E/\
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MC/XP?]$I^)7_ (3%[_\ &J/^&,_C!_T2GXE?^$Q>_P#QJC^TL)_S]C_X$O\
M,/[+QO\ SYG_ . O_(\UHKTK_AC/XP?]$I^)7_A,7O\ \:H_X8S^,'_1*?B5
M_P"$Q>__ !JC^TL)_P _8_\ @2_S#^R\;_SYG_X"_P#(\UHKTK_AC/XP?]$I
M^)7_ (3%[_\ &J/^&,_C!_T2GXE?^$Q>_P#QJC^TL)_S]C_X$O\ ,/[+QO\
MSYG_ . O_(]^^-O[7W@_X;?M%ZM<^'M+?6&US_A&DUW6XM8AU"UN;*SBL9Y;
M>TMTB18Y#)!&CM)-+S$X 0L=N.MGIOPR_:%^)/Q2N/&?@K6/"NL66N7&F06V
MMV]U>>(SJ=O/';V\EDK_ &F$AKE7E$\2!#"P/.W/C/\ PQG\8/\ HE/Q*_\
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M+;:7]GU)5>,1NQAM_GB58"5,1/,<?F+O\._X8S^,'_1*?B5_X3%[_P#&J/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_/Q<?\ ?PT?VK=?\_%Q_P!_#6?]H1[&G]GR[FWI?PY\/Z'_ &7]BT'1K/\
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M_P !9^N%%?D?_P /[/C!_P!"W\-?_!?>_P#R71_P_L^,'_0M_#7_ ,%][_\
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M  _L^,'_ $+?PU_\%][_ /)='_$-<Z_EC_X$@_XBOD'\T_\ P%GZX45^1_\
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M_0M_#7_P7WO_ ,ET?\0USK^6/_@2#_B*^0?S3_\  6?KA17Y'_\ #^SXP?\
M0M_#7_P7WO\ \ET?\/[/C!_T+?PU_P#!?>__ "71_P 0USK^6/\ X$@_XBOD
M'\T__ 6?KA17Y'_\/[/C!_T+?PU_\%][_P#)='_#^SXP?]"W\-?_  7WO_R7
M1_Q#7.OY8_\ @2#_ (BOD'\T_P#P%GZX45^1_P#P_L^,'_0M_#7_ ,%][_\
M)='_  _L^,'_ $+?PU_\%][_ /)='_$-<Z_EC_X$@_XBOD'\T_\ P%GZX45^
M1_\ P_L^,'_0M_#7_P %][_\ET?\/[/C!_T+?PU_\%][_P#)='_$-<Z_EC_X
M$@_XBOD'\T__  %GZX45^1__  _L^,'_ $+?PU_\%][_ /)='_#^SXP?]"W\
M-?\ P7WO_P ET?\ $-<Z_EC_ .!(/^(KY!_-/_P%GZX45^1__#^SXP?]"W\-
M?_!?>_\ R71_P_L^,'_0M_#7_P %][_\ET?\0USK^6/_ ($@_P"(KY!_-/\
M\!9^N%%?D?\ \/[/C!_T+?PU_P#!?>__ "77LG["G_!9#Q)\>OVAM+\'>/M+
M\)Z78^(%:UT^ZTN"XA9;PX,:/YDT@*O@H, '>R<XS7/C/#_.,/1E7G%-13;L
M[NRWT.K ^)F1XK$0PU.<E*;25XV5WM=]#]#****^)/T **** "BBB@ HHHH
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M+?SV['1;.=!'(+<K"I,A147S)O,?" 9P6#%Z7;\PM4MN9R_M/Z_#J/@^QO\
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M--N=*N9+=E6:.*>)HG*%@P#!6)!((SC(/2OC_P#X<)_!_P#Z&3XE?^#"R_\
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M867_ ,B5]N44?ZY9U_T$R_#_ "#_ %%R#_H%C^/^9\1_\.$_@_\ ]#)\2O\
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MM7_[LH_XAZO^JO?^6K_]V5^DU%'_ !$#/_\ G_\ ^20_^1#_ (AGPW_T#?\
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M_P F?FS_ ,0]7_57O_+5_P#NRC_B'J_ZJ]_Y:O\ ]V5^DU%'_$0,_P#^?_\
MY)#_ .1#_B&?#?\ T#?^3U/_ ),_-G_B'J_ZJ]_Y:O\ ]V4?\0]7_57O_+5_
M^[*_2:BC_B(&?_\ /_\ \DA_\B'_ !#/AO\ Z!O_ ">I_P#)GYL_\0]7_57O
M_+5_^[*/^(>K_JKW_EJ__=E?I-11_P 1 S__ )__ /DD/_D0_P"(9\-_] W_
M )/4_P#DS\V?^(>K_JKW_EJ__=E'_$/5_P!5>_\ +5_^[*_2:BC_ (B!G_\
MS_\ _)(?_(A_Q#/AO_H&_P#)ZG_R9^;/_$/5_P!5>_\ +5_^[*/^(>K_ *J]
M_P"6K_\ =E?I-11_Q$#/_P#G_P#^20_^1#_B&?#?_0-_Y/4_^3/S9_XAZO\
MJKW_ ):O_P!V4?\ $/5_U5[_ ,M7_P"[*_2:BC_B(&?_ //_ /\ )(?_ "(?
M\0SX;_Z!O_)ZG_R9^;/_ !#U?]5>_P#+5_\ NRC_ (AZO^JO?^6K_P#=E?I-
M11_Q$#/_ /G_ /\ DD/_ )$/^(9\-_\ 0-_Y/4_^3/S9_P"(>K_JKW_EJ_\
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M07&E:9!;/#*$D6WD\NY^XJ, X4%GR&50?J7_ (2:Q_Y[_P#CC?X4?\)-8_\
M/?\ \<;_  K;_6W$N"ISE%Q71I6WC+7OK%/YONS!<%X.,W5A&<9/JFT_AE'3
ML[2:T[+LCYGTW]C[Q?X(O/A7KGA/0_ VAZE\+(M1TJUT.;Q!=75C>VEW;8^T
M-=_84D6X%P2S)Y)5U9CYBDXJUX@_9TO_ -G[_@FHG@W[4NM7W@VW@UBYDMU*
M+*;?4$U&=8P>2JA'51U8*.,G%?1W_"36/_/?_P <;_"C_A)K'_GO_P".-_A7
M%C,^J8FE[&I)6O??7>35VVV[.<GWUU;LK>A@>':6$K>WI1=[6\MH)V222NJ<
M%HK+ET2N[\3KW@&X\??'+X=^.M-O-/FT/0](U2*0[V\RX^VBS:%XP%*E<0,2
M2P/S+@')QYQI'[,_CZP\2>$M+:;P?_PA_@_QU?\ BR"Y%W<'4KN&Y>]D6)H_
M)$:/&UZX)#L' 4_)M(?WW_A)K'_GO_XXW^%'_"36/_/?_P <;_"O*]M3_F7W
MGL^RJ?RO[CQ'X-_LL>(/AY_PIO[;>:-+_P *\L]7M]1\B61O.:[V^7Y.8QN
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MR_\ CE 'HU%><_\ #8GPC_Z*G\.?_"ELO_CE'_#8GPC_ .BI_#G_ ,*6R_\
MCE 'HU%><_\ #8GPC_Z*G\.?_"ELO_CE'_#8GPC_ .BI_#G_ ,*6R_\ CE '
MHU%><_\ #8GPC_Z*G\.?_"ELO_CE'_#8GPC_ .BI_#G_ ,*6R_\ CE 'HU%>
M<_\ #8GPC_Z*G\.?_"ELO_CE'_#8GPC_ .BI_#G_ ,*6R_\ CE 'HU%><_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ? _\
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M7*_!+X70_!;X4Z'X7ANI+_\ LFWV37<B;&O)F8O+,5R0I>1G? )QNQDUU5(
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK[_GO_XXO^%'_"37W_/?_P <7_"J%%'MJG\S^\/8T_Y5]Q?_ .$FOO\ GO\
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M /)=?$=%'^IN2_\ 0-'\?\P_UZS_ /Z"I_A_D?;G_#^SXP?]"W\-?_!?>_\
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M/C!_T+?PU_\ !?>__)='_#^SXP?]"W\-?_!?>_\ R77Q'11_J;DO_0-'\?\
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M/*:^2^BNHV4?.?+*"Y)S\V=G09X^@?\ A"?^GK_R'_\ 7H_X0G_IZ_\ (?\
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MV4?\0]7_ %5[_P M7_[LH_XB!D'_ #__ /))_P#R(?\ $,^)/^@;_P GI_\
MR9^;-%?I-_Q#U?\ 57O_ "U?_NRC_B'J_P"JO?\ EJ__ '91_P 1 R#_ )__
M /DD_P#Y$/\ B&?$G_0-_P"3T_\ Y,_-FBOTF_XAZO\ JKW_ ):O_P!V4?\
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MZTW0Y-!U#Q)X@T;Q#:W,>H><VF2Z=:O @'[I=Y9F#[OEV[<8;K7U5_Q#U?\
M57O_ "U?_NRC_B'J_P"JO?\ EJ__ '93_P!:N%7R_O%[NB]VIWB]?=UUC'>^
MWFQ+@[C)<R]D_>U?OT^TEI[VFDI;6WONE;YY^)G_  4-TCXT7/B5/$?@"ZCT
M_P 5>'M-T6\@T?7DLWCEM+Q[PSQ-):2JJR2-CRRAVKD!CP1XS\;/C-'\44\.
MZ;I>D_\ "/\ ACPCI_\ 9VDZ>;G[5*H9VEFFFEVH))I979F941?N@* HK[L_
MXAZO^JO?^6K_ /=E'_$/5_U5[_RU?_NREA.*.%<,TZ%6UMM*K5[*-[--7LK7
MWMZL>-X/XQQ::Q%&]]]:*;5W*UTT[<SO:]K^B/S9HK])O^(>K_JKW_EJ_P#W
M91_Q#U?]5>_\M7_[LKTO^(@9!_S_ /\ R2?_ ,B>3_Q#/B3_ *!O_)Z?_P F
M?FS17Z3?\0]7_57O_+5_^[*/^(>K_JKW_EJ__=E'_$0,@_Y__P#DD_\ Y$/^
M(9\2?] W_D]/_P"3/S9HK])O^(>K_JKW_EJ__=E'_$/5_P!5>_\ +5_^[*/^
M(@9!_P __P#R2?\ \B'_ !#/B3_H&_\ )Z?_ ,F?FS17Z3?\0]7_ %5[_P M
M7_[LH_XAZO\ JKW_ ):O_P!V4?\ $0,@_P"?_P#Y)/\ ^1#_ (AGQ)_T#?\
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M^+ES9^#=0\;Q^.=>FOO %[X2\2)HNK:/=ZM$\U]-*5DDU,M$\<MO*D9>&3S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/_/?_P <;_"N2HH^OU.R_KYA]0I]W_7R.\HHHKUCR0KSG_AL3X1_]%3^'/\
MX4ME_P#'*]&K^<NFE<#][O\ AL3X1_\ 14_AS_X4ME_\<H_X;$^$?_14_AS_
M .%+9?\ QROP1HI\H'[W?\-B?"/_ **G\.?_  I;+_XY1_PV)\(_^BI_#G_P
MI;+_ ..5^"-%'*!^]W_#8GPC_P"BI_#G_P *6R_^.4?\-B?"/_HJ?PY_\*6R
M_P#CE?@C11R@?O=_PV)\(_\ HJ?PY_\ "ELO_CE'_#8GPC_Z*G\.?_"ELO\
MXY7X(T4<H'[W?\-B?"/_ **G\.?_  I;+_XY1_PV)\(_^BI_#G_PI;+_ ..5
M^"-%'*!^]W_#8GPC_P"BI_#G_P *6R_^.4?\-B?"/_HJ?PY_\*6R_P#CE?@C
M11R@?O=_PV)\(_\ HJ?PY_\ "ELO_CE'_#8GPC_Z*G\.?_"ELO\ XY7XK7_[
M*/CS3O J^(GTBSDT]M)37O*AU:SFOET]V"B[-HDIN%ARPRYC"KU) !KSJCE
M_>[_ (;$^$?_ $5/X<_^%+9?_'*/^&Q/A'_T5/X<_P#A2V7_ ,<K\$:]$UC]
MD[XA:#9>,+BY\-SK#X!%JVO-'<PR_81<KOB.%<F0%?F)CW;!RVT4<H'[5?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA\V%?SEU_1I7XL?\.EOV@O\ HG__ )7--_\ DBJB!\Y45]&_\.EOV@O^B?\
M_E<TW_Y(H_X=+?M!?]$__P#*YIO_ ,D55P/G*BOHW_ATM^T%_P!$_P#_ "N:
M;_\ )%'_  Z6_:"_Z)__ .5S3?\ Y(HN!\Y45]&_\.EOV@O^B?\ _E<TW_Y(
MH_X=+?M!?]$__P#*YIO_ ,D47 ^<J*^C?^'2W[07_1/_ /RN:;_\D4?\.EOV
M@O\ HG__ )7--_\ DBBX'SE17T;_ ,.EOV@O^B?_ /E<TW_Y(H_X=+?M!?\
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MJ:EX \/:U8:YJVDW>O:E!-_9-P+.RANXA';_ &A7229;J%,&=]C1R >8650
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M WC"V\[2?&?A/5(?M<=AOL]7MYU^TR9\N'*N1YCX.U/O-@X!K4_X6'X?P_\
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M&-XB\/S>'H/AQX%\1:)J]Q=7MO)$'ETV*&"9/L\DCM'(X(&%\Q=IW(/E)O\
M@O1/%MDNOZ/#I.K?\+&GA\.W\UK-HVDV<JZ+9RM D]C&]Y>6JWR,LK;KF5!G
M;LC'EC/V/J.G6^L:?<6=Y;PW5K=1M#-#,@DCF1AAE93PRD$@@\$&L7P#\)/"
MOPH@N8_"WAGP_P"&X[UE:X32M.ALUG*Y"EQ&J[B,G&>F32L',?,O@KX$?$+P
MMI>@:]>>'=<U;4-)^)U_XFEL)KW3!J5S87-E+")F:.2.T$P>12\:,JYW[<@
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M"NE^-M!N-+UK3;#5]+O%"W%G>VZ7%O. 00&1P589 /(Z@56\$?#W0/AGHO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>afmd20191231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M'_H,V'_@0G^-'_"3:#_T&;#_ ,"$_P :\ \F+_GFOY4>3%_SS7\J/[+A_-^
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MP(*7ERI]V#?H10!<HJD&O8#\P2XCSU4;7'X=#^E3V]S'<QED)X.&##!4^A%
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M$EXKE]IW[P>@PW% '4]JY/Q!_P CQX4_W[G_ -%UUG85R?B#_D>/"G^_<_\
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M?DM<'K$%O!J>H1RLZ72.HLD@7]VZX'7C\Z[;_A$;/_GUA_7_ !I?^$2M./\
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M;V]NK1W<<LGFX9%<'Y2>#5.\A6VO9H$?<J/A6R#D?A4QJ*03@X[D*D"12P!
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M%%% !1110 4444 <K\0_^1*OO]Z/_P!#%=+#_J8_]T?RKFOB'_R)=]_O1_\
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M4>C2OI.KVUH)F=Y#MGC'*IZ8]_6D\3:?+;0X/K'O\MM#OZ*:.E.KJ.D****
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MQ47\3*+VTZ-M\IR< _*,]>G2D,$P5B89 %/S':>/K5Z+6[F%555 "E2,,1T
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M?9;?_GC'_P!\"G_:G]W\0_LC^\?.'GK[_P#?)H\]??\ [Y-?1_V6W_YXQ_\
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MAI7<SU_S$_O+^='F)_>7\Z\?GCN+:4Q3%ED7J-^<?D:($FN)?+C9BQ!;ECT
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M=U_7R#^U*?\ *_Z^9R_A?_D8[3ZM_(UZ@.M<_8:-I]K?1S0VP213P=Q/]:Z
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MQ_WVW^-*/#ND_P#/F/\ OMO\:GV5=O=?<7[7"K[+,C3=5MYYFDFD6*54(WR
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MTON,?:85Z\K.=GUR"<N3$Q^614RHX#* !^8-7;36+6[OBTQ\L+O*,P"X! P
M?7K6K_PCND_\^:_]]M_C2_\ ".Z3M_X\Q_WVW^-4J==.[::_KR)E4PUG9-'%
MZI()=3G=9A*I;AP,54KO_P#A'=)_Y\Q_WVW^-'_".Z3_ ,^8_P"^V_QKEE@J
MDFW=?U\CKAF5.,5%)Z' 45W_ /PCND_\^8_[[;_&D/A[2O\ GT7_ +[;_&E]
M0GW1?]IT_P"5E#P%_P ?%]_N)_,T5T.C:;:6+S-;0B,N &Y)SCZT5[F#@X45
+%GA8NHJE9S74_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>afmd20191231x20f003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
M"BBB@ IM.IIZ4 )YB[MNX9^M#,JKN9@ .Y->9^(6,?B;4I \8:,P,H,A$G;/
MECH<UKW][J$\&N%[B-K2V&U(&A'.0#DGO6GL]-S+VIVAEC4!F=0IX!)ZT\L%
M!)( '4FO.-6U*XO+A;>6[C2."]@1+3R\,1P=^>N*LQZWJ%]<7X:Z3R(DGWP,
MJ8('"@=_K3]BQ>VB=Z'5E!5@0>00>M'!KS[^V-66Q,EK.D,-K:V\GE>2#N+=
M1GL*NP:QJ-WXK:TCNUB@CGVO&57!3:#QGG<32]C*UP557LSLS49EC\T1&1!(
M1D)NYQ]*Y37M:O+;4[B&.\2T2" 2Q*Z!OM#?W1G\N/6DT-)[CQ;?74[G<+>+
M]V4&4W#)&?:A4W:]Q^T7-:QUZ2(V=K X.#@]#3\CUKA1?7XNEMK*9+;[1J4T
M3OY0;@+D?CFHX]=U>\AMUAND@D-O-)(YA#;C&<#CMFCV3%[6SLSO:,BN OO$
M][#:VD\=P1,T44DL.Q=K;B >3R?PZ4DFJW^FOK12],T@O$0(ZC,:-C+#V[>E
M-4F-UDCT$4M8WAR[N;RP=[F2.0K(51T9267MG;QFMBLVK.QI%W5Q:**2D,6B
MDI: "BBDS1< I"0.II:P?%427&CF-KR*V^<$-*<*Q'\)]C32N[";LKFX'5AE
M2"#W!H1T<91@P]0:\]M[N61M$:&5=.MUGFC=4^:-B!Q@GJ#3X=4U%4M;>SG2
MV5XKF9L1!LE&X'XU;I>9DJIZ!Q2-(B#+.J@G ).*X$:_K4>FO.TZ2RRV(NH\
M1 "([@"/?BG7NKOJDMS$LR2VT4]J8V3L2<MS0J3'[5;H[W(]:3S$WA-PW$9
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MD<44MV)X;;4HXHYDC7;,".I'3@\<5O:YJ5Q:ZI:6:WT=A \;.TS(&W$8PO/
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MU3R4VK]T;1@?2D\JW\P )'N4'CC(!Z\>]<9%XAU/4=.N;FW=(%@"1G?A<O\
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MH2H.X?*,9]:<8[9E;Y(F4C:W3&/0UP%W,;>/5HM%=CIJ11;FC8LJ,6^?:?\
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MU;>E7FH7NMWXDG46ENRHL03DDJ#R?8U+A)*]QJI%NUC:6VA14C6-%1#E5"\
MTES';N@,Z1LH.1YF,+[\US)UB[.IZH/MD:?8RRPV6P%I1LR&SUSGTK(GU&_U
M'PW=/<S131L(9!@KN5BXR-HY ^M-0;UN#J16ECM8K*TCU&XU$-F9T$;,6&%
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M0LBO]DB[Q)V_A].GY416<$#,T,,<9<Y8HH!/UJQ1BB["R$7@4ZDI:!A1110
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MKFUA,OG&",RXQOVC./K34L+50^VUA42<OM0#<?>K5&*+L5D0^1&-P6-0K'+
M#J:9]E@R#Y"9&,':.,=/RJSBC%%V.R*_V2#;@P1D<\;1WZT?9HL$>2F#C/RC
MG'2K%%%V*R,&#PM96^H"\5YF9)&D1&;@,W4^M;@Z4[%%#;8**6P"EHHH&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 UE#*5(!!X(-0_982@C,4>Q3E5VC _"IZ
M*!%=+&VCD,B6\*N>K*@!_.D:QMC-YWV>(R]-Y0;OSJS13NPY41QQ+$H1%55
MX"C J044M(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% "8I:**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3-&: %HI*6@ HHI
M,T +13<TI.!0 M%-W#O2[J %HI-W/2DW>U #J0G%)NS396*QDK@L!QF@!^>:
M6L2+7XEMU>X0K(1G:G([_P"%.'B&WSAH9D;D@$=0.O\ *JY6/E9LTA.*S5UB
M)[99UBDP\AC0$8W$=?I51O$2/=P101DI))L+."._:ERL+,WJ*:.XYIU(044E
M'% "T4G%'% "T4G%&: %HI,TM !12<49H 6BDS1GFE<!:*3BCBF M%)Q1Q0
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MB&&YB1R#=1@R?0A!S]:4S>*9=,F@31+)-Z<$3$!L]_8UU0C;]T(G2V8<R0J
M<U'']DENI982WVA/E=<D#/TZ4^4?,><:+J4UGXJ@@U9+>8W,+)$4(VB4=0<]
M">G/>G_$+Q#<&T?3+/28I$C=/M4<J9/J  IY%3>+/#[WE\]Z;0P%V#[2<*[
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M"",<$&K-%,"H+.W%M]G$*^5MV;2.WI1;6%O:H4BB !;<<DGGUYJW12 ;@ <
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MK_T#[C_OV:8'J7PX_P"137_KN_\ 2NMKE_ %O/:^&1%<0M%()G.UA@]JZBI
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M "BBB@ HHHH **** "BBB@ '2EHHH **** "BBB@ HHHH *:>%-%% "T444
M%%%% !1110 4444 %%%% !1110 4"BB@!:*** "BBB@ HHHH **** &CI2T4
L4 %%%% !1110 4444 %%%% !1110 4A)W"BB@ 7I3J** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>afmd20191231x20f004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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MSJ[?_P#(.N?^N3_R-4O#/_(N6/\ US% &M1110 4444 %%%% !1110 4444
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M)HP'B)'&"..1_.NHKB/ UO'_ &CJ][-JBZEJ,TBBXEACVQK@$!5]<>U=N.E
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MCF\-6+QL&79C(J&WT<6FAW(NUBFN'6261BN0'(/3/2K'A=0GANRV@ %,\#%
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M\?0>E>EZ+#Y.DP)STS0!?%+0.E% !1110 4444 %%%% !1110 4444 %%%%
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M#F6XE.?QKTH=.:X+X-Q^7\,=+XP6#.>O<UWHH 6BBB@ HHHH **** "BBB@
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M/S=: .D\(Q^3X/T>,C&VTC&/^ UMUGZ*@BT'3T QBWCX/^Z*OCU]J %HHHH
M**** "BBB@ HHHH **** "BBB@!#7&^!M>O=8N]<CNY?,^RW1CCP,84=J[%S
MA2?0$UYG\*I-^J^)B3R;K/ZF@#TZBD!R?PZ4M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 <IXOOKV.33M(TZ007.H2E/.
MQ_JU'+8]\46/A$:3<+>6^K7\C(K>8LTI=9#MZX[5;\3:%-K%O!+9S>1?VDGF
MP2GD ]"#[&JMA)XNNKM$U""RM[9582&,DF0XXQZ"@#F="T*\U309]6BUN^AO
MO,D**TFY/E)P,>E:\MY+X@^'<E[-/+;W4".SM ^W<Z<?E5+3-.\9:?I$VD6U
MK:11N[A;AWS@,>N*Z*+P_P#8?!<VBVS>9(8'&YOXV/4T 1PZY_9?@&UU2Y9I
M9/LR8R,F20C@?B:S/#>KDV]_:7WVN'5YH7NF2X!  (_A]A5S4/#=W>^";'34
M94O+012+G[I=.QJ.VT;6-1UA]5U2*&W>*S:V@BB.=Q/<GTH XWPUJ;G5=%>V
MUF\N+RXN62ZMYV.P)GDC/?TKN?'VHW^F:#!<Z:X2Z^V1J@/1LDC'XUSFF^%_
M$3KI5A=6EI;VME="X:X4YD8 YQ76>+](N=9TVUM[0 LEY%*VX\;5;)H P-<\
M5->>#-14%[+5[<*)H<D,O(Y'J#FK_BC7+VQT:PM=+P^IW**R@\D*H!8U/XN\
M'6_B2R4HYM[Y54+,IQN&?NMZBJ)\%OK6LR7>M-*L<$*0VJP2E2 !ACGWH U+
MI+CQ5H-C)97C6D$I#7#)PVWN >QJCX.:5-;UJS@N9KG3(&587D;=A_X@#WYJ
MFNB^(-$T'4=&T2-7A>0_9)7?F-&ZY/<UM^$;2^T[3_L5SIJ6B1@$.)=YD8]2
M3ZT =(.G3%% Z44 +1110 4444 %%%)GCCG% %>__P"0?<_]<7_E5+PR/^*=
ML?\ KG5V^(_L^ZZC$3?R-4?#9'_".67.,Q\4 :]%(*"<4 &>>AKSSXT'=X",
M>3B2ZA&!W^<5Z'^'7G!KSGXR-GPM9)T+W\(ZC^^* ._L5VZ?;+C&(E&/P%6*
MAMAMM85QC$:C]*E!SUH 6BDR>..IHR?0=N] "T4G.,\^V>]&<=>GK[4 +13/
M,7NR?]]4GG(/XT]OF% $E%5WO+9/OW$2^V\5%_:MAG!OH<YZ;Q0!=HK-;7=*
M0X;4K<'']\57D\5Z%$P#ZI N1G[PH VJ*YQO'7AN/[VK0D#O59_B-X8C# ZF
MN1QTH ZB=ML,C'H$)S7D?PEN=WB;78@P(9BYQ_O&NGO_ (G>&A:RQQ7K.SH=
MN%->;^ =17P]XDAU._)@LM0$B"5NY!S_ %H ^@!2US!\?>&4ZZK&.!V-1O\
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M12#I10 M%%% !1110 4F*6B@"M? #3[G'_/)N_L:H^&A_P 4[8G/_+.K]_\
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MXEM[26<V=C^[0MGS2<8%-L+[Q+>:?!<"SL2)(P<^8>_X?YQ0!T]%8'G>)O\
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MQ'&/]:?\* -[(]12UR]W>^+(V@\JPLSND"OB0G ]?:K/G>)LY^Q6'7/^M/\
MA_G- &_16!YOB4?\N-AQ_P!-3_A_G-'F^)>]E8?]_3_A_G- &]D9QD>E&1ZB
MN;O;[Q/:V$]Q]CL?W49?_6GL,T6=[XEN;*"<6ED1)&K@^:>XS0!TM%8'F^)?
M^?&PY_Z:G_/_ .JCSO$V<_8K#_OZ?\__ *J -^DR#T(K!\[Q*,9LK' Z?O3Q
M^E2:3<ZU+>W<6IVT44<84Q-&<AL]: -NB@=.** "BBB@ HHHH CFABGB:*9%
M>-A@JW0BJQTRP-E]D-G +4?,(M@P#ZXJ[2$<8H S-1U'3]&M8UN<1QL/+2-5
MS^&!V_PJL?$.CV,%J!<!89E#1[$) 'J?0=J3Q->&QL5EBM))[IFV1%8R_E[N
M"3CL*YW[$UC;RPQ6MQ=1W=@(8'\H\N3R&'\.22>: .K_ +<L/[4&GBY!N#T
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>afmd20191231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M5VB@"E]EN_\ G^;_ +]BC[+=_P#/\W_?L5=HH I?9;O_ )_F_P"_8H^RW?\
MS_-_W[%7:* *7V6[_P"?YO\ OV*/LMW_ ,_S?]^Q5VB@"E]EN_\ G^;_ +]B
MC[+=_P#/\W_?L5=HH I?9;O_ )_F_P"_8H^RW?\ S_-_W[%7:* *7V6[_P"?
MYO\ OV*/LMW_ ,_S?]^Q5VB@"E]EN_\ G^;_ +]BC[+=_P#/\W_?L5=HH I?
M9;O_ )_F_P"_8H^RW?\ S_-_W[%7:* *7V6[_P"?YO\ OV*/LMW_ ,_S?]^Q
M5VB@"E]EN_\ G^;_ +]BC[+=_P#/\W_?L5=HH I?9;O_ )_F_P"_8H^RW?\
MS_-_W[%7:* *7V6[_P"?YO\ OV*/LMW_ ,_S?]^Q5VB@"E]EN_\ G^;_ +]B
MC[+=_P#/\W_?L5=HH I?9;O_ )_F_P"_8H^RW?\ S_-_W[%7:* *7V6[_P"?
MYO\ OV*/LMW_ ,_S?]^Q5VB@"E]EN_\ G^;_ +]BC[+=_P#/\W_?L5=HH I?
M9;O_ )_F_P"_8H^RW?\ S_-_W[%7:* *7V6[_P"?YO\ OV*/LMW_ ,_S?]^Q
M5VB@"E]EN_\ G^;_ +]BC[+=_P#/\W_?L5=HH I?9;O_ )_F_P"_8H^RW?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+24
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M4;[_ *_Y?YUYYJO_ "%[W_KLW\Z] ^"*F/P5=(3DK>2*3ZXXKS_5?^0O>_\
M79OYTA,I^OTKM_A=_P C)-_UR-<1Z_2NW^%W_(R3?]<C5"/8Q2T@I:DH****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>R,8S\[;0/,&<\UL>(]&M-8\.76GWB$VYB.0#CH.*0SC/@L5;P?>NN"K7TK
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MY7O^^*]'YI#/%_B7_P C7G_IG_A7'=Z['XE?\C4?^N8KC:: U?#9/_"2Z?\
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M;"TS_P >Z?E3H]/M#-&/L\?WAU%.P'J/_"]/"_\ <N?^^:/^%Z^%_P"Y<_\
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M616#74JDC@?=X]:74$=EHMHMCI5O;).+A8UP)1CFM.L3PQ)YOAZS<P"'*?<
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MO<_'_P#R*-W]17AE.XKA7M7PV_Y%.+_KH:\5KVKX;?\ (J1?]=&H"YV-?/\
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M5\)O];J'T7^M>H5Y?\)O];J'T7^M>H4AHRY?^/K4/^N(_E6'6Y+_ ,?6H?\
M7'^E8= SI+3_ (^KO_KH/Y5:\M=^\JN[UQS56T_X^KO_ *Z#^57: $Q12TF:
M %K-U^XDM/#^H7$49DDC@=E4=SBM'/M5>^(_L^X_ZYM_*@#SKX'L7\&W+E=K
M->2$CT)KTZO-/@M_R*M]_P!?\O\ .O2Z "BBB@ HHHH **** "BBB@ HHHH
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M\^:<]#Z5U_B^\U*R\'W=QIMOYUX(N$QGJ.:Z#8O]T<=..E0WHQ87'_7)OY4
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MC2 4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYHS5+^S+7^X__?9H_LRU_N/_ -]F@"[FC-4O[,M?[C_]]FC^S+7^X_\ WV:
M+N:,U2_LRU_N/_WV:/[,M?[C_P#?9H NYHS5+^S+7^X__?9H_LRU_N/_ -]F
M@"[FC-4O[,M?[C_]]FC^S+7^X_\ WV: +N:,U2_LRU_N/_WV:/[,M?[C_P#?
M9H NYHS5+^S+7^X__?9H_LRU_N/_ -]F@"[FC-4O[,M?[C_]]FC^S+7^X_\
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9[PKIHK*WB#A$^^,-DYS4?]DV?_/(4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>afmd20191231x20f006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 afmd20191231x20f006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\ ?LU=HH I?VE%_P \YO\
MOV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\ ?LU=HH I?VE%_P \
MYO\ OV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\ ?LU=HH I?VE%
M_P \YO\ OV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\ ?LU=HH I
M?VE%_P \YO\ OV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\ ?LU=
MHH I?VE%_P \YO\ OV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:/[2B_YYS?\
M?LU=HH I?VE%_P \YO\ OV:/[2B_YYS?]^S5VB@"E_:47_/.;_OV:#J47_/.
M;_OV:NTE $$-W'/&KH3@MMP1CFBJ=MQ"O_7T:* )[/\ X^KS_KI_2KM4K/\
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M48%+10 F!1@4M% "8%&,TM% "8%-/3'2GT4 <M)#<2^*%BMM3NPL7[R="PV
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M&X,PW,QQ%&L6< ],$=?QKKUT+2U>)ULX@T0PF!TI%T'3!),WV*+=+]XXZT7
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M]O>M+X>?\B'H_/\ RP% '44444 %%%% !1110 4449H **** "BBB@ HHHH
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MN&(SY:^M=%\//^1#TCI_J!R*QOC$I;X>7N+GR,8Y)^][5M?#W_D0]'XQ^X%
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M%+,8W)92%_=B>:]1KA=: 'Q6T#C_ )=I?YBNZH **** "BBB@ HHHH ****
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MN6\%:L]YICV%T<7E@WDR@]P. ?QKJ!TH 6BBB@ HHHH **** "BBB@ HHHH
MKW__ "#KG_KDW\JY;X9_\B?%_P!=I/\ T(UU-_\ \@ZY_P"N3?RKEOAG_P B
M?%_UVD_]"- '8T444 %%%% !1110 4F:6FNP522< #)- '/^+];.DZ/M@.;R
MY/DP(.NX\9_"L:_T5=#^&&H6Y^:9[=GG?NSD<T:4I\5>+9M7<;M/L28K;T9N
M[5M>-_\ D2M6S_S[M0!R; Z)#X;\0(N(G@CM[K'3:1P3^->E1NLB*R\JPR#7
M,VNF1ZQ\/K:Q?_EK9J%/H<<&G>"-4DOM$^S7)_TNS<P2#OQP#0!T]%(.E+0
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M<,V3C</2M;X>_P#(AZ/_ -<!7/?&:\L8O TUM>+*SSG]SL7(##U]JZ#X>?\
M(AZ1R/\ 4#I0(ZBBBB@ IK' R>G>G5C^*=1&E>&[V[!^98B$QUR>!0!@^$Q_
M:OB?6M<89CW_ &:!O9>M=M7/^#-._LWPU:1$8DD7S9/]YN3704 %%%% !111
M0 F.<UP_B!1X9\4VNOQC;:W)$%V ./8UW-9/B2U@O/#U]%<#,9B))],4 ::,
M&0,I!4C(([TX'-?//A;QU?6.J-!J-S=3VT6U8ML@VCZU]!PN)(4<=&7- $E%
M%% !1110 4444 %(>E+44TR00/+(P5$4LQ/84 >?_%5[FYTN#2+23;)=$D@=
M<"N&^'/A;Q%I5NVNZ<RR1DLIAW<M@FN]T>)_$%_JGB2Y4^2J/#:*>RC^*K_P
MSX\&Q_\ 7:0_^/&@#5\/^);;6X63'D7D?$UN_#*?\*W <UR_B'PHNH3#4M.D
M^R:I'RLJ\;_9J;X?\5M<SG2]8B^QZI%P5?A9?=3WH ZND- -!Z4 <3K&J:Y9
M^+=/TJ*[A$-[N()CY4"NRBW+&JR-N;&"P'6N*\1?\E*\-C/\+]ZZW4K^+3-.
MGO9VQ'$NX^] ',>,KN74KJV\-69/F71S<,/X(Q@UUEE9PV-G#;0*%BB7:H%<
MMX*TZ:?[3X@O@?M5\V4!_@3G KL * %%<_XX_P"1*U;_ *]VKH*Y_P ;_P#(
MEZM_U[M0!9\+_P#(KZ9_U[I_*M4@'K65X7_Y%?3/^O=/Y5K8H XC1#_PCWC*
M\T=SMM;P>?;@] ?X@*[<=*Y'QW8R?8H-9M@?M6G2"0$=2O<5TFG7L>H:=!>0
MG*3(&6@"R6"\D@#U)IHE0M@,I/H&J*\M8KRV>*8$J1D@'%<5\.;2-XM2N'+O
M+%>R1HSN3A0: .^KBO',K7]QIOAZ(Y:\F#2@=HQUKM,\5Q'AX?VWXSU36VYA
MMO\ 18,^H^\10!V<,*00I$@PJ*% ]A4M%% '"ZW_ ,E6T#_KVD_G7=5PNM_\
ME6T#_KVD_G7=4 %%%% !1110 4444 %%%% !24M)0!F6_P#JE_Z^O\:*+?\
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MTG_H1KHM8N!;Z3=.49OW; !1DGBN3^&-WGPXEJ\$\<BR.Q\Q,#DT =W1110
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M0!F6_P#JE_Z^O\:*+?\ U2_]?7^-% $UG_Q]7G_72K$\GE022'G:"<5!9_\
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M/L0G:OK0!W$,4<,2QQ(J(HX51P*EJM:7,=Y;+/$3L;ID8-6: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &O]UOI7%?#?_CPU;_L(R_SK
MM&^ZWTKB_AO_ ,>&J_\ 81E_G0!V]%%% !1VHHH \XUG4;<_$O1[D>88(()$
ME<(2%:O0T<.BNIRK#(-(8(N28T))Y)44X\)P.@XH =FEKQK2KSQTWQ1EBG2?
M^SO-(;>/W?EYX(KT/Q--=1I:):F?+R$'RNO2D%CH3TIOF() A8;B,@5P]Q;^
M)A%YB22[R^"N>@[57%EXB^WI<2K.TJH4E=3P1G^&JL"/0Z*X&-/%(EEVB4J5
M(C+G[H_QKI?#:Z@NGXU$DR;N-W7%(#9HHHH *2EI* ,RW_U2_P#7U_C11;_Z
MI?\ KZ_QHH GL_\ CZO/^NG]*NU2L_\ CZO/^NG]*NT %!Z444 9FM330:7,
M]N_ERX^5B,XKF+?7-2DN8%+.,,% VY$QS@\UVY0,,,H(/8TGE(",(OR_=XZ4
M >;?&FXNXO!QAM[(3PS$^>Q&?+'K73?#W_D0]'YS^X%8OQC4M\/+W;<^1@@_
M[_M6S\//^1#T?K_J!CB@#J**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IA0'D@$_2GT4 -V@# %.HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH K7ES#:6[S3N$C Y)%<1\-[ZW\C4K??B62^DD564C*D\
M&N]=%=2&4,IZ@BF+;PQMN2)%/J%Q0!,.E%%% !1110 4AZ4M0W+R):RM"NZ4
M*=B^I[4 5X-0L[B]GM(ID:X@_P!8@ZKFK$CQ)AI&08. 6->0>%O#WC73/'\^
MLWMNAMKMR)QY@X7/'%>D^(K6YO+:*.VMQ*Q;#9;&T>M2]QFM+<PP*&ED5 3@
M9-/!!.:X2_\ #&KW5Y$05-L%50"_*@'^=7+RRU&#2;6UVR2OYY!"O_#VR:KH
M%M#L<TSS$,A3<-P&2,]*XR71M=V$"1C+WD#\;?[N/ZU-H6BZI:SW<UR<220;
M$??GFA".L2>)Y'C5@73[RYY%2;AZBN @\/:Q'>7$PC91(!@>=_%_>S_2FOH?
MB=O,47!*$Y8[^6^E 'H6:2JVGQ30V,$4[%I50!CZFK- &9;_ .J7_KZ_QHHM
M_P#5+_U]?XT4 3V?_'U>?]=/Z5=JE9_\?5Y_UT_I5V@ HHHH *0]*">*K2W]
MK#.D$DZ+*_W5)Y- '#_&1H%^'MYY\32#<H7!^Z?4UM?#S/\ P@>CY_YX"LCX
MP//_ ,*]O5MVC#-C<'(Y7OCWJ]\/]0L8_ VD*]W C"#D-( 10!V-%5/[4T__
M )_K;_OZO^-']J:?_P _UM_W]7_&@"W153^U-/\ ^?\ M?\ O\O^-']J:?\
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M-']J:?\ \_UM_P!_5_QH MT54_M33_\ G^MO^_J_XT?VII__ #_VO_?Y?\:
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M_P TG_"E_#G_ #WO_P#O^:](HH \X_X4OX<_Y[7_ /W_ #1_PI?PY_SWO_\
MO^:]'HH \X_X4OX<_P">]_\ ]_S1_P *7\.?\][_ /[_ )KT>B@#D_#/@#2O
M"E[)=6$ERTDB;")9-PQ75#(IU)0!F6_^J7_KZ_QHHM_]4O\ U]?XT4 3V?\
MQ]7G_73^E7:I6?\ Q]7G_73^E7: "BBB@ HHHH *0G I:@O',5G,XZJI(YH
MFW5A>(;*XO9=,:"/<(;E7?V%<U-XJU26P011*AD?8KY.[^56;CQO/ T4:VR-
M(5_>98_+@XIV!:G<9&:4')KAH_&-R&F(MQM3Y@')RV?3BMOP_K5QJ<DBW$*Q
MD('7;Z&BVEQV-^BBBD(**** "BBB@ HHHH **** "DS2U7NY#%:3.N=RJ2*
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M+24 9EO_ *I?^OK_ !HHM_\ 5+_U]?XT4 3V?_'U>?\ 73^E7:I6?_'U>?\
M73^E7: "BBB@ HHHH *JWM[!96YDN&(0\<#)-6JIZAI\>H0"-W="IW*R=0:
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M6\J"5L9VX -/A\/HF@)IAGD0 ?,\9Y)I8/#D4%W'<BZG8QC 1L;:8C;HHHI
M%%%% !1110 4444 %%%% !1110 4E+24 9EO_JE_Z^O\:*+?_5+_ -?7^-%
M$]F?]*O/^NG]*NUG".[@N9VCC1TD;<"6P:D\V_\ ^?>/_OY0!=HJEYM__P ^
M\?\ W\H\V_\ ^?>/_OY0!=HJEYM__P ^\?\ W\H\V_\ ^?>/_OY0!=HJEYM_
M_P ^\?\ W\H\V_\ ^?>/_OY0!=I",U3\V_\ ^?>/_OY1YM__ ,^\?_?R@"YC
MG-&*I^;?_P#/O'_W\H\V_P#^?>/_ +^4 7:*I>;?_P#/O'_W\H\V_P#^?>/_
M +^4 7:*I>;?_P#/O'_W\H\V_P#^?>/_ +^4 7:*I>;?_P#/O'_W\H\V_P#^
M?>/_ +^4 7:*I>;?_P#/O'_W\H\V_P#^?>/_ +^4 7:*I>;?_P#/O'_W\H\V
M_P#^?>/_ +^4 7:2J?FW_P#S[Q_]_*/-O_\ GWC_ ._E %RBJ?FW_P#S[Q_]
M_*/-O_\ GWC_ ._E %S%&*I^;?\ _/O'_P!_*/-O_P#GWC_[^4 7,4M4O-O_
M /GWC_[^4>;?_P#/O'_W\H NT52\V_\ ^?>/_OY1YM__ ,^\?_?R@"[15+S;
M_P#Y]X_^_E'FW_\ S[Q_]_* +M%4O-O_ /GWC_[^4>;?_P#/O'_W\H N'FC%
M4_-O_P#GWC_[^4>;?_\ /O'_ -_* +F*,53\V_\ ^?>/_OY1YM__ ,^\?_?R
M@"[15+S;_P#Y]X_^_E'FW_\ S[Q_]_* +M%4O-O_ /GWC_[^4>;?_P#/O'_W
M\H NT52\V_\ ^?>/_OY1YM__ ,^\?_?R@"[2$<53\V__ .?>/_OY1YM__P ^
M\?\ W\H N8XHQ5/S;_\ Y]X_^_E'FW__ #[Q_P#?R@"[15+S;_\ Y]X_^_E'
MFW__ #[Q_P#?R@"[15+S;_\ Y]X_^_E'FW__ #[Q_P#?R@"[15+S;_\ Y]X_
M^_E'FW__ #[Q_P#?R@"[15+S;_\ Y]X_^_E'FW__ #[Q_P#?R@"[15+S;_\
MY]X_^_E'FW__ #[Q_P#?R@"[15+S;_\ Y]X_^_E'FW__ #[Q_P#?R@"[2&J?
MFW__ #[Q_P#?RD,M_P#\\(O^^Z (;;_5+_U]?XT5+;6TRPJ)<!O.\P@=J* +
MQI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM110 O>BBB@#
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>15
<FILENAME>afmd-20191231.xml
<DESCRIPTION>EX-101.INS
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:31 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:afmd="http://www.affimed.com/20191231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="afmd-20191231.xsd" />
  <!--Context Section-->
  <context id="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsVestingAxis">afmd:TrancheIMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-20</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsVestingAxis">afmd:TrancheIiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-20</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIiiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsVestingAxis">afmd:TrancheIiiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-20</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="As_Of_9_30_2017_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-09-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AbCheckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_LeukemiaAndLymphomaSocietyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AbCheckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_LeukemiaAndLymphomaSocietyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:LeukemiaAndLymphomaSocietyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_AmphivenaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AmphivenaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AbCheckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:ServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:CollaborationServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:ServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:CollaborationServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:ServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">afmd:CollaborationServiceMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_srt_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_srt_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_srt_EuropeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RetrospectiveApplicationAndRetrospectiveRestatementAxis">ifrs-full:FinancialEffectOfChangesInAccountingPolicyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ThirdPartyServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:CostsOfMaterialsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ThirdPartyServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:CostsOfMaterialsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ThirdPartyServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndPatentExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:CostsOfMaterialsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:LoanAgreementWithUniCreditLeasingCZMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedUnderAtMarketSalesAgreementMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedUnderAtMarketSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_MajorCustomersAxis_afmd_GenentechInc.Member_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">afmd:GenentechInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_MajorCustomersAxis_afmd_GenentechInc.Member_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">afmd:GenentechInc.Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_MajorCustomersAxis_afmd_TopFourCustomersMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">afmd:TopFourCustomersMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfLiabilitiesAxis_afmd_ValueAddedTaxReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">afmd:ValueAddedTaxReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfLiabilitiesAxis_afmd_ValueAddedTaxReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">afmd:ValueAddedTaxReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_11_13_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-13</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedUnderAtMarketSalesAgreementMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedUnderAtMarketSalesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">afmd:CumulativePreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">afmd:CumulativePreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_CZ">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CZ</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_CZ">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CZ</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_US">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:US</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_DE">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DE</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_CZ">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CZ</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_OtherPriceRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:OtherPriceRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">afmd:IFRS16Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-01-01</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:PersonnelExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:OtherExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndAuditExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:PersonnelExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:OtherExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndAuditExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:PersonnelExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:OtherExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:LegalConsultingAndAuditExpensesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:OtherFinanceIncomeFinanceCostsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestSVBLoanAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:InterestCertificatesOfDepositMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfIncomeExpenseAxis">afmd:ForeignExchangeDifferencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:GeneralAndAdministrativeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:GeneralAndAdministrativeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:ResearchAndDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:NatureOfExpensesAxis">afmd:GeneralAndAdministrativeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsRevisionOfPriorPeriodAxis">afmd:IfrsPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsRevisionOfPriorPeriodAxis">afmd:IfrsPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsRevisionOfPriorPeriodAxis">afmd:IfrsPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsRevisionOfPriorPeriodAxis">afmd:IfrsPreviouslyReportedMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="afmd:IfrsRevisionOfPriorPeriodAxis">afmd:IfrsPreviouslyReportedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RevaluationSurplusMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LongTermFinancialAssetsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:LongTermFinancialAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_ContractLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:ContractLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LongTermFinancialAssetsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:LongTermFinancialAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_ContractLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:ContractLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_LeaseLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TemporaryDifferenceBorrowingsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TemporaryDifferenceBorrowingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_LeaseLiabilitiesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:LeaseLiabilitiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">ifrs-full:IntangibleAssetsOtherThanGoodwillMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherReceivablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TradeAndOtherReceivablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherPayablesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TradeAndOtherPayablesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TemporaryDifferenceBorrowingsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:AssetsAndLiabilitiesAxis">afmd:TemporaryDifferenceBorrowingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToReferencesToConceptionalFrameworkMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToReferencesToConceptionalFrameworkMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs3BusinessCombinationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIfrs3BusinessCombinationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIas1AndIas8DefinitionOfMaterialMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifrs16Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:Ifrs16Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:Ifric23UncertaintyOverIncomeTaxTreatmentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AnnualImprovementsToIfrsStandards20152017CycleMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AnnualImprovementsToIfrsStandards20152017CycleMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">afmd:AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_GbpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:GbpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_GbpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:GbpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:ThereofAssetsPledgedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:ThereofAssetsPledgedMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfInterestRatesAxis_afmd_OneMonthEuriborMember_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">afmd:OneMonthEuriborMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_TypesOfInterestRatesAxis_afmd_OneMonthEURIBORMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">afmd:OneMonthEURIBORMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-11-30</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_4_30_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:LoanAgreementWithUniCreditLeasingCZMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-04-30</instant>
    </period>
  </context>
  <context id="As_Of_5_31_2017_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SeniorSecuredTermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityTrancheOneMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SeniorSecuredTermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_GbpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:GbpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_GbpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:GbpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_USDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:USDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_CZKMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">afmd:CZKMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:MotorVehiclesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfAssetsAxis">ifrs-full:BuildingsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CreditRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_11_13_2019_To_11_13_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-11-13</startDate>
      <endDate>2019-11-13</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">afmd:SharesIssuedInPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:LiquidityRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AmphivenaMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AmphivenaMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_WolfgangFischerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:WolfgangFischerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_UlrichGrauMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:UlrichGrauMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_ThomasHechtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:ThomasHechtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MathieuSimonMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:MathieuSimonMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MartinTrederMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:MartinTrederMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_LeilaAllandMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:LeilaAllandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_FerdinandVerdonckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:FerdinandVerdonckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BernhardEhmerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:BernhardEhmerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BemdtModigMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:BemdtModigMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_AdiHoessMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:AdiHoessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_WolfgangFischerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:WolfgangFischerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_UlrichGrauMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:UlrichGrauMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_ThomasHechtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:ThomasHechtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MathieuSimonMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:MathieuSimonMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MartinTrederMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:MartinTrederMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_LeilaAllandMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:LeilaAllandMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_FerdinandVerdonckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:FerdinandVerdonckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BernhardEhmerMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:BernhardEhmerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BemdtModigMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:BemdtModigMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_AdiHoessMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:AdiHoessMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_1_1_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-01</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AbCheckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:AbCheckMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_1_1_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">afmd:IFRS16Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-01</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_MajorCustomersAxis_afmd_TopFourCustomersMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">afmd:TopFourCustomersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:InitiallyAppliedIFRSsAxis">afmd:IFRS16Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="As_Of_1_1_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <instant>2019-01-01</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">afmd:SupervisoryBoardDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_4_20_2018_To_4_20_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2018-04-20</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="As_Of_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-11-30</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">afmd:Esop2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SeniorSecuredTermLoanFacilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:LoanAgreementWithUniCreditLeasingCZMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:InterestRateRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:BorrowingsByNameAxis">afmd:SiliconValleyBankLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-11-30</startDate>
      <endDate>2016-11-30</endDate>
    </period>
  </context>
  <context id="Duration_10_1_2018_To_10_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
      <segment>
        <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">afmd:GenentechIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-10-01</startDate>
      <endDate>2018-10-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2019_To_12_31_2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001608390</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit114">
    <measure>afmd:EquityInstruments</measure>
  </unit>
  <unit id="Unit113">
    <measure>afmd:Y</measure>
  </unit>
  <unit id="Unit112">
    <divide>
      <unitNumerator>
        <measure>iso4217:GBP</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>iso4217:EUR</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit111">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>iso4217:EUR</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit110">
    <divide>
      <unitNumerator>
        <measure>iso4217:CZK</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>iso4217:EUR</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit19">
    <divide>
      <unitNumerator>
        <measure>iso4217:EUR</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit18">
    <measure>afmd:shareholder</measure>
  </unit>
  <unit id="Unit17">
    <measure>afmd:customer</measure>
  </unit>
  <unit id="Unit16">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="Unit15">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit14">
    <measure>afmd:tranche</measure>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>iso4217:EUR</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <afmd:AdditionsOfNewLeaseContracts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">492000</afmd:AdditionsOfNewLeaseContracts>
  <afmd:AdditionsOfNewLeaseContracts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">492000</afmd:AdditionsOfNewLeaseContracts>
  <afmd:AuthorizedCapital contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">3200000</afmd:AuthorizedCapital>
  <afmd:AuthorizedCapital contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">3200000</afmd:AuthorizedCapital>
  <afmd:CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="-5">4400000</afmd:CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones>
  <afmd:CollaborationAgreementInitialUpfrontPayment contextRef="Duration_10_1_2018_To_10_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit1" decimals="-5">83200000</afmd:CollaborationAgreementInitialUpfrontPayment>
  <afmd:CollaborationAgreementInitialUpfrontPayment contextRef="Duration_10_1_2018_To_10_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit12" decimals="-5">96000000</afmd:CollaborationAgreementInitialUpfrontPayment>
  <afmd:DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit13" decimals="2">0.10</afmd:DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal>
  <afmd:DebtInstrumentFloorRate contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit13" decimals="3">0.055</afmd:DebtInstrumentFloorRate>
  <afmd:DebtInstrumentFloorRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit13" decimals="INF">0</afmd:DebtInstrumentFloorRate>
  <afmd:DebtInstrumentLegalAndArrangementFees contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">236000</afmd:DebtInstrumentLegalAndArrangementFees>
  <afmd:DebtInstrumentMonthlyRepaymentInstallmentAmount contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember" unitRef="Unit1" decimals="-3">8000</afmd:DebtInstrumentMonthlyRepaymentInstallmentAmount>
  <afmd:DebtInstrumentNumberOfTranches contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember" unitRef="Unit14" decimals="INF">3</afmd:DebtInstrumentNumberOfTranches>
  <afmd:DisclosureOfCashOutflowRelatedToLeasesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;"&gt;Cash outflow related to leases are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 405&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest on lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Short-term lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 66&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Cash outflow from leasing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 495&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:DisclosureOfCashOutflowRelatedToLeasesTableTextBlock>
  <afmd:DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future contractually agreed undiscounted lease payments are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019: Leases&lt;br /&gt;under IFRS&lt;br /&gt;16&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018:&lt;br /&gt;Operating&lt;br /&gt;Leases under&lt;br /&gt;IAS 17&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments within one year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 553&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 675&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments between one and five years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 276&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 541&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 829&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,216&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock>
  <afmd:DisclosureOfLongTermFinancialAssetsTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;13.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Long term financial assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Company holds preferred shares in Amphivena recognized at their fair value of &amp;#x20AC;3.2 million (2018: &amp;#x20AC;3.8 million). The Company recognized losses from the change in fair value of &amp;#x20AC;0.6 million in other comprehensive income in 2019 (2018: &amp;#x20AC;4.7 million).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:DisclosureOfLongTermFinancialAssetsTextBlock>
  <afmd:DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Movements of lease liabilities reconcile to cash flows arising from financing activities as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Changes from financing cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (405)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; (405)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Other Changes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;New lease contracts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 804&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock>
  <afmd:ExercisePeriodOfShareOptions contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">P10Y</afmd:ExercisePeriodOfShareOptions>
  <afmd:ExpectedExercisePeriodOfWarrants contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">P5Y</afmd:ExpectedExercisePeriodOfWarrants>
  <afmd:ExpectedUnvestedShareOptionsForfeitureRate contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit13" decimals="3">0.040</afmd:ExpectedUnvestedShareOptionsForfeitureRate>
  <afmd:ExpectedUnvestedShareOptionsForfeitureRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit13" decimals="3">0.040</afmd:ExpectedUnvestedShareOptionsForfeitureRate>
  <afmd:ExpectedVolatilityOfWarrants contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" unitRef="Unit13" decimals="2">0.75</afmd:ExpectedVolatilityOfWarrants>
  <afmd:ExpectedVolatilityOfWarrants contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember" unitRef="Unit13" decimals="2">0.80</afmd:ExpectedVolatilityOfWarrants>
  <afmd:ExpirationPeriodOfWarrants contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">P10Y</afmd:ExpirationPeriodOfWarrants>
  <afmd:ExpirationPeriodOfWarrants contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember">P10Y</afmd:ExpirationPeriodOfWarrants>
  <afmd:FuturePaymentLicenseFeeObligationDue contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">25000</afmd:FuturePaymentLicenseFeeObligationDue>
  <afmd:IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit15" decimals="2">2.30</afmd:IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <afmd:IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit15" decimals="2">2.00</afmd:IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <afmd:IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit16" decimals="INF">53395</afmd:IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <afmd:IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit16" decimals="INF">166297</afmd:IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <afmd:IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember">P1Y</afmd:IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <afmd:IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember">P4Y</afmd:IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <afmd:IFRSLineOfCreditFacilityMaximumBorrowingCapacity contextRef="As_Of_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember" unitRef="Unit1" decimals="-5">10000000</afmd:IFRSLineOfCreditFacilityMaximumBorrowingCapacity>
  <afmd:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="Duration_4_20_2018_To_4_20_2018">P3Y</afmd:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
  <afmd:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">P3Y</afmd:IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod>
  <afmd:IfrsShortTermLeasePayments contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">66000</afmd:IfrsShortTermLeasePayments>
  <afmd:IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">81000</afmd:IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity>
  <afmd:IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">8000</afmd:IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity>
  <afmd:KeyManagementPersonnelCompensationForServices contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">375000</afmd:KeyManagementPersonnelCompensationForServices>
  <afmd:KeyManagementPersonnelCompensationForServices contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">382000</afmd:KeyManagementPersonnelCompensationForServices>
  <afmd:KeyManagementPersonnelCompensationForServices contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">382000</afmd:KeyManagementPersonnelCompensationForServices>
  <afmd:LeasePayableDiscountedUsingIncrementalBorrowingRate contextRef="As_Of_1_1_2019" unitRef="Unit1" decimals="-3">27000</afmd:LeasePayableDiscountedUsingIncrementalBorrowingRate>
  <afmd:LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;2.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Local exemption rules applied by subsidiaries of the Group&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed GmbH, Heidelberg, Germany, makes use of the exemption clause, available under &amp;#xA7; 264 (3) HGB in 2019. The consolidated financial statements of Affimed N.V. as of and for the year ended 31 December 2019 will be filed in Germany as a supplement to the financial statements of Affimed&amp;nbsp;&amp;nbsp;GmbH, in order to meet the requirements of the exemption clause available under &amp;#xA7; 264 (3) HGB in 2019.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock>
  <afmd:MaximumExposureToForeignCurrencyRisk contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit1" decimals="-3">47524000</afmd:MaximumExposureToForeignCurrencyRisk>
  <afmd:MaximumExposureToForeignCurrencyRisk contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit1" decimals="-3">56531000</afmd:MaximumExposureToForeignCurrencyRisk>
  <afmd:MaximumTaxLossDueToOwnershipChanges contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-6">59000000</afmd:MaximumTaxLossDueToOwnershipChanges>
  <afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17 contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1216000</afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17>
  <afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17 contextRef="As_Of_12_31_2018_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="Unit1" decimals="-3">541000</afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17>
  <afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17 contextRef="As_Of_12_31_2018_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember" unitRef="Unit1" decimals="-3">675000</afmd:MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17>
  <afmd:MinimumMaturityPeriodOfCertificateOfDeposits contextRef="Duration_1_1_2019_To_12_31_2019">P3M</afmd:MinimumMaturityPeriodOfCertificateOfDeposits>
  <afmd:MinimumOperatingLeasePaymentsAs17 contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit1" decimals="-3">406000</afmd:MinimumOperatingLeasePaymentsAs17>
  <afmd:NetLossInCaseOfCurrencyExchangeDeviation contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit1" decimals="-3">4787000</afmd:NetLossInCaseOfCurrencyExchangeDeviation>
  <afmd:NetLossInCaseOfCurrencyExchangeDeviation contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit1" decimals="-3">5677000</afmd:NetLossInCaseOfCurrencyExchangeDeviation>
  <afmd:NumberOfMajorCustomers contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_MajorCustomersAxis_afmd_TopFourCustomersMember" unitRef="Unit17" decimals="INF">4</afmd:NumberOfMajorCustomers>
  <afmd:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit16" decimals="INF">40038</afmd:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement>
  <afmd:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit16" decimals="INF">19795</afmd:NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement>
  <afmd:NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit18" decimals="INF">0</afmd:NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights>
  <afmd:NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit18" decimals="INF">0</afmd:NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights>
  <afmd:NumberOfShareOptionsIssuedInShareBasedPaymentArrangement contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit16" decimals="INF">240000</afmd:NumberOfShareOptionsIssuedInShareBasedPaymentArrangement>
  <afmd:NumberOfTranches contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit14" decimals="INF">3</afmd:NumberOfTranches>
  <afmd:OperatingLeaseCommittmentIas17 contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1154000</afmd:OperatingLeaseCommittmentIas17>
  <afmd:OperatingLeasesWeightedAverageDiscountRate contextRef="Duration_1_1_2019_To_1_1_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit13" decimals="4">0.0405</afmd:OperatingLeasesWeightedAverageDiscountRate>
  <afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-5">166200000</afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
  <afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="As_Of_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember" unitRef="Unit1" decimals="-3">423000</afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
  <afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-5">199200000</afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
  <afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes contextRef="As_Of_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember" unitRef="Unit1" decimals="-3">296000</afmd:OperatingLossCarryforwardsForCorporateIncomeTaxPurposes>
  <afmd:OperatingLossCarryforwardsForTradeTaxPurposes contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-5">165400000</afmd:OperatingLossCarryforwardsForTradeTaxPurposes>
  <afmd:OperatingLossCarryforwardsForTradeTaxPurposes contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-5">198400000</afmd:OperatingLossCarryforwardsForTradeTaxPurposes>
  <afmd:PaymentOfTerminationOfProgram contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-5">900000</afmd:PaymentOfTerminationOfProgram>
  <afmd:PaymentsForIncidentalRentalCostsAndOtherRentalPayments contextRef="Duration_1_1_2019_To_1_1_2019" unitRef="Unit1" decimals="-3">312000</afmd:PaymentsForIncidentalRentalCostsAndOtherRentalPayments>
  <afmd:PercentageOfDeemedEuriborRateIfLessThanZeroPercent contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit13" decimals="INF">0</afmd:PercentageOfDeemedEuriborRateIfLessThanZeroPercent>
  <afmd:PercentageOfDeviationBetweenCurrencyExchangeRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit13" decimals="2">0.10</afmd:PercentageOfDeviationBetweenCurrencyExchangeRate>
  <afmd:PercentageOfOwnershipInterestWithWhichLoanIsCollateralized contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit13" decimals="2">1.00</afmd:PercentageOfOwnershipInterestWithWhichLoanIsCollateralized>
  <afmd:PercentageOfShiftInExchangeRateConsideredRealisticScenario contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember" unitRef="Unit13" decimals="2">0.10</afmd:PercentageOfShiftInExchangeRateConsideredRealisticScenario>
  <afmd:ProgramTerminationCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-5">1400000</afmd:ProgramTerminationCost>
  <afmd:PurchaseOfLongTermFinancialAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</afmd:PurchaseOfLongTermFinancialAssets>
  <afmd:PurchaseOfLongTermFinancialAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">861000</afmd:PurchaseOfLongTermFinancialAssets>
  <afmd:PurchaseOfLongTermFinancialAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</afmd:PurchaseOfLongTermFinancialAssets>
  <afmd:RecognisedFinanceLeaseAsAssetsIas17 contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">0</afmd:RecognisedFinanceLeaseAsAssetsIas17>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_AdiHoessMember" unitRef="Unit1" decimals="-3">0</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BemdtModigMember" unitRef="Unit1" decimals="-3">10000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BernhardEhmerMember" unitRef="Unit1" decimals="-3">17000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_FerdinandVerdonckMember" unitRef="Unit1" decimals="-3">11000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_LeilaAllandMember" unitRef="Unit1" decimals="-3">40000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MartinTrederMember" unitRef="Unit1" decimals="-3">9000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MathieuSimonMember" unitRef="Unit1" decimals="-3">0</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_ThomasHechtMember" unitRef="Unit1" decimals="-3">21000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_UlrichGrauMember" unitRef="Unit1" decimals="-3">21000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_WolfgangFischerMember" unitRef="Unit1" decimals="-3">0</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_AdiHoessMember" unitRef="Unit1" decimals="-3">5000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BemdtModigMember" unitRef="Unit1" decimals="-3">9000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_BernhardEhmerMember" unitRef="Unit1" decimals="-3">20000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_FerdinandVerdonckMember" unitRef="Unit1" decimals="-3">11000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_LeilaAllandMember" unitRef="Unit1" decimals="-3">0</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MartinTrederMember" unitRef="Unit1" decimals="-3">0</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_MathieuSimonMember" unitRef="Unit1" decimals="-3">9000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_ThomasHechtMember" unitRef="Unit1" decimals="-3">26000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_UlrichGrauMember" unitRef="Unit1" decimals="-3">21000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors contextRef="As_Of_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_WolfgangFischerMember" unitRef="Unit1" decimals="-3">1000</afmd:RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors>
  <afmd:ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest SVB Loan Agreement (see note 19)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (483)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (847)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (690)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Foreign exchange differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (175)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 651&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest on certificates of deposit with maturities of more than three months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 602&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 77&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other finance income/finance costs - net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 71&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 251&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 15&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,983)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock>
  <afmd:ServiceFeesToBeReceived contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AmphivenaMember" unitRef="Unit1" decimals="-6">16000000</afmd:ServiceFeesToBeReceived>
  <afmd:ShareBasedCompensationArrangementFairValueOfAwardsGranted contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit1" decimals="-3">133000</afmd:ShareBasedCompensationArrangementFairValueOfAwardsGranted>
  <afmd:SharePricePerShare contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit19" decimals="2">1.80</afmd:SharePricePerShare>
  <afmd:SharePricePerShare contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit19" decimals="2">2.00</afmd:SharePricePerShare>
  <afmd:SharePricePerShare contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit19" decimals="2">2.50</afmd:SharePricePerShare>
  <afmd:SharesPrice contextRef="Duration_11_13_2019_To_11_13_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember" unitRef="Unit19" decimals="2">2.50</afmd:SharesPrice>
  <afmd:SharesValue contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">3800000</afmd:SharesValue>
  <afmd:SharesValue contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">3200000</afmd:SharesValue>
  <afmd:SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Short-term employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,598&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,683&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Termination benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 264&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Share-based payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,738&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,229&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,379&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,912&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,917&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock>
  <afmd:SummaryOfEmployeeBenefitTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Wages and salaries&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11,587&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,027&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,475&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Social security costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,620&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,092&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 931&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,207&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11,119&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,406&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfEmployeeBenefitTableTextBlock>
  <afmd:SummaryOfExchangeRatesTableTextBlock contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD or&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD or&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;or GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;CZK&amp;nbsp;- Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03896&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03899&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03799&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;CZK&amp;nbsp;- Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03936&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03887&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03916&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USD&amp;nbsp;- Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.89326&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.84674&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.88519&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USD&amp;nbsp;- Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.89015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.87336&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.83382&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;GBP - Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.1393&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.13031&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;GBP - Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.1754&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.11791&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfExchangeRatesTableTextBlock>
  <afmd:SummaryOfFairValueOfAssetsPledgedTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.80%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Book&amp;nbsp;value&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Book&amp;nbsp;value&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Consolidated&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;thereof&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Consolidated&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;financial&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;financial&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;thereof&amp;nbsp;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;statements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;pledged&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;statements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;pledged&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Leasehold improvements and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,291&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,503&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,414&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,174&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Inventories&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 296&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 247&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 260&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 235&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Trade and other receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,482&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 864&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,429&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,007&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 387&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Financial assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,902&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,902&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,974&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,974&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 95,234&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 93,606&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 94,829&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 92,933&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 108,205&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 105,122&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 112,293&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 109,323&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfFairValueOfAssetsPledgedTableTextBlock>
  <afmd:SummaryOfGeneralAndAdministrativeExpenseTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Personnel expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,357&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,929&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,521&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Legal, consulting and audit expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,055&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,881&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,945&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,853&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,828&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,520&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,266&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,638&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,986&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfGeneralAndAdministrativeExpenseTableTextBlock>
  <afmd:SummaryOfImpactOfLeaseTransitionTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Right-of-use assets &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfImpactOfLeaseTransitionTableTextBlock>
  <afmd:SummaryOfIncomeTaxReconciliationTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Loss before tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (32,361)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (19,476)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (30,243)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Income tax benefit at tax rate of 29.825 %&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,652&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,809&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adjustments of deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (9,822)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (5,318)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (9,036)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (29)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (462)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (93)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adjustments for local tax rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (34)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 195&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Non deductible expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (43)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (53)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 16&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (82)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfIncomeTaxReconciliationTableTextBlock>
  <afmd:SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Annual Improvements to IFRS Standards 2015&lt;/font&gt;&lt;font style="display:inline;font-family:MS Gothic;color:#000000;"&gt;&amp;#x2011;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;2017 Cycle&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 19: Plan Amendment, Curtailment or Settlement&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRIC 23 Uncertainty over Income Tax Treatments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock>
  <afmd:SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to References to the Conceptional Framework&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 1 and IAS 8: Definition of Material&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 3 Business Combination&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock>
  <afmd:SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&amp;nbsp;balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adi Hoess&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Wolfgang Fischer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Martin Treder&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Leila Alland&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 40&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Thomas Hecht&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 26&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Mathieu Simon&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Berndt Modig&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Ferdinand Verdonck&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Ulrich Grau&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Bernhard Ehmer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 17&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock>
  <afmd:SummaryOfResearchAndDevelopmentExpenseTableTextBlock contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Third-party services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 27,338&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,127&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 12,299&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Personnel expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,055&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,639&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Legal, consulting and patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,983&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,672&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 890&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Cost of Materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,547&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 994&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amortisation and depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 725&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 351&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 309&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,044&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,804&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,358&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 43,791&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 35,148&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,489&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
  <afmd:TaxEffectDueToAdjustmentsOfDeferredAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">9036000</afmd:TaxEffectDueToAdjustmentsOfDeferredAssets>
  <afmd:TaxEffectDueToAdjustmentsOfDeferredAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">5318000</afmd:TaxEffectDueToAdjustmentsOfDeferredAssets>
  <afmd:TaxEffectDueToAdjustmentsOfDeferredAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">9822000</afmd:TaxEffectDueToAdjustmentsOfDeferredAssets>
  <afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-16000</afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet>
  <afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">53000</afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet>
  <afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">43000</afmd:TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet>
  <afmd:TaxEffectOfLocalTaxRates contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-195000</afmd:TaxEffectOfLocalTaxRates>
  <afmd:TaxEffectOfLocalTaxRates contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">34000</afmd:TaxEffectOfLocalTaxRates>
  <afmd:TaxEffectOfLocalTaxRates contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-5000</afmd:TaxEffectOfLocalTaxRates>
  <afmd:TaxEffectOfPermanentDifferences contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">93000</afmd:TaxEffectOfPermanentDifferences>
  <afmd:TaxEffectOfPermanentDifferences contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">462000</afmd:TaxEffectOfPermanentDifferences>
  <afmd:TaxEffectOfPermanentDifferences contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">29000</afmd:TaxEffectOfPermanentDifferences>
  <afmd:ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-8">5000000000</afmd:ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones>
  <afmd:TransitionPolicyPolicyTextBlock contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"&gt;Transition &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On transition to IFRS 16, Affimed elected to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not reassessed. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As a lessee, Affimed previously classified leases as operating or finance leases based on its assessment of whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Affimed recognizes right-of-use assets and lease liabilities for most leases &amp;#x2013; i.e. these leases are on-balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;At transition, for leases classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Company&amp;#x2019;s incremental borrowing rates for similar assets as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On transition to IFRS 16, the Company recognized additional right-of-use assets, including property, plant and equipment and additional lease liabilities. The impact on transition is summarized below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Right-of-use assets &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group discounted lease payments using a weighted average discount rate of 4.05% as of January 1, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In relation to those leases under IFRS 16, Affimed has recognized depreciation and interest costs, instead of operating lease expense. In 2019, the Group recognized depreciation expense for right-of-use assets of &amp;#x20AC;385 and interest cost related to the lease liability of &amp;#x20AC;24 instead of operating lease expense of &amp;#x20AC;406.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The transition between operating lease commitments disclosed applying IAS 17 as of December 31, 2018 and the lease liabilities recognized in the statement of financial position at the date of initial application, January 1, 2019, is shown below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Operating lease commitment as of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Recognition exemption for short-term leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (98)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments for incidental rental costs and other rental payments (Not part of the lease)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (312)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Discounting using the incremental borrowing rate as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (27)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</afmd:TransitionPolicyPolicyTextBlock>
  <afmd:WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit1" decimals="-3">133000</afmd:WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded>
  <afmd:WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit12" decimals="-3">164000</afmd:WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded>
  <afmd:WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay contextRef="Duration_4_20_2018_To_4_20_2018">P15D</afmd:WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay>
  <dei:AmendmentFlag contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2019_To_12_31_2019">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentAnnualReport contextRef="Duration_1_1_2019_To_12_31_2019">true</dei:DocumentAnnualReport>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2019_To_12_31_2019">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2019_To_12_31_2019">2019</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2019_To_12_31_2019">2019-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentShellCompanyReport contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:DocumentShellCompanyReport>
  <dei:DocumentTransitionReport contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:DocumentTransitionReport>
  <dei:DocumentType contextRef="Duration_1_1_2019_To_12_31_2019">20-F</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2019_To_12_31_2019">0001608390</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit16" decimals="INF">76249901</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="Duration_1_1_2019_To_12_31_2019">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2019_To_12_31_2019">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityInteractiveDataCurrent contextRef="Duration_1_1_2019_To_12_31_2019">No</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2019_To_12_31_2019">Affimed N.V.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="Duration_1_1_2019_To_12_31_2019">false</dei:EntityShellCompany>
  <dei:EntityVoluntaryFilers contextRef="Duration_1_1_2019_To_12_31_2019">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="Duration_1_1_2019_To_12_31_2019">No</dei:EntityWellKnownSeasonedIssuer>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">492000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember" unitRef="Unit1" decimals="-3">492000</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdditionsToRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember" unitRef="Unit1" decimals="-3">0</ifrs-full:AdditionsToRightofuseAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-44000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-36000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-399000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">121000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">340000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1140000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-322000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">33000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">351000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">403000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">906000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-2983000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">60000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForFinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">15000</ifrs-full:AdjustmentsForFinanceIncomeCost>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">19000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-25000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">5000</ifrs-full:AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment>
  <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-20000</ifrs-full:AdjustmentsForIncomeTaxExpense>
  <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1000</ifrs-full:AdjustmentsForIncomeTaxExpense>
  <ifrs-full:AdjustmentsForIncomeTaxExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">4000</ifrs-full:AdjustmentsForIncomeTaxExpense>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-1018000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">66856000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-791000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1943000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2035000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:AdjustmentsForSharebasedPayments contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">2469000</ifrs-full:AdjustmentsForSharebasedPayments>
  <ifrs-full:ApplicableTaxRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="INF">0.29825</ifrs-full:ApplicableTaxRate>
  <ifrs-full:Assets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">116174000</ifrs-full:Assets>
  <ifrs-full:Assets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">112359000</ifrs-full:Assets>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03799</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.88519</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03899</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_GbpMember" unitRef="Unit112" decimals="5">1.13031</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.84674</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03896</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_GbpMember" unitRef="Unit112" decimals="4">1.1393</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:AverageForeignExchangeRate contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.89326</ifrs-full:AverageForeignExchangeRate>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit19" decimals="2">-0.69</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit19" decimals="2">-0.32</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BasicAndDilutedEarningsLossPerShare contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit19" decimals="2">-0.50</ifrs-full:BasicAndDilutedEarningsLossPerShare>
  <ifrs-full:BorrowingCostsCapitalised contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">847000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:BorrowingCostsCapitalised contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">489000</ifrs-full:BorrowingCostsCapitalised>
  <ifrs-full:Borrowings contextRef="As_Of_12_31_2016_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" unitRef="Unit1" decimals="-5">5000000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="As_Of_5_31_2017_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" unitRef="Unit1" decimals="-5">2500000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="As_Of_4_30_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember" unitRef="Unit1" decimals="-3">562000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember" unitRef="Unit1" decimals="-3">368000</ifrs-full:Borrowings>
  <ifrs-full:Borrowings contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit1" decimals="-5">2000000</ifrs-full:Borrowings>
  <ifrs-full:BorrowingsAdjustmentToInterestRateBasis contextRef="As_Of_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember_ifrs-full_TypesOfInterestRatesAxis_afmd_OneMonthEURIBORMember" unitRef="Unit13" decimals="3">0.055</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
  <ifrs-full:BorrowingsAdjustmentToInterestRateBasis contextRef="As_Of_12_31_2019_ifrs-full_TypesOfInterestRatesAxis_afmd_OneMonthEuriborMember_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit13" decimals="INF">0.055</ifrs-full:BorrowingsAdjustmentToInterestRateBasis>
  <ifrs-full:CapitalReserve contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">239055000</ifrs-full:CapitalReserve>
  <ifrs-full:CapitalReserve contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">270451000</ifrs-full:CapitalReserve>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">35407000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">39837000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">39837000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">94829000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">94829000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">94829000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">94829000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">92933000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">94800000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">95234000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">95234000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">95234000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">93606000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashAndCashEquivalents contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">95200000</ifrs-full:CashAndCashEquivalents>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">23797000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">20495000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">26038000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">8050000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-15610000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">4340000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-25549000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">49438000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-29056000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-25306000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">49563000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:CashFlowsFromUsedInOperations contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-29460000</ifrs-full:CashFlowsFromUsedInOperations>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-24985000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-17073000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-29006000</ifrs-full:CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital>
  <ifrs-full:CashOutflowForLeases contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">495000</ifrs-full:CashOutflowForLeases>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03916</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2017_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.83382</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03887</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_GbpMember" unitRef="Unit112" decimals="5">1.11791</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.87336</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_CZKMember" unitRef="Unit110" decimals="5">0.03936</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_GbpMember" unitRef="Unit112" decimals="4">1.1754</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ClosingForeignExchangeRate contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_afmd_USDMember" unitRef="Unit111" decimals="5">0.89015</ifrs-full:ClosingForeignExchangeRate>
  <ifrs-full:ComprehensiveIncome contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30223000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-24208000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ComprehensiveIncome contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32997000</ifrs-full:ComprehensiveIncome>
  <ifrs-full:ContractLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">61847000</ifrs-full:ContractLiabilities>
  <ifrs-full:ContractLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">59314000</ifrs-full:ContractLiabilities>
  <ifrs-full:CurrentAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">110879000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">105914000</ifrs-full:CurrentAssets>
  <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">3083000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
  <ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">2105000</ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings>
  <ifrs-full:CurrentContractLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">24335000</ifrs-full:CurrentContractLiabilities>
  <ifrs-full:CurrentContractLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">21353000</ifrs-full:CurrentContractLiabilities>
  <ifrs-full:CurrentFinancialAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">13974000</ifrs-full:CurrentFinancialAssets>
  <ifrs-full:CurrentFinancialAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">8902000</ifrs-full:CurrentFinancialAssets>
  <ifrs-full:CurrentLeaseLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLeaseLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">532000</ifrs-full:CurrentLeaseLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">36843000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">35181000</ifrs-full:CurrentLiabilities>
  <ifrs-full:CurrentPortionOfLongtermBorrowings contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember" unitRef="Unit1" decimals="-3">91000</ifrs-full:CurrentPortionOfLongtermBorrowings>
  <ifrs-full:CurrentProvisions contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-5">500000</ifrs-full:CurrentProvisions>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0005" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0003" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0002" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0004" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AnnualImprovementsToIfrsStandards20152017CycleMember">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0006" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially id="Item-0001" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifrs16Member">2019-01-01</ifrs-full:DateAsAtWhichEntityPlansToApplyNewIFRSInitially>
  <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember">2020-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
  <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs3BusinessCombinationMember">2020-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
  <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember">2020-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
  <ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToReferencesToConceptionalFrameworkMember">2020-01-01</ifrs-full:DateByWhichApplicationOfNewIFRSIsRequired>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TemporaryDifferenceBorrowingsMember" unitRef="Unit1" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherPayablesMember" unitRef="Unit1" decimals="-3">27000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherReceivablesMember" unitRef="Unit1" decimals="-3">334000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" unitRef="Unit1" decimals="-3">415000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_LeaseLiabilitiesMember" unitRef="Unit1" decimals="-3">0</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TemporaryDifferenceBorrowingsMember" unitRef="Unit1" decimals="-3">70000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherPayablesMember" unitRef="Unit1" decimals="-3">23000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_TradeAndOtherReceivablesMember" unitRef="Unit1" decimals="-3">243000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_IntangibleAssetsOtherThanGoodwillMember" unitRef="Unit1" decimals="-3">283000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxAssets contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_ifrs-full_LeaseLiabilitiesMember" unitRef="Unit1" decimals="-3">121000</ifrs-full:DeferredTaxAssets>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_ContractLiabilitiesMember" unitRef="Unit1" decimals="-3">0</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" unitRef="Unit1" decimals="-3">0</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2018_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LongTermFinancialAssetsMember" unitRef="Unit1" decimals="-3">774000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_ContractLiabilitiesMember" unitRef="Unit1" decimals="-3">308000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" unitRef="Unit1" decimals="-3">226000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DeferredTaxLiabilities contextRef="As_Of_12_31_2019_ifrs-full_AssetsAndLiabilitiesAxis_afmd_LongTermFinancialAssetsMember" unitRef="Unit1" decimals="-3">1218000</ifrs-full:DeferredTaxLiabilities>
  <ifrs-full:DepreciationRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">384000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit1" decimals="-3">385000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember" unitRef="Unit1" decimals="-3">371000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DepreciationRightofuseAssets contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember" unitRef="Unit1" decimals="-3">13000</ifrs-full:DepreciationRightofuseAssets>
  <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Loss per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group has granted warrants under certain loan agreements (see note 19) and options under share-based payment programs (see note 17) which potentially have a dilutive effect; no instruments actually had a dilutive effect.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Employee benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Short-term employee benefits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a)&amp;nbsp;the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b)&amp;nbsp;the obligation can be estimated reliably.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share-based payment transactions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s share-based payment awards outstanding as of December&amp;nbsp;31, 2018 and 2019, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;(iii)&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;;font-size: 10pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;Termination benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Termination benefits are expensed when the Group can no longer withdraw the offer of those benefits. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Fair Value Measurement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;All assets and liabilities for which fair value is recognized in the consolidated financial statements are &lt;/font&gt;&lt;font style="display:inline;"&gt;classified &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 1&amp;nbsp;&amp;#x2013; Prices for identical assets or liabilities quoted in active markets (non-adjusted)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 2&amp;nbsp;&amp;#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 3&amp;nbsp;&amp;#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 19).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance income and finance costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance costs comprise primarily interest expense on borrowings.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Non-derivative financial assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group&amp;#x2019;s non-derivative financial assets include preferred shares in Amphivena, &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three&amp;nbsp;months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Cash and cash equivalents comprise cash balances and call deposits with original maturities of three&amp;nbsp;months or less.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group holds &lt;/font&gt;&lt;font style="display:inline;"&gt;preferred shares in Amphivena &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;designated at fair value through other comprehensive income (see note 13).&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Non-derivative financial liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Compound financial instruments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 19). The number of shares to be issued does not vary with changes in their fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Government grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group receives certain government grants that support its research effort in specific projects. &lt;/font&gt;&lt;font style="display:inline;"&gt;These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants.&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt; Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group recognizes income from government grants under &amp;#x2018;Other income&amp;nbsp;- net&amp;#x2019; in the consolidated statement of comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForGovernmentGrants>
  <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Impairment&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Trade and other receivables&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group&amp;#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed determines the counterparties&amp;#x2019; lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2017, 2018 or 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Intangible assets and leasehold improvements and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset&amp;#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&amp;#x2019;s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Income taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the&amp;nbsp;year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForIncomeTaxExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Policy applicable from 1 January 2019&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred. Subsequently, the right-of-use asset is&amp;nbsp;&amp;nbsp;depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Affimed&amp;#x2019;s incremental borrowing rate. Generally, Affimed uses its incremental borrowing rate as the discount rate. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group determines the incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and the type of the asset leased.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The lease liability is subsequently&amp;nbsp;&amp;nbsp;measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed has elected not to recognize right-of-use assets and lease liabilities for some short-term leases (leases with less than 12 months of lease term) and right-of-use assets and liabilities for leases of low value assets. Lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Policy applicable before 1 January 2019&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For impact on transition please refer to &amp;#x201C;New standards and interpretations applied for the first time&amp;#x201D; below.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
  <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Revenue recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a &amp;#x201C;best efforts&amp;#x201D; basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provide the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Such agreements may comprise more than one research program, platform licenses or intellectual property &lt;/font&gt;&lt;font style="display:inline;"&gt;licenses &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;originally generated by the Group. Usually each of those promises is considered to meet the &lt;/font&gt;&lt;font style="display:inline;"&gt;definition&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt; of a separate performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses, a residual approach is used. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight-line basis until the use of the license by the customer ends. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group&amp;#x2019;s view, uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
  <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Research and development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group&amp;#x2019;s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
  <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"&gt;New standards and interpretations not yet adopted&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2019, and have not been applied in preparing these consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to References to the Conceptional Framework&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 1 and IAS 8: Definition of Material&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 3 Business Combination&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;1 Shall apply for periods beginning on or after the date shown in the effective date column.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit13" decimals="2">0.72</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="2">0.82</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
  <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;New standards and interpretations applied for the first time&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&amp;nbsp;1, 2019, and have been applied in preparing these financial statements:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Annual Improvements to IFRS Standards 2015&lt;/font&gt;&lt;font style="display:inline;font-family:MS Gothic;color:#000000;"&gt;&amp;#x2011;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;2017 Cycle&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 19: Plan Amendment, Curtailment or Settlement&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRIC 23 Uncertainty over Income Tax Treatments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;1 &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Shall apply for periods beginning on or after the date shown in the effective date column.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &amp;#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &amp;#xB4;Determining Whether an Arrangement contains a Lease&amp;#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit113" decimals="INF">5.9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit113" decimals="INF">2</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit113" decimals="INF">5.9</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit13" decimals="4">0.0034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit13" decimals="4">0.0209</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
  <ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit16" decimals="INF">0</ifrs-full:DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares>
  <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Critical judgments and accounting estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In preparing these financial statements, the critical judgments made by management in applying the Group&amp;#x2019;s accounting policies resulted in the following accounting estimates&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share-based payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On April&amp;nbsp;20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in note&amp;nbsp;17. Incorporating the market condition in the fair value estimate requires the use of a simulation technique (Monte Carlo simulation), which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be &amp;#x20AC;133.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Revenue recognition&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;"&gt;The Group&amp;#x2019;s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iv)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial instruments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group holds preferred shares in Amphivena classified as equity instruments at fair value through other comprehensive income (level 2) and&amp;nbsp;&amp;nbsp;recognized as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2019 (see note 13). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (v)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether Affimed is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognized. As at December 31, 2019, no renewal options were incorporated into the determining the lease term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (vi)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;"&gt;Provisions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the second quarter of 2019, Affimed decided to terminate the Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager as a part of its strategic plans (see note 18).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
  <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Basis of preparation &amp;#x2013; consolidated financial statements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Statement of compliance&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The consolidated financial statements were authorized for issuance by the management board on April&amp;nbsp;28, 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Basis of measurement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The consolidated financial statements have been prepared on the historical cost basis except for financial instruments measured at fair value (see note 13) and monetary assets and liabilities denominated in foreign currencies which are translated at period-end exchange rates. The Group did not opt for a valuation of liabilities at fair value through profit or loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Consolidation&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group controls an entity when it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control is obtained by the Group. It is de-consolidated from the date control ceases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Functional and presentation currency&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The consolidated financial statements are presented in euro, which is also the functional currency. All financial information presented in euro unless otherwise noted has been rounded to the nearest thousand (abbreviated &amp;#x20AC;) or million (abbreviated &amp;#x20AC; million).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Presentation of consolidated statements of comprehensive loss&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As a clinical-stage biopharmaceutical company with a primary focus on research and development activities, cost of sales and gross profit are not considered meaningful measures for Affimed and therefore are not presented. &lt;/font&gt;&lt;font style="display:inline;"&gt;See note 4 for the Group&amp;#x2019;s accounting policies related to revenue recognition and research and development expenses.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Foreign currency transactions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Transactions denominated in currencies other than the euro are translated at exchange rates at the date of the transaction. Monetary assets and liabilities denominated in currencies other than the euro are translated at the exchange rate at the date of the consolidated statement of financial position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Foreign currency gains or losses that relate to borrowings, cash and cash equivalents and financial assets, except for financial instruments at fair value through other comprehensive income are presented in the statement of comprehensive loss within &amp;#x2018;Finance income / (costs)&amp;nbsp;- net&amp;#x2019;. All other foreign exchange gains and losses are presented in the statement of comprehensive loss within &amp;#x2018;Other income&amp;nbsp;&amp;#x2013; net&amp;#x2019;.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfBorrowingsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;19.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Borrowings&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Silicon Valley Bank&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On November&amp;nbsp;30, 2016, Affimed entered into a loan agreement with Silicon Valley Bank (the &amp;#x201C;SVB loan&amp;#x201D;) which provides the Group with a senior secured term loan facility originally for up to &amp;#x20AC;10.0 million, which agreement was amended in May&amp;nbsp;2017 to provide that such amount would be available in three tranches. In December&amp;nbsp;2016, the Group drew an initial tranche of &amp;#x20AC;5.0 million and in May&amp;nbsp;2017, a second tranche of &amp;#x20AC;2.5 million; the availability of a third tranche of &amp;#x20AC;2.5 million expired in September&amp;nbsp;2017 with such amount remaining undrawn.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of &amp;#x20AC;236 and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement, the Group also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten&amp;nbsp;years from the grant date. The fair value of the warrants of &amp;#x20AC;192 less deferred taxes and transaction costs of &amp;#x20AC;81 and &amp;#x20AC;8, respectively, was recorded as an addition to capital reserves in equity. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75&amp;#8209;80% and an expected exercise period of five&amp;nbsp;years to exercise of the warrant. The contractual maturity of the warrants is ten&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The loan is secured by a pledge of 100% of Group&amp;#x2019;s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements with the following book values:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.80%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Book&amp;nbsp;value&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Book&amp;nbsp;value&amp;nbsp;as&amp;nbsp;of&amp;nbsp;December&amp;nbsp;31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Consolidated&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;thereof&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Consolidated&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;financial&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;financial&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;thereof&amp;nbsp;assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;statements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;pledged&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;statements&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;pledged&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Leasehold improvements and equipment&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,291&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,503&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,414&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,174&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Inventories&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 296&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 247&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 260&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 235&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Trade and other receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,482&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 864&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,429&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,007&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 387&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Financial assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,902&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,902&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,974&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,974&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 95,234&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 93,606&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 94,829&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 92,933&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 108,205&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 105,122&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 112,293&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 109,323&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As of December&amp;nbsp;31, 2019 and 2018, the fair value of the liability did not differ significantly from its carrying amount (&amp;#x20AC;2,013 and &amp;#x20AC;4,773). The loan has a maturity date of May&amp;nbsp;31, 2020, repayment started in December&amp;nbsp;2017 with amortized payments of principal and interest in equal&amp;nbsp;monthly installments. As of December&amp;nbsp;31, 2019, &amp;#x20AC;2,013 (2018: &amp;nbsp;&amp;#x20AC;3,083) were classified as current liabilities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;UniCredit Leasing CZ&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for &amp;#x20AC;562. After an initial instalment of &amp;#x20AC;127 in the second quarter of 2019, repayment is effected in monthly instalments of &amp;#x20AC;8 until November 2023. As at December 31, 2019, an amount of &amp;#x20AC;368 was outstanding, of which &amp;#x20AC;91 was classified as current liabilities. As of December 31, 2019, the fair value of the liability did not differ significantly from its carrying amount.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Reconciliation to cash flows from financing&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Movements of liabilities reconcile to cash flows arising from financing activities as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,169&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Changes from financing cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Proceeds from borrowings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 562&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of borrowings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (3,277)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,917)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,715)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; (2,917)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Other Changes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Capitalized borrowing costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 489&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 847&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest paid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (164)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (326)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 325&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 531&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,383&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfBorrowingsExplanatory>
  <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;22.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other commitments and contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Commitments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;"&gt;The Group has entered into agreements for the use of licenses. In 2019, license fees of &amp;#x20AC;92 have been recognized in consolidated statement of comprehensive income (2018: &amp;#x20AC;124, 2017: &amp;#x20AC;174), related future payment obligations under non-cancellable fees amount to &amp;#x20AC;25.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Contingencies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed has entered into various license agreements that contingently trigger payments upon achievement of certain milestones and royalty payments upon commercialization of a product in the future.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfContingentLiabilitiesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 204&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 210&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Contract liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 59,314&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 61,847&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfContingentLiabilitiesExplanatory>
  <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Major service lines:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Collaboration revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 19,685&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 390&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Service revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,706&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,620&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Revenue:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Point in time&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,783&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,863&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Over time&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 15,608&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,872&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,777&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
  <ifrs-full:DisclosureOfEmployeeBenefitsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;10.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Employee benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table shows the items of employee benefits for the&amp;nbsp;years ended December&amp;nbsp;31:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Wages and salaries&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11,587&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,027&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,475&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Social security costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,620&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,092&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 931&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 13,207&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11,119&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,406&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The employer&amp;#x2019;s contributions to pension insurance plans of &amp;#x20AC;696 (2018: &amp;#x20AC;502, 2017: &amp;#x20AC;438) are classified as payments under a defined contribution plan, and are recognized as an expense.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfEmployeeBenefitsExplanatory>
  <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;25.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Subsequent events&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Company announced early February 2020 that Dr. Florian Fischer, Chief Financial Officer (CFO) of Affimed, passed away. Affimed has commenced a process for a new permanent CFO. As part of the transition, Harry Welten will assume the operating responsibilities as CFO advisor to Affimed during the search and will continue to operate in that capacity until a permanent successor has been appointed.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In addition, the Company announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020 and the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As circumstances around the COVID-19 pandemic continue to rapidly evolve, the Group is continuously assessing possible effects on its clinical trials and adapting the risk mitigation measures implemented. Affimed is closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of its global workforce and help limit the spread of COVID-19, while maintaining business continuity. The Group has taken mitigation steps to ensure that drug supply and other trial-related materials are ready and available for the patients enrolled in its clinical trials. Due to the ongoing assessment of the potential impact of the COVID-19 pandemic on patient enrollment and site activation in its clinical studies, Affimed will update trial timelines after it has more visibility on the length and extent of the COVID-19 crisis.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
  <ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;11.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Finance income and finance costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table shows the items of finance income and costs for the&amp;nbsp;years ended December&amp;nbsp;31:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest SVB Loan Agreement (see note 19)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (483)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (847)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (690)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Foreign exchange differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (175)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 651&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,378)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest on certificates of deposit with maturities of more than three months&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 602&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 77&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other finance income/finance costs - net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 71&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 251&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;8
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 15&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 60&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,983)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory>
  <ifrs-full:DisclosureOfFinancialAssetsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;14.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Financial assets&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial assets contain of U.S. Dollar denominated certificates of deposit with original maturities of more than three&amp;nbsp;months. As of December 31, 2019, the fair value (level 1) of the financial assets did not differ significantly from its carrying amount.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFinancialAssetsExplanatory>
  <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;24.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Financial risk management&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial risk management objectives and policies&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s principal financial instruments comprise cash and cash equivalents, certificates of deposit at commercial banks, a convertible loan, warrants and investor loans presented in borrowings. The main purpose of these financial instruments is to raise funds for the Group&amp;#x2019;s operations. The Group has various other financial assets and liabilities such as trade and other receivables and trade and other payables, which arise directly from its operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The main risks arising from the Group&amp;#x2019;s financial instruments are credit risk and liquidity risk. The measures taken by management to manage each of these risks are summarized below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Credit risk&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s financial assets comprise to a large extent cash and cash equivalents. In addition, financial assets include shares, certificates of deposit, trade and other receivables. The total carrying amount of shares (&amp;#x20AC;3.2 million, 2018: &amp;#x20AC;3.8 million) cash and cash equivalents&amp;nbsp; (&amp;#x20AC;95.2&amp;nbsp;million, 2018: &amp;#x20AC;94.8 million), trade and other receivables (&amp;#x20AC;1.5 million, 2018:&amp;nbsp;&amp;#x20AC;1.4 million), and certificates of deposit (&amp;#x20AC;8.9 million, 2018:&amp;nbsp;&amp;#x20AC;14.0 million), represents the maximum credit exposure of &amp;#x20AC;108.8 million (2018: &amp;#x20AC;114.1 million).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The cash and cash equivalents and certificates of deposit are held with banks, which are rated BBB+ to AA- based on Standard&amp;nbsp;&amp;amp; Poor&amp;#x2019;s and Moody&amp;#x2019;s.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Interest rate risk&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s interest rate risk arises from cash accounts and long-term borrowings at variable rates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed entered into the SVB loan pursuant to which the Group borrowed &amp;#x20AC;7.5 million with an outstanding balance of &amp;#x20AC;2.0 million as at December&amp;nbsp;31, 2019, with a variable interest rate of an annual rate of 5.5% plus one-month EURIBOR, with EURIBOR deemed to equal zero&amp;nbsp;percent if EURIBOR is less than zero&amp;nbsp;percent. The Group does not expect the EURIBOR to exceed the floor of 0% within the foreseeable future, and considers the interest risk to be low.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Market interest&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; rates on cash and cash equivalents as well as on term deposits &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;were&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; low&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt; in 2019,&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; resulting in interest income of &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;&amp;#x20AC;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;715 in 2019. &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A shift in interest rates (increase or decrease) would not have a material impact on the loss of the Group.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iv)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Other price risks&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The fair value of the shares in Amphivena depends on the share price. The total exposure of the Group amounts to &amp;#x20AC;3.2 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (v)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Foreign currency risk&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Foreign exchange risk arises when future commercial transactions or recognized assets or liabilities are denominated in a currency that is not the entity&amp;#x2019;s functional currency.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s entities are exposed to Czech Koruna (CZK) and US Dollars (USD) and British Pound (GBP). The net exposure as of December&amp;nbsp;31, 2019 was &amp;#x20AC;56,531 (2018: &amp;#x20AC;47,524) &amp;nbsp;and mainly relates to US Dollars.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2019, if the Euro had weakened/strengthened by 10% against the US dollar with all other variables held constant, the loss would have been &amp;#x20AC;5,677 (2018: &amp;#x20AC;4,787) higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated financial assets. The Group considers a shift in the exchange rates of 10% as a realistic scenario.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Loss is more sensitive to movement in exchange rates shifts in 2019 than in 2018 because of the increased volume of US dollar-denominated transactions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following significant exchange rates have been applied during the&amp;nbsp;year:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD or&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;CZK&amp;nbsp;or USD or&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;or GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;GBP/EUR&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;CZK&amp;nbsp;- Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03896&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03899&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03799&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;CZK&amp;nbsp;- Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03936&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03887&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.03916&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USD&amp;nbsp;- Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.89326&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.84674&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.88519&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USD&amp;nbsp;- Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.89015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.87336&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.83382&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;GBP - Average Rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.1393&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.13031&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;GBP - Spot rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.1754&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.11791&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (vi)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Liquidity risk&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities which are normally settled by delivering cash. The Group&amp;#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group continually monitors its risk of a shortage of funds using short and mid-term liquidity planning. This takes account of the expected cash flows from all activities. The supervisory board undertakes regular reviews of the budget.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2017 and 2018 and 2019, Affimed raised significant funding that it estimates will enable the Group to fund operating expenses and capital expenditure requirements at least into the fourth quarter of 2021.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2017, the Group issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of &amp;#x20AC;16.4 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2018, the Group issued 13,225,000 common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately &amp;#x20AC;19.7 million and 2,373,716 common shares in connection with its at-the-market sales agreement for net proceeds of &amp;#x20AC;3.8 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2019,&amp;nbsp;&amp;nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &amp;#x20AC;29.5 million (see note 16).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group expects to require additional funding to complete the development of the existing product candidates. In addition, the Group expects to require additional capital to commercialize the products if regulatory approval is received.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (vii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Capital management&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The primary objective of the Group&amp;#x2019;s capital management is to ensure that it maintains its liquidity in order to finance its operating activities and meet its liabilities when due.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group manages its capital structure primarily through equity.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
  <ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;9.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;General and administrative expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table shows the different types of expenses allocated to general and administrative costs for the&amp;nbsp;years ended December&amp;nbsp;31:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Personnel expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,357&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,929&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,521&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Legal, consulting and audit expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,055&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,881&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,945&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,853&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,828&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,520&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,266&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,638&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,986&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfGeneralAndAdministrativeExpenseExplanatory>
  <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Reporting entity&lt;a name="a1Reportingentity_514365"&gt;&lt;/a&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed N.V. is a Dutch company with limited liability (&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"&gt;naamloze vennootschap&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;) and has its corporate seat in Amsterdam, the Netherlands.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed&amp;nbsp;Inc., Delaware, USA and AbCheck&amp;nbsp;Inc., Delaware, USA (together &amp;#x201C;Affimed&amp;#x201D; or the &amp;#x201C;Group&amp;#x201D;).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The Group&amp;#x2019;s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body&amp;#x2019;s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, where the Group is performing research services for third parties.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
  <ifrs-full:DisclosureOfGeographicalAreasExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Revenue:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 80&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Europe&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,646&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,236&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USA&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 19,745&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 694&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Non-current assets as of December, 31:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,224&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 957&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Czech Republic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 870&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 246&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 221&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USA&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,558&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,825&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 6,445&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,295&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,178&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfGeographicalAreasExplanatory>
  <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;12.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Income taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group did not incur any material income tax in the periods presented. As of December 31, 2019, deferred tax assets from differences resulting from intangible assets (&amp;#x20AC;283; 2018: &amp;#x20AC;415), trade and other receivables (&amp;#x20AC;243; 2018: &amp;#x20AC;334), borrowings (&amp;#x20AC;70; 2018: &amp;#x20AC;0), lease liabilities (&amp;#x20AC;121; 2018: &amp;#x20AC;0) and trade and other payables (&amp;#x20AC;23; 2018: &amp;#x20AC;27) have not been recognized as deferred tax assets as no sufficient future taxable profits or offsetting deferred tax liabilities are available. As of December 31, 2019 deferred tax liabilities from temporary differences result mainly leasehold improvements and equipment and right-of-use assets (&amp;#x20AC;226; 2018: &amp;#x20AC;0), long term financial assets (&amp;#x20AC;1,218; &amp;nbsp;2018: &amp;#x20AC;774) and contract liabilities (&amp;#x20AC;308; 2018: &amp;#x20AC;0). Deferred tax liabilities are not recognized as there is an excess of deferred tax assets over deferred tax liabilities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&amp;#x2019;s applicable tax rate is presented below for the&amp;nbsp;years ended December&amp;nbsp;31:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Loss before tax&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (32,361)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (19,476)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (30,243)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Income tax benefit at tax rate of 29.825 %&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,652&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,809&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 9,020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adjustments of deferred tax assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (9,822)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (5,318)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (9,036)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Permanent differences&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (29)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (462)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (93)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adjustments for local tax rates&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (34)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 195&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Non deductible expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (43)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (53)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 16&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 57&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (82)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Income taxes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In Germany, Affimed has tax losses carried forward of &amp;#x20AC;199.2 million (2018: &amp;#x20AC;166.2 million) for corporate income tax purposes and of &amp;#x20AC;198.4 million (2018: &amp;#x20AC;165.4 million) for trade tax purposes that are available indefinitely for offsetting against future taxable profits of that entity. Restrictions on the utilization of tax losses in case of a change of control of ownership in Affimed were mitigated by the enactment of the Economic Growth Acceleration Act (&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"&gt;Wachstumsbeschleunigungsgesetz&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;"&gt;2009&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;). According to the provisions of this act unused tax losses of a corporation as at the date of a qualified change in ownership are preserved to the extent they are compensated by an excess of the fair value of equity for tax purposes above its carrying amount of the Group. The maximum amount of tax losses at risk of being lost due to ownership changes is approximately &amp;#x20AC;59 million. Deferred tax assets have not been recognized in respect of any losses carried forward as no sufficient taxable profits of Affimed are expected.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Tax losses of Abcheck s.r.o. amount to &amp;#x20AC;296 as at December&amp;nbsp;31, 2019 (2018: &amp;#x20AC;423).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
  <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Fair value at grant date &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Share price at grant date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.44&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.91&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Exercise price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.44&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.92&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 82&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.34&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
  <ifrs-full:DisclosureOfIssuedCapitalExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;16.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Equity&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As of December 31, 2019, the share capital of &amp;#x20AC;762 (2018: &amp;#x20AC;624) is composed of 76,249,901 (2018: 62,430,106) common shares with a par value of &amp;#x20AC;0.01.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On November 13, 2019,&amp;nbsp;&amp;nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &amp;#x20AC;29.5 million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As at 31, December 2019 and 2018, the authorized share capital amounted to &amp;#x20AC;3,200 consisting of 155,975,000 common shares and 155,975,000&amp;nbsp;cumulative preference shares, each with a par value of &amp;#x20AC;0.01 per share.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfIssuedCapitalExplanatory>
  <ifrs-full:DisclosureOfLeasesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;21.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;"&gt;Affimed presents right-of-use assets for offices, laboratories and vehicles leased in a separate line item from the line item &amp;#x201C;Leasehold improvements and equipment&amp;#x201D; that presents other assets of the same nature that Affimed owns. The agreements have an average non-cancellable term of between one and four&amp;nbsp;years with renewal options included in some contracts. For equipment leased with contract terms that are short term and/or leases of low-value items the Group has elected not to recognize right-of-use assets and lease liabilities for these leases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of right-of-use assets reconcile as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Carrying&amp;nbsp;amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Buildings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Cars&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1, 2019 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 695&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Depreciation charge for the year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (371)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (13)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (384)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Additions to right-of-use assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 816&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 824&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;"&gt;Cash outflow related to leases are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 405&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest on lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 24&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Short-term lease payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 66&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Cash outflow from leasing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 495&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In 2018 and 2017, lease expenses of &amp;#x20AC;562 and &amp;#x20AC;472 have been recognized in the consolidated statement of comprehensive income.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Future contractually agreed undiscounted lease payments are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2019: Leases&lt;br /&gt;under IFRS&lt;br /&gt;16&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;2018:&lt;br /&gt;Operating&lt;br /&gt;Leases under&lt;br /&gt;IAS 17&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments within one year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 553&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 675&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments between one and five years&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 276&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 541&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 829&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,216&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Movements of lease liabilities reconcile to cash flows arising from financing activities as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Changes from financing cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (405)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; (405)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Other Changes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;New lease contracts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 804&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
  <ifrs-full:DisclosureOfOperatingSegmentsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Segment reporting&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Information about reportable segment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project development or for third party companies. Management of resources and reporting to the chief operating decision maker is based on the Group as a whole.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Geographic information&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The geographic information below analyses the Group&amp;#x2019;s revenue and non-current assets by country. In presenting the following information, segment revenue has been based on the geographic location of the customers and segment assets were based on the geographic location of the assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Discovery activities and research services are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from Heidelberg.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Revenue:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 80&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Europe&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,646&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,175&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,236&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USA&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 19,745&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,529&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 694&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Non-current assets as of December, 31:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Germany&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,224&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 957&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Czech Republic&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 870&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 246&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 221&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;USA&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,558&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,825&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 6,445&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,295&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,178&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Major Customers&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2018 and 2019, the Group&amp;#x2019;s revenue with Genentech&amp;nbsp;Inc. exceeded 10% of total revenues. For the year ended December 31, 2017, the Group&amp;#x2019;s revenue with four customers exceeded 10% of total revenues.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
  <ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;7.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Other income and expenses&amp;nbsp;- net&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Other income and expenses, net mainly comprises foreign exchange gains of &amp;#x20AC;251 (2018: &amp;#x20AC;1,523, 2017: losses of &amp;#x20AC;7). Income from government grants for research and development projects amounted to &amp;#x20AC;19 in 2019, &amp;#x20AC;10 in 2018 and &amp;#x20AC;195 in 2017.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory>
  <ifrs-full:DisclosureOfProvisionsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;18.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Provisions&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to &amp;#x20AC;1.4 million, whereof &amp;#x20AC;0.9 million were already incurred in 2019 and estimated costs of &amp;#x20AC;0.5 million expected to incur in 2020 were recognized in provisions.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfProvisionsExplanatory>
  <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The carrying amounts of right-of-use assets reconcile as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="bottom" style="width:27.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Carrying&amp;nbsp;amount&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Buildings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Cars&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1, 2019 &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 695&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Depreciation charge for the year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (371)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (13)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (384)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Additions to right-of-use assets&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 492&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 816&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 824&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
  <ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 7,169&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Changes from financing cash flows&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Proceeds from borrowings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 562&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Repayment of borrowings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (3,277)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,917)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (2,715)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; (2,917)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Other Changes&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Capitalized borrowing costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 489&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 847&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Interest paid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (164)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (326)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 325&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt; 531&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Balance as of December 31, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,383&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,773&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory>
  <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;23.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Related parties&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Shareholders&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As of December&amp;nbsp;31, 2019 and 2018, no shareholder holds more than 20% of the voting rights.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Transactions with key management personnel&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The compensation of managing directors and other key management personnel comprised of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Short-term employee benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,598&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,683&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,538&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Termination benefits&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 264&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Share-based payments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,738&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,229&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,379&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 4,600&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 3,912&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,917&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Remuneration of Affimed&amp;#x2019;s managing directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive a severance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Compensation for other key management personnel comprises fixed and variable components and share-based payment awards.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of &amp;#x20AC;382 (2018: &amp;#x20AC;382; 2017: &amp;#x20AC;375). In 2019, the Group recognized expenses for share-based payments for supervisory board members of &amp;#x20AC;243 (2018: &amp;#x20AC;117, 2017: &amp;#x20AC;144).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table provides the total amounts of outstanding balances for supervisory board compensation and expense reimbursement related to key management personnel:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:25.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Outstanding&amp;nbsp;balances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Adi Hoess&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;5&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Wolfgang Fischer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Martin Treder&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Leila Alland&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 40&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Thomas Hecht&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 26&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Mathieu Simon&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Berndt Modig&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; &amp;nbsp;9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Ferdinand Verdonck&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 11&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Ulrich Grau&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Bernhard Ehmer&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 17&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
  <ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;8.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Research and development expenses&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table shows the different types of expenses allocated to research and development costs for the&amp;nbsp;years ended December&amp;nbsp;31:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Third-party services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 27,338&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,127&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 12,299&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Personnel expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 10,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 8,055&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,639&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Legal, consulting and patent expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,983&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,672&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 890&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Cost of Materials&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,547&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,140&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 994&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amortisation and depreciation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 725&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 351&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 309&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Other expenses&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,044&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,804&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,358&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 43,791&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 35,148&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,489&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfResearchAndDevelopmentExpenseExplanatory>
  <ifrs-full:DisclosureOfRevenueExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Collaboration agreement with Amphivena&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Until July 2016, Affimed was party to a collaboration with Amphivena. The purpose of the collaboration was the development of a product candidate for hematological malignancies. The collaboration included a License and Development Agreement between Amphivena and Affimed, which expired when Amphivena obtained the approval of an investigational new drug application (IND) from the FDA in July 2016.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Pursuant to the license and development agreement between Affimed and Amphivena, Affimed granted a license to intellectual property and agreed to perform certain services for Amphivena related to the development of a product candidate for hematological malignancies. In &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;consideration&lt;/font&gt;&lt;font style="display:inline;"&gt; for the research and development work that was performed, Amphivena was required to pay to Affimed service fees totaling approximately &amp;#x20AC;16 million payable according to the achievement of milestones and phase progressions as described under the license and development agreement. Since the expiration of the agreement, the parties have been closing out the collaboration by exchanging documentation and transferring materials and third-party contracts. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;During the year ended December 31, 2017, the Company recognized revenue upon achievement of milestones and for the performance of research and development services totaling &amp;#x20AC;0.2 million. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Collaboration agreement The Leukemia&amp;nbsp;&amp;amp; Lymphoma Society (LLS)&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed is party to a collaboration with LLS to fund the development of a specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group&amp;#x2019;s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In June&amp;nbsp;2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;During the&amp;nbsp;years ended December&amp;nbsp;31, 2017 and 2018, the Group achieved several milestones and recognized revenue totaling &amp;#x20AC;0.2 million and &amp;#x20AC;0.2 million, respectively. Open milestones as at December 31, 2019 are expected to have no significant impact on future revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Collaboration with Genentech&amp;nbsp;Inc.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed is providing services related to the development of novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October&amp;nbsp;2018. Under the terms of the agreement, Affimed received $96.0 million (&amp;#x20AC;83.2 million) in an initial upfront payment and committed funding on October&amp;nbsp;31, 2018. The Group recognized &amp;#x20AC;19.7 million as revenue in 2019 (2018: &amp;#x20AC;21.8 million) and &amp;#x20AC;59.3 million (December 31, 2018: &amp;#x20AC;61.4 million) under contract liabilities, which will be recognized as revenue in subsequent periods as services are provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Research service agreements&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group, through its subsidiary AbCheck has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Group recognized revenue of &amp;#x20AC;1.7 million, &amp;#x20AC;1.7 million and &amp;#x20AC;1.6 million during the&amp;nbsp;years ended December&amp;nbsp;31, 2019, 2018 and 2017 respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Contract balances&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following table provides information about receivables and contract liabilities from contracts with customers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;December&amp;nbsp;31,&amp;nbsp;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Receivables&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 204&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 210&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Contract liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 59,314&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 61,847&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;An amount of &amp;#x20AC;14,795 that was recognized in contract liabilities at the beginning of the period was recognized as revenue during the period ended December 31,&amp;nbsp;2019 (2018: &amp;#x20AC;230).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The remaining performance obligations at December&amp;nbsp;31, 2019 are approximately &amp;#x20AC;59.3 million and are expected to be recognized as revenue to a large extent over the next two&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Disaggregation of revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2017
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Major service lines:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Collaboration revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 19,685&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 22,018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 390&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Service revenue&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,706&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,620&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"&gt;Revenue:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Point in time&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5,783&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,863&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 233&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Over time&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 15,608&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,872&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,777&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 21,391&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 23,735&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2,010&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;"&gt;
			&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
  <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;17.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Share based payments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Under this program, the Group granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share based payments with service condition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The majority of the awards vest in installments over three&amp;nbsp;years and can be exercised up to 10&amp;nbsp;years after the grant date. In 2019 and 2018, the Group granted 1,736,803 awards and 2,332,296 awards to employees, the Management Board and Supervisory Board.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2019, 357,879&lt;/font&gt;&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;ESOP 2014 awards were cancelled or forfeited due to termination of employment or termination of consulting agreements with non-employees (2018: 424,688), and 19,795 options were exercised at an average exercise price of $1.54 (2018: 40,038 ESOP 2014 awards &lt;/font&gt;&lt;font style="display:inline;"&gt;at an average exercise price of $1.98).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As of December&amp;nbsp;31, 2019, 7,307,567 ESOP 2014 awards were outstanding (December&amp;nbsp;31, 2018: 5,948,438), 4,773,840 awards (December&amp;nbsp;31, 2018: &amp;nbsp;2,814,547) were vested. The options outstanding at December&amp;nbsp;31, 2019 had an exercise price in the range of $1.30 to $13.47 (2018: $1.30 to $13.47) and weighted average remaining contractual life of 8.9&amp;nbsp;years (2018: 9.3&amp;nbsp;years). In 2019 and 2018, the Group estimated an annual forfeiture rate of 4.0% for unvested options.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share based payments with market condition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On April&amp;nbsp;20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading&amp;nbsp;days) reaches a certain hurdle ($6.15, &amp;nbsp;$8.20 and $10.25). Fair value of the awards at grant date amounts to &amp;#x20AC;133 &amp;nbsp;($164 thousand) and the contractual life time of the options is two&amp;nbsp;years. As at December&amp;nbsp;31, 2019 no options were exercisable. Fair value was determined using the Monte Carlo Simulation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share based payment expense&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In 2019, an expense of &amp;#x20AC;2,469 was recognized affecting research and development expenses (&amp;#x20AC;904) and general and administrative expenses (&amp;#x20AC;1,565). In 2018, an expense of &amp;#x20AC;2,035 was recognized affecting research and development expenses (&amp;#x20AC;852) and general and administrative expenses (&amp;#x20AC;1,183). In 2017, an expense of &amp;#x20AC;1,943 was recognized affecting research and development expenses (&amp;#x20AC;522) and general and administrative expenses (&amp;#x20AC;1,421). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Fair value measurement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2019
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"&gt;&lt;div style="float:left"&gt;&lt;/div&gt;2018
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Fair value at grant date &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2.10&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Share price at grant date&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.44&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.91&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Exercise price &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.44&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1.92&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected volatility&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 82&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 72&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected life&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 5.9&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Expected dividends&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 2.09&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 0.34&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;%&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
  <ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Significant accounting policies&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Revenue recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a &amp;#x201C;best efforts&amp;#x201D; basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provide the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Such agreements may comprise more than one research program, platform licenses or intellectual property &lt;/font&gt;&lt;font style="display:inline;"&gt;licenses &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;originally generated by the Group. Usually each of those promises is considered to meet the &lt;/font&gt;&lt;font style="display:inline;"&gt;definition&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt; of a separate performance obligation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses, a residual approach is used. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight-line basis until the use of the license by the customer ends. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group&amp;#x2019;s view, uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Research and development&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group&amp;#x2019;s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Employee benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Short-term employee benefits&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a)&amp;nbsp;the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b)&amp;nbsp;the obligation can be estimated reliably.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share-based payment transactions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s share-based payment awards outstanding as of December&amp;nbsp;31, 2018 and 2019, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;(iii)&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;;font-size: 10pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"&gt;&lt;/font&gt;Termination benefits&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Termination benefits are expensed when the Group can no longer withdraw the offer of those benefits. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Government grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group receives certain government grants that support its research effort in specific projects. &lt;/font&gt;&lt;font style="display:inline;"&gt;These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants.&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt; Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group recognizes income from government grants under &amp;#x2018;Other income&amp;nbsp;- net&amp;#x2019; in the consolidated statement of comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Leases&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-weight:bold;"&gt;Policy applicable from 1 January 2019&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred. Subsequently, the right-of-use asset is&amp;nbsp;&amp;nbsp;depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Affimed&amp;#x2019;s incremental borrowing rate. Generally, Affimed uses its incremental borrowing rate as the discount rate. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group determines the incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and the type of the asset leased.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The lease liability is subsequently&amp;nbsp;&amp;nbsp;measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed has elected not to recognize right-of-use assets and lease liabilities for some short-term leases (leases with less than 12 months of lease term) and right-of-use assets and liabilities for leases of low value assets. Lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Policy applicable before 1 January 2019&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;For impact on transition please refer to &amp;#x201C;New standards and interpretations applied for the first time&amp;#x201D; below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance income and finance costs&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Finance costs comprise primarily interest expense on borrowings.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial instruments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Non-derivative financial assets&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group&amp;#x2019;s non-derivative financial assets include preferred shares in Amphivena, &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three&amp;nbsp;months.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Cash and cash equivalents comprise cash balances and call deposits with original maturities of three&amp;nbsp;months or less.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group holds &lt;/font&gt;&lt;font style="display:inline;"&gt;preferred shares in Amphivena &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;designated at fair value through other comprehensive income (see note 13).&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Non-derivative financial liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group&amp;#x2019;s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Compound financial instruments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 19). The number of shares to be issued does not vary with changes in their fair value.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Impairment&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Trade and other receivables&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group&amp;#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed determines the counterparties&amp;#x2019; lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2017, 2018 or 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Intangible assets and leasehold improvements and equipment&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset&amp;#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&amp;#x2019;s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Income taxes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Current tax is the expected tax payable or receivable on the taxable income or loss for the&amp;nbsp;year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous&amp;nbsp;years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Fair Value Measurement&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;All assets and liabilities for which fair value is recognized in the consolidated financial statements are &lt;/font&gt;&lt;font style="display:inline;"&gt;classified &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 1&amp;nbsp;&amp;#x2013; Prices for identical assets or liabilities quoted in active markets (non-adjusted)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 2&amp;nbsp;&amp;#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 17.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:11pt;"&gt;&lt;p style="width:11pt;width:11pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Level 3&amp;nbsp;&amp;#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 19).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Loss per share&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group has granted warrants under certain loan agreements (see note 19) and options under share-based payment programs (see note 17) which potentially have a dilutive effect; no instruments actually had a dilutive effect.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Critical judgments and accounting estimates&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In preparing these financial statements, the critical judgments made by management in applying the Group&amp;#x2019;s accounting policies resulted in the following accounting estimates&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (i)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Share-based payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On April&amp;nbsp;20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in note&amp;nbsp;17. Incorporating the market condition in the fair value estimate requires the use of a simulation technique (Monte Carlo simulation), which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be &amp;#x20AC;133.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (ii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Revenue recognition&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;"&gt;The Group&amp;#x2019;s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iii)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Accrued expenses&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (iv)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Financial instruments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;The Group holds preferred shares in Amphivena classified as equity instruments at fair value through other comprehensive income (level 2) and&amp;nbsp;&amp;nbsp;recognized as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2019 (see note 13). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (v)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;color:#000000;"&gt;Lease payments&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;Affimed has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether Affimed is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognized. As at December 31, 2019, no renewal options were incorporated into the determining the lease term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 20.00pt;"&gt;
			&lt;p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
				&lt;font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"&gt; (vi)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:16pt;"&gt;&lt;p style="width:16pt;width:16pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;"&gt;Provisions&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;In the second quarter of 2019, Affimed decided to terminate the Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager as a part of its strategic plans (see note 18).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;New standards and interpretations applied for the first time&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&amp;nbsp;1, 2019, and have been applied in preparing these financial statements:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRS 16 Leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9: Prepayment Features with Negative Compensation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Annual Improvements to IFRS Standards 2015&lt;/font&gt;&lt;font style="display:inline;font-family:MS Gothic;color:#000000;"&gt;&amp;#x2011;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;2017 Cycle&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 19: Plan Amendment, Curtailment or Settlement&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;IFRIC 23 Uncertainty over Income Tax Treatments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div&gt;&lt;hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"&gt;&lt;/hr&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%"&gt;1 &amp;nbsp;&lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Shall apply for periods beginning on or after the date shown in the effective date column.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &amp;#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &amp;#xB4;Determining Whether an Arrangement contains a Lease&amp;#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"&gt;Transition &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On transition to IFRS 16, Affimed elected to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not reassessed. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;As a lessee, Affimed previously classified leases as operating or finance leases based on its assessment of whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Affimed recognizes right-of-use assets and lease liabilities for most leases &amp;#x2013; i.e. these leases are on-balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;At transition, for leases classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Company&amp;#x2019;s incremental borrowing rates for similar assets as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;On transition to IFRS 16, the Company recognized additional right-of-use assets, including property, plant and equipment and additional lease liabilities. The impact on transition is summarized below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Right-of-use assets &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The Group discounted lease payments using a weighted average discount rate of 4.05% as of January 1, 2019. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;In relation to those leases under IFRS 16, Affimed has recognized depreciation and interest costs, instead of operating lease expense. In 2019, the Group recognized depreciation expense for right-of-use assets of &amp;#x20AC;385 and interest cost related to the lease liability of &amp;#x20AC;24 instead of operating lease expense of &amp;#x20AC;406.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The transition between operating lease commitments disclosed applying IAS 17 as of December 31, 2018 and the lease liabilities recognized in the statement of financial position at the date of initial application, January 1, 2019, is shown below.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Operating lease commitment as of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Recognition exemption for short-term leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (98)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments for incidental rental costs and other rental payments (Not part of the lease)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (312)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Discounting using the incremental borrowing rate as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (27)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"&gt;New standards and interpretations not yet adopted&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2019, and have not been applied in preparing these consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Standard/interpretation&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;Effective Date &lt;/font&gt;&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%"&gt;1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to References to the Conceptional Framework&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IAS 1 and IAS 8: Definition of Material&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Amendments to IFRS 3 Business Combination&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;January 1, 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;1 Shall apply for periods beginning on or after the date shown in the effective date column.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="Duration_1_1_2018_To_12_31_2018">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;20.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Trade and other payables&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;Trade and other payables comprise trade payables of &amp;#x20AC;10,249 (2018: &amp;#x20AC;8,482). Other payables mainly comprise payroll and employee related liabilities for withholding taxes and social security contributions of &amp;#x20AC;801 (2018: &amp;#x20AC;885) and payables due to employees for unused holidays and other accruals. Other payables are normally settled within 30&amp;nbsp;days.&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
  <ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory contextRef="Duration_1_1_2019_To_12_31_2019">&lt;div&gt; &lt;div&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;15.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Trade and other receivables&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;"&gt;The trade receivables as of December&amp;nbsp;31, 2019 and 2018, of &amp;#x20AC;204 and &amp;#x20AC;210, respectively, are all due in the short-term, do not bear interest and are not impaired. Other receivables are all due short-term and mainly comprise value-added tax receivables of &amp;#x20AC;453 (2018: &amp;#x20AC;839).&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-1867000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">669000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-917000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
  <ifrs-full:EmployeeBenefitsExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">8406000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">11119000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployeeBenefitsExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">13207000</ifrs-full:EmployeeBenefitsExpense>
  <ifrs-full:EmployerContributions contextRef="Duration_1_1_2016_To_12_31_2016" unitRef="Unit1" decimals="-3">438000</ifrs-full:EmployerContributions>
  <ifrs-full:EmployerContributions contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">502000</ifrs-full:EmployerContributions>
  <ifrs-full:EmployerContributions contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">696000</ifrs-full:EmployerContributions>
  <ifrs-full:Equity contextRef="As_Of_12_31_2016" unitRef="Unit1" decimals="-3">38751000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">190862000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">333000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-152444000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2016_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">0</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">38904000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember" unitRef="Unit1" decimals="-3">31579000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">213778000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">468000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-182667000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">7325000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">213778000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">468000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-182667000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2017_afmd_IfrsRevisionOfPriorPeriodAxis_afmd_IfrsPreviouslyReportedMember_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">0</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">40129000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">40129000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">40129000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">239055000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">239055000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">624000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">624000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-202144000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-202144000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">2594000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">2594000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">38667000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">38667000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">270451000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">762000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-234508000</ifrs-full:Equity>
  <ifrs-full:Equity contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">1962000</ifrs-full:Equity>
  <ifrs-full:EquityAndLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">116174000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:EquityAndLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">112359000</ifrs-full:EquityAndLiabilities>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="As_Of_12_31_2018_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">1.30</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="As_Of_12_31_2018_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">13.47</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="As_Of_12_31_2019_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">1.30</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceOfOutstandingShareOptions2019 contextRef="As_Of_12_31_2019_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">13.47</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="2">1.92</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExercisePriceShareOptionsGranted2019 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="2">1.44</ifrs-full:ExercisePriceShareOptionsGranted2019>
  <ifrs-full:ExpectedDividendShareOptionsGranted contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit12" decimals="2">0.00</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpectedDividendShareOptionsGranted contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit12" decimals="2">0.00</ifrs-full:ExpectedDividendShareOptionsGranted>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1943000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember" unitRef="Unit1" decimals="-3">1421000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember" unitRef="Unit1" decimals="-3">522000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">144000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2035000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember" unitRef="Unit1" decimals="-3">1183000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember" unitRef="Unit1" decimals="-3">852000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">117000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">2469000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_GeneralAndAdministrativeMember" unitRef="Unit1" decimals="-3">1565000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_ResearchAndDevelopmentMember" unitRef="Unit1" decimals="-3">904000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_afmd_SupervisoryBoardDirectorsMember" unitRef="Unit1" decimals="-3">243000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
  <ifrs-full:ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member">&lt;div&gt; &lt;div&gt;
		&lt;div style="width:100%;"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&lt;font style="display:inline;font-size:1pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;"&gt;January&amp;nbsp;1,&amp;nbsp;2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Operating lease commitment as of December 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 1,154&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Recognition exemption for short-term leases&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (98)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Payments for incidental rental costs and other rental payments (Not part of the lease)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (312)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Discounting using the incremental borrowing rate as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; (27)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;Lease liabilities as of January 1, 2019&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"&gt;
					&lt;p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
						&lt;font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"&gt; 717&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;"&gt;
			&lt;font style="display:inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;&lt;div /&gt;&lt;/div&gt; &lt;/div&gt;</ifrs-full:ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory>
  <ifrs-full:ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue contextRef="Duration_1_1_2019_To_12_31_2019">The remaining performance obligations at December&#xA0;31, 2019 are approximately &#x20AC;59.3 million and are expected to be recognized as revenue to a large extent over the next two&#xA0;years.</ifrs-full:ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember" unitRef="Unit1" decimals="-5">3800000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember" unitRef="Unit1" decimals="-5">3200000</ifrs-full:FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-2983000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-2983000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember" unitRef="Unit1" decimals="-3">-2378000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember" unitRef="Unit1" decimals="-3">77000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember" unitRef="Unit1" decimals="-3">-690000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember" unitRef="Unit1" decimals="-3">8000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">60000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">60000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember" unitRef="Unit1" decimals="-3">651000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember" unitRef="Unit1" decimals="-3">5000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember" unitRef="Unit1" decimals="-3">-847000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember" unitRef="Unit1" decimals="-3">251000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">15000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">15000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_ForeignExchangeDifferencesMember" unitRef="Unit1" decimals="-3">-175000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_InterestCertificatesOfDepositMember" unitRef="Unit1" decimals="-3">602000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_InterestSVBLoanAgreementMember" unitRef="Unit1" decimals="-3">-483000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinanceIncomeCost contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfIncomeExpenseAxis_afmd_OtherFinanceIncomeFinanceCostsMember" unitRef="Unit1" decimals="-3">71000</ifrs-full:FinanceIncomeCost>
  <ifrs-full:FinancialAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">13974000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">13974000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">8902000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssets contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">8902000</ifrs-full:FinancialAssets>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">112293000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">109323000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">108205000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">105122000</ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">4773000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:FinancialLiabilitiesAtFairValue contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">2013000</ifrs-full:FinancialLiabilitiesAtFairValue>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember" unitRef="Unit1" decimals="-5">-4700000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember" unitRef="Unit1" decimals="-5">-600000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-7000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1523000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">251000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">7986000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">7986000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember" unitRef="Unit1" decimals="-3">1945000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">1520000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">4521000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">9638000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">9638000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember" unitRef="Unit1" decimals="-3">2881000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">1828000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">4929000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">10266000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">10266000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndAuditExpensesMember" unitRef="Unit1" decimals="-3">3055000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">1853000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GeneralAndAdministrativeExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">5357000</ifrs-full:GeneralAndAdministrativeExpense>
  <ifrs-full:GrossLeaseLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">829000</ifrs-full:GrossLeaseLiabilities>
  <ifrs-full:GrossLeaseLiabilities contextRef="As_Of_12_31_2019_ifrs-full_MaturityAxis_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" unitRef="Unit1" decimals="-3">276000</ifrs-full:GrossLeaseLiabilities>
  <ifrs-full:GrossLeaseLiabilities contextRef="As_Of_12_31_2019_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember" unitRef="Unit1" decimals="-3">553000</ifrs-full:GrossLeaseLiabilities>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
  <ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-20000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-20000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">4000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">4000</ifrs-full:IncomeTaxExpenseContinuingOperations>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">6297000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">54323000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">1322000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">71000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">71000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">26000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">26000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
  <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="Duration_11_30_2016_To_11_30_2016_ifrs-full_BorrowingsByNameAxis_afmd_SiliconValleyBankLoanMember" unitRef="Unit1" decimals="-3">192000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-2917000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-2715000</ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">531000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">325000</ifrs-full:IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1943000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">1943000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2035000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">2035000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">2469000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">2469000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">56000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:IntangibleAssetsOtherThanGoodwill contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">137000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">24000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit1" decimals="-3">24000</ifrs-full:InterestExpenseOnLeaseLiabilities>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">326000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestPaidClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">164000</ifrs-full:InterestPaidClassifiedAsFinancingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">349000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">342000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestPaidClassifiedAsOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">224000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">106000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">218000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:InterestReceivedClassifiedAsOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">628000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">260000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">260000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">235000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">296000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">296000</ifrs-full:Inventories>
  <ifrs-full:Inventories contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">247000</ifrs-full:Inventories>
  <ifrs-full:IssuedCapital contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">624000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">624000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">762000</ifrs-full:IssuedCapital>
  <ifrs-full:IssuedCapital contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">762000</ifrs-full:IssuedCapital>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">51000</ifrs-full:IssueOfConvertibleInstruments>
  <ifrs-full:IssueOfConvertibleInstruments contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">51000</ifrs-full:IssueOfConvertibleInstruments>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">21057000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">20922000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">135000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">23327000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">23171000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">156000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">29039000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember" unitRef="Unit1" decimals="-3">28901000</ifrs-full:IssueOfEquity>
  <ifrs-full:IssueOfEquity contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember" unitRef="Unit1" decimals="-3">138000</ifrs-full:IssueOfEquity>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2917000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">3912000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensation contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">4600000</ifrs-full:KeyManagementPersonnelCompensation>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1379000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1229000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">1738000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1538000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2683000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">2598000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">264000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
  <ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed contextRef="As_Of_1_1_2019" unitRef="Unit1" decimals="-3">98000</ifrs-full:LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed>
  <ifrs-full:LeaseLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">717000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="As_Of_1_1_2019" unitRef="Unit1" decimals="-3">717000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="As_Of_1_1_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit1" decimals="-3">717000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LeaseLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">804000</ifrs-full:LeaseLiabilities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">7169000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">4773000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">4773000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LiabilitiesArisingFromFinancingActivities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">2383000</ifrs-full:LiabilitiesArisingFromFinancingActivities>
  <ifrs-full:LongtermBorrowings contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1690000</ifrs-full:LongtermBorrowings>
  <ifrs-full:LongtermBorrowings contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">278000</ifrs-full:LongtermBorrowings>
  <ifrs-full:LongtermDeposits contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">14000000</ifrs-full:LongtermDeposits>
  <ifrs-full:LongtermDeposits contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">8900000</ifrs-full:LongtermDeposits>
  <ifrs-full:MaximumExposureToCreditRisk contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">114100000</ifrs-full:MaximumExposureToCreditRisk>
  <ifrs-full:MaximumExposureToCreditRisk contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">108800000</ifrs-full:MaximumExposureToCreditRisk>
  <ifrs-full:MaximumExposureToCreditRisk contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_OtherPriceRiskMember" unitRef="Unit1" decimals="-5">3200000</ifrs-full:MaximumExposureToCreditRisk>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="-3">1178000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_CZ" unitRef="Unit1" decimals="-3">221000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">957000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2017_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">0</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">5295000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">5295000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_CZ" unitRef="Unit1" decimals="-3">246000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">1224000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2018_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">3825000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">6445000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">6445000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_CZ" unitRef="Unit1" decimals="-3">870000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">2017000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentAssets contextRef="As_Of_12_31_2019_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">3558000</ifrs-full:NoncurrentAssets>
  <ifrs-full:NoncurrentContractLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">37512000</ifrs-full:NoncurrentContractLiabilities>
  <ifrs-full:NoncurrentContractLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">37961000</ifrs-full:NoncurrentContractLiabilities>
  <ifrs-full:NoncurrentFinancialAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">3825000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:NoncurrentFinancialAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">3193000</ifrs-full:NoncurrentFinancialAssets>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLeaseLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">272000</ifrs-full:NoncurrentLeaseLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">39202000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NoncurrentLiabilities contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">38511000</ifrs-full:NoncurrentLiabilities>
  <ifrs-full:NotionalAmount contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit1" decimals="-5">7500000</ifrs-full:NotionalAmount>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">2332296</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">1736803</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">2814547</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">4773840</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">424688</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">357879</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="As_Of_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">5948438</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement contextRef="As_Of_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit114" decimals="INF">7307567</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="-3">0</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="Duration_4_20_2018_To_4_20_2018" unitRef="Unit1" decimals="INF">240000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
  <ifrs-full:NumberOfSharesAuthorised contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesAuthorised>
  <ifrs-full:NumberOfSharesAuthorised contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesAuthorised>
  <ifrs-full:NumberOfSharesAuthorised contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesAuthorised>
  <ifrs-full:NumberOfSharesAuthorised contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesAuthorised>
  <ifrs-full:NumberOfSharesIssued contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit16" decimals="INF">10646762</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit16" decimals="INF">13225000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="As_Of_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedUnderAtMarketSalesAgreementMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit16" decimals="INF">2373716</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="As_Of_11_13_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember" unitRef="Unit16" decimals="INF">13800000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesIssued contextRef="As_Of_12_31_2019_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit16" decimals="INF">13800000</ifrs-full:NumberOfSharesIssued>
  <ifrs-full:NumberOfSharesOutstanding contextRef="As_Of_12_31_2018" unitRef="Unit16" decimals="INF">62430106</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="As_Of_12_31_2019" unitRef="Unit16" decimals="INF">76249901</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:NumberOfSharesOutstanding contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit16" decimals="INF">155975000</ifrs-full:NumberOfSharesOutstanding>
  <ifrs-full:OtherAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">387000</ifrs-full:OtherAssets>
  <ifrs-full:OtherAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:OtherAssets>
  <ifrs-full:OtherAssets contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">0</ifrs-full:OtherAssets>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-4731000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-4731000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">-4731000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-632000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-632000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncome contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember" unitRef="Unit1" decimals="-3">-632000</ifrs-full:OtherComprehensiveIncome>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-4731000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-632000</ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments>
  <ifrs-full:OtherCurrentAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">387000</ifrs-full:OtherCurrentAssets>
  <ifrs-full:OtherCurrentAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:OtherCurrentAssets>
  <ifrs-full:OtherCurrentPayables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">3083000</ifrs-full:OtherCurrentPayables>
  <ifrs-full:OtherCurrentPayables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">2013000</ifrs-full:OtherCurrentPayables>
  <ifrs-full:OtherFeeAndCommissionExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">174000</ifrs-full:OtherFeeAndCommissionExpense>
  <ifrs-full:OtherFeeAndCommissionExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">124000</ifrs-full:OtherFeeAndCommissionExpense>
  <ifrs-full:OtherFeeAndCommissionExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">92000</ifrs-full:OtherFeeAndCommissionExpense>
  <ifrs-full:OtherIncome contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">205000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1515000</ifrs-full:OtherIncome>
  <ifrs-full:OtherIncome contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">290000</ifrs-full:OtherIncome>
  <ifrs-full:OtherPayables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">885000</ifrs-full:OtherPayables>
  <ifrs-full:OtherPayables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">801000</ifrs-full:OtherPayables>
  <ifrs-full:OtherReceivables contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfLiabilitiesAxis_afmd_ValueAddedTaxReceivablesMember" unitRef="Unit1" decimals="-3">839000</ifrs-full:OtherReceivables>
  <ifrs-full:OtherReceivables contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfLiabilitiesAxis_afmd_ValueAddedTaxReceivablesMember" unitRef="Unit1" decimals="-3">453000</ifrs-full:OtherReceivables>
  <ifrs-full:OtherReserves contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">2594000</ifrs-full:OtherReserves>
  <ifrs-full:OtherReserves contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">1962000</ifrs-full:OtherReserves>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">82000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-57000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-233000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2018" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2019" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_afmd_CumulativePreferenceSharesMember" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:ParValuePerShare contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember" unitRef="Unit19" decimals="INF">0.01</ifrs-full:ParValuePerShare>
  <ifrs-full:PaymentsForDebtIssueCosts contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">11000</ifrs-full:PaymentsForDebtIssueCosts>
  <ifrs-full:PaymentsForDebtIssueCosts contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:PaymentsForDebtIssueCosts>
  <ifrs-full:PaymentsForDebtIssueCosts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:PaymentsForDebtIssueCosts>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">1648000</ifrs-full:PaymentsForShareIssueCosts>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1701000</ifrs-full:PaymentsForShareIssueCosts>
  <ifrs-full:PaymentsForShareIssueCosts contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">2215000</ifrs-full:PaymentsForShareIssueCosts>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">405000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">405000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">405000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">405000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_MajorCustomersAxis_afmd_TopFourCustomersMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" unitRef="Unit13" decimals="2">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_MajorCustomersAxis_afmd_GenentechInc.Member_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" unitRef="Unit13" decimals="2">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:PercentageOfEntitysRevenue contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_MajorCustomersAxis_afmd_GenentechInc.Member_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember" unitRef="Unit13" decimals="2">0.10</ifrs-full:PercentageOfEntitysRevenue>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2500000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">562000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">562000</ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">22063000</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
  <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
  <ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">50945000</ifrs-full:ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">23123000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit1" decimals="-5">16400000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">25113000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit1" decimals="-5">19700000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedUnderAtMarketSalesAgreementMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit1" decimals="-5">3800000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">31373000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember_ifrs-full_TypesOfRisksAxis_ifrs-full_LiquidityRiskMember" unitRef="Unit1" decimals="-5">29500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="Duration_11_13_2019_To_11_13_2019_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_ifrs-full_ComponentsOfEquityAxis_afmd_SharesIssuedInPublicOfferingMember" unitRef="Unit1" decimals="-5">29500000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">35000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30223000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30223000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30223000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-30223000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19477000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19477000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19477000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-19477000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32365000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32365000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32365000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLoss contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember" unitRef="Unit1" decimals="-3">-32365000</ifrs-full:ProfitLoss>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30243000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-30243000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19476000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19476000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32361000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossBeforeTax contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32361000</ifrs-full:ProfitLossBeforeTax>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-27260000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-19536000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:ProfitLossFromOperatingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-32376000</ifrs-full:ProfitLossFromOperatingActivities>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1414000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1414000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">1174000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">2291000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">2291000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:PropertyPlantAndEquipment contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">1503000</ifrs-full:PropertyPlantAndEquipment>
  <ifrs-full:Provisions contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:Provisions>
  <ifrs-full:Provisions contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">517000</ifrs-full:Provisions>
  <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">13084000</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
  <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">14029000</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
  <ifrs-full:PurchaseOfAvailableforsaleFinancialAssets contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">45131000</ifrs-full:PurchaseOfAvailableforsaleFinancialAssets>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">43000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">30000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">150000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">296000</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
  <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">0</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
  <ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">0</ifrs-full:PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">625000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">691000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">1324000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
  <ifrs-full:ReceivablesFromContractsWithCustomers contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">210000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <ifrs-full:ReceivablesFromContractsWithCustomers contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">204000</ifrs-full:ReceivablesFromContractsWithCustomers>
  <ifrs-full:RentalExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">472000</ifrs-full:RentalExpense>
  <ifrs-full:RentalExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">562000</ifrs-full:RentalExpense>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">167000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2917000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">2917000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">3277000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">3277000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
  <ifrs-full:RepaymentsOfNoncurrentBorrowings contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_LoanAgreementWithUniCreditLeasingCZMember" unitRef="Unit1" decimals="-3">127000</ifrs-full:RepaymentsOfNoncurrentBorrowings>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">21489000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">21489000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember" unitRef="Unit1" decimals="-3">994000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember" unitRef="Unit1" decimals="-3">890000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">1358000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">5639000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember" unitRef="Unit1" decimals="-3">12299000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2017_To_12_31_2017_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="Unit1" decimals="-3">309000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">35148000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">35148000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember" unitRef="Unit1" decimals="-3">1140000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember" unitRef="Unit1" decimals="-3">1672000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">1804000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">8055000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember" unitRef="Unit1" decimals="-3">22127000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2018_To_12_31_2018_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="Unit1" decimals="-3">351000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">43791000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">43791000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_CostsOfMaterialsMember" unitRef="Unit1" decimals="-3">1547000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_LegalConsultingAndPatentExpensesMember" unitRef="Unit1" decimals="-3">1983000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_OtherExpensesMember" unitRef="Unit1" decimals="-3">2044000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_PersonnelExpensesMember" unitRef="Unit1" decimals="-3">10154000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_afmd_ThirdPartyServicesMember" unitRef="Unit1" decimals="-3">27338000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:ResearchAndDevelopmentExpense contextRef="Duration_1_1_2019_To_12_31_2019_afmd_NatureOfExpensesAxis_ifrs-full_AccumulatedDepreciationAndAmortisationMember" unitRef="Unit1" decimals="-3">725000</ifrs-full:ResearchAndDevelopmentExpense>
  <ifrs-full:RetainedEarnings contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">-202144000</ifrs-full:RetainedEarnings>
  <ifrs-full:RetainedEarnings contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">-234508000</ifrs-full:RetainedEarnings>
  <ifrs-full:RevaluationSurplus contextRef="As_Of_12_31_2017_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" unitRef="Unit1" decimals="-3">7325000</ifrs-full:RevaluationSurplus>
  <ifrs-full:RevaluationSurplus contextRef="As_Of_12_31_2017_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RevaluationSurplusMember_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" unitRef="Unit1" decimals="-3">7325000</ifrs-full:RevaluationSurplus>
  <ifrs-full:Revenue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2010000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2010000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">80000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">694000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_GeographicalAreasAxis_srt_EuropeMember" unitRef="Unit1" decimals="-3">1236000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">23735000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">23735000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">31000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">22529000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_GeographicalAreasAxis_srt_EuropeMember" unitRef="Unit1" decimals="-3">1175000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">21391000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">21391000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_country_DE" unitRef="Unit1" decimals="-3">0</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_country_US" unitRef="Unit1" decimals="-3">19745000</ifrs-full:Revenue>
  <ifrs-full:Revenue contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_GeographicalAreasAxis_srt_EuropeMember" unitRef="Unit1" decimals="-3">1646000</ifrs-full:Revenue>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2010000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">2010000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember" unitRef="Unit1" decimals="-3">390000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember" unitRef="Unit1" decimals="-3">1620000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" unitRef="Unit1" decimals="-3">233000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember" unitRef="Unit1" decimals="-3">1777000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">23735000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">23735000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember" unitRef="Unit1" decimals="-3">22018000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember" unitRef="Unit1" decimals="-3">1717000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" unitRef="Unit1" decimals="-3">21863000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember" unitRef="Unit1" decimals="-3">1872000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">21391000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">21391000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ProductsAndServicesAxis_afmd_CollaborationServiceMember" unitRef="Unit1" decimals="-3">19685000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_ProductsAndServicesAxis_afmd_ServicesMember" unitRef="Unit1" decimals="-3">1706000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" unitRef="Unit1" decimals="-3">5783000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromContractsWithCustomers contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_ifrs-full_GoodsOrServicesTransferredOverTimeMember" unitRef="Unit1" decimals="-3">15608000</ifrs-full:RevenueFromContractsWithCustomers>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">195000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">10000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromGovernmentGrants contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">19000</ifrs-full:RevenueFromGovernmentGrants>
  <ifrs-full:RevenueFromInterest contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_InterestRateRiskMember" unitRef="Unit1" decimals="-3">715000</ifrs-full:RevenueFromInterest>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember" unitRef="Unit1" decimals="-5">1600000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_AmphivenaMember" unitRef="Unit1" decimals="-5">200000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2017_To_12_31_2017_ifrs-full_CounterpartiesAxis_afmd_LeukemiaAndLymphomaSocietyMember" unitRef="Unit1" decimals="-5">200000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember" unitRef="Unit1" decimals="-5">1700000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit1" decimals="-5">21800000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_LeukemiaAndLymphomaSocietyMember" unitRef="Unit1" decimals="-5">200000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_AbCheckMember" unitRef="Unit1" decimals="-5">1700000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueFromRenderingOfServices contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit1" decimals="-5">19700000</ifrs-full:RevenueFromRenderingOfServices>
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">230000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit1" decimals="-5">61400000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">14795000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CounterpartiesAxis_afmd_GenentechIncMember" unitRef="Unit1" decimals="-5">59300000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">717000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember" unitRef="Unit1" decimals="-3">695000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2018_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember" unitRef="Unit1" decimals="-3">22000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_1_1_2019_ifrs-full_InitiallyAppliedIFRSsAxis_afmd_IFRS16Member" unitRef="Unit1" decimals="-3">717000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">824000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">824000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_BuildingsMember" unitRef="Unit1" decimals="-3">816000</ifrs-full:RightofuseAssets>
  <ifrs-full:RightofuseAssets contextRef="As_Of_12_31_2019_ifrs-full_ClassesOfAssetsAxis_ifrs-full_MotorVehiclesMember" unitRef="Unit1" decimals="-3">9000</ifrs-full:RightofuseAssets>
  <ifrs-full:SocialSecurityContributions contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">931000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:SocialSecurityContributions contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">1092000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:SocialSecurityContributions contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">1620000</ifrs-full:SocialSecurityContributions>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">-9020000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">-5809000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">-9652000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember">Amendments to IAS 1 and IAS 8: Definition of Material</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs3BusinessCombinationMember">Amendments to IFRS 3 Business Combination</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember">Amendments to IFRS 9: Prepayment Features with Negative Compensation</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AmendmentsToReferencesToConceptionalFrameworkMember">Amendments to References to the Conceptional Framework</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_AnnualImprovementsToIfrsStandards20152017CycleMember">Annual Improvements to IFRS Standards 2015&#x2011;2017 Cycle</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember">IFRIC 23 Uncertainty over Income Tax Treatments</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TitleOfNewIFRS contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_NewIFRSsAxis_afmd_Ifrs16Member">IFRS 16 Leases</ifrs-full:TitleOfNewIFRS>
  <ifrs-full:TradeAndOtherCurrentPayables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">9425000</ifrs-full:TradeAndOtherCurrentPayables>
  <ifrs-full:TradeAndOtherCurrentPayables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">10674000</ifrs-full:TradeAndOtherCurrentPayables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1429000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">1429000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2018_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">1007000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2018_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">1400000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">1482000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">1482000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2019_ifrs-full_BorrowingsByNameAxis_afmd_ThereofAssetsPledgedMember" unitRef="Unit1" decimals="-3">864000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherCurrentReceivables contextRef="As_Of_12_31_2019_ifrs-full_TypesOfRisksAxis_ifrs-full_CreditRiskMember" unitRef="Unit1" decimals="-5">1500000</ifrs-full:TradeAndOtherCurrentReceivables>
  <ifrs-full:TradeAndOtherPayables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">8482000</ifrs-full:TradeAndOtherPayables>
  <ifrs-full:TradeAndOtherPayables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">10249000</ifrs-full:TradeAndOtherPayables>
  <ifrs-full:TradeReceivables contextRef="As_Of_12_31_2018" unitRef="Unit1" decimals="-3">210000</ifrs-full:TradeReceivables>
  <ifrs-full:TradeReceivables contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-3">204000</ifrs-full:TradeReceivables>
  <ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations contextRef="As_Of_12_31_2019" unitRef="Unit1" decimals="-5">59300000</ifrs-full:TransactionPriceAllocatedToRemainingPerformanceObligations>
  <ifrs-full:UndrawnBorrowingFacilities contextRef="As_Of_9_30_2017_ifrs-full_BorrowingsByNameAxis_afmd_SeniorSecuredTermLoanFacilityMember" unitRef="Unit1" decimals="-5">2500000</ifrs-full:UndrawnBorrowingFacilities>
  <ifrs-full:WagesAndSalaries contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="-3">7475000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WagesAndSalaries contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit1" decimals="-3">10027000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WagesAndSalaries contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit1" decimals="-3">11587000</ifrs-full:WagesAndSalaries>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">1.98</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019 contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member" unitRef="Unit15" decimals="2">1.54</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="As_Of_12_31_2018" unitRef="Unit12" decimals="2">1.20</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="As_Of_12_31_2019" unitRef="Unit12" decimals="2">2.10</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="Duration_1_1_2018_To_12_31_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">P9Y3M18D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_afmd_Esop2014Member">P8Y10M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
  <ifrs-full:WeightedAverageSharePrice2019 contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit15" decimals="2">1.91</ifrs-full:WeightedAverageSharePrice2019>
  <ifrs-full:WeightedAverageSharePrice2019 contextRef="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIiiMember" unitRef="Unit15" decimals="2">10.25</ifrs-full:WeightedAverageSharePrice2019>
  <ifrs-full:WeightedAverageSharePrice2019 contextRef="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIiMember" unitRef="Unit15" decimals="2">8.20</ifrs-full:WeightedAverageSharePrice2019>
  <ifrs-full:WeightedAverageSharePrice2019 contextRef="Duration_4_20_2018_To_4_20_2018_afmd_IfrsVestingAxis_afmd_TrancheIMember" unitRef="Unit15" decimals="2">6.15</ifrs-full:WeightedAverageSharePrice2019>
  <ifrs-full:WeightedAverageSharePrice2019 contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit15" decimals="2">1.44</ifrs-full:WeightedAverageSharePrice2019>
  <ifrs-full:WeightedAverageShares contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit16" decimals="0">43746073</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="Duration_1_1_2018_To_12_31_2018" unitRef="Unit16" decimals="0">60514407</ifrs-full:WeightedAverageShares>
  <ifrs-full:WeightedAverageShares contextRef="Duration_1_1_2019_To_12_31_2019" unitRef="Unit16" decimals="0">64242396</ifrs-full:WeightedAverageShares>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-0005" xlink:label="Item-0005_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0005_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0003" xlink:label="Item-0003_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0003_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0002" xlink:label="Item-0002_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0002_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0004" xlink:label="Item-0004_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0004_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0006" xlink:label="Item-0006_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0006_lbl" xlink:to="Footnote-01" order="1" />
    <link:loc xlink:type="locator" xlink:href="#Item-0001" xlink:label="Item-0001_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-0001_lbl" xlink:to="Footnote-01" order="1" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Standard/interpretation&#xA0;&#xA0;&#xA0;&#xA0;Effective Date 1IFRS 16 LeasesJanuary 1, 2019Amendments to IFRS 9: Prepayment Features with Negative CompensationJanuary 1, 2019Amendments to IAS 28: Long-term Interests in Associates and Joint VenturesJanuary 1, 2019Annual Improvements to IFRS Standards 20152017 CycleJanuary 1, 2019Amendments to IAS 19: Plan Amendment, Curtailment or SettlementJanuary 1, 2019IFRIC 23 Uncertainty over Income Tax TreatmentsJanuary 1, 20191 Shall apply for periods beginning on or after the date shown in the effective date column.</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>afmd-20191231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:41 PM-->
<!--Modified on: 4/28/2020 3:58:41 PM-->
<xsd:schema xmlns:attributeFormDefault="unqualified" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:afmd="http://www.affimed.com/20191231" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ifrs="http://xbrl.ifrs.org/taxonomy/2018-03-16/ifrs-full" targetNamespace="http://www.affimed.com/20191231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00100 - Statement - Consolidated statements of comprehensive loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition" id="StatementConsolidatedStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - Consolidated statements of financial position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows" id="StatementConsolidatedStatementOfCashFlows">
        <link:definition>00300 - Statement - Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails" id="Disclosure10EmployeeBenefitsDetails">
        <link:definition>41001 - Disclosure - 10. Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesDetails" id="Disclosure12IncomeTaxesDetails">
        <link:definition>41201 - Disclosure - 12. Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure19BorrowingsDetails" id="Disclosure19BorrowingsDetails">
        <link:definition>41901 - Disclosure - 19. Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails" id="Disclosure23RelatedPartiesCompensationDetails">
        <link:definition>42301 - Disclosure - 23. Related Parties - Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity" id="StatementConsolidatedStatementOfChangesInEquity">
        <link:definition>00400 - Statement - Consolidated Statement of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies" id="Disclosure4SignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - 4. Significant accounting policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables" id="Disclosure4SignificantAccountingPoliciesTables">
        <link:definition>30403 - Disclosure - 4. Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails" id="Disclosure4SignificantAccountingPoliciesDetails">
        <link:definition>40401 - Disclosure - 4. Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails" id="Disclosure4SignificantAccountingPoliciesLeaseDetails">
        <link:definition>40403 - Disclosure - 4. Significant Accounting Policies -Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails" id="Disclosure5SegmentReportingGeographicInformationDetails">
        <link:definition>40501 - Disclosure - 5. Segment Reporting - Geographic information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails" id="Disclosure5SegmentReportingNarrativeDetails">
        <link:definition>40502 - Disclosure - 5. Segment Reporting - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails" id="Disclosure6RevenueNarrativeDetails">
        <link:definition>40601 - Disclosure - 6. Revenue - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails" id="Disclosure6RevenueDisaggregationOfRevenueDetails">
        <link:definition>40603 - Disclosure - 6. Revenue - Disaggregation of revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails" id="Disclosure8ResearchAndDevelopmentExpensesDetails">
        <link:definition>40801 - Disclosure - 8. Research and Development Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails" id="Disclosure9GeneralAndAdministrativeExpensesDetails">
        <link:definition>40901 - Disclosure - 9. General and Administrative Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails" id="Disclosure11FinanceIncomeAndFinanceCostsDetails">
        <link:definition>41101 - Disclosure - 11. Finance Income and Finance Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails" id="Disclosure12IncomeTaxesNarrativeDetails">
        <link:definition>41202 - Disclosure - 12. Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails" id="Disclosure13LongTermFinancialAssetsDetails">
        <link:definition>41301 - Disclosure - 13. Long term financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails" id="Disclosure15TradeAndOtherReceivablesDetails">
        <link:definition>41501 - Disclosure - 15. Trade and Other Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure16EquityDetails" id="Disclosure16EquityDetails">
        <link:definition>41601 - Disclosure - 16. Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails" id="Disclosure17ShareBasedPaymentsNarrativeDetails">
        <link:definition>41702 - Disclosure - 17. Share Based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails" id="Disclosure19BorrowingsNarrativeDetails">
        <link:definition>41902 - Disclosure - 19. Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails" id="Disclosure21LeasesNarrativeDetails">
        <link:definition>42101 - Disclosure - 21. Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" id="Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails">
        <link:definition>42102 - Disclosure - 21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" id="Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails">
        <link:definition>42104 - Disclosure - 21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails" id="Disclosure23RelatedPartiesOutstandingBalancesDetails">
        <link:definition>42302 - Disclosure - 23. Related Parties - Outstanding Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails" id="Disclosure23RelatedPartiesNarrativeDetails">
        <link:definition>42303 - Disclosure - 23. Related Parties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails" id="Disclosure24FinancialRiskManagementNarrativeDetails">
        <link:definition>42401 - Disclosure - 24. Financial Risk Management - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails" id="Disclosure24FinancialRiskManagementExchangeRatesDetails">
        <link:definition>42402 - Disclosure - 24. Financial Risk Management - Exchange Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure1ReportingEntity" id="Disclosure1ReportingEntity">
        <link:definition>10101 - Disclosure - 1. Reporting Entity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup" id="Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup">
        <link:definition>10201 - Disclosure - 2. Local exemption rules applied by subsidiaries of the Group</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure3BasisOfPreparationConsolidatedFinancialStatements" id="Disclosure3BasisOfPreparationConsolidatedFinancialStatements">
        <link:definition>10301 - Disclosure - 3. Basis of preparation &#x2013; consolidated financial statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies" id="Disclosure4SignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - 4. Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure5SegmentReporting" id="Disclosure5SegmentReporting">
        <link:definition>10501 - Disclosure - 5. Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure6Revenue" id="Disclosure6Revenue">
        <link:definition>10601 - Disclosure - 6. Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNet" id="Disclosure7OtherIncomeAndExpensesNet">
        <link:definition>10701 - Disclosure - 7. Other Income and Expenses - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpenses" id="Disclosure8ResearchAndDevelopmentExpenses">
        <link:definition>10801 - Disclosure - 8. Research and Development Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpenses" id="Disclosure9GeneralAndAdministrativeExpenses">
        <link:definition>10901 - Disclosure - 9. General and Administrative Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefits" id="Disclosure10EmployeeBenefits">
        <link:definition>11001 - Disclosure - 10. Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCosts" id="Disclosure11FinanceIncomeAndFinanceCosts">
        <link:definition>11101 - Disclosure - 11. Finance Income and Finance Costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxes" id="Disclosure12IncomeTaxes">
        <link:definition>11201 - Disclosure - 12. Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure13LongTermFinancialAssets" id="Disclosure13LongTermFinancialAssets">
        <link:definition>11301 - Disclosure - 13. Long Term Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure14FinancialAssets" id="Disclosure14FinancialAssets">
        <link:definition>11401 - Disclosure - 14. Financial Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivables" id="Disclosure15TradeAndOtherReceivables">
        <link:definition>11501 - Disclosure - 15. Trade and Other Receivables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure16Equity" id="Disclosure16Equity">
        <link:definition>11601 - Disclosure - 16. Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPayments" id="Disclosure17ShareBasedPayments">
        <link:definition>11701 - Disclosure - 17. Share Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure18Provisions" id="Disclosure18Provisions">
        <link:definition>11801 - Disclosure - 18. Provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure19Borrowings" id="Disclosure19Borrowings">
        <link:definition>11901 - Disclosure - 19. Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure20TradeAndOtherPayables" id="Disclosure20TradeAndOtherPayables">
        <link:definition>12001 - Disclosure - 20. Trade and Other Payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21Leases" id="Disclosure21Leases">
        <link:definition>12101 - Disclosure - 21. Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingencies" id="Disclosure22OtherCommitmentsAndContingencies">
        <link:definition>12201 - Disclosure - 22. Other Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure23RelatedParties" id="Disclosure23RelatedParties">
        <link:definition>12301 - Disclosure - 23. Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagement" id="Disclosure24FinancialRiskManagement">
        <link:definition>12401 - Disclosure - 24. Financial Risk Management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure25SubsequentEvents" id="Disclosure25SubsequentEvents">
        <link:definition>12501 - Disclosure - 25. Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingTables" id="Disclosure5SegmentReportingTables">
        <link:definition>30503 - Disclosure - 5. Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure6RevenueTables" id="Disclosure6RevenueTables">
        <link:definition>30603 - Disclosure - 6. Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesTables" id="Disclosure8ResearchAndDevelopmentExpensesTables">
        <link:definition>30803 - Disclosure - 8. Research and Development Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesTables" id="Disclosure9GeneralAndAdministrativeExpensesTables">
        <link:definition>30903 - Disclosure - 9. General and Administrative Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsTables" id="Disclosure10EmployeeBenefitsTables">
        <link:definition>31003 - Disclosure - 10. Employee Benefits (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsTables" id="Disclosure11FinanceIncomeAndFinanceCostsTables">
        <link:definition>31103 - Disclosure - 11. Finance Income and Finance Costs (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesTables" id="Disclosure12IncomeTaxesTables">
        <link:definition>31203 - Disclosure - 12. Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsTables" id="Disclosure17ShareBasedPaymentsTables">
        <link:definition>31703 - Disclosure - 17. Share Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure19BorrowingsTables" id="Disclosure19BorrowingsTables">
        <link:definition>31903 - Disclosure - 19. Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesTables" id="Disclosure21LeasesTables">
        <link:definition>32103 - Disclosure - 21. Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesTables" id="Disclosure23RelatedPartiesTables">
        <link:definition>32303 - Disclosure - 23. Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementTables" id="Disclosure24FinancialRiskManagementTables">
        <link:definition>32403 - Disclosure - 24. Financial Risk Management (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesNarrativeDetails" id="Disclosure4SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40402 - Disclosure - 4. Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure6RevenueDetails" id="Disclosure6RevenueDetails">
        <link:definition>40602 - Disclosure - 6. Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNetDetails" id="Disclosure7OtherIncomeAndExpensesNetDetails">
        <link:definition>40701 - Disclosure - 7. Other Income and Expenses - Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsNarrativeDetails" id="Disclosure10EmployeeBenefitsNarrativeDetails">
        <link:definition>41002 - Disclosure - 10. Employee Benefits - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure14FinancialAssetsDetails" id="Disclosure14FinancialAssetsDetails">
        <link:definition>41401 - Disclosure - 14. Financial assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsDetails" id="Disclosure17ShareBasedPaymentsDetails">
        <link:definition>41701 - Disclosure - 17. Share Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure18ProvisionsDetails" id="Disclosure18ProvisionsDetails">
        <link:definition>41801 - Disclosure - 18. Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails" id="Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails">
        <link:definition>41903 - Disclosure - 19. Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure20TradeAndOtherPayablesDetails" id="Disclosure20TradeAndOtherPayablesDetails">
        <link:definition>42001 - Disclosure - 20. Trade and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails" id="Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails">
        <link:definition>42103 - Disclosure - 21. Leases - Schedule of Cash Outflow Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails" id="Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails">
        <link:definition>42105 - Disclosure - 21. Leases - Movements of lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails" id="Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>42202 - Disclosure - 22. Other Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="afmd-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="afmd-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="afmd-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="afmd-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <import namespace="http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full" schemaLocation="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_ReportingEntityAbstract" name="ReportingEntityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" name="BasisOfPreparationConsolidatedFinancialStatementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SignificantAccountingPoliciesAbstract" name="SignificantAccountingPoliciesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_OtherIncomeAndExpensesNetAbstract" name="OtherIncomeAndExpensesNetAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ResearchAndDevelopmentExpensesAbstract" name="ResearchAndDevelopmentExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_GeneralAndAdministrativeExpensesAbstract" name="GeneralAndAdministrativeExpensesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_EmployeeBenefitsAbstract" name="EmployeeBenefitsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_FinanceIncomeAndFinanceCostsAbstract" name="FinanceIncomeAndFinanceCostsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_FinancialAssetsAbstract" name="FinancialAssetsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ShareBasedPaymentsAbstract" name="ShareBasedPaymentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_FinancialRiskManagementAbstract" name="FinancialRiskManagementAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SignificantAccountingPoliciesPoliciesAbstract" name="SignificantAccountingPoliciesPoliciesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" name="SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock" name="SummaryOfIncomeTaxReconciliationTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock" name="SummaryOfFairValueOfAssetsPledgedTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" name="SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" name="SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SummaryOfExchangeRatesTableTextBlock" name="SummaryOfExchangeRatesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_AmphivenaMember" name="AmphivenaMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_LeukemiaAndLymphomaSocietyMember" name="LeukemiaAndLymphomaSocietyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_AbCheckMember" name="AbCheckMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NatureOfExpensesAxis" name="NatureOfExpensesAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NatureOfExpensesDomain" name="NatureOfExpensesDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ThirdPartyServicesMember" name="ThirdPartyServicesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_PersonnelExpensesMember" name="PersonnelExpensesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_LegalConsultingAndPatentExpensesMember" name="LegalConsultingAndPatentExpensesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_CostsOfMaterialsMember" name="CostsOfMaterialsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_OtherExpensesMember" name="OtherExpensesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NatureOfIncomeExpenseAxis" name="NatureOfIncomeExpenseAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NatureOfIncomeExpenseDomain" name="NatureOfIncomeExpenseDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_InterestSVBLoanAgreementMember" name="InterestSVBLoanAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ForeignExchangeDifferencesMember" name="ForeignExchangeDifferencesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_InterestCertificatesOfDepositMember" name="InterestCertificatesOfDepositMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_OtherFinanceIncomeFinanceCostsMember" name="OtherFinanceIncomeFinanceCostsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="afmd_TaxEffectOfPermanentDifferences" name="TaxEffectOfPermanentDifferences" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_TaxEffectOfLocalTaxRates" name="TaxEffectOfLocalTaxRates" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_TemporaryDifferenceBorrowingsMember" name="TemporaryDifferenceBorrowingsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_TradeAndOtherReceivablesMember" name="TradeAndOtherReceivablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" name="OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_OperatingLossCarryforwardsForTradeTaxPurposes" name="OperatingLossCarryforwardsForTradeTaxPurposes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_ValueAddedTaxReceivablesMember" name="ValueAddedTaxReceivablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_Esop2014Member" name="Esop2014Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ResearchAndDevelopmentMember" name="ResearchAndDevelopmentMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_GeneralAndAdministrativeMember" name="GeneralAndAdministrativeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ThereofAssetsPledgedMember" name="ThereofAssetsPledgedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ThomasHechtMember" name="ThomasHechtMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_BemdtModigMember" name="BemdtModigMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_FerdinandVerdonckMember" name="FerdinandVerdonckMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_UlrichGrauMember" name="UlrichGrauMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_BernhardEhmerMember" name="BernhardEhmerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SupervisoryBoardDirectorsMember" name="SupervisoryBoardDirectorsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_KeyManagementPersonnelCompensationForServices" name="KeyManagementPersonnelCompensationForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="afmd_CZKMember" name="CZKMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_USDMember" name="USDMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_MaximumExposureToForeignCurrencyRisk" name="MaximumExposureToForeignCurrencyRisk" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_LongTermFinancialAssetsMember" name="LongTermFinancialAssetsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_TradeAndOtherPayablesMember" name="TradeAndOtherPayablesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_PurchaseOfLongTermFinancialAssets" name="PurchaseOfLongTermFinancialAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="afmd_CollaborationServiceMember" name="CollaborationServiceMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_ServicesMember" name="ServicesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_GenentechIncMember" name="GenentechIncMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_CollaborationAgreementInitialUpfrontPayment" name="CollaborationAgreementInitialUpfrontPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="afmd_MinimumMaturityPeriodOfCertificateOfDeposits" name="MinimumMaturityPeriodOfCertificateOfDeposits" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" name="SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_SharesValue" name="SharesValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_LeilaAllandMember" name="LeilaAllandMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_MartinTrederMember" name="MartinTrederMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" name="NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_DisclosureOfLongTermFinancialAssetsTextBlock" name="DisclosureOfLongTermFinancialAssetsTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" name="IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" name="IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="afmd_CumulativePreferenceSharesMember" name="CumulativePreferenceSharesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" name="IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted" name="ShareBasedCompensationArrangementFairValueOfAwardsGranted" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="afmd_TopFourCustomersMember" name="TopFourCustomersMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_GenentechInc.Member" name="GenentechInc.Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" name="CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="afmd_SharesPrice" name="SharesPrice" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" name="ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="afmd_MaximumTaxLossDueToOwnershipChanges" name="MaximumTaxLossDueToOwnershipChanges" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_ExpectedUnvestedShareOptionsForfeitureRate" name="ExpectedUnvestedShareOptionsForfeitureRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_NumberOfTranches" name="NumberOfTranches" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" name="NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" name="WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" name="WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="afmd_IfrsVestingAxis" name="IfrsVestingAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_IfrsVestingDomain" name="IfrsVestingDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_TrancheIMember" name="TrancheIMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_TrancheIiMember" name="TrancheIiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_TrancheIiiMember" name="TrancheIiiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SharesIssuedInPublicOfferingMember" name="SharesIssuedInPublicOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" name="SharesIssuedUnderAtMarketSalesAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_OneMonthEuriborMember" name="OneMonthEuriborMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" name="PercentageOfDeemedEuriborRateIfLessThanZeroPercent" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_ExercisePeriodOfShareOptions" name="ExercisePeriodOfShareOptions" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_DebtInstrumentFloorRate" name="DebtInstrumentFloorRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" name="PercentageOfDeviationBetweenCurrencyExchangeRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_NetLossInCaseOfCurrencyExchangeDeviation" name="NetLossInCaseOfCurrencyExchangeDeviation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" name="PercentageOfShiftInExchangeRateConsideredRealisticScenario" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SharePricePerShare" name="SharePricePerShare" nillable="true" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_SiliconValleyBankLoanMember" name="SiliconValleyBankLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SeniorSecuredTermLoanFacilityMember" name="SeniorSecuredTermLoanFacilityMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" name="SeniorSecuredTermLoanFacilityTrancheOneMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" name="SeniorSecuredTermLoanFacilityTrancheTwoMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" name="IFRSLineOfCreditFacilityMaximumBorrowingCapacity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <element id="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" name="RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element id="afmd_DebtInstrumentNumberOfTranches" name="DebtInstrumentNumberOfTranches" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_OneMonthEURIBORMember" name="OneMonthEURIBORMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="afmd_DebtInstrumentLegalAndArrangementFees" name="DebtInstrumentLegalAndArrangementFees" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" name="DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_ExpirationPeriodOfWarrants" name="ExpirationPeriodOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" name="IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" name="IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="afmd_ExpectedVolatilityOfWarrants" name="ExpectedVolatilityOfWarrants" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_ExpectedExercisePeriodOfWarrants" name="ExpectedExercisePeriodOfWarrants" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" name="PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="afmd_Ifrs16Member" name="Ifrs16Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" name="AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" name="AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" name="AnnualImprovementsToIfrsStandards20152017CycleMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" name="AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" name="AmendmentsToIas1AndIas8DefinitionOfMaterialMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" name="SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_SummaryOfEmployeeBenefitTableTextBlock" name="SummaryOfEmployeeBenefitTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" name="ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" name="DisclosureOfResearchAndDevelopmentExpenseTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" name="DisclosureOfResearchAndDevelopmentExpenseLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" name="DisclosureOfGeneralAndAdministrativeExpenseTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" name="DisclosureOfGeneralAndAdministrativeExpenseLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" name="DisclosureOfFinanceIncomeAndFinanceCostsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" name="DisclosureOfFinanceIncomeAndFinanceCostsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfIncomeTaxTable" name="DisclosureOfIncomeTaxTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfIncomeTaxLineItems" name="DisclosureOfIncomeTaxLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfTradeAndOtherReceivableTable" name="DisclosureOfTradeAndOtherReceivableTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfTradeAndOtherReceivableLineItems" name="DisclosureOfTradeAndOtherReceivableLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_ServiceFeesToBeReceived" name="ServiceFeesToBeReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_MathieuSimonMember" name="MathieuSimonMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" name="SummaryOfImpactOfLeaseTransitionTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IFRS16Member" name="IFRS16Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_OperatingLeasesWeightedAverageDiscountRate" name="OperatingLeasesWeightedAverageDiscountRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" name="DebtInstrumentMonthlyRepaymentInstallmentAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LoanAgreementWithUniCreditLeasingCZMember" name="LoanAgreementWithUniCreditLeasingCZMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_MinimumOperatingLeasePaymentsAs17" name="MinimumOperatingLeasePaymentsAs17" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_FuturePaymentLicenseFeeObligationDue" name="FuturePaymentLicenseFeeObligationDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" name="Ifric23UncertaintyOverIncomeTaxTreatmentsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToReferencesToConceptionalFrameworkMember" name="AmendmentsToReferencesToConceptionalFrameworkMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" name="AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AmendmentsToIfrs3BusinessCombinationMember" name="AmendmentsToIfrs3BusinessCombinationMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AdiHoessMember" name="AdiHoessMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_WolfgangFischerMember" name="WolfgangFischerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_GbpMember" name="GbpMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" name="LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" name="LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_TransitionPolicyPolicyTextBlock" name="TransitionPolicyPolicyTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" name="MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" name="PaymentsForIncidentalRentalCostsAndOtherRentalPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" name="LeasePayableDiscountedUsingIncrementalBorrowingRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AdditionsOfNewLeaseContracts" name="AdditionsOfNewLeaseContracts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" name="DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" name="DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" name="DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" name="LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_ContractLiabilitiesMember" name="ContractLiabilitiesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_AuthorizedCapital" name="AuthorizedCapital" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_ProgramTerminationCost" name="ProgramTerminationCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_PaymentOfTerminationOfProgram" name="PaymentOfTerminationOfProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfLeasesForLesseeTable" name="DisclosureOfLeasesForLesseeTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_DisclosureOfLeaseForLesseeLineItems" name="DisclosureOfLeaseForLesseeLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" name="IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" name="TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_LegalConsultingAndAuditExpensesMember" name="LegalConsultingAndAuditExpensesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IfrsRevisionOfPriorPeriodAxis" name="IfrsRevisionOfPriorPeriodAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IfrsRevisionOfPriorPeriodDomain" name="IfrsRevisionOfPriorPeriodDomain" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IfrsPreviouslyReportedMember" name="IfrsPreviouslyReportedMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_RecognisedFinanceLeaseAsAssetsIas17" name="RecognisedFinanceLeaseAsAssetsIas17" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_OperatingLeaseCommittmentIas17" name="OperatingLeaseCommittmentIas17" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" name="TaxEffectDueToAdjustmentsOfDeferredAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="afmd_IfrsShortTermLeasePayments" name="IfrsShortTermLeasePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>afmd-20191231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:41 PM-->
<!--Modified on: 4/28/2020 3:58:41 PM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementOfCashFlows" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure10EmployeeBenefitsDetails" roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxesDetails" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsDetails" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesCompensationDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails" />
  <calculationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00100 - Statement - Consolidated statements of comprehensive loss">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637236863189413561" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_637236863189413561" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncome_637236863189413561" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_637236863189433496" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_637236863189433496" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637236863189433496" xlink:to="ifrs-full_ProfitLossBeforeTax_637236863189433496" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637236863189433496" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" xlink:to="ifrs-full_OtherIncome_637236863189433496" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637236863189433496" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637236863189433496" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_637236863189433496" xlink:to="ifrs-full_Revenue_637236863189433496" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_637236863189433496" xlink:to="ifrs-full_FinanceIncomeCost_637236863189433496" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863189433496" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_637236863189433496" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863189433496" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Consolidated statements of financial position">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity_637236863189543213" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_637236863189543213" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" xlink:to="ifrs-full_IssuedCapital_637236863189543213" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" xlink:to="ifrs-full_CapitalReserve_637236863189543213" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" xlink:to="ifrs-full_OtherReserves_637236863189543213" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent_637236863189543213" xlink:to="ifrs-full_RetainedEarnings_637236863189543213" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_637236863189543213" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637236863189543213" xlink:to="ifrs-full_LongtermBorrowings_637236863189543213" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637236863189543213" xlink:to="ifrs-full_NoncurrentContractLiabilities_637236863189543213" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637236863189543213" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637236863189543213" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_637236863189543213" xlink:to="ifrs-full_DeferredTaxLiabilities_637236863189543213" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_CurrentLiabilities_637236863189543213" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637236863189543213" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_637236863189543213" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637236863189543213" xlink:to="ifrs-full_Provisions_637236863189543213" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_637236863189543213" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637236863189543213" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_637236863189543213" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637236863189543213" xlink:to="ifrs-full_CurrentLeaseLiabilities_637236863189553185" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_637236863189543213" xlink:to="ifrs-full_CurrentContractLiabilities_637236863189553185" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_636879908919176368" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets_636879908919176368" xlink:to="ifrs-full_NoncurrentAssets_637236863189553185" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637236863189553185" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="ifrs-full_PropertyPlantAndEquipment_637236863189553185" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="ifrs-full_NoncurrentFinancialAssets_637236863189553185" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="ifrs-full_RightofuseAssets_637236863189553185" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RecognisedFinanceLeaseAsAssetsIas17" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="afmd_RecognisedFinanceLeaseAsAssetsIas17_637236863189553185" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_637236863189553185" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_637236863189553185" xlink:to="ifrs-full_DeferredTaxAssets_637236863189553185" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Assets_636879908919176368" xlink:to="ifrs-full_CurrentAssets_637236863189563162" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637236863189563162" xlink:to="ifrs-full_CashAndCashEquivalents_637236863189563162" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637236863189563162" xlink:to="ifrs-full_CurrentFinancialAssets_637236863189563162" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637236863189563162" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637236863189563162" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637236863189563162" xlink:to="ifrs-full_Inventories_637236863189563162" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_637236863189563162" xlink:to="ifrs-full_OtherCurrentAssets_637236863189563162" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_637236863189563162" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_ProfitLoss_637236863189573476" order="1" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637236863189573476" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637236863189573476" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637236863189573476" order="4" use="optional" weight="-1" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_637236863189573476" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863189563162" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_637236863189573476" order="6" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637236863189573476" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637236863189573476" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637236863189573476" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations_637236863189563162" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637236863189573476" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637236863189573476" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863189563162" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637236863189573476" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637236863189573476" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637236863189573476" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863189583447" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863189583447" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637236863189583447" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_637236863189583447" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_637236863189583447" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PurchaseOfLongTermFinancialAssets" xlink:label="afmd_PurchaseOfLongTermFinancialAssets_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863189573476" xlink:to="afmd_PurchaseOfLongTermFinancialAssets_637236863189583447" order="7" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863189583447" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637236863189583447" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863189583447" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863189583447" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_PaymentsForDebtIssueCosts_637236863189593087" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863189593087" order="5" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863189583447" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863189593087" order="6" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - 10. Employee Benefits (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense_636879908919421601" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense_636879908919421601" xlink:to="ifrs-full_WagesAndSalaries_637236863189593087" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_EmployeeBenefitsExpense_636879908919421601" xlink:to="ifrs-full_SocialSecurityContributions_637236863189593087" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - 12. Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_637236863189593087" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfLocalTaxRates" xlink:label="afmd_TaxEffectOfLocalTaxRates_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="afmd_TaxEffectOfLocalTaxRates_637236863189593087" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_637236863189593087" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_637236863189593087" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_637236863189593087" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_637236863189603398" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfPermanentDifferences" xlink:label="afmd_TaxEffectOfPermanentDifferences_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="afmd_TaxEffectOfPermanentDifferences_637236863189603398" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - 19. Borrowings (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_PropertyPlantAndEquipment_637236863189603398" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_Inventories_637236863189603398" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637236863189603398" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_OtherAssets_637236863189603398" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_FinancialAssets_637236863189603398" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863189603398" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_636879908919512215" xlink:to="ifrs-full_CashAndCashEquivalents_637236863189603398" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails" xlink:type="extended" xlink:title="42301 - Disclosure - 23. Related Parties - Compensation (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_636879908919532269" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_637236863189643309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation_636879908919532269" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_637236863189643309" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_637236863189643309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation_636879908919532269" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_637236863189643309" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_637236863189643309" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_KeyManagementPersonnelCompensation_636879908919532269" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_637236863189643309" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>afmd-20191231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:41 PM-->
<!--Modified on: 4/28/2020 3:58:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementOfChangesInEquity" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesPolicies" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesTables" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesDetails" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesLeaseDetails" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReportingGeographicInformationDetails" roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReportingNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueDisaggregationOfRevenueDetails" roleURI="http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure8ResearchAndDevelopmentExpensesDetails" roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure9GeneralAndAdministrativeExpensesDetails" roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure11FinanceIncomeAndFinanceCostsDetails" roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure13LongTermFinancialAssetsDetails" roleURI="http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure15TradeAndOtherReceivablesDetails" roleURI="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure16EquityDetails" roleURI="http://www.affimed.com/role/Disclosure16EquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure17ShareBasedPaymentsNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesOutstandingBalancesDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagementNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagementExchangeRatesDetails" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <definitionLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statement of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637236863190021940" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_637236863190021940" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplusMember" xlink:label="ifrs-full_RevaluationSurplusMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RevaluationSurplusMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodAxis" xlink:label="afmd_IfrsRevisionOfPriorPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="afmd_IfrsRevisionOfPriorPeriodAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodDomain" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_IfrsRevisionOfPriorPeriodAxis" xlink:to="afmd_IfrsRevisionOfPriorPeriodDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodDomain" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain_637236863190031907" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="afmd_IfrsRevisionOfPriorPeriodAxis" xlink:to="afmd_IfrsRevisionOfPriorPeriodDomain_637236863190031907" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsPreviouslyReportedMember" xlink:label="afmd_IfrsPreviouslyReportedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_IfrsRevisionOfPriorPeriodDomain" xlink:to="afmd_IfrsPreviouslyReportedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637236863190031907" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_637236863190031907" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplus" xlink:label="ifrs-full_RevaluationSurplus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_RevaluationSurplus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfConvertibleInstruments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - 4. Significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_637236863190071799" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_637236863190071799" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember" xlink:to="afmd_IFRS16Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TransitionPolicyPolicyTextBlock" xlink:label="afmd_TransitionPolicyPolicyTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_TransitionPolicyPolicyTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - 4. Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember" xlink:to="afmd_IFRS16Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" xlink:label="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - 4. Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="ifrs-full_NewIFRSsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember_637236863190101726" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember_637236863190101726" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifrs16Member" xlink:label="afmd_Ifrs16Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_Ifrs16Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToReferencesToConceptionalFrameworkMember" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToReferencesToConceptionalFrameworkMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs3BusinessCombinationMember" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="afmd_AmendmentsToIfrs3BusinessCombinationMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="ifrs-full_TitleOfNewIFRS" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_TitleOfNewIFRS" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" xlink:label="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails" xlink:type="extended" xlink:title="40403 - Disclosure - 4. Significant Accounting Policies -Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember" xlink:to="afmd_IFRS16Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_LeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeasesWeightedAverageDiscountRate" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_OperatingLeasesWeightedAverageDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumOperatingLeasePaymentsAs17" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_MinimumOperatingLeasePaymentsAs17" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeaseCommittmentIas17" xlink:label="afmd_OperatingLeaseCommittmentIas17" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_OperatingLeaseCommittmentIas17" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - 5. Segment Reporting - Geographic information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_637236863190131658" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_637236863190131658" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_EuropeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CZ" xlink:label="country_CZ" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CZ" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_NoncurrentAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails" xlink:type="extended" xlink:title="40502 - Disclosure - 5. Segment Reporting - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="ifrs-full_DisclosureOfMajorCustomersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637236863190141619" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_637236863190141619" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_637236863190141619" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_637236863190141619" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TopFourCustomersMember" xlink:label="afmd_TopFourCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="afmd_TopFourCustomersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechInc.Member" xlink:label="afmd_GenentechInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="afmd_GenentechInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="ifrs-full_DisclosureOfMajorCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:to="ifrs-full_DisclosureOfMajorCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfMajorCustomers" xlink:label="afmd_NumberOfMajorCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:to="afmd_NumberOfMajorCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - 6. Revenue - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_637236863190151937" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember_637236863190151937" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmphivenaMember" xlink:label="afmd_AmphivenaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="afmd_AmphivenaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeukemiaAndLymphomaSocietyMember" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="afmd_LeukemiaAndLymphomaSocietyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AbCheckMember" xlink:label="afmd_AbCheckMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="afmd_AbCheckMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechIncMember" xlink:label="afmd_GenentechIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="afmd_GenentechIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServiceFeesToBeReceived" xlink:label="afmd_ServiceFeesToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="afmd_ServiceFeesToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromRenderingOfServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementInitialUpfrontPayment" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="afmd_CollaborationAgreementInitialUpfrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" xlink:label="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails" xlink:type="extended" xlink:title="40603 - Disclosure - 6. Revenue - Disaggregation of revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_637236863190161900" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember_637236863190161900" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationServiceMember" xlink:label="afmd_CollaborationServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="afmd_CollaborationServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServicesMember" xlink:label="afmd_ServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="afmd_ServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863190171569" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863190171569" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - 8. Research and Development Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xlink:to="afmd_NatureOfExpensesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_NatureOfExpensesAxis" xlink:to="afmd_NatureOfExpensesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain_637236863190171569" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="afmd_NatureOfExpensesAxis" xlink:to="afmd_NatureOfExpensesDomain_637236863190171569" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThirdPartyServicesMember" xlink:label="afmd_ThirdPartyServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_ThirdPartyServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PersonnelExpensesMember" xlink:label="afmd_PersonnelExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_PersonnelExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndPatentExpensesMember" xlink:label="afmd_LegalConsultingAndPatentExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_LegalConsultingAndPatentExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CostsOfMaterialsMember" xlink:label="afmd_CostsOfMaterialsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_CostsOfMaterialsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherExpensesMember" xlink:label="afmd_OtherExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_OtherExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:to="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - 9. General and Administrative Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xlink:to="afmd_NatureOfExpensesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_NatureOfExpensesAxis" xlink:to="afmd_NatureOfExpensesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PersonnelExpensesMember" xlink:label="afmd_PersonnelExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_PersonnelExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndAuditExpensesMember" xlink:label="afmd_LegalConsultingAndAuditExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_LegalConsultingAndAuditExpensesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherExpensesMember" xlink:label="afmd_OtherExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_OtherExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:to="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:to="ifrs-full_GeneralAndAdministrativeExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 11. Finance Income and Finance Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseAxis" xlink:label="afmd_NatureOfIncomeExpenseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xlink:to="afmd_NatureOfIncomeExpenseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseDomain" xlink:label="afmd_NatureOfIncomeExpenseDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_NatureOfIncomeExpenseAxis" xlink:to="afmd_NatureOfIncomeExpenseDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseDomain" xlink:label="afmd_NatureOfIncomeExpenseDomain_637236863190191489" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="afmd_NatureOfIncomeExpenseAxis" xlink:to="afmd_NatureOfIncomeExpenseDomain_637236863190191489" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestSVBLoanAgreementMember" xlink:label="afmd_InterestSVBLoanAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_NatureOfIncomeExpenseDomain" xlink:to="afmd_InterestSVBLoanAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ForeignExchangeDifferencesMember" xlink:label="afmd_ForeignExchangeDifferencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_NatureOfIncomeExpenseDomain" xlink:to="afmd_ForeignExchangeDifferencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestCertificatesOfDepositMember" xlink:label="afmd_InterestCertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_NatureOfIncomeExpenseDomain" xlink:to="afmd_InterestCertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherFinanceIncomeFinanceCostsMember" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="afmd_NatureOfIncomeExpenseDomain" xlink:to="afmd_OtherFinanceIncomeFinanceCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:to="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:to="ifrs-full_FinanceIncomeCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41202 - Disclosure - 12. Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxTable" xlink:label="afmd_DisclosureOfIncomeTaxTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfIncomeTaxTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AbCheckMember" xlink:label="afmd_AbCheckMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="afmd_AbCheckMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="afmd_DisclosureOfIncomeTaxTable" xlink:to="ifrs-full_AssetsAndLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="ifrs-full_AssetsAndLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="ifrs-full_AssetsAndLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="ifrs-full_AssetsAndLiabilitiesMember_637236863190201457" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="ifrs-full_AssetsAndLiabilitiesMember_637236863190201457" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TemporaryDifferenceBorrowingsMember" xlink:label="afmd_TemporaryDifferenceBorrowingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_TemporaryDifferenceBorrowingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LongTermFinancialAssetsMember" xlink:label="afmd_LongTermFinancialAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_LongTermFinancialAssetsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ContractLiabilitiesMember" xlink:label="afmd_ContractLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_ContractLiabilitiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherReceivablesMember" xlink:label="afmd_TradeAndOtherReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_TradeAndOtherReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherPayablesMember" xlink:label="afmd_TradeAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="afmd_TradeAndOtherPayablesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxLineItems" xlink:label="afmd_DisclosureOfIncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="afmd_DisclosureOfIncomeTaxTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="ifrs-full_DeferredTaxLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="ifrs-full_DeferredTaxAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="ifrs-full_ApplicableTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumTaxLossDueToOwnershipChanges" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="afmd_MaximumTaxLossDueToOwnershipChanges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForTradeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="afmd_OperatingLossCarryforwardsForTradeTaxPurposes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - 13. Long term financial assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637236863190221403" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637236863190221403" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - 15. Trade and Other Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableTable" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_637236863190231373" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember_637236863190231373" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ValueAddedTaxReceivablesMember" xlink:label="afmd_ValueAddedTaxReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="afmd_ValueAddedTaxReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:to="afmd_DisclosureOfTradeAndOtherReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:to="ifrs-full_TradeReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:to="ifrs-full_OtherReceivables" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure16EquityDetails" xlink:type="extended" xlink:title="41601 - Disclosure - 16. Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedInPublicOfferingMember" xlink:label="afmd_SharesIssuedInPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="afmd_SharesIssuedInPublicOfferingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CumulativePreferenceSharesMember" xlink:label="afmd_CumulativePreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="afmd_CumulativePreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AuthorizedCapital" xlink:label="afmd_AuthorizedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="afmd_AuthorizedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssuedCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesPrice" xlink:label="afmd_SharesPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="afmd_SharesPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails" xlink:type="extended" xlink:title="41702 - Disclosure - 17. Share Based Payments - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637236863190281244" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637236863190281244" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Esop2014Member" xlink:label="afmd_Esop2014Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="afmd_Esop2014Member" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="afmd_NatureOfExpensesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_NatureOfExpensesAxis" xlink:to="afmd_NatureOfExpensesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentMember" xlink:label="afmd_ResearchAndDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_ResearchAndDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeMember" xlink:label="afmd_GeneralAndAdministrativeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_GeneralAndAdministrativeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingAxis" xlink:label="afmd_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="afmd_IfrsVestingAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingDomain" xlink:label="afmd_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="afmd_IfrsVestingAxis" xlink:to="afmd_IfrsVestingDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingDomain" xlink:label="afmd_IfrsVestingDomain_637236863190291279" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="afmd_IfrsVestingAxis" xlink:to="afmd_IfrsVestingDomain_637236863190291279" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIMember" xlink:label="afmd_TrancheIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_IfrsVestingDomain" xlink:to="afmd_TrancheIMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiMember" xlink:label="afmd_TrancheIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_IfrsVestingDomain" xlink:to="afmd_TrancheIiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiiMember" xlink:label="afmd_TrancheIiiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="afmd_IfrsVestingDomain" xlink:to="afmd_TrancheIiiMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedUnvestedShareOptionsForfeitureRate" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_ExpectedUnvestedShareOptionsForfeitureRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfTranches" xlink:label="afmd_NumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_NumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExercisePeriodOfShareOptions" xlink:label="afmd_ExercisePeriodOfShareOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_ExercisePeriodOfShareOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - 19. Borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_637236863190371019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember_637236863190371019" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThereofAssetsPledgedMember" xlink:label="afmd_ThereofAssetsPledgedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="afmd_ThereofAssetsPledgedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Inventories" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_OtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails" xlink:type="extended" xlink:title="41902 - Disclosure - 19. Borrowings - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_637236863190400934" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember_637236863190400934" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEURIBORMember" xlink:label="afmd_OneMonthEURIBORMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="afmd_OneMonthEURIBORMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_BorrowingsByNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SiliconValleyBankLoanMember" xlink:label="afmd_SiliconValleyBankLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="afmd_SiliconValleyBankLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_SiliconValleyBankLoanMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="afmd_SeniorSecuredTermLoanFacilityMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_SeniorSecuredTermLoanFacilityMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LoanAgreementWithUniCreditLeasingCZMember" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="afmd_LoanAgreementWithUniCreditLeasingCZMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentNumberOfTranches" xlink:label="afmd_DebtInstrumentNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_DebtInstrumentNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="ifrs-full_UndrawnBorrowingFacilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_UndrawnBorrowingFacilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFloorRate" xlink:label="afmd_DebtInstrumentFloorRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_DebtInstrumentFloorRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentLegalAndArrangementFees" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_DebtInstrumentLegalAndArrangementFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpirationPeriodOfWarrants" xlink:label="afmd_ExpirationPeriodOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_ExpirationPeriodOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedVolatilityOfWarrants" xlink:label="afmd_ExpectedVolatilityOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_ExpectedVolatilityOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedExercisePeriodOfWarrants" xlink:label="afmd_ExpectedExercisePeriodOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_ExpectedExercisePeriodOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfNoncurrentBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_RepaymentsOfNoncurrentBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_CurrentPortionOfLongtermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_OtherCurrentPayables" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - 21. Leases - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeasesForLesseeTable" xlink:label="afmd_DisclosureOfLeasesForLesseeTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="afmd_DisclosureOfLeasesForLesseeTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeaseForLesseeLineItems" xlink:label="afmd_DisclosureOfLeaseForLesseeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="afmd_DisclosureOfLeaseForLesseeLineItems" xlink:to="afmd_DisclosureOfLeasesForLesseeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="afmd_DisclosureOfLeaseForLesseeLineItems" xlink:to="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" xlink:type="extended" xlink:title="42102 - Disclosure - 21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637236863190480723" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_637236863190480723" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_BuildingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="ifrs-full_MotorVehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_MotorVehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_RightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DepreciationRightofuseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_AdditionsToRightofuseAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" xlink:type="extended" xlink:title="42104 - Disclosure - 21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_637236863190510642" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_637236863190510642" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_GrossLeaseLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails" xlink:type="extended" xlink:title="42302 - Disclosure - 23. Related Parties - Outstanding Balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863190530592" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863190530592" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AdiHoessMember" xlink:label="afmd_AdiHoessMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_AdiHoessMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WolfgangFischerMember" xlink:label="afmd_WolfgangFischerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_WolfgangFischerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MartinTrederMember" xlink:label="afmd_MartinTrederMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_MartinTrederMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeilaAllandMember" xlink:label="afmd_LeilaAllandMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_LeilaAllandMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThomasHechtMember" xlink:label="afmd_ThomasHechtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_ThomasHechtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MathieuSimonMember" xlink:label="afmd_MathieuSimonMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_MathieuSimonMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BemdtModigMember" xlink:label="afmd_BemdtModigMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_BemdtModigMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FerdinandVerdonckMember" xlink:label="afmd_FerdinandVerdonckMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_FerdinandVerdonckMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_UlrichGrauMember" xlink:label="afmd_UlrichGrauMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_UlrichGrauMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BernhardEhmerMember" xlink:label="afmd_BernhardEhmerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_BernhardEhmerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails" xlink:type="extended" xlink:title="42303 - Disclosure - 23. Related Parties - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SupervisoryBoardDirectorsMember" xlink:label="afmd_SupervisoryBoardDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="afmd_SupervisoryBoardDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_KeyManagementPersonnelCompensationForServices" xlink:label="afmd_KeyManagementPersonnelCompensationForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="afmd_KeyManagementPersonnelCompensationForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails" xlink:type="extended" xlink:title="42401 - Disclosure - 24. Financial Risk Management - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_FloatingInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEuriborMember" xlink:label="afmd_OneMonthEuriborMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="afmd_OneMonthEuriborMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637236863190600397" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_637236863190600397" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CreditRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_InterestRateRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherPriceRiskMember" xlink:label="ifrs-full_OtherPriceRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_OtherPriceRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedInPublicOfferingMember" xlink:label="afmd_SharesIssuedInPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="afmd_SharesIssuedInPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesValue" xlink:label="afmd_SharesValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_SharesValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_CashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_LongtermDeposits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_MaximumExposureToCreditRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_Borrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFloorRate" xlink:label="afmd_DebtInstrumentFloorRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_DebtInstrumentFloorRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_RevenueFromInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumExposureToForeignCurrencyRisk" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_MaximumExposureToForeignCurrencyRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NetLossInCaseOfCurrencyExchangeDeviation" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_NetLossInCaseOfCurrencyExchangeDeviation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharePricePerShare" xlink:label="afmd_SharePricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="afmd_SharePricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails" xlink:type="extended" xlink:title="42402 - Disclosure - 24. Financial Risk Management - Exchange Rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CZKMember" xlink:label="afmd_CZKMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="afmd_CZKMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_USDMember" xlink:label="afmd_USDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="afmd_USDMember" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GbpMember" xlink:label="afmd_GbpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="afmd_GbpMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_AverageForeignExchangeRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_ClosingForeignExchangeRate" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>afmd-20191231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:41 PM-->
<!--Modified on: 4/28/2020 3:58:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated statements of comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherIncome" xlink:to="ifrs-full_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income - net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income / (costs) - net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income), continuing operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income / (loss) Items that will not be reclassified to profit or loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, gains (losses) from investments in equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity investments at fair value OCI - net change in fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income / (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings / (loss) per share in &#x20AC; per share (undiluted = diluted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per share in &#x20AC; per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted number of common shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated statements of financial position</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RecognisedFinanceLeaseAsAssetsIas17" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_RecognisedFinanceLeaseAsAssetsIas17" xlink:to="afmd_RecognisedFinanceLeaseAsAssetsIas17_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of assets recognised by the entity, which are leased under finance leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognised finance lease as assets IAS 17</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxAssets" xlink:to="ifrs-full_DeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of the year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentAssets" xlink:to="ifrs-full_OtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY AND LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReserves" xlink:to="ifrs-full_OtherReserves_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReserves_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAttributableToOwnersOfParent" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity attributable to owners of parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sum controlling interests</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current portion of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_LongtermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Provisions" xlink:to="ifrs-full_Provisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Provisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current borrowings and current portion of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL EQUITY AND LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of cash flows [abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for the period:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortisation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net gain from disposal of leasehold improvements and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net gain from disposal of leasehold improvements and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income / costs - net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income / costs - net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operations before changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in trade, other payables, provisions and contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in trade, other payables, provisions and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid (refund), classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Paid income tax</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of leasehold improvements and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from the sale of leasehold improvements and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from the sale of leasehold improvements and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of investments other than investments accounted for using equity method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for investments in convertible note and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of available-for-sale financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for investments in financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from maturity of financial assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PurchaseOfLongTermFinancialAssets" xlink:label="afmd_PurchaseOfLongTermFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PurchaseOfLongTermFinancialAssets" xlink:to="afmd_PurchaseOfLongTermFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PurchaseOfLongTermFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for the purchase of long term financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PurchaseOfLongTermFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Of Long Term Financial Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_PurchaseOfLongTermFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for investments in long term financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used for investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs related to issue of common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForDebtIssueCosts" xlink:to="ifrs-full_PaymentsForDebtIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for debt issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction costs related to borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flow from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange-rate related changes of cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange-rate related changes of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net changes to cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplusMember" xlink:label="ifrs-full_RevaluationSurplusMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevaluationSurplusMember" xlink:to="ifrs-full_RevaluationSurplusMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevaluationSurplusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation Surplus [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevaluationSurplusMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodAxis" xlink:label="afmd_IfrsRevisionOfPriorPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsRevisionOfPriorPeriodAxis" xlink:to="afmd_IfrsRevisionOfPriorPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsRevisionOfPriorPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsRevisionOfPriorPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Revision of Prior Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodDomain" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsRevisionOfPriorPeriodDomain" xlink:to="afmd_IfrsRevisionOfPriorPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Revision Of Prior Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Revision of Prior Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsPreviouslyReportedMember" xlink:label="afmd_IfrsPreviouslyReportedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsPreviouslyReportedMember" xlink:to="afmd_IfrsPreviouslyReportedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Previously Reported [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsPreviouslyReportedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously Reported</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplus" xlink:label="ifrs-full_RevaluationSurplus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevaluationSurplus" xlink:to="ifrs-full_RevaluationSurplus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevaluationSurplus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation surplus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevaluationSurplus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revaluation shares Amphivena (first time adoption IFRS 9)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of common shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share based payment awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity-settled share based payment awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfConvertibleInstruments" xlink:to="ifrs-full_IssueOfConvertibleInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfConvertibleInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of warrant note (loan Silicon Valley Bank)</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ReportingEntityAbstract" xlink:label="afmd_ReportingEntityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ReportingEntityAbstract" xlink:to="afmd_ReportingEntityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ReportingEntityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Entity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general information about financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reporting Entity</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" xlink:to="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local exemption rules applied by subsidiaries of the Group</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" xlink:to="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for Local exemption rules applied by subsidiaries of the Group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Exemption Rules Applied By Subsidiaries Of Group [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local exemption rules applied by subsidiaries of the Group</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:label="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:to="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation &#x2013; consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation and changes to Group&#x2019;s accounting policies</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="afmd_SignificantAccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SignificantAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant accounting policies [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of revenue [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherIncomeAndExpensesNetAbstract" xlink:label="afmd_OtherIncomeAndExpensesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OtherIncomeAndExpensesNetAbstract" xlink:to="afmd_OtherIncomeAndExpensesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OtherIncomeAndExpensesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income And Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income and Expenses - Net</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentExpensesAbstract" xlink:label="afmd_ResearchAndDevelopmentExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ResearchAndDevelopmentExpensesAbstract" xlink:to="afmd_ResearchAndDevelopmentExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ResearchAndDevelopmentExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeExpensesAbstract" xlink:label="afmd_GeneralAndAdministrativeExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_GeneralAndAdministrativeExpensesAbstract" xlink:to="afmd_GeneralAndAdministrativeExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_GeneralAndAdministrativeExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general and administrative expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_EmployeeBenefitsAbstract" xlink:label="afmd_EmployeeBenefitsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="afmd_EmployeeBenefitsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_EmployeeBenefitsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:label="afmd_FinanceIncomeAndFinanceCostsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:to="afmd_FinanceIncomeAndFinanceCostsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_FinanceIncomeAndFinanceCostsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Income And Finance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of finance income (cost) [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Income and Finance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Financial Assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLongTermFinancialAssetsTextBlock" xlink:label="afmd_DisclosureOfLongTermFinancialAssetsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfLongTermFinancialAssetsTextBlock" xlink:to="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of long term financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Long Term Financial Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Financial Assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialAssetsAbstract" xlink:label="afmd_FinancialAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_FinancialAssetsAbstract" xlink:to="afmd_FinancialAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_FinancialAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Receivables.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of issued capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedPaymentsAbstract" xlink:label="afmd_ShareBasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="afmd_ShareBasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ShareBasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_ProvisionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProvisionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfProvisionsExplanatory" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of provisions [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of borrowings [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and Other Payables.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of leases [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of commitments and contingent liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Parties</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialRiskManagementAbstract" xlink:label="afmd_FinancialRiskManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_FinancialRiskManagementAbstract" xlink:to="afmd_FinancialRiskManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_FinancialRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Risk Management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Risk Management</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:to="afmd_SignificantAccountingPoliciesPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SignificantAccountingPoliciesPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies Policies</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of initial application of standards or interpretations [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of initial application of standards or interpretations [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for employee benefits [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for finance income and costs [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Income and Finance Costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Critical Judgments and Accounting Estimates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Standards and Interpretations Applied for the First Time</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of right-of-use assets and lease liabilities</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TransitionPolicyPolicyTextBlock" xlink:label="afmd_TransitionPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TransitionPolicyPolicyTextBlock" xlink:to="afmd_TransitionPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TransitionPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of accounting policy for Ifrs 16.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TransitionPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transition Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TransitionPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Standards and Interpretations Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Table information related to new standards and interpretations applied for the first time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary Of New Standards And Interpretations Applied For First Time [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Standards and Interpretations Applied for First Time</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" xlink:label="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" xlink:to="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of difference between operating lease commitments disclosed applying IAS 17 and lease liabilities recognised at date of initial application of IFRS 16 [text block]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" xlink:to="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of impact on transition of leased assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary Of Impact Of Lease Transition [Table text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of impact on transition</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Standards and Interpretations Not Yet Adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of geographical areas [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of revenue and non-current assets by geographic information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of contingent liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract liabilities from customer</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Disaggregation of Revenue</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:label="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Research and Development Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" xlink:label="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" xlink:to="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of General and Administrative Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfEmployeeBenefitTableTextBlock" xlink:label="afmd_SummaryOfEmployeeBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfEmployeeBenefitTableTextBlock" xlink:to="afmd_SummaryOfEmployeeBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SummaryOfEmployeeBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfEmployeeBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Employee Benefit [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SummaryOfEmployeeBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefits</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" xlink:label="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" xlink:to="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of finance income and costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finance Income and Finance Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Income and Finance Costs</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfIncomeTaxReconciliationTableTextBlock" xlink:label="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock" xlink:to="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions of Options Granted</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock" xlink:label="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock" xlink:to="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Assets Pledged</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of reconciliation of liabilities arising from financing activities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movements of liabilities reconcile to cash flows arising from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying amounts of right-of-use reconcile</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" xlink:label="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" xlink:to="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of cash outflow related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Cash Outflow Related To Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cash outflow related to leases</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" xlink:label="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" xlink:to="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of future contractually agreed undiscounted cash flows for leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Future Contractually Agreed Undiscounted Cash Flows For Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future contractually agreed undiscounted cash flows for leases</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" xlink:label="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" xlink:to="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of movements of lease liabilities reconcile to cash flows arising from financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Movements Of Lease Liabilities Reconcile To Cash Flows Arising From Financing Activities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movements of lease liabilities reconcile to cash flows arising from financing activities</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" xlink:label="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" xlink:to="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation of Managing Directors and Other Key Management Personnel</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" xlink:label="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" xlink:to="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Balances Related to Key Management Personnel</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfExchangeRatesTableTextBlock" xlink:label="afmd_SummaryOfExchangeRatesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SummaryOfExchangeRatesTableTextBlock" xlink:to="afmd_SummaryOfExchangeRatesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SummaryOfExchangeRatesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange Rates</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="ifrs-full_TitleOfNewIFRS" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TitleOfNewIFRS" xlink:to="ifrs-full_TitleOfNewIFRS_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TitleOfNewIFRS_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Standard/amendment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" xlink:label="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" xlink:to="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:to="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Date by which application of new IFRS is required</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective date for new standards and interpretations not yet adopted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive effect of convertible instruments on number of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive effect of loan agreements and options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options issued</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:to="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted" xlink:label="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted" xlink:to="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The fair value of awards granted under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Fair Value Of Awards Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of awards granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities as of January 1, 2019</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeasesWeightedAverageDiscountRate" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OperatingLeasesWeightedAverageDiscountRate" xlink:to="afmd_OperatingLeasesWeightedAverageDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate for operating lease calculated at point in time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Weighted Average Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationRightofuseAssets" xlink:to="ifrs-full_DepreciationRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation charge for the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense on lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumOperatingLeasePaymentsAs17" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MinimumOperatingLeasePaymentsAs17" xlink:to="afmd_MinimumOperatingLeasePaymentsAs17_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The portion of operating lease payments that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with any amounts guaranteed by the lessee or by a party related to the lessee recognised as an expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Operating Lease Payments AS17</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeaseCommittmentIas17" xlink:label="afmd_OperatingLeaseCommittmentIas17" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OperatingLeaseCommittmentIas17" xlink:to="afmd_OperatingLeaseCommittmentIas17_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OperatingLeaseCommittmentIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating lease committments under IAS 17.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OperatingLeaseCommittmentIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Committment IAS 17</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OperatingLeaseCommittmentIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease commitment as of December 31, 2018</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease commitments for short-term leases for which recognition exemption has been used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition exemption for short-term leases</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" xlink:to="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payments for incidental rental costs and other rental payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments For Incidental Rental Costs And Other Rental Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for incidental rental costs and other rental payments (Not part of the lease)</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" xlink:to="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of lease payable discounted using incremental borrowing rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Payable Discounted Using Incremental Borrowing Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Discounting using the incremental borrowing rate as of January 1, 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="ifrs-full_DisclosureOfMajorCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable" xlink:to="ifrs-full_DisclosureOfMajorCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMajorCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of major customers [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bottom Of Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customers [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TopFourCustomersMember" xlink:label="afmd_TopFourCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TopFourCustomersMember" xlink:to="afmd_TopFourCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TopFourCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to top four customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TopFourCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Top Four Customers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TopFourCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Top Four Customers</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechInc.Member" xlink:label="afmd_GenentechInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_GenentechInc.Member" xlink:to="afmd_GenentechInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_GenentechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Genentech Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_GenentechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_GenentechInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech Inc.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="ifrs-full_DisclosureOfMajorCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:to="ifrs-full_DisclosureOfMajorCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfMajorCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of major customers [line items]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfMajorCustomers" xlink:label="afmd_NumberOfMajorCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NumberOfMajorCustomers" xlink:to="afmd_NumberOfMajorCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NumberOfMajorCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of major customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NumberOfMajorCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Major Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NumberOfMajorCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customers</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of entity's revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmphivenaMember" xlink:label="afmd_AmphivenaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmphivenaMember" xlink:to="afmd_AmphivenaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmphivenaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to amphivena.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmphivenaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amphivena [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmphivenaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amphivena</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeukemiaAndLymphomaSocietyMember" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LeukemiaAndLymphomaSocietyMember" xlink:to="afmd_LeukemiaAndLymphomaSocietyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to leukemia &amp; lymphoma society</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leukemia And Lymphoma Society [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leukemia &amp; Lymphoma Society</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AbCheckMember" xlink:label="afmd_AbCheckMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AbCheckMember" xlink:to="afmd_AbCheckMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AbCheckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to AbCheck</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AbCheckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ab Check [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AbCheckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">AbCheck</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechIncMember" xlink:label="afmd_GenentechIncMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_GenentechIncMember" xlink:to="afmd_GenentechIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_GenentechIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Genentech Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_GenentechIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_GenentechIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genentech Inc</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other revenue information</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServiceFeesToBeReceived" xlink:label="afmd_ServiceFeesToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ServiceFeesToBeReceived" xlink:to="afmd_ServiceFeesToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ServiceFeesToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service fees to be received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ServiceFeesToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service fees to be received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRenderingOfServices" xlink:to="ifrs-full_RevenueFromRenderingOfServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from rendering of services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" xlink:to="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of contingent payment upon achievement of certain milestone under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Contingent Payment Upon Achievement Of Certain Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent payment upon achievement of certain milestone under the collaboration agreement</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementInitialUpfrontPayment" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CollaborationAgreementInitialUpfrontPayment" xlink:to="afmd_CollaborationAgreementInitialUpfrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of initial upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Initial Upfront Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement initial upfront payment received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue that was included in contract liability balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue under contract liabilities</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" xlink:to="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold amount that may be eligible to receive including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Amount Eligible To Receive Overtime Upon Achievement Of Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional payments upon achievement of milestones</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transaction price allocated to remaining performance obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining performance obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" xlink:label="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" xlink:to="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of when entity expects to recognise transaction price allocated to remaining performance obligations as revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance obligations description</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromContractsWithCustomers" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from contracts with customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gains (losses)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xlink:to="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Research and Development Expense [Table]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NatureOfExpensesAxis" xlink:to="afmd_NatureOfExpensesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NatureOfExpensesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of expenses [Axis]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NatureOfExpensesDomain" xlink:to="afmd_NatureOfExpensesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NatureOfExpensesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Expenses [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NatureOfExpensesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Expenses [Domain]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThirdPartyServicesMember" xlink:label="afmd_ThirdPartyServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ThirdPartyServicesMember" xlink:to="afmd_ThirdPartyServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ThirdPartyServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to third party services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ThirdPartyServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ThirdPartyServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party services</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PersonnelExpensesMember" xlink:label="afmd_PersonnelExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PersonnelExpensesMember" xlink:to="afmd_PersonnelExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PersonnelExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to personnel expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PersonnelExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PersonnelExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndPatentExpensesMember" xlink:label="afmd_LegalConsultingAndPatentExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LegalConsultingAndPatentExpensesMember" xlink:to="afmd_LegalConsultingAndPatentExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LegalConsultingAndPatentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to legal, consulting and patent expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LegalConsultingAndPatentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Consulting And Patent Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LegalConsultingAndPatentExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal, consulting and patent expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CostsOfMaterialsMember" xlink:label="afmd_CostsOfMaterialsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CostsOfMaterialsMember" xlink:to="afmd_CostsOfMaterialsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CostsOfMaterialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to cost of materials.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CostsOfMaterialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs Of Materials [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CostsOfMaterialsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs of materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation And Amortisation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortisation and depreciation</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherExpensesMember" xlink:label="afmd_OtherExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OtherExpensesMember" xlink:to="afmd_OtherExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OtherExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to other expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OtherExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OtherExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expenses</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:to="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Research and Development Expense [Line Items]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xlink:to="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of General and Administrative Expense Table]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:to="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of General and Administrative Expense [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WagesAndSalaries" xlink:to="ifrs-full_WagesAndSalaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WagesAndSalaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wages and salaries</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SocialSecurityContributions" xlink:to="ifrs-full_SocialSecurityContributions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SocialSecurityContributions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Social security costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployeeBenefitsExpense" xlink:to="ifrs-full_EmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EmployerContributions" xlink:label="ifrs-full_EmployerContributions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EmployerContributions" xlink:to="ifrs-full_EmployerContributions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EmployerContributions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer's contributions</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xlink:to="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Finance Income and Finance Costs Table]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseAxis" xlink:label="afmd_NatureOfIncomeExpenseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NatureOfIncomeExpenseAxis" xlink:to="afmd_NatureOfIncomeExpenseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NatureOfIncomeExpenseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase"></label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NatureOfIncomeExpenseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of income expense [Axis]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseDomain" xlink:label="afmd_NatureOfIncomeExpenseDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NatureOfIncomeExpenseDomain" xlink:to="afmd_NatureOfIncomeExpenseDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NatureOfIncomeExpenseDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase"></label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NatureOfIncomeExpenseDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Income Expense [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NatureOfIncomeExpenseDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature Of Income Expense [Domain]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestSVBLoanAgreementMember" xlink:label="afmd_InterestSVBLoanAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_InterestSVBLoanAgreementMember" xlink:to="afmd_InterestSVBLoanAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_InterestSVBLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to interest SVB loan agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_InterestSVBLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest S V B Loan Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_InterestSVBLoanAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest SVB Loan Agreement</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ForeignExchangeDifferencesMember" xlink:label="afmd_ForeignExchangeDifferencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ForeignExchangeDifferencesMember" xlink:to="afmd_ForeignExchangeDifferencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ForeignExchangeDifferencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to foreign exchange differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ForeignExchangeDifferencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Exchange Differences [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ForeignExchangeDifferencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange differences</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestCertificatesOfDepositMember" xlink:label="afmd_InterestCertificatesOfDepositMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_InterestCertificatesOfDepositMember" xlink:to="afmd_InterestCertificatesOfDepositMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_InterestCertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to interest certificates deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_InterestCertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Certificates Of Deposit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_InterestCertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on certificates of deposit with maturities of more than three months</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherFinanceIncomeFinanceCostsMember" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OtherFinanceIncomeFinanceCostsMember" xlink:to="afmd_OtherFinanceIncomeFinanceCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to other finance income / finance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Finance Income Finance Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other finance income/finance costs - net</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:to="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Finance Income and Finance Costs Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income) at applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit at tax rate of 29.825 %</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" xlink:to="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments of deferred tax assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Effect Due To Adjustments of Deferred Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfPermanentDifferences" xlink:label="afmd_TaxEffectOfPermanentDifferences" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TaxEffectOfPermanentDifferences" xlink:to="afmd_TaxEffectOfPermanentDifferences_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TaxEffectOfPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effects due to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TaxEffectOfPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_TaxEffectOfPermanentDifferences_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfLocalTaxRates" xlink:label="afmd_TaxEffectOfLocalTaxRates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TaxEffectOfLocalTaxRates" xlink:to="afmd_TaxEffectOfLocalTaxRates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TaxEffectOfLocalTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effects due to local tax rates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TaxEffectOfLocalTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for local tax rates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_TaxEffectOfLocalTaxRates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for local tax rates</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" xlink:to="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss), net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax effect of expense not deductible in determining taxable profit (tax loss), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non deductible expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other tax effects for reconciliation between accounting profit and tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxTable" xlink:label="afmd_DisclosureOfIncomeTaxTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfIncomeTaxTable" xlink:to="afmd_DisclosureOfIncomeTaxTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfIncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfIncomeTaxTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Income Tax [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAndLiabilitiesAxis" xlink:to="ifrs-full_AssetsAndLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAndLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="ifrs-full_AssetsAndLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAndLiabilitiesMember" xlink:to="ifrs-full_AssetsAndLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAndLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets And Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAndLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets and liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TemporaryDifferenceBorrowingsMember" xlink:label="afmd_TemporaryDifferenceBorrowingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TemporaryDifferenceBorrowingsMember" xlink:to="afmd_TemporaryDifferenceBorrowingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TemporaryDifferenceBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to temporary differences in borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TemporaryDifferenceBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Difference Borrowings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TemporaryDifferenceBorrowingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" xlink:to="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to leasehold improvements and equipment and right-of-use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold Improvements And Equipment And Right Of Use Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements and equipment and right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LongTermFinancialAssetsMember" xlink:label="afmd_LongTermFinancialAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LongTermFinancialAssetsMember" xlink:to="afmd_LongTermFinancialAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LongTermFinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information related to long term financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LongTermFinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long Term Financial Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LongTermFinancialAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term financial assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ContractLiabilitiesMember" xlink:label="afmd_ContractLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ContractLiabilitiesMember" xlink:to="afmd_ContractLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ContractLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ContractLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ContractLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherReceivablesMember" xlink:label="afmd_TradeAndOtherReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TradeAndOtherReceivablesMember" xlink:to="afmd_TradeAndOtherReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Receivables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other receivables</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherPayablesMember" xlink:label="afmd_TradeAndOtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TradeAndOtherPayablesMember" xlink:to="afmd_TradeAndOtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information related to trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Payables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets Other Than Goodwill [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxLineItems" xlink:label="afmd_DisclosureOfIncomeTaxLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfIncomeTaxLineItems" xlink:to="afmd_DisclosureOfIncomeTaxLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfIncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfIncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Income Tax [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DisclosureOfIncomeTaxLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ApplicableTaxRate" xlink:to="ifrs-full_ApplicableTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Applicable tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ApplicableTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit at tax rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" xlink:to="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tax loss carryforward for corporate income tax purposes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax loss carryforward for corporate income tax purposes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax loss carryforward for corporate income tax purposes</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumTaxLossDueToOwnershipChanges" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MaximumTaxLossDueToOwnershipChanges" xlink:to="afmd_MaximumTaxLossDueToOwnershipChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum tax losses at the risk of being lost due to ownership changes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Tax Loss Due To Ownership Changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum tax loss due to ownership changes</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForTradeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OperatingLossCarryforwardsForTradeTaxPurposes" xlink:to="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tax loss carryforward for trade tax purposes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax loss carryforward for trade tax purposes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax loss carryforward for trade tax purposes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes Of Share Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preference Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial assets [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:to="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in equity instruments designated at fair value through other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of preferred shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains (losses) on change in fair value of derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumMaturityPeriodOfCertificateOfDeposits" xlink:label="afmd_MinimumMaturityPeriodOfCertificateOfDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MinimumMaturityPeriodOfCertificateOfDeposits" xlink:to="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the minimum maturity period of certificate of deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Maturity Period Of Certificate Of Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Maturity period of certificate of deposits</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableTable" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableTable" xlink:to="afmd_DisclosureOfTradeAndOtherReceivableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Trade and Other Receivable [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ValueAddedTaxReceivablesMember" xlink:label="afmd_ValueAddedTaxReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ValueAddedTaxReceivablesMember" xlink:to="afmd_ValueAddedTaxReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ValueAddedTaxReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to value-added tax receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ValueAddedTaxReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value Added Tax Receivables [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ValueAddedTaxReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value-added tax receivables</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:to="afmd_DisclosureOfTradeAndOtherReceivableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Trade and Other Receivable [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other receivables</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:to="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to shares issued under at the market sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued Under At Market Sales Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At-the-market sales agreement</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedInPublicOfferingMember" xlink:label="afmd_SharesIssuedInPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SharesIssuedInPublicOfferingMember" xlink:to="afmd_SharesIssuedInPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SharesIssuedInPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to shares issued in public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SharesIssuedInPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued In Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SharesIssuedInPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CumulativePreferenceSharesMember" xlink:label="afmd_CumulativePreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CumulativePreferenceSharesMember" xlink:to="afmd_CumulativePreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CumulativePreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cumulative preference shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CumulativePreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Preference Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CumulativePreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative preference shares</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AuthorizedCapital" xlink:label="afmd_AuthorizedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AuthorizedCapital" xlink:to="afmd_AuthorizedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AuthorizedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of shares authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AuthorizedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AuthorizedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorized capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesPrice" xlink:label="afmd_SharesPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SharesPrice" xlink:to="afmd_SharesPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SharesPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks of a company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SharesPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SharesPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value at grant date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price at grant date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price, share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpectedDividendShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpectedDividendShareOptionsGranted" xlink:to="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividends</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased Payment Arrangements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Esop2014Member" xlink:label="afmd_Esop2014Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_Esop2014Member" xlink:to="afmd_Esop2014Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_Esop2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to ESOP 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_Esop2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Esop2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_Esop2014Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ESOP 2014</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentMember" xlink:label="afmd_ResearchAndDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ResearchAndDevelopmentMember" xlink:to="afmd_ResearchAndDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ResearchAndDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeMember" xlink:label="afmd_GeneralAndAdministrativeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_GeneralAndAdministrativeMember" xlink:to="afmd_GeneralAndAdministrativeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_GeneralAndAdministrativeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to general and administrative.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_GeneralAndAdministrativeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General And Administrative [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_GeneralAndAdministrativeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingAxis" xlink:label="afmd_IfrsVestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsVestingAxis" xlink:to="afmd_IfrsVestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vestings [Axis]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingDomain" xlink:label="afmd_IfrsVestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsVestingDomain" xlink:to="afmd_IfrsVestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting schedule for share-based compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIMember" xlink:label="afmd_TrancheIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TrancheIMember" xlink:to="afmd_TrancheIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TrancheIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to tranche one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TrancheIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche I [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TrancheIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche I</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiMember" xlink:label="afmd_TrancheIiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TrancheIiMember" xlink:to="afmd_TrancheIiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TrancheIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to tranche two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TrancheIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Ii [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TrancheIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche II</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiiMember" xlink:label="afmd_TrancheIiiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_TrancheIiiMember" xlink:to="afmd_TrancheIiiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_TrancheIiiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to tranche three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_TrancheIiiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche Iii [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_TrancheIiiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tranche III</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Top Of Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards granted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards cancelled or forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards cancelled or forfeited</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards outstanding</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:to="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of other equity instruments (i.e other than share options) exercised in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Other Equity Instruments Exercised in Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average exercise price of awards exercised</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Awards vested</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedUnvestedShareOptionsForfeitureRate" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ExpectedUnvestedShareOptionsForfeitureRate" xlink:to="afmd_ExpectedUnvestedShareOptionsForfeitureRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of share options forfeited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Unvested Share Options, Forfeiture Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual forfeiture rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life of outstanding share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual life</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfTranches" xlink:label="afmd_NumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NumberOfTranches" xlink:to="afmd_NumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches under share based award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExercisePeriodOfShareOptions" xlink:label="afmd_ExercisePeriodOfShareOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ExercisePeriodOfShareOptions" xlink:to="afmd_ExercisePeriodOfShareOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ExercisePeriodOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period over which shares can be exercised from grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ExercisePeriodOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise Period of Share Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ExercisePeriodOfShareOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise period</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" xlink:to="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The preceding consecutive trading period should be considered for weighted average share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Share Price Period Considered, Preceding Consecutive Trading Day</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading days</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" xlink:to="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of fair value of shares at grant date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Fair Value at Measurement Date Share Based Payment Award Awarded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant date fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options exercisable in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share based expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based expense</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" xlink:to="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options issued in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options Issued In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options issued</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ProgramTerminationCost" xlink:label="afmd_ProgramTerminationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ProgramTerminationCost" xlink:to="afmd_ProgramTerminationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ProgramTerminationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of program termination cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ProgramTerminationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program Termination Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ProgramTerminationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination cost</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PaymentOfTerminationOfProgram" xlink:label="afmd_PaymentOfTerminationOfProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PaymentOfTerminationOfProgram" xlink:to="afmd_PaymentOfTerminationOfProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PaymentOfTerminationOfProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash outflow for payment of program termination cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PaymentOfTerminationOfProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of Termination of Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PaymentOfTerminationOfProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination cost incurred</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected termination cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameAxis" xlink:to="ifrs-full_BorrowingsByNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsByNameMember" xlink:to="ifrs-full_BorrowingsByNameMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings By Name [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsByNameMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings by name [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThereofAssetsPledgedMember" xlink:label="afmd_ThereofAssetsPledgedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ThereofAssetsPledgedMember" xlink:to="afmd_ThereofAssetsPledgedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ThereofAssetsPledgedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to thereof assets pledged</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ThereofAssetsPledgedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof Assets Pledged [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ThereofAssetsPledgedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof Assets Pledged</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about borrowings [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherAssets" xlink:to="ifrs-full_OtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_OtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets pledged as collateral for liabilities or contingent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of interest rates [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_InterestRateTypesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Rate Types [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate types [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEURIBORMember" xlink:label="afmd_OneMonthEURIBORMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OneMonthEURIBORMember" xlink:to="afmd_OneMonthEURIBORMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OneMonthEURIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the one month EURIBOR interest rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OneMonthEURIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Month E U R I B O R [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OneMonthEURIBORMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EURIBOR</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SiliconValleyBankLoanMember" xlink:label="afmd_SiliconValleyBankLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SiliconValleyBankLoanMember" xlink:to="afmd_SiliconValleyBankLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SiliconValleyBankLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Silicon Valley Bank loan,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SiliconValleyBankLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Silicon Valley Bank Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SiliconValleyBankLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB loan</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SeniorSecuredTermLoanFacilityMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to senior secured term loan facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to senior secured term loan facility one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility Tranche One</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to senior secured term loan facility tranche two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Term Loan Facility Tranche Two</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LoanAgreementWithUniCreditLeasingCZMember" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LoanAgreementWithUniCreditLeasingCZMember" xlink:to="afmd_LoanAgreementWithUniCreditLeasingCZMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to the loan agreement with UniCredit Leasing CZ.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan Agreement With Uni Credit Leasing C Z [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan agreement with UniCredit Leasing CZ</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I F R S Line of Credit Facility, Maximum Borrowing Capacity"</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentNumberOfTranches" xlink:label="afmd_DebtInstrumentNumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DebtInstrumentNumberOfTranches" xlink:to="afmd_DebtInstrumentNumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of tranches under the debt instrument agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Number Of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DebtInstrumentNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of tranches</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings [Default Label]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_Borrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="ifrs-full_UndrawnBorrowingFacilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UndrawnBorrowingFacilities" xlink:to="ifrs-full_UndrawnBorrowingFacilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UndrawnBorrowingFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undrawn borrowing facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_UndrawnBorrowingFacilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Undrawn borrowings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:to="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings, adjustment to interest rate basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Variable interest rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFloorRate" xlink:label="afmd_DebtInstrumentFloorRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DebtInstrumentFloorRate" xlink:to="afmd_DebtInstrumentFloorRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DebtInstrumentFloorRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of floor of a debt instrument.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DebtInstrumentFloorRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Floor Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DebtInstrumentFloorRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Floor rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentLegalAndArrangementFees" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DebtInstrumentLegalAndArrangementFees" xlink:to="afmd_DebtInstrumentLegalAndArrangementFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of legal and arrangement fees under the debt instrument arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Legal And Arrangement Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and arrangement fee</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" xlink:to="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of principal as the final payment fee under the debt instrument arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Final Payment Fee As A Percentage Of Principal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Final payment fee percentage on principal</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of securities into which the class of warrant or right may be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I F R S Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to purchase common shares</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I F R S Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of share</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpirationPeriodOfWarrants" xlink:label="afmd_ExpirationPeriodOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ExpirationPeriodOfWarrants" xlink:to="afmd_ExpirationPeriodOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ExpirationPeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period from grant date that an warrant to exercise common stock expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ExpirationPeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration Period Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ExpirationPeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through exercise of warrants, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" xlink:to="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from the deferred tax assets on exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) Through Deferred Taxes On Warrants Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in deferred tax on warrant equity</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" xlink:to="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in equity resulting from the transaction costs on grants of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) Through Transaction Costs On Warrants Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in transaction cost</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedVolatilityOfWarrants" xlink:label="afmd_ExpectedVolatilityOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ExpectedVolatilityOfWarrants" xlink:to="afmd_ExpectedVolatilityOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ExpectedVolatilityOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected volatility of the share price used to calculate the fair value of the warrants. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ExpectedVolatilityOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ExpectedVolatilityOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedExercisePeriodOfWarrants" xlink:label="afmd_ExpectedExercisePeriodOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ExpectedExercisePeriodOfWarrants" xlink:to="afmd_ExpectedExercisePeriodOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ExpectedExercisePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The expected exercise period of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ExpectedExercisePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Exercise Period Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ExpectedExercisePeriodOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise period</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" xlink:to="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of ownership interest with which the loan is secured by a pledge.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Ownership Interest With Which The Loan Is collateralized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of ownership interest pledged as security</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValue" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, at fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfNoncurrentBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:to="ifrs-full_RepaymentsOfNoncurrentBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RepaymentsOfNoncurrentBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan repaid</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" xlink:to="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of monthly installment to be paid under the debt agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Monthly Repayment Installment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monthly repayment installment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:to="ifrs-full_CurrentPortionOfLongtermBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of non-current borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan payable, current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loan payable, current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:to="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in liabilities arising from financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movements of liabilities reconcile to cash flows arising from financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through financing cash flows, liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes from financing cash flows</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingCostsCapitalised" xlink:to="ifrs-full_BorrowingCostsCapitalised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BorrowingCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowing costs capitalised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BorrowingCostsCapitalised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized borrowing costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through other changes, liabilities arising from financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Changes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPayables" xlink:to="ifrs-full_OtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other payables</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeasesForLesseeTable" xlink:label="afmd_DisclosureOfLeasesForLesseeTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfLeasesForLesseeTable" xlink:to="afmd_DisclosureOfLeasesForLesseeTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfLeasesForLesseeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfLeasesForLesseeTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Leases for Lessee [Table]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeaseForLesseeLineItems" xlink:label="afmd_DisclosureOfLeaseForLesseeLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_DisclosureOfLeaseForLesseeLineItems" xlink:to="afmd_DisclosureOfLeaseForLesseeLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_DisclosureOfLeaseForLesseeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_DisclosureOfLeaseForLesseeLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Lease For Lessee [Line Items]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of quantitative information about right-of-use assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsToRightofuseAssets" xlink:to="ifrs-full_AdditionsToRightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsToRightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions to right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShortTermLeasePayments" xlink:label="afmd_IfrsShortTermLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IfrsShortTermLeasePayments" xlink:to="afmd_IfrsShortTermLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IfrsShortTermLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for short-term lease payment excluded from lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IfrsShortTermLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Short-term Lease Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IfrsShortTermLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term lease payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashOutflowForLeases" xlink:to="ifrs-full_CashOutflowForLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash outflow for leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashOutflowForLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash outflow from leasing</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RentalExpense" xlink:to="ifrs-full_RentalExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossLeaseLiabilities" xlink:to="ifrs-full_GrossLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future contractually agreed undiscounted cash flows</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" xlink:to="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of future minimum lease payments payable under non-cancellable operating leases under IAS 17.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Lease Payments Payable Under Non cancellable Operating Lease IAS17</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease commitment under IAS 17</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AdditionsOfNewLeaseContracts" xlink:label="afmd_AdditionsOfNewLeaseContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AdditionsOfNewLeaseContracts" xlink:to="afmd_AdditionsOfNewLeaseContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AdditionsOfNewLeaseContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additions in new contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AdditionsOfNewLeaseContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions Of New Lease Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AdditionsOfNewLeaseContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New lease contracts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="ifrs-full_OtherFeeAndCommissionExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFeeAndCommissionExpense" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FuturePaymentLicenseFeeObligationDue" xlink:label="afmd_FuturePaymentLicenseFeeObligationDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_FuturePaymentLicenseFeeObligationDue" xlink:to="afmd_FuturePaymentLicenseFeeObligationDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_FuturePaymentLicenseFeeObligationDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of future payment obligations under non-cancellable license fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_FuturePaymentLicenseFeeObligationDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future Payment License Fee Obligation Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_FuturePaymentLicenseFeeObligationDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future payment obligations under non-cancellable fees</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term employee benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination benefits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_KeyManagementPersonnelCompensation" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel compensation</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" xlink:to="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of Remuneration payable to key management personnel and supervisory directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remuneration payable to key management personnel and supervisory directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key management personnel outstanding balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entitys Total For Related Parties [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SupervisoryBoardDirectorsMember" xlink:label="afmd_SupervisoryBoardDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SupervisoryBoardDirectorsMember" xlink:to="afmd_SupervisoryBoardDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SupervisoryBoardDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to supervisory board of directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SupervisoryBoardDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory Board Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SupervisoryBoardDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory Board Directors</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" xlink:to="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of shareholders holding more than twenty percent of voting rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Shareholders Holding More Than Twenty Percent Voting Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shareholder holds more than 20% of the voting rights</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_KeyManagementPersonnelCompensationForServices" xlink:label="afmd_KeyManagementPersonnelCompensationForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_KeyManagementPersonnelCompensationForServices" xlink:to="afmd_KeyManagementPersonnelCompensationForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_KeyManagementPersonnelCompensationForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation received for their services</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FloatingInterestRateMember" xlink:to="ifrs-full_FloatingInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Floating Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FloatingInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Floating interest rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEuriborMember" xlink:label="afmd_OneMonthEuriborMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_OneMonthEuriborMember" xlink:to="afmd_OneMonthEuriborMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_OneMonthEuriborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the one month EURIBOR interest rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_OneMonthEuriborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Month Euribor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_OneMonthEuriborMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One Month Euribor</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types Of Risks [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CreditRiskMember" xlink:to="ifrs-full_CreditRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CreditRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateRiskMember" xlink:to="ifrs-full_InterestRateRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Rate Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InterestRateRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherPriceRiskMember" xlink:label="ifrs-full_OtherPriceRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPriceRiskMember" xlink:to="ifrs-full_OtherPriceRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPriceRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Price Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPriceRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other price risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidity risk</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesValue" xlink:label="afmd_SharesValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SharesValue" xlink:to="afmd_SharesValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SharesValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying amount of shares as on the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SharesValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SharesValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total carrying amount of shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermDeposits" xlink:to="ifrs-full_LongtermDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LongtermDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates of deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LongtermDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates of deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaximumExposureToCreditRisk" xlink:to="ifrs-full_MaximumExposureToCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MaximumExposureToCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum credit exposure</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotionalAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal amount</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" xlink:to="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of deemed EURIBOR rate if it is less than zero percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Deemed EURIBOR Rate If less Than Zero Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of deemed EURIBOR rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromInterest" xlink:to="ifrs-full_RevenueFromInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumExposureToForeignCurrencyRisk" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MaximumExposureToForeignCurrencyRisk" xlink:to="afmd_MaximumExposureToForeignCurrencyRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Maximum foreign currency exposure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum foreign currency exposure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum foreign currency exposure</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" xlink:to="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of weakening/strengthening difference between currencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Deviation Between Currency Exchange Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of deviation between currency exchange rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NetLossInCaseOfCurrencyExchangeDeviation" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_NetLossInCaseOfCurrencyExchangeDeviation" xlink:to="afmd_NetLossInCaseOfCurrencyExchangeDeviation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net loss the company would have accounted in case of currency exchange deviation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss In Case Of Currency Exchange Deviation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss in currency exchange deviation</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" xlink:to="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of shift in exchange rate considered a realistic scenario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Shift In Exchange Rate Considered A Realistic Scenario</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of shift in exchange rate</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharePricePerShare" xlink:label="afmd_SharePricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_SharePricePerShare" xlink:to="afmd_SharePricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_SharePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price of a single share of a number of saleable stocks of a company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_SharePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price, Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_SharePricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CZKMember" xlink:label="afmd_CZKMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CZKMember" xlink:to="afmd_CZKMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CZKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to CZK.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CZKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C Z K [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CZKMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CZK</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_USDMember" xlink:label="afmd_USDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_USDMember" xlink:to="afmd_USDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_USDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_USDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U S D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_USDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GbpMember" xlink:label="afmd_GbpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_GbpMember" xlink:to="afmd_GbpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_GbpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_GbpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gbp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_GbpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GBP</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AverageForeignExchangeRate" xlink:to="ifrs-full_AverageForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AverageForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClosingForeignExchangeRate" xlink:to="ifrs-full_ClosingForeignExchangeRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClosingForeignExchangeRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Spot rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Reserve [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Reserves</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restated [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:to="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Effect Of Changes In Accounting Policy [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change due to adoption of IFRS 9</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initially applied IFRSs [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initially Applied I F R Ss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initially applied IFRSs [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_IFRS16Member" xlink:to="afmd_IFRS16Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_IFRS16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to IFRS 16 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_IFRS16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">I F R S16 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_IFRS16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS 16</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New IFRSs [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="ifrs-full_NewIFRSsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NewIFRSsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New I F R Ss [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NewIFRSsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New IFRSs [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifrs16Member" xlink:label="afmd_Ifrs16Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_Ifrs16Member" xlink:to="afmd_Ifrs16Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_Ifrs16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to IFRS 16 Leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_Ifrs16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs16 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_Ifrs16Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS 16 Leases</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" xlink:to="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Amendments to IFRS 9: Prepayment Features with Negative Compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ifrs9 Prepayment Features With Negative Compensation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments to IFRS 9: Prepayment Features with Negative Compensation</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" xlink:to="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ias28 Long Term Interests In Associates And Joint Ventures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" xlink:to="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Annual Improvements to IFRS Standards 2015&#x2011;2017 Cycle.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Improvements To Ifrs Standards20152017 Cycle [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual Improvements to IFRS Standards 2015&#x2011;2017 Cycle</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" xlink:to="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Amendments to IAS 19: Plan Amendment, Curtailment or Settlement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ias19 Plan Amendment Curtailment Or Settlement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" xlink:to="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to IFRIC 23 Uncertainty over Income Tax Treatments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifric23 Uncertainty Over Income Tax Treatments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRIC 23 Uncertainty Over Income Tax Treatments</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToReferencesToConceptionalFrameworkMember" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToReferencesToConceptionalFrameworkMember" xlink:to="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Amendments to References to the Conceptional Framework.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To References To Conceptional Framework [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To References To The Conceptional Framework</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" xlink:to="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Amendments to IAS 1 and IAS 8: Definition of Material.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ias1 And Ias8 Definition Of Material [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments to IAS 1 and IAS 8: Definition of Material</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" xlink:to="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ifrs9 Ias39 And Ifrs7 Interest Rate Benchmark Reform [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To IFRS 9, IAS 39 And IFRS 7: Interest Rate Benchmark Reform</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs3BusinessCombinationMember" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AmendmentsToIfrs3BusinessCombinationMember" xlink:to="afmd_AmendmentsToIfrs3BusinessCombinationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Amendments to IFRS 3 Business Combination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments To Ifrs3 Business Combination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendments to IFRS 3 Business Combination</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical Areas [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">D [E]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_EuropeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Europe</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U [S]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CZ" xlink:label="country_CZ" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CZ" xlink:to="country_CZ_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CZ_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C [Z]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CZ_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Czech Republic</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationServiceMember" xlink:label="afmd_CollaborationServiceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_CollaborationServiceMember" xlink:to="afmd_CollaborationServiceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_CollaborationServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_CollaborationServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_CollaborationServiceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServicesMember" xlink:label="afmd_ServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ServicesMember" xlink:to="afmd_ServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Timing of transfer of goods or services [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Timing Of Transfer Of Goods Or Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Timing of transfer of goods or services [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goods Or Services Transferred At Point In Time [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Point in time</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goods Or Services Transferred Over Time [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over time</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndAuditExpensesMember" xlink:label="afmd_LegalConsultingAndAuditExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LegalConsultingAndAuditExpensesMember" xlink:to="afmd_LegalConsultingAndAuditExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LegalConsultingAndAuditExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to legal, consulting and audit expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LegalConsultingAndAuditExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Consulting And Audit Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LegalConsultingAndAuditExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal, consulting and audit expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilitiesMember" xlink:to="ifrs-full_LeaseLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LeaseLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of assets [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes Of Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="ifrs-full_MotorVehiclesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MotorVehiclesMember" xlink:to="ifrs-full_MotorVehiclesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MotorVehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Motor Vehicles [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MotorVehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Car</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated Time Bands [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not Later Than One Year [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments within one year</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Later Than One Year And Not Later Than Five Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments between one and five years</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AdiHoessMember" xlink:label="afmd_AdiHoessMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_AdiHoessMember" xlink:to="afmd_AdiHoessMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_AdiHoessMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adi Hoess.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_AdiHoessMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adi Hoess [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_AdiHoessMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adi Hoess</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WolfgangFischerMember" xlink:label="afmd_WolfgangFischerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_WolfgangFischerMember" xlink:to="afmd_WolfgangFischerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_WolfgangFischerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Wolfgang Fischer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_WolfgangFischerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wolfgang Fischer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_WolfgangFischerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Wolfgang Fischer</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MartinTrederMember" xlink:label="afmd_MartinTrederMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MartinTrederMember" xlink:to="afmd_MartinTrederMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MartinTrederMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Martin Treder.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MartinTrederMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Martin Treder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MartinTrederMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Martin Treder</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeilaAllandMember" xlink:label="afmd_LeilaAllandMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_LeilaAllandMember" xlink:to="afmd_LeilaAllandMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_LeilaAllandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Leila Alland.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_LeilaAllandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leila Alland [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_LeilaAllandMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leila Alland</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThomasHechtMember" xlink:label="afmd_ThomasHechtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_ThomasHechtMember" xlink:to="afmd_ThomasHechtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_ThomasHechtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to thomas hecht</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_ThomasHechtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thomas Hecht [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_ThomasHechtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Thomas Hecht</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MathieuSimonMember" xlink:label="afmd_MathieuSimonMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_MathieuSimonMember" xlink:to="afmd_MathieuSimonMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_MathieuSimonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Mathieu Simon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_MathieuSimonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mathieu Simon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_MathieuSimonMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mathieu Simon</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BemdtModigMember" xlink:label="afmd_BemdtModigMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_BemdtModigMember" xlink:to="afmd_BemdtModigMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_BemdtModigMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to bemdt modig</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_BemdtModigMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bemdt Modig [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_BemdtModigMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Berndt Modig</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FerdinandVerdonckMember" xlink:label="afmd_FerdinandVerdonckMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_FerdinandVerdonckMember" xlink:to="afmd_FerdinandVerdonckMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_FerdinandVerdonckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Ferdinand Verdonck</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_FerdinandVerdonckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ferdinand Verdonck [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_FerdinandVerdonckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ferdinand Verdonck</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_UlrichGrauMember" xlink:label="afmd_UlrichGrauMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_UlrichGrauMember" xlink:to="afmd_UlrichGrauMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_UlrichGrauMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Ulrich Grau</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_UlrichGrauMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ulrich Grau [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_UlrichGrauMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ulrich Grau</label>
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BernhardEhmerMember" xlink:label="afmd_BernhardEhmerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="afmd_BernhardEhmerMember" xlink:to="afmd_BernhardEhmerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="afmd_BernhardEhmerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member represents information pertaining to Bernhard Ehmer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="afmd_BernhardEhmerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bernhard Ehmer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="afmd_BernhardEhmerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Bernhard Ehmer</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>afmd-20191231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.0.116 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2020 3:58:41 PM-->
<!--Modified on: 4/28/2020 3:58:41 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.affimed.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementsOfFinancialPosition" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementOfCashFlows" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#StatementConsolidatedStatementOfChangesInEquity" roleURI="http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure1ReportingEntity" roleURI="http://www.affimed.com/role/Disclosure1ReportingEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup" roleURI="http://www.affimed.com/role/Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure3BasisOfPreparationConsolidatedFinancialStatements" roleURI="http://www.affimed.com/role/Disclosure3BasisOfPreparationConsolidatedFinancialStatements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPolicies" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReporting" roleURI="http://www.affimed.com/role/Disclosure5SegmentReporting" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6Revenue" roleURI="http://www.affimed.com/role/Disclosure6Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure7OtherIncomeAndExpensesNet" roleURI="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure8ResearchAndDevelopmentExpenses" roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure9GeneralAndAdministrativeExpenses" roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure10EmployeeBenefits" roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure11FinanceIncomeAndFinanceCosts" roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxes" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure13LongTermFinancialAssets" roleURI="http://www.affimed.com/role/Disclosure13LongTermFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure14FinancialAssets" roleURI="http://www.affimed.com/role/Disclosure14FinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure15TradeAndOtherReceivables" roleURI="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure16Equity" roleURI="http://www.affimed.com/role/Disclosure16Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure17ShareBasedPayments" roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure18Provisions" roleURI="http://www.affimed.com/role/Disclosure18Provisions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19Borrowings" roleURI="http://www.affimed.com/role/Disclosure19Borrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure20TradeAndOtherPayables" roleURI="http://www.affimed.com/role/Disclosure20TradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21Leases" roleURI="http://www.affimed.com/role/Disclosure21Leases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure22OtherCommitmentsAndContingencies" roleURI="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedParties" roleURI="http://www.affimed.com/role/Disclosure23RelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagement" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure25SubsequentEvents" roleURI="http://www.affimed.com/role/Disclosure25SubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesPolicies" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesTables" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReportingTables" roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueTables" roleURI="http://www.affimed.com/role/Disclosure6RevenueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure8ResearchAndDevelopmentExpensesTables" roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure9GeneralAndAdministrativeExpensesTables" roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure10EmployeeBenefitsTables" roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure11FinanceIncomeAndFinanceCostsTables" roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxesTables" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure17ShareBasedPaymentsTables" roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsTables" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesTables" roleURI="http://www.affimed.com/role/Disclosure21LeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesTables" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagementTables" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesDetails" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure4SignificantAccountingPoliciesLeaseDetails" roleURI="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReportingGeographicInformationDetails" roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure5SegmentReportingNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueDetails" roleURI="http://www.affimed.com/role/Disclosure6RevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure6RevenueDisaggregationOfRevenueDetails" roleURI="http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure7OtherIncomeAndExpensesNetDetails" roleURI="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure8ResearchAndDevelopmentExpensesDetails" roleURI="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure9GeneralAndAdministrativeExpensesDetails" roleURI="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure10EmployeeBenefitsDetails" roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure10EmployeeBenefitsNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure10EmployeeBenefitsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure11FinanceIncomeAndFinanceCostsDetails" roleURI="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxesDetails" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure12IncomeTaxesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure13LongTermFinancialAssetsDetails" roleURI="http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure14FinancialAssetsDetails" roleURI="http://www.affimed.com/role/Disclosure14FinancialAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure15TradeAndOtherReceivablesDetails" roleURI="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure16EquityDetails" roleURI="http://www.affimed.com/role/Disclosure16EquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure17ShareBasedPaymentsDetails" roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure17ShareBasedPaymentsNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure18ProvisionsDetails" roleURI="http://www.affimed.com/role/Disclosure18ProvisionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails" roleURI="http://www.affimed.com/role/Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure20TradeAndOtherPayablesDetails" roleURI="http://www.affimed.com/role/Disclosure20TradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails" roleURI="http://www.affimed.com/role/Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesCompensationDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesOutstandingBalancesDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure23RelatedPartiesNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagementNarrativeDetails" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="afmd-20191231.xsd#Disclosure24FinancialRiskManagementExchangeRatesDetails" roleURI="http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.affimed.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637236863190949475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637236863190949475" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637236863190969410" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637236863190969410" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637236863191119009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637236863191119009" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637236863191119009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637236863191119009" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637236863191119009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637236863191119009" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637236863191119009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637236863191119009" order="6" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637236863191119009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637236863191119009" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637236863191128966" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637236863191128966" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637236863191128966" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637236863191128966" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637236863191128966" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637236863191128966" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637236863191128966" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637236863191128966" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637236863191128966" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637236863191128966" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637236863191128966" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637236863191128966" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637236863191158887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentShellCompanyReport_637236863191158887" order="19" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00100 - Statement - Consolidated statements of comprehensive loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637236863191158887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_Revenue_637236863191158887" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherIncome" xlink:label="ifrs-full_OtherIncome_637236863191158887" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherIncome_637236863191158887" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637236863191178861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637236863191178861" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637236863191178861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637236863191178861" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_637236863191178861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_637236863191178861" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_637236863191178861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncomeCost_637236863191178861" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_637236863191188837" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863191188837" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_637236863191188837" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_637236863191188837" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_637236863191188837" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments_637236863191188837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract_637236863191188837" xlink:to="ifrs-full_OtherComprehensiveIncome_637236863191188837" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_637236863191188837" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BasicAndDilutedEarningsLossPerShare" xlink:label="ifrs-full_BasicAndDilutedEarningsLossPerShare_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_BasicAndDilutedEarningsLossPerShare_637236863191188837" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_WeightedAverageShares_637236863191188837" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Consolidated statements of financial position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_636879908919166346" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract_636879908919166346" xlink:to="ifrs-full_AssetsAbstract_637236863191188837" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637236863191188837" xlink:to="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_637236863191188837" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_PropertyPlantAndEquipment_637236863191188837" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_NoncurrentFinancialAssets_637236863191188837" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_RightofuseAssets_637236863191188837" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RecognisedFinanceLeaseAsAssetsIas17" xlink:label="afmd_RecognisedFinanceLeaseAsAssetsIas17_637236863191188837" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="afmd_RecognisedFinanceLeaseAsAssetsIas17_637236863191188837" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_DeferredTaxAssets_637236863191198803" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_637236863191188837" xlink:to="ifrs-full_NoncurrentAssets_637236863191198803" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_637236863191188837" xlink:to="ifrs-full_CurrentAssetsAbstract_637236863191198803" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_CashAndCashEquivalents_637236863191198803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_CurrentFinancialAssets_637236863191198803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637236863191198803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_Inventories_637236863191198803" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentAssets" xlink:label="ifrs-full_OtherCurrentAssets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_OtherCurrentAssets_637236863191198803" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_CurrentAssets_637236863191198803" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_637236863191198803" xlink:to="ifrs-full_Assets_637236863191198803" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract_636879908919166346" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_637236863191198803" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637236863191198803" xlink:to="ifrs-full_EquityAbstract_637236863191198803" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_IssuedCapital_637236863191198803" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_CapitalReserve_637236863191198803" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReserves" xlink:label="ifrs-full_OtherReserves_637236863191198803" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_OtherReserves_637236863191198803" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_RetainedEarnings_637236863191208776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAttributableToOwnersOfParent" xlink:label="ifrs-full_EquityAttributableToOwnersOfParent_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_EquityAttributableToOwnersOfParent_637236863191208776" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_637236863191198803" xlink:to="ifrs-full_Equity_637236863191208776" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637236863191198803" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_LongtermBorrowings_637236863191208776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_NoncurrentContractLiabilities_637236863191208776" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_637236863191208776" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_DeferredTaxLiabilities_637236863191208776" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_NoncurrentLiabilities_637236863191208776" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_637236863191198803" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_637236863191208776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_637236863191208776" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Provisions" xlink:label="ifrs-full_Provisions_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_Provisions_637236863191218761" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings" xlink:label="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings_637236863191218761" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_CurrentLeaseLiabilities_637236863191218761" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_CurrentContractLiabilities_637236863191218761" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_CurrentLiabilities_637236863191218761" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_637236863191218761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_637236863191208776" xlink:to="ifrs-full_EquityAndLiabilities_637236863191218761" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statement of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_636879908919201770" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract_636879908919201770" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637236863191248670" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637236863191248670" xlink:to="ifrs-full_ProfitLoss_637236863191248670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncomeTaxExpense" xlink:label="ifrs-full_AdjustmentsForIncomeTaxExpense_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForIncomeTaxExpense_637236863191248670" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_637236863191248670" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment_637236863191248670" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_637236863191248670" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForFinanceIncomeCost" xlink:label="ifrs-full_AdjustmentsForFinanceIncomeCost_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForFinanceIncomeCost_637236863191248670" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital" xlink:label="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital_637236863191248670" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_637236863191248670" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_637236863191248670" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_637236863191248670" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_637236863191248670" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_637236863191248670" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637236863191248670" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_637236863191248670" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_637236863191258625" order="13" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_637236863191258625" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_637236863191248670" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_637236863191258625" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract_636879908919201770" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_637236863191258625" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863191258625" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_637236863191258625" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod" xlink:label="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod_637236863191258625" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PurchaseOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PurchaseOfAvailableforsaleFinancialAssets_637236863191258625" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets" xlink:label="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets_637236863191258625" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PurchaseOfLongTermFinancialAssets" xlink:label="afmd_PurchaseOfLongTermFinancialAssets_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="afmd_PurchaseOfLongTermFinancialAssets_637236863191258625" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_637236863191258625" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract_636879908919201770" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191268597" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PaymentsForShareIssueCosts_637236863191268597" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863191268597" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsForDebtIssueCosts" xlink:label="ifrs-full_PaymentsForDebtIssueCosts_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PaymentsForDebtIssueCosts_637236863191268597" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191268597" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863191268597" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_637236863191268597" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_637236863191268597" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_637236863191268597" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863191268597" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_CashAndCashEquivalents_637236863191268597" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_CashAndCashEquivalents_637236863191278572" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6372368631912785721" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_637236863191258625" xlink:to="ifrs-full_CashAndCashEquivalents_6372368631912785721" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statement of Changes in Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_636879908919255860" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract_636879908919255860" xlink:to="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" xlink:to="ifrs-full_ComponentsOfEquityAxis_637236863191278572" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191278572" xlink:to="ifrs-full_IssuedCapitalMember_637236863191278572" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191278572" xlink:to="ifrs-full_CapitalReserveMember_637236863191278572" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplusMember" xlink:label="ifrs-full_RevaluationSurplusMember_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191278572" xlink:to="ifrs-full_RevaluationSurplusMember_637236863191278572" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191278572" xlink:to="ifrs-full_RetainedEarningsMember_637236863191278572" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637236863191278572" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191278572" xlink:to="ifrs-full_EquityMember_637236863191278572" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodAxis" xlink:label="afmd_IfrsRevisionOfPriorPeriodAxis_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" xlink:to="afmd_IfrsRevisionOfPriorPeriodAxis_637236863191288544" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsPreviouslyReportedMember" xlink:label="afmd_IfrsPreviouslyReportedMember_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsRevisionOfPriorPeriodAxis_637236863191288544" xlink:to="afmd_IfrsPreviouslyReportedMember_637236863191288544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsRevisionOfPriorPeriodDomain" xlink:label="afmd_IfrsRevisionOfPriorPeriodDomain_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsRevisionOfPriorPeriodAxis_637236863191288544" xlink:to="afmd_IfrsRevisionOfPriorPeriodDomain_637236863191288544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637236863191288544" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember" xlink:label="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637236863191288544" xlink:to="ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember_637236863191288544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_637236863191288544" xlink:to="ifrs-full_RestatedMember_637236863191288544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191278572" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_Equity_637236863191288544" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevaluationSurplus" xlink:label="ifrs-full_RevaluationSurplus_637236863191288544" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_RevaluationSurplus_637236863191288544" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_IssueOfEquity_637236863191298543" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_637236863191298543" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_637236863191298543" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssueOfConvertibleInstruments" xlink:label="ifrs-full_IssueOfConvertibleInstruments_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_IssueOfConvertibleInstruments_637236863191298543" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_ProfitLoss_637236863191298543" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_OtherComprehensiveIncome_637236863191298543" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_637236863191298543" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191288544" xlink:to="ifrs-full_Equity_637236863191298543" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure1ReportingEntity" xlink:type="extended" xlink:title="10101 - Disclosure - 1. Reporting Entity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ReportingEntityAbstract" xlink:label="afmd_ReportingEntityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_637236863191308506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ReportingEntityAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_637236863191308506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup" xlink:type="extended" xlink:title="10201 - Disclosure - 2. Local exemption rules applied by subsidiaries of the Group" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock" xlink:label="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_637236863191308506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract" xlink:to="afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock_637236863191308506" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure3BasisOfPreparationConsolidatedFinancialStatements" xlink:type="extended" xlink:title="10301 - Disclosure - 3. Basis of preparation &#x2013; consolidated financial statements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:label="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637236863191308506" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_637236863191308506" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - 4. Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesAbstract_636879908919275937" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory" xlink:label="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637236863191318478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract_636879908919275937" xlink:to="ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_637236863191318478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReporting" xlink:type="extended" xlink:title="10501 - Disclosure - 5. Segment Reporting" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_637236863191318478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_637236863191318478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure6Revenue" xlink:type="extended" xlink:title="10601 - Disclosure - 6. Revenue" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_637236863191318478" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_637236863191318478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNet" xlink:type="extended" xlink:title="10701 - Disclosure - 7. Other Income and Expenses - Net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherIncomeAndExpensesNetAbstract" xlink:label="afmd_OtherIncomeAndExpensesNetAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_637236863191328455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_OtherIncomeAndExpensesNetAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory_637236863191328455" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpenses" xlink:type="extended" xlink:title="10801 - Disclosure - 8. Research and Development Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentExpensesAbstract" xlink:label="afmd_ResearchAndDevelopmentExpensesAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_637236863191328455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ResearchAndDevelopmentExpensesAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory_637236863191328455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpenses" xlink:type="extended" xlink:title="10901 - Disclosure - 9. General and Administrative Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeExpensesAbstract" xlink:label="afmd_GeneralAndAdministrativeExpensesAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_637236863191328455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_GeneralAndAdministrativeExpensesAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory_637236863191328455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure10EmployeeBenefits" xlink:type="extended" xlink:title="11001 - Disclosure - 10. Employee Benefits" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_EmployeeBenefitsAbstract" xlink:label="afmd_EmployeeBenefitsAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_637236863191338424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfEmployeeBenefitsExplanatory_637236863191338424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCosts" xlink:type="extended" xlink:title="11101 - Disclosure - 11. Finance Income and Finance Costs" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:label="afmd_FinanceIncomeAndFinanceCostsAbstract_636879908919285959" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637236863191338424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinanceIncomeAndFinanceCostsAbstract_636879908919285959" xlink:to="ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory_637236863191338424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxes" xlink:type="extended" xlink:title="11201 - Disclosure - 12. Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_637236863191338424" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_637236863191338424" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure13LongTermFinancialAssets" xlink:type="extended" xlink:title="11301 - Disclosure - 13. Long Term Financial Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLongTermFinancialAssetsTextBlock" xlink:label="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_637236863191348382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="afmd_DisclosureOfLongTermFinancialAssetsTextBlock_637236863191348382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure14FinancialAssets" xlink:type="extended" xlink:title="11401 - Disclosure - 14. Financial Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialAssetsAbstract" xlink:label="afmd_FinancialAssetsAbstract_636879908919295986" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialAssetsExplanatory_637236863191348382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialAssetsAbstract_636879908919295986" xlink:to="ifrs-full_DisclosureOfFinancialAssetsExplanatory_637236863191348382" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivables" xlink:type="extended" xlink:title="11501 - Disclosure - 15. Trade and Other Receivables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract_636879908919295986" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_637236863191348382" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract_636879908919295986" xlink:to="ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory_637236863191348382" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure16Equity" xlink:type="extended" xlink:title="11601 - Disclosure - 16. Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIssuedCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfIssuedCapitalExplanatory_637236863191358366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_DisclosureOfIssuedCapitalExplanatory_637236863191358366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure17ShareBasedPayments" xlink:type="extended" xlink:title="11701 - Disclosure - 17. Share Based Payments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedPaymentsAbstract" xlink:label="afmd_ShareBasedPaymentsAbstract_636879908919295986" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637236863191358366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract_636879908919295986" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_637236863191358366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure18Provisions" xlink:type="extended" xlink:title="11801 - Disclosure - 18. Provisions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfProvisionsExplanatory" xlink:label="ifrs-full_DisclosureOfProvisionsExplanatory_637236863191358366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_DisclosureOfProvisionsExplanatory_637236863191358366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure19Borrowings" xlink:type="extended" xlink:title="11901 - Disclosure - 19. Borrowings" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract_636879908919295986" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfBorrowingsExplanatory" xlink:label="ifrs-full_DisclosureOfBorrowingsExplanatory_637236863191368336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract_636879908919295986" xlink:to="ifrs-full_DisclosureOfBorrowingsExplanatory_637236863191368336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure20TradeAndOtherPayables" xlink:type="extended" xlink:title="12001 - Disclosure - 20. Trade and Other Payables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract_636879908919295986" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_637236863191368336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract_636879908919295986" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_637236863191368336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21Leases" xlink:type="extended" xlink:title="12101 - Disclosure - 21. Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfLeasesExplanatory" xlink:label="ifrs-full_DisclosureOfLeasesExplanatory_637236863191368336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfLeasesExplanatory_637236863191368336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingencies" xlink:type="extended" xlink:title="12201 - Disclosure - 22. Other Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_637236863191378321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_637236863191378321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedParties" xlink:type="extended" xlink:title="12301 - Disclosure - 23. Related Parties" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_637236863191378321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_637236863191378321" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagement" xlink:type="extended" xlink:title="12401 - Disclosure - 24. Financial Risk Management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialRiskManagementAbstract" xlink:label="afmd_FinancialRiskManagementAbstract_636879908919306013" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialRiskManagementAbstract_636879908919306013" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_637236863191388285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure25SubsequentEvents" xlink:type="extended" xlink:title="12501 - Disclosure - 25. Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_637236863191388285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - 4. Significant accounting policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191388285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191388285" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191388285" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191388285" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_637236863191388285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember_637236863191388285" xlink:to="afmd_IFRS16Member_637236863191388285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191388285" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_637236863191398265" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_637236863191398265" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory_637236863191398265" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants_637236863191398265" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_637236863191398265" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory_637236863191398265" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory_637236863191398265" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory_637236863191398265" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory_637236863191398265" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637236863191398265" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_637236863191398265" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_637236863191408232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_637236863191408232" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_637236863191408232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_637236863191408232" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_637236863191408232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_637236863191408232" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TransitionPolicyPolicyTextBlock" xlink:label="afmd_TransitionPolicyPolicyTextBlock_637236863191408232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="afmd_TransitionPolicyPolicyTextBlock_637236863191408232" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_637236863191408232" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191388285" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_637236863191408232" order="15" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - 4. Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191418207" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191418207" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191418207" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191418207" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_637236863191418207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember_637236863191418207" xlink:to="afmd_IFRS16Member_637236863191418207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191418207" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock_637236863191418207" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_637236863191418207" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory" xlink:label="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" xlink:to="ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory_637236863191418207" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock" xlink:label="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" xlink:to="afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock_637236863191418207" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock" xlink:label="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock_637236863191418207" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191418207" xlink:to="afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock_637236863191418207" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReportingTables" xlink:type="extended" xlink:title="30503 - Disclosure - 5. Segment Reporting (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasExplanatory" xlink:label="ifrs-full_DisclosureOfGeographicalAreasExplanatory_637236863191428178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasExplanatory_637236863191428178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueTables" xlink:type="extended" xlink:title="30603 - Disclosure - 6. Revenue (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_637236863191428178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfContingentLiabilitiesExplanatory_637236863191428178" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637236863191428178" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_637236863191428178" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesTables" xlink:type="extended" xlink:title="30803 - Disclosure - 8. Research and Development Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentExpensesAbstract" xlink:label="afmd_ResearchAndDevelopmentExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:label="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_637236863191438154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ResearchAndDevelopmentExpensesAbstract" xlink:to="afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_637236863191438154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesTables" xlink:type="extended" xlink:title="30903 - Disclosure - 9. General and Administrative Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeExpensesAbstract" xlink:label="afmd_GeneralAndAdministrativeExpensesAbstract_636879908919326745" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock" xlink:label="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_637236863191438154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_GeneralAndAdministrativeExpensesAbstract_636879908919326745" xlink:to="afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock_637236863191438154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure10EmployeeBenefitsTables" xlink:type="extended" xlink:title="31003 - Disclosure - 10. Employee Benefits (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_EmployeeBenefitsAbstract" xlink:label="afmd_EmployeeBenefitsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfEmployeeBenefitTableTextBlock" xlink:label="afmd_SummaryOfEmployeeBenefitTableTextBlock_637236863191438154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="afmd_SummaryOfEmployeeBenefitTableTextBlock_637236863191438154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsTables" xlink:type="extended" xlink:title="31103 - Disclosure - 11. Finance Income and Finance Costs (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:label="afmd_FinanceIncomeAndFinanceCostsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock" xlink:label="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_637236863191448128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:to="afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock_637236863191448128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxesTables" xlink:type="extended" xlink:title="31203 - Disclosure - 12. Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfIncomeTaxReconciliationTableTextBlock" xlink:label="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock_637236863191448128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_SummaryOfIncomeTaxReconciliationTableTextBlock_637236863191448128" order="1" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsTables" xlink:type="extended" xlink:title="31703 - Disclosure - 17. Share Based Payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedPaymentsAbstract" xlink:label="afmd_ShareBasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_637236863191458108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_637236863191458108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsTables" xlink:type="extended" xlink:title="31903 - Disclosure - 19. Borrowings (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock" xlink:label="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock_637236863191458108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock_637236863191458108" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory" xlink:label="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_637236863191458108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory_637236863191458108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesTables" xlink:type="extended" xlink:title="32103 - Disclosure - 21. Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_637236863191468108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock" xlink:label="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock_637236863191468108" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock" xlink:label="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock_637236863191468108" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock" xlink:label="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock_637236863191468108" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesTables" xlink:type="extended" xlink:title="32303 - Disclosure - 23. Related Parties (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock" xlink:label="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock_637236863191468108" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock" xlink:label="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock_637236863191468108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock_637236863191468108" order="2" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagementTables" xlink:type="extended" xlink:title="32403 - Disclosure - 24. Financial Risk Management (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialRiskManagementAbstract" xlink:label="afmd_FinancialRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SummaryOfExchangeRatesTableTextBlock" xlink:label="afmd_SummaryOfExchangeRatesTableTextBlock_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialRiskManagementAbstract" xlink:to="afmd_SummaryOfExchangeRatesTableTextBlock_637236863191478051" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - 4. Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191478051" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191478051" xlink:to="ifrs-full_NewIFRSsAxis_637236863191478051" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsAxis_637236863191478051" xlink:to="ifrs-full_NewIFRSsMember_637236863191478051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifrs16Member" xlink:label="afmd_Ifrs16Member_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_Ifrs16Member_637236863191478051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember" xlink:label="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_637236863191478051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember_637236863191478051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember" xlink:label="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember_637236863191488023" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AnnualImprovementsToIfrsStandards20152017CycleMember" xlink:label="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AnnualImprovementsToIfrsStandards20152017CycleMember_637236863191488023" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember" xlink:label="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember_637236863191488023" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember" xlink:label="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember_637236863191488023" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToReferencesToConceptionalFrameworkMember" xlink:label="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToReferencesToConceptionalFrameworkMember_637236863191488023" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember" xlink:label="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember_637236863191488023" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember" xlink:label="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember_637236863191488023" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmendmentsToIfrs3BusinessCombinationMember" xlink:label="afmd_AmendmentsToIfrs3BusinessCombinationMember_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_637236863191478051" xlink:to="afmd_AmendmentsToIfrs3BusinessCombinationMember_637236863191488023" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191478051" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191488023" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TitleOfNewIFRS" xlink:label="ifrs-full_TitleOfNewIFRS_637236863191488023" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191488023" xlink:to="ifrs-full_TitleOfNewIFRS_637236863191488023" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially" xlink:label="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191488023" xlink:to="ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially_637236863191497996" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired" xlink:label="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191488023" xlink:to="ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired_637236863191497996" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40402 - Disclosure - 4. Significant Accounting Policies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SignificantAccountingPoliciesAbstract" xlink:label="afmd_SignificantAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables" xlink:label="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables_637236863191497996" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares" xlink:label="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares_637236863191497996" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637236863191497996" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637236863191497996" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637236863191497996" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted" xlink:label="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SignificantAccountingPoliciesAbstract" xlink:to="afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted_637236863191507972" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails" xlink:type="extended" xlink:title="40403 - Disclosure - 4. Significant Accounting Policies -Lease (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:label="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191507972" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191507972" xlink:to="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191507972" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis_637236863191507972" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_637236863191507972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRS16Member" xlink:label="afmd_IFRS16Member_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InitiallyAppliedIFRSsMember_637236863191507972" xlink:to="afmd_IFRS16Member_637236863191507972" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsTable_637236863191507972" xlink:to="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_RightofuseAssets_637236863191507972" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_LeaseLiabilities_637236863191507972" order="2" use="optional" priority="6" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeasesWeightedAverageDiscountRate" xlink:label="afmd_OperatingLeasesWeightedAverageDiscountRate_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="afmd_OperatingLeasesWeightedAverageDiscountRate_637236863191507972" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_DepreciationRightofuseAssets_637236863191507972" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_637236863191507972" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_637236863191507972" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumOperatingLeasePaymentsAs17" xlink:label="afmd_MinimumOperatingLeasePaymentsAs17_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="afmd_MinimumOperatingLeasePaymentsAs17_637236863191539976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLeaseCommittmentIas17" xlink:label="afmd_OperatingLeaseCommittmentIas17_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="afmd_OperatingLeaseCommittmentIas17_637236863191539976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed" xlink:label="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed_637236863191539976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments" xlink:label="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments_637236863191539976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate" xlink:label="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate_637236863191539976" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637236863191539976" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems_637236863191507972" xlink:to="ifrs-full_LeaseLiabilities_637236863191539976" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails" xlink:type="extended" xlink:title="40501 - Disclosure - 5. Segment Reporting - Geographic information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_637236863191547855" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable_637236863191547855" xlink:to="ifrs-full_GeographicalAreasAxis_637236863191547855" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_637236863191547855" xlink:to="ifrs-full_GeographicalAreasMember_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_DE" xlink:label="country_DE_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637236863191547855" xlink:to="country_DE_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637236863191547855" xlink:to="srt_EuropeMember_637236863191547855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="country_US_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637236863191547855" xlink:to="country_US_637236863191547855" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CZ" xlink:label="country_CZ_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_637236863191547855" xlink:to="country_CZ_637236863191547855" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable_637236863191547855" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_637236863191547855" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems_637236863191547855" xlink:to="ifrs-full_Revenue_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems_637236863191547855" xlink:to="ifrs-full_NoncurrentAssets_637236863191547855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails" xlink:type="extended" xlink:title="40502 - Disclosure - 5. Segment Reporting - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersTable" xlink:label="ifrs-full_DisclosureOfMajorCustomersTable_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfMajorCustomersTable_637236863191547855" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable_637236863191547855" xlink:to="ifrs-full_RangeAxis_637236863191547855" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637236863191547855" xlink:to="ifrs-full_RangesMember_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191547855" xlink:to="ifrs-full_BottomOfRangeMember_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable_637236863191547855" xlink:to="ifrs-full_MajorCustomersAxis_637236863191547855" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_637236863191547855" xlink:to="ifrs-full_MajorCustomersMember_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TopFourCustomersMember" xlink:label="afmd_TopFourCustomersMember_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637236863191547855" xlink:to="afmd_TopFourCustomersMember_637236863191547855" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechInc.Member" xlink:label="afmd_GenentechInc.Member_637236863191547855" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_637236863191547855" xlink:to="afmd_GenentechInc.Member_637236863191547855" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfMajorCustomersLineItems" xlink:label="ifrs-full_DisclosureOfMajorCustomersLineItems_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMajorCustomersTable_637236863191547855" xlink:to="ifrs-full_DisclosureOfMajorCustomersLineItems_637236863191557825" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfMajorCustomers" xlink:label="afmd_NumberOfMajorCustomers_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems_637236863191557825" xlink:to="afmd_NumberOfMajorCustomers_637236863191557825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMajorCustomersLineItems_637236863191557825" xlink:to="ifrs-full_PercentageOfEntitysRevenue_637236863191557825" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - 6. Revenue - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191557825" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191557825" xlink:to="ifrs-full_CounterpartiesAxis_637236863191557825" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_637236863191557825" xlink:to="ifrs-full_CounterpartiesMember_637236863191557825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AmphivenaMember" xlink:label="afmd_AmphivenaMember_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_637236863191557825" xlink:to="afmd_AmphivenaMember_637236863191557825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeukemiaAndLymphomaSocietyMember" xlink:label="afmd_LeukemiaAndLymphomaSocietyMember_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_637236863191557825" xlink:to="afmd_LeukemiaAndLymphomaSocietyMember_637236863191557825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AbCheckMember" xlink:label="afmd_AbCheckMember_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_637236863191557825" xlink:to="afmd_AbCheckMember_637236863191557825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GenentechIncMember" xlink:label="afmd_GenentechIncMember_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_637236863191557825" xlink:to="afmd_GenentechIncMember_637236863191557825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191557825" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServiceFeesToBeReceived" xlink:label="afmd_ServiceFeesToBeReceived_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="afmd_ServiceFeesToBeReceived_637236863191557825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="ifrs-full_RevenueFromRenderingOfServices_637236863191557825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones" xlink:label="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones_637236863191557825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationAgreementInitialUpfrontPayment" xlink:label="afmd_CollaborationAgreementInitialUpfrontPayment_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="afmd_CollaborationAgreementInitialUpfrontPayment_637236863191557825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_637236863191557825" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones" xlink:label="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_637236863191557825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones_637236863191557825" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations" xlink:label="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations_637236863191567798" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue" xlink:label="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191557825" xlink:to="ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue_637236863191567798" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueDetails" xlink:type="extended" xlink:title="40602 - Disclosure - 6. Revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ReceivablesFromContractsWithCustomers" xlink:label="ifrs-full_ReceivablesFromContractsWithCustomers_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_ReceivablesFromContractsWithCustomers_637236863191567798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_ContractLiabilities_637236863191567798" order="2" use="optional" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails" xlink:type="extended" xlink:title="40603 - Disclosure - 6. Revenue - Disaggregation of revenue (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191567798" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191567798" xlink:to="ifrs-full_ProductsAndServicesAxis_637236863191567798" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_637236863191567798" xlink:to="ifrs-full_ProductsAndServicesMember_637236863191567798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CollaborationServiceMember" xlink:label="afmd_CollaborationServiceMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637236863191567798" xlink:to="afmd_CollaborationServiceMember_637236863191567798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ServicesMember" xlink:label="afmd_ServicesMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_637236863191567798" xlink:to="afmd_ServicesMember_637236863191567798" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191567798" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_637236863191567798" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_637236863191567798" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863191567798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863191567798" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_637236863191567798" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_637236863191567798" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember_637236863191567798" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191567798" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_637236863191567798" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191567798" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_637236863191567798" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_637236863191577771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNetDetails" xlink:type="extended" xlink:title="40701 - Disclosure - 7. Other Income and Expenses - Net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherIncomeAndExpensesNetAbstract" xlink:label="afmd_OtherIncomeAndExpensesNetAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:label="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_OtherIncomeAndExpensesNetAbstract" xlink:to="ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_637236863191577771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_OtherIncomeAndExpensesNetAbstract" xlink:to="ifrs-full_RevenueFromGovernmentGrants_637236863191577771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - 8. Research and Development Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentExpensesAbstract" xlink:label="afmd_ResearchAndDevelopmentExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseTable" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ResearchAndDevelopmentExpensesAbstract" xlink:to="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_637236863191577771" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_637236863191577771" xlink:to="afmd_NatureOfExpensesAxis_637236863191577771" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesAxis_637236863191577771" xlink:to="afmd_NatureOfExpensesDomain_637236863191577771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThirdPartyServicesMember" xlink:label="afmd_ThirdPartyServicesMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="afmd_ThirdPartyServicesMember_637236863191577771" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PersonnelExpensesMember" xlink:label="afmd_PersonnelExpensesMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="afmd_PersonnelExpensesMember_637236863191577771" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndPatentExpensesMember" xlink:label="afmd_LegalConsultingAndPatentExpensesMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="afmd_LegalConsultingAndPatentExpensesMember_637236863191577771" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CostsOfMaterialsMember" xlink:label="afmd_CostsOfMaterialsMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="afmd_CostsOfMaterialsMember_637236863191577771" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:label="ifrs-full_AccumulatedDepreciationAndAmortisationMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="ifrs-full_AccumulatedDepreciationAndAmortisationMember_637236863191577771" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherExpensesMember" xlink:label="afmd_OtherExpensesMember_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191577771" xlink:to="afmd_OtherExpensesMember_637236863191577771" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems" xlink:label="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_637236863191577771" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseTable_637236863191577771" xlink:to="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_637236863191577771" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems_637236863191577771" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_637236863191587745" order="1" use="optional" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - 9. General and Administrative Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeExpensesAbstract" xlink:label="afmd_GeneralAndAdministrativeExpensesAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseTable" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_GeneralAndAdministrativeExpensesAbstract" xlink:to="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_637236863191587745" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_637236863191587745" xlink:to="afmd_NatureOfExpensesAxis_637236863191587745" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesAxis_637236863191587745" xlink:to="afmd_NatureOfExpensesDomain_637236863191587745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PersonnelExpensesMember" xlink:label="afmd_PersonnelExpensesMember_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191587745" xlink:to="afmd_PersonnelExpensesMember_637236863191587745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LegalConsultingAndAuditExpensesMember" xlink:label="afmd_LegalConsultingAndAuditExpensesMember_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191587745" xlink:to="afmd_LegalConsultingAndAuditExpensesMember_637236863191587745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherExpensesMember" xlink:label="afmd_OtherExpensesMember_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191587745" xlink:to="afmd_OtherExpensesMember_637236863191587745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems" xlink:label="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseTable_637236863191587745" xlink:to="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_637236863191587745" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems_637236863191587745" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_637236863191587745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - 10. Employee Benefits (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_EmployeeBenefitsAbstract" xlink:label="afmd_EmployeeBenefitsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WagesAndSalaries" xlink:label="ifrs-full_WagesAndSalaries_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="ifrs-full_WagesAndSalaries_637236863191587745" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SocialSecurityContributions" xlink:label="ifrs-full_SocialSecurityContributions_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="ifrs-full_SocialSecurityContributions_637236863191587745" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EmployeeBenefitsExpense" xlink:label="ifrs-full_EmployeeBenefitsExpense_637236863191587745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="ifrs-full_EmployeeBenefitsExpense_637236863191587745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure10EmployeeBenefitsNarrativeDetails" xlink:type="extended" xlink:title="41002 - Disclosure - 10. Employee Benefits - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_EmployeeBenefitsAbstract" xlink:label="afmd_EmployeeBenefitsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EmployerContributions" xlink:label="ifrs-full_EmployerContributions_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_EmployeeBenefitsAbstract" xlink:to="ifrs-full_EmployerContributions_637236863191597718" order="1" use="optional" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails" xlink:type="extended" xlink:title="41101 - Disclosure - 11. Finance Income and Finance Costs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:label="afmd_FinanceIncomeAndFinanceCostsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinanceIncomeAndFinanceCostsAbstract" xlink:to="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_637236863191597718" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseAxis" xlink:label="afmd_NatureOfIncomeExpenseAxis_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_637236863191597718" xlink:to="afmd_NatureOfIncomeExpenseAxis_637236863191597718" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfIncomeExpenseDomain" xlink:label="afmd_NatureOfIncomeExpenseDomain_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfIncomeExpenseAxis_637236863191597718" xlink:to="afmd_NatureOfIncomeExpenseDomain_637236863191597718" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestSVBLoanAgreementMember" xlink:label="afmd_InterestSVBLoanAgreementMember_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfIncomeExpenseDomain_637236863191597718" xlink:to="afmd_InterestSVBLoanAgreementMember_637236863191597718" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ForeignExchangeDifferencesMember" xlink:label="afmd_ForeignExchangeDifferencesMember_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfIncomeExpenseDomain_637236863191597718" xlink:to="afmd_ForeignExchangeDifferencesMember_637236863191597718" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_InterestCertificatesOfDepositMember" xlink:label="afmd_InterestCertificatesOfDepositMember_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfIncomeExpenseDomain_637236863191597718" xlink:to="afmd_InterestCertificatesOfDepositMember_637236863191597718" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OtherFinanceIncomeFinanceCostsMember" xlink:label="afmd_OtherFinanceIncomeFinanceCostsMember_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfIncomeExpenseDomain_637236863191597718" xlink:to="afmd_OtherFinanceIncomeFinanceCostsMember_637236863191597718" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems" xlink:label="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsTable_637236863191597718" xlink:to="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_637236863191597718" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems_637236863191597718" xlink:to="ifrs-full_FinanceIncomeCost_637236863191597718" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxesDetails" xlink:type="extended" xlink:title="41201 - Disclosure - 12. Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_637236863191597718" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:label="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_637236863191597718" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectDueToAdjustmentsOfDeferredAssets" xlink:label="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_TaxEffectDueToAdjustmentsOfDeferredAssets_637236863191597718" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfPermanentDifferences" xlink:label="afmd_TaxEffectOfPermanentDifferences_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_TaxEffectOfPermanentDifferences_637236863191597718" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfLocalTaxRates" xlink:label="afmd_TaxEffectOfLocalTaxRates_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_TaxEffectOfLocalTaxRates_637236863191597718" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet" xlink:label="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet_637236863191597718" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:label="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_637236863191597718" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_637236863191597718" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_637236863191607691" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="41202 - Disclosure - 12. Income Taxes - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxTable" xlink:label="afmd_DisclosureOfIncomeTaxTable_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="afmd_DisclosureOfIncomeTaxTable_637236863191607691" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxTable_637236863191607691" xlink:to="ifrs-full_CounterpartiesAxis_637236863191607691" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_637236863191607691" xlink:to="ifrs-full_CounterpartiesMember_637236863191607691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AbCheckMember" xlink:label="afmd_AbCheckMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_637236863191607691" xlink:to="afmd_AbCheckMember_637236863191607691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesAxis_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxTable_637236863191607691" xlink:to="ifrs-full_AssetsAndLiabilitiesAxis_637236863191607691" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AssetsAndLiabilitiesMember" xlink:label="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesAxis_637236863191607691" xlink:to="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TemporaryDifferenceBorrowingsMember" xlink:label="afmd_TemporaryDifferenceBorrowingsMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_TemporaryDifferenceBorrowingsMember_637236863191607691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember" xlink:label="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember_637236863191607691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LongTermFinancialAssetsMember" xlink:label="afmd_LongTermFinancialAssetsMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_LongTermFinancialAssetsMember_637236863191607691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ContractLiabilitiesMember" xlink:label="afmd_ContractLiabilitiesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_ContractLiabilitiesMember_637236863191607691" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherReceivablesMember" xlink:label="afmd_TradeAndOtherReceivablesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_TradeAndOtherReceivablesMember_637236863191607691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilitiesMember" xlink:label="ifrs-full_LeaseLiabilitiesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="ifrs-full_LeaseLiabilitiesMember_637236863191607691" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TradeAndOtherPayablesMember" xlink:label="afmd_TradeAndOtherPayablesMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="afmd_TradeAndOtherPayablesMember_637236863191607691" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAndLiabilitiesMember_637236863191607691" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_637236863191607691" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfIncomeTaxLineItems" xlink:label="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxTable_637236863191607691" xlink:to="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="ifrs-full_DeferredTaxLiabilities_637236863191617668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DeferredTaxAssets" xlink:label="ifrs-full_DeferredTaxAssets_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="ifrs-full_DeferredTaxAssets_637236863191617668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ApplicableTaxRate" xlink:label="ifrs-full_ApplicableTaxRate_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="ifrs-full_ApplicableTaxRate_637236863191617668" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes_637236863191617668" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumTaxLossDueToOwnershipChanges" xlink:label="afmd_MaximumTaxLossDueToOwnershipChanges_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="afmd_MaximumTaxLossDueToOwnershipChanges_637236863191617668" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OperatingLossCarryforwardsForTradeTaxPurposes" xlink:label="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfIncomeTaxLineItems_637236863191607691" xlink:to="afmd_OperatingLossCarryforwardsForTradeTaxPurposes_637236863191617668" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - 13. Long term financial assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsTable" xlink:label="ifrs-full_DisclosureOfFinancialAssetsTable_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialAssetsTable_637236863191617668" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable_637236863191617668" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637236863191617668" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637236863191617668" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637236863191617668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637236863191617668" xlink:to="ifrs-full_PreferenceSharesMember_637236863191617668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfFinancialAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialAssetsLineItems_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsTable_637236863191617668" xlink:to="ifrs-full_DisclosureOfFinancialAssetsLineItems_637236863191617668" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome" xlink:label="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_637236863191617668" xlink:to="ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome_637236863191617668" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_637236863191617668" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialAssetsLineItems_637236863191617668" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_637236863191617668" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure14FinancialAssetsDetails" xlink:type="extended" xlink:title="41401 - Disclosure - 14. Financial assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialAssetsAbstract" xlink:label="afmd_FinancialAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumMaturityPeriodOfCertificateOfDeposits" xlink:label="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialAssetsAbstract" xlink:to="afmd_MinimumMaturityPeriodOfCertificateOfDeposits_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails" xlink:type="extended" xlink:title="41501 - Disclosure - 15. Trade and Other Receivables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherReceivablesAbstract" xlink:label="ifrs-full_TradeAndOtherReceivablesAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableTable" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableTable_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherReceivablesAbstract" xlink:to="afmd_DisclosureOfTradeAndOtherReceivableTable_637236863191627639" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableTable_637236863191627639" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_637236863191627639" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis_637236863191627639" xlink:to="ifrs-full_LiabilitiesMember_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ValueAddedTaxReceivablesMember" xlink:label="afmd_ValueAddedTaxReceivablesMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember_637236863191627639" xlink:to="afmd_ValueAddedTaxReceivablesMember_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfTradeAndOtherReceivableLineItems" xlink:label="afmd_DisclosureOfTradeAndOtherReceivableLineItems_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableTable_637236863191627639" xlink:to="afmd_DisclosureOfTradeAndOtherReceivableLineItems_637236863191627639" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems_637236863191627639" xlink:to="ifrs-full_TradeReceivables_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfTradeAndOtherReceivableLineItems_637236863191627639" xlink:to="ifrs-full_OtherReceivables_637236863191627639" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure16EquityDetails" xlink:type="extended" xlink:title="41601 - Disclosure - 16. Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_637236863191627639" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191627639" xlink:to="ifrs-full_ComponentsOfEquityAxis_637236863191627639" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191627639" xlink:to="ifrs-full_EquityMember_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_637236863191627639" xlink:to="ifrs-full_IssuedCapitalMember_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalMember_637236863191627639" xlink:to="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_637236863191627639" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedInPublicOfferingMember" xlink:label="afmd_SharesIssuedInPublicOfferingMember_637236863191627639" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalMember_637236863191627639" xlink:to="afmd_SharesIssuedInPublicOfferingMember_637236863191627639" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191627639" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_637236863191637610" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_637236863191637610" xlink:to="ifrs-full_ClassesOfShareCapitalMember_637236863191637610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637236863191637610" xlink:to="ifrs-full_OrdinarySharesMember_637236863191637610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CumulativePreferenceSharesMember" xlink:label="afmd_CumulativePreferenceSharesMember_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_637236863191637610" xlink:to="afmd_CumulativePreferenceSharesMember_637236863191637610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_637236863191627639" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AuthorizedCapital" xlink:label="afmd_AuthorizedCapital_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="afmd_AuthorizedCapital_637236863191637610" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_IssuedCapital_637236863191637610" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_NumberOfSharesOutstanding_637236863191637610" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_ParValuePerShare_637236863191637610" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_NumberOfSharesIssued_637236863191637610" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesPrice" xlink:label="afmd_SharesPrice_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="afmd_SharesPrice_637236863191637610" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191637610" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_637236863191637610" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_637236863191637610" xlink:to="ifrs-full_NumberOfSharesAuthorised_637236863191637610" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - 17. Share Based Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedPaymentsAbstract" xlink:label="afmd_ShareBasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_WeightedAverageSharePrice2019_637236863191647583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceShareOptionsGranted2019" xlink:label="ifrs-full_ExercisePriceShareOptionsGranted2019_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_ExercisePriceShareOptionsGranted2019_637236863191647583" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_637236863191647583" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_637236863191647583" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpectedDividendShareOptionsGranted" xlink:label="ifrs-full_ExpectedDividendShareOptionsGranted_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_ExpectedDividendShareOptionsGranted_637236863191647583" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_637236863191647583" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails" xlink:type="extended" xlink:title="41702 - Disclosure - 17. Share Based Payments - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ShareBasedPaymentsAbstract" xlink:label="afmd_ShareBasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_ShareBasedPaymentsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637236863191647583" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_637236863191647583" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_Esop2014Member" xlink:label="afmd_Esop2014Member_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_637236863191647583" xlink:to="afmd_Esop2014Member_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesAxis" xlink:label="afmd_NatureOfExpensesAxis_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" xlink:to="afmd_NatureOfExpensesAxis_637236863191647583" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NatureOfExpensesDomain" xlink:label="afmd_NatureOfExpensesDomain_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesAxis_637236863191647583" xlink:to="afmd_NatureOfExpensesDomain_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ResearchAndDevelopmentMember" xlink:label="afmd_ResearchAndDevelopmentMember_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191647583" xlink:to="afmd_ResearchAndDevelopmentMember_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GeneralAndAdministrativeMember" xlink:label="afmd_GeneralAndAdministrativeMember_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_NatureOfExpensesDomain_637236863191647583" xlink:to="afmd_GeneralAndAdministrativeMember_637236863191647583" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingAxis" xlink:label="afmd_IfrsVestingAxis_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" xlink:to="afmd_IfrsVestingAxis_637236863191647583" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsVestingDomain" xlink:label="afmd_IfrsVestingDomain_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsVestingAxis_637236863191647583" xlink:to="afmd_IfrsVestingDomain_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIMember" xlink:label="afmd_TrancheIMember_637236863191647583" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsVestingDomain_637236863191647583" xlink:to="afmd_TrancheIMember_637236863191647583" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiMember" xlink:label="afmd_TrancheIiMember_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsVestingDomain_637236863191647583" xlink:to="afmd_TrancheIiMember_637236863191657557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_TrancheIiiMember" xlink:label="afmd_TrancheIiiMember_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_IfrsVestingDomain_637236863191647583" xlink:to="afmd_TrancheIiiMember_637236863191657557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" xlink:to="ifrs-full_RangeAxis_637236863191657557" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637236863191657557" xlink:to="ifrs-full_RangesMember_637236863191657557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191657557" xlink:to="ifrs-full_BottomOfRangeMember_637236863191657557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191657557" xlink:to="ifrs-full_TopOfRangeMember_637236863191657557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_637236863191647583" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod" xlink:label="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod_637236863191657557" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_637236863191657557" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_637236863191657557" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_637236863191657557" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement_637236863191657557" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_637236863191657557" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_637236863191657557" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_637236863191657557" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_637236863191657557" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedUnvestedShareOptionsForfeitureRate" xlink:label="afmd_ExpectedUnvestedShareOptionsForfeitureRate_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_ExpectedUnvestedShareOptionsForfeitureRate_637236863191667530" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:label="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_637236863191667530" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_637236863191667530" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfTranches" xlink:label="afmd_NumberOfTranches_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_NumberOfTranches_637236863191667530" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExercisePeriodOfShareOptions" xlink:label="afmd_ExercisePeriodOfShareOptions_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_ExercisePeriodOfShareOptions_637236863191667530" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay" xlink:label="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay_637236863191667530" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_WeightedAverageSharePrice2019_637236863191667530" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded" xlink:label="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded_637236863191667530" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:label="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_637236863191667530" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_637236863191667530" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637236863191667530" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637236863191667530" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement" xlink:label="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_637236863191677503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_637236863191657557" xlink:to="afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement_637236863191677503" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure18ProvisionsDetails" xlink:type="extended" xlink:title="41801 - Disclosure - 18. Provisions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProvisionsAbstract" xlink:label="ifrs-full_ProvisionsAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ProgramTerminationCost" xlink:label="afmd_ProgramTerminationCost_637236863191677503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="afmd_ProgramTerminationCost_637236863191677503" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PaymentOfTerminationOfProgram" xlink:label="afmd_PaymentOfTerminationOfProgram_637236863191677503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="afmd_PaymentOfTerminationOfProgram_637236863191677503" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_637236863191677503" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProvisionsAbstract" xlink:to="ifrs-full_CurrentProvisions_637236863191677503" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsDetails" xlink:type="extended" xlink:title="41901 - Disclosure - 19. Borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191687482" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191687482" xlink:to="ifrs-full_BorrowingsByNameAxis_637236863191687482" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_637236863191687482" xlink:to="ifrs-full_BorrowingsByNameMember_637236863191687482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThereofAssetsPledgedMember" xlink:label="afmd_ThereofAssetsPledgedMember_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_637236863191687482" xlink:to="afmd_ThereofAssetsPledgedMember_637236863191687482" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191687482" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_PropertyPlantAndEquipment_637236863191687482" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_Inventories_637236863191687482" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637236863191687482" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherAssets" xlink:label="ifrs-full_OtherAssets_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_OtherAssets_637236863191687482" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets_637236863191687482" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_FinancialAssets_637236863191687482" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_CashAndCashEquivalents_637236863191697456" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities" xlink:label="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191687482" xlink:to="ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities_637236863191697456" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails" xlink:type="extended" xlink:title="41902 - Disclosure - 19. Borrowings - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" xlink:to="ifrs-full_RangeAxis_637236863191697456" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637236863191697456" xlink:to="ifrs-full_RangesMember_637236863191697456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191697456" xlink:to="ifrs-full_BottomOfRangeMember_637236863191697456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637236863191697456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191697456" xlink:to="ifrs-full_TopOfRangeMember_637236863191697456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" xlink:to="ifrs-full_TypesOfInterestRatesAxis_637236863191707460" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis_637236863191707460" xlink:to="ifrs-full_InterestRateTypesMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEURIBORMember" xlink:label="afmd_OneMonthEURIBORMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember_637236863191707460" xlink:to="afmd_OneMonthEURIBORMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" xlink:to="ifrs-full_BorrowingsByNameAxis_637236863191707460" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameAxis_637236863191707460" xlink:to="ifrs-full_BorrowingsByNameMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SiliconValleyBankLoanMember" xlink:label="afmd_SiliconValleyBankLoanMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_637236863191707460" xlink:to="afmd_SiliconValleyBankLoanMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SiliconValleyBankLoanMember_637236863191707460" xlink:to="afmd_SeniorSecuredTermLoanFacilityMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheOneMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SeniorSecuredTermLoanFacilityMember_637236863191707460" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheOneMember_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember" xlink:label="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_SeniorSecuredTermLoanFacilityMember_637236863191707460" xlink:to="afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember_637236863191707460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LoanAgreementWithUniCreditLeasingCZMember" xlink:label="afmd_LoanAgreementWithUniCreditLeasingCZMember_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsByNameMember_637236863191707460" xlink:to="afmd_LoanAgreementWithUniCreditLeasingCZMember_637236863191707460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems" xlink:label="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable_637236863191697456" xlink:to="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity_637236863191707460" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentNumberOfTranches" xlink:label="afmd_DebtInstrumentNumberOfTranches_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_DebtInstrumentNumberOfTranches_637236863191707460" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_Borrowings_637236863191707460" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_UndrawnBorrowingFacilities" xlink:label="ifrs-full_UndrawnBorrowingFacilities_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_UndrawnBorrowingFacilities_637236863191707460" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_637236863191707460" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_637236863191707460" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFloorRate" xlink:label="afmd_DebtInstrumentFloorRate_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_DebtInstrumentFloorRate_637236863191717399" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentLegalAndArrangementFees" xlink:label="afmd_DebtInstrumentLegalAndArrangementFees_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_DebtInstrumentLegalAndArrangementFees_637236863191717399" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal" xlink:label="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal_637236863191717399" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637236863191717399" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_637236863191717399" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpirationPeriodOfWarrants" xlink:label="afmd_ExpirationPeriodOfWarrants_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_ExpirationPeriodOfWarrants_637236863191717399" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_637236863191717399" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity_637236863191717399" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity" xlink:label="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity_637236863191717399" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedVolatilityOfWarrants" xlink:label="afmd_ExpectedVolatilityOfWarrants_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_ExpectedVolatilityOfWarrants_637236863191717399" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ExpectedExercisePeriodOfWarrants" xlink:label="afmd_ExpectedExercisePeriodOfWarrants_637236863191717399" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_ExpectedExercisePeriodOfWarrants_637236863191717399" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized" xlink:label="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized_637236863191727371" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValue" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValue_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValue_637236863191727371" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfNoncurrentBorrowings" xlink:label="ifrs-full_RepaymentsOfNoncurrentBorrowings_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_RepaymentsOfNoncurrentBorrowings_637236863191727371" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount" xlink:label="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount_637236863191727371" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrentPortionOfLongtermBorrowings" xlink:label="ifrs-full_CurrentPortionOfLongtermBorrowings_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_CurrentPortionOfLongtermBorrowings_637236863191727371" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_637236863191727371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems_637236863191707460" xlink:to="ifrs-full_OtherCurrentPayables_637236863191727371" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails" xlink:type="extended" xlink:title="41903 - Disclosure - 19. Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract" xlink:label="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_637236863191737346" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_637236863191737346" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_637236863191737346" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities_637236863191737346" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingCostsCapitalised" xlink:label="ifrs-full_BorrowingCostsCapitalised_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_BorrowingCostsCapitalised_637236863191737346" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestPaidClassifiedAsFinancingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_InterestPaidClassifiedAsFinancingActivities_637236863191737346" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities_637236863191737346" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivities" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivities_6372368631917373461" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract_637236863191737346" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivities_6372368631917373461" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure20TradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="42001 - Disclosure - 20. Trade and Other Payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables_637236863191737346" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherPayables_637236863191737346" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherPayables" xlink:label="ifrs-full_OtherPayables_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TradeAndOtherPayablesAbstract" xlink:to="ifrs-full_OtherPayables_637236863191747315" order="2" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - 21. Leases - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeasesForLesseeTable" xlink:label="afmd_DisclosureOfLeasesForLesseeTable_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_DisclosureOfLeasesForLesseeTable_637236863191747315" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfLeasesForLesseeTable_637236863191747315" xlink:to="ifrs-full_RangeAxis_637236863191747315" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_637236863191747315" xlink:to="ifrs-full_RangesMember_637236863191747315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191747315" xlink:to="ifrs-full_BottomOfRangeMember_637236863191747315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_637236863191747315" xlink:to="ifrs-full_TopOfRangeMember_637236863191747315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DisclosureOfLeaseForLesseeLineItems" xlink:label="afmd_DisclosureOfLeaseForLesseeLineItems_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfLeasesForLesseeTable_637236863191747315" xlink:to="afmd_DisclosureOfLeaseForLesseeLineItems_637236863191747315" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_DisclosureOfLeaseForLesseeLineItems_637236863191747315" xlink:to="afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract_637236863191747315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails" xlink:type="extended" xlink:title="42102 - Disclosure - 21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191747315" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191747315" xlink:to="ifrs-full_ClassesOfAssetsAxis_637236863191747315" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_637236863191747315" xlink:to="ifrs-full_ClassesOfAssetsMember_637236863191747315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637236863191747315" xlink:to="ifrs-full_BuildingsMember_637236863191747315" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MotorVehiclesMember" xlink:label="ifrs-full_MotorVehiclesMember_637236863191747315" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_637236863191747315" xlink:to="ifrs-full_MotorVehiclesMember_637236863191747315" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191747315" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637236863191757291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" xlink:to="ifrs-full_RightofuseAssets_637236863191757291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DepreciationRightofuseAssets" xlink:label="ifrs-full_DepreciationRightofuseAssets_637236863191757291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" xlink:to="ifrs-full_DepreciationRightofuseAssets_637236863191757291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AdditionsToRightofuseAssets" xlink:label="ifrs-full_AdditionsToRightofuseAssets_637236863191797184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" xlink:to="ifrs-full_AdditionsToRightofuseAssets_637236863191797184" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_637236863191797184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191757291" xlink:to="ifrs-full_RightofuseAssets_637236863191797184" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails" xlink:type="extended" xlink:title="42103 - Disclosure - 21. Leases - Schedule of Cash Outflow Related to Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191807163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:label="ifrs-full_InterestExpenseOnLeaseLiabilities_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_InterestExpenseOnLeaseLiabilities_637236863191807163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_IfrsShortTermLeasePayments" xlink:label="afmd_IfrsShortTermLeasePayments_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_IfrsShortTermLeasePayments_637236863191807163" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashOutflowForLeases" xlink:label="ifrs-full_CashOutflowForLeases_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_CashOutflowForLeases_637236863191807163" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RentalExpense" xlink:label="ifrs-full_RentalExpense_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_RentalExpense_637236863191807163" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails" xlink:type="extended" xlink:title="42104 - Disclosure - 21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191807163" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191807163" xlink:to="ifrs-full_MaturityAxis_637236863191807163" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_637236863191807163" xlink:to="ifrs-full_AggregatedTimeBandsMember_637236863191807163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_637236863191807163" xlink:to="ifrs-full_NotLaterThanOneYearMember_637236863191807163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_637236863191807163" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_637236863191807163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:label="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_637236863191807163" xlink:to="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191807163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_GrossLeaseLiabilities" xlink:label="ifrs-full_GrossLeaseLiabilities_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191807163" xlink:to="ifrs-full_GrossLeaseLiabilities_637236863191807163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17" xlink:label="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_637236863191807163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_637236863191807163" xlink:to="afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17_637236863191807163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="42105 - Disclosure - 21. Leases - Movements of lease liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_LeaseLiabilities_637236863191817134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_637236863191817134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AdditionsOfNewLeaseContracts" xlink:label="afmd_AdditionsOfNewLeaseContracts_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="afmd_AdditionsOfNewLeaseContracts_637236863191817134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities_6372368631918171341" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_LeaseLiabilities_6372368631918171341" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42202 - Disclosure - 22. Other Commitments and Contingencies - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherFeeAndCommissionExpense" xlink:label="ifrs-full_OtherFeeAndCommissionExpense_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="ifrs-full_OtherFeeAndCommissionExpense_637236863191817134" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FuturePaymentLicenseFeeObligationDue" xlink:label="afmd_FuturePaymentLicenseFeeObligationDue_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfContingentLiabilitiesAbstract" xlink:to="afmd_FuturePaymentLicenseFeeObligationDue_637236863191817134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails" xlink:type="extended" xlink:title="42301 - Disclosure - 23. Related Parties - Compensation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_637236863191817134" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:label="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_637236863191817134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_637236863191817134" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:label="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_637236863191827105" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_KeyManagementPersonnelCompensation" xlink:label="ifrs-full_KeyManagementPersonnelCompensation_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_KeyManagementPersonnelCompensation_637236863191827105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails" xlink:type="extended" xlink:title="42302 - Disclosure - 23. Related Parties - Outstanding Balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191827105" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191827105" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191827105" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191827105" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_AdiHoessMember" xlink:label="afmd_AdiHoessMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_AdiHoessMember_637236863191827105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_WolfgangFischerMember" xlink:label="afmd_WolfgangFischerMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_WolfgangFischerMember_637236863191827105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MartinTrederMember" xlink:label="afmd_MartinTrederMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_MartinTrederMember_637236863191827105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_LeilaAllandMember" xlink:label="afmd_LeilaAllandMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_LeilaAllandMember_637236863191827105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_ThomasHechtMember" xlink:label="afmd_ThomasHechtMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_ThomasHechtMember_637236863191827105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MathieuSimonMember" xlink:label="afmd_MathieuSimonMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_MathieuSimonMember_637236863191827105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BemdtModigMember" xlink:label="afmd_BemdtModigMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_BemdtModigMember_637236863191827105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FerdinandVerdonckMember" xlink:label="afmd_FerdinandVerdonckMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_FerdinandVerdonckMember_637236863191827105" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_UlrichGrauMember" xlink:label="afmd_UlrichGrauMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_UlrichGrauMember_637236863191827105" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_BernhardEhmerMember" xlink:label="afmd_BernhardEhmerMember_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191827105" xlink:to="afmd_BernhardEhmerMember_637236863191827105" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191827105" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191827105" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors" xlink:label="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_637236863191827105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191827105" xlink:to="afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors_637236863191827105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails" xlink:type="extended" xlink:title="42303 - Disclosure - 23. Related Parties - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191837078" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191837078" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191837078" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_637236863191837078" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SupervisoryBoardDirectorsMember" xlink:label="afmd_SupervisoryBoardDirectorsMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_637236863191837078" xlink:to="afmd_SupervisoryBoardDirectorsMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_637236863191837078" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191837078" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights" xlink:label="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191837078" xlink:to="afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_KeyManagementPersonnelCompensationForServices" xlink:label="afmd_KeyManagementPersonnelCompensationForServices_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191837078" xlink:to="afmd_KeyManagementPersonnelCompensationForServices_637236863191837078" order="2" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_637236863191837078" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_637236863191837078" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails" xlink:type="extended" xlink:title="42401 - Disclosure - 24. Financial Risk Management - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialRiskManagementAbstract" xlink:label="afmd_FinancialRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" xlink:to="ifrs-full_TypesOfInterestRatesAxis_637236863191837078" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis_637236863191837078" xlink:to="ifrs-full_InterestRateTypesMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_FloatingInterestRateMember" xlink:label="ifrs-full_FloatingInterestRateMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember_637236863191837078" xlink:to="ifrs-full_FloatingInterestRateMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_OneMonthEuriborMember" xlink:label="afmd_OneMonthEuriborMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FloatingInterestRateMember_637236863191837078" xlink:to="afmd_OneMonthEuriborMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" xlink:to="ifrs-full_TypesOfRisksAxis_637236863191837078" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637236863191837078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_637236863191837078" xlink:to="ifrs-full_TypesOfRisksMember_637236863191837078" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CreditRiskMember" xlink:label="ifrs-full_CreditRiskMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191837078" xlink:to="ifrs-full_CreditRiskMember_637236863191847051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_InterestRateRiskMember" xlink:label="ifrs-full_InterestRateRiskMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191837078" xlink:to="ifrs-full_InterestRateRiskMember_637236863191847051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_OtherPriceRiskMember" xlink:label="ifrs-full_OtherPriceRiskMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191837078" xlink:to="ifrs-full_OtherPriceRiskMember_637236863191847051" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191837078" xlink:to="ifrs-full_CurrencyRiskMember_637236863191847051" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191837078" xlink:to="ifrs-full_LiquidityRiskMember_637236863191847051" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" xlink:to="ifrs-full_ComponentsOfEquityAxis_637236863191847051" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_637236863191847051" xlink:to="ifrs-full_EquityMember_637236863191847051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_637236863191847051" xlink:to="ifrs-full_IssuedCapitalMember_637236863191847051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedInPublicOfferingMember" xlink:label="afmd_SharesIssuedInPublicOfferingMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalMember_637236863191847051" xlink:to="afmd_SharesIssuedInPublicOfferingMember_637236863191847051" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesIssuedUnderAtMarketSalesAgreementMember" xlink:label="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_637236863191847051" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IssuedCapitalMember_637236863191847051" xlink:to="afmd_SharesIssuedUnderAtMarketSalesAgreementMember_637236863191847051" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191837078" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharesValue" xlink:label="afmd_SharesValue_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_SharesValue_637236863191857036" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_CashAndCashEquivalents_637236863191857036" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_637236863191857036" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_LongtermDeposits" xlink:label="ifrs-full_LongtermDeposits_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_LongtermDeposits_637236863191857036" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_MaximumExposureToCreditRisk" xlink:label="ifrs-full_MaximumExposureToCreditRisk_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_MaximumExposureToCreditRisk_637236863191857036" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_NotionalAmount_637236863191857036" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_Borrowings_637236863191857036" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_BorrowingsAdjustmentToInterestRateBasis" xlink:label="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_BorrowingsAdjustmentToInterestRateBasis_637236863191857036" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent" xlink:label="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent_637236863191857036" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_DebtInstrumentFloorRate" xlink:label="afmd_DebtInstrumentFloorRate_637236863191857036" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_DebtInstrumentFloorRate_637236863191857036" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_RevenueFromInterest" xlink:label="ifrs-full_RevenueFromInterest_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_RevenueFromInterest_637236863191866999" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_MaximumExposureToForeignCurrencyRisk" xlink:label="afmd_MaximumExposureToForeignCurrencyRisk_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_MaximumExposureToForeignCurrencyRisk_637236863191866999" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfDeviationBetweenCurrencyExchangeRate" xlink:label="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_PercentageOfDeviationBetweenCurrencyExchangeRate_637236863191866999" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_NetLossInCaseOfCurrencyExchangeDeviation" xlink:label="afmd_NetLossInCaseOfCurrencyExchangeDeviation_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_NetLossInCaseOfCurrencyExchangeDeviation_637236863191866999" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario" xlink:label="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario_637236863191866999" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_NumberOfSharesIssued_637236863191866999" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_SharePricePerShare" xlink:label="afmd_SharePricePerShare_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="afmd_SharePricePerShare_637236863191866999" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191866999" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191857036" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_637236863191866999" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails" xlink:type="extended" xlink:title="42402 - Disclosure - 24. Financial Risk Management - Exchange Rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_FinancialRiskManagementAbstract" xlink:label="afmd_FinancialRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="afmd_FinancialRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191877009" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191877009" xlink:to="ifrs-full_TypesOfRisksAxis_637236863191877009" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_637236863191877009" xlink:to="ifrs-full_TypesOfRisksMember_637236863191877009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_CZKMember" xlink:label="afmd_CZKMember_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191877009" xlink:to="afmd_CZKMember_637236863191877009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_USDMember" xlink:label="afmd_USDMember_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191877009" xlink:to="afmd_USDMember_637236863191877009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="afmd-20191231.xsd#afmd_GbpMember" xlink:label="afmd_GbpMember_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_637236863191877009" xlink:to="afmd_GbpMember_637236863191877009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191877009" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_637236863191877009" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191877009" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_AverageForeignExchangeRate" xlink:label="ifrs-full_AverageForeignExchangeRate_637236863191886948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191877009" xlink:to="ifrs-full_AverageForeignExchangeRate_637236863191886948" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.ifrs.org/taxonomy/2019-03-27/full_ifrs/full_ifrs-cor_2019-03-27.xsd#ifrs-full_ClosingForeignExchangeRate" xlink:label="ifrs-full_ClosingForeignExchangeRate_637236863191886948" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_637236863191877009" xlink:to="ifrs-full_ClosingForeignExchangeRate_637236863191886948" order="2" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626269328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Finance Income and Finance Costs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory', window );">Finance Income and Finance Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finance income and finance costs</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the items of finance income and costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest SVB Loan Agreement (see note 19)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (483)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (847)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (690)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Foreign exchange differences</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (175)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 651</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,378)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on certificates of deposit with maturities of more than three months</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 602</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 77</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other finance income/finance costs - net</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 71</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 251</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 60</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,983)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of finance income (cost). [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626269328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Other Income and Expenses - Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OtherIncomeAndExpensesNetAbstract', window );"><strong>Other Income And Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory', window );">Other Income and Expenses - Net</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other income and expenses&nbsp;- net</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other income and expenses, net mainly comprises foreign exchange gains of &#x20AC;251 (2018: &#x20AC;1,523, 2017: losses of &#x20AC;7). Income from government grants for research and development projects amounted to &#x20AC;19 in 2019, &#x20AC;10 in 2018 and &#x20AC;195 in 2017.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OtherIncomeAndExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OtherIncomeAndExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income or expense. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6650230544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfIncomeTaxReconciliationTableTextBlock', window );">Income Tax Reconciliation</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss before tax</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,361)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,243)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income tax benefit at tax rate of 29.825 %</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,652</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,809</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments of deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,822)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (5,318)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,036)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (29)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (462)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (93)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments for local tax rates</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (34)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Non deductible expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (43)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (53)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 57</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (82)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfIncomeTaxReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfIncomeTaxReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6732429584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant accounting policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue Recognition</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a &#x201C;best efforts&#x201D; basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provide the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Such agreements may comprise more than one research program, platform licenses or intellectual property </font><font style="display:inline;">licenses </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">originally generated by the Group. Usually each of those promises is considered to meet the </font><font style="display:inline;">definition</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> of a separate performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses, a residual approach is used. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight-line basis until the use of the license by the customer ends. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group&#x2019;s view, uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and Development</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group&#x2019;s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Employee benefits</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefits</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a)&nbsp;the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b)&nbsp;the obligation can be estimated reliably.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payment transactions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s share-based payment awards outstanding as of December&nbsp;31, 2018 and 2019, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(iii)<font style="display:inline;font-family:Arial,Helvetica,sans-serif;;font-size: 10pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Termination benefits</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Termination benefits are expensed when the Group can no longer withdraw the offer of those benefits. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants', window );">Government Grants</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group receives certain government grants that support its research effort in specific projects. </font><font style="display:inline;">These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group recognizes income from government grants under &#x2018;Other income&nbsp;- net&#x2019; in the consolidated statement of comprehensive loss.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Policy applicable from 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred. Subsequently, the right-of-use asset is&nbsp;&nbsp;depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Affimed&#x2019;s incremental borrowing rate. Generally, Affimed uses its incremental borrowing rate as the discount rate. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group determines the incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and the type of the asset leased.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is subsequently&nbsp;&nbsp;measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has elected not to recognize right-of-use assets and lease liabilities for some short-term leases (leases with less than 12 months of lease term) and right-of-use assets and liabilities for leases of low value assets. Lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Policy applicable before 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">For impact on transition please refer to &#x201C;New standards and interpretations applied for the first time&#x201D; below.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory', window );">Finance Income and Finance Costs</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income and finance costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance costs comprise primarily interest expense on borrowings.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial assets</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group&#x2019;s non-derivative financial assets include preferred shares in Amphivena, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three&nbsp;months.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cash and cash equivalents comprise cash balances and call deposits with original maturities of three&nbsp;months or less.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group holds </font><font style="display:inline;">preferred shares in Amphivena </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">designated at fair value through other comprehensive income (see note 13).</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial liabilities</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compound financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 19). The number of shares to be issued does not vary with changes in their fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Impairment</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group&#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed determines the counterparties&#x2019; lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2017, 2018 or 2019.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intangible assets and leasehold improvements and equipment</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the&nbsp;year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair Value Measurement</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Fair Value Measurement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All assets and liabilities for which fair value is recognized in the consolidated financial statements are </font><font style="display:inline;">classified </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 1&nbsp;&#x2013; Prices for identical assets or liabilities quoted in active markets (non-adjusted)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 2&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 3&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 19).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss Per Share</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group has granted warrants under certain loan agreements (see note 19) and options under share-based payment programs (see note 17) which potentially have a dilutive effect; no instruments actually had a dilutive effect.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Critical Judgments and Accounting Estimates</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Critical judgments and accounting estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In preparing these financial statements, the critical judgments made by management in applying the Group&#x2019;s accounting policies resulted in the following accounting estimates</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On April&nbsp;20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in note&nbsp;17. Incorporating the market condition in the fair value estimate requires the use of a simulation technique (Monte Carlo simulation), which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be &#x20AC;133.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">The Group&#x2019;s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Accrued expenses</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group holds preferred shares in Amphivena classified as equity instruments at fair value through other comprehensive income (level 2) and&nbsp;&nbsp;recognized as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2019 (see note 13). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (v)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Lease payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether Affimed is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognized. As at December 31, 2019, no renewal options were incorporated into the determining the lease term.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vi)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Provisions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In the second quarter of 2019, Affimed decided to terminate the Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager as a part of its strategic plans (see note 18).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New Standards and Interpretations Applied for the First Time</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">New standards and interpretations applied for the first time</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&nbsp;1, 2019, and have been applied in preparing these financial statements:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRS 16 Leases</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9: Prepayment Features with Negative Compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Annual Improvements to IFRS Standards 2015</font><font style="display:inline;font-family:MS Gothic;color:#000000;">&#x2011;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2017 Cycle</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRIC 23 Uncertainty over Income Tax Treatments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></hr></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &#xB4;Determining Whether an Arrangement contains a Lease&#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">New Standards and Interpretations Not Yet Adopted</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">New standards and interpretations not yet adopted</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2019, and have not been applied in preparing these consolidated financial statements.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to References to the Conceptional Framework</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 1 and IAS 8: Definition of Material</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 3 Business Combination</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1 Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member', window );">IFRS 16</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_TransitionPolicyPolicyTextBlock', window );">Transition</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Transition </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, Affimed elected to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not reassessed. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a lessee, Affimed previously classified leases as operating or finance leases based on its assessment of whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Affimed recognizes right-of-use assets and lease liabilities for most leases &#x2013; i.e. these leases are on-balance sheet.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">At transition, for leases classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Company&#x2019;s incremental borrowing rates for similar assets as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, the Company recognized additional right-of-use assets, including property, plant and equipment and additional lease liabilities. The impact on transition is summarized below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Right-of-use assets </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group discounted lease payments using a weighted average discount rate of 4.05% as of January 1, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In relation to those leases under IFRS 16, Affimed has recognized depreciation and interest costs, instead of operating lease expense. In 2019, the Group recognized depreciation expense for right-of-use assets of &#x20AC;385 and interest cost related to the lease liability of &#x20AC;24 instead of operating lease expense of &#x20AC;406.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The transition between operating lease commitments disclosed applying IAS 17 as of December 31, 2018 and the lease liabilities recognized in the statement of financial position at the date of initial application, January 1, 2019, is shown below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating lease commitment as of December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,154</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Recognition exemption for short-term leases</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (98)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments for incidental rental costs and other rental payments (Not part of the lease)</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (312)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Discounting using the incremental borrowing rate as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (27)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_TransitionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for Ifrs 16.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_TransitionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for finance income and costs. [Refer: Finance income (cost)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinanceIncomeAndCostsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for government grants, including the methods of presentation adopted in the financial statements. [Refer: Government [member]; Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2019-01-01<br> -Paragraph 39<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_39_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for the impairment of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6650230544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Research and Development Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research And Development Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Third-party services</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 27,338</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,127</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 12,299</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,154</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,639</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,983</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,672</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 890</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cost of Materials</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,547</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,140</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 994</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amortisation and depreciation</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 725</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 351</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 309</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,044</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,804</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,358</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 43,791</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 35,148</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,489</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739954128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Research and Development Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">&#8364; 43,791<span></span>
</td>
<td class="nump">&#8364; 35,148<span></span>
</td>
<td class="nump">&#8364; 21,489<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_ThirdPartyServicesMember', window );">Third-party services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">27,338<span></span>
</td>
<td class="nump">22,127<span></span>
</td>
<td class="nump">12,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember', window );">Personnel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">10,154<span></span>
</td>
<td class="nump">8,055<span></span>
</td>
<td class="nump">5,639<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndPatentExpensesMember', window );">Legal, consulting and patent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_CostsOfMaterialsMember', window );">Costs of materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortisation and depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems', window );"><strong>Disclosure of Research and Development Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses.</a></td>
<td class="nump">&#8364; 2,044<span></span>
</td>
<td class="nump">&#8364; 1,804<span></span>
</td>
<td class="nump">&#8364; 1,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfResearchAndDevelopmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_ThirdPartyServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_ThirdPartyServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndPatentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndPatentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_CostsOfMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_CostsOfMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6741815120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Revenue - Narrative (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones', window );">Contingent payment upon achievement of certain milestone under the collaboration agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue under contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14,795<span></span>
</td>
<td class="nump">&#8364; 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones', window );">Additional payments upon achievement of milestones | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations', window );">Remaining performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 59,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue', window );">Performance obligations description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The remaining performance obligations at December&#160;31, 2019 are approximately &#8364;59.3 million and are expected to be recognized as revenue to a large extent over the next two&#160;years.<span></span>
</td>
<td class="text">The remaining performance obligations at December&#160;31, 2019 are approximately &#8364;59.3 million and are expected to be recognized as revenue to a large extent over the next two&#160;years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=afmd_AmphivenaMember', window );">Amphivena</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ServiceFeesToBeReceived', window );">Service fees to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=afmd_LeukemiaAndLymphomaSocietyMember', window );">Leukemia &amp; Lymphoma Society</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=afmd_AbCheckMember', window );">AbCheck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">&#8364; 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=afmd_GenentechIncMember', window );">Genentech Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="nump">21,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_CollaborationAgreementInitialUpfrontPayment', window );">Collaboration agreement initial upfront payment received</a></td>
<td class="nump">$ 96.0<span></span>
</td>
<td class="nump">&#8364; 83,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue under contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 59,300<span></span>
</td>
<td class="nump">&#8364; 61,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent payment upon achievement of certain milestone under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_CollaborationAgreementContingentPaymentUponAchievementOfCertainMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_CollaborationAgreementInitialUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of initial upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_CollaborationAgreementInitialUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ServiceFeesToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service fees to be received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ServiceFeesToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The threshold amount that may be eligible to receive including payments upon achievement of specified development, regulatory and commercial milestones, and royalties on sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ThresholdAmountEligibleToReceiveOvertimeUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of when the entity expects to recognise the transaction price allocated to the remaining performance obligations as revenue. [Refer: Revenue from contracts with customers; Transaction price allocated to remaining performance obligations]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 120<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_120_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfWhenEntityExpectsToRecogniseTransactionPriceAllocatedToRemainingPerformanceObligationsAsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the rendering of services. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 116<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the transaction price allocated to the performance obligations that are unsatisfied (or partially unsatisfied) as of the end of the reporting period. The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties (for example, some sales taxes). [Refer: Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 120<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_120_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransactionPriceAllocatedToRemainingPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=afmd_AmphivenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=afmd_AmphivenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=afmd_LeukemiaAndLymphomaSocietyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=afmd_LeukemiaAndLymphomaSocietyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=afmd_AbCheckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=afmd_AbCheckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=afmd_GenentechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=afmd_GenentechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738848176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Finance Income and Finance Costs (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems', window );"><strong>Disclosure of Finance Income and Finance Costs Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="nump">&#8364; 15<span></span>
</td>
<td class="nump">&#8364; 60<span></span>
</td>
<td class="num">&#8364; (2,983)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfIncomeExpenseAxis=afmd_InterestSVBLoanAgreementMember', window );">Interest SVB Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems', window );"><strong>Disclosure of Finance Income and Finance Costs Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="num">(483)<span></span>
</td>
<td class="num">(847)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfIncomeExpenseAxis=afmd_ForeignExchangeDifferencesMember', window );">Foreign exchange differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems', window );"><strong>Disclosure of Finance Income and Finance Costs Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="num">(175)<span></span>
</td>
<td class="nump">651<span></span>
</td>
<td class="num">(2,378)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfIncomeExpenseAxis=afmd_InterestCertificatesOfDepositMember', window );">Interest on certificates of deposit with maturities of more than three months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems', window );"><strong>Disclosure of Finance Income and Finance Costs Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfIncomeExpenseAxis=afmd_OtherFinanceIncomeFinanceCostsMember', window );">Other finance income/finance costs - net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems', window );"><strong>Disclosure of Finance Income and Finance Costs Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="nump">&#8364; 71<span></span>
</td>
<td class="nump">&#8364; 251<span></span>
</td>
<td class="nump">&#8364; 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfFinanceIncomeAndFinanceCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfIncomeExpenseAxis=afmd_InterestSVBLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfIncomeExpenseAxis=afmd_InterestSVBLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfIncomeExpenseAxis=afmd_ForeignExchangeDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfIncomeExpenseAxis=afmd_ForeignExchangeDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfIncomeExpenseAxis=afmd_InterestCertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfIncomeExpenseAxis=afmd_InterestCertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfIncomeExpenseAxis=afmd_OtherFinanceIncomeFinanceCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfIncomeExpenseAxis=afmd_OtherFinanceIncomeFinanceCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6742495264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of period</a></td>
<td class="nump">&#8364; 717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge for the year</a></td>
<td class="num">(384)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of period</a></td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of period</a></td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge for the year</a></td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of period</a></td>
<td class="nump">816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember', window );">Car</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at beginning of period</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation charge for the year</a></td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions to right-of-use assets</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Balance at end of period</a></td>
<td class="nump">&#8364; 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_BuildingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfAssetsAxis=ifrs-full_MotorVehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615102816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>22. Other Commitments and Contingencies - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract', window );"><strong>Other Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherFeeAndCommissionExpense', window );">License fees</a></td>
<td class="nump">&#8364; 92<span></span>
</td>
<td class="nump">&#8364; 124<span></span>
</td>
<td class="nump">&#8364; 174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FuturePaymentLicenseFeeObligationDue', window );">Future payment obligations under non-cancellable fees</a></td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FuturePaymentLicenseFeeObligationDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future payment obligations under non-cancellable license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FuturePaymentLicenseFeeObligationDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFeeAndCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fee and commission expense that the entity does not separately disclose in the same statement or note. [Refer: Fee and commission expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFeeAndCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6740271376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Segment Reporting - Narrative (Details) - customer<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=afmd_TopFourCustomersMember', window );">Top Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NumberOfMajorCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Top Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | Genentech Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfMajorCustomersLineItems', window );"><strong>Disclosure of major customers [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Percentage of entity's revenue</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMajorCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMajorCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=afmd_TopFourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=afmd_TopFourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=afmd_GenentechInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=afmd_GenentechInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735390560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>19. Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock', window );">Fair Value of Assets Pledged</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.80%;">
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof&nbsp;assets</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,291</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,503</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,414</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 296</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 247</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 260</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 235</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Trade and other receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,482</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 864</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,429</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,007</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 387</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 95,234</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 93,606</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 94,829</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 92,933</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 108,205</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 105,122</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 112,293</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 109,323</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory', window );">Schedule of movements of liabilities reconcile to cash flows arising from financing activities</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,169</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Proceeds from borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 562</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (3,277)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,715)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Capitalized borrowing costs</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 489</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 847</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest paid</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (164)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (326)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 325</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 531</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,383</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfFairValueOfAssetsPledgedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739834512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_Ifrs16Member', window );">IFRS 16 Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">IFRS 16 Leases<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember', window );">Amendments to IFRS 9: Prepayment Features with Negative Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IFRS 9: Prepayment Features with Negative Compensation<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember', window );">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AnnualImprovementsToIfrsStandards20152017CycleMember', window );">Annual Improvements to IFRS Standards 2015&#8209;2017 Cycle</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Annual Improvements to IFRS Standards 2015&#8209;2017 Cycle<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember', window );">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember', window );">IFRIC 23 Uncertainty Over Income Tax Treatments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">IFRIC 23 Uncertainty over Income Tax Treatments<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially', window );">Effective date</a></td>
<td class="text">Jan.  01,  2019<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToReferencesToConceptionalFrameworkMember', window );">Amendments To References To The Conceptional Framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to References to the Conceptional Framework<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Effective date for new standards and interpretations not yet adopted</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember', window );">Amendments to IAS 1 and IAS 8: Definition of Material</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IAS 1 and IAS 8: Definition of Material<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Effective date for new standards and interpretations not yet adopted</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember', window );">Amendments To IFRS 9, IAS 39 And IFRS 7: Interest Rate Benchmark Reform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Effective date for new standards and interpretations not yet adopted</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs3BusinessCombinationMember', window );">Amendments to IFRS 3 Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TitleOfNewIFRS', window );">Standard/amendment</a></td>
<td class="text">Amendments to IFRS 3 Business Combination<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired', window );">Effective date for new standards and interpretations not yet adopted</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Standard/interpretation&#160;&#160;&#160;&#160;Effective Date 1IFRS 16 LeasesJanuary 1, 2019Amendments to IFRS 9: Prepayment Features with Negative CompensationJanuary 1, 2019Amendments to IAS 28: Long-term Interests in Associates and Joint VenturesJanuary 1, 2019Annual Improvements to IFRS Standards 20152017 CycleJanuary 1, 2019Amendments to IAS 19: Plan Amendment, Curtailment or SettlementJanuary 1, 2019IFRIC 23 Uncertainty over Income Tax TreatmentsJanuary 1, 20191 Shall apply for periods beginning on or after the date shown in the effective date column.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date on which the entity plans to apply a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateAsAtWhichEntityPlansToApplyNewIFRSInitially</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The date by which the entity is required to apply a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DateByWhichApplicationOfNewIFRSIsRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TitleOfNewIFRS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The title of a new IFRS that has been issued but is not yet effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TitleOfNewIFRS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_Ifrs16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_Ifrs16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9PrepaymentFeaturesWithNegativeCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas28LongTermInterestsInAssociatesAndJointVenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AnnualImprovementsToIfrsStandards20152017CycleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AnnualImprovementsToIfrsStandards20152017CycleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas19PlanAmendmentCurtailmentOrSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_Ifric23UncertaintyOverIncomeTaxTreatmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToReferencesToConceptionalFrameworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToReferencesToConceptionalFrameworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIas1AndIas8DefinitionOfMaterialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs9Ias39AndIfrs7InterestRateBenchmarkReformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs3BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=afmd_AmendmentsToIfrs3BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6742429984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. Share Based Payments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>USD ($) </div>
<div>Y </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>EUR (&#8364;) </div>
<div>Y </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EquityInstruments </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>EquityInstruments </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EquityInstruments </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>EquityInstruments </div>
<div>Y </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of options issued | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay', window );">Trading days</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price at grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded', window );">Grant date fair value</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">&#8364; 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | Y</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,035,000<span></span>
</td>
<td class="nump">&#8364; 1,943,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement', window );">Number of options issued | shares</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsVestingAxis=afmd_TrancheIMember', window );">Tranche I</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price at grant date</a></td>
<td class="nump">$ 6.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsVestingAxis=afmd_TrancheIiMember', window );">Tranche II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price at grant date</a></td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsVestingAxis=afmd_TrancheIiiMember', window );">Tranche III</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price at grant date</a></td>
<td class="nump">$ 10.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_ResearchAndDevelopmentMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,000<span></span>
</td>
<td class="nump">522,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_GeneralAndAdministrativeMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based expense | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,183,000<span></span>
</td>
<td class="nump">&#8364; 1,421,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=afmd_Esop2014Member', window );">ESOP 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Awards granted | EquityInstruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,332,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Awards cancelled or forfeited | EquityInstruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">357,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Awards outstanding | EquityInstruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,307,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,948,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement', window );">Awards exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Average exercise price of awards exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Awards vested | EquityInstruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,773,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,814,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExpectedUnvestedShareOptionsForfeitureRate', window );">Annual forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExercisePeriodOfShareOptions', window );">Exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=afmd_Esop2014Member', window );">ESOP 2014 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=afmd_Esop2014Member', window );">ESOP 2014 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ExercisePeriodOfShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period over which shares can be exercised from grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ExercisePeriodOfShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ExpectedUnvestedShareOptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of share options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ExpectedUnvestedShareOptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (i.e other than share options) exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NumberOfOtherEquityInstrumentsExercisedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options issued in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NumberOfShareOptionsIssuedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of tranches under share based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fair value of shares at grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_WeightedAverageFairValueAtMeasurementDateShareBasedPaymentAwardAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The preceding consecutive trading period should be considered for weighted average share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_WeightedAverageSharePricePeriodConsideredPrecedingConsecutiveTradingDay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsVestingAxis=afmd_TrancheIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsVestingAxis=afmd_TrancheIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsVestingAxis=afmd_TrancheIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsVestingAxis=afmd_TrancheIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsVestingAxis=afmd_TrancheIiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsVestingAxis=afmd_TrancheIiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_GeneralAndAdministrativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_GeneralAndAdministrativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=afmd_Esop2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=afmd_Esop2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626060992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. Financial assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MinimumMaturityPeriodOfCertificateOfDeposits', window );">Minimum Maturity period of certificate of deposits</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_MinimumMaturityPeriodOfCertificateOfDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum maturity period of certificate of deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_MinimumMaturityPeriodOfCertificateOfDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>36
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_PNPBX8N[7_V/@LV+7PZU]T7U!+ P04    " !1B)Q0F5R<(Q &  "<)P
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MO>N^^>H'5G5#8\G&[G;S%U!+ P04    " !1B)Q0$=!Y+6T#  !:#@  &
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M7C^Z,'*\%N/U%)\_QEN2Q4UB)\EYDH!V) VN,8DT<M%&SFV0+K8WB7GH C$
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M0]/T<6A3?1C:/,9R?[^HXJ$?3]UPWMXVL&X7?7.9-^>R^P[AYE]02P,$%
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MV[)LM$G)OIDNW>ED<[K)]+9I+P-S71T_(1UOFG+??QYS3]_H%O\#4$L#!!0
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M?;#%D-!8?_S@SGH>L]FP.,0?Q)9O7/X#4$L#!!0    ( %&(G%"Q<9P/M@$
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M,%1?2B1;)4[)?_3TL,U/-RVFD9^^LYAN"V2; ED4R-X)9!]ZW,)\=,E6AZK
MMG&<'*G,H.,HK[++Q-XG\5+^P:=Q_\9M*[0C%^/Q:N,%-,9X0"N[&YRA#E_8
M$DAH?-A^PKV=YFP*O.GG)\26=US^!5!+ P04    " !1B)Q0P;0;KK@!  #3
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6QM4^V.FS 0?!7+#W!.
M()>D$2!=KJI:J96BJ]K^=F !Z_Q!;1.N;]^UX2AWY0_V+C.SL_8Z&XQ]=BV
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M<&G2$R#E$E6MU$JG5&U_^V !*_Z@MCG2M^_:$$I2\@=[EYG967N=C\8^N0[
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M?F_F.9L#IX?TA,CRCJO?4$L#!!0    ( %&(G%#F3'8\M0$  -,#   9
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M&X6+"WB=_GT!$\=J_ +,<,[,F6$H)FU>;0_@T)L4RI:X=VXX$F+K'B2S-WH
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M\U<;+Z#5VH&WLKOS,]3[%[8$ EH7M@]^;]*<I<#I87Y"9'G'U2]02P,$%
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M/,O9-0K-F-.$X2O,;D$P5%]*\*T2)_X??7^[S=]O6MPG_OXOBV\8.&P*')+
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M6?9(_6O] Q\&X1>FJJ;5P5D:^^;]RRRE-&!KB1[L_:GM[)T"#J5QVXW=JV$
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M(]^K5_]-755LY44E=HZ=CO/RU]M=<J.3.HLM)9&OU3%*R^.MNC.9U6$X@.H
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M/<S4N.LO=?U$\M9>6*/AUKS\!U!+ P04    " !1B)Q0FGDK:_("  #("P
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M<#F,Q+AJ;AS-A+-2WZ:<]DJW_ ]02P,$%     @ 48B<4)AZA03, 0  700
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M<S9[+'&><C8X?/RZ'=:7R-]&ZO1+732';=ZIXQ&J>LG#^X<47;30A"E&3+#
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MPZ0D1Z&&H1RSKB=V$T&;OM\[PT]'^@]02P,$%     @ 48B<4//K?@(O @
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M.RCH0>INHOK<5@]V(%G=5$9>6Y[-_P%02P,$%     @ 48B<4&KA+>BW @
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M]L+AHMB8VMXE_?O:AB4LL?J"[</,G!FPG4Z,OXH.0#IOE PB<SLIQR-"HNJ
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M:*2>/J@YGX_AO)!L7&X8M%YS^3]02P,$%     @ 48B<4./ 7A2Y 0  TP,
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MJ7$[](/#1(K&]+K1V'"O_@%02P,$%     @ 48B<4!(KR&0^ @  B <  !D
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M]5BXP\%-%.^&<X^,A^_F-U!+ P04    " !1B)Q0UL^46ZX$   '&   &0
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M    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;'U4VVZ<,!3\%>0/B+DMV:X
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MV4Y* U8OOK.WN;=O?1DPZ(SKWMN^FF[\-#!RF!\S7OXH]5]02P,$%     @
M48B<4+/B U#> 0  ^P0  !D   !X;"]W;W)K<VAE971S+W-H965T-S(N>&UL
MC53;;IPP$/T5Y ^(N4-7@)1-5;52*ZU2M7WVPG!1;$QMLZ1_7]L02A,_Y 5[
MQF?.G!D\+A8NGF0/H+QG1D=9HEZIZ82QK'M@1-[Q"49]TG+!B-*FZ+"<!)#&
M!C&*0]]/,2/#B*K"^BZB*OBLZ##"17AR9HR(/V>@?"E1@%X<CT/7*^/ 53&1
M#KZ#^C%=A+;PSM(,#$8Y\-$3T);H/CB=<X.W@)\#+/*P]TPE5\Z?C/&E*9%O
M! &%6AD&HI<;/ "EADC+^+UQHCVE"3SN7]@_V=IU+5<BX8'37T.C^A+ER&N@
M)3-5CWSY#%L]"?*VXK_"#:B&&R4Z1\VIM%^OGJ7B;&/14AAY7M=AM.NRGL3Q
M%N8."+> < \(4EO+FL@J_T@4J0K!%T^LO9^(^<7!*=2]J8W3ML*>:?%2>V]5
MDN8%OAFB#7->,>$!$^P(K-GW%*$KQ3E\$QXE[OC(*3&R\?%_$C^X"6(G06P)
MHB-!YKL)$B=!\E9!%KQJD@L3NI.DSB2I@R!R$V1.@NS]9>9.@OP=9;HP\:LD
M^'#Y&(C.CIWT:CZ/=N0/WGVR[T-[>?_!UV?A&Q'=,$KORI4> 7M16\X5:"G^
MG6YYKU^BW:#0*K/-]%ZL\[@:BD_;4X/W]Z[Z"U!+ P04    " !1B)Q0Y;Z[
MMX8"  !)"0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6R55EV/FS 0
M_"N(]SNP^8X(4G)5U4JM=+KJVF>'. $=8&H[X?KO:QM"N;!(]"789G9FU^S$
M3CO&WT1!J;3>ZZH16[N0LMTXCL@+6A/QR%K:J#<GQFLBU92?'=%R2HXFJ*X<
M[+JA4Y.RL;/4K#WS+&47694-?>:6N-0UX7_VM&+=UD;V;>&E/!=2+SA9VI(S
M_4'E:_O,U<P968YE31M1LL;B]+2U=VBS1XD.,(B?)>W$9&SI4@Z,O>G)U^/6
M=G5&M**YU!1$/:[TB5:59E)Y_!Y([5%3!T['-_;/IGA5S($(^L2J7^51%EL[
MMJTC/9%+)5]8]X4.!06V-53_C5YII> Z$Z61LTJ87RN_",GJ@46E4I/W_EDV
MYMD-_+<P.  / 7@,P'TMO9#)_!.1)$LYZRS>;WY+]#=&&ZSV)M>+9BO,.Y6\
M4*O7+(B"U+EJH@&S[S%X@D$CPE'LHP2&)/9X%NZ%(4S@@3EZAL";$& W@0E\
MD, W!/ZTR""Y*[+'A ;3&$R$(E@D $6"N4@4WHGTF& B\N#%/JP2@BHAH!+=
MJ80S%3_!L$@$BD1SD="_$XEF(C%>J"0&16*@DA@F2$""9'U;(!=N?G=%8PR@
M::5A$BSH+)@,K>B- ?2Q.:(%IR'0:CN$5[3' %K5'PAV)/)6=,@ ^M B:,'X
M"#8N IP;+7UCV)8H^(\V@3V' -/-VV3N.KRTJ;#K$&"[>9?,??> O 4=V'@(
M<MZL2>*9CKN@ KL3)6M:))G]Z]Y_&F=RDM64G\T9+JR<71IS@9BLCO>$'38G
MX3]X?\GX3OBY;(1U8%*=I^;4.S$FJ<K$?525%NI>,TXJ>I)Z&*DQ[P_W?B)9
M.UQ<G/'VE/T%4$L#!!0    ( %*(G% Q[[]<-0(  (T&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#<T+GAM;'U5;6^;,!#^*X@?4/,.C0A2DZC:I$V*.FW[
M[)!+0+4QM9W0_?O9AE "5KZ ?3PO=P<^\H[Q=U$!2.>3DD:LW4K*=H60*"N@
M6#RQ%AKUY,0XQ5)M^1F)E@,^&A(E*/"\!%%<-VZ1F]B>%SF[2%(WL.>.N%"*
M^;\-$-:M7=^]!=[J<R5U !5YB\_P"^3O=L_5#HTJQYI"(VK6.!Q.:_?%7^TR
MC3> /S5T8K)V="4'QM[UYOMQ[7HZ(2!02JV U>T*6R!$"ZDT/@9-=[34Q.GZ
MIOYJ:E>U'+" +2-_ZZ.LUF[F.D<XX0N1;ZS[!D,]L>L,Q?^ *Q %UYDHCY(1
M8:Y.>1&2T4%%I4+Q9W^O&W/O!OT;S4X(!D(P$OSD(2$<".$7(7I(B 9"-".@
MOA33FQV6N,@YZQS>O]T6ZX_(7T6J^Z4.FF:;9ZH]0D6O19QY.;IJH0&SZ3'!
M!../"*341XO 9K$)%O0POG?86B#)/61G@:3V+$)KH:'AAQ-^X#W;!2*K0&0$
MHFD7_%F2FQZ3&$QC,)$WKW6)F?5[]PAQEVAL331>)!I.6M4GVF/BB440V3T2
MJT>R\(@S?^:1+#R2Q.Z16CU2BT<P\TB7#7^.[2:9U22SF(2S-Y8M3.)DELAN
MB8G28)8(FAQ*"OQL!IYP2G9II/ZT)]%QIKX$^E#/XALU:_O1^"73#^J?F)_K
M1C@')M7(, ?[Q)@$E:+WI%Y%I?X-XX; 2>IEJM:\GY#]1K)V&/YH_ ,5_P%0
M2P,$%     @ 4HB<4(A\5X88 @  M 8  !D   !X;"]W;W)K<VAE971S+W-H
M965T-S4N>&ULC57ICILP$'X5Q .LL3D3 5*3JFJE5HJVZO:WDTP"6H.I[83M
MV]<V!+%9I^(/OKYC9O"1]UR\R@I >6\-:V7A5TIU:X3DH8*&RB?>0:M73EPT
M5.FA."/9":!'2VH8(D&0H(;6K5_F=FXGRIQ?%*M;V E/7IJ&BK\;8+PO?.S?
M)I[K<Z7,!"KSCI[A)ZA?W4[H$9I4CG4#K:QYZPDX%?XGO-YB8@@6\5)#+V=]
MSZ2RY_S5#+X="S\P$0&#@S(25#=7V )C1DG'\6<4]2=/0YSW;^I?;/(ZF3V5
ML.7L=WU45>%GOG>$$[TP]<S[KS F%/O>F/UWN +3<!.)]CAP)NW7.URDXLVH
MHD-IZ-O0UJUM^U'_1G,3R$@@$P%'_R6$(R&\(Z A,IOJ9ZIHF0O>>V+X6QTU
MFP*O0UW,@YFTM;-K.ENI9Z]EG$4YNAJA$;,9,&2&">/WD*T#DDP0I".8PB#.
M,(CEAS,^"59N@= I$%J!Z%T>=T%N!DQB,:W%9.2!2>0TB1PFR5TEH@\FF. '
MM8B=+K'#)74+)$Z!9'DQ4Z= NJ"8 R:>Y1G'H=LD<YID"XJ9?3!)TMAMLG*:
MK!PFF5L !^X#$BRO)GYPQO"">HZ@^<8AZ8-]@]V'"),%)1U!<Y\XPG<^:'9]
MF/O\!Q7GNI7>GBM]$]G[XL2Y BT8/.G?4^DG9!HP."G3375?#/?H,%"\&]\(
M-#U4Y3]02P,$%     @ 4HB<4#@!_F0H @  *P8  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL?57;CILP$/T5Q'O7W$DB@K0DJEJIE:*MVCX[9!+0
M&DQM)VS_OKZP+ $W+[$]G,O,@"=93]DKKP"$\]:0EF_=2HAN@Q O*V@P?Z(=
MM/+)F;(&"WED%\0[!OBD20U!@><EJ,%UZ^:9CAU8GM&K('4+!^;P:]-@]K<
M0ONMZ[OO@9?Z4@D50'G6X0O\ /&S.S!Y0J/*J6Z@Y35M'0;GK?OL;_:IPFO
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M]_"><\4T7_Q!6WO46Z1^4+&],J<+?2ZZ?4(W4+QU>Z"HWXBM_P%02P,$%
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M=QS#AV[@3SK;WUYR?6C[Q[A[KL=KMO&EK2[F"C&XW6.N_@=02P,$%     @
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MEEWKT$VT:/NV*!IZL^5?4$L#!!0    ( %*(G% NE#C8_H4  "_^ 0 4
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MA"A6T4M\&>0)<0W+7$"9VB,)PY+@5]0;*U*H29,!?0KO71BCW6*B+-YG\56
MC-N+W\H9$H.T9X6E$HZ\;!R+K/FY2 S0GBBM<+BW1%A\)0)V@/1\D'S]R-E*
M7%_+T>HUR&_/L$^5G JQJZ9>LW/<16;<_A#[":]3@TQGHTPF\@=_+HLO63 \
M#7"'R7GA "EQ S>CX(L'-'WP&S_AOU RC'F %F44KE2R /$$P% !*0Q7U.R'
MJ99PEQRU>%CRP'@Z-B6E*I_*YH'(PM@<Y+&^E[+&VI(R\QNR7E@5-U2>_AD9
M>/[<L4)"\?97R+$/NB/.X L^ZGB]&""=,VM)O.K9MXS2#[:/G +#'T(/4K>Q
M!E9_H#L&@8%NTT;\_^Y^L)QT9/(8V!VHJ00?P RJ,/GG+W S6^O-FPZKQ_BH
M*^]M+\F-@?P0]@XN(1*'<'V^H^'EO#N1H@"?PA# 6E49Y)J@TM^>COPHJ^%J
M)F"L#)U]\F<G8DCQ(D&/3#GP2'%5B7-)W0&5E2P!!^EWF(TI,IJKH9R^SS3C
M-\AF\K@K;-/$T!EG_$@9*JBM< W(%XHL>6>EE,_19I-)]!@Z_G^CJY*2'EKZ
MUI7+:B=B0+)'>\0%,?.#6ZB9KN,*YU+'B'H"UT!P=;L_&!*:(VCFZTJI\ L5
M5C@]Y/PD2., *Q+>=":G<_NL#R5(XS*GF;BM%Q?/:[#PZL>B<*287)27R8>'
M^G"\HJJ.HO7 F1\#*Q,7Z\Q&=D&@@[(AIS;[)DJFH>!F1ZJ7IM[Q74*WYV:0
M7)L<UU!IU6/+=_@5[_-@I86*6#A%"N2D7P?%7&[KZ@0D#%K]17YIKMH#*9/J
M,]P6]^KRI6 +2W:C%&(E=XY*,"Z.9T$#B$3"E*.\<6YOMRA5G'5+656]N.69
MF/$]OT'O$[--=%H]#N#HZ.Q@.Z_"7.@P-MJZTDW'*YP^;0NO)4?.9<)IRC1-
M%'/+,E;2?%$[TG='DKM^:9M7HH^90)5F<\M#T?LR*[&;<:]UO\A\MJD\] QS
M:6&'2&#^9L;6CN:):$F2BA8.R:_K RIR->\$^;O0$,,D!9KA(.W:=YDNC8%6
M@)]L<#E8Z(>V>!"V4&5[D)H28DRW<41P:E3HO]SFZT]7']8/-<CSJ^^!!=84
M[D0=2':;_\/["?G&N?U'AS:G%SKW85GM3VBQ'/(=O@3<J?Q4A&^QWNC$OP]%
M9L);)5V?U-C,\5NZG6"HPL%LI1Z-L_E9W97$G@S4+[PFH(GSJV#Q?+JZ W7:
M!X/1=(_&A97>%<S/#TH(I%9+I,-6P=$UVW,('W?)0Q$T"'DBOS4!2T%:"<\!
MTP70A6GRVD23A,L)M_,C[3A3H9?^EO\YE5<$/9P&2%64!C ;I*3-(?_"L\7(
MNX\ Z' @!^_"L5$<1)Q0+Y0DW$O =#3&*#^B+K5BW!O=7:-H>68^2+[#"U31
M>NGF&3ZCY-LX6^\^?IC5(TR<A<^10N-$'L?E\*8Y>RL0O;!R&2/4BQUCU?P#
M= R1VE_N;D^'QBFSY';^[!0$*X-5@6Z;<OQ)5#DHJDQN3_H11]3Y&/-92AU0
MQR,J.M;,&CA70URB?6+>?Z;+9X<OLTPCRF.^%_O?X^12N@5DZ$L%,GL!W,'+
M*')?,#():U.1ZXA#JZG%*&OJ"@41:J[(USJ(0IS#[&OVD0),Z3]T<$+9=PG=
MFZB_,FMATMZ5R)>:/:T[OU3^E+$0CH4FC3G!4)!%5JF7[2'V99MYM>FW9*7K
ML? %UU8/*1MOVHLVX/:N[LAIZ$O2<?>)9]+HUI 3ICTKS09OIT'8A S=YOZ<
MH7:*Q2 A%(@FH1R'1\X_6--Z:"ZC](]Y=<(30<W E0&8F8M[/8 M86TPJFYU
M:4+\9[)K@(X]:R5VW3$8;;HZ!ZUJ@-20N=1.CN:JQY:>UV-3WV8\'YN6A-8+
M/^ ,]!VA#APY),3 0P\=$\\D"%<]NN]R>#+B1!B&]BX6E7]=R]THLD.@$80^
M7!#@#[5)36U-2PU-D^K$ZT-^07X=[S/LGPK?3+1&R4>Q.:U9QRUWH(0?Z&.<
MX4,:-Q6",$"4V5H5%Z!7&7G:]!P+WY#XK'J)@/VBK-0'2DQTF,[13+F/:$!H
M*+!]GL:Z\=L?*"BX?DSE<>Y!_EI]R#B<D,MC(/8=3%2^*6'N/JKKTD>< F_C
MKRZIC 8">U\EHL\Z.?D\CK[WU S3%?%@UAT6*H]G1KI]E*1I5@O-9D@@%Z/N
M]0DU*XJ$;HT'7/-7*/V>ZH24)G*#=T+,^6[+Z> JUX+3=(K?X]Z=,Y,J_;[I
MI9W N6G))THI],?=D:;(5TZ3Q#TU;Z) 3FZAN]A5%!$C>OKQ0[1O]G&JN$-\
M2@P"$"W:7VE>HJ.ZY?=8R(^FCL@$Y_F*N"PH2N_/&U:>@('2)]>^SETWN&E4
MAFB*#IC2#JCC0&=><61BKS$5HTGH:?/DU(;8T,?3H]&ES[Z--RD:P1=CHGE?
M;'D/Y$$GI3IXF^1IQ/@+[$XE+<6[%>BI)KV0?W*1+@<'\TC9]AR6:TUZ/QQ]
M4H;&$>HO<DC\^"!]%]%.VY'?%#I VS,E&2,8T^N-!#H]S B(#HU A&"D$[P/
MQ"43G,>1Z9X79Y*8*I9GS(V.PG(#2M0E083JNM12<%[4GA="&0Y("9(@^$/Q
MA9-QN-BJ$N <$!]'=79)_J7ZGWRMNTLHQ(Q-^'28(NN3>T5)C1_P^HEC)U;G
M<W^\!<L!]^TVKSZA'H!JH[A$[4M1Z@>%HL$V.)RH!/-I'N:FQRJ*RX7CDH62
M KCRAJ$>G^BL T39RLEU9Q8S,<7JT4=R24#>DRU)G\5X>YP<C6>-\1)3/F2?
M\>P=V8^B*KHODO^#PZ=2,40>4<0 1'>[E#3'^=@=3K7J_!L^KGI0XT<0$ZC^
M7D 3LG,05D\EC2/[HT#@D3F$4 5*+Z02S3"5! AUAD@)KT]N/#Z@FX59%09S
MW/=%*SJ_3,Y,+7]AIJU: [&%;A7KKZ?ZJ'&!5 !O@;0^%4=4]-'1L2ENCV&J
M.[Q*R$R21(N* %@R&*YUWZ!23]CS<B_Q$:73H,0.E&<Q"W$J>*G9*]N128]X
MFR)U^-+7Y ]TLZ)Q'UM1W1"1T+F_ SUCG1\.99>:,4CZ06K<561GMBT@0R7<
M\82SIV[/FE@L9C(;K0]WN3E/LO AC$"K-^SK:A""HDMQ:/=>/2,+.^X?^:&+
M" <T*))$R!#'F%A%[ $:M#32D6]RYK+;#]K H284,H'(:1S% ^**L<B)\97*
M)NG<JG%:T@YL[RY^**D%39!M&$=TT"!XP%R(3<9@#@3>09K<'HQ7]7,BY#(6
MYG47IQB*"C/@16$C*!N3=@T:(]88DW(F)89'+7A6Q#0*O*AF&:''FCBF6F\>
M7B;R["&)HX?;D.+JLN42YH%9J92)N,C;9U1QZ):%"C%<!'\;Q.)PF^]R?9RJ
M GL ES5O0OU'B4^6$49.,/EC5V[S@SU55\(@.\5K$<GG/_O4ESH*O=H3$+NX
M_^C9^X5>9V^4M8?HV!;K!"%,-O&8F+*4K._=.#3T6VRWSCTK-;O76W3-4[,<
M)&^="X14BS-8N.=^ZUB("!**"*L3QR5]P^1*]KD ?]\4VS#OES&6NN!AJ*0;
M35&\GSP(!E_8L7('AU:A9P>[/P"M2! 33%$,UR#_0&8!K 1X(]B?:[J+Y*;6
MC+%!^H?Z"V8I918X@%SGFN/0")6LC_5!E 7,3G-?ERBWGQJFK1]]]CZ%L3*1
MPB8W)L=X++W0E>,$:X#W#X_B( =;&4L?746X2WACDZ7P!F7D&6&'T$%J8M3E
MNBWO"HI"=1V0KU2AD#$;^UOR!3>4DZ*3QQ2;HS%UW& X/#.$SDL8E 7X0+(@
M>-)Z;;B3DUB<[]]M'2>!Q.GC+[=UC7R28D;Y+1E<H=/P'%$?U&]@@FEA%*JW
M\H>=*#71/Z'+4\1P'0M;]D!2QB9-Q)1+A?/0!]$SUS$J$CGKUI)X1W>+CH2<
M"I131QSG[NBP$EKLH!U,T215+).P(Z(94Q7W@IS/Z =UZ-O9J-MHK:B9(OSR
MHXTXT'_WYQ&D[]QGO9DBJ^7@%:\7]7#"_R"Z XU5?'8F_]!3'XJ/<@UD\Y@Y
M B*# $QV9)=KNER.[6+2C%/758G/Q&GKJ=&?+.5)D3)!QLWAM#^N'_W9^HD<
MBOIPGU<N ^::L@5[*)"\.AIV]*YKWJ+GN"<XH'4G_B4Q:K9P,&1$2X4GJ#I8
M]FK/J)%@5&X%"E,")0(WUH='F%R!6YWO""<I9,+O?,I"_'#92*(H!:TZP4+2
M'VKS&MD&FEO:A-\7D)AP5Q L4+)%:L90$N6^A9SOW6M/8.TFU_R\,QZ-Y-M8
MA&OT%;*<E.I"FAUFHLH!F^U %1B7Y3CKP>IPZ_*P/NW0$;2F/_#]EX#AX4!Y
M#W(D**!\GP=DT'BJ@_2Z9_>M2\:<[.VC8L9(V9!)PPL_B/7@"#[+L7/W1?E9
M8F2MOVL5/Z82LV;;^I#1SLAWZ:+5#@L<CT524BJ,+2"Q5%=M5P!WP"BXH%MA
M-QV3;1V+DW8VB9FXJ-_ ;@F!\L9W]0C^PYC):HA3K%WL67AFX%K^Q+\\Y[Y+
M6;[3OHZ%8MR56OE/EY,Q%,Q0KC#1I11Q\4JGM2SX/3)/F)J>H_?FP]_4EU];
MT:8B Q[@R#UOCL[?HI]EJAG#6"SKP;RGT:G [!8O @HCK$65'W(%+0O31GQD
MSP5L>#]UBF'^A)('S0(6^LH<0G1=PA=A4Q')$DN*G+72!.9*=&T8]:W?O6[%
MAD-[.!T0Y*BQZ!(TE,.UQKUE=[(\.DCC);#9$*8M=DX^5DU[)ENV@$B$<6P+
MA<8I#YWZ!\6=['M,K3S%/+U%&N![O[O5: NO'/DNJ2'PK)1.&LB"2C;BE@NP
M ^2I>#>"N*RC-L?9HQB5^MJIBKUKSWPZN(BUS&N\9"+F7V1TGY/\)&F+:1-S
MFF I/8<38EA@BQX^+HWZ44XI?0KH8%TP1);6'M9W=S HYKQN6I_J2'X]542&
M^(C&U_'?V;IHA*=A_3VQUL[]RWK85U\Z>WC*C4-']*B$JM^X(LA'53]/F/;W
M*RKCG1MI94*/-: >5,TQZ)V[SZ(+5\&GJE5"O[A<9EV&@F\-$H-4_;W!K4,-
M\@P/X47?!8F;[1RG9T+J^N3:GJ2NNQJU2XH1^R\^E"#U#^N'Q_@B@.G=8 P<
M*#W.\71\P.KS\A[[;XA!^H^8%(T7R;_\\V@Y^39Y1R./'.K*>U^]CE84HU_)
MWM6'8.M,', & 9KT IVMFB=R&7YI[+YD#@C/&R@#/:J9M^"?7/]O6#?EX#B$
M@0.IB&V\ 7Q?!N0UA6N8_.>O(41*>/XZ/G9HPBA@X8*<CV-U1ZJ>"G#UN>NE
M>EL3 02!^!=%:Q UTBP_!#JS!<CYK9;F^L<;GW/;#;V$UC\K_P5C-F\1%)%U
M<+O3[8G(7\2]_(" RR)W[AW\#?FD951;J1*[@LF)?M'AZ+_$_7%\8"L79]=)
M;-X-WJ2C"7T?W>%)V.3-_Z=UO%.!>+Y=2VW8[2,G<:L'CL/WMNY'U_I%V\'E
M:*W<%\]I"]>&_PKB5KDO&G ! TXYZ(LY!/Y_)C+) .?WNHHF'!*%>7EQ*9=U
M7Z-$8I\ZZ1TY[,?V9-PYWS*6A@EL:HD=>W^BQ\$"P,@=LM"_G#;WWD8V6IBZ
M=SCD8L%NNX#B.N4.MZHA9&L))["W6*I>&^NWI?3;3X6?3^9GP%-KFM-N;]U(
M"N-9:,:( ZCI@+]2E?L@S1K::GQFA4AFTRP<=F!Z[8 T3EL!]6'UQV5%>G@7
M+&!\'2S!%#G8U02Z"KM60=NH.2>C*1NL5M6N3PP3T#JC#O/27(Z Z\?O?*:T
M*(YK4\J$Z&9:4,?;C$K,6P7.E=L2<#%_[)EXU5L$1MDZ<%'-J3. #&^)"[0]
M@0&)6V^3\U5KZ=R7%U*5UKIQ3-91^5!0KN%AD>,>"O]5/!-'C;^F/.;9)5M!
MX175?/UG5VI%H=R_2W7/CP[C>LA^3I]M*Q0XG@ZSX7 821&TE\SF7462) L6
M2EF4R $V#%=KL/8T.RV=$&Z]OD$MW NQ^AC(@) 3<M'8/%4:[%[BQ2)YF9 ,
M5+U(7I&VN1.?<@A(*81X@\GH#;"/6[[D(@NYDH7;C>B=DYFX&A3'$SR%N=Q5
M)W/HPC0^Z'W2.@U%XDHOL']\D=[DAVUMGKAT"\5$;,J%$.>G124@6CJ 67[P
M!J6/L?@@?I!@X5"WNI4Z*08,"9X]&H(Z/)I,Q"U^%G31^X"U'85D&Q@TE8HQ
M-1P"7A_ W1^%K_,=H\VE\]+5X"'YS-W[NF8/B2_*-0A 3R/*864:4VH7IMD9
MC+80CI !YYJ6QXN)5<ZK%X$N K *H^0M:#0J>-C4G(R>6?.'V3K&.!V\8EE)
M!KO693._X^QU'(T7R>!FK[<6.3K UZM"+,AS@(@M<)DK1I=QM62*"FF":%JR
M_ZA@17>%YMBWT":" @)_"*A0&ZRAOLT.#2LWN0CSY&L!?*S'QN%9M++HVD&5
MKX/SZ=FEH,CP:^9^%GNH'<*W:<MQ.QE/!+WYS];Z\8J4<WA%@!X6/T7"E0V-
MVT:"8[E%5\_665BRK()"+\59^<+QS #)1::A)]1&GR&VY"!E>G:#[$Q-11/$
M/!8$J+H")]Z>#L)"0&A+)4K' 9$T?0*MR9<KM>)VLE#>>9?IJN:,J7_H)3\/
M7M@!48>>[%-C\,<8%XQ299Q<5#U=\_"N*;?;&S^&*K@HIS$MBEB9B!%<!9XJ
MWW[)'[E30\DY-R#@+NC!?'L9+"IG7P#NM^2A@MJ <!1<KO?6IN.)MTF&W;B(
MO4+]L[-3B8P-MUP61=Q:W1^^8/Y<]7)4V>=>\HB0_O7VW+D/11WD33!D)L$]
M2+C'\LF@# [-Z!+O#*]E?0+Z>]1L)7])G2\WPHC 4-A%^?FR)X7>>#N>D:7;
M!=.0_DWXX1?B2;J,JWB)'Z+K_:JK3RR8X[9+H L\<;<VUQK!!66,,2HYBUYK
M44A6T2RMAZ^1UGT!=L4J2C@VZAS;,G@P[FLDF8UKT(4WE 2#?BS&CX?JLU\@
MY]A2)!CU?,P9MJ!O\/N'8G_TW:;@T.',PV*>H'I)XV$X4>>&\1E2Y&MS]3F^
M4$G+:56'=/X%#I?D%.XO)$BB:4"@-A5?,!2_%P42=ZR[T,MTN^NNZ')6+:E/
MSF"GNIPFFK9J[<:AC:FI$GX,+W:[.*NOHLH3*5%A%X40IE&T:DYB*)TEH^G+
M1\/WG9?35$9=? :.[)O4)P*1UB >U";]ZPEX*=ND_&&?4.BJ$E2F\*F^IUSG
MD>LOHE8C$=R;[T<CK *\>35:?7/S:G+%^';DCRI=3M-':IN7%M5]?E]P19^#
M1"+;U+7%8U76W)?EY2#Y6PJCI.N$<_P _6Q<>D X*.P^I_%PU7[K&P>;NLM%
MV15A0(GW*P#O\E796H[FCII;#<68^N7S/&8O$NVM]4TXP>2UF]LK/+I10O[3
MT3R5&OIH'LEUL!6<FOLB?7]P/9W?%#EC:I&H^$&3 F^,Y^2I0:\_I./EB_2=
M8\M:*<9R0K,.>/__2(K(G^!E_&I[:-[MMS972R?N^XW!HS,*;0U7WU)"6'KS
MN-X6SYCH"%</Y)>ZGS),T@$^LF6F<P"6B=XF"L?&X\$TWMZDXTGZL]$K28N2
MQ*"/^2_I1VU(V5[="*%]MENI!J+,I!ZR\HF>I"PT#]2U4E(T'0U(+ZCM:5<-
M.OFX4H=W2^Y A2!1#21UJ#V>I !F9Z*4>_>P@3S43-$[E_UA_>P=V332WPI4
M[(H+8TB 1;LRH#X7E/>[):N,T^(IN/ Y#*'YS >%2]#]X\1 !R"U" -G2(RY
M]&2B<&@Y .51\Q!DS(R439].IH$!W1(BGX5H)%MEU99[B#^0(7PI3N VK",H
MH6?#UN8.:QYQX[BXDT9B#<EP,XS=@ P),W:?U:$2'[QA_8>-BLJP6\U+Q3@A
MHP.Z@\S409DYA /R $HD4FOBG<5FT.9Q8%$WR0#$\RU4$S"^>2HAR$3YXGI=
M?*1YNGS:M5]0Z$+7(,[!;(<1EOZ:Z]90(0P;1:+" GHLB@;6%B0JL4G8N-(9
MK"/2!+2.V,4@^=E0EI72SO^7'[UU"5I"L9=\+#$ ,07U@$FE3H=E.#FY>(I_
M(@1,W&N*+3V7PV]?&>WBSWZ\:S.>#(2G1^*%7QRD/^MP2+]^VA70CJ0[-\9&
M]?.WLVO<Y((T$B3+N+D$5UHS@+7YK4$;4O+'G_I&Z2*4_!C\R^?BT2''.%S\
M.@"C1B0$2BT1VP;3I+A=8N2B+DW;H3L!]',^N &W$&//ZX]!C;A*-KN+"B"
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M!"@NP2I'I13,=_*_7DRR\0*3Z(&;C?B?B]',_S<S5_D\L$A2IAA&VN'*<G7
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M07SIIQTB6.W@WY"L?I\"/O9N_L\U!^NI?9P@M'^T?;-(G?A48(FKRW/;*RH
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MX&09IZ'#7[X-.>QDX?-_^IHA.=V)N^*T299_:,W$Y/OZ0NZ8YZ.*%O+\Z53
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M0[$5'YXP,;V8G%^_25^^?/G?*>1_?>73(+6=FB#[OZ]K#_R$7_R^KC>NJ>A
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M\KEX=-@]KCU"'6"2(Q8%)<N(V8398MS-+O)^VX;+=X+(Z-Q[OT%K^@$8UW_
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M,9OBYHZFPV0%%^R:<$X:;R=:JRY9P"68S$;)9 @,FKBA^Q1LV72*6SK$_YW
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M;.6P(/!W5L( 3@5'%6% [@(68M&'>,$$1N?>0!AO*_0%F*0<L!B=LK\+W&"
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M9EM$ $O["XY(QNS9S"O_&YC^!E!+ P04    " !2B)Q00-/>R$D&  #N-0
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MA_\E^>/]_G4^F_^@?_D$4$L! A0#%     @ 48B<4!\CSP/     $P(   L
M             ( !     %]R96QS+RYR96QS4$L! A0#%     @ 48B<4"?H
MAPZ"    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    " !1B)Q01//B+.X    K @  $0              @ &9 0
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !1B)Q0F5R<(Q &  "<)P
M$P              @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( %&(G%#B_;_WJ@(  .D*   8              "  ?<(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !1B)Q0$=!Y+6T#  !:#@
M&               @ '7"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ 48B<4!?.W 0F!   +10  !@              ( !>@\  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %&(G%#KXRG1H04
M "@>   8              "  =83  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " !1B)Q0+,+K="8$  "O$P  &               @ &M
M&0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 48B<4(!>
MVLBT 0  TP,  !@              ( !"1X  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( %&(G%"SF_WIMP$  -,#   8
M  "  ?,?  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !1
MB)Q0[#EQ(;<!  #3 P  &               @ '@(0  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ 48B<4!'ZBO&U 0  TP,  !@
M         ( !S2,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( %&(G% DTFXQMP$  -,#   9              "  ;@E  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 48B<4#N:_EBW 0  T@,
M !D              ( !IB<  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " !1B)Q0L7&<#[8!  #3 P  &0              @ &4*0
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %&(G%#!M!NN
MN $  -,#   9              "  8$K  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ 48B<4!Z%6;&W 0  TP,  !D
M ( !<"T  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !1
MB)Q0?NMUR[4!  #3 P  &0              @ %>+P  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( %&(G%"D,HK+N $  -,#   9
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M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 48B<4%/
M5^RW 0  TP,  !D              ( !_S@  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    " !1B)Q0^/_EM[4!  #1 P  &0
M    @ 'M.@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M %&(G%#C5S0XMP$  -,#   9              "  =D\  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ 48B<4-QMY->V 0  TP,  !D
M             ( !QSX  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " !1B)Q0?)@0&[8!  #1 P  &0              @ &T0   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %&(G%!TDUW=N $
M -,#   9              "  :%"  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ 48B<4".BU/&W 0  TP,  !D              ( !
MD$0  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !1B)Q0
M3G&TS;4!  #3 P  &0              @ %^1@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( %&(G%!T+'5NM0$  -,#   9
M      "  6I(  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ 48B<4'\V*$NV 0  TP,  !D              ( !5DH  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !1B)Q0E'9M?+8!  #3 P
M&0              @ %#3   >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( %&(G%");KKIDP(  /L)   9              "  3!.  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 48B<4 1:$@7_
M 0  [04  !D              ( !^E   'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " !1B)Q0J'.LZ[@!  #3 P  &0
M@ $P4P  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %&(
MG%"N]@X>Q@$  #@$   9              "  1]5  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ 48B<4-CA/Z^Z 0  TP,  !D
M         ( !'%<  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    " !1B)Q05=[:][D!  #3 P  &0              @ $-60  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %&(G%"@A6+6N $  -,#
M   9              "  ?U:  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ 48B<4!QC4WBZ 0  TP,  !D              ( ![%P
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !1B)Q02'#-
MR[D!  #3 P  &0              @ '=7@  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( %&(G%"=1+!<N $  -,#   9
M  "  <U@  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M48B<4&<O&SC" 0  -P0  !D              ( !O&(  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " !1B)Q0X:;$KMT!   "!0  &0
M            @ &U9   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( %&(G%#5N%B2QP$  #@$   9              "  <EF  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 48B<4$5R@LZX 0
MTP,  !D              ( !QV@  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " !1B)Q0;K\\JFL#  !P$@  &0              @ &V
M:@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( %&(G%"?
M&)_.!@(  # &   9              "  5AN  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ 48B<4/>!(&S$ @  00L  !D
M     ( !E7   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %&(G%!Q7C8LI@(  ,()   9              "
M 8M^  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ 48B<
M4,%L!44) @  A@4  !D              ( !:($  'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " !1B)Q0()_&N/L"   V#   &0
M        @ &H@P  >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( %&(G%"?= W4? (  ( (   9              "  =J&  !X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ 48B<4//K?@(O @  008
M !D              ( !C8D  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " !1B)Q08KB>9_,!  #<!   &0              @ 'SBP
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( %&(G%!K$W*Z
MFP(  *H)   9              "  1V.  !X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ 48B<4&KA+>BW @  JPD  !D
M ( ![Y   'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !1
MB)Q0M%['V$X#   Y#P  &0              @ '=DP  >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( %&(G%"V4;S(\ $  /($   9
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M970V-2YX;6Q02P$"% ,4    " !1B)Q0UL^46ZX$   '&   &0
M    @ $#HP  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M %&(G% [<F8"XP$  *$$   9              "  >BG  !X;"]W;W)K<VAE
M971S+W-H965T-C<N>&UL4$L! A0#%     @ 48B<4'E*RP<& P  2 P  !D
M             ( ! JH  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"
M% ,4    " !1B)Q0/./9=2($   ?%0  &0              @ $_K0  >&PO
M=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( %&(G%!DX>WYG0(
M /L(   9              "  9BQ  !X;"]W;W)K<VAE971S+W-H965T-S N
M>&UL4$L! A0#%     @ 48B<4%@$YLK) 0  700  !D              ( !
M;+0  'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    " !1B)Q0
ML^(#4-X!  #[!   &0              @ %LM@  >&PO=V]R:W-H965T<R]S
M:&5E=#<R+GAM;%!+ 0(4 Q0    ( %&(G%#EOKNWA@(  $D)   9
M      "  8&X  !X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%
M  @ 4HB<4#'OOUPU @  C08  !D              ( !/KL  'AL+W=O<FMS
M:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !2B)Q0B'Q7AA@"  "T!@
M&0              @ &JO0  >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+
M 0(4 Q0    ( %*(G% X ?YD* (  "L&   9              "  ?F_  !X
M;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ 4HB<4,FRRH;\
M 0  /@4  !D              ( !6,(  'AL+W=O<FMS:&5E=',O<VAE970W
M-RYX;6Q02P$"% ,4    " !2B)Q0D+@)*4@"  #G!@  &0
M@ &+Q   >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( %*(
MG%#&*=*_W@(  )0-   9              "  0K'  !X;"]W;W)K<VAE971S
M+W-H965T-SDN>&UL4$L! A0#%     @ 4HB<4#_WB.5+ @  0@<  !D
M         ( !'\H  'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M    " !2B)Q0!G)HYTP$  #3%   &0              @ &AS   >&PO=V]R
M:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( %*(G%"MF4SKL@(  *<)
M   9              "  231  !X;"]W;W)K<VAE971S+W-H965T.#(N>&UL
M4$L! A0#%     @ 4HB<4"Z4.-C^A0  +_X! !0              ( !#=0
M 'AL+W-H87)E9%-T<FEN9W,N>&UL4$L! A0#%     @ 4HB<4-BFJ&Z8 @
M*!    T              ( !/5H! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !2B)Q00-/>R$D&  #N-0  #P              @ $ 70$ >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ 4HB<4"731@.- @  ^S   !H
M ( !=F,! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M4HB<4,TC\;,J @  J"\  !,              ( !.V8! %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     %L 6P#O&   EF@!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735494448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory', window );">Significant Accounting Policies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant accounting policies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Such services are performed on a &#x201C;best efforts&#x201D; basis without a guarantee of technological or commercial success. For some research programs, Affimed entered into collaborations with other companies that provide the Group with funding or other resources such as access to technologies. From time to time, the Group also licenses its intellectual property to third parties who use it to develop product candidates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Collaboration and license agreements are evaluated to determine whether they involve multiple promises that represent separate performance obligations. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Such agreements may comprise more than one research program, platform licenses or intellectual property </font><font style="display:inline;">licenses </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">originally generated by the Group. Usually each of those promises is considered to meet the </font><font style="display:inline;">definition</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> of a separate performance obligation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The total consideration is generally allocated to separate performance obligations based on relative stand-alone selling prices. Usually sales prices for research and development activities and licenses are not directly observable or highly variable across customers. Therefore, we use estimation techniques to determine stand-alone selling prices for such services and licenses. The stand-alone selling prices for research activities are determined based on an expected cost plus a margin approach. For licenses of intangible assets where little or no incremental costs are incurred in providing such licenses, a residual approach is used. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Performance obligations from research programs are satisfied over time because the work performed by the Group either enhances a license that the customer already controls or because the work does not result in an asset with an alternative use for the Group due to contractual restrictions.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Therefore, revenue for such performance obligations is recognized according to the stage of completion measured by reference to costs incurred in relation to anticipated total costs of the research program.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized at a point in time if their nature is a right to use the intellectual property as it exists at the point in time at which the license is granted. This is usually the case when there is no significant continuing involvement by the Group. In these cases, revenue is recognized when control of the license is transferred. Control is considered to be transferred when the customer received all necessary documents and information to begin to use and benefit from the license.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Platform licenses or intellectual property licenses originally generated by the Group are recognized over time if their nature is to access the intellectual property as it exists throughout the license period. This might be the case when there is significant continuing involvement by the Group. In these cases, revenue is recognized on a straight-line basis until the use of the license by the customer ends. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments received from customers commonly include non-refundable upfront payments that are initially recognized as a contract liability, and subsequently recognized as revenue as the related performance obligation is fulfilled. The Group concluded that non-refundable upfront payments do not include financing components because the advance payments arise for reasons other than the provision of financing.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In addition, payment terms may also include payments to be received from customers at a later point in time upon the achievement of certain milestones. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Milestone payments are contingent upon the achievement of contractually stipulated targets. The achievement of these targets or milestones depends largely on meeting specific requirements laid out in the respective agreement. Milestone payments are included in the transaction price when it is highly probable that a significant reversal of revenue recognized will not occur when the uncertainty associated with the milestone is subsequently resolved. In the Group&#x2019;s view, uncertainty is sufficiently resolved only when the milestone is reached. Reaching a milestone will result in a cumulative catch up of revenue for the performance to date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group distinguishes development and registration milestones and sales based milestones. Whereas development and registration milestone payments are generally recognized on reaching the defined milestones, revenues for sales based milestones are recognized on achievement of contractually stipulated underlying revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research and development</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Costs incurred related to research activities are expensed in the period when they are incurred. Costs incurred on development projects are recognized as intangible assets beginning on the date it can be established that it is probable that future economic benefits attributable to the asset will flow to the Group considering its technological and commercial feasibility. Given the current stage of the development of the Group&#x2019;s candidates and technologies, no development expenditures have been capitalized in any of the periods presented in these consolidated financial statements. Intellectual property-related costs for patents are part of the expenditure for the research and development projects. Therefore, registration costs for patents are recognized as expensed when incurred as long as the research and development project concerned does not meet the criteria for capitalization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Employee benefits</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefits</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related service is provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A liability is recognized for the amount expected to be paid under a short-term cash bonus, if (a)&nbsp;the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and (b)&nbsp;the obligation can be estimated reliably.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payment transactions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s share-based payment awards outstanding as of December&nbsp;31, 2018 and 2019, are classified as equity-settled share-based plans. The fair value of share-based equity-settled awards granted to employees is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. Share-based payment awards with non-employees are measured and recognized when services are received. Fair value is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate, the expected forfeiture rate and the time to maturity of the option. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">(iii)<font style="display:inline;font-family:Arial,Helvetica,sans-serif;;font-size: 10pt;font-family:Arial,Helvetica,sans-serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font>Termination benefits</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Termination benefits are expensed when the Group can no longer withdraw the offer of those benefits. If benefits are not expected to be settled wholly within 12 months of the reporting date, then they are discounted.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group receives certain government grants that support its research effort in specific projects. </font><font style="display:inline;">These grants are generally provided in the form of reimbursement of approved costs incurred as defined in the respective grants.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> Income in respect of grants also includes contributions towards the costs of research and development. Income is recognized when costs under each grant are incurred in accordance with the terms and conditions of the grant and the collectability of the receivable is reasonably assured.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Government grants relating to costs are deferred and recognized in the income statement over the period necessary to match them with the costs they are intended to compensate. When the cash in relation to recognized government grants is not yet received the amount is included as a receivable on the statement of financial position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group recognizes income from government grants under &#x2018;Other income&nbsp;- net&#x2019; in the consolidated statement of comprehensive loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">Policy applicable from 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed recognizes a right-of-use asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred. Subsequently, the right-of-use asset is&nbsp;&nbsp;depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain re-measurements of the lease liability.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, Affimed&#x2019;s incremental borrowing rate. Generally, Affimed uses its incremental borrowing rate as the discount rate. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group determines the incremental borrowing rate by obtaining interest rates from various external financing sources and makes certain adjustments to reflect the terms of the lease and the type of the asset leased.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The lease liability is subsequently&nbsp;&nbsp;measured at amortized cost using the effective interest method. It is re-measured when there is a change in future lease payments arising from a change in an index or rate, a change in the estimate of the amount expected to be payable under a residual value guarantee, or as appropriate, changes in the assessment of whether a purchase or extension option is reasonably certain to be exercised or a termination option is reasonably certain not to be exercised. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has elected not to recognize right-of-use assets and lease liabilities for some short-term leases (leases with less than 12 months of lease term) and right-of-use assets and liabilities for leases of low value assets. Lease payments associated with these leases are recognized as an expense on a straight-line basis over the lease term. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Policy applicable before 1 January 2019</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Payments made under operating leases are recognized in profit or loss on a straight-line basis over the term of the lease. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">For impact on transition please refer to &#x201C;New standards and interpretations applied for the first time&#x201D; below.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income and finance costs</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance income comprises interest income from interest bearing bank deposits. Interest income is recognized as it accrues using the effective interest method.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance costs comprise primarily interest expense on borrowings.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial assets</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group&#x2019;s non-derivative financial assets include preferred shares in Amphivena, </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">trade and other receivables, cash and cash equivalents and certificates of deposit at banks with original maturities of more than three&nbsp;months.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Those debt instruments are hold to collect solely payments of principal and interest. The Group decided to not apply the fair value through OCI option for those instruments. They are included in current assets and are subsequently carried at amortized cost.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Cash and cash equivalents comprise cash balances and call deposits with original maturities of three&nbsp;months or less.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group holds </font><font style="display:inline;">preferred shares in Amphivena </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">designated at fair value through other comprehensive income (see note 13).</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Non-derivative financial liabilities</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s classes of financial liabilities are borrowings and trade and other payables. The Group initially recognizes non-derivative financial liabilities on the date that they are originated and measures them at amortized cost using the effective interest rate method. The Group derecognizes a financial liability when its contractual obligations are discharged, cancelled or expire.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compound financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group entered into certain loan agreements pursuant to which it issued warrants to purchase common shares of the Group at the option of the respective holders (see note 19). The number of shares to be issued does not vary with changes in their fair value.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The liability component of the loans was recognized initially at the fair value of a similar liability without a warrant. The equity component was recognized initially at the difference between the fair value of the compound financial instrument as a whole and the fair value of the liability component. Subsequent to initial recognition, the liability component is measured at amortized cost using the effective interest method. The equity component is not re-measured subsequent to initial recognition.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Impairment</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other receivables at amortized cost are subject to the expected credit loss model according to IFRS 9. The Group&#x2019;s exposure to credit risk is influenced mainly by the individual characteristics of each customer. However, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which customers operate.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed determines the counterparties&#x2019; lifetime expected credit losses that result from all possible default events over the expected life of a financial instrument based on an estimated rating and corresponding probability of default rates according to the Bloomberg database.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, trade and other receivables are assessed at each reporting date to determine whether there is objective evidence that they are impaired. Trade or other receivables are impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the receivable, and such loss event had a negative effect on the estimated future cash flows of that receivable that can be estimated reliably. Loss events include indications that a debtor is experiencing significant financial difficulty, default or delinquency in interest or principal payments, the probability that they will enter bankruptcy or other financial reorganization.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All receivables are assessed for specific impairment. Losses are recognized in profit or loss and reflected in an allowance account against receivables. When a subsequent event causes the amount of impairment loss to decrease, the decrease in impairment loss is reversed through profit or loss. No impairments or reversals of impairments were recognized in 2017, 2018 or 2019.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intangible assets and leasehold improvements and equipment</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable. An impairment loss is recognized as the amount by which an asset&#x2019;s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset&#x2019;s fair value less costs of disposal and value in use. Non- financial assets that were previously impaired are reviewed for possible reversal of the impairment at each reporting date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Income taxes comprise current and deferred tax. Current and deferred taxes are recognized in profit or loss except to the extent that it relates to items recognized directly in equity or in other comprehensive loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Current tax is the expected tax payable or receivable on the taxable income or loss for the&nbsp;year, using tax rates enacted or substantively enacted at the reporting date, and adjustments to taxes payable in respect of previous&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for temporary differences associated with assets and liabilities if the transaction which led to their initial recognition is a transaction that is not a business combination and that affects neither accounting nor taxable profit or loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax is measured at tax rates that are expected to be applied to temporary differences when they reverse, based on the laws that have been enacted or substantively enacted by the reporting date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Deferred tax assets and liabilities are presented net if there is a legally enforceable right to offset.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Fair Value Measurement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">All assets and liabilities for which fair value is recognized in the consolidated financial statements are </font><font style="display:inline;">classified </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">in accordance with the following fair value hierarchy, based on the lowest level input parameter that is significant on the whole for fair value measurement:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 1&nbsp;&#x2013; Prices for identical assets or liabilities quoted in active markets (non-adjusted)</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 2&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 17.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Symbol;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:11pt;"><p style="width:11pt;width:11pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Level 3&nbsp;&#x2013; Measurement procedures, in which the lowest level input parameter significant on the whole for fair value measurement is not directly or indirectly observable for on the market</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The carrying amount of all trade and other receivables, certificates of deposit, cash and cash equivalents and trade and other payables is a reasonable approximation of the fair value and therefore information about the fair values of those financial instruments has not been disclosed. The measurement of the fair value of the shares held by the group and note disclosure for the fair value of a loan (financial liability) is based on level 2 measurement procedures (see notes 13 and 19).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per share</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss per common share is calculated by dividing the loss of the period by the weighted average number of common shares outstanding during the period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group has granted warrants under certain loan agreements (see note 19) and options under share-based payment programs (see note 17) which potentially have a dilutive effect; no instruments actually had a dilutive effect.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Critical judgments and accounting estimates</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;color:#000000;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In preparing these financial statements, the critical judgments made by management in applying the Group&#x2019;s accounting policies resulted in the following accounting estimates</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">:</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share-based payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of stock options issued by Affimed N.V. is estimated using the Black-Scholes-Merton formula. The formula determines the value of an option based on input parameters like the value of the underlying instrument, the exercise price, the expected volatility of share price returns, dividends, the risk-free interest rate and the time to maturity of the option. The fair value of share-based equity-settled compensation plans is measured at grant date and compensation cost is recognized over the vesting period with a corresponding increase in equity. The number of stock options expected to vest is estimated at each measurement date.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On April&nbsp;20, 2018, Affimed issued 240,000 options under its share-based-payment program, the vesting of which deviates from the standard 3year vesting scheme and depends upon a market parameter, which is the average price of Affimed shares during a certain period of time as described in note&nbsp;17. Incorporating the market condition in the fair value estimate requires the use of a simulation technique (Monte Carlo simulation), which implies a higher uncertainty with regard to the estimated fair value. The Group determined the fair value of the awards at grant date to be &#x20AC;133.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Revenue recognition</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 8pt;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">The Group&#x2019;s contracts with customers contain multiple performance obligations. Judgment is required in determining whether a good or service is considered a separate performance obligation. If standalone selling prices are not directly observable, the Group allocates the transaction price to the performance obligations by reference to the expected cost plus a margin. In doing so, observable input data such as internal project plans and margins are used.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Elements of consideration in collaboration and license agreements are non-refundable up-front research funding payments, technology access fees and milestone payments. Generally, the Group has continuing performance obligations and therefore up-front payments are initially recognized as a contract liability, and the related revenues are subsequently recognized as the related performance obligation is fulfilled. Technology access fees are generally initially recognized as a contract liability and subsequently recognized over the expected term of the research service agreement on a straight-line basis.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group estimates that the achievement of a milestone reflects a stage of completion under the terms of the agreements and recognizes revenue when a milestone is achieved as then the uncertainty is resolved. If the research service is cancelled due to technical failure, the remaining contract liability from non-refundable upfront payments, if any, is recognized as revenue.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The determination of whether a performance obligation is satisfied at a point in time versus over time might also requires judgment.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Accrued expenses</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group obtains services from third parties who do not always invoice their (partial) performance as per the balance sheet date. If the Group is not invoiced or otherwise notified of the actual accrued cost for the services as of the reporting date, the amount of the services performed as of the balance sheet date has to be estimated. For this purpose, the Group periodically confirms the accuracy of its estimates with the service providers.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial instruments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The Group holds preferred shares in Amphivena classified as equity instruments at fair value through other comprehensive income (level 2) and&nbsp;&nbsp;recognized as a long-term financial asset. As Amphivena is not a public company substantial judgment was required in estimating the fair value as at December 31, 2019 (see note 13). The Group based its judgment on information available for the valuation of the shares of Amphivena in its latest private financing in September 2019.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (v)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;color:#000000;">Lease payments</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed has applied judgement to determine the lease term for some lease contracts in which it is a lessee that include renewal options. The assessment of whether Affimed is reasonably certain to exercise such options impacts the lease term, which significantly affects the amount of lease liabilities and right-of-use assets recognized. As at December 31, 2019, no renewal options were incorporated into the determining the lease term.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vi)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Arial,Helvetica,sans-serif;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Provisions</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In the second quarter of 2019, Affimed decided to terminate the Phase 1 clinical program of AFM11, a CD19/CD3-targeting bispecific T cell engager as a part of its strategic plans (see note 18).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">New standards and interpretations applied for the first time</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&nbsp;1, 2019, and have been applied in preparing these financial statements:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRS 16 Leases</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9: Prepayment Features with Negative Compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Annual Improvements to IFRS Standards 2015</font><font style="display:inline;font-family:MS Gothic;color:#000000;">&#x2011;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2017 Cycle</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRIC 23 Uncertainty over Income Tax Treatments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></hr></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &#xB4;Determining Whether an Arrangement contains a Lease&#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Transition </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, Affimed elected to apply the practical expedient to grandfather the assessment of which transactions are leases. It applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were previously not identified as leases were not reassessed. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a lessee, Affimed previously classified leases as operating or finance leases based on its assessment of whether the lease transferred substantially all of the risks and rewards of ownership. Under IFRS 16, Affimed recognizes right-of-use assets and lease liabilities for most leases &#x2013; i.e. these leases are on-balance sheet.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">At transition, for leases classified as operating leases under IAS 17, lease liabilities were measured at the present value of the remaining lease payments, discounted at the Company&#x2019;s incremental borrowing rates for similar assets as of January 1, 2019. Right-of-use assets are measured at an amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On transition to IFRS 16, the Company recognized additional right-of-use assets, including property, plant and equipment and additional lease liabilities. The impact on transition is summarized below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Right-of-use assets </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group discounted lease payments using a weighted average discount rate of 4.05% as of January 1, 2019. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In relation to those leases under IFRS 16, Affimed has recognized depreciation and interest costs, instead of operating lease expense. In 2019, the Group recognized depreciation expense for right-of-use assets of &#x20AC;385 and interest cost related to the lease liability of &#x20AC;24 instead of operating lease expense of &#x20AC;406.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The transition between operating lease commitments disclosed applying IAS 17 as of December 31, 2018 and the lease liabilities recognized in the statement of financial position at the date of initial application, January 1, 2019, is shown below.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating lease commitment as of December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,154</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Recognition exemption for short-term leases</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (98)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments for incidental rental costs and other rental payments (Not part of the lease)</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (312)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Discounting using the incremental borrowing rate as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (27)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">New standards and interpretations not yet adopted</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following new standards and amendments to standards are effective for annual periods beginning after December 31, 2019, and have not been applied in preparing these consolidated financial statements.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to References to the Conceptional Framework</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 1 and IAS 8: Definition of Material</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 3 Business Combination</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1 Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The amended standards are not expected to have a significant effect on the consolidated financial statements of the Group.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant accounting policies applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 117<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739066944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Affimed N.V.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001608390<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">76,249,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739021872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th">
<div>Issued Capital </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Issued Capital</div></th>
<th class="th">
<div>Capital Reserves </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Capital Reserves</div></th>
<th class="th">
<div>Fair Value Reserves </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Fair Value Reserves</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Previously Reported</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Previously Reported</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, beginning at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 190,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (152,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 38,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfConvertibleInstruments', window );">Issue of warrant note (loan Silicon Valley Bank)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,223)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, ending at Dec. 31, 2017</a></td>
<td class="nump">&#8364; 468<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">&#8364; 213,778<span></span>
</td>
<td class="nump">213,778<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">7,325<span></span>
</td>
<td class="num">&#8364; (182,667)<span></span>
</td>
<td class="num">(182,667)<span></span>
</td>
<td class="nump">&#8364; 31,579<span></span>
</td>
<td class="nump">38,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevaluationSurplus', window );">Revaluation shares Amphivena (first time adoption IFRS 9) | Change due to adoption of IFRS 9</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, ending at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">239,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(202,144)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of share based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Equity-settled share based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,365)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(632)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance, ending at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 270,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (234,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 38,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfConvertibleInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in equity resulting from the issuing of convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfConvertibleInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevaluationSurplus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the accumulated revaluation surplus on the revaluation of assets recognised in other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 39<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_39&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevaluationSurplus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_FinancialEffectOfChangesInAccountingPolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626553312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>19. Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBorrowingsExplanatory', window );">Borrowings</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrowings</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Silicon Valley Bank</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November&nbsp;30, 2016, Affimed entered into a loan agreement with Silicon Valley Bank (the &#x201C;SVB loan&#x201D;) which provides the Group with a senior secured term loan facility originally for up to &#x20AC;10.0 million, which agreement was amended in May&nbsp;2017 to provide that such amount would be available in three tranches. In December&nbsp;2016, the Group drew an initial tranche of &#x20AC;5.0 million and in May&nbsp;2017, a second tranche of &#x20AC;2.5 million; the availability of a third tranche of &#x20AC;2.5 million expired in September&nbsp;2017 with such amount remaining undrawn.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Finance costs comprise the interest rate of one-month EURIBOR plus an applicable margin of 5.5%, with a floor of 5.5%, related one-time legal and arrangement fees of &#x20AC;236 and a final payment fee equal to 10% of the total principal amount to be paid with the last instalment. Pursuant to the loan agreement, the Group also granted the lender 166,297 and 53,395 warrants with an exercise price of $2.00 and $2.30 per share, respectively. Each warrant can be used to purchase common shares of Affimed at the respective exercise price for a period of ten&nbsp;years from the grant date. The fair value of the warrants of &#x20AC;192 less deferred taxes and transaction costs of &#x20AC;81 and &#x20AC;8, respectively, was recorded as an addition to capital reserves in equity. The fair value of the warrants was determined using the Black-Scholes-Merton valuation model, with an expected volatility of 75&#8209;80% and an expected exercise period of five&nbsp;years to exercise of the warrant. The contractual maturity of the warrants is ten&nbsp;years.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The loan is secured by a pledge of 100% of Group&#x2019;s ownership interest in Affimed GmbH, all intercompany claims owed to Affimed N.V. by its subsidiaries, and collateral agreements for all bank accounts, inventory, trade receivables and other receivables of Affimed N.V. and Affimed GmbH recognized in the consolidated financial statements with the following book values:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.80%;">
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:12.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Book&nbsp;value&nbsp;as&nbsp;of&nbsp;December&nbsp;31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:24.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:25.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Consolidated</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">financial</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">thereof&nbsp;assets</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">statements</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">pledged</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leasehold improvements and equipment</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,291</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,503</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,414</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,174</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Inventories</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 296</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 247</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 260</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 235</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Trade and other receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,482</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 864</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,429</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,007</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 387</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Financial assets</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,902</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,974</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cash and cash equivalents</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 95,234</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 93,606</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 94,829</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 92,933</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:46.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 108,205</font></p>
				</td>
				<td valign="bottom" style="width:02.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 105,122</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 112,293</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 109,323</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019 and 2018, the fair value of the liability did not differ significantly from its carrying amount (&#x20AC;2,013 and &#x20AC;4,773). The loan has a maturity date of May&nbsp;31, 2020, repayment started in December&nbsp;2017 with amortized payments of principal and interest in equal&nbsp;monthly installments. As of December&nbsp;31, 2019, &#x20AC;2,013 (2018: &nbsp;&#x20AC;3,083) were classified as current liabilities.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">UniCredit Leasing CZ</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In April 2019, the Group entered into a loan agreement with UniCredit Leasing CZ for &#x20AC;562. After an initial instalment of &#x20AC;127 in the second quarter of 2019, repayment is effected in monthly instalments of &#x20AC;8 until November 2023. As at December 31, 2019, an amount of &#x20AC;368 was outstanding, of which &#x20AC;91 was classified as current liabilities. As of December 31, 2019, the fair value of the liability did not differ significantly from its carrying amount.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Reconciliation to cash flows from financing</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Movements of liabilities reconcile to cash flows arising from financing activities as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,169</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Proceeds from borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 562</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of borrowings</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (3,277)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,715)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (2,917)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Capitalized borrowing costs</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 489</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 847</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest paid</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (164)</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (326)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 325</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 531</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:78.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,383</font></p>
				</td>
				<td valign="bottom" style="width:02.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,773</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBorrowingsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBorrowingsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735474064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>15. Trade and Other Receivables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherReceivablesAbstract', window );"><strong>Trade and Other Receivables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory', window );">Trade and Other Receivables</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other receivables</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The trade receivables as of December&nbsp;31, 2019 and 2018, of &#x20AC;204 and &#x20AC;210, respectively, are all due in the short-term, do not bear interest and are not impaired. Other receivables are all due short-term and mainly comprise value-added tax receivables of &#x20AC;453 (2018: &#x20AC;839).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other receivables. [Refer: Trade and other receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635195136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>23. Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Parties</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Related parties</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shareholders</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019 and 2018, no shareholder holds more than 20% of the voting rights.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Transactions with key management personnel</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The compensation of managing directors and other key management personnel comprised of the following:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,598</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,683</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,538</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Termination benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 264</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share-based payments</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,738</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,229</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,379</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,600</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,912</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,917</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Remuneration of Affimed&#x2019;s managing directors comprises fixed and variable components and share-based payment awards. In addition, the managing directors receive supplementary benefits such as fringe benefits and allowances. In the case of an early termination, the managing directors receive a severance.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Compensation for other key management personnel comprises fixed and variable components and share-based payment awards.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The supervisory directors of Affimed N.V. received compensation for their services on the supervisory board of &#x20AC;382 (2018: &#x20AC;382; 2017: &#x20AC;375). In 2019, the Group recognized expenses for share-based payments for supervisory board members of &#x20AC;243 (2018: &#x20AC;117, 2017: &#x20AC;144).</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table provides the total amounts of outstanding balances for supervisory board compensation and expense reimbursement related to key management personnel:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding&nbsp;balances</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adi Hoess</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Martin Treder</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leila Alland</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 40</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 26</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 17</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Section Disclosures<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626704848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. Share Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ShareBasedPaymentsAbstract', window );"><strong>Share Based Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Assumptions of Options Granted</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value at grant date </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.10</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.20</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share price at grant date</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.91</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exercise price </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.92</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 82</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 72</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected life</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.09</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.34</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ShareBasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ShareBasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730311568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>24. Financial Risk Management (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfExchangeRatesTableTextBlock', window );">Exchange Rates</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">or GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03896</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03899</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03799</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03936</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03887</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03916</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89326</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.84674</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.88519</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.87336</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.83382</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1393</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.13031</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1754</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.11791</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfExchangeRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfExchangeRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739158880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Segment Reporting - Geographic information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">&#8364; 21,391<span></span>
</td>
<td class="nump">&#8364; 23,735<span></span>
</td>
<td class="nump">&#8364; 2,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">2,017<span></span>
</td>
<td class="nump">1,224<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">1,646<span></span>
</td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_US', window );">USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenues</a></td>
<td class="nump">19,745<span></span>
</td>
<td class="nump">22,529<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">3,558<span></span>
</td>
<td class="nump">3,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CZ', window );">Czech Republic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Non-current assets</a></td>
<td class="nump">&#8364; 870<span></span>
</td>
<td class="nump">&#8364; 246<span></span>
</td>
<td class="nump">&#8364; 221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.
Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649473952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>18. Provisions (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ProgramTerminationCost', window );">Termination cost</a></td>
<td class="nump">&#8364; 1.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PaymentOfTerminationOfProgram', window );">Termination cost incurred</a></td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Expected termination cost</a></td>
<td class="nump">&#8364; 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PaymentOfTerminationOfProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for payment of program termination cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PaymentOfTerminationOfProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ProgramTerminationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of program termination cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ProgramTerminationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626704848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>15. Trade and Other Receivables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfTradeAndOtherReceivableLineItems', window );"><strong>Disclosure of Trade and Other Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 204<span></span>
</td>
<td class="nump">&#8364; 210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=afmd_ValueAddedTaxReceivablesMember', window );">Value-added tax receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfTradeAndOtherReceivableLineItems', window );"><strong>Disclosure of Trade and Other Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">&#8364; 453<span></span>
</td>
<td class="nump">&#8364; 839<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfTradeAndOtherReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfTradeAndOtherReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=afmd_ValueAddedTaxReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=afmd_ValueAddedTaxReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738874816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statement of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="nump">&#8364; 32,365<span></span>
</td>
<td class="nump">&#8364; 19,477<span></span>
</td>
<td class="nump">&#8364; 30,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for the period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncomeTaxExpense', window );">Income taxes</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and amortisation</a></td>
<td class="nump">906<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment', window );">Net gain from disposal of leasehold improvements and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share based payments</a></td>
<td class="nump">2,469<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">1,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncomeCost', window );">Finance income / costs - net</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital', window );">Total</a></td>
<td class="num">(29,006)<span></span>
</td>
<td class="num">(17,073)<span></span>
</td>
<td class="num">(24,985)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Change in trade and other receivables</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(322)<span></span>
</td>
<td class="nump">1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Change in inventories</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(44)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Change in other assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="num">(399)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Change in trade, other payables, provisions and contract liabilities</a></td>
<td class="num">(791)<span></span>
</td>
<td class="nump">66,856<span></span>
</td>
<td class="num">(1,018)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(29,460)<span></span>
</td>
<td class="nump">49,563<span></span>
</td>
<td class="num">(25,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">628<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Paid interest</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Paid income tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(29,056)<span></span>
</td>
<td class="nump">49,438<span></span>
</td>
<td class="num">(25,549)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(150)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of leasehold improvements and equipment</a></td>
<td class="num">(1,324)<span></span>
</td>
<td class="num">(691)<span></span>
</td>
<td class="num">(625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Cash received from the sale of leasehold improvements and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod', window );">Cash paid for investments in convertible note and warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PurchaseOfAvailableforsaleFinancialAssets', window );">Cash paid for investments in financial assets</a></td>
<td class="num">(45,131)<span></span>
</td>
<td class="num">(14,029)<span></span>
</td>
<td class="num">(13,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets', window );">Cash received from maturity of financial assets</a></td>
<td class="nump">50,945<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PurchaseOfLongTermFinancialAssets', window );">Cash paid for investments in long term financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
<td class="nump">4,340<span></span>
</td>
<td class="num">(15,610)<span></span>
</td>
<td class="nump">8,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="nump">31,373<span></span>
</td>
<td class="nump">25,113<span></span>
</td>
<td class="nump">23,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Transaction costs related to issue of common shares</a></td>
<td class="num">(2,215)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
<td class="num">(1,648)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsForDebtIssueCosts', window );">Transaction costs related to borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="num">(405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(3,277)<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flow from financing activities</a></td>
<td class="nump">26,038<span></span>
</td>
<td class="nump">20,495<span></span>
</td>
<td class="nump">23,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Exchange-rate related changes of cash and cash equivalents</a></td>
<td class="num">(917)<span></span>
</td>
<td class="nump">669<span></span>
</td>
<td class="num">(1,867)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net changes to cash and cash equivalents</a></td>
<td class="nump">1,322<span></span>
</td>
<td class="nump">54,323<span></span>
</td>
<td class="nump">6,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the beginning of the period</a></td>
<td class="nump">94,829<span></span>
</td>
<td class="nump">39,837<span></span>
</td>
<td class="nump">35,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the period</a></td>
<td class="nump">95,234<span></span>
</td>
<td class="nump">94,829<span></span>
</td>
<td class="nump">39,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">&#8364; 95,234<span></span>
</td>
<td class="nump">&#8364; 94,829<span></span>
</td>
<td class="nump">&#8364; 39,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PurchaseOfLongTermFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of long term financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PurchaseOfLongTermFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncomeTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncomeTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow (outflow) from the entity's operations before changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 20<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the disposal or maturity of available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2021-01-01<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromDisposalOrMaturityOfAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfAvailableforsaleFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of available-for-sale financial assets. [Refer: Financial assets available-for-sale]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Note Expiry date 2021-01-01<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_16&amp;doctype=Standard&amp;book=b<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfAvailableforsaleFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of investments other than investments accounted for using equity method. [Refer: Investments accounted for using equity method; Investments other than investments accounted for using equity method]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfInvestmentsOtherThanInvestmentsAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735507936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>3. Basis of preparation &#8211; consolidated financial statements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract', window );"><strong>Basis of preparation &#8211; consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation and changes to Group&#8217;s accounting policies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis of preparation &#x2013; consolidated financial statements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Statement of compliance</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board (IFRS).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements were authorized for issuance by the management board on April&nbsp;28, 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Basis of measurement</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements have been prepared on the historical cost basis except for financial instruments measured at fair value (see note 13) and monetary assets and liabilities denominated in foreign currencies which are translated at period-end exchange rates. The Group did not opt for a valuation of liabilities at fair value through profit or loss.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Consolidation</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group controls an entity when it has power over the investee, is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity. A subsidiary is consolidated from the date on which control is obtained by the Group. It is de-consolidated from the date control ceases.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Intercompany transactions, balances and unrealized gains on transactions between group companies are eliminated.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Functional and presentation currency</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements are presented in euro, which is also the functional currency. All financial information presented in euro unless otherwise noted has been rounded to the nearest thousand (abbreviated &#x20AC;) or million (abbreviated &#x20AC; million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Presentation of consolidated statements of comprehensive loss</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As a clinical-stage biopharmaceutical company with a primary focus on research and development activities, cost of sales and gross profit are not considered meaningful measures for Affimed and therefore are not presented. </font><font style="display:inline;">See note 4 for the Group&#x2019;s accounting policies related to revenue recognition and research and development expenses.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency transactions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Transactions denominated in currencies other than the euro are translated at exchange rates at the date of the transaction. Monetary assets and liabilities denominated in currencies other than the euro are translated at the exchange rate at the date of the consolidated statement of financial position.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The foreign currency gain or loss on monetary items is the difference between amortized cost in the functional currency at the beginning of the period, adjusted for effective interest and payments during the period, and the amortized cost in foreign currency translated at the exchange rate at the end of the reporting period.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency gains or losses that relate to borrowings, cash and cash equivalents and financial assets, except for financial instruments at fair value through other comprehensive income are presented in the statement of comprehensive loss within &#x2018;Finance income / (costs)&nbsp;- net&#x2019;. All other foreign exchange gains and losses are presented in the statement of comprehensive loss within &#x2018;Other income&nbsp;&#x2013; net&#x2019;.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_BasisOfPreparationConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730336864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>24. Financial Risk Management<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinancialRiskManagementAbstract', window );"><strong>Financial Risk Management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Financial Risk Management</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial risk management</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial risk management objectives and policies</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s principal financial instruments comprise cash and cash equivalents, certificates of deposit at commercial banks, a convertible loan, warrants and investor loans presented in borrowings. The main purpose of these financial instruments is to raise funds for the Group&#x2019;s operations. The Group has various other financial assets and liabilities such as trade and other receivables and trade and other payables, which arise directly from its operations.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The main risks arising from the Group&#x2019;s financial instruments are credit risk and liquidity risk. The measures taken by management to manage each of these risks are summarized below.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Credit risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s financial assets comprise to a large extent cash and cash equivalents. In addition, financial assets include shares, certificates of deposit, trade and other receivables. The total carrying amount of shares (&#x20AC;3.2 million, 2018: &#x20AC;3.8 million) cash and cash equivalents&nbsp; (&#x20AC;95.2&nbsp;million, 2018: &#x20AC;94.8 million), trade and other receivables (&#x20AC;1.5 million, 2018:&nbsp;&#x20AC;1.4 million), and certificates of deposit (&#x20AC;8.9 million, 2018:&nbsp;&#x20AC;14.0 million), represents the maximum credit exposure of &#x20AC;108.8 million (2018: &#x20AC;114.1 million).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The cash and cash equivalents and certificates of deposit are held with banks, which are rated BBB+ to AA- based on Standard&nbsp;&amp; Poor&#x2019;s and Moody&#x2019;s.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Interest rate risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s interest rate risk arises from cash accounts and long-term borrowings at variable rates.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed entered into the SVB loan pursuant to which the Group borrowed &#x20AC;7.5 million with an outstanding balance of &#x20AC;2.0 million as at December&nbsp;31, 2019, with a variable interest rate of an annual rate of 5.5% plus one-month EURIBOR, with EURIBOR deemed to equal zero&nbsp;percent if EURIBOR is less than zero&nbsp;percent. The Group does not expect the EURIBOR to exceed the floor of 0% within the foreseeable future, and considers the interest risk to be low.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Market interest</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> rates on cash and cash equivalents as well as on term deposits </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">were</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> low</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> in 2019,</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> resulting in interest income of </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x20AC;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">715 in 2019. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A shift in interest rates (increase or decrease) would not have a material impact on the loss of the Group.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iv)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Other price risks</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of the shares in Amphivena depends on the share price. The total exposure of the Group amounts to &#x20AC;3.2 million.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (v)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign currency risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Foreign exchange risk arises when future commercial transactions or recognized assets or liabilities are denominated in a currency that is not the entity&#x2019;s functional currency.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group&#x2019;s entities are exposed to Czech Koruna (CZK) and US Dollars (USD) and British Pound (GBP). The net exposure as of December&nbsp;31, 2019 was &#x20AC;56,531 (2018: &#x20AC;47,524) &nbsp;and mainly relates to US Dollars.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, if the Euro had weakened/strengthened by 10% against the US dollar with all other variables held constant, the loss would have been &#x20AC;5,677 (2018: &#x20AC;4,787) higher/lower, mainly as a result of foreign exchange gains/losses on translation of US dollar-denominated financial assets. The Group considers a shift in the exchange rates of 10% as a realistic scenario.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Loss is more sensitive to movement in exchange rates shifts in 2019 than in 2018 because of the increased volume of US dollar-denominated transactions.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following significant exchange rates have been applied during the&nbsp;year:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">CZK&nbsp;or USD or</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">or GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">GBP/EUR</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03896</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03899</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03799</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">CZK&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03936</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03887</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.03916</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89326</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.84674</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.88519</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USD&nbsp;- Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.89015</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.87336</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.83382</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Average Rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1393</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.13031</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:59.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">GBP - Spot rate</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.1754</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.11791</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vi)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Liquidity risk</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Liquidity risk is the risk that the Group will encounter difficulties in meeting the obligations associated with its financial liabilities which are normally settled by delivering cash. The Group&#x2019;s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group continually monitors its risk of a shortage of funds using short and mid-term liquidity planning. This takes account of the expected cash flows from all activities. The supervisory board undertakes regular reviews of the budget.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2017 and 2018 and 2019, Affimed raised significant funding that it estimates will enable the Group to fund operating expenses and capital expenditure requirements at least into the fourth quarter of 2021.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2017, the Group issued 10,646,762 common shares in a public offering at a price of $1.80 per common share for net proceeds of &#x20AC;16.4 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2018, the Group issued 13,225,000 common shares in a public offering at a price of $2.00 per common share for net proceeds of approximately &#x20AC;19.7 million and 2,373,716 common shares in connection with its at-the-market sales agreement for net proceeds of &#x20AC;3.8 million.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019,&nbsp;&nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &#x20AC;29.5 million (see note 16).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group expects to require additional funding to complete the development of the existing product candidates. In addition, the Group expects to require additional capital to commercialize the products if regulatory approval is received.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (vii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Capital management</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The primary objective of the Group&#x2019;s capital management is to ensure that it maintains its liquidity in order to finance its operating activities and meet its liabilities when due.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group manages its capital structure primarily through equity.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinancialRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinancialRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6709448368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>20. Trade and Other Payables<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and Other Payables.</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade and other payables</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Trade and other payables comprise trade payables of &#x20AC;10,249 (2018: &#x20AC;8,482). Other payables mainly comprise payroll and employee related liabilities for withholding taxes and social security contributions of &#x20AC;801 (2018: &#x20AC;885) and payables due to employees for unused holidays and other accruals. Other payables are normally settled within 30&nbsp;days.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6644222288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory', window );">Equity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December 31, 2019, the share capital of &#x20AC;762 (2018: &#x20AC;624) is composed of 76,249,901 (2018: 62,430,106) common shares with a par value of &#x20AC;0.01.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On November 13, 2019,&nbsp;&nbsp;the Group issued 13,800,000 common shares in a public offering at a price of $2.50 per common share resulting in aggregate net proceeds of &#x20AC;29.5 million.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As at 31, December 2019 and 2018, the authorized share capital amounted to &#x20AC;3,200 consisting of 155,975,000 common shares and 155,975,000&nbsp;cumulative preference shares, each with a par value of &#x20AC;0.01 per share.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIssuedCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of issued capital. [Refer: Issued capital]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIssuedCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730351584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group did not incur any material income tax in the periods presented. As of December 31, 2019, deferred tax assets from differences resulting from intangible assets (&#x20AC;283; 2018: &#x20AC;415), trade and other receivables (&#x20AC;243; 2018: &#x20AC;334), borrowings (&#x20AC;70; 2018: &#x20AC;0), lease liabilities (&#x20AC;121; 2018: &#x20AC;0) and trade and other payables (&#x20AC;23; 2018: &#x20AC;27) have not been recognized as deferred tax assets as no sufficient future taxable profits or offsetting deferred tax liabilities are available. As of December 31, 2019 deferred tax liabilities from temporary differences result mainly leasehold improvements and equipment and right-of-use assets (&#x20AC;226; 2018: &#x20AC;0), long term financial assets (&#x20AC;1,218; &nbsp;2018: &#x20AC;774) and contract liabilities (&#x20AC;308; 2018: &#x20AC;0). Deferred tax liabilities are not recognized as there is an excess of deferred tax assets over deferred tax liabilities.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">A reconciliation between actual income taxes and the expected tax benefit from the loss before tax multiplied by the Group&#x2019;s applicable tax rate is presented below for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Loss before tax</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (32,361)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (19,476)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (30,243)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income tax benefit at tax rate of 29.825 %</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,652</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,809</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments of deferred tax assets</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,822)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (5,318)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (9,036)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Permanent differences</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (29)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (462)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (93)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adjustments for local tax rates</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (34)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 195</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Non deductible expenses</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (43)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (53)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 16</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 57</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (82)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Income taxes</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (4)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (1)</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In Germany, Affimed has tax losses carried forward of &#x20AC;199.2 million (2018: &#x20AC;166.2 million) for corporate income tax purposes and of &#x20AC;198.4 million (2018: &#x20AC;165.4 million) for trade tax purposes that are available indefinitely for offsetting against future taxable profits of that entity. Restrictions on the utilization of tax losses in case of a change of control of ownership in Affimed were mitigated by the enactment of the Economic Growth Acceleration Act (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">Wachstumsbeschleunigungsgesetz</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">2009</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">). According to the provisions of this act unused tax losses of a corporation as at the date of a qualified change in ownership are preserved to the extent they are compensated by an excess of the fair value of equity for tax purposes above its carrying amount of the Group. The maximum amount of tax losses at risk of being lost due to ownership changes is approximately &#x20AC;59 million. Deferred tax assets have not been recognized in respect of any losses carried forward as no sufficient taxable profits of Affimed are expected.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Tax losses of Abcheck s.r.o. amount to &#x20AC;296 as at December&nbsp;31, 2019 (2018: &#x20AC;423).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735458784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>8. Research and Development Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ResearchAndDevelopmentExpensesAbstract', window );"><strong>Research And Development Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory', window );">Research and Development Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 10pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the different types of expenses allocated to research and development costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Third-party services</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 27,338</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,127</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 12,299</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,154</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,639</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and patent expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,983</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,672</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 890</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Cost of Materials</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,547</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,140</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 994</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amortisation and depreciation</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 725</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 351</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 309</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,044</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,804</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,358</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 43,791</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 35,148</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,489</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ResearchAndDevelopmentExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ResearchAndDevelopmentExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735425920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>25. Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subsequent events</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company announced early February 2020 that Dr. Florian Fischer, Chief Financial Officer (CFO) of Affimed, passed away. Affimed has commenced a process for a new permanent CFO. As part of the transition, Harry Welten will assume the operating responsibilities as CFO advisor to Affimed during the search and will continue to operate in that capacity until a permanent successor has been appointed.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In addition, the Company announced the appointment of Dr. Andreas Harstrick as Chief Medical Officer, starting in March 2020 and the appointment of Dr. Arndt Schottelius as Chief Scientific Officer, effective April 2020.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As circumstances around the COVID-19 pandemic continue to rapidly evolve, the Group is continuously assessing possible effects on its clinical trials and adapting the risk mitigation measures implemented. Affimed is closely monitoring and adhering to relevant federal and local guidelines on COVID-19 to ensure the safety and health of its global workforce and help limit the spread of COVID-19, while maintaining business continuity. The Group has taken mitigation steps to ensure that drug supply and other trial-related materials are ready and available for the patients enrolled in its clinical trials. Due to the ongoing assessment of the potential impact of the COVID-19 pandemic on patient enrollment and site activation in its clinical studies, Affimed will update trial timelines after it has more visibility on the length and extent of the COVID-19 crisis.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635141136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory', window );">Schedule of contract liabilities from customer</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 204</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 210</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 59,314</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 61,847</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Major service lines:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Collaboration revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,685</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 390</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Service revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,706</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,717</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Point in time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,783</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,863</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Over time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15,608</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,872</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,777</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2019-01-01<br> -Paragraph 86<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_86&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6621484800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>11. Finance Income and Finance Costs (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinanceIncomeAndFinanceCostsAbstract', window );"><strong>Finance Income And Finance Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock', window );">Finance Income and Finance Costs</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest SVB Loan Agreement (see note 19)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (483)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (847)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (690)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Foreign exchange differences</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (175)</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 651</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,378)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on certificates of deposit with maturities of more than three months</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 602</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 77</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other finance income/finance costs - net</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 71</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 251</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 60</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (2,983)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinanceIncomeAndFinanceCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinanceIncomeAndFinanceCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of finance income and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ScheduleOfFinanceIncomeAndFinanceCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6733467712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Income Taxes (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="num">&#8364; (32,361)<span></span>
</td>
<td class="num">&#8364; (19,476)<span></span>
</td>
<td class="num">&#8364; (30,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Income tax benefit at tax rate of 29.825 %</a></td>
<td class="nump">9,652<span></span>
</td>
<td class="nump">5,809<span></span>
</td>
<td class="nump">9,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_TaxEffectDueToAdjustmentsOfDeferredAssets', window );">Adjustments of deferred tax assets</a></td>
<td class="num">(9,822)<span></span>
</td>
<td class="num">(5,318)<span></span>
</td>
<td class="num">(9,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_TaxEffectOfPermanentDifferences', window );">Permanent differences</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_TaxEffectOfLocalTaxRates', window );">Adjustments for local tax rates</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet', window );">Non deductible expenses</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">&#8364; (4)<span></span>
</td>
<td class="num">&#8364; (1)<span></span>
</td>
<td class="nump">&#8364; 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_TaxEffectDueToAdjustmentsOfDeferredAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_TaxEffectDueToAdjustmentsOfDeferredAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_TaxEffectOfLocalTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effects due to local tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_TaxEffectOfLocalTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_TaxEffectOfPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax effects due to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_TaxEffectOfPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6740266672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. General and Administrative Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems', window );"><strong>Disclosure of General and Administrative Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 10,266<span></span>
</td>
<td class="nump">&#8364; 9,638<span></span>
</td>
<td class="nump">&#8364; 7,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember', window );">Personnel expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems', window );"><strong>Disclosure of General and Administrative Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">5,357<span></span>
</td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">4,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndAuditExpensesMember', window );">Legal, consulting and audit expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems', window );"><strong>Disclosure of General and Administrative Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">2,881<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember', window );">Other expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems', window );"><strong>Disclosure of General and Administrative Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">&#8364; 1,853<span></span>
</td>
<td class="nump">&#8364; 1,828<span></span>
</td>
<td class="nump">&#8364; 1,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfGeneralAndAdministrativeExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_PersonnelExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndAuditExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_LegalConsultingAndAuditExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NatureOfExpensesAxis=afmd_OtherExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626273936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>6. Revenue (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ReceivablesFromContractsWithCustomers', window );">Receivables</a></td>
<td class="nump">&#8364; 204<span></span>
</td>
<td class="nump">&#8364; 210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 59,314<span></span>
</td>
<td class="nump">&#8364; 61,847<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s right to consideration in exchange for goods or services that the entity has transferred to a customer that is unconditional. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649844864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfLeaseForLesseeLineItems', window );"><strong>Disclosure Of Lease For Lessee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfLeaseForLesseeLineItems', window );"><strong>Disclosure Of Lease For Lessee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfLeaseForLesseeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfLeaseForLesseeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsLesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730499296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>24. Financial Risk Management - Exchange Rates (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#163; / &#8364; </div>
<div>$ / &#8364; </div>
<div>K&#269; / &#8364;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>&#163; / &#8364; </div>
<div>$ / &#8364; </div>
<div>K&#269; / &#8364;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / &#8364; </div>
<div>K&#269; / &#8364;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=afmd_CZKMember', window );">CZK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate | K&#269; / &#8364;</a></td>
<td class="nump">0.03896<span></span>
</td>
<td class="nump">0.03899<span></span>
</td>
<td class="nump">0.03799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Spot rate | K&#269; / &#8364;</a></td>
<td class="nump">0.03936<span></span>
</td>
<td class="nump">0.03887<span></span>
</td>
<td class="nump">0.03916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=afmd_USDMember', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate | $ / &#8364;</a></td>
<td class="nump">0.89326<span></span>
</td>
<td class="nump">0.84674<span></span>
</td>
<td class="nump">0.88519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Spot rate | $ / &#8364;</a></td>
<td class="nump">0.89015<span></span>
</td>
<td class="nump">0.87336<span></span>
</td>
<td class="nump">0.83382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=afmd_GbpMember', window );">GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AverageForeignExchangeRate', window );">Average rate | &#163; / &#8364;</a></td>
<td class="nump">1.1393<span></span>
</td>
<td class="nump">1.13031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClosingForeignExchangeRate', window );">Spot rate | &#163; / &#8364;</a></td>
<td class="nump">1.1754<span></span>
</td>
<td class="nump">1.11791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AverageForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AverageForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClosingForeignExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClosingForeignExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=afmd_CZKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=afmd_CZKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=afmd_USDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=afmd_USDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=afmd_GbpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=afmd_GbpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735507936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases - Movements of lease liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at beginning of period</a></td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="num">(405)<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_AdditionsOfNewLeaseContracts', window );">New lease contracts</a></td>
<td class="nump">492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Balance at end of period</a></td>
<td class="nump">&#8364; 804<span></span>
</td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_AdditionsOfNewLeaseContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additions in new contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_AdditionsOfNewLeaseContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6732976496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. Share Based Payments (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>Y</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Y </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ShareBasedPaymentsAbstract', window );"><strong>Share Based Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Fair value at grant date | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Share price at grant date | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 1.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExercisePriceShareOptionsGranted2019', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | Y</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpectedDividendShareOptionsGranted', window );">Expected dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ShareBasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ShareBasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceShareOptionsGranted2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceShareOptionsGranted2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626067904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Long term financial assets (Details) - Preferred Shares - EUR (&#8364;)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsLineItems', window );"><strong>Disclosure of financial assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome', window );">Fair value of preferred shares</a></td>
<td class="nump">&#8364; 3.2<span></span>
</td>
<td class="nump">&#8364; 3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="num">&#8364; (0.6)<span></span>
</td>
<td class="num">&#8364; (4.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: At fair value [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 11A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_11A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 8<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_8_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FairValueOfInvestmentsInEquityInstrumentsDesignatedAsMeasuredAtFairValueThroughOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6744001040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>19. Borrowings - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2016 </div>
<div>EUR (&#8364;) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentPayables', window );">Loan payable, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_SiliconValleyBankLoanMember', window );">SVB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentFloorRate', window );">Floor rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentLegalAndArrangementFees', window );">Legal and arrangement fee</a></td>
<td class="nump">&#8364; 236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal', window );">Final payment fee percentage on principal</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase common shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExpirationPeriodOfWarrants', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Change in fair value of warrant</a></td>
<td class="nump">&#8364; 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity', window );">Change in deferred tax on warrant equity</a></td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity', window );">Change in transaction cost</a></td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExpectedExercisePeriodOfWarrants', window );">Exercise period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized', window );">Percentage of ownership interest pledged as security</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValue', window );">Fair value of financial liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityMember', window );">Senior Secured Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">&#8364; 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_UndrawnBorrowingFacilities', window );">Undrawn borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheOneMember', window );">Senior Secured Term Loan Facility Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember', window );">Senior Secured Term Loan Facility Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_LoanAgreementWithUniCreditLeasingCZMember', window );">Loan agreement with UniCredit Leasing CZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="nump">&#8364; 562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfNoncurrentBorrowings', window );">Loan repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount', window );">Monthly repayment installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentPortionOfLongtermBorrowings', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEURIBORMember', window );">EURIBOR | SVB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Variable interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | SVB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExpectedVolatilityOfWarrants', window );">Volatility</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum | SVB loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ExpectedVolatilityOfWarrants', window );">Volatility</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of principal as the final payment fee under the debt instrument arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentFinalPaymentFeeAsPercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of floor of a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentLegalAndArrangementFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of legal and arrangement fees under the debt instrument arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentLegalAndArrangementFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly installment to be paid under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentMonthlyRepaymentInstallmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of tranches under the debt instrument agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ExpectedExercisePeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected exercise period of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ExpectedExercisePeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ExpectedVolatilityOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the warrants. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ExpectedVolatilityOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ExpirationPeriodOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an warrant to exercise common stock expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ExpirationPeriodOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IFRSClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IFRSClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IFRSLineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the deferred tax assets on exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IncreaseDecreaseThroughDeferredTaxesOnWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the transaction costs on grants of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IncreaseDecreaseThroughTransactionCostsOnWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership interest with which the loan is secured by a pledge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PercentageOfOwnershipInterestWithWhichLoanIsCollateralized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPortionOfLongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPortionOfLongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current payables that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for repayments of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UndrawnBorrowingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 50<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_50_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UndrawnBorrowingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_SiliconValleyBankLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_SiliconValleyBankLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_SeniorSecuredTermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_LoanAgreementWithUniCreditLeasingCZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_LoanAgreementWithUniCreditLeasingCZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEURIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEURIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735499040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Schedule of carrying amounts of right-of-use reconcile</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of right-of-use assets reconcile as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying&nbsp;amount</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Buildings</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cars</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1, 2019 </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 695</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Depreciation charge for the year</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (371)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (13)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (384)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Additions to right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 816</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 824</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock', window );">Schedule of cash outflow related to leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">Cash outflow related to leases are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 405</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 24</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Cash outflow from leasing</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 495</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock', window );">Schedule of future contractually agreed undiscounted cash flows for leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Future contractually agreed undiscounted lease payments are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019: Leases<br />under IFRS<br />16</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018:<br />Operating<br />Leases under<br />IAS 17</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments within one year</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 553</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 675</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments between one and five years</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 276</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 541</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 829</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,216</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock', window );">Schedule of movements of lease liabilities reconcile to cash flows arising from financing activities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Movements of lease liabilities reconcile to cash flows arising from financing activities as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">New lease contracts</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 804</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash outflow related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfCashOutflowRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future contractually agreed undiscounted cash flows for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfFutureContractuallyAgreedUndiscountedCashFlowsForLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movements of lease liabilities reconcile to cash flows arising from financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfMovementsOfLeaseLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739366832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Accounting Policies - Narrative (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 20, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SignificantAccountingPoliciesAbstract', window );"><strong>Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables', window );">Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares', window );">Dilutive effect of loan agreements and options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted in share-based payment arrangement</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted', window );">Fair value of awards granted</a></td>
<td class="nump">&#8364; 133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of awards granted under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ShareBasedCompensationArrangementFairValueOfAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of dilutive potential ordinary shares that relate to the assumed conversion of the entity's convertible instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutiveEffectOfConvertibleInstrumentsOnNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735411664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>22. Other Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract', window );"><strong>Other Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Other Commitments and Contingencies</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other commitments and contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Commitments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">The Group has entered into agreements for the use of licenses. In 2019, license fees of &#x20AC;92 have been recognized in consolidated statement of comprehensive income (2018: &#x20AC;124, 2017: &#x20AC;174), related future payment obligations under non-cancellable fees amount to &#x20AC;25.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Contingencies</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has entered into various license agreements that contingently trigger payments upon achievement of certain milestones and royalty payments upon commercialization of a product in the future.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfContingentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfContingentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6598583504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>18. Provisions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProvisionsAbstract', window );"><strong>Provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfProvisionsExplanatory', window );">Provisions</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provisions</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In 2019, the group recognized costs related to the termination of the AFM 11 program totalling to &#x20AC;1.4 million, whereof &#x20AC;0.9 million were already incurred in 2019 and estimated costs of &#x20AC;0.5 million expected to incur in 2020 were recognized in provisions.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfProvisionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of provisions. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfProvisionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738871312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated statements of comprehensive loss - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Consolidated statements of comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 21,391<span></span>
</td>
<td class="nump">&#8364; 23,735<span></span>
</td>
<td class="nump">&#8364; 2,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherIncome', window );">Other income - net</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(43,791)<span></span>
</td>
<td class="num">(35,148)<span></span>
</td>
<td class="num">(21,489)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(10,266)<span></span>
</td>
<td class="num">(9,638)<span></span>
</td>
<td class="num">(7,986)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(32,376)<span></span>
</td>
<td class="num">(19,536)<span></span>
</td>
<td class="num">(27,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Finance income / (costs) - net</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="num">(2,983)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before tax</a></td>
<td class="num">(32,361)<span></span>
</td>
<td class="num">(19,476)<span></span>
</td>
<td class="num">(30,243)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Loss for the period</a></td>
<td class="num">(32,365)<span></span>
</td>
<td class="num">(19,477)<span></span>
</td>
<td class="num">(30,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Other comprehensive income / (loss) Items that will not be reclassified to profit or loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments', window );">Equity investments at fair value OCI - net change in fair value</a></td>
<td class="num">(632)<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income / (loss)</a></td>
<td class="num">(632)<span></span>
</td>
<td class="num">(4,731)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">&#8364; (32,997)<span></span>
</td>
<td class="num">&#8364; (24,208)<span></span>
</td>
<td class="num">&#8364; (30,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BasicAndDilutedEarningsLossPerShare', window );">Loss per share in &#8364; per share</a></td>
<td class="num">&#8364; (0.50)<span></span>
</td>
<td class="num">&#8364; (0.32)<span></span>
</td>
<td class="num">&#8364; (0.69)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of common shares outstanding</a></td>
<td class="nump">64,242,396<span></span>
</td>
<td class="nump">60,514,407<span></span>
</td>
<td class="nump">43,746,073<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicAndDilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of earnings per share when the basic and diluted measurements are equal. [Refer: Basic earnings (loss) per share; Diluted earnings (loss) per share]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicAndDilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, related to gains (losses) from changes in the fair value of investments in equity instruments that the entity has designated at fair value through other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesFromInvestmentsInEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2019-01-01<br> -Paragraph 39L<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2019-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2021-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2019-01-01<br> -Paragraph IE33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 126<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.
Effective 2020-01-01: The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 34<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 103<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2019-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735477648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>1. Reporting Entity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ReportingEntityAbstract', window );"><strong>Reporting Entity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Reporting Entity</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reporting entity<a name="a1Reportingentity_514365"></a></font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed N.V. is a Dutch company with limited liability (</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;">naamloze vennootschap</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">) and has its corporate seat in Amsterdam, the Netherlands.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The consolidated financial statements are comprised of Affimed N.V., and its controlled (and wholly owned) subsidiaries Affimed GmbH, Heidelberg, Germany, AbCheck s.r.o., Plzen, Czech Republic, Affimed&nbsp;Inc., Delaware, USA and AbCheck&nbsp;Inc., Delaware, USA (together &#x201C;Affimed&#x201D; or the &#x201C;Group&#x201D;).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The Group&#x2019;s product candidates are developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body&#x2019;s own immune defenses to fight tumor cells. Affimed has its own research and development programs, strategic collaborations and service contracts, where the Group is performing research services for third parties.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ReportingEntityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ReportingEntityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 51<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6732937168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock', window );">New Standards and Interpretations Applied for First Time</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRS 16 Leases</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9: Prepayment Features with Negative Compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Annual Improvements to IFRS Standards 2015</font><font style="display:inline;font-family:MS Gothic;color:#000000;">&#x2011;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2017 Cycle</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRIC 23 Uncertainty over Income Tax Treatments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">Schedule of right-of-use assets and lease liabilities</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">New standards and interpretations applied for the first time</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following amendments to standards and new or amended interpretations are effective for annual periods beginning on or before January&nbsp;1, 2019, and have been applied in preparing these financial statements:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRS 16 Leases</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9: Prepayment Features with Negative Compensation</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 28: Long-term Interests in Associates and Joint Ventures</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Annual Improvements to IFRS Standards 2015</font><font style="display:inline;font-family:MS Gothic;color:#000000;">&#x2011;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">2017 Cycle</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 19: Plan Amendment, Curtailment or Settlement</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:81.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">IFRIC 23 Uncertainty over Income Tax Treatments</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2019</font></p>
				</td>
			</tr>
		</table></div>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="left"></hr></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">1 &nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Shall apply for periods beginning on or after the date shown in the effective date column.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed has applied IFRS 16 using the modified retrospective approach, under which the cumulative effect of initial application is recognized in retained earnings as of January 1, 2019. Accordingly, any comparative information presented for any periods in 2018 and 2017 has not been restated &#x2013; i.e. it is presented, as previously reported, under IAS 17 and related interpretations. The nature and effect of the application of IFRS 16 are summarized below. The other amendments had no effect on the consolidated financial statements of the Company.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The new standard specifies how to recognize, measure, present and disclose lease agreements. The standard provides a single lessee accounting model, requiring lessees to recognize right-of-use assets representing its rights to use the underlying assets and lease liabilities representing its obligation to make lease payments. Lessor accounting remains similar to previous accounting policies.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under IAS 17, Affimed determined at contract inception whether an arrangement was or contained a lease under IFRIC 4 &#xB4;Determining Whether an Arrangement contains a Lease&#xB4;. Under IFRS 16, Affimed now assesses whether a contract is or contains a lease based on the new definition of a lease. This definition says that a contract is or contains a lease if the contract conveys a right to control the use of an identified asset for a period of time in exchange for consideration.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock', window );">Summary of impact on transition</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;">
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Right-of-use assets </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:81.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:16.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock', window );">New Standards and Interpretations Not Yet Adopted</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Standard/interpretation</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Effective Date </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;font-size:4pt;top:-3.2pt;position:relative;line-height:106.67%">1</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to References to the Conceptional Framework</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IAS 1 and IAS 8: Definition of Material</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 9, IAS 39 and IFRS 7: Interest Rate Benchmark Reform</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:82.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Amendments to IFRS 3 Business Combination</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">January 1, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member', window );">IFRS 16</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory', window );">Explanation of difference between operating lease commitments disclosed applying IAS 17 and lease liabilities recognised at date of initial application of IFRS 16 [text block]</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">January&nbsp;1,&nbsp;2019</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Operating lease commitment as of December 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,154</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Recognition exemption for short-term leases</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (98)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments for incidental rental costs and other rental payments (Not part of the lease)</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (312)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Discounting using the incremental borrowing rate as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (27)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:84.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Lease liabilities as of January 1, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:12.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impact on transition of leased assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfImpactOfLeaseTransitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Table information related to new standards and interpretations applied for the first time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfNewStandardsAndInterpretationsAppliedForFirstTimeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfNewStandardsAndInterpretationsNotYetAdoptedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The explanation of the difference between: (a) operating lease commitments disclosed applying IAS 17 at the end of the annual reporting period immediately preceding the date of initial application of IFRS 16, discounted using the incremental borrowing rate at the date of initial application; and (b) lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph C12<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_C12_b&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfDifferenceBetweenOperatingLeaseCommitmentsDisclosedApplyingIAS17AndLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16Explanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739007472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. General and Administrative Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,357</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,929</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,521</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and audit expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,881</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,945</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,853</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,828</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,520</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,266</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,638</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,986</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfGeneralAndAdministrativeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>267</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>95</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated statements of comprehensive loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated statements of comprehensive loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated statements of financial position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/StatementConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated statements of financial position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/StatementConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statement of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/StatementConsolidatedStatementOfChangesInEquity</Role>
      <ShortName>Consolidated Statement of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - 1. Reporting Entity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure1ReportingEntity</Role>
      <ShortName>1. Reporting Entity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - 2. Local exemption rules applied by subsidiaries of the Group</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure2LocalExemptionRulesAppliedBySubsidiariesOfGroup</Role>
      <ShortName>2. Local exemption rules applied by subsidiaries of the Group</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - 3. Basis of preparation ??? consolidated financial statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure3BasisOfPreparationConsolidatedFinancialStatements</Role>
      <ShortName>3. Basis of preparation ??? consolidated financial statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - 4. Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies</Role>
      <ShortName>4. Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - 5. Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure5SegmentReporting</Role>
      <ShortName>5. Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - 6. Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure6Revenue</Role>
      <ShortName>6. Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - 7. Other Income and Expenses - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNet</Role>
      <ShortName>7. Other Income and Expenses - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - 8. Research and Development Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpenses</Role>
      <ShortName>8. Research and Development Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - 9. General and Administrative Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpenses</Role>
      <ShortName>9. General and Administrative Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - 10. Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure10EmployeeBenefits</Role>
      <ShortName>10. Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - 11. Finance Income and Finance Costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCosts</Role>
      <ShortName>11. Finance Income and Finance Costs</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - 12. Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure12IncomeTaxes</Role>
      <ShortName>12. Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - 13. Long Term Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure13LongTermFinancialAssets</Role>
      <ShortName>13. Long Term Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - 14. Financial Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure14FinancialAssets</Role>
      <ShortName>14. Financial Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - 15. Trade and Other Receivables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure15TradeAndOtherReceivables</Role>
      <ShortName>15. Trade and Other Receivables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - 16. Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure16Equity</Role>
      <ShortName>16. Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - 17. Share Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure17ShareBasedPayments</Role>
      <ShortName>17. Share Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11801 - Disclosure - 18. Provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure18Provisions</Role>
      <ShortName>18. Provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11901 - Disclosure - 19. Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure19Borrowings</Role>
      <ShortName>19. Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>12001 - Disclosure - 20. Trade and Other Payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure20TradeAndOtherPayables</Role>
      <ShortName>20. Trade and Other Payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>12101 - Disclosure - 21. Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21Leases</Role>
      <ShortName>21. Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12201 - Disclosure - 22. Other Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingencies</Role>
      <ShortName>22. Other Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12301 - Disclosure - 23. Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure23RelatedParties</Role>
      <ShortName>23. Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>12401 - Disclosure - 24. Financial Risk Management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure24FinancialRiskManagement</Role>
      <ShortName>24. Financial Risk Management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>12501 - Disclosure - 25. Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure25SubsequentEvents</Role>
      <ShortName>25. Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>20402 - Disclosure - 4. Significant accounting policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesPolicies</Role>
      <ShortName>4. Significant accounting policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30403 - Disclosure - 4. Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables</Role>
      <ShortName>4. Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure4SignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30503 - Disclosure - 5. Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure5SegmentReportingTables</Role>
      <ShortName>5. Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure5SegmentReporting</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30603 - Disclosure - 6. Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure6RevenueTables</Role>
      <ShortName>6. Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure6Revenue</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30803 - Disclosure - 8. Research and Development Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesTables</Role>
      <ShortName>8. Research and Development Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>30903 - Disclosure - 9. General and Administrative Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesTables</Role>
      <ShortName>9. General and Administrative Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31003 - Disclosure - 10. Employee Benefits (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure10EmployeeBenefitsTables</Role>
      <ShortName>10. Employee Benefits (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure10EmployeeBenefits</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31103 - Disclosure - 11. Finance Income and Finance Costs (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsTables</Role>
      <ShortName>11. Finance Income and Finance Costs (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCosts</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31203 - Disclosure - 12. Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure12IncomeTaxesTables</Role>
      <ShortName>12. Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure12IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31703 - Disclosure - 17. Share Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure17ShareBasedPaymentsTables</Role>
      <ShortName>17. Share Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure17ShareBasedPayments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31903 - Disclosure - 19. Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure19BorrowingsTables</Role>
      <ShortName>19. Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure19Borrowings</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>32103 - Disclosure - 21. Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesTables</Role>
      <ShortName>21. Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure21Leases</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>32303 - Disclosure - 23. Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure23RelatedPartiesTables</Role>
      <ShortName>23. Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure23RelatedParties</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>32403 - Disclosure - 24. Financial Risk Management (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure24FinancialRiskManagementTables</Role>
      <ShortName>24. Financial Risk Management (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure24FinancialRiskManagement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40401 - Disclosure - 4. Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesDetails</Role>
      <ShortName>4. Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40402 - Disclosure - 4. Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>4. Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40403 - Disclosure - 4. Significant Accounting Policies -Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesLeaseDetails</Role>
      <ShortName>4. Significant Accounting Policies -Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure4SignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40501 - Disclosure - 5. Segment Reporting - Geographic information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure5SegmentReportingGeographicInformationDetails</Role>
      <ShortName>5. Segment Reporting - Geographic information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40502 - Disclosure - 5. Segment Reporting - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure5SegmentReportingNarrativeDetails</Role>
      <ShortName>5. Segment Reporting - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40601 - Disclosure - 6. Revenue - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure6RevenueNarrativeDetails</Role>
      <ShortName>6. Revenue - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40602 - Disclosure - 6. Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure6RevenueDetails</Role>
      <ShortName>6. Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure6RevenueTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40603 - Disclosure - 6. Revenue - Disaggregation of revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure6RevenueDisaggregationOfRevenueDetails</Role>
      <ShortName>6. Revenue - Disaggregation of revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40701 - Disclosure - 7. Other Income and Expenses - Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNetDetails</Role>
      <ShortName>7. Other Income and Expenses - Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure7OtherIncomeAndExpensesNet</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40801 - Disclosure - 8. Research and Development Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>8. Research and Development Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure8ResearchAndDevelopmentExpensesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40901 - Disclosure - 9. General and Administrative Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>9. General and Administrative Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure9GeneralAndAdministrativeExpensesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - 10. Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure10EmployeeBenefitsDetails</Role>
      <ShortName>10. Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure10EmployeeBenefitsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41002 - Disclosure - 10. Employee Benefits - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure10EmployeeBenefitsNarrativeDetails</Role>
      <ShortName>10. Employee Benefits - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41101 - Disclosure - 11. Finance Income and Finance Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsDetails</Role>
      <ShortName>11. Finance Income and Finance Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure11FinanceIncomeAndFinanceCostsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - 12. Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure12IncomeTaxesDetails</Role>
      <ShortName>12. Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure12IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41202 - Disclosure - 12. Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure12IncomeTaxesNarrativeDetails</Role>
      <ShortName>12. Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41301 - Disclosure - 13. Long term financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure13LongTermFinancialAssetsDetails</Role>
      <ShortName>13. Long term financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41401 - Disclosure - 14. Financial assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure14FinancialAssetsDetails</Role>
      <ShortName>14. Financial assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41501 - Disclosure - 15. Trade and Other Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure15TradeAndOtherReceivablesDetails</Role>
      <ShortName>15. Trade and Other Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure15TradeAndOtherReceivables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41601 - Disclosure - 16. Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure16EquityDetails</Role>
      <ShortName>16. Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure16Equity</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41701 - Disclosure - 17. Share Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure17ShareBasedPaymentsDetails</Role>
      <ShortName>17. Share Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure17ShareBasedPaymentsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41702 - Disclosure - 17. Share Based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure17ShareBasedPaymentsNarrativeDetails</Role>
      <ShortName>17. Share Based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41801 - Disclosure - 18. Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure18ProvisionsDetails</Role>
      <ShortName>18. Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure18Provisions</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41901 - Disclosure - 19. Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure19BorrowingsDetails</Role>
      <ShortName>19. Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure19BorrowingsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41902 - Disclosure - 19. Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure19BorrowingsNarrativeDetails</Role>
      <ShortName>19. Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41903 - Disclosure - 19. Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure19BorrowingsMovementsOfLiabilitiesReconcileToCashFlowsArisingFromFinancingActivitiesDetails</Role>
      <ShortName>19. Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>42001 - Disclosure - 20. Trade and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure20TradeAndOtherPayablesDetails</Role>
      <ShortName>20. Trade and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.affimed.com/role/Disclosure20TradeAndOtherPayables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>42101 - Disclosure - 21. Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesNarrativeDetails</Role>
      <ShortName>21. Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>42102 - Disclosure - 21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesScheduleOfCarryingAmountsOfRightOfUseAssetsReconcileDetails</Role>
      <ShortName>21. Leases - Schedule of Carrying Amounts of Right-of-Use Assets Reconcile (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>42103 - Disclosure - 21. Leases - Schedule of Cash Outflow Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesScheduleOfCashOutflowRelatedToLeasesDetails</Role>
      <ShortName>21. Leases - Schedule of Cash Outflow Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>42104 - Disclosure - 21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesFutureContractuallyAgreedUndiscountedLeasePaymentsDetails</Role>
      <ShortName>21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>42105 - Disclosure - 21. Leases - Movements of lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure21LeasesMovementsOfLeaseLiabilitiesDetails</Role>
      <ShortName>21. Leases - Movements of lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>42202 - Disclosure - 22. Other Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure22OtherCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>22. Other Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>42301 - Disclosure - 23. Related Parties - Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure23RelatedPartiesCompensationDetails</Role>
      <ShortName>23. Related Parties - Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>42302 - Disclosure - 23. Related Parties - Outstanding Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure23RelatedPartiesOutstandingBalancesDetails</Role>
      <ShortName>23. Related Parties - Outstanding Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>42303 - Disclosure - 23. Related Parties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure23RelatedPartiesNarrativeDetails</Role>
      <ShortName>23. Related Parties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>42401 - Disclosure - 24. Financial Risk Management - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure24FinancialRiskManagementNarrativeDetails</Role>
      <ShortName>24. Financial Risk Management - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="afmd-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>42402 - Disclosure - 24. Financial Risk Management - Exchange Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.affimed.com/role/Disclosure24FinancialRiskManagementExchangeRatesDetails</Role>
      <ShortName>24. Financial Risk Management - Exchange Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>afmd-20191231.xml</File>
    <File>afmd-20191231.xsd</File>
    <File>afmd-20191231_cal.xml</File>
    <File>afmd-20191231_def.xml</File>
    <File>afmd-20191231_lab.xml</File>
    <File>afmd-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.ifrs.org/taxonomy/2019-03-27/ifrs-full</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649489024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory', window );">Employee Benefits</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employee benefits</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the items of employee benefits for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wages and salaries</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,587</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,027</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,475</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Social security costs</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,092</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 931</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,207</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,119</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,406</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The employer&#x2019;s contributions to pension insurance plans of &#x20AC;696 (2018: &#x20AC;502, 2017: &#x20AC;438) are classified as payments under a defined contribution plan, and are recognized as an expense.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEmployeeBenefitsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2019-01-01<br> -Section Scope<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IAS19_g2-7_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEmployeeBenefitsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730325152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Collaboration agreement with Amphivena</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Until July 2016, Affimed was party to a collaboration with Amphivena. The purpose of the collaboration was the development of a product candidate for hematological malignancies. The collaboration included a License and Development Agreement between Amphivena and Affimed, which expired when Amphivena obtained the approval of an investigational new drug application (IND) from the FDA in July 2016.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the license and development agreement between Affimed and Amphivena, Affimed granted a license to intellectual property and agreed to perform certain services for Amphivena related to the development of a product candidate for hematological malignancies. In </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">consideration</font><font style="display:inline;"> for the research and development work that was performed, Amphivena was required to pay to Affimed service fees totaling approximately &#x20AC;16 million payable according to the achievement of milestones and phase progressions as described under the license and development agreement. Since the expiration of the agreement, the parties have been closing out the collaboration by exchanging documentation and transferring materials and third-party contracts. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the year ended December 31, 2017, the Company recognized revenue upon achievement of milestones and for the performance of research and development services totaling &#x20AC;0.2 million. </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Collaboration agreement The Leukemia&nbsp;&amp; Lymphoma Society (LLS)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Affimed is party to a collaboration with LLS to fund the development of a specific product candidates (immune cell engagers). Under the terms of the agreement, LLS has agreed to contribute up to $4.4 million contingent upon the achievement of certain milestones.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In the event that the research and development is successful, Affimed must proceed with commercialization of the licensed product. If Affimed decides for business reasons not to continue the commercialization, Affimed must at its option either repay the amount funded or grant a license to LLS to enable LLS to continue with the development program. In addition, LLS is entitled to receive royalties from Affimed based on the Group&#x2019;s future revenue from any licensed product, with the amount of royalties not to exceed three times the amount funded.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In June&nbsp;2016, the research funding agreement with LLS was amended to reflect a shift to the development of combination therapeutic approaches so that the milestones now relate primarily to the development of a combination therapy.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">During the&nbsp;years ended December&nbsp;31, 2017 and 2018, the Group achieved several milestones and recognized revenue totaling &#x20AC;0.2 million and &#x20AC;0.2 million, respectively. Open milestones as at December 31, 2019 are expected to have no significant impact on future revenues.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Collaboration with Genentech&nbsp;Inc.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In August 2018, Affimed entered into a strategic collaboration agreement with Genentech Inc., headquartered in South San Francisco, USA. Under the terms of the agreement Affimed is providing services related to the development of novel NK cell engager-based immunotherapeutics to treat multiple cancers. The Genentech agreement became effective at the beginning of October&nbsp;2018. Under the terms of the agreement, Affimed received $96.0 million (&#x20AC;83.2 million) in an initial upfront payment and committed funding on October&nbsp;31, 2018. The Group recognized &#x20AC;19.7 million as revenue in 2019 (2018: &#x20AC;21.8 million) and &#x20AC;59.3 million (December 31, 2018: &#x20AC;61.4 million) under contract liabilities, which will be recognized as revenue in subsequent periods as services are provided.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under the terms of the agreement, Affimed is eligible to receive up to an additional $5.0 billion over time, including payments upon achievement of specified development, regulatory and commercial milestones. Affimed is also eligible to receive royalties on any potential sales.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Research service agreements</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group, through its subsidiary AbCheck has entered into certain research service agreements. These research service agreements provide for non-refundable upfront technology access research funding or capacity reservation fees and milestone payments. The Group recognized revenue of &#x20AC;1.7 million, &#x20AC;1.7 million and &#x20AC;1.6 million during the&nbsp;years ended December&nbsp;31, 2019, 2018 and 2017 respectively.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Contract balances</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table provides information about receivables and contract liabilities from contracts with customers.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Receivables</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 204</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 210</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:66.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Contract liabilities</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 59,314</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:14.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 61,847</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">An amount of &#x20AC;14,795 that was recognized in contract liabilities at the beginning of the period was recognized as revenue during the period ended December 31,&nbsp;2019 (2018: &#x20AC;230).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The remaining performance obligations at December&nbsp;31, 2019 are approximately &#x20AC;59.3 million and are expected to be recognized as revenue to a large extent over the next two&nbsp;years.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;">Disaggregation of revenue</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Major service lines:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Collaboration revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,685</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,018</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 390</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Service revenue</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,706</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,717</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Point in time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,783</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,863</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 233</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Over time</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 15,608</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,872</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,777</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt;line-height:107.08%;color:#000000;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0pt 0pt;line-height:107.08%;text-align:right;color:#000000;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626553312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>14. Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_FinancialAssetsAbstract', window );"><strong>Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory', window );">Financial Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Financial assets contain of U.S. Dollar denominated certificates of deposit with original maturities of more than three&nbsp;months. As of December 31, 2019, the fair value (level 1) of the financial assets did not differ significantly from its carrying amount.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_FinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_FinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626166624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>23. Related Parties - Compensation (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee benefits</a></td>
<td class="nump">&#8364; 2,598<span></span>
</td>
<td class="nump">&#8364; 2,683<span></span>
</td>
<td class="nump">&#8364; 1,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based payments</a></td>
<td class="nump">1,738<span></span>
</td>
<td class="nump">1,229<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Key management personnel compensation</a></td>
<td class="nump">&#8364; 4,600<span></span>
</td>
<td class="nump">&#8364; 3,912<span></span>
</td>
<td class="nump">&#8364; 2,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739935728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>19. Borrowings - Movements of Liabilities Reconcile to Cash Flows Arising from Financing Activities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract', window );"><strong>Movements of liabilities reconcile to cash flows arising from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance at beginning of period</a></td>
<td class="nump">&#8364; 4,773<span></span>
</td>
<td class="nump">&#8364; 7,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities', window );">Proceeds from borrowings</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">&#8364; 2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(3,277)<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities', window );">Changes from financing cash flows</a></td>
<td class="num">(2,715)<span></span>
</td>
<td class="num">(2,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingCostsCapitalised', window );">Capitalized borrowing costs</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities', window );">Interest paid</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities', window );">Other Changes</a></td>
<td class="nump">325<span></span>
</td>
<td class="nump">531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LiabilitiesArisingFromFinancingActivities', window );">Balance at end of period</a></td>
<td class="nump">&#8364; 2,383<span></span>
</td>
<td class="nump">&#8364; 4,773<span></span>
</td>
<td class="nump">&#8364; 7,169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingCostsCapitalised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest and other costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 23<br> -IssueDate 2019-01-01<br> -Paragraph 26<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=23&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_26_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingCostsCapitalised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInLiabilitiesArisingFromFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 44B<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44B_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in liabilities arising from financing activities resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 44B<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44B_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughOtherChangesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 31<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 44D<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44D&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowings obtained. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730444128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>23. Related Parties - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>EUR (&#8364;) </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>EUR (&#8364;) </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights', window );">Number of shareholder holds more than 20% of the voting rights | shareholder</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based expense</a></td>
<td class="nump">&#8364; 2,469<span></span>
</td>
<td class="nump">&#8364; 2,035<span></span>
</td>
<td class="nump">&#8364; 1,943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_SupervisoryBoardDirectorsMember', window );">Supervisory Board Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_KeyManagementPersonnelCompensationForServices', window );">Compensation received for their services</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based expense</a></td>
<td class="nump">&#8364; 243<span></span>
</td>
<td class="nump">&#8364; 117<span></span>
</td>
<td class="nump">&#8364; 144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_KeyManagementPersonnelCompensationForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_KeyManagementPersonnelCompensationForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shareholders holding more than twenty percent of voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NumberOfShareholdersHoldingMoreThanTwentyPercentVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_SupervisoryBoardDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_SupervisoryBoardDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634831360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases - Schedule of Cash Outflow Related to Leases (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Repayment of lease liabilities</a></td>
<td class="nump">&#8364; 405<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_IfrsShortTermLeasePayments', window );">Short-term lease payments</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Cash outflow from leasing</a></td>
<td class="nump">&#8364; 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RentalExpense', window );">Lease expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 562<span></span>
</td>
<td class="nump">&#8364; 472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_IfrsShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_IfrsShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognised on rental activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 85<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6732146096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Employee Benefits - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployerContributions', window );">Employer's contributions</a></td>
<td class="nump">&#8364; 696<span></span>
</td>
<td class="nump">&#8364; 502<span></span>
</td>
<td class="nump">&#8364; 438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployerContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of employer contributions to retirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2019-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35_b_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployerContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738567488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>7. Other Income and Expenses - Net (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OtherIncomeAndExpensesNetAbstract', window );"><strong>Other Income And Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange gains (losses)</a></td>
<td class="nump">&#8364; 251<span></span>
</td>
<td class="nump">&#8364; 1,523<span></span>
</td>
<td class="num">&#8364; (7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromGovernmentGrants', window );">Income from government grants</a></td>
<td class="nump">&#8364; 19<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="nump">&#8364; 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OtherIncomeAndExpensesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OtherIncomeAndExpensesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2019-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income recognised in relation to government grants. [Refer: Government grants]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 20<br> -IssueDate 2019-01-01<br> -Paragraph 39<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=20&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_39_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626982224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory', window );">Summary of revenue and non-current assets by geographic information</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 31</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Europe</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,646</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,175</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,236</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,745</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,529</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 694</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Non-current assets as of December, 31:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,017</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,224</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 957</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Czech Republic</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 870</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 246</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 221</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,558</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,825</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 6,445</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,295</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,178</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of geographical information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 33<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_33&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6650230544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Employee Benefits (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfEmployeeBenefitTableTextBlock', window );">Employee Benefits</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wages and salaries</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,587</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,027</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,475</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Social security costs</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,620</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,092</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 931</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 13,207</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11,119</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 8,406</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfEmployeeBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfEmployeeBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6718977360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>13. Long Term Financial Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialAssetsAbstract', window );"><strong>Long Term Financial Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfLongTermFinancialAssetsTextBlock', window );">Long Term Financial Assets</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long term financial assets</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Company holds preferred shares in Amphivena recognized at their fair value of &#x20AC;3.2 million (2018: &#x20AC;3.8 million). The Company recognized losses from the change in fair value of &#x20AC;0.6 million in other comprehensive income in 2019 (2018: &#x20AC;4.7 million).</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfLongTermFinancialAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of long term financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfLongTermFinancialAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6626269328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>9. General and Administrative Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_GeneralAndAdministrativeExpensesAbstract', window );"><strong>General And Administrative Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory', window );">General and Administrative Expenses</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The following table shows the different types of expenses allocated to general and administrative costs for the&nbsp;years ended December&nbsp;31:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Personnel expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,357</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,929</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,521</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Legal, consulting and audit expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,055</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,881</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,945</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Other expenses</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,853</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,828</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,520</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10,266</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 9,638</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 7,986</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_GeneralAndAdministrativeExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_GeneralAndAdministrativeExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of general and administrative expenses. [Refer: Administrative expenses]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralAndAdministrativeExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6735465328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>5. Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Segment Reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Segment Reporting</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Segment reporting</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (i)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Information about reportable segment</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The Group is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The activities are either conducted as own project development or for third party companies. Management of resources and reporting to the chief operating decision maker is based on the Group as a whole.</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (ii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Geographic information</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The geographic information below analyses the Group&#x2019;s revenue and non-current assets by country. In presenting the following information, segment revenue has been based on the geographic location of the customers and segment assets were based on the geographic location of the assets.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Discovery activities and research services are conducted in both the Heidelberg and Plzen premises. Pre-clinical and clinical activities are conducted and coordinated from Heidelberg.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Revenue:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 31</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Europe</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,646</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,175</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,236</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 19,745</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22,529</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 694</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21,391</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 23,735</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,010</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Non-current assets as of December, 31:</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Germany</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,017</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,224</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 957</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Czech Republic</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 870</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 246</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 221</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">USA</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,558</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,825</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 6,445</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5,295</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,178</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%"><table style="width:100%;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 20.00pt;">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
				<font style="margin:0pt 0pt 12pt;font-family:Arial,Helvetica,sans-serif;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-size:10pt;;"> (iii)</font>
			</p>
		</td><td style="width:16pt;"><p style="width:16pt;width:16pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;margin:0pt 0pt 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Major Customers</font></p></td></tr></table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2018 and 2019, the Group&#x2019;s revenue with Genentech&nbsp;Inc. exceeded 10% of total revenues. For the year ended December 31, 2017, the Group&#x2019;s revenue with four customers exceeded 10% of total revenues.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739007472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>20. Trade and Other Payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesAbstract', window );"><strong>Trade and Other Payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables</a></td>
<td class="nump">&#8364; 10,249<span></span>
</td>
<td class="nump">&#8364; 8,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherPayables', window );">Other payables</a></td>
<td class="nump">&#8364; 801<span></span>
</td>
<td class="nump">&#8364; 885<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6741034832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>24. Financial Risk Management - Narrative (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 95,234<span></span>
</td>
<td class="nump">&#8364; 94,829<span></span>
</td>
<td class="nump">&#8364; 39,837<span></span>
</td>
<td class="nump">&#8364; 35,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="nump">31,373<span></span>
</td>
<td class="nump">25,113<span></span>
</td>
<td class="nump">&#8364; 23,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember', window );">Credit risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SharesValue', window );">Total carrying amount of shares</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">95,200<span></span>
</td>
<td class="nump">94,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LongtermDeposits', window );">Certificates of deposit</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum credit exposure</a></td>
<td class="nump">108,800<span></span>
</td>
<td class="nump">114,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember', window );">Interest rate risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings</a></td>
<td class="nump">&#8364; 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent', window );">Percentage of deemed EURIBOR rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DebtInstrumentFloorRate', window );">Floor rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromInterest', window );">Interest income</a></td>
<td class="nump">&#8364; 715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_OtherPriceRiskMember', window );">Other price risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaximumExposureToCreditRisk', window );">Maximum credit exposure</a></td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Foreign currency risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MaximumExposureToForeignCurrencyRisk', window );">Maximum foreign currency exposure</a></td>
<td class="nump">&#8364; 56,531<span></span>
</td>
<td class="nump">47,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PercentageOfDeviationBetweenCurrencyExchangeRate', window );">Percentage of deviation between currency exchange rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_NetLossInCaseOfCurrencyExchangeDeviation', window );">Net loss in currency exchange deviation</a></td>
<td class="nump">&#8364; 5,677<span></span>
</td>
<td class="nump">&#8364; 4,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario', window );">Percentage of shift in exchange rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="nump">13,225,000<span></span>
</td>
<td class="nump">10,646,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SharePricePerShare', window );">Share price</a></td>
<td class="nump">&#8364; 2.50<span></span>
</td>
<td class="nump">&#8364; 2.00<span></span>
</td>
<td class="nump">&#8364; 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="nump">&#8364; 29,500<span></span>
</td>
<td class="nump">&#8364; 19,700<span></span>
</td>
<td class="nump">&#8364; 16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember', window );">Liquidity risk | At-the-market sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,373,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEuriborMember', window );">One Month Euribor | Interest rate risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis', window );">Variable interest rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DebtInstrumentFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of floor of a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DebtInstrumentFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_MaximumExposureToForeignCurrencyRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information pertaining to Maximum foreign currency exposure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_MaximumExposureToForeignCurrencyRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_NetLossInCaseOfCurrencyExchangeDeviation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net loss the company would have accounted in case of currency exchange deviation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_NetLossInCaseOfCurrencyExchangeDeviation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of deemed EURIBOR rate if it is less than zero percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PercentageOfDeemedEuriborRateIfLessThanZeroPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PercentageOfDeviationBetweenCurrencyExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of weakening/strengthening difference between currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PercentageOfDeviationBetweenCurrencyExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shift in exchange rate considered a realistic scenario.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PercentageOfShiftInExchangeRateConsideredRealisticScenario</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of shares as on the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAdjustmentToInterestRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 7<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAdjustmentToInterestRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of long-term deposits held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaximumExposureToCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35K<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35K_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expiry date 2021-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_36_a&amp;doctype=Standard&amp;book=b<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaximumExposureToCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_e&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CreditRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_InterestRateRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_OtherPriceRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_OtherPriceRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_LiquidityRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedInPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedInPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedUnderAtMarketSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedUnderAtMarketSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEuriborMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=afmd_OneMonthEuriborMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6733617904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>21. Leases - Future Contractually Agreed Undiscounted Lease Payments (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Future contractually agreed undiscounted cash flows</a></td>
<td class="nump">&#8364; 829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17', window );">Operating lease commitment under IAS 17</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Payments within one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Future contractually agreed undiscounted cash flows</a></td>
<td class="nump">553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17', window );">Operating lease commitment under IAS 17</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Payments between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Future contractually agreed undiscounted cash flows</a></td>
<td class="nump">&#8364; 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17', window );">Operating lease commitment under IAS 17</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 541<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of future minimum lease payments payable under non-cancellable operating leases under IAS 17.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_MinimumLeasePaymentsPayableUnderNoncancellableOperatingLeaseIas17</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 58<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6733929024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>23. Related Parties - Outstanding Balances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_AdiHoessMember', window );">Adi Hoess</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">&#8364; 5<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_WolfgangFischerMember', window );">Wolfgang Fischer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MartinTrederMember', window );">Martin Treder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_LeilaAllandMember', window );">Leila Alland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_ThomasHechtMember', window );">Dr. Thomas Hecht</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MathieuSimonMember', window );">Mathieu Simon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BemdtModigMember', window );">Berndt Modig</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_FerdinandVerdonckMember', window );">Ferdinand Verdonck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_UlrichGrauMember', window );">Dr. Ulrich Grau</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BernhardEhmerMember', window );">Dr. Bernhard Ehmer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Disclosure of transactions between related parties [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors', window );">Key management personnel outstanding balance</a></td>
<td class="nump">&#8364; 20<span></span>
</td>
<td class="nump">&#8364; 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of Remuneration payable to key management personnel and supervisory directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_RemunerationPayableToKeyManagementPersonnelAndSupervisoryDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_AdiHoessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_AdiHoessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_WolfgangFischerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_WolfgangFischerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MartinTrederMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MartinTrederMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_LeilaAllandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_LeilaAllandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_ThomasHechtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_ThomasHechtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MathieuSimonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_MathieuSimonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BemdtModigMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BemdtModigMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_FerdinandVerdonckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_FerdinandVerdonckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_UlrichGrauMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_UlrichGrauMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BernhardEhmerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=afmd_BernhardEhmerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730422256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>10. Employee Benefits (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_EmployeeBenefitsAbstract', window );"><strong>Employee Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_WagesAndSalaries', window );">Wages and salaries</a></td>
<td class="nump">&#8364; 11,587<span></span>
</td>
<td class="nump">&#8364; 10,027<span></span>
</td>
<td class="nump">&#8364; 7,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_SocialSecurityContributions', window );">Social security costs</a></td>
<td class="nump">1,620<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">931<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee benefits</a></td>
<td class="nump">&#8364; 13,207<span></span>
</td>
<td class="nump">&#8364; 11,119<span></span>
</td>
<td class="nump">&#8364; 8,406<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_EmployeeBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_EmployeeBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 102<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 99<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 104<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SocialSecurityContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2019-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SocialSecurityContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WagesAndSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2019-01-01<br> -Paragraph 9<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_9&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WagesAndSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>97
<FILENAME>0001558370-20-004500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-20-004500-xbrl.zip
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MRQS5.MHR$UL>_2+"Z'<!%.@KM?BP8.;9@D2/5325,'J;D./RHE\!<F^;77/
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MF=O_1E_410,R>QQ8439S,3'5*#51^ZK:#O+W C?,N;&[CL,-)J_^!.OK'QQ
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MB+GPTS<@ECNNJ8'!-&VJ@S"BHO&>YZMJ%B//,G3!J',8"@2%)J'0%$T)[$E
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MM\OBZHKA*[:+-N->+K?'NKT>&\!,?!X\_W&L_4&A>PN0X^58^PQF$[''Q]J
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M2XQLIZ[)_N"@WN*9PA.*MZ4AMQ-R3@>F^Y6;["7>E.@1Y"GUM B[#X;W57]
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MZ87.F78GZ)",Y<?:-27N2%!'>V-N7_M&7Y0UHEWP@2S34%8GKWP"5#(M@;H
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M)1V*&7UNF5'W.EKY$?Y6-PK<]KX'-PH4DU _Z#03W(\)T7/;%ED1%!_I-I;
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MBB<O9I&/S;R7\,*46&]8PR ON#Y[,45.0;=H"I*9Y-SR/)KBC[!P&R5JFUO
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MDLB>TS/<N7"DF1+ I(GBFF :!!Y'*:97W$D,<R(!6VU180FC7@;3V<@Q-7[
M8.VTZ"';U4[/+N7'!K.J9PLH57V+)S\-.\.C=S*_R6$@0W+FX&B9B4NUZH!
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MH:_-AN?,>[(RM_9HO3UX29%YDZ6(QS!I6X D'F].W5F[#Y&8TA!A7K$=8\_
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M+7T9>4IO0:CW4#TPHW"&W-8RY(A!*$GN@82X.[GF(%E$M-N-T_YJI[<80!A
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M[T"=>2"P[T!(1BIJB*N1IX;P-0"8P;R.C\.AYP ./+MZ]_$Y LXE_&&LW 8
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M)PH3OR.9[WIZ%+BQ^.*,P(A6OI?H_.E?' \N!,WHY"]0PZ%R8N]&B<M)!,R
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M_K<A_E?!ZO@#%5TWQ'L%*B&8-L3EX&JDG.]"-Z-F"&_YY/^M@H:X^EL!VP.
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M$X\E[X")QY*WE\2K1$H?5PWF!@\U)SL7B]YT2OF!%XOF!@\LV2S9591L;O#
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MT8#1@-& T>#L_*1F+B2'I^K30Y!I73]EP:'('=B4[4;WO(K9> P@#" ,($\
M(-U&KUO%$!4#" ,( \@3 $BCU:Y;%G#=$*3Z_FKU*%JQ>N-,():@PR802]">
M$X@E:,\)Q!*T,P(=OLW.\8 MU$S](PR.G22*L &GU%IAUU"-W47?*$>-!RIJ
MB&Z;*ZHR-W%TB:-+7 .1T831A-%D'UB$T831A-&$T627:'+X/C7C"5=491Y@
MG<*Y_ZOG3/08"Q@+& MJCP7M1J>SVDD@Q@+& L:"*F+!^>EJ5L'A>Y <JWH\
MVUS]K9R1^*PFR<#WG JJ$F825C(<T-R^^NGWJMC@@]&#T8/1XPF"6ER3F=&#
MT8/18\WB6*M5,3A\UY?Q@RNJ,OVKJ#^X:MK6U$2W<7K:9S!@,& P8##H-OJ=
M*I:N83!@,& P>*(NU8?O2'*(JCYU:IC6]5,:'([<077NQDDE&W<P?C!^,'YL
M'S].&YUSQ@_&#\8/QH]U6]2N%N>>\6/-5SGP57:SZ]T4?[U+*/LPR[V0P4<X
M>]D*3-+9P^3%B]FE$,4OO[SPAI$^'B:^?_'&TXX?ZB12'X?O[81@W/YEI*1^
M^P.&$<@XC*:__O,?0ORR^+X/@1..U5?YHW"]<&" L&B?U?#5T9LDDK$7!M_:
M\%^GU3[_]C7\UNY\ZYIO1[_:<6<C79* [<X<!0$25B%'L>K36F1?AYY+#I">
MU^XT%QZ_?L0G0RX1RQ]*W\-+ZRW^OLG.*FO]=:3$>T#TB7 ]%] ^%E[@))&0
MP52,)8P;;L<_V=6#CR*&6R;P0^AJ,8F45C ]MRDN2Z7!1+?=$,CH#>&JH8HB
MY=+]MH[8, K'\,8A_*("1VD!STG\&#2(^0F63 ;7'@!<>L<S(N9//SJMRZN7
MG7[W)3Z]?R&*?SYIGSYOB#B2+MP6N"*$H4;P:$=Y-PB6LT\Y6?B4;O<$G@*:
M, IO84 S-_5:B^YIP1T^H(<2OB<'GN_%WNS;VIWVXCMIJ+.#GLCIHA$O''"G
M]UR,Y(TB\@V4"G#*X74 K.-BQ;9%!( _!Z'0R7#H.1X6>!LF,0 ;7H+O!<*&
M0P^N"R.@ZA!N(=J4GE2<J81;Y8WT?+SY3EZX^WXB>JS&DS"2 *3SG ',"-P]
M-8L\ N@2WAC&>*/&,'A-"Z?^2KS)F(K5P3<R(X[#X7&B[^"ASMF=E QAKL#[
M8S'T ADX* .+'M%N=-K]8G!Z_G&]WHDA,.J&2#KQW0S2;?47#Z@)*WG/NB/5
MRP1'#E+"PV41Z@<L(I%C$1O  D9W4J6Y'E)6"R O:6V!!V!A4)^#@,6W*&-
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MQB-QZ3C*5Y$9R*43BV=S6/%XCC(<BT^X\&(0",?PV'^D,])Q,M8#I9V1KY+
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M32H0D7+"ZP# V\55A&6;*(=&!TA[%[ "38)0Z 0DW?%H6><!)X4!7&P\-^'
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MJCWX%N1>P\P#%/BQ#&Z5N(4KJ"QE!A8W;UYW+SKB!>+:=>GK3NNBVS,H<RU
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MY+)PE$3JAHH-,X@L9/@OP*Z.U'J&[&D4#3$.Q<Y.P]$I+&):LAFY(G \'[\
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M/9UBOH6 B^X\I[*UWEBGCEEECU+F=A[(XU,8F\FJ[;=ZO0$#" ,( P@#R#H
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MF\?M6U$TOW5XYY%>R/S&AV-400@?Q1__;\FJ/C4& MG;84$91/00L)MBL()
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M&'M1NI8M^*3$KZ!FIP(^P]A=(>^E=B,1A\)1.I9>("9J,E0Z$N&(+O\=H,<
MD?@YA&O-0SXG4VQD$R$FV:]!H9^JR=0/9THA3D6)'\,[(J"W*](?HLW3J%'
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M0YW 0V Y%9$5_@<LT@#,4U 8D\2/O:E/<C?QHI1%M+(* B0!R(%=EJT4@%9
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M8(X V?MWI8WJF+60W%YEDKK+EWSS9F9(0Z>1V]W[%][+.6ZK8;<RT<J,=?D
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M-_D[*J!R(7Y('5!P>8H<.C\0^XT]$#Y6?K:C<6N.FP>N.45NGXH!W*S*?N7
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ML<UJF$145]STXDW7A1SIOJU%[:=U,(JG1VV;+LI2,:UYLU6KZ0.<$LB47)\
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MU ]G2F5M,(JGY5 )W'OQ> P\3)GL\KLR:?51:(!&.8G&+ADHDMH;)N; 0F7
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M1'XG/?UO[.N!3'*G(L-J[P-3_>9]$,4Z,=RGL*L;ONPF^AT8+M'(7MGM7\8
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M7]=4RH/[H#-A2.0?D3GT57[O3 [>,=9$/=1"*88&[_;1,'1)JM'UZ:FAT:X
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MS#3'M/-N9J\@9('H0*NDT.#UVS-TPRI8<E]!2 '1Q5S5D,8'<LX$;\&3Z 7
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M_'^[#\]B% '7(_]+[@HB#&%?O_+-^_W#2A0HEY,;17/>*:0%9??5GTJF$25
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M\%N6E,)+&N:_PZX3A&XO+)>1F8+_UUPG:_*/FJ;5M,W6&_4:S >&\8E@'TS
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M(CX^3HMZ/K5YT?A#?OL_4$L#!!0    ( %*(G%!WL+B54C   '02 P 5
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MXC5_Z/,<$'0PO$933'T+A==6 V-X9M%Z+:+*3/O4AF!]-V"P]8WUP!SHV\C
M#E+5+@'=YLS:'V#9" !G0":X4D^ Q6YVE]P *;@<I-+PEY1L?$DJ)'HMM.8L
M^Y.8C!?G ]%\[Q5U3[8??^^>'"XL>=%RO:\664Q42]169OMF:2C#J?6O UG*
M9?_@#X";ZPT^^*,8T*!?VRCX2$R)KVU4&)M)*1))21:I9$VSD+I"\[DZ<LU%
M:D M$IDI>%93!<SL9%)%L]A:.-9R"R[E#V1=GGT&]4Q96<*4PJSDXA&:3#%Q
MR'SE>KK"A.!W/QSI[B#95(.Q:IG5;W4OR095-9$WS%3@&:WO)E."XW35G.2;
M?\Y\$?C)?G_R1^-H,/Q.48Q(%XZ3OS48M[\SR*P(V,HC>.YQ.'I!9!(;SKX3
M&$6GKP#C)9DLTM'CJ>&9C_2+ :JEQU08QKLM&1BOP5+]PPC$\;AG27AVXYS\
M?!^J6TX,-6"\H))E)3$  KI5$Y.I_39-51S&"R5VXC*CJ7R(/#KS+.-CLSB,
MMS[R#HY--&UX1N$NC)Q0O#D2HQ9 7L9.R!-=O?M!8!@WUO5AO+B1=2!9PZOZ
M4&_I![$^P9/5 '!<IP8B/9O;]/_LTD'<-8HSQPEF+-51.=14Q4$=R>G%:P;3
MACESC?9X5K 1V:)DXT$E!:6UP-$&0?6FT\!W^<3!"']R(G6(NZ1DXY$G>00E
MP5']W9XIXH?*X>@>4]IW")D/,7EWB$=O,>ECPOU0$5HB>)RQ3ZC\P;C<336>
M+2+C$I<;:.72?' ^_,ELPJEGI%W/T L>O(>(T+$_[8O(/JGDK*HUGF@BHY2L
M0#4[OH0!4F14;3?0I!%6^EC:AM=<F,^IPH68+=+G5')WY_2PP]ON1*SQSG#1
M>L<1S>_*.U\;7+-_Q4M>$<HFI1]P,='!\'GL$-1WIG[$*-6&$:EK-!]-E%UV
M&Y$K:G! =YE2BDUA1KHZ8,[SC:II(3K@;N*2A9<^[#[IGAV?0CK3+T^@4J!
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M[\.K 3_OW7M#A.W3$^>_QM-N5P7&K%NU(NDXT(8YJ<^8P]%G$+JN"HREH_(
M;PT'<MGWOQ_%K$XLW'_[_U!+ P04    " !2B)Q0U>5ES>:#   ": @ %0
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MH]^F.&F%?B#6JG6R151N@GH8UDMJO4TDJ!%%;IC[!@:K[T&46DMRN%Q,Z?C
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MU@LU !@+;QV@ P-Q'"&O/I5X(+["KC-+U\G1C YZQ[ TC7ZZ-"""VFUL=1G
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M/\*26S6$;K@V)WL=5-QU2K[J11XIK UE2(>'97>SR_)RH*)UL6M5"% >C97
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M40SI62G+X>7^R#])ZHMXV)-"ZI(N#%24Q;:C@SW\Z:N6@[OP$'FH"\]D79)
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M.Y3I3PT]7/4RTVF:G04IU/#43R-;UWHLG0LQ*<$@&,,CH.>H/<UN,A-<-)K
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M['CD,39WP9]H$+#W2QK^>A?14(\@S<TQXXB!HCF:-+3%CBDFHCM %OW)M1*
M2 D(B$ "+L.'<8%F2#O4J0CDI\2;0?7]Z5+\A"YAAX5^%#^R]3%F'ER, '%O
MZ1I6_.\-\&/4#34,F2M>P%%['_2PU$&%0>$I$8*01$HB;@"(L4TV2IB1 Z(Q
M#"-Y$,5$7+>2>)7QF12X,!A@+&13Q> A.+3#N!H"LT4[G3',<.^T]ZP14*O,
MM%@(BT=,>.C<3.W(J%@26&)B1<EIS3(R=CZ]1OVPLTQ@[MAY9HQ.V)GW_A*P
M\UR9B;%3O=)"TM<((8:Z,Y<Y6'">V#%T(K,XQ%#@L=C&3%1B@FIX/X;^%9?
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M3_G8VN\YWHO'J*T.-KJ"_<T;GVC\A/&Y;,WR+^T0OIW6+&'=T$3M6-Y":+8
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MAU.W(#H :N>G7F8G1FU]YH#>;2J?(;BNPUQ0O%5^)TB>;Q$4P#-19#JXWCD
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MEM+Q/L&NPD"F@4=\R6-A!+DJSLA/M",PD*Z/FM\:V;P+MQ96<HB*?6Z(#+1
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MU::ZR[IX\YLN#K9T0XKW714_O4S8U =UT&<HNOWENXP\0/'9GCGE/)#MEM]
MG8[WY D"Q=LHKMKD$]L_LUAK3+.^Z%V@@PFJ?F#0$;4S=)'?UB,4#R*8B%J@
MB@VYS[Q"<IJL;LUX5O@M%/, ,\#5XS-PV->;H<<ZJ#3'7T8T]O*)OM:O#;L@
M=><N"N?+DY;VV-<>IN+;+RS\A,AA62XC6BY)Q05(J2\>P.5Q<CD4?@:)8!8<
M-B;6+B>&-DZ)/A$,2,YA(DB;6FV'R/7Y",*N-N)D9A<%'M?Y7_G_^#C[%,7L
M:4?#IU<^&-_YDF;-__]3!-=\1!&FVKV;GO0P8YX+4^6 V(<8=K1THIO]SD(.
MG^F.D5#( NB8E*0A.RD.V7-Y>#L:DE1(!#"[9G)_YT6()4N"C;U%,ZD))7.X
M-%1F3Q1_ @(0D(!($8B2@4@AB)1B D3&8+3J0!/C+"F-LN]^]]]$XA<?F97A
MY1#1VX\9>.S]"%/+^JQ&A14!S)AM98P<I#OU1K@ [:&$];Y,B2X/9=?,?X&B
M='P9QL>\'Y-$,<*U-U/.!OU,X5["(O1NWE)NL=7FP4]^K7E+D ;+,$EC,15V
M2.[O11ZIJPUE2'T6LCUMA&XZF(INLI1#(8@X@6%"%+'C"L+4/A1* [YNS07"
M>8O@-HA$N8+LG>,'FK*6+=C&+NC]LEWAJJ_IVZ/V'P.QK:^K*=(D?QL;B$^^
MISJ&QGZF<<R).XQ45R'[! _AW!QC_SF*]7NENH9(W:Y=N3S"K&V%?7W?++2C
MA3N\F"2>22(W/SXL+U</U6$X\GI\&)4Y5?))ZBCI3KF?.9**N *!)\XTR4*K
MIOR#FH9(T:==N9.7L4]:H9[@M<):G[P P2*@Q9@X4-:Y)4BM;3JK<=H4E)ZW
MF\U8=75.*$;K:D,>Y&B=./@<0$.E6(\C^@%3UV+F^2E(V.*&-0W1.Z%.N9.$
MM)-6J!U0*ZSUYJ8@*)QO<M\;2CF8!W&Y77EI:^!\VN;H7;!9T:HCUK=%[8XM
M(EL_"5/9CT'AFT-K"@M@A(XJRM_=Q_[:Q$TUC=$[:9.2-64,3UJB=M!&@:TW
M ( H$51Q..> 6AZ$EO@<\^H8QRQ<OYN$KG5-T3NE7L&3\/6L'6J';!#7.LI3
M)''XX@ *WD8Q\[<A66>*XG/'._]O1Y_'VB;^6-\6O4,VJ%CUR)J&J%VR25[[
MRKZ*)@ZG'%9%?.[8.^GBKE.9P=XLT#N_>X,Z3@2ZFUV)0D=JHD@("OK5,]1=
MP8*LV^0G&M27*Z]^C=2%=(H4UZB*[[ G"=2)VJ?NPIK&\3L,K:( @TBTYF,N
M(5$H<@;4A7?^!6,I\<9/$W"IM*1%!+$IKC>Y_/W$74SM+X@K'+B+PBW4?KQF
MARAI*NY6TQ IKK0K=Q*4G[1"/4UJA;5>(K,X]3<^'W0R,\"3A"<+QR?2;UHO
M_$3?X$VSF[>#"#N>HN*\2VNIYC[H?=- Y:J;-G1 [;$F<ML.;D6;K.5I)E,\
MIG)>!*I.Z\>?(P@0:; 0<[[63F?-T'MKO6)5!ZVV0>V3&E&M;T,J<BK6F\K]
M'&MU'_M\/7O0JM5C^:JNI-(M7^Q?,[9GGLJ7A3/DY>:.)0G<7_UW%D>J:5W0
M;D4%J:OU-$N^9NY.XO^O[MIZV]:1\%\AL, ^I:>;!GO:=!<+.$[2DVU:!W':
M8MN' T6B;:&R9$ARTIQ?OR1UETCJ1I&CAZ*V10[GF\Q\'(HWZ$/K$8C&C, /
M>;-)UD@;SA?GLR4)[@:1CLBE]YU'4;+A^2^B1%93\V#<@)F*)NDBS<NJB=CZ
ME)M-8ARV?YXVG>V>-S#$-VL@O@_!RE[N\1/VCYB^8,T6WPC[&GY9H.3:"6(U
MF>$4!)W1R/0=O0*+Y '!WMBHP@"T$:E-8PR43M&7)_]Y]-2Q'M (ZPT]3UBZ
M5(*>HO3"H&#'H/BDM&R4O*FO"\G&RYJS$BV6:05M(-N "5S9D.W)3:_S8+>X
M9:"N?MDD@]IBFE&UIV"=9$#FNZ$F$0S6V@5 Y\'!>-0-U)ZQ]1-3-GP=Q:2]
M;;QCWY#C;C:8*H#SJP?3:'&UW[BLW4SU@5K:)$K;1/DRR:Q5-GHS/D;3:QDV
M0LLL4_,1RJBI912?"O$9Q[=!%-WX2Z+/:E,'F1N!9ZT>=2'3:%\3%*=*=JP(
MG39[XQA#E\5R!!_'R NBY  *>F6.Y;^@Y^#H.6AG/9&2MDV+8H?DF\@F FBE
M9D#D0:/[T$A=5B,-(=H2NB%,2<U .+3)F'E[)HZ"U&D*YC(NCQH=D0D4I9WK
MG;N);_QR![ ,_,AU2,?NW&/+<Z/8M=>DO!6Z05O_TEL:9 X=;R9N4MI/%'2>
M58!,T7$_U9PUHKK0D*HD&822,WV0A<),)12E.AE,6C4;KYJ^LL8I%U>2550H
M@!8HUP%E2AA.9LU93.A?JE<CLTV&I&'VA6</;BG(I"J&55VB7"D"G00E&H]8
M*& S1[,070[OX62E:_)+Z4ARR\/LYK,H#NR?4?(XS3M-K%Q6:P0F)=GY>T)G
M.9/3Q$TM99X"&]OOJY UEM\_B@]!+#^$S!$-$#DUY$^@,T)3T>'CRYX7NY"F
M-4>^.K!+]!U]-'F$H4(HWS\JC.LOZTMQ7)<?0H[K!H@\KO,GT..ZJ>A0__!?
M6WJC5)WJ7] :79J,4H50UI<*H_3#XT$<I>6'D*.T 2*/TOP)]"AM*CJ;*%6G
M.I%D,D85 KFX@[6F;_&$0VN+T]4'D@GZCE6 LD$?P-6%?N+RH-?[=5![J ^G
MH@$N4%UZ 3L!H(<S2ZN =^9VP+43GX3E03MS![4'O[HX!,-O<IC0DZV#&UO>
M/:8W1+5=QB(H#-][)2#K-[\W2\+V6)G"@X?AB5"42C5^-)(.D,".0[C'<1A$
M!VS'[A->' X>W3A.,O>%[U0>$>U)2L\NF9->I#!<'OCH'FFJ^G:+0<) <\18
M3,/GFDO"D54TS,XP"BM/PZ)MD+=!I+9Q6GK(1K$91 \/6#THRF6 ^SI7U>$N
MG(@SW@4JQI6LS(J]%Y3A WGU0WZ\VM5F0XABM5FRA#RZ\1?)FD"2K-\%A%9>
MVJX1["\(?.0.-4[MRL&>4D!'_V P@X^]S<_:2UID2S*3-NG*H*)5E#1KG$>T
M6VB9+LD\8CK/:CG!@64 P0;=7-^OT3DLPKGQW9@8QWMA:1)VJ([R&\ID-<!3
M2"O<^NT7@N*@2:%=Z^&;=U/)27)+NE$F&V0"R[5"ZYTNLCKS]&[Y[2[""O/S
M<&6WGV0^OLA\'%VC>[0V?P^:'MBUT!Z1)PLFP*G@T]_%<^"UYT##3@@EGPDO
M/X0^&<[5==(-\RP;.OT]7;6F>3&:4K@I/Q L!F?2U2)*_C:P.O3/^+D].ZT5
M LH=<E"UP_U*)4!WREQ%A^]W>P:<6V906]+)1K'9N*,L::R6F85+*J)%YI10
MDL$IL$V6\1&MI1E?]3G0,!%"*3*^TD/P&1]/5VW[#[+L[Q:3^KJ/ 5$*/1%F
M-/53"J?RAU'( 0OBC0Z[FN4AH!J?WQ%'L5[H+]>8W?02?7/CW6>\M>@$Z3+8
M'[ ?,=\1$X<*H9#91IG1<HH:+1$ZKZD#J(T,"Y5S:CQ_CPJ]4:8X>B::HTQU
M5-9=,X6:MW+): _$:%0'KLF^"4UFDK-!V6^PTTW5/5C1FW?T/I(''.ZS T/I
MC%T4!;9+[Q-9^,Y_ ]>/OY(*5,>./<1PN;/I)$::CM]/#!0ZJZYB+$93O<5B
MC=Z\>X^HZJ_H_3TH5YX>/%&HS]:@,0 H0V"RSS!E[EJW0=5@MD,/5=O=5&RW
M:-@.3.<!P) CW5!E+^+[1\N[V1_"X F7NM=U3)JU0B<B5?Y)_KU=OM@>?_7_
M&#F@>XD1IBEZA0%"P/<"8S#I8WVF)2JKF>=MN::(JOKWO_TB_YW^BZJ,F,ZZ
M>=Z$07GV2<<%J-%P8A:C% [%1EU]:+I4__3\CN#)?UP>J=M[].,J7.,X]IBF
MG3/\GN) 4_9X0XGR^3ZRP!.X F@&L_=3.NPFS1>/3E!):12$J%#;;,JNU;2-
M3/WTO&:GBIE693,!RLY-V6R(=ZF=\G/M-V=?",,Q]X]?5D\XO&&7OCQ8OQY"
M;,5,4>FL8$\1D,E\H$'*<XM]ZD,G[:%P%)T#*YV9O%FB-V>HI!HBZ5*($N40
MT0X5ZNF?NM1JMK2]BC%60F,8G@75:QF>GXA-,U'^?(_3RS7(YV7"0.PFTNO0
MVN/G(/S9+6_N+@8RQ8XP##=/[B@#.M6.@30YW58SED(]^HW6+"N)<BT-IL&Z
M+%A-?TN&(=_X1H&2]$*PT(/0=29\D;'P'?+?NTN\<>ENBL!?;3Y9Q&ZNY75_
M?=%%R%Q(N)=1A*\J6B7,B8#[ 3+Y6H+-U-!/[]ZC0E6ZD353UO#+B.G-V'P%
MP68"::MEDZP*DT#A8.WVZ>XU4ZXI)'C/SBEN\N5M-@-)CS.[(#W#;F^%/TDW
M04*@QXK"WB)G0\[##29>3=A/WJR(>P0\S5ETLICKA(7AV7D2D?2GM^_S6?GD
MZI9<:Y2H;7H1H6;S\I80,A42EJ=*M!@,#-V;MU[5YQ:=?6["[N#LXABY/HZB
M9;!_=/V>:\FEM>=$\NUF$/*YN.K<J+L#$A,L?88RO5!),<,\/*&MFI3+MP D
M8M5C#KE'P-K_^@$'V] Z[%S;(I2&+?F>;%%IH!S:$69U4RRW*.B]L7*-!Q_#
M7Y**+"H6Y ;N!OB6G=SB\O-S8MG>;D'A>3FR(FZNN/(B<67#>[ZU0$VC=N3Y
MF%$6N!&V?]L&3Z_987LA"]NWV1>:P[]]]8_35VD6G_[\Y^55S025!T!#KJD\
MC:WB5X!!Q%%NJ M=HA]7FN-"H?8?,,G8_9>QG=3&BAZ9^"B,6?_T&GMQ1+^]
M2KJBW-/)3W]>'</@P-^$P'D,U.M%0*COUY\!C "ABD,]*1%FJ*>8"(V1/H I
MR@OW7@@,]0&%\N4^X,L:8 1PE!OJ+5_0C[6A/D"%]NN%$4=??A=@8@^ .WJA
M?-G1E]\!.WI)N<%G/*,?WPTYN@KM_\+V#MWCP_'1<VU8 _.[,'".=DPWK:YQ
M^.3:6/YN25P>:.!TAEH=F L* PRS[CH/]=],+IO8C%+)(%\S<2S0\J))5F..
M'BU[V20L/C>O5I1LYWY-)T_7N5\;?N>D 6\UCM4?/[@,/"(K"-E,2@I"/ \L
M+0TT!CO"S.=YQ46AS^MVT'S28ZOM<ON:YVDGQ%X1G9&/R4E875@5THRTB^>7
M@$PGXBZ<\Q@Z;2CNNA91Y$:Q10QX0KC"]HX.H8<3]'B,D1_$R'/W+KUD+ Y.
M4$P&6W[@!=N7$_*[C?T(LPYO3W>,83^147Z0]H0GU1*!Z[&G6RLZ81\V^4U,
M:07-9*38HH;SG0DAP1J2/!#7]+>KS4-H^=$&AZO-AR!P(KH7O<-PNVMMH+PV
MT S584NGJJ"',/T0#-Z#PEJA*__CM!WZ>4M;HJ<.@!ZXMUJH91C?O?[\(T4V
MQ.]8>=[1HFK/5A(OJPW*6J*?65O)X29 7@AHMD<[?XQ<J3+1"K.J33)CA=A9
MQ'?T^,,;GP#DOX88+@4\FPPR2VV-6A\1H)EE&)+!:UP:3%)J$"UBQ)JD!Y_2
M1HW3C%[C)-A='\5$YER8A)XV,HI$&@)FS!]\8W2ECFKMF;*& ,0TA,&.N@'.
M%(H-PB /)0C!2\-;O+6\9>!'1X]>1;WPG<71<>.K7_20?=F[Q*X5@89T?_#Y
MF\=.M:"_D.P'0MLY$!Y5ZP39N6+L7:-%54,XU4WSBT8]EF*MH*(9-@G+&D)9
M2R9?36HT0LM?'U9RQ*ZING6M1]=S8[?UO8RP.%"6[ JTFN;PRX).:EI4'N[0
MY#]4DFL\69D4J%?(A16F2\^*"'>L-@OR7RR?8^"7!1^@$HC5Z.04!!V:,GT'
M3\$G,ND+/8M)!3D+4$/>TK>(2L_-<V4]"[?HG+Q7U1*2U']7&[1(_==POS(-
MS@P<R%?L%T?7H^LNV@*S60Y\2 J@58.Q5@AT&(IT'>J8N3SC@3<9,EC!]BD@
MC7W%.]?V6D=9_++@@TX"L1IXG(*@@T^F[U W93)1)M1X%$X!<6F%P&*07LCJ
MQB_2X5.M$/RHXX"JA5NI!.PXXRDZ.,!282!'1HOM-J07 F.'3J]<6+[3UB?(
M:H#WT5:X58<5%@?MO>U:#QY%Y)*3"4,FVWB7H04OG2U$CPE>D(.HST%\2P]F
M?MA9_LK'_\-6V!+)LAK@([D5;C62A<5!1W*[UD,]FTA&3#2BLA$1CJATX[$\
M'>([ZR4YG_'9C7>NCP("^05#RPSKX!>^4S;)M?O$?FZ='NLK!GR\#S-,;3JM
MEPS0S# 0RN!9*0Y5T'GU&HW09ME#\TF!9@/E[/*(XV>,$WI)=G<])3RC].(P
MQ_TCP)%D45&C!-  E\ ISK*N/(:^'DB@[:1[F4F;B#6J^[QIM5AS&$8/C9X(
MD\+P_Q9XFRU1Y]J-[!WFI_G2@I#)0 HNYP1N*>C4(%=Z4H;(FD9IVYJ)8AKD
M=5 F:4,/0H4D\LD*8]=_"+$C8Q!N*<CT(8:5<T>S"'3BD&@\*6LD[:*D8<V4
M,0'F"AR39#$U-J7;&ES/6GA$*T>VA:%9"#))"$&5MB;42D"G"+'"DS($:Q8E
M[6K?3J :<1F,V3T"4R)32 X/NV!O17]@>Q>+R8%7"#(Y"$'EY- H 9T<Q IK
MVX\4,Q70CNJ@ER>F ,^P,)$F>4(]LLOP-U1&IW2\$>]<?%R[>]G=?=Q2D-E"
M#*LTWJ@7@<X7$HVU$4:J V)*:!][*,=?@6-V[#$M-H64<8'W3OPI<-RMF# X
M92#3A0A23A;U M"I0JBO-J)XI!J@/55!+TLHA\X$(B;1)$-,@"OT,V *Z>$:
MAPX].]/Y2CZ0N/LI9@EQ4<ADT0(PYPQ!.>C4T::V-@;)%4&9)GJ)9"I#-'&9
MI!5]*!5RS!<O=.W=A] ZBLF%4P8RJX@@Y712+P"=1X3Z:B.01 -$5=#+',JA
MEY"8Y KEN.B+#<E?:=0@)?1W5NA<[?:RB51^,<@\(0%6&JTTRD!G"YG*V@@C
M4P(Q+70/6]0;H(K'[.!%/3I*'N*_V+]?%TK<DD_DQ^RG5,)__@]02P,$%
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M\\<D9%AT56$&\RE6&FM5F*_]_L9XD0MSQ*-E#'?ES:80T<KCS@JS1Z-1^2U
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ME:J[[<"B@E[D\4P>NN[+[GEIAS\=U_T.PPOP"*:N'03.W,%/Q2/!37PLNN\
MB1[-JER/G\9O-@R7QY84+_2L_![*H&,92YB)E+[9CA=@L0%R&KGU7D$0O?Y.
M*KG?>DB.FZ38'L>GJ.HK!D+[V/!D>C>URICSVJ_\G"AT%7G<.2$-[T^D2B&5
M![K23OG4EF,'NG-S0">#MWI K>QZ+X$.:LAQ>7@8=&=S80?.%%]'..X&'9FN
M;=_#N<WP/'P /HFL8L)%H&_#X%.48UZP=*.N '\"G/L+S,:OZ)R_ %%D'A-
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M9KY+Z"(TP*ADS1A)D>2EP7)#+**_Q=F/?JS1;Y%&D!SP/R?S2^"'MN/=.RY
M4O4.L*66>%L1> 0IFI5+60JE<5J='VNDFZT8Q'%([?Z)M!)R,JMZHO95]GEI
MAS_M !V+W,T,URQ-5)"D8OJXL%W;FX)Q> $6CN>158-:\U,I[;9B6+\0M>9E
M/E,5WH=^&RRA.QNO\(G_VG46N,+S,XPWQQ-2\WD%#A8,_F*N@&Q;@:E5?F8E
M@-9G=)]]VPN0"A!W#S[:=H]=,@ PPQ)<H8U.5-F79&9#4WKR@@0<)=1CVMKB
M)+.:Z \&HV$KD*Q-=EJ35$M;5GTHOGY?HQ4G5LO/)?"BH"-<'@#IA!@#G/ X
M ,7E.\Z-]CKF(#YG2N72+IL06VQN'2'<33;*[>!1>2K*[3.RK4H&\(X'^_<#
M]D3CL"70VT"S(Q2?5IPYK='-!M4JVC_#\?)$4]K6%1BBK A$*/>.:;+IZZNL
M)>]QXY6S'['@W/(_K7SE#-0H?KD^9D 3Y_7*//'@P]EF2@IU)'=PW"!F1GL#
M,:!)O30DR0BE]O#("7!F]C 0(C)Z$]0[AU=3PV8S5U4Q'^SX/';K>BB8,U;>
M%5X^IZ:JESMO*2V:ID;QF=G$I^S/SHK<Q!&'V!R_[OT&(:Z4([3:"_4V$#!'
M7/N+BTCF>%D#(.7L"P3[&PBFXAHNA!>3EQB-=46R0DBD@U@:AP_0P:$S2')Y
MF=*DJ-01:D++GDIYM!)R.'Z@%-JR!%H-- %1-'C[5</G+D;@\X@;.(TRU)'5
MZ"@/'J2O$7-Z9J4S0/_7J37"^&KGA%%*BDCK1>3@"'=7 U+]^=9#OP+H](X#
M-;P !-]!*'=M-3A,LS,XL0AQ*Z)NV=[,2NCCQ#L@U']EQ7"Y,)EFW$")=C+%
M4GRS'2^X@P$:W\2[?I\N<?;>*V>.( F\*?XAV0"X!#G;F)S9K??@P[D33GS<
ME[VM4D'=&(LC!XB]794V26@U+'USD)HRN]\@VHEZ. [X&Q(:IZP*IT\C4"7+
MGZ+M^<%;SV/$3@P?$0DDSB42T!7BVX5KS&TB*[E%:'BX" UQ[$3T!;( I;ZQ
M6XRJ6H;XO//6(M&>2BXHTCLQ[H=I@0P%*)@UB>64M+W54,"RCD1KK)RK=DA&
MNF7K\-*!V<XL=2F0^YXFA7E6E A-4$57$(=)BR@I:FF6FH2%FJ,,#F^5>T:9
M;]8<?_9@^^%'_LTOJZW9RN0H94^=4OR9JM '1!!Z'G 3_MGZ9#1MBCIEV*O<
MJ<Q,4K>PW4OH!1L7)QU :\>#':96?%ZJ.I&>3=%U"6Y-38!V"8,PP'FV$67'
M=CFJIK=LBFHEN&MP)K3Q=+I9;5S\*.T*(':F3J0Z#[]J]D,G(/_,N8*4(=(
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M3U'9&5R$*X%CNT$E6-)9,6.)\/- TIH;J-TBFJ,>U\49KE=05,1,SJ$]W<A
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M-B.O@&028!GB5^?%1Y%7;FA>D7\PPZ0RK=H,!AF1)"A066_-2//RX,,I +.
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M+3(P,3DQ,C,Q+GAS9%!+ 0(4 Q0    ( %*(G%#_QXK,G0T  (C/   5
M          "  3)V 0!A9FUD+3(P,3DQ,C,Q7V-A;"YX;6Q02P$"% ,4
M" !2B)Q0=["XE5(P  !T$@, %0              @ $"A $ 869M9"TR,#$Y
M,3(S,5]D968N>&UL4$L! A0#%     @ 4HB<4-7E9<WF@P   F@( !4
M         ( !A[0! &%F;60M,C Q.3$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M %*(G%#')K%@=%<  #(<!@ 5              "  : X @!A9FUD+3(P,3DQ
A,C,Q7W!R92YX;6Q02P4&      8 !@"* 0  1Y "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739227600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>6. Revenue - Disaggregation of revenue (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 21,391<span></span>
</td>
<td class="nump">&#8364; 23,735<span></span>
</td>
<td class="nump">&#8364; 2,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">5,783<span></span>
</td>
<td class="nump">21,863<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">15,608<span></span>
</td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">1,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=afmd_CollaborationServiceMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">19,685<span></span>
</td>
<td class="nump">22,018<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=afmd_ServicesMember', window );">Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Other revenue information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenues</a></td>
<td class="nump">&#8364; 1,706<span></span>
</td>
<td class="nump">&#8364; 1,717<span></span>
</td>
<td class="nump">&#8364; 1,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 114<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=afmd_CollaborationServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=afmd_CollaborationServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=afmd_ServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=afmd_ServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739445616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>19. Borrowings (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Leasehold improvements and equipment</a></td>
<td class="nump">&#8364; 2,291<span></span>
</td>
<td class="nump">&#8364; 1,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">13,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">95,234<span></span>
</td>
<td class="nump">94,829<span></span>
</td>
<td class="nump">&#8364; 39,837<span></span>
</td>
<td class="nump">&#8364; 35,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Total</a></td>
<td class="nump">108,205<span></span>
</td>
<td class="nump">112,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_BorrowingsByNameAxis=afmd_ThereofAssetsPledgedMember', window );">Thereof Assets Pledged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems', window );"><strong>Disclosure of detailed information about borrowings [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Leasehold improvements and equipment</a></td>
<td class="nump">1,503<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">864<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">13,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">93,606<span></span>
</td>
<td class="nump">92,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities', window );">Total</a></td>
<td class="nump">&#8364; 105,122<span></span>
</td>
<td class="nump">&#8364; 109,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35H<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35I<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35M<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 35N<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 14<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_14_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsByNameAxis=afmd_ThereofAssetsPledgedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsByNameAxis=afmd_ThereofAssetsPledgedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6738919584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>16. Equity (Details) - EUR (&#8364;)<br> &#8364; / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_AuthorizedCapital', window );">Authorized capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,200<span></span>
</td>
<td class="nump">&#8364; 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 762<span></span>
</td>
<td class="nump">&#8364; 624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,249,901<span></span>
</td>
<td class="nump">62,430,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 31,373<span></span>
</td>
<td class="nump">&#8364; 25,113<span></span>
</td>
<td class="nump">&#8364; 23,123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=afmd_CumulativePreferenceSharesMember', window );">Cumulative preference shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="nump">&#8364; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="nump">155,975,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedInPublicOfferingMember', window );">Public offering | Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">13,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SharesPrice', window );">Share price</a></td>
<td class="nump">&#8364; 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issue of common shares</a></td>
<td class="nump">&#8364; 29,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_AuthorizedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_AuthorizedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SharesPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SharesPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 17<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=afmd_CumulativePreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=afmd_CumulativePreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedInPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=afmd_SharesIssuedInPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6740066816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>12. Income Taxes - Narrative (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Income tax benefit at tax rate</a></td>
<td class="nump">29.825%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes', window );">Tax loss carryforward for corporate income tax purposes</a></td>
<td class="nump">&#8364; 199,200<span></span>
</td>
<td class="nump">&#8364; 166,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MaximumTaxLossDueToOwnershipChanges', window );">Maximum tax loss due to ownership changes</a></td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OperatingLossCarryforwardsForTradeTaxPurposes', window );">Tax loss carryforward for trade tax purposes</a></td>
<td class="nump">198,400<span></span>
</td>
<td class="nump">165,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TemporaryDifferenceBorrowingsMember', window );">Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember', window );">Leasehold improvements and equipment and right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_LongTermFinancialAssetsMember', window );">Long term financial assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_ContractLiabilitiesMember', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherReceivablesMember', window );">Trade and other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherPayablesMember', window );">Trade and other payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=afmd_AbCheckMember', window );">AbCheck</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_DisclosureOfIncomeTaxLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes', window );">Tax loss carryforward for corporate income tax purposes</a></td>
<td class="nump">&#8364; 296<span></span>
</td>
<td class="nump">&#8364; 423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_DisclosureOfIncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_DisclosureOfIncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_MaximumTaxLossDueToOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of maximum tax losses at the risk of being lost due to ownership changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_MaximumTaxLossDueToOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax loss carryforward for corporate income tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OperatingLossCarryforwardsForCorporateIncomeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OperatingLossCarryforwardsForTradeTaxPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tax loss carryforward for trade tax purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OperatingLossCarryforwardsForTradeTaxPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 56<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TemporaryDifferenceBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_TemporaryDifferenceBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_LeaseholdImprovementsAndEquipmentAndRightOfUseAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_LongTermFinancialAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_LongTermFinancialAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_ContractLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_ContractLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_LeaseLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=afmd_TradeAndOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AssetsAndLiabilitiesAxis=ifrs-full_IntangibleAssetsOtherThanGoodwillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=afmd_AbCheckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=afmd_AbCheckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6617228512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>23. Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock', window );">Compensation of Managing Directors and Other Key Management Personnel</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2017
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term employee benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,598</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,683</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,538</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Termination benefits</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 264</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share-based payments</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,738</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,229</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,379</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 4,600</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 3,912</font></p>
				</td>
				<td valign="bottom" style="width:02.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2,917</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock', window );">Outstanding Balances Related to Key Management Personnel</a></td>
<td class="text"><div> <div>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:25.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Outstanding&nbsp;balances</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Adi Hoess</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;5</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Wolfgang Fischer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;1</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Martin Treder</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Leila Alland</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 40</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Thomas Hecht</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 26</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Mathieu Simon</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Berndt Modig</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 10</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ferdinand Verdonck</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 11</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Ulrich Grau</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 21</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:72.68%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Bernhard Ehmer</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 20</font></p>
				</td>
				<td valign="bottom" style="width:01.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:11.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 17</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfCompensationOfManagingDirectorsAndOtherKeyManagementPersonnelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_SummaryOfOutstandingBalancesRelatedToKeyManagementPersonnelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6740084624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>4. Significant Accounting Policies -Lease (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 824<span></span>
</td>
<td class="nump">&#8364; 717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OperatingLeaseCommittmentIas17', window );">Operating lease commitment as of December 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed', window );">Recognition exemption for short-term leases</a></td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments', window );">Payments for incidental rental costs and other rental payments (Not part of the lease)</a></td>
<td class="num">(312)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate', window );">Discounting using the incremental borrowing rate as of January 1, 2019</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities as of January 1, 2019</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">804<span></span>
</td>
<td class="nump">&#8364; 717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member', window );">IFRS 16</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of initial application of standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_OperatingLeasesWeightedAverageDiscountRate', window );">Weighted average discount rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation, right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_MinimumOperatingLeasePaymentsAs17', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities as of January 1, 2019</a></td>
<td class="nump">&#8364; 717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of lease payable discounted using incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_LeasePayableDiscountedUsingIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_MinimumOperatingLeasePaymentsAs17">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of operating lease payments that the lessee is or can be required to make, excluding contingent rent, costs for services and taxes to be paid by, and reimbursed to, the lessor, together with any amounts guaranteed by the lessee or by a party related to the lessee recognised as an expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_MinimumOperatingLeasePaymentsAs17</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OperatingLeaseCommittmentIas17">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease committments under IAS 17.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OperatingLeaseCommittmentIas17</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_OperatingLeasesWeightedAverageDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_OperatingLeasesWeightedAverageDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments for incidental rental costs and other rental payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_PaymentsForIncidentalRentalCostsAndOtherRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInitialApplicationOfStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the lease commitments for short-term leases accounted for applying paragraph 6 of IFRS 16. Short-term lease is a lease that, at the commencement date, has a lease term of 12 months or less. A lease that contains a purchase option is not a short-term lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseCommitmentsForShorttermLeasesForWhichRecognitionExemptionHasBeenUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InitiallyAppliedIFRSsAxis=afmd_IFRS16Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6622496288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>21. Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leases</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">Affimed presents right-of-use assets for offices, laboratories and vehicles leased in a separate line item from the line item &#x201C;Leasehold improvements and equipment&#x201D; that presents other assets of the same nature that Affimed owns. The agreements have an average non-cancellable term of between one and four&nbsp;years with renewal options included in some contracts. For equipment leased with contract terms that are short term and/or leases of low-value items the Group has elected not to recognize right-of-use assets and lease liabilities for these leases.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">The carrying amounts of right-of-use assets reconcile as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="bottom" style="width:27.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying&nbsp;amount</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Buildings</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Cars</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1, 2019 </font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 695</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 22</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Depreciation charge for the year</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (371)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (13)</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (384)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Additions to right-of-use assets</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;0</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:70.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 816</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> &nbsp;9</font></p>
				</td>
				<td valign="bottom" style="width:02.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:07.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 824</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:normal;">Cash outflow related to leases are as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 405</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Interest on lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 24</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Short-term lease payments</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 66</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Cash outflow from leasing</font></p>
				</td>
				<td valign="bottom" style="width:02.76%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 495</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">In 2018 and 2017, lease expenses of &#x20AC;562 and &#x20AC;472 have been recognized in the consolidated statement of comprehensive income.</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Future contractually agreed undiscounted lease payments are as follows:</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2019: Leases<br />under IFRS<br />16</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">2018:<br />Operating<br />Leases under<br />IAS 17</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments within one year</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 553</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 675</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Payments between one and five years</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 276</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 541</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:77.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 829</font></p>
				</td>
				<td valign="bottom" style="width:02.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1,216</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Movements of lease liabilities reconcile to cash flows arising from financing activities as follows:</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:center;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of January 1</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 717</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Changes from financing cash flows</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Repayment of lease liabilities</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> (405)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">Other Changes</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">New lease contracts</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;color:#000000;"> 492</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:87.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Balance as of December 31, 2019</font></p>
				</td>
				<td valign="bottom" style="width:02.78%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 804</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 1pt;">
			<font style="display:inline;font-size:1pt;">&nbsp;</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Presentation<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Section Disclosure<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6649489024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>17. Share Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_ShareBasedPaymentsAbstract', window );"><strong>Share Based Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share Based Payments</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share based payments</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2014, an equity-settled share-based payment program was established by Affimed N.V. (ESOP 2014).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Under this program, the Group granted awards to certain members of the Management Board, the Supervisory Board, non-employee consultants and employees.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payments with service condition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The majority of the awards vest in installments over three&nbsp;years and can be exercised up to 10&nbsp;years after the grant date. In 2019 and 2018, the Group granted 1,736,803 awards and 2,332,296 awards to employees, the Management Board and Supervisory Board.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, 357,879</font><font style="display:inline;">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">ESOP 2014 awards were cancelled or forfeited due to termination of employment or termination of consulting agreements with non-employees (2018: 424,688), and 19,795 options were exercised at an average exercise price of $1.54 (2018: 40,038 ESOP 2014 awards </font><font style="display:inline;">at an average exercise price of $1.98).</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">As of December&nbsp;31, 2019, 7,307,567 ESOP 2014 awards were outstanding (December&nbsp;31, 2018: 5,948,438), 4,773,840 awards (December&nbsp;31, 2018: &nbsp;2,814,547) were vested. The options outstanding at December&nbsp;31, 2019 had an exercise price in the range of $1.30 to $13.47 (2018: $1.30 to $13.47) and weighted average remaining contractual life of 8.9&nbsp;years (2018: 9.3&nbsp;years). In 2019 and 2018, the Group estimated an annual forfeiture rate of 4.0% for unvested options.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payments with market condition</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">On April&nbsp;20, 2018, Affimed issued 240,000 options, of which each grant consists of three tranches that vest when the volume-weighted average share price (measured based on Affimed closing share prices over the preceding fifteen trading&nbsp;days) reaches a certain hurdle ($6.15, &nbsp;$8.20 and $10.25). Fair value of the awards at grant date amounts to &#x20AC;133 &nbsp;($164 thousand) and the contractual life time of the options is two&nbsp;years. As at December&nbsp;31, 2019 no options were exercisable. Fair value was determined using the Monte Carlo Simulation.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Share based payment expense</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">In 2019, an expense of &#x20AC;2,469 was recognized affecting research and development expenses (&#x20AC;904) and general and administrative expenses (&#x20AC;1,565). In 2018, an expense of &#x20AC;2,035 was recognized affecting research and development expenses (&#x20AC;852) and general and administrative expenses (&#x20AC;1,183). In 2017, an expense of &#x20AC;1,943 was recognized affecting research and development expenses (&#x20AC;522) and general and administrative expenses (&#x20AC;1,421). </font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Fair value measurement</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">The fair value of options was determined using the Black-Scholes valuation model. The significant inputs into the valuation model of share based payment grants with service conditions are as follows (weighted average):</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2019
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:09.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;;font-weight:bold;color:#000000;font-family:Arial,Helvetica,sans-serif;font-size:8pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2018
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:8pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Fair value at grant date </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.10</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.20</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Share price at grant date</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.91</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Exercise price </font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.44</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 1.92</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected volatility</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 82</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 72</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected life</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 5.9</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Expected dividends</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.00</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:73.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">Risk-free interest rate</font></p>
				</td>
				<td valign="bottom" style="width:02.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 2.09</font></p>
				</td>
				<td valign="bottom" style="width:03.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:08.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 3pt 0.05pt 0pt;text-align:right;color:#000000;line-height:106.67%;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;"> 0.34</font></p>
				</td>
				<td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">
					<p style="margin:0pt 0pt 0.05pt;color:#000000;line-height:106.67%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">%</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:107.08%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Expected volatility is estimated based on the observed daily share price returns of a peer group measured over a historic period equal to the expected life of the awards.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_ShareBasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_ShareBasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 44<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6739603120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated statements of financial position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 137<span></span>
</td>
<td class="nump">&#8364; 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Leasehold improvements and equipment</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Long term financial assets</a></td>
<td class="nump">3,193<span></span>
</td>
<td class="nump">3,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">824<span></span>
</td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_RecognisedFinanceLeaseAsAssetsIas17', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">5,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">95,234<span></span>
</td>
<td class="nump">94,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Financial assets</a></td>
<td class="nump">8,902<span></span>
</td>
<td class="nump">13,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade and other receivables</a></td>
<td class="nump">1,482<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">296<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherCurrentAssets', window );">Other assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">387<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">105,914<span></span>
</td>
<td class="nump">110,879<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">112,359<span></span>
</td>
<td class="nump">116,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserves</a></td>
<td class="nump">270,451<span></span>
</td>
<td class="nump">239,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_OtherReserves', window );">Fair value reserves</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(234,508)<span></span>
</td>
<td class="num">(202,144)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">38,667<span></span>
</td>
<td class="nump">40,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">278<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">37,961<span></span>
</td>
<td class="nump">37,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">38,511<span></span>
</td>
<td class="nump">39,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">10,674<span></span>
</td>
<td class="nump">9,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_Provisions', window );">Provisions.</a></td>
<td class="nump">517<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings', window );">Borrowings</a></td>
<td class="nump">2,105<span></span>
</td>
<td class="nump">3,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">532<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">21,353<span></span>
</td>
<td class="nump">24,335<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">35,181<span></span>
</td>
<td class="nump">36,843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL EQUITY AND LIABILITIES</a></td>
<td class="nump">&#8364; 112,359<span></span>
</td>
<td class="nump">&#8364; 116,174<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_RecognisedFinanceLeaseAsAssetsIas17">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets recognised by the entity, which are leased under finance leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_RecognisedFinanceLeaseAsAssetsIas17</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2020-01-01: The amount of resources: (a) controlled by the entity as a result of past events; and (b) from which future economic benefits are expected to flow to the entity.
Effective 2020-01-01: The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2019-01-01<br> -Paragraph 23<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 45<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2019-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2019-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2019-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 68<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 66<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2019-01-01<br> -Paragraph 105<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2019-01-01<br> -Paragraph 25<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 69<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2019-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 55<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Provisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities of uncertain timing or amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Provisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph IG6<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2019-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2019-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2019-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2019-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2019-03-27<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730325152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>2. Local exemption rules applied by subsidiaries of the Group<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract', window );"><strong>Local exemption rules applied by subsidiaries of the Group</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock', window );">Local exemption rules applied by subsidiaries of the Group</a></td>
<td class="text"><div> <div>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Arial,Helvetica,sans-serif;font-weight:bold;text-align:justify;text-justify:inter-ideograph;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Local exemption rules applied by subsidiaries of the Group</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;text-align:justify;text-justify:inter-ideograph;font-family:Arial,Helvetica,sans-serif;font-size: 10pt;">
			<font style="display:inline;">Affimed GmbH, Heidelberg, Germany, makes use of the exemption clause, available under &#xA7; 264 (3) HGB in 2019. The consolidated financial statements of Affimed N.V. as of and for the year ended 31 December 2019 will be filed in Germany as a supplement to the financial statements of Affimed&nbsp;&nbsp;GmbH, in order to meet the requirements of the exemption clause available under &#xA7; 264 (3) HGB in 2019.</font>
		</p><div /></div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Local exemption rules applied by subsidiaries of the Group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">afmd_LocalExemptionRulesAppliedBySubsidiariesOfGroupTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>afmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
